<SEC-DOCUMENT>0001178879-23-000004.txt : 20230301
<SEC-HEADER>0001178879-23-000004.hdr.sgml : 20230301
<ACCEPTANCE-DATETIME>20230301160725
ACCESSION NUMBER:		0001178879-23-000004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		23693501

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fold-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:981bea1b-b87d-4677-ae2e-8728c40b94b3,g:80eaf27f-6f35-4ae6-9648-0cd9017af6e5,d:60868bb9516a413c82303f6b0d1ba997--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:fold="http://www.amicustherapeutics.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>fold-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV8zLTEtMS0xLTMzNDg0_8711408a-c382-468e-8f17-cf9c4fa726e8">0001178879</ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV80LTEtMS0xLTMzNDg0_3cb4b284-6987-45ae-acde-292955d48a2b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV81LTEtMS0xLTMzNDg0_c1168db6-d983-4617-9889-f4b25e1b0953">2022</ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV82LTEtMS0xLTMzNDg0_8e45c8c2-503b-446d-8e81-1f0809d5ff57">FY</ix:nonNumeric><ix:nonNumeric contextRef="i5e5211df4e48468b80d3325414933d9f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i9f56a09188ad4413a91488ec17aa68c9_D20220101-20221231" decimals="4" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDAvZnJhZzo5NjI1OTliMmVmOTI0NDc0YTBmOTY0OTdiMWMyNTJhMy90YWJsZTo5NTIwMzc2YmI1NzY0NGEyOGU1YTg3OTcwNTZiNTJhNC90YWJsZXJhbmdlOjk1MjAzNzZiYjU3NjQ0YTI4ZTVhODc5NzA1NmI1MmE0XzAtMS0xLTEtMzM0ODQ_a4541521-3307-4c25-bf8a-dcf0de38c5ce">0.0208</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="fold-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8346990c1864a19a63bcc7bbf6367c7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id6fffb5d4f854f989389548059d508dc_I20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id6fb65dbd72b492e80987a09a840570c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2fe03ce4e8348beb3ff495315b993c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d6b75012b24abc830ece41c6c75656_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98d799a4ea240c598fa644f12ddd44d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida6ebb73d0a44583a25622bc2ff8bc70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55cdc3ed7a544ad78b27effbad17252b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i331f4737a70b494d8165d7ad00b4f89c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica44d8bb33204fffa5ffdcad376a613c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20d67fb12e4438dbfce2517356c6668_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a54e11bb144d7283f688389627911d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2920a3c79ee544bfb57550e1524b3be6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ce7db741914e24aba11ec227d80098_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1c8441149f45b193c288045bfccb67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5867ad5312c144e38a3ba1be62b312de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15c8302234e443c5bca532c176601a9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140a0265db284ab18fc85a7c566f5e3c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia67c1c4115c1453abb07a9ff877be186_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedae25f2203048fdaca67cfcf5b407cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8aefd971cde4f12941d682724a9a606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25d57483c4a54eef8994b3bbaa7ffb31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied530d85f0df4c79aa2114bf41baf122_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e0d3884d4a4e348b28d2bf23c7218e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47380801e43942c98bd579021cd66466_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafcc84ae1f04e7c9f6fe592d37ff72b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae02215294ea4a709fe26968153b5d93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04eb74993b34416ac4dae1ade133ddc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10fab736f36145b7ad0b9d9e1984f370_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed4526deb5b484388e6c5a3f6743677_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517924c9e42841189538479018e06f92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b0d6f1aad064e62b2c5e3d60a822ed4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5211df4e48468b80d3325414933d9f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f3176f304064948be4451df697aa412_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a136c7711d044a09a19e03c25fe39dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:GalafoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5074d507bd1e4529aa53cc1be1409baf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:GalafoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i508c824fb1844b0ca8a046ab3f8321c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:GalafoldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71deb9575b294adb91ff789973f65bbf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia738717e166c41c2a4392a1967ef4025_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2c3883ff4d64b8e9595b3e84e9edfe4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i102ca847ccf94fb3ac9a236e09d1fd19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b7fa862c79461ba0d440ef1d4f8431_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be0f0c66b2b4c8cbdda482aa8ee8d15_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc1cdb41092f4d06b127a3529fd12fa3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df5e946794844e891a2510cf44b7066_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8a70346b0774591a4bd99dd9b48cdb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1d53e258e9423497806e3919e31742_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>fold:plan</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>fold:segment</xbrli:measure></xbrli:unit><xbrli:unit id="unit"><xbrli:measure>fold:unit</xbrli:measure></xbrli:unit><xbrli:context id="i7ee0584c009d47bdb038931ceca9c5e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79ec32aa3cf74295bf4d454eeeda3370_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6e594e389f4523b7a7c9bab80844f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbcc912009f4550a0f6de763f637746_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i877c2edcab8a4345bf7101d61ccf2c15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9e1d0ccde74a5397233b019d1d1666_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeff130df8d84f32801b649c773d0d55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if837fc4ce0e8435692a6f567914b6ed3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd29482ac05d44c7ab8df32cee3dca44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e615ec9f7c64a478d960eb4430d471b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ffd34918454b17a538f8040e16bd9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d1abcfa0ef48a8900c4f3cd89f734f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e219ba46f9f454e81973029cbfee478_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3636fa399a0c4c1eba1f0545ca9be836_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1e9bf5a1cc64621922ffe1980b7dac7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676babb093b5444588a41929a2ea1306_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483ff1106b53432cbdf57bb9830bf8d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628f96c5cfa5476392fcbe4410976f8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d7c1f78a2d4edfbd5dbd117237d2e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia903203eb4da4bd3902cc71800cfbd03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe1f1cffd554a4b994d3edcc31500b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf9b84e7254d4fec87bd8e31221e830a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef01c16ab7e44bdb0fe14f5f6770e1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144d3b85e0f54b78b3e35a0ab3f69126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>fold:vote</xbrli:measure></xbrli:unit><xbrli:context id="icb2d2c63506847d38297b26fc2a46816_D20221101-20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:AtTheMarketEquityProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbc7ec2bc82472e8d78a51e83eca27b_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc3b62495104669997b8f552c55251a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i684e59baa0d248038199064182a492cf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9f39dd6e7249298a92876de6b1e0e0_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb10a0ab84743b8a633a5e8af451568_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5e203f768a4aaf8bcf9130761b750a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7688b5af5be343ee94e09246b4b087c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf13e1ea84ff4fe7aa83be773a9ca942_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2b79da371e47f782a538b4f4a5a21e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434e5978cdfe47e2b88de10d3e704e27_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebd9dd9985e24306a01c58683a8c7ab2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a60c7a011cd48f384a926bf46f56bb5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f56a09188ad4413a91488ec17aa68c9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8462cf871c7a45aaa1430ee2bee44c64_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0893f89fb16742748936ee83717865e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb57920f3b814e169748405b9928e37d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69703642df9a437496988406ce21d664_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270475db6676442a85109f9df17c710f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0df69ddff74c2089537bf0e99a1af4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd0892a63d24555a0be7d1e129099a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25971519a474cb89a00ac0fe4405077_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4aebf956783144d080e2da4950f36772_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7974cd6b41a844d691c4317454a8e713_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic11a83d2050e4006b0d4257abc62732d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62bbbab375e34720aaff75d13f751ff3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id791547accfd4c4ca3c15fd099f6a3c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id344688a9ae545c792aa423f39c5e57d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0583f7b3d714281b74c55de8631a291_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c47266244c044308efa79fbb42126c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f66037dfaf441895506fef26bb3f6c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73e550190f24545ba9da5442ddcbd4c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea79d58e95c74a5991a23d4e79a1accb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7bc093340f94793b9356a4ad70fd286_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c8c2cd061443e8b7635a574a7eb008_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief04e0e1c5f64e7ea10b52c1ac3b2b1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i050f1ac85c0b486fb9e3931da07d4215_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11c64b571a447ccae1108601a456bd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ec9eab666f04c9ba3be68d4ffd794f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863463917abd46488618f36fe6140b3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36478174e3aa4ca6a302830abc0b3fd0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0914d34ae7a54148af314b77afd45e1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e3c044f256444559188d07ee55b2357_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b64c874c8c44ab193d9b7e4e27fc831_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b5d30d91b5477cb000659e1d65b4e9_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofpayments"><xbrli:measure>fold:numberOfPayments</xbrli:measure></xbrli:unit><xbrli:context id="i7ede13529d0c4d9b9a5b6711cd1a2495_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4688884f4dfe4ebb993267308aba950f_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if96cae15f3fe42258129198c088db297_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib91a2c830ad742d79faac258a290765d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e2344e04a24467a4594a535befc1ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeca2fca010445d2b6ac75145dc51d86_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ebce9bdfa62478e987dab4fc8cb80a4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b2989cb3ff43f08613f1bb07e232a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib98e12399cbf4ef187963beeca3c3e2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fold:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib99cd8bfa1ce4661a32f07a098c4ad73_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TerminationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9793bb80591f4cbe82d14a2f6ce6c5ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a10a61a90a344cc83adebf491256426_I20131130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c471c92318746a9b8b1e5af997f548b_D20131101-20131130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-11-01</xbrli:startDate><xbrli:endDate>2013-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>fold:market</xbrli:measure></xbrli:unit><xbrli:context id="iba37a657d80947ab943a84d5c6b181e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5673e90eb6f14cadab1e4565ba42932c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0862ce94c414f10953150dfe32fbbaf_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>fold:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="id13e58186fce456cb1f8099e4d16a816_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe76a53ea05f4538ab0428dc6a0d71ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i368b9dd19078410ea03a553d29d85a22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4ae1b3663f48dc81a42db36e0a2c47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b18190ecdd4603980cfb4ea1d75b83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac3baf5d87f4121b825257bdbd8cdfc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9f9812c5e347c0a7f7930aed8b7d7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39d797c28b2c491eaa21d972d9a071a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i080e37076a644122a897798491e8bdd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7edd439e87db45d786c45396af394cbd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc776c099cb497d877ef435b98b54e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a0f47df35a4dfa8f233290926fed7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i60868bb9516a413c82303f6b0d1ba997_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU3_34247cee-fb3e-4281-8f01-b899acc15faf">10-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjY2_7f41bd09-33a5-4d89-b86b-4520202be786">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8yMjE_8010d765-08ce-4ab8-a344-c5d7289e1b84"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8yMjE_bb80fbdd-43f1-46bb-b9b1-7a56215c9bb2">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYz_c8c6e852-020c-4421-b549-d3d6fa1c0f22">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU4_84f084b3-1bd6-4847-a8ae-95fc9a0567bc">001-33497</ix:nonNumeric> </span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU0_0cd5372c-e496-420c-aa2b-2909affa2cc4">Amicus Therapeutics,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:22.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.722%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl8wLTAtMS0xLTMzNDg0_eb2825db-065d-433e-a040-b8c91efbcb56">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl8wLTQtMS0xLTMzNDg0_975d93cb-fd92-4774-b3d1-033c0c19746c">71-0869350</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTAtMS0xLTMzNDg0_2e225512-eb8f-4fb7-a117-45d3a6fd2cb7">3675 Market Street,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTEtMS0xLTMzNDg0_c3b76afb-4a8e-40a4-9973-33a73c004642">Philadelphia,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTItMS0xLTMzNDg0_81b501fa-211b-4ee6-96fe-ae18cff036f3">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTQtMS0xLTMzNDg0_a3acc602-9acf-4fb6-9311-21f566d39edf">19104</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl83LTAtMS0xLTMzNDg0_3a708f34-b47d-4472-9201-1070e5e23236">(215)</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl83LTMtMS0xLTMzNDg0_a03a098f-18eb-4ee0-b4e6-7d65bbc868f5">921-7600</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant's Telephone Number,&#160;Including Area Code)</span></div></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6M2YwZjk5YWYxZThkNDNhMTk2NDJjNjY0OGI1YWIzNWQvdGFibGVyYW5nZTozZjBmOTlhZjFlOGQ0M2ExOTY0MmM2NjQ4YjVhYjM1ZF8xLTAtMS0xLTMzNDg0_afd8a757-951b-48d9-bd30-9ba2e3e4469b">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6M2YwZjk5YWYxZThkNDNhMTk2NDJjNjY0OGI1YWIzNWQvdGFibGVyYW5nZTozZjBmOTlhZjFlOGQ0M2ExOTY0MmM2NjQ4YjVhYjM1ZF8xLTEtMS0xLTMzNDg0_245904a9-33a0-44b8-9f1c-62681159471c">FOLD</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6M2YwZjk5YWYxZThkNDNhMTk2NDJjNjY0OGI1YWIzNWQvdGFibGVyYW5nZTozZjBmOTlhZjFlOGQ0M2ExOTY0MmM2NjQ4YjVhYjM1ZF8xLTItMS0xLTMzNDg0_2be7bc2f-3aff-45ac-bf5b-2cf8b9d6a34b">NASDAQ Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="margin-bottom:7pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjY1_50526d45-0455-47ab-8ae4-a36ee5b3a3e7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU5_28a369fc-ecbc-429c-9f90-80a13497fbce">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;  <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYw_ba30cb5d-9df0-4f7e-85d5-a5d2290674c2">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;  <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU1_bf9baa9f-a4bb-488e-b475-e23da218132c">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZjA2MTk5MDMxNTAwNGQ3NjkzNDY2OWU4ZDhlNmI1MzcvdGFibGVyYW5nZTpmMDYxOTkwMzE1MDA0ZDc2OTM0NjY5ZThkOGU2YjUzN18wLTAtMS0xLTMzNDg0_14a758a3-32af-4468-ba41-6b1306f76ce9">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZjA2MTk5MDMxNTAwNGQ3NjkzNDY2OWU4ZDhlNmI1MzcvdGFibGVyYW5nZTpmMDYxOTkwMzE1MDA0ZDc2OTM0NjY5ZThkOGU2YjUzN18xLTQtMS0xLTMzNDg0_98c6c46c-2985-436d-9601-610392401b44">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZjA2MTk5MDMxNTAwNGQ3NjkzNDY2OWU4ZDhlNmI1MzcvdGFibGVyYW5nZTpmMDYxOTkwMzE1MDA0ZDc2OTM0NjY5ZThkOGU2YjUzN18yLTQtMS0xLTMzNDg0_ce5fa66d-9e42-4670-a2a5-46843c0ad5fb">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report  .<ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYx_a11ec5ab-e15b-4d41-a318-13686988cf22">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).  Yes <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYy_36805ad3-41cc-43f1-8835-b8ff517f2448">&#9744;</ix:nonNumeric>  No &#9746;</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the 277,450,967 shares of voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as reported on The NASDAQ Global Market, as of the last business day of the registrant's most recently completed second fiscal quarter (June 30, 2022) was $<ix:nonFraction unitRef="usd" contextRef="ia8346990c1864a19a63bcc7bbf6367c7_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8xMDQ0NTM2MDQ2NzY0OA_5d895dc1-3b13-4f78-b874-c0974757520f">2,979,823,386</ix:nonFraction>. Shares of voting and non-voting stock held by executive officers, directors, and holders of more than 10% of the outstanding stock have been excluded from this calculation because such persons or institutions may be deemed affiliates. This determination of affiliate status is not a conclusive determination for other purposes.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant's common stock, $0.01 par value per share, as of February&#160;13, 2023 was <ix:nonFraction unitRef="shares" contextRef="id6fffb5d4f854f989389548059d508dc_I20230213" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zMzg1_c2ce02c6-f719-4e0d-9ee1-ed2254a2f5dc">282,714,738</ix:nonFraction> shares.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE: <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjY3_6d9a4fc7-b260-462b-8843-a4dca57aeb82" escape="true">Portions of the Proxy Statement for the registrant's 2022 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_19">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_22">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_25">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_28">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_31">71</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_37">MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_37">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_40">[RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_40">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_43">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_43">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_46">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_46">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_46">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_49">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_49">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_49">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_127">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_127">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_127">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_130">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_130">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_130">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_133">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_133">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_133">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_136">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_136">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_136">117</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_142">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_142">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_142">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_145">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_145">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_145">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_148">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_148">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_148">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_151">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_151">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_151">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_154">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_154">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_154">118</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_160">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_160">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_160">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_166">Item 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_166">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_166">123</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_169">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_169">124</a></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS and design, AMICUS ASSIST and design, CHART and design, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF, and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and design. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Annual Report on Form&#160;10-K contains forward-looking statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "might," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of clinical trials for our drug candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the estimates regarding the potential market opportunity for our product and product candidates, including AT-GAA; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, if approved and applicable, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-1-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including actions by us, governments, our customers, our suppliers, or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with, and our ability to comply with, emerging environmental, social and governance standards;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these risks and uncertainties, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in Part I, Item 1A "&#8212; Risk Factors", a summary of which may be found below, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Those factors and the other risk factors described herein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future collaborations, alliances, business combinations, partnerships, strategic out-licensing of certain assets, the acquisition of preclinical-stage, clinical-stage, marketed products or platform technologies or other investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we incorporate by reference in this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face and is qualified in its entirety by reference to the more detailed descriptions included in Part I, Item 1A "&#8212; Risk Factors". This summary should be read together with those more detailed descriptions, along with our other SEC filings before making an investment decision.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We depend heavily on sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe, the U.S. and Japan. If we are delayed or unable to commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> successfully, our business could be materially harmed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are not able to obtain, or delayed in obtaining, required regulatory approvals, we will not be able to commercialize our product or product candidates, materially impairing our ability to generate revenue.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are unable to establish and maintain sales and marketing capabilities, or relationships, to market and sell our product or, if approved, product candidates, their commercialization may suffer.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If the market opportunities for our product or product candidates are smaller than we believe they are, then our revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance necessary for commercial success.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">A variety of risks associated with international operations could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our product or any product candidates receiving approval may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are found to have promoted off-label uses by regulatory authorities, we may become subject to significant liability.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If applicable regulatory authorities approve generic or biosimilar products with claims that compete with our product or any of our product candidates, it could reduce our sales.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on an alternative for which there is a greater likelihood of success.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our product or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Any product or product candidate we obtain marketing approval for could be subject to restrictions or withdrawal from the market and we may be subject to penalties or enforcement actions if we fail to comply with regulatory requirements.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Certain relationships will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and corruption and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If clinical trials of our product candidates do not produce results satisfactory to regulatory authorities, the development and commercialization of our product candidates may not be completed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we experience unforeseen events in connection with our clinical trials, potential regulatory approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initial results from a clinical trial do not ensure that the trial will be successful and success in preclinical or early stage clinical trials does not ensure success in later-stage clinical trials.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If our competitors obtain orphan drug exclusivity for their products and we do not, we may not unable to have competing products approved in the applicable jurisdiction for a significant period of time.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Failure to obtain or maintain regulatory approval outside the U.S. would prevent us from marketing our products abroad.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business activities involve the use of hazardous materials which could subject us to significant adverse consequences if we fail to comply with the applicable laws regulating their use.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are unable to obtain marketing approval, or if approved unable to successfully commercialize AT-GAA, our business could be materially harmed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our gene therapy product candidates are based on novel technologies, which makes it difficult to predict the time and cost of their development and subsequently obtaining regulatory approval.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Use of third parties to manufacture our product or product candidates may increase the risk that we will not have sufficient quantities of our product or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may be unable to enter into agreements with third-party manufacturers, or unable to do so on acceptable terms. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We rely on third parties to conduct certain preclinical activities and our clinical trials, who may not perform satisfactorily.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, particularly in international markets, commercialize products.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Materials necessary to manufacture our product or product candidates may not be available on commercially reasonable terms, which may delay their development and commercialization.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Manufacturing issues may arise that could increase costs or delay commercialization.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We have incurred significant losses and anticipate that we will continue to incur losses in the future.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may never become profitable even though we currently generate revenue from the sale of products.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we require, and fail to obtain, additional necessary financing, we may be unable to complete the development and commercialization of our product and product candidates.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or product candidates.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Foreign currency exchange rate fluctuations could harm our financial results.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our executive officers, directors and principal stockholders maintain the ability to exert significant influence and control over matters submitted to our stockholders for approval.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We do not anticipate paying cash dividends so capital appreciation, if any, will be our stockholders sole source of gain.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we are unable to obtain and maintain sufficiently broad patent protection, our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We currently are and may become involved in lawsuits to protect or enforce our patents or other intellectual property.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights which could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Failure to secure trademark registrations could adversely affect our business.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our rights to develop and commercialize our gene therapy product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The novel coronavirus ("COVID-19") pandemic may negatively impact our business and operations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our employees, independent contractors, principal investigators, consultants and vendors may engage in misconduct or improper activities which could lead to significant liability and harm our reputation.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">If our enterprise risk program, global risk committee and other compliance methods are not effective, our business, financial condition and operating results may be adversely affected.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Our business and reputation may be adversely affected by environmental, social and governance matters. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_16"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease that is under review with the U.S. Food and Drug Administration ("FDA"), the European Medicines Agency ("EMA"), and the United Kingdom ("U.K.") Medicines and Healthcare products Regulatory Agency ("MHRA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of our portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), U.K., and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. In May 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. In October 2022, the FDA deferred action on the BLA for cipaglucosidase alfa, citing the inability to complete the manufacturing facility inspection prior to the PDUFA action date.  We are actively engaged with the FDA and an inspection has been scheduled. In December 2022, the Committee for Medicinal Products for Human Use ("CHMP") of the EMA adopted a positive opinion recommending market authorization of cipaglucosidase alfa, or Pombiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare diseases through internally developed, jointly developed, acquired, or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. We are leveraging our global capabilities to develop and broaden our lead franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel platform technologies. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the novel coronavirus ("COVID-19") pandemic. Our commercial operations have not been significantly impacted by the COVID-19 pandemic and we gradually continue to see an improvement in patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation. We have been able to continue to meet required commercial demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as supply our ongoing Pompe disease clinical studies and access programs including the Early Access to Medicines Scheme ("EAMS") without interruption. In regard to our regulatory operations, the FDA deferred action on the pending BLA for cipaglucosidase alfa, as a facility inspection was necessary, however, could not be completed by the PDUFA action date due to COVID-19 related travel restrictions. The facility inspection has subsequently been scheduled. Per FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, receipt of a deferral action indicates no deficiencies have been identified and the application otherwise satisfies the requirements for approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights of our progress include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial and regulatory success in Fabry disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the year ended December 31, 2022, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue was $329.0&#160;million of consolidated revenue, which represented an increase of $23.5&#160;million compared to the prior year. We continue to see strong commercial momentum and expansion into additional geographies. In countries where we have been operating the longest, we see an increasing proportion of previously untreated patients come onto Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to treatment experienced patients. In the U.S., we continue to see a significant increase in patients from a growing and very wide prescriber base. Across all markets, we see a high rate of compliance and adherence to this oral treatment option. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pompe disease program milestones</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. AT-GAA is under regulatory reviews in the U.S., E.U. and U.K., respectively. In December 2022, the CHMP of the EMA adopted a positive opinion recommending marketing authorization of Pombiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (cipaglucosidase alfa), a long-term enzyme replacement therapy ("ERT") used in combination with miglustat for adults with late-onset Pompe disease ("LOPD"). Additionally, multiple expanded access mechanisms are in place around the globe, including in the U.S., U.K., Germany, France, Japan, and others.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pipeline advancement and growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are leveraging our global capabilities to develop and broaden our lead franchises in Fabry and Pompe disease, with focused discovery work on next generation therapies and novel platform technologies. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Financial strength. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents, and marketable securities as of December 31, 2022 was $293.6 million. Based on the current operating model, we believe that the current cash position, which includes expected revenues, is sufficient to fund our operations and ongoing research programs for at least the next 12 months. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product and Product Candidates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(migalastat HCl) for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our oral precision medicine Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted accelerated approval by the FDA in August 2018 under the brand name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA has approved Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 350 amenable GLA variants. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable mutation (variant). The approved E.U. and U.K. labels include 1,384 mutations amenable to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment, which represent up to half of all patients with Fabry disease. In countries where mutations are provided only on the amenability website, these 1,384 amenable mutations are now available. Marketing authorization approvals have been granted in over 40 countries around the world. In July 2021, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. for adolescents aged 12 years and older weighing 45 kg or more. Throughout 2022, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in 7 additional countries, including the U.K. and Japan, for adolescents aged 12 years and older weighing 45 kg or more. We plan to continue to launch Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in additional countries during 2023, including for adolescents aged 12 years and older. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an orally administered monotherapy, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice ("GLP") cell-based amenability assay. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants, and at this time, it is not intended for concomitant use with ERT. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next Generation for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to continued innovation for all people living with Fabry disease. As part of our long-term commitment, we have an academic research collaboration agreement to explore next generation pharmacological chaperones for Fabry disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fabry Disease Background</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with Fabry disease have an inherited deficiency of the alpha-Gal A enzyme that would normally degrade the lipid substrate globotriaosylceramide in the lysosome. Genetic variants that cause changes in the amino acid sequence of alpha-Gal A result in an unstable enzyme that does not efficiently fold into its correct three-dimensional shape and cannot be trafficked properly in the cell, even if it has the potential for biological activity. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral small molecule pharmacological chaperone that is designed to bind to and stabilize a patient&#8217;s own endogenous target protein. This is considered a precision medicine because Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> targets only patients with GLA variants amenable to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fabry disease is an X-linked disease caused by mutations in the GLA gene, which encodes the alpha-Gal A enzyme. These mutations can cause alpha-Gal A to be either absent or deficient. When alpha-Gal A is absent or deficient the substrates, GL-3 and lyso-Gb3 accumulate, leading to damage of cells within affected parts of the individual's body and causing the various pathologies seen in Fabry disease. Fabry disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. The symptoms can be severe, differ from patient to patient, and begin at an early age, resulting in significant clinical, humanistic, and healthcare costs. Fabry disease requires lifelong medical intervention to manage the complications of this devastating disease across multiple organ systems.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fabry disease is a relatively rare disorder. The annual incidence of Fabry disease in newborn males has been historically estimated to be 1:40,000-1:60,000 (Journal of the American Medical Association January 1999 and The Metabolic and Molecular Bases of Inherited Disease 8th&#160;edition 2001). However, more recent newborn screening studies in Italy, Taiwan, Austria, Spain and the U.S., which collectively screened more than 500,000 male and female newborns, found the incidence of GLA mutations to be between 1:2,445 to 1:8,454, more than ten times higher than previous estimates for classic patients (American Journal of Human Genetics 2006, Human Mutation 2009, the Lancet 2011, Journal of Pediatrics 2017, and JAMA Pediatrics 2018). When looking at only male newborns within these studies, the incidence of Fabry disease mutations is as high as 1:1,316 &#8211; 1:7,575 (Circulation in Cardiovascular Genetics 2009, American Journal of Human Genetics 2006, European Journal of Pediatrics 2017).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that approximately 35-50% of the Fabry disease patient population may benefit from treatment with Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy. Additionally, we expect that as awareness of late-onset symptoms of Fabry disease grows, the number of patients diagnosed with the disease will increase. Increased awareness of Fabry disease, particularly for specialists not accustomed to treating Fabry disease patients, may lead to increased testing and diagnosis of patients with the disease.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, two other products, both ERTs, are approved for the treatment of Fabry disease: agalsidase beta by Sanofi Aventis and agalsidase alfa by Takeda, the latter of which is not approved in the U.S. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel ERT for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our biologics capabilities to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221, or miglustat, that functions as an enzyme stabilizer. Miglustat binds to and stabilizes ATB200 preventing inactivation of rhGAA in circulation to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, ("glycogen"). Miglustat is not an active ingredient that contributes directly to glycogen reduction. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated ATB200-03 (or "PROPEL"), a global Phase 3 clinical study of AT-GAA in adult patients with late onset Pompe disease in December 2018 and completed last patient, last visit in December 2020. In February 2021, we reported topline results from the Phase 3 PROPEL study. Patients in PROPEL were randomized 2:1 so that for every two patients randomized to be treated with AT-GAA, one was randomized to be treated with alglucosidase alfa. Of the Pompe disease patients enrolled, 77% were being treated with alglucosidase alfa (n=95) immediately prior to enrollment (&#8220;Switch&#8221;) and 23% had never been treated with any ERT (n=28) (&#8220;Na&#239;ve&#8221;). 117 patients completed the PROPEL study and all 117 voluntarily enrolled in the long-term extension study. The primary endpoint of the study was the mean change in 6-minute walk distance as compared with baseline measurements at 52 weeks across the combined ERT Switch and ERT Na&#239;ve patient populations. In this combined population patients taking AT-GAA (n=85) walked on average 21 meters farther at 52 weeks compared to 7 meters with those treated with alglucosidase alfa (n=37). This primary endpoint in the combined population was assessed for superiority and while numerically greater, statistical significance for superiority on this combined population was not achieved for the AT-GAA arm as compared to the alglucosidase alfa arm (p=0.072).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the hierarchy of the statistical analysis plan, the first key secondary endpoint of the study was the mean change in percent-predicted Forced Vital Capacity (&#8220;FVC&#8221;) at 52 weeks across the combined population. In this combined population patients taking AT-GAA demonstrated a nominally statistically significant and clinically meaningful difference for superiority over those treated with alglucosidase alfa. AT-GAA significantly slowed the rate of respiratory decline in patients after 52 weeks. Patients treated with AT-GAA showed a 0.9% absolute decline in percent-predicted FVC, compared to a 4.0% absolute decline in the alglucosidase alfa arm (p=0.023). Patients within the combined study population demonstrated statistically significant improvements on the Gait, Stairs, Gower&#8217;s Chair ("GSGC") key secondary endpoint, which captures strength, coordination and mobility, compared to a worsening for alglucosidase alfa treated patients in the overall population (p&lt;0.05). Additionally, lower Manual Muscle Testing ("MMT"), Patient-Reported Outcomes Measurement Information System (&#8220;PROMIS&#8221;) physical function and PROMIS fatigue secondary endpoints favored AT-GAA treated patients over alglucosidase alfa treated patients. Results also showed improvements in the two important biomarker endpoints of Pompe disease (Hex-4 and CK), which significantly favored AT-GAA compared to alglucosidase alfa (p&lt;0.001). AT-GAA demonstrated a similar safety profile to alglucosidase alfa. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROPEL Switch patients entered the study having been treated with alglucosidase alfa for a minimum of two years. More than two thirds (67%+) of those patients had been on ERT treatment for more than five years prior to entering the PROPEL study (mean of 7.4 years). A pre-specified analysis of the patients switching from alglucosidase alfa on 6-minute walk distance showed that after 52 weeks from switching, AT-GAA treated patients (n=65) walked 16.9 meters farther than their baseline, compared to 0.0 meters for those patients who were randomized to remain on alglucosidase alfa (n=30) (p=0.046). A pre-specified analysis of the patients switching from alglucosidase alfa on percent-predicted FVC showed that AT-GAA treated patients stabilized and slightly improved their respiratory function on this important measure while those patients remaining on alglucosidase alfa continued to significantly decline in respiratory muscle function. AT-GAA patients showed a 0.1% absolute increase in percent-predicted FVC while the alglucosidase alfa patients showed a 4.0% absolute decline over the course of the year (p=0.006).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROPEL Na&#239;ve patients treated with AT-GAA for 52 weeks (n=20) walked 33 meters farther than their baseline, on the 6-minute walk distance endpoint. The Na&#239;ve patients treated with alglucosidase alfa (n=7) walked 38 meters further than their baseline. The difference between the two groups was not statistically significant (p=0.60). Additionally, patients never previously treated with any ERT showed similar declines in percent-predicted FVC at 52 weeks of &#8211;4.1% for AT-GAA treated patients and &#8211;3.6% for alglucosidase alpha treated patients. The difference between the two groups was not statistically significant (p=0.57). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 and February 2023, we reported positive long-term data from our ongoing phase 1/2 clinical study and Phase 3 open-label extension study, respectively. Phase 1/2 and 3 study participants treated with AT-GAA for up to 48 months and up to 2 years, respectively, demonstrated persistent and durable effects on six-minute walk test distance and measures of motor function and muscle strength, stability, or increase in forced vital capacity, and reductions in biomarkers of muscle damage and disease substrate.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022 the CHMP of the EMA adopted a positive opinion recommending marketing authorization of cipaglucosidase alfa or Pombiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Additionally, we initiated the regulatory submission process with the U.K. MHRA in December 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are conducting ongoing clinical studies in pediatric patients for both LOPD and infantile-onset Pompe disease ("IOPD") populations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next Generation for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to continued innovation for all people living with Pompe disease. As part of our long-term commitment, we are also continuing discovery for next-generation genetic medicines for Pompe disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pompe Disease Background</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pompe disease is a lysosomal disorder ("LD") that results from a deficiency in an enzyme, GAA. Signs and symptoms of Pompe disease can be severe and debilitating and include progressive muscle weakness throughout the body, particularly the heart and skeletal muscles. GAA deficiency causes accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Pompe disease ranges from a rapidly fatal infantile form with severe cardiac involvement to a more slowly progressive, late-onset form primarily affecting skeletal muscle. All forms are characterized by severe muscle weakness that worsens over time. In the early-onset form, patients are usually diagnosed shortly after birth and often experience enlargement of the heart and severe muscle weakness. In late-onset Pompe disease, symptoms may not appear until late childhood or adulthood and patients often experience progressive muscle weakness.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to reported estimates of the Acid Maltase Deficiency Association, the United Pompe Foundation, and the Lysosomal Disease Program at Massachusetts General Hospital, there are 5,000-10,000 patients with Pompe disease worldwide.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, two products, both ERTs, are approved for the treatment of Pompe disease: alglucosidase alfa and avalglucosidase alfa-ngpt by Sanofi Aventis.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Development and Next Generation Programs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are researching potential therapies for CDKL5 deficiency disorder ("CDD"). We are collaborating with the LouLou Foundation to assess the natural history of the disease to identify endpoints for potential use in future studies. We also have a number of additional gene therapies in clinical and preclinical development, including potential gene therapies in multiple forms of Batten disease. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Alliances and Arrangements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to evaluate business development opportunities as appropriate to build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market technologies or products with a focus on rare and orphan diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include business combinations, partnerships, the strategic out-licensing of certain assets, or the acquisition of preclinical-stage, clinical-stage, or marketed products or platform technologies consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Celenex,&#160;Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Celenex, Inc. ("Celenex"), we may be obligated to pay up to an additional $10 million in connection with the achievement of certain development milestones, $220 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#8217;s Hospital ("Nationwide Children&#8217;s"). Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MiaMed,&#160;Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of MiaMed,&#160;Inc., ("MiaMed"), we may be obligated to pay up to an additional $83&#160;million in connection with the achievement of certain clinical, regulatory, and commercial milestones, for a potential aggregate deal value of $89.5&#160;million. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Callidus Biopharma,&#160;Inc.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Callidus Biopharma, Inc. ("Callidus"), we may be obligated to make additional payments to the former stockholders of Callidus upon the achievement of certain clinical milestones of up to $35&#160;million and regulatory milestones of up to $80&#160;million set forth in the merger agreement, provided that the aggregate merger consideration shall not exceed $130&#160;million. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents and Trade Secrets</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to maintain proprietary protection surrounding our product candidates, technology, and know-how, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by filing U.S. and foreign patent applications related to our proprietary technology, including both new inventions and improvements of existing technology, that are important to the development of our business, unless this proprietary position would be better protected using trade secrets. Our patent strategy includes obtaining patent protection, where possible, on compositions of matter, methods of manufacture, methods of use, combination therapies, dosing and administration regimens, formulations, therapeutic monitoring, screening methods, and assays. We also rely on trade secrets, know-how, continuing technological innovation, in-licensing, and partnership opportunities to develop and maintain our proprietary position. Lastly, we monitor third parties for activities that may infringe our proprietary rights, as well as the progression of third-party patent applications that may have the potential to create blocks to our products or otherwise interfere with the development of our business. We are aware, for example, of U.S. patents, and corresponding international counterparts, owned by third parties that contain claims related to ERTs, and small molecules for stabilizing enzymes. If any of these patents were to be asserted against us, there is no assurance that a court would find in our favor or that, if we choose or are required to seek a license, a license to any of these patents would be available to us on acceptable terms or at all.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or hold license rights to several issued patents and numerous pending and issued applications, filed in the U.S., Europe, Japan, and other jurisdictions that are related to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our ongoing clinical programs:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We own issued U.S. patents that cover the use of migalastat, the active pharmaceutical ingredients in Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the treatment of Fabry disease, which expire between 2027 and 2039 and are listed in the FDA Orange Book. Foreign counterparts of the U.S. patents are pending or issued in Europe, Japan, and certain other jurisdictions. Further, we have pending U.S. patent applications covering various aspects of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including composition-of-matter methods of treating a patient diagnosed with Fabry disease with migalastat and their foreign counterparts. Any patents issuing from these applications will expire between 2036 and 2043. We anticipate listing these patents in the FDA Orange Book if issued.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We own several issued U.S. patents that cover various aspects of our investigational new treatment for Pompe disease, AT-GAA (ATB200/AT2221, an ERT/pharmacological chaperone combination) as well as foreign counterparts to the issued patents, some of which are still pending. Issued U.S. patents cover ATB200 compositions-of-matter, formulations, methods of manufacturing and methods of treatment and will expire between 2033 and 2037. We also have pending U.S. patent applications covering compositions, methods of treatment, methods of manufacture, and formulations with anticipated expiry between 2033 and 2043.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From the Celenex acquisition, we acquired an exclusive license to composition-of-matter and intrathecal method of treatment patent applications covering the gene therapy for treating Batten disease that are pending in the U.S., Europe, Japan, and other jurisdictions. Any patents issued from these applications will expire in 2033 or 2040. The patent covering an intrathecal method of treatment, which expires in 2033, has issued in Europe and Japan.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From our agreement with Penn, we have a license to Penn&#8217;s patent portfolio pertaining to vector and other platform technologies for treating Pompe disease and Fabry disease. Any patents issued from these applications will expire in 2039.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term extensions and adjustments, supplementary protection certificates, and pediatric exclusivity periods are not reflected in the expiration dates listed above and may extend protection. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical programs, we actively monitor and file patent applications in the U.S. and in foreign countries on relevant technologies and pre-clinical programs. For example, we own or hold license rights to U.S. and foreign patents or patent applications covering the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene therapy protein engineering technology;</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene therapy (e.g., Pompe, Fabry) and ERT (e.g., CDKL5) programs and the use to treat specified diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain, however, that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Individual patents extend for varying periods depending on the effective date of filing of the patent application or the date of patent issuance, and the legal term of the patents in the countries in which they are obtained. Generally, patents issued in the U.S. are effective for 20&#160;years from the earliest nonprovisional filing date. This period may be shortened by terminal disclaimer or further extended by patent term adjustment or extension. The term of foreign patents varies in accordance with provisions of applicable local law, but typically is 20&#160;years from the earliest nonprovisional filing date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Drug Price Competition and Patent Term Restoration Act of 1984, and amendments thereto, more commonly known as the Hatch-Waxman Act, provides for an extension of one patent, known as a Hatch-Waxman statutory extension, for each New Chemical Entity ("NCE") to compensate for a portion of the time spent in clinical development and regulatory review. However, the maximum extension is five years and the extension cannot extend the patent beyond 14&#160;years from the NDA approval. Similar extensions are available in European countries, known as Supplemental Protection Certificate ("SPC") extensions, Japan, and other countries. However, in the U.S. we will not know what, if any, extensions are available until a drug is approved. In addition, in the U.S., under provisions of the Best Pharmaceuticals for Children Act, we may be entitled to an additional six-month period of patent protection or market exclusivity for completing pediatric clinical studies in response to an FDA issued Pediatric Written Request before said exclusivities expire.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we received Paragraph IV Certification Notice Letters from Teva Pharmaceuticals USA, Inc. ("Teva"), Aurobindo Pharma Limited ("Aurobindo"), and Lupin Limited ("Lupin") in connection with Abbreviated New Drug Applications (&#8220;ANDA&#8221;) filed with the FDA requesting approval to market generic Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2022, we filed four lawsuits against Teva, Lupin, and Aurobindo in the U.S. District Court for the District of Delaware for infringement of our Orange Book-listed patents and will vigorously enforce our Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property rights.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies like ours are generally uncertain and involve complex legal, technical, scientific, and factual questions. Our ability to maintain and solidify our proprietary position for our technology will depend on our success in promptly filing patent applications on new discoveries, and in obtaining effective claims and enforcing those claims once granted. We focus special attention on filing patent applications for formulations and delivery regimens for our products in development to further enhance our patent exclusivity for those products. We seek to protect our proprietary technology and processes, in part, by contracting with our employees, collaborators, scientific advisors, and our commercial consultants to ensure that any inventions resulting from the relationship are disclosed promptly, maintained in confidence until a patent application is filed, and preferably until publication of the patent application, and assigned to us or subject to a right to obtain a license. We do not know whether any of our owned patent applications or those patent applications that are licensed to us will result in the issuance of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, invalidated, circumvented, or be found to be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products and reduce the term of patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the first to invent the inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar technologies or duplicate any technology developed by us and the rights granted under any issued patents may not provide us with any meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that any related patent may expire prior to or shortly after commencing commercialization, thereby reducing the advantage of the patent to our business and products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets are difficult to protect. We seek to protect our trade secret technology and processes, in part, by entering into confidentiality agreements with commercial partners, collaborators, employees, consultants, scientific advisors, and other contractors, and by contracting with our employees and some of our commercial consultants to ensure that any trade secrets resulting from such employment or consulting are owned by us. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be discovered independently by others. To the extent that our consultants, contractors, or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired rights to develop and commercialize our product candidates through licenses granted by various parties. The following summarizes our material rights and obligations under those licenses:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nationwide Children's Hospital</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we expanded our pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through our acquisition of Celenex. Celenex has an exclusive license agreement with Nationwide Children&#8217;s. Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as amended, we entered into a collaboration agreement with Penn to pursue research and development of novel gene therapies. Our gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease and other rare diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we entered into a mutual termination agreement (the "Termination Agreement") pursuant to which we and Penn mutually agreed to terminate the collaboration agreement, as amended. In connection with the Termination Agreement, we agreed to pay Penn an aggregate of $23.7&#160;million in connection with an unpaid portion of the discovery support payments, research program wind-down activities, and outstanding patent costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, we entered into a license agreement with Penn pursuant to which we obtained a license with respect to the pre-clinical research and development of next generation parvovirus gene therapy products for the treatment of Pompe disease and Fabry disease. Under the agreement, we will be responsible for clinical development and commercialization of the licensed products for the indications and Penn is eligible to receive certain milestone and royalty payments with respect to licensed products for each indication, up to an aggregate of $86.5 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, as amended in November 2013, we entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to rely on contract manufacturers to supply the active biopharmaceutical ingredients and finished goods for our products and product candidates. The active biopharmaceutical ingredients and final formulations for these products are manufactured under current Good Manufacturing Practice ("cGMP"). The components in the final formulation for each product are commonly used in other biopharmaceutical products and are well characterized ingredients. Although we rely on contract manufacturers, we have personnel with extensive manufacturing and quality experience to oversee our contract manufacturers. We have implemented appropriate controls for assuring the quality of both active biopharmaceutical ingredients and final drug products. Product specifications will be established in concurrence with regulatory bodies at the time of product registration. Our current arrangement with third-party manufacturers provide sufficient quantities of our program materials to meet anticipated clinical and commercial demands.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. In addition, several large pharmaceutical companies are increasingly focused on developing therapies for the treatment of rare diseases through organic growth, acquisitions, and partnerships. While we believe that our technologies, knowledge, experience, and scientific resources, provide us with competitive advantages, we face potential competition from many different sources, including commercial enterprises, academic institutions, government agencies, and private and public research institutions. Any product candidates that we successfully develop and commercialize will compete with both existing and new therapies that may become available in the future.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors may have significantly greater financial resources and expertise associated with research and development, regulatory approvals, and marketing approved products. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, and/or are less expensive than products that we may develop. In addition, our ability to compete may be affected because in some cases insurers or other third-party payors seek to encourage the use of generic products. This may have the effect of making branded products less attractive to buyers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Major Competitors</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for LDs. Other competitors are pharmaceutical and biotechnology companies that have approved therapies or therapies in development for rare diseases for which pharmacological chaperone technology, or next-generation ERT may be applicable. Additionally, we are aware of several early-stage, niche pharmaceutical, and biotechnology companies whose core business revolves around protein misfolding; however, we are not aware that any of these companies are currently working to develop products that would directly compete with ours. We are also aware of several pharmaceutical and biotechnology companies who are developing various treatments for novel ERTs and gene therapy. The key competitive factors affecting the success of our product candidates are likely to be their efficacy, safety, convenience, and price.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. The following table lists our principal competitors and publicly available information on the status of their clinical-stage product offerings:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.128%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.093%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Competitor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class of Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022 Sales</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sanofi Aventis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabrazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Myozyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/ Lumizyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nexviazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/ Nexviadyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr style="height:29pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Venglustat</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oral glucosylceramide synthase ("GCS") Inhibitor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Takeda </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Replagal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#165;62,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Idorsia </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lucerastat</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oral GCS Inhibitor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Protalix Biotherapeutics / Chiesi Farmaceutici S.p.A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PRX-102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Regulatory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Freeline</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLT-190</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sangamo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Isaralgagene civaparvovec</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4DMT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fabry Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4D-310</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Bayer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACTUS-101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Astellas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AT-845</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Roche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPK-3006</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gene Therapy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maze Therapeutics </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pompe Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GYS1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oral glycogen synthase ("GYS1") Inhibitor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phase 1/2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:2pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects commercial products and product candidates for which IND has been filed or are in clinical development.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects running 12 month revenue as of December 31, 2022, as Takeda's fiscal year ends on March 31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., biopharmaceutical products, including gene therapies, are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, Public Health Services Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biopharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to file&#160;a marketing application, to issue complete response letters or to not approve pending NDAs or BLAs, or to issue warning letters, untitled letters, Form 483s, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, litigation, government investigation, and criminal prosecution.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical product development in the U.S. typically involves nonclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug application ("IND"), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required varies substantially based upon the type, complexity, and novelty of the product or disease. Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics, potential safety, and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including GLP. The results of preclinical testing are submitted to the FDA as part of an IND along with other information including information about product chemistry, manufacturing and controls, and at least one proposed clinical trial protocol. Long-term preclinical safety evaluations, such as animal tests of reproductive toxicity and carcinogenicity, continue during the IND phase of development. Reproductive toxicity studies are required to allow inclusion of women of childbearing potential in clinical trials, whereas carcinogenicity studies are required for registration. The results of these long-term studies would eventually be described in product labeling.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 30-day review period after the submission and receipt of an IND is required prior to the commencement of clinical testing in humans. The IND becomes effective 30&#160;days after its receipt by the FDA, and trials may begin at that point unless the FDA notifies the sponsor that the investigations are subject to a clinical hold.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials usually involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with applicable government regulations, Good Clinical Practice ("GCP"), as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an Institutional Review Board ("IRB"), for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support an NDA or BLA for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&#160;1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on pharmacodynamics effects and effectiveness.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase&#160;2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication or indications, dosage tolerance, and optimum dosage, and identify common adverse effects and safety risks. If a compound demonstrates evidence of efficacy and an acceptable safety profile in Phase&#160;2 evaluations, Phase&#160;3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients over longer treatment periods, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has established the Office of Tissue and Advanced Therapies within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving gene therapies. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire. NIH and the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information on gene therapy trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these trials. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA or BLA is prepared and submitted to the FDA for the determination of efficacy and safety. FDA approval of the NDA or BLA is required before marketing of the product may begin in the U.S. The NDA or BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, the submission of most NDAs and BLAs is additionally subject to a substantial application user fee; although for orphan drugs these fees are waived, and the holder of an approved NDA or BLA may also be subject to annual product and establishment user fees. These fees are typically increased annually.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60&#160;days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs and BLAs. Marketing applications are assigned review status during the filing period. Review status could be either standard or priority. Most such applications for standard review are reviewed within 12&#160;months under PDUFA V (two months for filing plus ten months for review). The FDA attempts to review a drug candidate that is eligible for priority review within six months, as discussed below. The review process may be extended by the FDA for three additional months to evaluate major amendments submitted during the pre-specified PDUFA V review clock. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for public review, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA may also undertake an audit of nonclinical and clinical trial sites. The FDA will not approve the product candidate unless compliance with cGMP is satisfactory and the NDA or BLA contains data that provide substantial evidence that the drug is safe and effective in the indication studied and to be marketed. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product candidate. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA or BLA and the manufacturing facilities, it issues an approval letter or a complete response letter. Complete response letters outline the deficiencies in the submission that prevent approval and may require substantial additional testing or information for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in an amendment submitted to the NDA or BLA, the FDA will then issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type and extent of information included.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA or BLA approval, the FDA may require substantial post-approval commitments or requirements to conduct additional testing and/or surveillance to monitor the drug's safety or efficacy and may impose other conditions, including distribution and labeling restrictions which can materially affect the potential market and profitability of the drug. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, problems are identified following initial marketing, or post-marketing commitments are not met.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, applicants are required to list with the FDA certain patent(s) with claims that cover the applicant's product or approved method of use. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA. An ANDA provides for marketing of a drug product that has the same route of administration, active ingredients strength, and dosage form as the listed drug and has been shown through bioequivalence testing to be, in most cases, therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of preclinical or clinical tests to prove the safety or effectiveness of their drug product, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as "generic equivalents" to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed "innovator" drug.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA's Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. A certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid is called a Paragraph&#160;4 certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA applicant submits a Paragraph&#160;4 certification to the FDA, the applicant must also send notice of the Paragraph&#160;4 certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;4 certification. The filing of a patent infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;4 certification automatically prevents the FDA from approving the ANDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent term and data exclusivity run in parallel. An ANDA application also will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired ("New Chemical Entity Market Exclusivity"). Federal law provides a period of five years following approval of a drug containing no previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted unless the submission contains a Paragraph&#160;4 certification that challenges a listed patent, in which case the submission may be made four years following the original product approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law provides for a period of three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted by or for the sponsor, during which the FDA cannot grant effective approval of an ANDA based on that listed drug for the same new dosage form, route of administration or combination, or new use.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, communications regarding unindicated uses, industry-sponsored scientific and educational activities, and promotional activities involving the internet. Products approved under Subpart H or Subpart E carry additional post-marketing considerations and requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs may be promoted only for approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, new safety information, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA, NDA supplement, BLA, or BLA supplement before the change can be implemented. New efficacy claims require submission and approval of an NDA supplement and BLA supplement for each new indication.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The efficacy claims typically require new clinical data similar to those included in the original application. The FDA uses the same procedures and actions in reviewing NDA and BLA supplements as it does in reviewing NDAs and BLAs. Additional exclusivity may be granted for new efficacy claims. Generic ANDAs cannot be labeled for these types of claims until the new exclusivity period expires.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA or BLA. The FDA also may require post-marketing testing, known as Phase&#160;4 testing, risk evaluation and mitigation strategies, and surveillance to monitor the effects of an approved product, or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures must continue to conform to cGMP, after approval. Drug manufacturers and certain subcontractors are required to register their establishments with FDA and certain state agencies and are subject to routine inspections by the FDA during which the agency inspects manufacturing facilities to access compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drugs</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. The first NDA or BLA applicant with FDA orphan drug designation for a particular active ingredient to receive FDA approval of the designated drug for the disease indication for which it has such designation, is entitled to a seven-year exclusive marketing period ("Orphan Drug Exclusivity") in the U.S. for that product, for that indication. During the seven-year period, the FDA may not finally approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the license holder cannot supply sufficient quantities of the product. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition, provided that the sponsor has conducted appropriate clinical trials required for approval. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application user fee for the orphan indication.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2007 ("PREA"), NDAs or supplements to NDAs and BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track Designation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Fast Track program, the sponsor of an IND may request the FDA to designate the drug candidate as a Fast Track drug if it is intended to treat a serious condition and fulfill an unmet medical need. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60&#160;days of receipt of the sponsor's request. Once the FDA designates a drug as a Fast Track candidate, it is required to facilitate the development and expedite the review of that drug by providing more frequent communication with and guidance to the sponsor.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other benefits such as greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug's NDA or BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA's review period as specified under PDUFA V for filing and reviewing an application does not begin until the last section of the NDA or BLA has been submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy Designation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A Breakthrough Therapy designation conveys all of the Fast Track program features, as well as more intensive FDA guidance on an efficient drug development program. The FDA also has an organizational commitment to involve senior management in such guidance.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Priority Review</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under FDA policies, a drug candidate is eligible for priority review, or review within six months from filing for a new molecular entity ("NME") or six months from submission for a non-NME if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis, or prevention of a disease, rather than the standard review of ten months under current PDUFA guidelines. A Fast Track designated drug candidate would ordinarily meet the FDA's criteria for priority review. The FDA makes its determination of priority or standard review during the 60-day filing period after an initial NDA or BLA submission.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDA's accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit. This approval mechanism is provided for under 21CRF314 Subpart&#160;H and Subpart&#160;E. In this case, clinical trials are conducted in which a surrogate endpoint is used as the primary outcome for approval. A surrogate endpoint is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. This surrogate endpoint substitutes for a direct measurement of how a patient feels, functions, or survives and is considered reasonably likely to predict clinical benefit. Such surrogate endpoints may be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. When the Phase&#160;4 commitment is successfully completed, the biomarker is deemed to be a surrogate endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, could lead the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;505(b) (2)&#160;New Drug Applications</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most drug products obtain FDA marketing approval pursuant to an NDA, an ANDA, or a BLA. A fourth alternative is a special type of NDA, commonly referred to as a Section&#160;505(b) (2)&#160;NDA, which enables the applicant to rely, in part, on the safety and efficacy data of an existing product, or published literature, in support of its application.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505(b) (2)&#160;NDAs often provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products. Section&#160;505(b)(2) permits the submission of an NDA for which at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon certain preclinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section&#160;505(b) (2)&#160;applicant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the Section&#160;505(b) (2)&#160;applicant is relying on studies conducted for an already-approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent as an ANDA applicant. Thus approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of an NCE, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph&#160;4 certification and subsequent patent infringement suit, until the earlier of 30&#160;months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section&#160;505(b)(2) applicant.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics Price Competition and Innovation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Act </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which was enacted as part of the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 ("PPACA") created an abbreviated approval pathway for biological products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-licensed reference biological product via an approved BLA. Biosimilarity to an approved reference product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity is demonstrated in steps beginning with rigorous analytical studies or "fingerprinting", in vitro studies, in vivo animal studies, and generally at least one clinical study, absent a waiver from the Secretary of Health and Human Services. The biosimilarity exercise tests the hypothesis that the investigational product and the reference product are the same. If at any point in the stepwise biosimilarity process a significant difference is observed, then the products are not biosimilar, and the development of a stand-alone NDA or BLA is necessary. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. Under the BPCIA, a reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback, False Claims Laws,&#160;the Prescription Drug Marketing Act and Other Regulations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil False Claims Act, and laws and regulations pertaining to limitations on and reporting of healthcare provider payments (physician sunshine laws). These laws and regulations are interpreted and enforced by various federal, state and local authorities including CMS, the Office of Inspector General for the U.S. Department of Health and Human Services, the U.S. Department of Justice, individual U.S. Attorney offices within the Department of Justice, and state and local governments. These laws include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. civil False Claims Act (which can be enforced through &#8220;qui tam,&#8221; or whistleblower actions, by private citizens on behalf of the federal government), prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, implemented as the Open Payments program, and its implementing regulations, requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; beginning in 2022, applicable manufacturers are required to report such information regarding payments and transfers of value provided, as well as ownership and investment interests held, during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of any of these laws or any other governmental regulations that may apply to us, may subject us to significant civil, criminal and administrative sanctions including penalties, damages, fines, imprisonment, and exclusion from government funded healthcare programs, such as Medicare and Medicaid, and/or adverse publicity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, government entities and private litigants have asserted claims under state consumer protection statutes against pharmaceutical and medical device companies for alleged false or misleading statements in connection with the marketing, promotion and/or sale of pharmaceuticals.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Drug Samples</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (the "PDMA") imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling, and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside the U.S.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of our products. Most countries outside the U.S. require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the U.S. before we can commence clinical studies or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval of an orphan drug under the E.U. regulatory system, we are mandated to submit a MAA to be assessed in the centralized procedure. The centralized procedure, which came into operation in 1995, allows applicants to obtain a marketing authorization that is valid throughout the E.U. It is compulsory for medicinal products manufactured using biotechnological processes, for orphan medicinal products and for human products containing a new active substance which was not authorized in the community before 20&#160;May 2004 (date of entry into force of Regulation (EC) No 726/2004) and which are intended for the treatment of AIDS, cancer, neurodegenerative disorder or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the community before 20&#160;May 2004 or for products which constitute a significant therapeutic, scientific or technical innovation or for which a community authorization is in the interests of patients at community level. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the EMA, to be assessed by the CHMP. The procedure results in a commission decision, which is valid in all E.U. member states. Centrally-authorized products may be marketed in all member states. Under the centralized procedure, full copies of the MAA are sent to a rapporteur and a co-rapporteur designated by the competent EMA scientific committee. They coordinate the EMA's scientific assessment of the medicinal product and prepare draft reports. Once the draft reports are prepared (other experts might be called upon for this purpose), they are sent to the CHMP, whose comments or objections are communicated to the applicant. The rapporteur is therefore the privileged interlocutor of the applicant and continues to play this role, even after the MAA has been granted approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapporteur and co-rapporteur then assess the applicant's replies, submit them for discussion to the CHMP and, taking into account the conclusions of this debate, prepare a final assessment report. Once the evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the authorization. When the opinion is favorable, it shall include the draft summary of the product's characteristics, the package leaflet and the texts proposed for the various packaging materials. The time limit for the evaluation procedure is 210&#160;days. The EMA then has fifteen days to forward its opinion to the commission. This is the start of the second phase of the procedure: the decision-making process. The Agency sends to the commission its opinion and assessment report, together with annexes containing: the SmPC ("Annex&#160;1"); the particulars of the MAH responsible for batch release, the particulars of the manufacturer of the active substance and the conditions of the marketing authorization ("Annex&#160;2"); and the labelling and the package leaflet ("Annex&#160;3"). The annexes are translated into the 22 other official languages of the E.U. During the decision-making process, the commission services verify that the marketing authorization complies with Union law. The commission has fifteen days to prepare a draft decision. The medicinal product is assigned a community registration number, which will be placed on its packaging if the marketing authorization is granted. During this period, various commission directorates-general are consulted on the draft marketing authorization decision.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The draft decision is then sent to the Standing Committee on Medicinal Products for Human Use, (member states have one representative each in both of these committees) for their opinions. The centralized procedure provides for the grant of a single marketing authorization that is valid for all E.U. member states. The "decentralized procedure" provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member state, known as the reference member state. Under this procedure, an applicant submits an application, or dossier, and related materials including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120&#160;days after receipt of a valid application. Within 90&#160;days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials. If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to the public health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all member states.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained an orphan medicinal product designation in the E.U. from the EMA for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease and the combination product, ATB200/AT2221, for the treatment of Pompe disease. Applications from persons or companies seeking "orphan medicinal product designation" for products they intend to develop for the diagnosis, prevention, or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 persons in the E.U. are reviewed by the Committee for Orphan Medicinal Products ("COMP"). In addition, orphan drug designation can be granted if the drug is intended for a life threatening, seriously debilitating, or serious and chronic condition in the E.U. and that without incentives it is unlikely that sales of the drug in the E.U. would be sufficient to justify developing the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the E.U. of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation provides opportunities for fee reductions, protocol assistance and access to the centralized procedure before and during the first year after marketing approval. Fee reductions are not limited to the first year after marketing approval for small and medium enterprises. In addition, if a product which has an orphan drug designation subsequently receives EMA marketing approval for the indication for which it has such designation, the product is entitled to orphan market exclusivity, which means the EMA may not approve any other application to market a similar drug for the same indication for a period of 10&#160;years. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Competitors may receive marketing approval of different drugs or biologics for the indications for which the orphan product has exclusivity. In order to do so, however, they must demonstrate that the new drugs or biologics are clinically superior over the existing orphan product. This demonstration of clinical superiority may be done at the time of initial approval or in post-approval studies, depending on the type of marketing authorization granted.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative, the Priority Medicines (&#8220;PRIME&#8221;) scheme, to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s committee level. An initial meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, AT-GTX-501 was granted PRIME designation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained a positive opinion for our pediatric investigation plan ("PIP") in the E.U. for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease as well. A PIP is a development plan aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for marketing authorization for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a marketing-authorization holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the development of pediatric medicines for children are available in the E.U. Medicines authorized across the E.U. with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate by six months. This is the case even when the studies' results are negative. For orphan medicines, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the agency are free of charge for questions relating to the development of pediatric medicines. Medicines developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate are eligible for a pediatric-use marketing authorization ("PUMA"). If a PUMA is granted, the product will benefit from 10&#160;years of market protection as an incentive.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2021, following the U.K. exit of the E.U., the MHRA is the U.K.&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules apply in Northern Ireland than in England, Wales and Scotland (together Great Britain, "GB"); broadly, Northern Ireland continues to follow the E.U. regulatory regime, but its national competent authority remains the MHRA. The MHRA has published a draft guidance outlining the various aspects of the U.K. regulatory regime for medicines in GB and in Northern Ireland. The guidance includes clinical trials, marketing authorizations, importing, exporting and pharmacovigilance and is relevant to any business involved in the research, development or commercialization of medicines in the U.K. The new guidance has been given effect via the Human Medicines Regulations ("Amendment etc.") ("E.U. Exit") Regulations 2019 (the "Exit Regulations"). The U.K. regulatory regime largely mirrors that of the E.U. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, an accelerated assessment procedure and new routes of evaluation for novel products and biotechnological products. All existing E.U. marketing authorizations ("MAs") for centrally authorized products were automatically converted ("grand fathered") into U.K. MAs free-of-charge on January 1, 2021. Amicus has completed the necessary baseline submission for conversion and was granted Marketing Authorization on August 4, 2021 with an effective date of January 1, 2021. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pre-marketing authorization orphan designation. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the GB market, e.g. the prevalence of the condition in GB (rather than the E.U.) must not be more than 5 in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in GB or E.U./European Economic Area, wherever is earliest.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PIP application process for applicants is simplified by offering an expedited assessment where possible, and by mirroring the submission format, content and terminology of the E.U.-PIP system. The MHRA is taking decisions on PIP and waiver opinions, modifications and compliance statements to support pediatric market authorization decisions, while acknowledging that Northern Ireland continues to be part of the E.U.&#8217;s system for pediatric medicines development including agreement of E.U. PIPs or waivers.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHRA has maintained the EAMS. EAMS is designed to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorization when there is a clear unmet medical need. Medicines with a positive EAMS opinion could be made available to patients 12-18 months ahead of formal marketing authorization. As the initial step in this process, the applicant must apply for and be granted a Promising Innovative Medicine (&#8220;PIM&#8221;) designation. The designation is issued after an MHRA scientific designation meeting on the basis of non-clinical and clinical data available on the product, in a defined disease area. Following designation, the applicant is expected to complete a clinical development program within a reasonable time period, in order to continue with an application under the EAMS. In January 2020, the MHRA issued a PIM designation for AT-GAA for the treatment of late-onset Pompe disease and subsequently granted a positive opinion under  EAMS in June 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained orphan drug designation in Japan for migalastat for the treatment of Fabry Disease. We also have other Orphan Drug applications approved in other world markets including Switzerland, Australia, South Korea and Taiwan. The Ministry of Health, Labor, and Welfare, based on the opinion of the Pharmaceutical Affairs and Food Sanitation Council, grants orphan status to drugs intended to address serious illnesses with high unmet medical need that affect fewer than 50,000 patients in Japan. In 2020, orphan drug designation was granted in Japan for AT-GAA for the treatment of Pompe disease. Orphan designation provides certain benefits and incentives, including priority review for marketing authorization and a period of 10&#160;years of market exclusivity if the drug candidate is approved for the designated indication.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Foreign Corrupt Practices Act</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or the FCPA, generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our industry is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Enforcement actions may be brought by the Department of Justice or the Securities and Exchanges Commission (&#8220;SEC&#8221;), and recent enacted legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims such as those under the FCPA from five years to ten years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> United States Healthcare Reform</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the Affordable Care Act, was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the Affordable Care Act that have been implemented since enactment and are of importance to the commercialization of our product and product candidates, if approved, are the following: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an annual, nondeductible fee on any entity that manufactures, or imports specified branded prescription drugs or biologic agents; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of healthcare fraud and abuse laws, including the U.S. civil False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of eligibility criteria for Medicaid programs; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">requirements to report certain financial arrangements with physicians and teaching hospitals; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been significant ongoing judicial, administrative, executive and legislative efforts to modify or eliminate the Affordable Care Act. For example, the Tax Act enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code, commonly referred to as the individual mandate. Other legislative changes have been proposed and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, which was designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 to March 31, 2022. As of July 2, 2022, the 2% sequester reduction resumed. The sequester will remain in place through 2030. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act has also been subject to challenges in the courts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An appeal was taken to the U.S. Supreme Court. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect that the Affordable Care Act, as well as other healthcare reform measures that have and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our product and product candidates, if approved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payers. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 (the "IRA") contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated "maximum fair price" for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the IRA. The IRA could have the effect of reducing the prices we can charge and reimbursement we receive for our products, if approved, thereby reducing our profitability, and could have a material adverse effect on our financial condition, results of operations, and growth prospects. The effects of the IRA on our business and the pharmaceutical industry in general is not yet known.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Amicus, one of our founding principles is that we believe in each other to foster teamwork and respect for each individuals' contribution. Our passion for making a difference unites us. Supporting our globally diverse employees is an essential part of the core values and culture at Amicus. Tied to these values and culture, we believe our success and our ability to help patients depends on our capability to attract, develop and retain key personnel. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the advancement of Diversity, Equity and Inclusion (&#8220;DEI&#8221;) in the workplace. DEI creates a work environment where every voice is heard and valued, resulting in a dimensional way of thinking that is used when meeting company goals. This ensures that every employee feels they are treated fairly regardless of identities and differences, which is evidenced through our most recent engagement survey where we came within 2% of the global benchmark for DEI. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 484 full-time employees. As of December 31, 2022, 57% of our global workforce, 45% of our executive management team and 30% of our board of directors were women. In addition, we have made a strong commitment to overall diversity, as 97% of all hiring slates included diverse candidates, where diversity is defined as maintaining/increasing gender diversity and increasing representation of minority race, veteran, disabled, and LGBTQ employees. We also saw the impact of this diversity in hiring and promoting, where 61% of all those hired or promoted to Director and above roles were diverse and 83% of all those hired or promoted to Associate Director and below roles were diverse.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Mission to &#8216;Always Put Patients First&#8217; helps keep our employees engaged with this sense of purpose. We support engagement through communicating frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, round tables, employee pulse surveys, company intranet, and we acknowledge individual contributions through a number of reward and recognition programs. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in a strong compliance culture and provide robust trainings to employees on our code of conduct and the various policies contained therein. As part of our commitment to our employees, these trainings cover our zero-tolerance policy towards the use of child labor, forced labor, or other forms of modern slavery, educating our workforce on discrimination and harassment, and periodically refreshing the organization&#8217;s understanding of our global anti-bribery and corruption policy.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support and develop our employees through global development programs that build and strengthen employees&#8217; leadership skills through global leadership development programs, targeted development for high-potential talent, development plans and career paths, tuition reimbursement, and the ability to attend industry conferences and trainings, and patient-mission focused Lunch and Learns. Additionally, we strive to attract and retain the most talented employees in the industry and across the globe by offering competitive compensation and benefits that support their health, financial and emotional well-being. Our compensation philosophy is based on rewarding each employee&#8217;s individual contributions and striving to achieve equal pay for equal work regardless of gender, race or ethnicity.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware on February&#160;4, 2002. The address of our global headquarters is 3675 Market Street, Philadelphia, PA 19104 and our telephone number is 215-921-7600. Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.amicusrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We make available free of charge on our website our annual, quarterly, and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the U.S. Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our corporate governance, including our Code of Business Conduct for Employees, Executive Officers and Directors (the "Code of Conduct"), Corporate Governance Guidelines, and information concerning our senior management team, Board of Directors, including Board Committees and Committee charters, and transactions in our securities by directors and executive officers, is available free of charge on our website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.amicusrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the "Investors&#160;&#8212; Corporate Governance" caption and in print to any stockholder upon written request to our Chief Legal Officer at the address set forth on the cover of this Annual Report. Any waivers or material amendments to the Code will be posted promptly on our website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  &#160;RISK FACTORS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider these risk factors, together with all of the other information included in this Annual Report on Form 10-K, including our Consolidated Financial Statements and the related notes thereto, before you decide whether to make an investment in our securities. The risks set forth below are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, prospects, financial condition, cash flows, liquidity, funds from operations, results of operations, stock price and ability to service our indebtedness. In such case, the value of our common stock and the trading price of our securities could decline, and you may lose all or a significant part of your investment. Some statements in the following risk factors constitute forward looking statements. Please refer to the explanation of the qualifications and limitations on forward-looking statements under &#8220;Forward-Looking Statements&#8221; of this Form 10-K.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Ability to Generate and Sustain Revenue</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on sales of our first product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, in Europe, the U.S., Japan, and other geographies. Moreover, if we are unable to commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> successfully, or experience significant delays in doing so, our business could be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the development of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease and rely upon sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily in Europe and growing sales in the U.S., Japan, and other geographies. Our ability to generate material product revenues will depend heavily on the successful development, regulatory approval, and commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will continue to study Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Phase 4 studies. If the results of the Phase 4 studies negatively change the benefit/risk profile of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the commercial success of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may be substantially diminished. Any adverse market event with respect to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including failure to obtain sufficient market acceptance, could have a material adverse effect on our business, financial condition and results of operations. If our sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were to decrease, or such sales were substantially or completely displaced in the market, or if we are unable to achieve sufficient market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by physicians, patients, third-party payors and others in the medical community, or if we fail to receive commercial approval in any additional jurisdictions, it could have a material adverse effect on our business, financial condition and results of operations. In addition, if Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or similar products from our competitors were to become the subject of litigation and/or an adverse governmental action requiring us or such competitors, as applicable, to cease sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such an event could have a material adverse effect on our business, financial condition and results of operations. In addition, the entry into the market of competitors with new or generic treatments, including oral, ERT and gene therapies, may erode the market for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have a material impact on our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or impediment in our ability to obtain regulatory approval in any region to commercialize, or, when approved, obtain coverage and adequate reimbursement from third parties, including government payors, for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may cause us to be unable to meet our revenue guidance or to generate the revenues necessary to continue our research and development pipeline activities, thereby adversely affecting our business and our prospects for future growth.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the success of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will depend on a number of factors, including the following:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining a sufficiently broad label in each territory that would not unduly restrict patient access;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining additional foreign approvals for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continuing to build and maintain an infrastructure capable of supporting product sales, marketing, and distribution of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., Europe, Japan and other territories where we pursue commercialization directly;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining commercial manufacturing arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">maintaining commercial distribution agreements with third-party distributors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">launching commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where approved, whether alone or in collaboration with others;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, where approved, by patients, the medical community and third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">effectively competing with other therapies, including potential generics and gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully identifying new patients who could benefit from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a continued acceptable safety profile of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">protecting and enforcing our rights in our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtaining and maintaining a commercially viable price for our product and product candidates, if approved; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continuing to successfully mitigate the impact of the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which would materially harm our business and ability to meet our financial goals.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product or product candidates and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product and product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, commercialization and reimbursement are subject to comprehensive regulation by the European Medicines Agency (&#8220;EMA&#8221;), the Pharmaceutical and Medical Devices Agency (&#8220;PMDA&#8221;), the Food and Drug Administration (&#8220;FDA&#8221;), and other regulatory agencies in the U.S. and by comparable authorities in other countries. Failure to obtain regulatory approval for our product and product candidates will prevent us from commercializing our product in jurisdictions beyond those in which we have obtained regulatory approval for our product or in any jurisdictions for our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval for all our product candidates, including AT-GAA, requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. We will continue to rely on third parties to assist us with filing and supporting the applications necessary to obtain marketing approvals for product candidates in this process. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Regulatory authorities may determine that any of our products or product candidates are not effective or only moderately effective, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining approval for all of our product candidates, including AT-GAA, is highly uncertain and we may fail to obtain regulatory approval in any or all jurisdictions. The review processes and the processes of regulatory authorities, including the FDA, EMA and PMDA, are extensive, lengthy, expensive, and uncertain, and such regulatory authorities may delay, limit, or deny the approval of any of our product candidates for many reasons, including, but not limited to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our failure to demonstrate to the satisfaction of the applicable regulatory authorities that any of our product candidates, including AT-GAA are safe and effective for a particular indication;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the results of clinical trials may not meet the level of statistical significance or other efficacy or safety parameters required by the applicable regulatory authorities for approval;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may disagree with the number, design, size, conduct, or implementation of our clinical trials or conclude that the data fail to meet statistical or clinical significance;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the product candidate's clinical and other benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may disagree with our interpretation of data from preclinical studies or clinical trials, and may reject conclusions from preclinical studies or clinical trials, or determine that primary or secondary endpoints from clinical trials were not met, or reject safety conclusions from such studies or trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may not accept data generated at one or more of our clinical trial sites;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may determine that we did not properly oversee our clinical trials or follow the regulatory authority's advice or recommendations in designing and conducting our clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an advisory committee, if convened by the applicable regulatory authority, may recommend against approval of our application or may recommend that the applicable regulatory authority require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the respective regulatory authority may still not approve the product candidate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may only approve a limited label for less than the full indicated population, as a second line or rescue therapy, or impose other label restrictions; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the applicable regulatory authority may identify deficiencies in the chemistry, manufacturing, and control sections of our application, our manufacturing processes, facilities, or analytical methods or those of our third-party contract manufacturers or be unable to complete any necessary manufacturing inspections of our third party manufacturers which may lead to significant delays in the approval of our product candidates or to the rejection of our applications altogether.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to market and sell our product or product candidates, we may not be successful in commercializing Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, or any product candidate, including AT-GAA, if and when they are approved.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve commercial success for any approved product, we must continue to develop and maintain a sales and marketing organization or outsource commercialization to third parties. We have established our own sales and marketing capabilities to promote Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe, Japan, the U.S. and other foreign jurisdictions with a targeted sales force and anticipate using these capabilities to support other product candidates, including AT-GAA, when approved. We have also entered into distribution agreements with third parties to market our products in jurisdictions in which we do not have our own sales and marketing capabilities. There are risks involved with establishing and maintaining our own sales and marketing capabilities and entering into arrangements with third parties to perform these services for our product or any of our product candidates, if approved. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate, if approved, for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. Similarly, if we enter into agreements with third parties, including the out licensing of our product or product candidates, we may choose to reduce or eliminate our sales and marketing operations and thereby lose our commercialization investment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or our product candidates, including AT-GAA, if and when they are approved by regulatory authorities, including the FDA, PMDA and EMA, on our own include:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability of sales personnel to obtain access to adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">misconduct by independent sales and marketing organizations that expose us to fines, penalties and other restrictions on our ability to effectively market and sell our products; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts by our competitors to commercialize products at or about the time when our product candidates would be coming to market.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also co-promote or out license our product or product candidates in various markets with pharmaceutical and biotechnology companies in instances where we believe that a larger sales and marketing presence will expand the market or accelerate penetration. If we do enter into co-promote or out licensing arrangements with third parties, our product revenues will be lower than if we directly sold and marketed our products and any revenues received under such arrangements will depend on the skills and efforts of others.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in entering into distribution arrangements and marketing alliances with third parties. Our failure to enter into these arrangements on favorable terms could delay or impair our ability to commercialize our product and product candidates, if approved, and could increase our costs of commercialization. Dependence on distribution arrangements and marketing alliances to commercialize our products and product candidates will subject us to a number of risks, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may not be able to control the amount and timing of resources that our distributors may devote to the commercialization of our product or product candidates, if approved;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may experience financial difficulties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may experience compliance related issues and associated government investigations;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may require transfer of the marketing authorization for our product and product candidates, if approved, and may refuse to relinquish them at the end of the distribution relationship;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our distributors may be out of compliance with applicable anti-bribery and corruption laws with an adverse effect on operations and expose us to liability;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business combinations or significant changes in a distributor's business strategy may also adversely affect a distributor's willingness or ability to complete its obligations under any arrangement; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">these arrangements are often terminated or allowed to expire, which could interrupt the marketing and sales of a product and decrease our revenue.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue at our current guidance and may not ever become profitable.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market opportunities for our product or product candidates are smaller than we believe they are, then our revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the diseases that our product and most advanced product candidates are being developed to address is rare. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product and product candidates, are based on estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, most reported estimates of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which are then extrapolated to estimate the prevalence of the diseases in the broader world population. In addition, as new studies are performed the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Fabry disease, Pompe disease, or other rare diseases in the study populations, particularly in these newer studies, accurately reflects the prevalence of these diseases in the broader world population. If our estimates of the prevalence of Fabry disease, Pompe disease, or other rare diseases or of the number of patients who may benefit from treatment with our product or product candidates prove to be incorrect, the market opportunities for our product and product candidates, if approved, may be smaller than we believe they are, our prospects for generating revenue at our guidance levels may be adversely affected and our business may suffer.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any of our product candidates that receive regulatory approval may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any of our other products or product candidates that receive regulatory approval may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the efficacy and potential advantages compared to competitive or alternative treatments, including generics and gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to offer our product and product candidates, if approved, for sale at competitive prices;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">publicity concerning our products or competing products and treatments;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition from other products for the same or similar indications; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sufficient third-party coverage or reimbursement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to negotiate, secure and maintain third-party coverage and reimbursement may be affected by political, economic and regulatory developments in the U.S., E.U., U.K. and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any of our product candidates that receive marketing approval and we may fail to meet our revenue targets.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and product candidates, including AT-GAA, and any products we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology and gene therapy companies worldwide. For example, several large pharmaceutical and biotechnology companies currently market and sell products for the treatment of lysosomal storage disorders, including Fabry disease. These products include Sanofi Aventis' Fabrazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Takeda&#8217;s Replagal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as well as other Fabry treatment products in development. In addition, Sanofi markets and sells Myozyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumizyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nexviazyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Nexviadyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Pompe disease. We are also aware of other enzyme replacement and substrate reduction therapies in development by third parties for Fabry and Pompe, as well as potential gene therapies for both Fabry and Pompe and our other product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or noncompetitive. Our competitors may also obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours, could achieve regulatory exclusivity and block us from approval and marketing our products for a significant period of time. We may also face competition from off-label use of other approved therapies. There can be no assurance that developments by others will not render our product candidates or any acquired products obsolete or noncompetitive either during the research phase or once the products reach commercialization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, prosecuting intellectual property rights and marketing approved products than we do. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to or necessary for our programs or advantageous to our business. In addition, if we obtain regulatory approvals for our product candidates, manufacturing efficiency and marketing capabilities are likely to be significant competitive factors. We currently rely on third-party manufacturers for our product and all of our product candidates. Further, many of our competitors have substantial resources and expertise in conducting collaborative arrangements, sourcing in-licensing arrangements, manufacturing and acquiring new business lines or businesses that are greater than our own.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and any of our other product candidates, including AT-GAA, that may be approved in the future for commercialization in the E.U., U.K. or in other foreign countries are or will be subject to additional risks related to international operations or entering into international business relationships, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different regulatory requirements for maintaining approval of drugs in foreign countries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced protection for contractual and intellectual property rights in some countries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unexpected changes in taxes, tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic weakness, including rising interest rates, inflation and political instability in particular foreign economies and markets;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability, and our commercialization partners ability, to comply with local laws, rules and regulations, including those relating to modern slavery;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anti-corruption laws in other jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">tighter restrictions on privacy and the collection and use of patient data; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business interruptions resulting from geopolitical actions (including war and terrorism), pandemic diseases (such as COVID-19), or natural disasters (including earthquakes, typhoons, floods and fires).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are complex regulatory, tax, labor and other legal requirements imposed by the E.U., U.K., and many of the individual countries in Europe, Asia and Latin America with which we will need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe and other international geographies to be very challenging.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following the receipt of marketing approval of our product or any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations and practices that govern marketing approvals, pricing, commercialization, coverage and reimbursement for new drug products vary widely from country to country and product to product. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries, including almost all of the member states of the European Economic Area, require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, including the European market, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted and approved products are subject to re-reviews, class reviews and other governmental controls which can negatively impact pricing originally approved. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact any revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. This is particularly true in the case of gene therapies for which payors and manufacturers must develop different pricing models for this growing area. Current pricing for gene therapies may not be sustainable in the future which would have a negative impact on our revenues and business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any product candidate, including AT-GAA, if approved, successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the European and U.S. healthcare industries and elsewhere is cost containment. It is currently unknown what impact, if any proposed changes by the federal and state governments in the U.S. and similar changes in foreign countries may have on pricing and reimbursement, particularly with respect to government programs such as Medicare and Medicaid and Pharmacy Benefit Managers for commercial plans, and including reimportation, reference pricing and limitations on manufacturer price increases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices at which we or our customers seek reimbursement for our products can be subject to challenge, reduction or denial by the government and other payers. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for pharmaceutical products. We cannot be sure that coverage and reimbursement will continue to be available for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any product candidate such as AT-GAA, if approved, that we commercialize, and in particular gene therapies, and, if coverage and reimbursement are available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any product candidate for which we obtain marketing approval. Obtaining reimbursement for our product candidates when approved may be particularly difficult because of the higher prices typically associated with drugs directed at smaller orphan populations of patients and the pricing and reimbursement of competitive products. In addition, third-party payors are likely to impose strict requirements for reimbursement of a higher priced drug. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product for which we obtain marketing approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. The Affordable Care Act was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been significant ongoing judicial, administrative, executive and legislative efforts to modify or eliminate the Affordable Care Act. For example, the Tax Cuts and Jobs Act enacted on December 22, 2017, repealed the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code (the &#8220;Code&#8221;), commonly referred to as the individual mandate. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions included aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. Subsequent litigation extended the 2% reduction, on average, to 2030 unless additional Congressional action is taken. In 2020 and 2021, during the COVID-19 pandemic, Congress passed several laws including the Coronavirus Aid, Relief, and Economic Security Act and Consolidated Appropriations Act of 2021, that temporarily suspended the 2% sequestration. At the end of 2021, Congress passed the Protecting Medicare and American Farmers from Sequester Cuts Act, which extended the suspension on the 2% sequestration through March 31, 2022, and adjusted the sequester to 1% for the period between April 1, 2022 and June 30, 2022. On January 2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act has also been subject to challenges in the courts. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the "individual mandate" was repealed by Congress. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional and remanded the case to the Texas District Court to reconsider its earlier invalidation of the entire Affordable Care Act. On June 17, 2021, the Supreme Court ruled that the plaintiffs lacked standing to challenge the law as they had not alleged personal injury traceable to the allegedly unlawful conduct. As a result, the Supreme Court did not rule on the constitutionality of the ACA or any of its provisions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further changes to and under the Affordable Care Act remain possible but it is unknown what form any such changes or any law proposed to replace or revise the Affordable Care Act would take, and how or whether it may affect our business in the future. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry.  We also expect that the Affordable Care Act, as well as other healthcare reform measures that have and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our product and product candidates, if approved. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 (the "IRA") contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated "maximum fair price" for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the IRA. Although the IRA exempts orphan drugs that treat only one rare disease from the drug pricing negotiation provisions, we do not know if additional drug pricing reforms could eliminate this exemption and therefore affect the prices we can charge and reimbursement we receive for our product and product candidates, if approved, thereby reducing our profitability. Any change to the exemption could have a material adverse effect on our financial condition, results of operations, and growth prospects. The effects of the IRA on the pharmaceutical industry in general are not yet known.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have promoted off-label uses, we may become subject to significant liability. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products. In particular, a product may not be promoted in the U.S. for uses that are not approved by the FDA as reflected in the product's approved labeling or prior to regulatory approval. Further, any labeling approved by the FDA for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our other product candidates, including AT-GAA, may include restrictions on use, use limited to specific populations or other limitations. The FDA may impose further requirements or restrictions on the distribution or use of any of our other product candidates as part of a REMS plan. Physicians may nevertheless prescribe such products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. Similarly, the FDA strictly regulates the promotion of investigational products prior to approval, known as pre-approval promotion. The federal government has levied large civil and criminal fines and / or other penalties against companies for alleged improper promotion and has investigated and / or prosecuted several companies in relation to off-label and/or pre-approval promotion. The FDA has also requested that certain companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed, curtailed or prohibited or have delayed approval of investigational products due to pre-approval conduct. Inappropriate promotional activities may also subject a company to investigations, prosecutions and litigation by other government entities or private citizens.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk when we commercially sell any products that we develop, including those which may arise from misuse or malfunction of, or design flaws in, such products, whether or not such problems directly relate to the products and services we have provided. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory investigations, prosecutions or enforcement actions that could require costly recalls or product modifications;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities placing ongoing clinical trials on clinical hold;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significant costs to defend the related litigation;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increased insurance costs, or an inability to maintain appropriate insurance coverage;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial monetary awards to trial participants or patients, including awards that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">loss of revenue; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. We have increased our insurance coverage for the commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and may increase insurance coverage when, and if, we begin commercializing any other product candidate that receives marketing approval. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or a series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our available cash and adversely affect our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or other applicable regulatory authorities approve generic or biosimilar products with claims that compete with our product or any of our product candidates, it could reduce our sales of our product or those product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., after an NDA is approved, such as Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the product covered thereby becomes a "listed drug" which can, in turn, be cited by potential competitors in support of approval of an abbreviated NDA, or ANDA. The Federal Food, Drug, and Cosmetic Act, or the FD&amp;C Act, FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes. These manufacturers might only be required to conduct a relatively inexpensive study to show that their product has the same active ingredients, dosage form, strength, route of administration, and conditions of use, or product labeling, as our product or product candidate and that the generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product or product candidate. These generic equivalents would be significantly less costly than ours to bring to market and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product or product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, would substantially limit our ability to generate revenues or achieve profitability with a negative impact on continued operations. As of the end of 2022, we received Para. 4 certifications from three ANDA filers for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and have initiated Hatch-Waxman litigation against these ANDA filers and will continue to vigorously defend our Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property rights.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act of 2010, or the ACA, Pub. L. No. 111-148 (2010). The BPCIA authorizes the FDA to approve "abbreviated" BLAs for products whose sponsors demonstrate they are "biosimilar" to reference products previously approved under BLAs, including AT-GAA, if approved. The FDA may also separately determine whether "biosimilar" products are "interchangeable" with their reference products. However, the FDA may not approve an "abbreviated" BLA for a biosimilar product until at least twelve years after the date on which the BLA for the reference product was approved. FDA approval of abbreviated BLAs could be further delayed if the reference products are subject to unexpired and otherwise valid patents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the enactment of the BPCIA, information in approved BLAs could not be relied upon by other manufacturers to establish the safety and efficacy of their products for which they were seeking FDA approval. Accordingly, if our products such as AT-GAA are approved under a BLA, other manufacturers potentially could develop and seek FDA approval of "biosimilar" products at some point in the future, including a biosimilar of AT-GAA.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product, product candidate or indication and fail to capitalize on a product, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically been focused on the development and commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a small molecule for Fabry disease and a next generation ERT treatment for Pompe disease, ATB-200. In 2018, we also made a significant investment in potential gene therapies for Fabry, Pompe, and other LDs. Notwithstanding our large investment in gene therapies and Pompe ERT to date and anticipated future expenditures in related proprietary technologies, we have not yet developed, and may never successfully develop, any marketed drugs using ERT and gene therapy approaches. As a result of pursuing the development and commercialization of our product and product candidates using our proprietary and licensed technologies, we may fail to develop products or product candidates, or address indications based on other scientific approaches that may offer greater commercial potential or for which there is a greater likelihood of success. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates yet fail to yield product candidates for clinical development.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Products and the Regulatory Approval and Clinical Development of our Product Candidates</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product or product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or product candidates including AT-GAA, could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA, EMA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our product or product candidates, if approved, and generating revenues from their sale. In addition, if we or others identify undesirable side effects caused by our products or product candidates after receipt of marketing approval:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may require the addition of restrictive labeling statements;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory authorities may withdraw their approval of the product; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be required to change the way the product is administered, or additional clinical trials are conducted.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or product candidate or could substantially increase the costs and expenses of commercializing the product or product candidate, if approved, which in turn could delay or prevent us from generating significant revenues from its sale and limiting our ability to meet our financial guidance or adversely affect our reputation.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product or product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to penalties or other enforcement actions if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product or our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product or product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA, EMA, PMDA and other regulatory authorities. For example, the FDA's requirements include submissions of safety and other post-marketing information and reports, registration requirements, Current Good Manufacturing Practices, or cGMP, requirements relating to manufacturing, quality control, quality assurance and complaints and corresponding maintenance of records and documents, requirements regarding the distribution of samples to healthcare professionals and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or may be subject to significant conditions of approval, including the requirement of a REMS. The FDA also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The labeling, advertising, promotion, marketing and distribution of a drug, biologic, or gene therapy product also must be in compliance with FDA requirements which include, among others, promotional activities, standards and regulations for direct-to-consumer advertising, promotional activities involving the internet, and industry sponsored scientific and educational activities. In general, all product promotion must be consistent with the labeling approved by the FDA for such product, contain a balanced presentation of information on the product's uses, benefits, risks, and important safety information and limitations on use, and otherwise not be false or misleading. The FDA has very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing a company to correct deviations from regulatory standards and enforcement actions that can include seizures, injunctions and criminal prosecution. Failure to comply with applicable FDA requirements and restrictions also may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of Justice ("DOJ") or the Office of the Inspector General of the U.S. Department of Health and Human Services ("HHS") as well as state authorities. This could subject us to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes its products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes to or restrictions on the labeling or marketing of a product;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions on product distribution or use;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to implement a REMS;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">warning letters, untitled letters or Form 483s;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawal of the products from the market;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">recall of products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">product seizure;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">injunctions; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with E.U. and U.K. requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the E.U.'s and U.K.'s requirements regarding the protection of personal information, which are effective as of May&#160;25, 2018, can also lead to significant penalties and sanctions and business restrictions.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or our suppliers, third-party contractors, clinical investigators or collaborators are slow to adapt, or are unable to adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, we or our collaborators may lose marketing approval for our products when and if any of them are approved, resulting in decreased revenue from milestones, product sales or royalties.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, healthcare providers, patients, patient organizations, charitable foundations and third-party payors are subject to applicable anti-kickback, fraud and abuse, anti-bribery and corruption and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of our product and any product candidates for which we may obtain marketing approval. Increasingly, patients, patient organizations and charitable foundations also can influence selection of and payment for therapies. Our current and future arrangements with payors, healthcare providers, patient organizations, charitable foundations and patients may expose us to broadly applicable fraud and abuse, anti-bribery and corruption, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product and any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal, state and foreign healthcare laws and regulations pertaining to fraud and abuse, anti-bribery and corruption, interaction with patient organizations, charitable foundations, and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Several other countries, including the U.K., have enacted similar anti-kickback, fraud and abuse, and healthcare laws and regulations;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. In addition, charitable contributions to foundations for use in supporting patients may expose those foundations and us to additional penalties and prosecution under the False Claims Act. There is also a separate false claims provision imposing criminal penalties. Applicable regulations of both the EMA and E.U. member states also impose liability for failing to comply with fraud and abuse laws or improperly using information obtained in in the course of clinical trials with the EMA or other regulatory authorities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The U.S. federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") which imposes criminal liability and amends provisions on the reporting, investigation, enforcement, and penalizing of civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation. This statute also may impose monetary penalties on any offers or transfers of remuneration to Medicare or Medicaid beneficiaries (patients) which is likely to influence the beneficiary's selection of particular supplier of government payable items. States, such as California have enacted their own privacy regulations and others may enact similar legislation. Similarly, the collection and use of personal health data in the E.U. is governed by the E.U. General Data Protection Regulation (the "GDPR"), with many requirements mandated by the GDPR for the consent of the individuals to whom the personal data relates, the information provided to the individuals, transfer of personal data within and outside of the E.U. and the security and confidentiality of the personal data. Enforcement of the GDPR began on May&#160;25, 2018, and failure to comply with the requirements of the GDPR may result in substantial fines and other administrative penalties. The GDPR increases our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and adversely affect our business, financial condition, results of operations and prospects;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. federal laws requiring drug manufacturers to report annually information related to certain payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives) and teaching hospitals, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities and requiring manufacturers to report marketing expenditures, payments and other transfers of value to physicians and other healthcare providers. Similarly, payments made to physicians in certain E.U. member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician's employer, his or her competent professional organization and/or the regulatory authorities of the individual E.U. member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the E.U. member states. In addition, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the E.U. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. federal government price reporting laws, which require us to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on our marketed drugs. Participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, potential liability for the failure to report such prices in an accurate and timely manner, and potentially limit our ability to offer certain marketplace discounts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">U.S. Foreign Corrupt Practices Act, which prohibit us and third parties working on our behalf from making payments to foreign government officials to assist in obtaining or retaining business. Specifically, the anti-bribery provisions of the FCPA prohibit the willful use of the mails or any means of instrumentality of interstate commerce corruptly in furtherance of any offer, payment, promise to pay, or authorization of the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business to, any person; enforcement actions may be brought by the Department of Justice or the SEC; legislation has expanded the SEC&#8217;s power to seek disgorgement in all FCPA cases filed in federal court and extended the statute of limitations in SEC enforcement actions in intent-based claims, such as those under the FCPA, from five years to ten years; and </span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state and foreign equivalents of each of the above laws, including foreign anti-bribery and corruption laws and state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not submit claims and our customers will make the ultimate decision on how to submit claims, in the U.S. we may provide reimbursement guidance and support regarding Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our other product candidates for which we receive regulatory approval, to our customers and patients. If a government authority were to conclude that we provided improper advice to our customers and patients and/or encouraged the submission of false claims for reimbursement, we could face action by government authorities. Similarly, if a government authority were to conclude that our patient support efforts or interactions with charitable foundations were improper, we could face action by government authorities. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, EMA, PMDA or other foreign regulatory authorities, or do not otherwise produce favorable results, we may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with seeking marketing approval from regulatory authorities for the sale of any product candidate, including AT-GAA, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. This is particularly the case with AT-GAA, as there can be no assurance that the Phase 3 PROPEL study results will meet regulatory standards for approval in every geography.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory pathways for gene therapies are evolving. In some cases, the FDA will approve gene therapies based on Phase 2 clinical trial data. If, however, the FDA decides we need to complete Phase&#160;3 clinical trial(s), we may need to expend significantly more capital to pursue FDA approval of gene therapies. If we are required to conduct additional clinical trials or other testing of our product candidates, including AT-GAA, or any gene therapies, that we develop beyond those tests and trials that we contemplate; if we are unable to successfully complete our clinical trials or other testing; if the results of these trials or tests are not positive or are only modestly positive; or if there are safety concerns, we may:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">choose not to seek regulatory approval in the U.S., E.U., U.K. or other key jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">not obtain marketing approval at all;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">be subject to additional post-marketing testing requirements, safety strategies or restrictions, such as a requirement of a risk evaluation and mitigation strategy, or REMS; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">have the product removed from the market after obtaining regulatory approval.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience any of a number of possible unforeseen events in connection with our clinical trials, potential regulatory approval or commercialization of our product candidates, if approved, could be delayed or prevented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials including ongoing clinical trials of AT-GAA in additional study populations that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may be unable to enroll a sufficient number of patients in our trials to ensure adequate statistical power to detect any statistically significant treatment effects;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators, institutional review boards, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulators, institutional review boards, or independent ethics committees may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, institutional review boards or independent ethics committees to suspend or terminate the trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in testing or regulatory approvals. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, allow our competitors to bring products to market before we do, or impair our ability to successfully commercialize our product candidates, and so may harm our business and results of operations.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Each of the diseases that our lead product candidates are intended to treat are characterized by small patient populations, which could result in slow enrollment of clinical trial participants. In addition, our competitors have ongoing clinical trials for product candidates that could be competitive with our product candidates. As a result, potential clinical trial sites may elect to dedicate their limited resources to participation in our competitors' clinical trials and not ours, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is affected by other factors including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">severity of the disease under investigation;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">eligibility criteria for the clinical trial in question;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patient referral practices of physicians;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing. Our inability to enroll a sufficient number of patients in any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial results from a clinical trial do not ensure that the trial will be successful and success in preclinical or early stage clinical trials does not ensure success in later-stage clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA or the applicable non-U.S. regulatory authority, in well-designed and conducted clinical trials, that the product candidate is safe and effective and otherwise meets the appropriate standards required for approval for a particular indication. Clinical trials are lengthy, complex and extremely expensive processes with uncertain duration and results. A failure of one or more of our clinical trials may occur at any stage of testing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. For some of our product candidates, we have no safety or efficacy data in humans. There can be no assurance that the results seen in preclinical studies for any product candidates will result in success in clinical trials. When administered in humans, the product candidates may perform differently than in preclinical studies. Product candidates may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies or animal studies, and may interact with human biological systems in unforeseen, ineffective or harmful ways. We may be unable to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial results from a clinical trial do not necessarily predict final results. We cannot be assured that these trials will ultimately be successful. In addition, patients may not be compliant with their dosing regimen or trial protocols or they may withdraw from the clinical trial at any time for any reason. In addition, while the clinical trials of our product candidates are designed based on the available relevant information, in view of the uncertainties inherent in drug development, such clinical trials may not be designed with focus on indications, patient populations, dosing regimens, safety or efficacy parameters or other variables that will provide the necessary safety or efficacy data to support regulatory approval to commercialize the resulting product candidates. This is particularly the case for emerging gene therapies where we do not yet have a defined regulatory pathway and there can be no assurance that regulators in the U.S., E.U., U.K., Japan or other jurisdictions will accept any gene therapy clinical data sets for approval and without additional clinical trials or that future trials will support approvals. In addition, individual patient responses to the dose administered of a product candidate may vary in a manner that is difficult to predict. Also, the methods we select to assess particular safety or efficacy parameters may not yield statistical precision in estimating our product candidates' effects on study participants. Even if we believe the data collected from clinical trials of our product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Preclinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us or our partners, which could delay, limit or prevent regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our product candidates are based on emerging gene therapy technologies. The FDA may require different endpoints than the endpoints we anticipate using or have used in our clinical trials, or a different analysis of those endpoints, it may be more difficult for us to obtain, or we may be delayed in obtaining, FDA approval of our product candidates. If we are not successful in commercializing any of our products or product candidates, if approved, or are significantly delayed in doing so, our business will be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain orphan drug exclusivity for our product or product candidates. If our competitors are able to obtain orphan drug exclusivity for their products, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the E.U., U.K., and the U.S., may designate drugs for relatively small patient populations as orphan drugs. We obtained orphan drug designations from the FDA for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease in February 2004. We also obtained orphan medicinal product designation in the E.U. and U.K. for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2006. AT-GAA has also received this designation from the FDA, EMA, and, in 2020, from PMDA. Our competitors have also received orphan designations. However, these orphan designations may be retracted following regulatory review of our or our competitor&#8217;s marketing authorization and/or BLA submissions and may not be reflected in the final approval of a product. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity, which, subject to certain exceptions, precludes the EMA from approving another marketing application for a similar medicinal product or the FDA from approving another marketing application for the same drug for the same indication for that time period. The FDA defines &#8220;same drug&#8221; as a drug or biologic that contains the same active moiety and is intended for the same use. The applicable market exclusivity period for orphan drugs is ten years in the E.U. and U.K. and seven years in the U.S. The E.U. and U.K. exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation, including if the drug is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U. and U.K., a "similar medicinal product" is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. If a competitor to AT-GAA or our other product candidates obtains orphan drug exclusivity for and approval of a product with the same indications as our product candidates as before we do and if the competitor's product is the same drug or a similar medicinal product as ours, we could be excluded from the market for a certain period of time.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain orphan drug exclusivity for other product candidates in these indications, we may not be able to maintain it. For example, if a competitive product that is the same drug or a similar medicinal product as our product or product candidate is shown to be clinically superior to our product or product candidate, as applicable, any orphan drug exclusivity we have obtained will not block the approval of such competitive product. In addition, orphan drug exclusivity will not prevent the approval of a product that is the same drug as our product or product candidate if the FDA finds that we cannot assure the availability of sufficient quantities of the drug to meet the needs of the persons with the disease or condition for which the drug was designated.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Reauthorization Act, signed into law in August 2017, authorizes the FDA to impose additional clinical trial requirements on manufacturers seeking orphan drug designation and/or pediatric indications. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA have obtained orphan drug designations from the FDA. The impact, however, of future regulations on other product candidates is uncertain and could result in the need for additional clinical trials.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or maintain regulatory approval in foreign jurisdictions would prevent us from marketing our products abroad.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in Europe and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, some countries outside the U.S. require approval of the sales price of a drug before it can be marketed. In many countries, separate procedures must be followed to obtain reimbursement. We may not obtain marketing, pricing or reimbursement approvals outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. Regulatory approvals in countries outside the U.S. do not ensure pricing approvals in those countries or in any other countries, and regulatory approvals and pricing approvals do not ensure that reimbursement will be obtained.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization of cipaglucosidase alfa used in combination with miglustat for adults with late-onset Pompe disease (LOPD). A CHMP decision on miglustat is expected to follow. We do not know if both components of AT-GAA will be approved or, if approved, whether cipaglucosidase alfa and miglustat will receive favorable pricing. If we are unable to secure full marketing approval for both components of AT-GAA, EU or other geographies, our business and results of operations may be materially harmed.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities involve the use of hazardous materials, which require compliance with environmental and occupational safety laws regulating the use of such materials. If we violate these laws, we could be subject to significant fines, liabilities or other adverse consequences.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs involve the controlled use of hazardous materials, including microbial agents, corrosive, explosive and flammable chemicals and other hazardous compounds in addition to certain biological hazardous waste. Additionally, the activities of our third-party product manufacturers of our product, and of our product candidates if and when they reach commercialization, will also require the use of hazardous materials. Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these materials comply in all material respects with the standards prescribed by local, state and federal regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. In addition, although our collaborators have environmental compliance processes in place, and we include oversight of these processes in our business reviews, they may not ultimately comply with these laws. In the event of an accident or failure to comply with environmental laws, we could be held liable for damages that result, and any such liability could exceed our assets and resources or we could be subject to limitations or stoppages related to our use of these materials which may lead to an interruption of our business operations or those of our third-party contractors. While we believe that our existing insurance coverage is generally adequate for our normal handling of these hazardous materials, it may not be sufficient to cover pollution conditions or other extraordinary or unanticipated events. Furthermore, an accident could damage or force us to shut down our operations. Changes in environmental laws may impose costly compliance requirements on us or otherwise subject us to future liabilities and additional laws relating to the management, handling, generation, manufacture, transportation, storage, use and disposal of materials used in or generated by the manufacture of our products or related to our clinical trials. In addition, we cannot predict the effect that these potential requirements may have on us, our suppliers and contractors or our customers.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain marketing approval for AT-GAA, or if it is approved and the label does not support reimbursement and we are unable to successfully commercialize AT-GAA, our business could be materially harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. In September 2021, the FDA accepted our AT-GAA BLA and NDA for review. Regulatory authorities, including FDA, may determine that AT-GAA is not effective or only moderately effective, have effect in only a limited population, or have undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use. In October 2022, FDA informed us that it has deferred action on the AT-GAA BLA, pending inspection of the proposed manufacturing site in China. The inspection has been delayed due to restrictions related to the COVID-19 pandemic and is now scheduled. This timing is subject to change and is dependent on a number of factors, including the evolving situation on the ground in China and the outcome of an inspection. There can be no assurance that an inspection will take place when scheduled or that an inspection will be successful if and when completed all of which may impact timing or probability of any approvals. If AT-GAA fails to receive marketing approval, is significantly delayed in receiving marketing approval or if the approved labeling is not as expected, AT-GAA may fail to receive market acceptance, receive reimbursement or be able to generate material revenue, any of which could substantially harm our future business and impact our ability to meet our financial guidance. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Preclinical Product Candidates</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only a few gene therapy products have been approved in the U.S., E.U., and U.K. We have acquired the rights to many potential gene therapies and have focused a substantial amount of our research and development efforts on these gene therapy platforms. There can be no assurance that any development problems we experience in the future related to our gene therapies will not cause significant delays or unanticipated costs, or that such development problems can be solved. In addition, the clinical study requirements of the FDA, the EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as our gene therapies can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. There is no guarantee that our potential gene therapies will ever receive regulatory approval, that we will have the resources to develop these therapies, that we will recoup our investments made in gene therapies or that we will meet any projected timelines for development.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Manufacture of our Product and Product Candidates and our Dependence on Third Parties</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of third parties to manufacture Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or AT-GAA may increase the risk that we will not have sufficient quantities of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate manufacturing facilities for clinical or commercial production of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or AT-GAA. We currently lack the resources and the capabilities to manufacture ourselves on a clinical or commercial scale. If we choose in the future to manufacture ourselves, we would face all of the risks and uncertainties of third-party manufacturers of our products. We currently outsource all manufacturing and packaging of our product and preclinical and clinical product candidates to third parties. The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. In particular, the manufacture of our biologic product candidate ATB200 for Pompe is highly complex and we may encounter difficulties in production. These problems include difficulties with production costs and yields and quality control, including stability of the product or product candidate. The occurrence of any of these problems could significantly delay our clinical trials or the commercial availability of our product or product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to enter into agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. Even if we enter into these agreements, the manufacturers of each product candidate will be single source suppliers to us for a significant period of time.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limitations on supply availability resulting from capacity and scheduling constraints of the third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to manufacture product that meets the regulatory requirements for product approval;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to manufacture batches that meet specifications and quality standards; </span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to hire and retain the skilled workers necessary to manufacture our products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">inability to meet environmental sustainability requirements;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet the demands of our customers;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; </span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the high cost of manufacturing processes and raw materials; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure of any of our contract manufacturers to maintain high manufacturing standards could result in injury or death of clinical trial participants or patients using products. Such failure could also result in product liability claims, product recalls, product seizures or withdrawals, delays or failures in testing or delivery, cost overruns or other problems that could seriously harm our business or profitability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and regulatory authorities in other jurisdictions require our contract manufacturers to comply with cGMP regulations. These regulations cover all aspects of the manufacturing, testing, quality control and recordkeeping relating to our product candidates and any products that we may commercialize, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA, and our gene therapy product candidates. The FDA and other regulatory authorities may, and often will, require the inspection of our contract manufacturers in order to approve, or maintain the approval of, our products or product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA. Different geopolitical situations, responses to COVID-19, or other unforeseeable events could impact the FDA, or other regulatory authorities, ability to timely inspect such contract manufacturers and such delays could materially harm our business and accuracy of our financial guidance projections.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure or the failure of our third-party manufacturers, to comply with applicable regulations could significantly and adversely affect regulatory approval and supplies of our product candidates. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing our products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the third parties that we engage to manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive regulatory approval on a timely and competitive basis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct certain preclinical development activities and our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not independently conduct clinical trials for our product candidates or certain preclinical development activities of our product candidates. We rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators and collaboration partners, to perform these functions. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for certain preclinical and clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, or GCP, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register certain ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within particular timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. Similar GCP and transparency requirements apply in the E.U. and U.K. Failure to comply with such requirements, including with respect to clinical trials conducted outside the E.U., U.K. and U.S., can also lead regulatory authorities to refuse to take into account clinical trial data submitted as part of an MAA.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties that we rely on for our clinical development activities may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on other third parties to obtain, store and distribute drug supplies for our preclinical development activities and clinical trials. In addition, in some instances we are required to purchase clinical supplies from our competitors, who may refuse to allow this purchase or do so at prohibitively high prices. Any performance failure on the part of our distributors or inability to secure supply from our competitors could delay preclinical and clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions, delays, suspensions or terminations of our preclinical development activities or our clinical trials as a result of the performance of our independent clinical investigators and CROs will delay, and make more costly, regulatory approval for any product candidates that we may develop. Any change in a CRO during an ongoing preclinical development activity or clinical trial could seriously delay that trial and potentially compromise the results of the activity or trial.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in maintaining or establishing collaborations, which could adversely affect our ability to develop and, particularly in international markets, commercialize products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are collaborating with physicians, academic institutions, hospitals, patient advocacy groups, foundations and government agencies in order to assist with the development of our products and each of our product candidates. We plan to pursue similar activities in future programs and plan to evaluate the merits of retaining commercialization rights for ourselves or entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies. We also may seek to establish collaborations for the sales, marketing and distribution of our products in all or select geographies. If we elect to seek collaborators in the future but are unable to reach agreements with suitable collaborators, we may fail to meet our business objectives for the affected product or program. We face, and will continue to face, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts, if any, to establish and implement collaborations or other alternative arrangements. The terms of any collaboration or other arrangements that we establish, if any, may not be favorable to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any collaboration that we enter into may not be successful. The success of our collaboration arrangements, if any, will depend heavily on the efforts and activities of our collaborators. It is likely that any collaborators of ours will have significant discretion in determining the efforts and resources that they will apply to these collaborations. The risks that we may be subject to in possible future collaborations include the following:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not pursue development and commercialization of our product or product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between the collaborator and us as to the ownership of intellectual property arising during the collaboration;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may grant rights to our collaborators to be the holder of any marketing authorizations in a jurisdiction;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we may grant exclusive rights to our collaborators, which would prevent us from collaborating with others;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations with pharmaceutical companies and other third parties often are terminated or allowed to expire by the other party. Such terminations or expirations may adversely affect us financially and could harm our business reputation in the event we elect to pursue collaborations that ultimately expire or are terminated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Materials necessary to manufacture our product or product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on the manufacturers of our product and product candidates to purchase from third-party suppliers the materials necessary to produce the compounds for our preclinical studies, clinical trials, and commercial supply and we rely, or will rely, on these other manufacturers for commercial distribution of our product and, if and when we obtain marketing approval, for any of our product candidates. Suppliers may not sell these materials to our manufacturers at the time we need them or on commercially reasonable terms and all such prices are susceptible to fluctuations in price and availability due to transportation costs, government regulations, price controls, geopolitical risk and changes in economic climate or other foreseen circumstances. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. We may enter into agreements to purchase certain materials and provide them to our manufacturers, with all the risks and uncertainties of supply associated with those purchases. If we or our manufacturers are unable to obtain these materials for our preclinical studies and clinical trials, product testing and potential regulatory approval of our product candidates would be delayed, significantly impacting our ability to develop and commercialize our product candidates. If our manufacturers or we are unable to purchase these materials for commercial distribution of our product or, after regulatory approval has been obtained, our product candidates, the commercial launch of our product and product candidates would be delayed or there would be a shortage in supply, which would materially affect our ability to generate revenues from the sale of our product or product candidates.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing of our product and product candidates requires us or our manufacturing partners to conduct required stability and comparability testing. We or our partners may encounter product, packaging, equipment and process-related issues that may require refinement or resolution in order to successfully commercialize our product and proceed with our planned clinical trials and obtain regulatory approval for commercial marketing of our product candidates. In the future, we may identify impurities, which could result in increased scrutiny by regulatory authorities, delays in our clinical programs and regulatory approval, increases in our operating expenses or failure to obtain or maintain approval for our product or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on WuXi Biologics Co., Ltd. ("Wuxi"), a company based in the People's Republic of China (the "PRC"), as the sole supplier of our biologic product, ATB200. Accordingly, there is a risk that supplies of our product may be significantly delayed by or may become unavailable as a result of manufacturing, equipment, process, regulatory or business-related issues affecting that company. We may also face additional manufacturing and supply-chain risks due to the regulatory and political structure of the PRC, or as a result of the international relationship between the PRC and the U.S. or any of the other countries in which our products are marketed. In addition, the out-breaks of SARS, COVID-19 or other similar illnesses in the PRC could impact operations at Wuxi. Although currently there has been no impact on our ability to obtain supply of ATB200, and we and Wuxi have robust mitigation plans in place, there can be no assurance that operations would not be impacted in the future with a negative impact on supply of our product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties manufacturing our gene therapy which could impact timing and availability of clinical and commercial supply.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in developing a sustainable, reproducible and commercial-scale manufacturing process or transferring that process to commercial partners for our gene therapy product candidates. There is intense competition for limited commercial manufacturing capacity in gene therapy and for base materials, such as plasmids, necessary to the manufacturing of gene therapy products. We do not currently have our own gene therapy manufacturing capacity and rely instead on commercial manufacturing partners. These commercial manufacturing partners are expanding rapidly and there can be no assurance that needed capacity will be available or that these partners will continue to meet evolving regulatory standards. Any delay in securing supply of these materials and the manufacturing slots with commercial partners may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, FDA and other regulatory bodies are continuing to evolve their guidance for gene therapy manufacturing and could impose rigorous requirements relating to the manufacturing and testing of clinical and commercial products that could add time, complexity and the risk that we or our manufacturing partners will be unable to meet these requirements.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Position</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have focused on developing and commercializing our first product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our pipeline product AT-GAA as well as our gene therapies. Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. Although the European Commission, PMDA and FDA have granted approval for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adults with a confirmed diagnosis of Fabry disease and who have an amenable genetic variant, and we are generating product sales, we continue to incur significant research, development, commercialization and other expenses related to our ongoing operations. As a result, we are not profitable, have incurred losses in each period since our inception, and may never be profitable on a non-GAAP or GAAP basis. For the year ended December 31, 2022, we have a net loss of $236.6 million, and we have an accumulated deficit of $2.5 billion at December 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant costs in the foreseeable future as we:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our development and commercialization of, and seek regulatory approvals for, product candidates, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and AT-GAA in the U.S., the E.U., U.K., Japan and other foreign countries, as applicable;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">conduct additional clinical trials to support the full approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and post-approval commitments or trials;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue communicating with the EMA, as necessary, regarding post-marketing requirements and clinical trials for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to or initiate the regulatory submission process for marketing approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the U.S. and E.U. and other foreign jurisdictions where approved, as applicable;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">build and maintain our commercial infrastructure so that it is capable of supporting product sales, marketing and distribution of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our other product candidates in Europe, Japan and the U.S. or other territories in which we have received or may receive regulatory approval;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prepare for launch of AT-GAA in the U.S., E.U., U.K. and other jurisdictions if approved by regulators;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our gene transfer discovery and next generation product research;</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our preclinical studies of and potentially conduct clinical studies of ERT and gene therapy for CDD; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue our rigorous prosecution and defense of our patent portfolio. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business. The size of our future losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If any of our product candidates fails in clinical trials or does not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders' equity and working capital.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never become profitable even though we currently generate revenue from the sale of products.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began the commercial launch of our first product, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in May 2016, with the U.S. and Japan commercial launches in 2018 and are now approved in over 40 countries. Our ability to generate material revenue and become profitable depends upon our ability to successfully commercialize our existing product and product candidates, or product candidates that we may in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for our product candidates, including AT-GAA, we do not know when any of these product candidates will generate revenue for us, if at all and we may not meet our current revenue, operating expense and profitability guidance. Our ability to generate revenue from our current or future product and product candidates depends on a number of factors, including our ability to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully complete development activities and obtain additional regulatory and pricing and reimbursement approvals for, and continue to successfully commercialize, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">complete and submit regulatory submissions to the FDA, EMA, MHRA, PDMA and others and obtain regulatory approval for AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop and maintain a commercial organization capable of sales, marketing, and distribution for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any product candidates we intend to market, including AT-GAA if approved, in the countries where we have chosen to commercialize the product candidates ourselves including the U.S. and Japan;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacture commercial quantities of our products at acceptable cost levels;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain a commercially viable price for our products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">obtain coverage and adequate reimbursement from third parties, including government payors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully satisfy post-marketing requirements that the FDA, EMA, or other foreign regulatory authorities may impose for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any of our other product candidates that may receive regulatory approval, including pediatric trials and patient registries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully develop or acquire new products and product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">successfully complete development activities, including the necessary preclinical studies and clinical trials, with respect to product candidates; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">continue to navigate any adverse impacts of the COVID-19 outbreak, including due to actions by us, governments, our customers, our suppliers or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to generate significant revenues from the sale of our products and accurately predict and control expenses, we may not reach our financial guidance or become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we require substantial additional capital to fund our operations and we fail to obtain necessary financing, we may be unable to complete the development and commercialization of our product and development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash. We expect to continue to spend substantial amounts to advance the preclinical and clinical development of our product candidates, and launch and commercialize our product and product candidates for which we may receive regulatory approval, including continuing to build our own commercial organization. We believe that our current cash position, including expected revenues, is sufficient to fund our operations and ongoing research programs for at least the next 12 months. Potential impacts of the COVID-19 pandemic, future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements. However, we may require substantial additional capital for the development and commercialization of our product and further development and commercialization of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts, when required or on acceptable terms, we could also be required to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significantly delay, scale back, or discontinue the development or the commercialization of our product or product candidates or one or more of our other research and development initiatives;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">seek collaborators for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA or one or more of our current or future product candidates at an earlier stage than otherwise would be desirable, or on terms that are less favorable than might otherwise be available;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relinquish or license on unfavorable terms our rights to our technologies, product or product candidates that we otherwise would seek to develop or commercialize ourselves;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">significantly curtail operations; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into strategic partnerships on unfavorable terms, including sale of our assets for less than full value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of commercialization activities, including maintaining sales, marketing, and distribution capabilities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates and any other product candidates that we may in-license or acquire;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of manufacturing drug supply for our preclinical studies, clinical trials, and commercial supply, including the significant cost of manufacturing AT-GAA and our gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome, timing, and cost of the regulatory approval process by the FDA, EMA, PMDA and other foreign regulatory authorities, including the potential for regulatory authorities to delay approvals pending site inspections or requiring that we perform more studies than those that we currently anticipate for our product and product candidates including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights; </span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost and timing of completion of existing or expanded commercial-scale outsourced manufacturing activities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of defending any claims asserted against us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of complying with new laws, rules or regulations in the geographies in which we operate;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of foreign exchange rates on our operating expenses and revenue projections; </span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which we acquire or invest in additional businesses, products, and technologies.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings, strategic collaborations and alliances, restructuring and licensing arrangements. We have an effective &#8220;shelf&#8221; registration statement on Form S-3 that allows us to issue securities in registered offerings as well as an available at-the-market financing facility that allows us to sell shares of our common stock through a placement agent at market prices.To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt, receivables, and royalty financings may be coupled with an equity component, such as warrants to purchase stock, which could also result in dilution of our existing stockholders' ownership. The incurrence of additional indebtedness beyond our existing indebtedness with the Senior Secured Term Loan due 2026 could also result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur further debt, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could have a material adverse effect on our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on any of our indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA or our other product candidates, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our technologies that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into the Senior Secured Term Loan due 2026 for a $400 million credit facility with Hayfin Capital Management, with an interest rate equal to 3-month LIBOR, subject to a 1% floor, plus 6.5% per annum that requires interest-only payments until mid-2024 and matures in six years in 2026. We received net proceeds of $385.9 million in July 2020, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Senior Secured Term Loan due 2026 contains a minimum liquidity covenant of $75 million, tested monthly and in effect at all times, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $140 million, beginning March 31, 2021, and peaks at $225 million by June 30, 2023, continuing at that level until the loan is repaid.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our cash and cash equivalents, together with funds generated by our operations and any future financings, will be sufficient to satisfy our debt payment obligations or that we will have sufficient equity to satisfy these obligations. Our inability to generate funds obtain financing sufficient to satisfy our debt payment obligations or remain in compliance with the debt covenants may result in such obligations being accelerated by our lenders, which would likely have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency exchange rate fluctuations could harm our financial results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct operations in many countries involving transactions denominated in a variety of currencies other than the U.S. dollar. The majority of our current Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue is derived from outside the U.S. Accordingly, changes in the value of currencies relative to the U.S. dollar may impact our consolidated revenues and operating results due to transactional and translational remeasurement that is reflected in our earnings. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Fluctuations in currency exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We are not currently engaged in any foreign currency hedging activities and there can be no assurance that currency exchange rate fluctuations will not adversely affect our results of operations, financial condition and cash flows. In addition, our outlooks do not assume fluctuations in currency exchange rates. Adverse fluctuations in currency exchange rates from the date of our outlooks could cause our actual results to differ materially from those anticipated in our outlooks and adversely impact our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face risks arising from the imposition of exchange controls and currency devaluations. Exchange controls may limit our ability to convert foreign currencies into U.S. dollars or to make payments by our foreign subsidiaries or businesses located in or conducted within a country imposing controls. Currency devaluations result in a diminished value of funds denominated in the currency of the country instituting the devaluation.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had federal and state net operating loss carry forwards ("NOLs") of approximately $1,183 million and $992&#160;million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the Tax Cuts and Jobs Act. Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2022 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended, as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past, and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section 382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. We may experience ownership changes in the future as a result of shifts in our stock ownership some of which are outside our control. We completed a detailed study of our NOLs for the tax year 2022 and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on our ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders maintain the ability to exert significant influence and control over matters submitted to our stockholders for approval.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and affiliated stockholders beneficially own shares representing approximately 49% of our common stock as of December 31, 2022. As a result, if these stockholders were to choose to act together, they would be able to exert significant influence and control over matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could influence the election of directors and approval of any merger, consolidation, sale of all or substantially all of our assets or other business combination or reorganization. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire. The interests of this group of stockholders may not always coincide with the interests of other stockholders, and they may act, whether by meeting or written consent of stockholders, in a manner that advances their best interests and not necessarily those of other stockholders, including obtaining a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital in the foreseeable future, capital appreciation, if any, will be our stockholders sole source of gain.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the development and growth of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be our stockholders sole source of gain for the foreseeable future. </span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations reflect the reality that judgments can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Intellectual Property</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the U.S. and in certain foreign jurisdictions related to our novel technologies, product and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering this intellectual property. These agreements could also give our licensors the right to enforce the licensed patents without our involvement, or to decide not to enforce the patents at all. Therefore, in these circumstances, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation, including U.S. Hatch-Waxman litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any patents issued to us or our licensors will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">licenses from other third parties will not be required to commercialize patented products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will develop additional proprietary technologies that are patentable;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will file patent applications for new proprietary technologies promptly or at all;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our patents will not expire prior to or shortly after commencing commercialization of a product;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the patents of others will not have a negative effect on our ability to do business;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patent authorities will not identify deficiencies in our patent applications and refuse to grant our patents; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">outcome of any patent litigation, including Hatch-Waxman litigation involving Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or AT-GAA, will demonstrate that our patents are valid and enforceable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot be assured that any of our pending patent applications will result in issued patents. In particular, we have filed patent applications in the U.S., the European Patent Office and other countries outside the U.S. that have not been issued as patents. These pending applications include, among others, some of the patent applications for AT-GAA, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and our gene therapy platforms and product candidates. If patents are not issued in respect of our pending patent applications, we may not be able to stop competitors from marketing similar products in Europe and other countries in which we do not have issued patents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection outside of the U.S., we intend to seek orphan medicinal product designation of our product candidates and to rely on statutory data exclusivity provisions in jurisdictions outside the U.S. where such protections are available, including Europe. The patent rights that we own or have licensed relating to our product candidates are limited in ways that may affect our ability to exclude third parties from competing against us if we obtain regulatory approval to market these product candidates. In particular:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We have multiple composition of matter patents covering Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and multiple method of treatment patents issued and listed in the Orange Book. We have composition of matter, method of treatment, method of manufacture, formulation and other patents issued for AT-GAA. We also have several pending applications covering Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA and gene therapy. There can be no assurance that these applications will be allowed or that allowed applications will be issued or that the scope of such patents, if they issue, will be sufficient to protect our product. Composition of matter patents can provide protection for pharmaceutical products to the extent that the specifically covered compositions are important. For our product candidates for which we do not hold composition of matter patents, competitors who obtain the requisite regulatory approval can offer products with the same composition as our products so long as the competitors do not infringe any method of use patents that we may hold.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">For some of our product candidates the principal patent protection that covers or those we expect will cover our product candidate is a method of use patent. This type of patent only protects the product when used or sold for the specified method. However, this type of patent does not limit a competitor from making and marketing a product that is identical to our product that is labeled for an indication that is outside of the patented method, or for which there is a substantial use in commerce outside the patented method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, physicians may prescribe such a competitive identical product for indications other than the one for which the product has been approved, or off-label indications, that are covered by the applicable patents. Although such off-label prescriptions may infringe or induce infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Certain foreign jurisdictions may not recognize or enforce any patents granted or patent applications filed in those jurisdictions. In addition, we may not pursue or obtain patent protection in all major markets. Assuming the other requirements for patentability are met, currently, the first to file&#160;a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the U.S., the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office or become involved in opposition, derivation, reexamination,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post grant review, interference proceedings or other patent office proceedings or litigation, in the U.S. or elsewhere, challenging our patent rights or the patent rights of others, including U.S. Hatch-Waxman litigation. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. In addition, other companies may attempt to circumvent any regulatory data protection or market exclusivity that we obtain under applicable legislation, which may require us to allocate significant resources to preventing such circumvention. Legal and regulatory developments in the E.U. and elsewhere may also result in clinical trial data submitted as part of an MAA becoming publicly available. Such developments could enable other companies to circumvent our intellectual property rights and use our clinical trial data to obtain marketing authorizations in the E.U. and in other jurisdictions. Such developments may also require us to allocate significant resources to prevent other companies from circumventing or violating our intellectual property rights. Our attempts to prevent third parties from circumventing our intellectual property and other rights may ultimately be unsuccessful. We may also fail to take the required actions or pay the necessary fees to maintain our patents.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, litigation, interferences, oppositions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity. Litigation, interference, oppositions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our products, or&#160;the technologies or processes used to formulate or manufacture those products may now, or in the future, infringe the patent rights of third parties. It is also possible that third parties will obtain patent or other proprietary rights that might be necessary or useful for the development, manufacture or sale of our products. We may need to obtain licenses for intellectual property rights from others and may not be able to&#160;obtain these licenses on commercially reasonable terms, if at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently and may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been, and we expect that there may continue to be, significant litigation in the industry regarding patents and other intellectual property rights. Litigation, arbitrations, administrative proceedings and other legal actions with private parties and governmental authorities concerning patents and other intellectual property rights may be protracted, expensive and distracting to management. Competitors may sue us as a way of delaying the introduction of our drugs or to remove our drugs from the market. Any litigation, including litigation related to Abbreviated New Drug Applications, or ANDA, litigation related to 505(b)(2) applications, interference proceedings to determine priority of inventions, derivations proceedings, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, oppositions to patents in foreign countries, litigation against our collaborators or similar actions, may be costly and time consuming and could harm our business. We expect that litigation may be necessary in some instances to determine the validity and scope of certain of our proprietary rights. Litigation may be necessary in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. Ultimately, the outcome of such litigation could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that valid present or future third-party patents or other intellectual property rights cover our drugs, drug candidates or technologies, we or our strategic collaborators may seek licenses or other agreements from the holders of such rights in order to avoid or settle legal claims. Such licenses may not be available on acceptable terms, which may hinder our ability to, or prevent us from being able to, manufacture and market our drugs. Payments under any licenses that we are able to obtain would reduce our profits derived from the covered products.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the approval process for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, FDA granted us a New Chemical Entity (&#8220;NCE&#8221;) exclusivity period during which other manufacturers&#8217; applications for approval of generic versions of our product will not be approved. Generic manufacturers may challenge the patents protecting products that have been granted NCE exclusivity one year prior to the end of the NCE exclusivity period. Generic manufacturers have sought and may continue to seek FDA approval for a similar or identical drug through an abbreviated new drug application (&#8220;ANDA&#8221;), the application form typically used by manufacturers seeking approval of a generic drug. The sale of generic versions of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> earlier than their patent expiration would have a significant negative effect on our revenues and results of operations. To seek approval for a generic version of a product having NCE status, a generic company may submit its ANDA to FDA four years after the branded product&#8217;s approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in October 2022, we received letters from Aurobindo Pharma Ltd., Lupin Ltd., and Teva Pharmaceutical, Inc. (collectively, &#8220;generic manufacturers&#8221;) indicating that they have submitted ANDAs to FDA requesting permission to market and manufacture generic versions of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. They have challenged the validity of all or some of the patents listed on the Orange Book associated with Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We filed lawsuits against the generic manufacturers, and we intend to enforce and defend our intellectual property. Although we cannot predict with certainty the ultimate outcome of the foregoing actions, or any other litigation that we may have with generic manufacturers in the future, an adverse judgment could result in substantial monetary damages, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s lost revenues, and we may spend significant resources enforcing and defending our patents. If we are unsuccessful in these lawsuits, some or all of our original claims in the patents may be narrowed or invalidated, and the patent protection for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States may be shortened.  Further, if all the patents are invalidated, the FDA could approve the requests to manufacture a generic version of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States prior to the expiration date of those patents.  Moreover, we may be forced to settle litigation on terms that are unfavorable and result in sales of generic versions of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to expiration of our patents.  The sale of generic version of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> earlier than the patent expiration would have a significant negative effect on our revenues, projections of profitability and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or AT-GAA, may infringe or be accused of infringing one or more claims of an issued patent or may fall within the scope of one or more claims in a published patent application that may subsequently issue and to which we do not hold a license or other rights. Third parties may own or control these patents or patent applications in the U.S. and abroad. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No assurance can be given that patents do not exist, have not been filed, or could not be filed or issued, which contain claims covering our product candidates, technology or methods. Because of the number of patents issued and patent applications filed in our field, we believe there is a risk that third parties may allege they have patent rights encompassing our product candidates, technology or methods.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these patents were to be asserted against us, while we do not believe that our product candidates would be found to infringe any valid claim of such patents, there is no assurance that a court would find in our favor. If we were to challenge the validity of any issued U.S. patent in court, we would need to overcome a presumption of validity that attaches to every patent. This burden is high and would require us to present clear and convincing evidence as to the invalidity of the patent's claims. There is no assurance that a court would find in our favor on infringement or validity. Furthermore, during the course of litigation, confidential information may be disclosed in the form of documents or testimony in connection with discovery requests, depositions or trial testimony. Disclosure of our confidential information and our involvement in intellectual property litigation could materially adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to avoid or settle potential claims with respect to any patent rights of third parties, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. This could harm our business significantly. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference proceedings declared by the U.S. Patent and Trademark Office and opposition proceedings in the European Patent Office, regarding intellectual property rights with respect to our products and technology. Even if we prevail, the cost to us of any patent litigation or other proceeding could be substantial.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from any litigation could significantly limit our ability to continue our operations. Patent litigation and other proceedings may also absorb significant management time.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee's former employer. Litigation may be necessary to defend against these claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to license agreements with Nationwide Children&#8217;s Hospital ("Nationwide Children&#8217;s") and University of Pennsylvania ("Penn") pursuant to which we license key intellectual property relating to our gene therapy product candidates. We expect to enter into additional licenses in the future. Our existing licenses impose, and we expect that future licenses will impose, various diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents.</span></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our gene therapy product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries, especially in the gene therapy field, are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions. We are aware of companies focused on developing gene therapies in various indications as well as several companies addressing other methods for delivering or modifying genes and regulating gene expression. Any advances in gene therapy technology made by a competitor may be used to develop therapies that could compete against any of our product candidates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own patents, we have acquired licenses to certain patent rights and proprietary technology from third parties, including our current partners at Nationwide Children&#8217;s and Penn, that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product and product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. Licenses to additional third-party technology that may be required for our development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The novel coronavirus ("COVID-19") pandemic and efforts to reduce its spread may negatively impact our business and operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has substantially burdened healthcare systems worldwide which may impact progression of our clinical trials, development and manufacturing of our product and product candidates and continued commercialization of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Required inspections and reviews by regulatory agencies may also be delayed due to the focus of resources on COVID-19 as well as travel and other restrictions. In October 2022, FDA informed us that it has deferred action on the AT-GAA BLA, pending inspection of the proposed manufacturing site in China. The inspection has been delayed due to restrictions related to the COVID-19 pandemic and although now scheduled, we do not know whether the FDA will inspect when scheduled, whether the situation on the ground in China will change, nor the outcome of those inspections. Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize some assets in our product pipeline. Lack of normal access by patients to the healthcare system, along with concern about the continued supply of medications, may result in changes in buying patterns throughout the supply chain, including by patients, which could increase or decrease demand for our products. COVID-19 could also have an adverse impact on our supply chain and distribution systems, which could impact our ability to distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, increase our expenses and have a material adverse effect on our ability to generate revenue. In addition, the conditions created by the pandemic may intensify other risks inherent in our business, including, among other things, risks related to drug pricing and access, intellectual property protection, product safety and efficacy concerns, product liability and other litigation, and the impact of adverse global and local economic conditions.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employment, Environmental, Social and Governance Matters</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our Chief Executive Officer and other key personnel and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on Bradley&#160;L. Campbell, our President and Chief Executive Officer, Daphne Quimi, our Chief Financial Officer, and John F. Crowley, our Executive Chairman, each of whom has significant pharmaceutical industry experience. The loss of the services of any of these individuals might impede the achievement of our research, development and commercialization objectives and materially adversely affect our business and we may not be able to replace them with candidates with similar background and experience in the event of the loss of their services. We do not maintain "key person" insurance on Mr.&#160;Campbell or on any of our other key personnel.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical and sales and marketing personnel will also be critical to our success, including for our Global Headquarters in Philadelphia. In addition, maintaining a qualified finance and legal department is key to our ability to meet our regulatory obligations as a public company and important in any potential capital raising activities. Our industry has experienced a high rate of turnover in recent years. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel, particularly in New Jersey and Philadelphia and their surrounding areas. Although we believe we offer competitive salaries and benefits, we may have to increase spending in order to retain personnel. If we fail to retain our remaining qualified personnel or replace them when they leave, we may be unable to recruit replacements nor continue our development and commercialization activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 484 full-time employees. As our development and commercialization strategies develop, we will need additional managerial, operational, sales, marketing, financial, technical operations and other resources. Our management, personnel and systems currently in place may not be adequate to support this future growth. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product candidates and we may not be able to replace key personnel in the event of turnover. Future growth would impose significant added responsibilities on members of management, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing the development and commercialization of any product candidates approved for marketing;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">overseeing our ongoing preclinical studies and clinical trials effectively;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">identifying, recruiting, maintaining, motivating and integrating additional employees, including any sales and marketing personnel engaged in connection with the commercialization of any approved product;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing our collaboration partners and associated joint steering committees;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">managing any clinical or commercial collaborations with third parties;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">improving our managerial, development, operational and financial systems and procedures;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">monitoring and improving diversity, inclusion and pay-equity initiatives;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing our compliance infrastructure and processes to ensure compliance with regulations applicable to public companies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developing biologics and gene therapy manufacturing expertise; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expanding our facilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations expand, we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent conduct, harassment or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">FDA or similar regulations of foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">manufacturing standards;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state healthcare fraud and abuse laws and regulations, anti-bribery and corruption laws, anti-discrimination and harassment laws, privacy and similar laws and regulations established and enforced by foreign regulatory authorities; or</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws that require the reporting of financial information or data accurately.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, bribery and corruption and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, a robust Enterprise Risk Management Program, and conduct comprehensive training, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our enterprise risk program, global risk committee and other compliance methods are not effective, our business, financial condition and operating results may be adversely affected</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to identify, manage and respond to the various risks related to our business is largely dependent on our established and maintained compliance, risk, audit and reporting systems and procedures. The Board of Directors has ultimate responsibility for risk oversight of the Company and carries out this duty through its Committees. Our Audit and Compliance Committee, Nominating and Corporate Governance Committee, Compensation and Leadership Development Committee and Science and Technology Committee have each been delegated oversight authority by the Board of Directors with respect to issues in their applicable areas of expertise. These committees are responsible for identifying, monitoring and reporting areas of concern to the full Board of Directors. At the Company level, our senior management team similarly monitors risk through the Global Risk Committee. Membership of the Global Risk Committee consists primarily of key department heads who are asked to bring to such committee relevant items for discussion that they or their teams have identified at the numerous sub-committees these individuals chair or attend. The Global Risk Committee then uses this information to develop an Enterprise Risk Management Program, which identifies key risks and mitigation strategies and which is reported directly to the Audit and Compliance Committee on a quarterly basis, and to the full Board of Directors on a yearly basis. Our international business segment also has its own companion committee which operates in substantially the same way as the Global Risk Committee and reports key risks to the Global Risk Committee for inclusion in the Enterprise Risk Management Program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our policies, procedures, and compliance systems, including our Enterprise Risk Management Program and the Global Risk Committee are not effective, or if we are not successful in monitoring or evaluating the risks to which we are or may be exposed, our business, reputation, financial condition and operating results could be materially adversely affected. We cannot provide assurance that our policies and procedures will always be effective, or that our management, the Enterprise Risk Management Program or the Global Risk Committee would be able to identify any such ineffectiveness. If our compliance and risk management strategies are not effective, our business, financial condition and operating results may be adversely affected.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and reputation may be adversely affected by environmental, social and governance matters.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are being increasingly judged by not just their financial performance, but also by their performance on a variety of environmental, social and governance (&#8220;ESG&#8221;) matters. These matters include, among others, (i) the company&#8217;s efforts and contributions to or impacts on climate change and human rights matters, (ii) ethics and compliance with law, (iii) diversity and inclusion, and (iv) the role of the company&#8217;s board of directors in supervising various sustainability issues. Additionally, in the healthcare, pharmaceutical and life sciences industries, the public&#8217;s ability to access our medicines is of particular importance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in funds that specialize in companies that perform well in ESG assessments are increasingly popular, and major institutional investors and advisors have publicly emphasized the importance of ESG measures to their investment decisions and recommendations. Investors who are focused on ESG matters may seek enhanced ESG disclosures or to implement policies adverse to our business, and there can be no assurances that stockholders will not advocate, via proxy contests, media campaigns or other public or private means, for us to make corporate governance changes or engage in certain corporate actions. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there can be no certainty that we will successfully navigate or manage ESG issues or that we will successfully meet society&#8217;s expectations as to our proper role in the economy at large or as a global citizen. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation with governments, customers, employees, other third parties and the communities and industries in which we operate and on our business, share price, financial condition, access to capital or results of operations, including the sustainability of our business over time.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, and those of our CROs, contract manufacturing organizations and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, ransomware attacks and other security breaches, natural disasters, terrorism, war and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations and could result in a material disruption of our clinical activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our commercialization of our product and our product candidate development programs. For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruptions or security breach were to result in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur significant unexpected losses, expenses and liabilities, we could face litigation or suffer reputational harm and the further development of our product candidates could be delayed.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire or divest assets or businesses, or form collaborations or make investments in other companies or technologies that could harm our operating results, dilute our stockholders' ownership, increase our debt, or cause us to incur significant expense.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may continue to pursue acquisitions or licenses of assets or businesses, or strategic alliances and collaborations, to expand our existing technologies and operations, such as our acquisition of Celenex in 2018 and license agreement with Penn in 2022. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any such transaction, any of which could have a detrimental effect on our financial condition, results of operations, and cash flows. We may not be able to find suitable acquisition or licensing candidates, and if we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities in connection therewith. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management resources that would otherwise focus on developing our existing business. We may not be able to find suitable collaboration partners or identify other investment opportunities, and we may experience losses related to any such investments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions, licenses or collaborations, we may choose to issue debt or shares of our common stock as consideration. Any such issuance of shares would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may divest or license all or a portion of certain businesses and/or facilities, joint venture or minority equity investment interests, subsidiaries, distributorships, or product categories, which could cause a decline in revenue or profitability and may make our financial results more volatile. We may be unable to complete any such divestiture or license on terms </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favorable to us, within the expected timeframes, or at all. We may have continued financial exposure to divested or licensed businesses following the completion of any such transaction, including increased costs due to potential litigation, contingent liabilities and indemnification of the buyer or licensee related to, among other things, lawsuits, regulatory matters or tax liabilities. Such divestitures or licenses may also divert management&#8217;s attention from our core businesses and lead to potential issues with employees, customers or suppliers.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish a classified board of directors, and, as a result, not all directors are elected at one time;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit the manner in which stockholders can remove directors from our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit who may call stockholder meetings;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize our board of directors to issue preferred stock, without stockholder approval, which could be used to institute a "poison pill" that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require the approval of the holders of at least 67% of the outstanding voting stock to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is sensitive to global economic conditions, which can be adversely affected by public health crises (including the COVID-19 pandemic) and epidemics, political and military conflict, trade and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, trade policies and geopolitical disputes (including as a result of China-Taiwan relations) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures occur in regions where we source our components or raw materials. For example, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from China mainland, as well as other business restrictions. Tariffs increase the costs of the components and raw materials we source. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company&#8217;s operations and supply chain. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, military conflicts or wars (such as the ongoing conflict between Russia and Ukraine) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to numerous factors, some of which are beyond our control. In addition to the factors discussed in this Annual Report on Form&#160;10-K, these factors include:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory actions with respect to our product or product candidates or our competitors' products or product candidates;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome of any patent infringement or other litigation that may be brought against us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">results of clinical trials of our product candidates or those of our competitors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments in the E.U., U.K., U.S. and other countries;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of expenses related to our product or any of our product candidates or clinical development programs;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated variations in our quarterly operating results;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the number and characteristics of our efforts to in-license or acquire additional product candidates or products;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">introduction of new products or services by us or our competitors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in accounting practices;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lawsuits and other claims asserted against us;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic, industry and market conditions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">publication of research reports about us, our competitors or our industry, or positive or negative recommendations or withdrawal of research coverage by securities or industry analysts;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other events or factors, many of which are beyond our control; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the other factors described in this "Risk Factors" section.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks stated above could have a material adverse effect on the market price of our common stock.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we operate in the pharmaceutical and biotechnology industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares may be sold into the market. This could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have registered on a Form&#160;S-8 registration statement all shares of common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. In addition, certain of our employees, executive officers and directors have entered into, or may enter into, Rule&#160;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule&#160;10b5-1 plan, a broker executes trades pursuant to parameters established by the employee, director or officer when entering into the plan, without further direction from the employee, officer or director. A Rule&#160;10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers and directors may also buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they are not in possession of material, nonpublic information. In September 2021, we entered into a securities purchase agreement an investor for the private placement of, among other things, pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. Each pre-funded warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Finally, in November 2022, we announced an "at the market offering" under which we may offer and sell shares of our common stock having an aggregate offering amount of up to $250,000,000.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to qualify for continued listing on The NASDAQ Global Market which could make it more difficult for investors to sell their shares.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on The NASDAQ Global Market, or NASDAQ. As a NASDAQ listed company, we are required to satisfy the continued listing requirements of NASDAQ for inclusion in the Global Market to maintain such listing, including, among other things, the maintenance of a minimum closing bid price of $1.00 per share and stockholders' equity of at least $10.0&#160;million. There can be no assurance that we will be able to maintain compliance with the continued listing requirements or that our common stock will not be delisted from NASDAQ in the future. If our common stock is delisted by NASDAQ, we could face significant material adverse consequences, including:</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reduced liquidity with respect to our securities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a determination that our shares are a "penny stock," which will require brokers trading in our shares to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares;</span></div><div style="margin-bottom:6pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a decreased ability to issue additional securities or obtain additional financing in the future.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our common stock and trading volume could decline.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If securities or industry analysts do not initiate or continue coverage of us, the trading price for our common stock would be negatively affected. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our common stock, the price of our common stock would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our common stock could decrease, which could cause the price of our common stock or trading volume to decline.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have broad discretion in the use of our cash and cash equivalents, and investors must rely on the judgment of our management regarding the use of our cash and cash equivalents. Our management may not use cash and cash equivalents in ways that ultimately increase the value of your investment. Our failure to use our cash and cash equivalents effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product and product candidates. Pending their use, we may invest our cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may not yield favorable returns. If we do not invest or apply our cash and cash equivalents in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause the price of our common stock to decline.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be obtained or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation may adversely affect our business, financial condition, results of operations or liquidity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to the risk of litigation by employees, consumers, vendors, competitors, intellectual property rights holders, stockholders, government agencies and others through private actions, class actions, administrative proceedings, regulatory actions, Hatch-Waxman or other litigation. For example, we and certain of our current and former officers have previously been parties to securities class action lawsuits against us, all of which have been settled or dismissed, and we are currently involved in Hatch-Waxman litigation. The outcome of litigation, particularly class action lawsuits, regulatory actions and intellectual property claims, is difficult to assess or quantify. Plaintiffs in these types of lawsuits may seek recovery of very large or indeterminate amounts, and the magnitude of the potential loss relating to these lawsuits may remain unknown for substantial periods of time. In addition, certain of these lawsuits, if decided against us or settled by us, may result in liability </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material to our Consolidated Financial Statements as a whole or may negatively affect our operating results if changes to our business operation are required. The cost to prosecute or defend litigation may be significant. There also may be adverse publicity associated with litigation that could negatively affect customer perception of our business, regardless of whether the allegations are valid or whether we are ultimately found liable. As a result, litigation may adversely affect our business, financial condition, results of operations or liquidity.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be exposed to employment-related claims and losses which could have an adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to increase the size of our workforce, the risk of potential employment-related claims will also increase. As such, we may be subject to claims, allegations or legal proceedings related to employment matters including, but not limited to, discrimination, harassment (sexual or otherwise), wrongful termination or retaliation, local, state or federal labor law violations, injury, and wage violations. In the event we are subject to one or more employment-related claims, allegations or legal proceedings, we may incur substantial costs, losses or other liabilities in the defense, investigation, settlement or other disposition of such claims. In addition to the economic impact, we may also suffer reputational harm as a result of such claims, allegations and legal proceedings and the investigation, defense and prosecution of such claims, allegations and legal proceedings could cause substantial disruption in our business and operations. While we do have policies and procedures in place to reduce our exposure to these risks, there can be no assurance that such policies and procedures will be effective or that we will not be exposed to such claims, allegations or legal proceedings.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_22"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_25"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table contains information about our current significant leased properties as of December 31, 2022. </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:38.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Square Feet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease expiry date </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Philadelphia, Pennsylvania, U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2044</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marlow, United Kingdom</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Princeton, New Jersey, U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2034</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Includes renewal options on leases which we are reasonably certain to exercise.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, we also maintain offices in other U.S. and international jurisdictions in which we operate. We believe that our current office and laboratory facilities are adequate and suitable for our current and anticipated needs. We believe that, to the extent required, we will be able to lease or buy additional facilities at commercially reasonable rates.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_28"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the information set forth in Note 15 &#8220;Legal Proceedings&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_31"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_37"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market for Our Common Stock</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been traded on the NASDAQ Global Market under the symbol "FOLD" since May&#160;31, 2007. Prior to that time, there was no public market for our common stock. The closing price for our common stock as reported by the NASDAQ Global Market on February&#160;13, 2023 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share. As of February&#160;13, 2023, there were 19 holders of record of our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our capital stock. We currently intend to retain any future earnings to finance the development and growth of our business. We do not intend to declare or pay cash dividends to our stockholders in the foreseeable future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph compares the cumulative total return on our common stock during the last five fiscal years with the NASDAQ Composite Index (U.S.) and the NASDAQ Biotechnology Index during the same period. The graph shows the value at the end of each of the last five fiscal years, of $100 invested in our common stock. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><img src="fold-20221231_g1.jpg" alt="fold-20221231_g1.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"/></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:24.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amicus Therapeutics, Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$160</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$83</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NASDAQ Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$187</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$227</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NASDAQ Biotechnology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$113</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$141</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$124</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to purchase of our common stock during the three months ended December 31, 2022:</span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 1, 2022 through October 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 1, 2022 through November 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2022 through December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.99&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock awards.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_40"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span><br/></span></div><div id="i60868bb9516a413c82303f6b0d1ba997_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease that is under review with the U.S. Food and Drug Administration ("FDA"), the European Medicines Agency ("EMA"), and the United Kingdom ("U.K.") Medicines and Healthcare products Regulatory Agency ("MHRA"). We are committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of our portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), U.K., and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. In May 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. In October 2022, the FDA deferred action on the BLA for cipaglucosidase alfa, citing the inability to complete the manufacturing facility inspection prior to the PDUFA action date.  We are actively engaged with the FDA and an inspection has been scheduled. In December 2022, the Committee for Medicinal Products for Human Use ("CHMP") of the EMA adopted a positive opinion recommending market authorization of cipaglucosidase alfa, or Pombiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the novel coronavirus ("COVID-19") pandemic. Our commercial operations have not been significantly impacted by the COVID-19 pandemic and we gradually continue to see an improvement in patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation. We have maintained operations in all geographies, secured our global supply chain for our commercial and clinical products, as well as maintained the operational integrity of our clinical trials, with minimum disruptions. We have been able to continue to meet required commercial demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as supply our ongoing Pompe disease clinical studies and access programs including the Early Access to Medicines Scheme ("EAMS") without interruption. In regard to our regulatory operations, the FDA deferred action on the pending BLA for cipaglucosidase alfa, as a facility inspection was necessary, however, could not be completed by the PDUFA action date due to COVID-19 related travel restrictions. The facility inspection has subsequently been scheduled. Per FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, receipt of a deferral action indicates no deficiencies have been identified and the application otherwise satisfies the requirements for approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the Consolidated Financial Statements and related notes included elsewhere in this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following section generally discusses 2022 and 2021 items and year-to-year comparisons between 2022 and 2021. Discussions of 2020 items and year-to-year comparisons between 2021 and 2020 that are not included in this Form 10-K can be found in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which comparisons are hereby incorporated by reference.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December 31, 2022 Compared to Year Ended December 31, 2021 </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected financial information for the Company:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:57.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of goods sold as a percentage of net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss on impairment of assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(867)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236,568)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,460)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales increased $23.7 million during the year ended December 31, 2022 compared to the prior year. The increase was primarily due to continued growth in the U.S., Europe, and Japan markets, partially offset by the $26.1&#160;million unfavorable impact of foreign currency exchange.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal product development programs for each product candidate in development, and the out-of-pocket, third-party expenses incurred with respect to each product candidate:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:66.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Projects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party direct project expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Fabry Disease)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AT-GAA (Pompe Disease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gene therapy programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-clinical and other programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total third-party direct project expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other project costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other project costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,009&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $4.6 million increase in research and development expense was primarily due to an increase in personnel share-based compensation and Fabry disease clinical research. These costs were partially offset by a decrease in Pompe disease clinical research due to active studies nearing completion and the timing of manufacturing costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expense increased $20.3 million, primarily driven by the strategic prioritization of our gene therapy portfolio that resulted in the write-off of cloud computing costs and software licensing fees, as well as increases in share-based compensation, marketing, and travel to support our organizational growth. These costs were partially offset by a reduction in third-party professional fees.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Fair Value of Contingent Consideration Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Changes in fair value of contingent consideration payable decreased $5.4&#160;million, primarily due to achievement of two regulatory milestones during the year ended December 31, 2021, as well as changes to certain valuation inputs resulting from the strategic prioritization of our gene therapy portfolio during the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Impairment of Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the strategic prioritization of our gene therapy portfolio, the Company performed an assessment of its assets and recognized a $6.6&#160;million loss on impairment of assets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest expense increased $4.6 million during the year ended December 31, 2022. The increase was due to a higher LIBOR year over year. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The $7.1 million variance was primarily related to foreign exchange gains caused by local currency remeasurement of U.S. dollar balances.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax benefit for the year ended December 31, 2022 was $5.5 million. We are subject to income taxes in various jurisdictions but due to the offset of taxable income with net operating losses and full valuation allowance, there is nominal tax expense in 2022 for taxes in U.S. federal and state jurisdictions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP"). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the following discussion represents our critical accounting policies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net product sales primarily consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of Fabry disease. We have recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are generally received from distributors and pharmacies with the ultimate payor often a government authority.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when our performance obligation with our customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in our customer contracts and is recorded net of estimates for variable consideration, which are primarily third-party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is recognized. We recognize revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. We evaluate these estimates each reporting period to reflect known changes.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our Consolidated Financial Statements, we are required to estimate and accrue our research and development expenses, including those related to clinical studies and drug manufacturing. This process involves reviewing contracts and purchase orders, identifying services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for preclinical studies, clinical studies and manufacturing activities are recognized based on an evaluation of our vendors&#8217; progress towards completion of specific tasks, using data such as clinical site activations, clinical site maintenance, clinical site close out, patient out of pocket cost reimbursements, or information provided to us by our vendors regarding their actual costs incurred. Payments for these activities are based on the terms of individual contracts and payment timing may differ significantly from the period in which the services were performed. We determine accrual estimates through reports from and discussions with applicable personnel and outside service providers as to the progress or state of completion of studies, or the services completed. Our estimates of accrued expenses as of each balance sheet date are based on the facts and circumstances known at the time. Costs that are paid in advance of performance are deferred as a prepaid expense and amortized over the service period as the services are provided.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:27.8pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the applicable accounting guidance, we estimate the fair value of each equity award on the day of grant. We chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model when estimating the grant date fair value for share-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is based on our historical volatility since our initial public offering in May 2007. We determine the average expected life using our actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on historical analysis of actual option forfeitures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the plan are generally subject to graded vesting and are contingent on an employee's continued service on such date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We expense the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. In addition, certain of our share-based awards are market- and performance-based and dependent upon achieving certain goals. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized on a straight-line basis over the vesting term. With respect to performance-based awards, we estimate the probability that the performance conditions will be achieved. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased in-process research and development ("IPR&amp;D") is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which our single reporting unit's carrying value, including goodwill, exceeds its fair value.  An IPR&amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event. For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones. Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved, and the consideration is paid or becomes payable.  Contingent consideration obligations in business acquisitions are recorded at fair value on the acquisition date. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of contingent consideration obligations through a probability weighted discounted cash flow valuation approach based on various assumptions and incorporating estimated success rates. Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Each period we reassess the fair value of the contingent consideration payable and recognize changes within the Consolidated Statements of Operations. Changes in the fair value of the contingent consideration payable can result from changes in estimated probability adjustments with respect to regulatory approval, changes in the assumed timing of when milestones are likely to be achieved and changes in assumed discount periods and rates. Significant judgment is employed in determining the appropriateness of these assumptions each period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described in the accounting for business combinations above can materially impact the amount of contingent consideration expense that we record and, therefore, our results of operations in any given period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuance, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we entered into a Sales Agreement with The Goldman Sachs &amp; Co. LLC to create an at-the-market ("ATM") equity program, pursuant to which we may offer to sell shares of our common stock having an aggregate offering gross proceeds of up to $250.0 million. At December 31, 2022, no shares have been issued under the ATM equity program.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into securities purchase agreements with certain investors for the private placement of an aggregate of 11,296,660 shares of our common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. The net proceeds from these private placements were approximately $199.8 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flow Discussion</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had cash, cash equivalents, and marketable securities of $293.6 million. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "&#8212; Note 4.&#160;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the year ended December 31, 2022 was $166.6 million. The components of net cash used in operations included the net loss for the year ended December 31, 2022 of $236.6 million and the net change in operating assets and liabilities of $39.9 million. The change in operating assets was primarily due to increases in accounts receivable of $17.3 million due to increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an increase in prepaid and other current assets of $6.2 million to support commercial activities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase in inventory of $5.3 million. The net cash used in operations was also impacted by a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accounts payable and accrued expenses of $6.4 million, associated with payments of contract manufacturing and third party development services partially offset by increases in sales rebates and royalties associated with increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the year ended December 31, 2021 was $202.5 million. The components of net cash used in operations included the net loss for the year ended December 31, 2021 of $250.5 million, and the net change in operating assets and liabilities of $28.9 million. The change in operating assets was primarily due to increases in accounts receivable of $8.2 million due to increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an increase in inventory of $7.8 million, and increase in prepaid and other current assets of $5.9 million to support commercial activities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The net cash used in operations was also impacted by an increase in accounts payable and accrued expenses of $7.4 million, mainly related to program expenses and support for the commercial activities of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and a decrease due to payment of contingent consideration of $10.4 million associated with meeting certain regulatory milestones during the year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Investing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2022 was $92.3 million. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $335.9 million for the sale and redemption of marketable securities and $3.4 million of proceeds from the sale of our property and equipment, partially offset by $243.3 million for the purchase of marketable securities and $3.8 million for capital expenditures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2021 was $78.8 million. Our investing activities have consisted primarily of purchases, sales, and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $424.0 million for the sale and redemption of marketable securities, partially offset by $341.4 million for the purchase of marketable securities and $3.9 million for capital expenditures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash (Used in) Provided by Financing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December 31, 2022 was $7.5 million. Net cash used in financing activities primarily reflects $11.5 million from payments of employee withholding taxes related to restricted stock unit vesting, partially offset by $4.3 million from the exercise of stock options.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2021 was $212.1 million. Net cash provided by financing activities primarily reflects $199.8 million in net proceeds from the September 2021 private placement of securities, $19.2 million from the exercise of warrants and $10.2 million from the exercise of stock options, partially offset by $15.0 million from payments of employee withholding taxes related to restricted stock unit vesting.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant costs in the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials.&#160;Our future capital requirements will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of clinical trials for our drug candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa");</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the estimates regarding the potential market opportunity for our product and product candidates, including AT-GAA; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory applications are approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, if approved and applicable, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory applications are approved, AT-GAA;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of litigation that has been or may be brought against us or of litigation that we are pursuing or may pursue against others, including Hatch-Waxman litigation;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, or successfully divest or license existing products and technologies from our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish licensing agreements, collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including actions by us, governments, our customers, our suppliers, or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with, and our ability to comply with, emerging environmental, social and governance standards;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to accurately forecast revenue, operating expenditures, or other metrics impacting profitability;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional funding through public or private financings of debt or equity. Based on our current operating model, we believe that the current cash position, which includes expected revenues, is sufficient to fund our operations and ongoing research programs for at least the next 12 months. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, remaining maturities, including interest, on our Senior Secured Term Loan due 2026 was $517.7&#160;million. Refer to "&#8212; Note 11. Debt," to the Consolidated Financial Statements for more information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are lessees to various operating leases for facilities and equipment. As of December 31, 2022, our undiscounted cash liabilities for operating leases were $168.8&#160;million, with maturities ranging up through fiscal 2044. Refer to &#8220;&#8212; Note 12. Leases,&#8221; to the Consolidated Financial Statements for more information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of binding minimum purchase and manufacturing commitments due to our third-party manufacturers. As of December 31, 2022, these purchase and manufacturing obligations totaled $62.4&#160;million. Contracts for which our commitment is variable, based on volumes, with no fixed minimum quantities, and contracts that can be canceled without payment penalties have been excluded. These purchase obligations are in addition to amounts recorded on our December 31, 2022 Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements as of December 31, 2022 and 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milestone Payments / Royalties</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Callidus - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Callidus Biopharma, Inc. ("Callidus"), we may be obligated to make additional payments to the former stockholders of Callidus upon the achievement of certain clinical milestones of up to $35 million and regulatory milestones of up to $80 million set forth in the merger agreement, provided that the aggregate merger consideration shall not exceed $130 million. As of December 31, 2022, $20 million and $68 million remain outstanding, respectively. Refer to &#8220;&#8212; Note 10. Assets and Liabilities Measured at Fair Value,&#8221; to the Consolidated Financial Statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celenex - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Celenex, Inc. ("Celenex"), we may be obligated to pay up to an additional $10 million in connection with the achievement of certain development milestones, $220 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#8217;s Hospital ("Nationwide Children&#8217;s"). Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with our license agreement with the University of Pennsylvania ("Penn"), Penn is eligible to receive up to an aggregate of $86.5 million for the achievement of certain milestones and royalty payments with respect to licensed products for each indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our collaboration agreement with GlaxoSmithKline ("GSK"), pursuant to which we obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to "&#8212; Note&#160;2. Summary of Significant Accounting Policies," in our Notes to the Consolidated Financial Statements.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_46"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents, and marketable securities. We place our investments in high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities, and U.S. government agency notes with maturities of less than one year, which we believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are subject to minimal interest rate risk. We believe that a 1% (100 basis points) change in average interest rates would either increase or decrease the market value of our investment portfolio by $0.5&#160;million as of December 31, 2022. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk with respect to variable rate debt. At December 31, 2022, we had a $400 million Senior Secured Term Loan due 2026 that bears interest at a rate equal to the 3-month LIBOR, subject to a 1% floor, plus 6.5% per year. We do not currently hedge our variable interest rate debt. The annual average variable interest rate for our variable rate debt as of December 31, 2022 was 8.5%. A hypothetical 100 basis point increase or decrease in the average interest rate on our variable rate debt would result in $4.1 million change in the interest expense as of December 31, 2022. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Conduct Authority has announced the intent to phase out the use of LIBOR by mid-2023. If LIBOR is discontinued, we may need to renegotiate the terms of the Senior Secured Term Loan due 2026 in order to replace LIBOR with an alternative standard. As a result, we may incur incremental costs in transitioning to a new standard, and interest rates on our current or future indebtedness may be adversely affected by the new standard. The potential effect of any such event on our cost of capital cannot yet be determined, but we do not expect it to have a material impact on our consolidated financial condition, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. We are not currently engaged in any foreign currency hedging activities. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates may be partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Consolidated Financial Statements and</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of Amicus Therapeutics,&#160;Inc. has prepared, and is responsible for the Company's Consolidated Financial Statements and related footnotes. These Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S.&#160;GAAP").</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of the Company's principal executive and principal financial officers and effected by the Company's board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;GAAP and includes those policies and procedures that:</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of Amicus Therapeutics,&#160;Inc.;</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of Amicus therapeutics,&#160;Inc. are being made only in accordance with authorizations of management and directors of Amicus therapeutics,&#160;Inc.; and</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Amicus Therapeutics,&#160;Inc. that could have a material effect on the financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) ("COSO") in Internal Control&#160;&#8212; Integrated Framework. Based on our assessment we believe that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company's internal control over financial reporting as of December 31, 2022 has been audited by Ernst&#160;&amp; Young&#160;LLP, an independent registered public accounting firm, as stated in their report. This report appears on the following page.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated March&#160;1, 2023 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:37.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;BRADLEY L. CAMPBELL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DAPHNE QUIMI</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_52"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:0.05pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amicus Therapeutics,&#160;Inc.&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Amicus Therapeutics,&#160;Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated March&#160;1, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Consolidated Financial Statements and Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  Ernst&#160;&amp; Young&#160;LLP</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:0.05pt"><span><br/></span></div><div style="margin-bottom:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Amicus Therapeutics,&#160;Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March&#160;1, 2023 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:12pt;margin-top:0.05pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement of the Contingent Consideration</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As described in Note 10 to the consolidated financial statements, the Company has a $21.4 million contingent consideration liability recorded as of December 31, 2022 representing the fair value of additional amounts that management believes are likely to be paid to the former stockholders of Callidus Biopharma, Inc. The determination of the recorded amount of the contingent consideration liabilities requires the Company to make significant estimates and assumptions.</span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We identified the measurement of the contingent consideration liability as a critical audit matter because auditing the Company&#8217;s valuation of the contingent consideration liability involved complex and challenging auditor judgment as the inputs to such valuation, such as the estimated probability of achieving milestones, the assumed timing of milestones and the discount rates, are largely unobservable. </span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;margin-top:0.05pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the estimated fair value of the contingent consideration liability, we performed audit procedures that included testing the operating effectiveness of internal controls relating to management&#8217;s fair value measurement of the contingent consideration liability including controls over the Company&#8217;s model, significant assumptions, and data. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our procedures also included, among others, assessing the terms of the arrangement, evaluating the methodology used, testing the significant assumptions discussed above and the completeness, accuracy and relevance of the underlying data used by management in its analysis. We also performed analyses of certain assumptions to assess the impact of changes in certain assumptions on the Company&#8217;s determination of the fair value of the contingent consideration liability. Evaluating the assumptions also involved evaluating whether the assumptions used by management were consistent with external market data and evidence obtained in other areas of the audit.</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181NS9mcmFnOmIxOThjOTI3MThlNDRiNWNhYmQ0ZmJkNjA0MmYwOGE3L3RhYmxlOjg1ZDBiY2YxZDFkMzRhYjc4Y2Y5MzI1NTg2Y2I5ODU5L3RhYmxlcmFuZ2U6ODVkMGJjZjFkMWQzNGFiNzhjZjkzMjU1ODZjYjk4NTlfMC0wLTEtMS0zMzQ4NC90ZXh0cmVnaW9uOjMxMjNjMTJjYWFlZjQyZjliMGU5ZTJlOWFjYjc4YjgxXzk_d48c3a0c-678e-4f2a-915f-c03bb73aa5c9">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2003.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181NS9mcmFnOmIxOThjOTI3MThlNDRiNWNhYmQ0ZmJkNjA0MmYwOGE3L3RleHRyZWdpb246YjE5OGM5MjcxOGU0NGI1Y2FiZDRmYmQ2MDQyZjA4YTdfMzQzOQ_f6e5f871-a51e-41ae-bb17-2eaa94557704">Iselin, New Jersey</ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2023 </span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNC0xLTEtMS0zMzQ4NA_e0b35bdd-1bc3-4502-a35c-2ad302f94a18">148,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNC0zLTEtMS0zMzQ4NA_c3cc282e-9baa-4281-8fc5-1e5433621775">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNS0xLTEtMS0zMzQ4NA_cde497d7-9c58-45cc-bc1b-85187d141a0f">144,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNS0zLTEtMS0zMzQ4NA_ba1f2ab6-c23f-4761-8839-fe62cd107adc">237,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNi0xLTEtMS0zMzQ4NA_e0fa8574-4c49-423a-a863-b17a64e092f4">66,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNi0zLTEtMS0zMzQ4NA_9707df5b-e54d-42be-a706-e54d076a23a6">52,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNy0xLTEtMS0zMzQ4NA_293f39ca-350e-490a-bcb8-0d2d67ad49ce">23,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNy0zLTEtMS0zMzQ4NA_aa430f4e-74c0-48d5-9dbc-b8175984ddce">26,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOC0xLTEtMS0zMzQ4NA_54d52069-606d-44d4-8af5-187623261345">40,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOC0zLTEtMS0zMzQ4NA_a984fd77-74f6-458c-9c95-6ae90cf92672">34,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOS0xLTEtMS0zMzQ4NA_42dd43aa-7c76-4c0f-b7a9-43fe267e7ff8">423,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOS0zLTEtMS0zMzQ4NA_7e950689-2465-4207-9ad9-9b55634216c9">596,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTAtMS0xLTEtMzM0ODQ_aa639658-4e7f-4f94-a097-d631f9989352">29,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTAtMy0xLTEtMzM0ODQ_f4004a8c-9fbb-4e79-bf83-9f36be730074">20,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, less accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjowMjg0ZDMyMzYxYTA0OGU0OWJlZDE0ZTY3NjdhOWJmNV82MQ_9dbe595f-1401-463f-b512-118ec76d9349">22,281</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjowMjg0ZDMyMzYxYTA0OGU0OWJlZDE0ZTY3NjdhOWJmNV82OA_aabf6636-40c5-40b0-9926-8cd99c300b5d">19,882</ix:nonFraction> at December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMS0xLTEtMzM0ODQ_2df47375-11cf-400b-a52b-52cf7cbf4f0f">30,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMy0xLTEtMzM0ODQ_f77a434c-bca6-457b-a2e9-4dc08435d4b0">42,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research&#160;&amp; development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTItMS0xLTEtMzM0ODQ_93314b6e-b796-4cfe-a17d-243d3c30a41e">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTItMy0xLTEtMzM0ODQ_529a523d-d5b8-4d68-b627-efd5df6166b7">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTMtMS0xLTEtMzM0ODQ_45fc8156-8c24-452e-a964-78c50e4f2d4e">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTMtMy0xLTEtMzM0ODQ_4ef8e7da-aedc-492c-8dab-b8d86f2e2946">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTQtMS0xLTEtMzM0ODQ_e20ab0bf-8037-4763-b51a-0ab9c2632b44">19,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTQtMy0xLTEtMzM0ODQ_f9724e85-4752-48c3-a3f5-fee16ff587ca">24,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTUtMS0xLTEtMzM0ODQ_9f9e7b81-efca-42e5-9a4e-c075bbb6521b">724,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTUtMy0xLTEtMzM0ODQ_05f8bec7-9215-4533-a8e7-a7b2ec88361d">905,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTgtMS0xLTEtMzM0ODQ_465f3fde-c944-4a7d-bc62-3488413846cf">15,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTgtMy0xLTEtMzM0ODQ_86f23e4d-31ac-43fc-9466-4293bebc59ff">21,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTktMS0xLTEtMzM0ODQ_52669fef-fd05-4542-b75e-bfdf752bc92b">93,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTktMy0xLTEtMzM0ODQ_2dc20a38-0d86-429a-ac9f-914a9b560028">98,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjAtMS0xLTEtMzM0ODQ_d21b6c5d-936c-417b-81b1-e16cf4b7be74">21,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjAtMy0xLTEtMzM0ODQ_30dd32a9-3b7c-4b81-bde1-3d5c2c55401f">18,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjEtMS0xLTEtMzM0ODQ_495542b3-4ce7-4344-be21-94c2587be30d">8,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjEtMy0xLTEtMzM0ODQ_89790829-aa9e-4b5f-836b-e59f505e287d">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjItMS0xLTEtMzM0ODQ_e2e26cf2-7476-4fbd-b1dd-3244c38651bd">139,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjItMy0xLTEtMzM0ODQ_e8738b0a-c19a-45d1-8232-3b67c1273893">145,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMS0xLTEtMzY1NzE_83e5a4dc-c733-4563-86bc-263b5a8c4b40">391,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMy0xLTEtMzY1NzE_a5ba31d0-94ff-4fe2-9c28-deed8c5f8b76">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjQtMS0xLTEtMzY1Nzg_d973b853-3638-4e9e-8a0c-39b12e467b21">51,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjQtMy0xLTEtMzY1Nzg_fa1e0777-b95e-45e0-9cdb-1c988357172e">43,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjUtMS0xLTEtNDAxNjc_769e3af3-28cb-47fc-96da-8badfe01e49c">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjUtMy0xLTEtNDAxNjc_b8b2a0c5-6698-42a2-9a42-e1684ae3ccf6">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMS0xLTEtMzM0ODQ_b412a83f-2214-46a3-9521-91479ea652fc">4,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMy0xLTEtMzM0ODQ_dd20b774-f043-487d-80f3-05dc5ceef507">5,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjgtMS0xLTEtMzM0ODQ_a20c1c23-9e44-4288-afdf-6bbf1cc23725">8,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjgtMy0xLTEtMzM0ODQ_29a2933e-ff93-4346-8ba2-5a9a3e9d441f">8,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjktMS0xLTEtMzM0ODQ_da789686-b976-4814-b903-e56e5d359799">601,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjktMy0xLTEtMzM0ODQ_46484c2f-ab5c-4628-897d-777c1c55549e">597,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzAtMS0xLTEtMzM0ODQ_3e7c1942-9d55-4eb9-a734-d2f26e2b9da7"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzAtMy0xLTEtMzM0ODQ_69fb141f-e134-4433-a2ca-9c05850f2894"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8xOA_1d1164fe-e625-4842-a073-f74a071d93be"><ix:nonFraction unitRef="usdPerShare" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8xOA_c1f1f0fb-6a93-46fb-9149-8dcfcdafde7c">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8zMg_5c275367-540c-4f2d-a7b4-a49af084d086"><ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8zMg_88121304-0622-48a3-938c-a70320bbea01">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV81NA_09713280-82a8-4a7e-a419-10a5957374a9"><ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV81NA_a53b67bf-0e4d-4466-b6d5-0c2c9de5e612">281,108,273</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV82MQ_2ab2ae72-d059-4474-819a-183613931e59"><ix:nonFraction unitRef="shares" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV82MQ_9261f9c5-c16a-458e-9e8c-cade8ea5b4c6">278,912,800</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMS0xLTEtMzM0ODQ_dcb7dc09-faae-4cf5-a4c4-301f296a399d">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMy0xLTEtMzM0ODQ_8f95a0fd-73b0-4458-aaf0-06285ac1f78c">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzMtMS0xLTEtMzM0ODQ_ca1dcf3c-59e3-4371-be86-8af5b3e447c6">2,664,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzMtMy0xLTEtMzM0ODQ_ead0e5d3-deda-4c9c-a358-3cb2169d6c58">2,595,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) gain:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzUtMS0xLTEtMzM0ODQ_7030cd0c-f0ab-488b-90b5-b532159dd7b9">11,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzUtMy0xLTEtMzM0ODQ_d235ad0d-b027-4d88-a261-b0996c468c97">5,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzYtMS0xLTEtMzM0ODQ_94d6ca12-d010-4a35-a15f-07bdb20621f3">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzYtMy0xLTEtMzM0ODQ_a5115124-a31b-480b-9c84-69678a1f7abe">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzctMS0xLTEtMzM0ODQ_64b19cb4-4aca-4186-9c68-197fdd7ed1e8">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzctMy0xLTEtMzM0ODQ_101ef394-9db3-49ef-bf57-5a34fa392afd">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzgtMS0xLTEtMzM0ODQ_67f417cf-4dfd-4c05-9960-5dd19583c0d3">2,532,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzgtMy0xLTEtMzM0ODQ_c2512754-0f5e-4be5-8539-ff9018a48ba7">2,295,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzktMS0xLTEtMzM0ODQ_9dd23619-d20f-4bb5-8158-68ab15a2bd25">123,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzktMy0xLTEtMzM0ODQ_00c49b07-ce95-414a-b35b-a4a0a08beae3">307,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders' Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNDAtMS0xLTEtMzM0ODQ_fe47d58d-05bc-4d98-92a2-778adc98f640">724,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNDAtMy0xLTEtMzM0ODQ_2ea62abc-8043-426b-974c-7e502d4adab6">905,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMi0xLTEtMS0zMzQ4NA_d591b5a5-9c11-4491-9054-15f7ef62577d">329,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMi0zLTEtMS0zMzQ4NA_e9df2e14-24a6-4d01-bb75-960c7af5660b">305,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMi01LTEtMS0zMzQ4NA_e5056927-fd4f-46e8-bc9c-ee5decba5ae7">260,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMy0xLTEtMS0zMzQ4NA_218ce292-5c25-4c01-98e7-dfd0001bacc7">38,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMy0zLTEtMS0zMzQ4NA_9c1e6f49-801a-4330-a9c6-09e872991a16">34,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMy01LTEtMS0zMzQ4NA_1979fa72-c314-4717-9383-7e661786e3e8">31,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNC0xLTEtMS0zMzQ4NA_f94566a7-a14a-4f48-80d9-d01410f916fd">290,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNC0zLTEtMS0zMzQ4NA_4fdcc392-d1b5-4a66-8815-f6a2e7fe69f1">271,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNC01LTEtMS0zMzQ4NA_893c9afd-e2cd-4659-a9f5-fec4cc5259ab">229,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNi0xLTEtMS0zMzQ4NA_d7004e9b-debc-4c28-b43a-7a876fcec3dd">276,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNi0zLTEtMS0zMzQ4NA_45c6dd63-f64a-49a0-9259-cc88b05c7aea">272,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNi01LTEtMS0zMzQ4NA_7dfd3c3d-2dd0-4e51-a526-c1df284e4349">308,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNy0xLTEtMS0zMzQ4NA_6a868185-1146-4bac-ac5a-4c7a27395e9a">213,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNy0zLTEtMS0zMzQ4NA_334926a4-ac4a-41fb-8910-cce002eacf9c">192,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNy01LTEtMS0zMzQ4NA_4303b871-759a-4917-a04a-af8848230cd3">156,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOC0xLTEtMS0zMzQ4NA_30fd46cf-6fdd-4832-8556-7d39891ba8d6">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOC0zLTEtMS0zMzQ4NA_bc137bfe-3852-442e-a796-76fa066026d2">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOC01LTEtMS0zMzQ4NA_424ceb7d-5ad1-4fc2-b9a6-9e848024d38c">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0xLTEtMS0zNjY0NQ_cef65ca6-a38f-4470-9a52-1f6fe1c56856">6,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0zLTEtMS0zNjY1Mw_ac273bbb-fbcf-43da-9877-81b6db49d637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS01LTEtMS0zNjY2Mg_27b6a77e-02a1-471c-ab0c-77d6dac1b939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0xLTEtMS0zMzQ4NA_610bd037-06c5-4cd6-b3fe-1175f900649c">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0zLTEtMS0zMzQ4NA_dea730ec-db15-4f15-9991-4b80dcb0c7b2">6,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS01LTEtMS0zMzQ4NA_500248fd-7205-4eed-a61b-335117b61f6c">8,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTAtMS0xLTEtMzM0ODQ_e46dc9bb-87ef-482b-93f2-8f6ce980da9f">502,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTAtMy0xLTEtMzM0ODQ_a55920fb-b664-46e0-8b6e-6777c21292fa">477,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTAtNS0xLTEtMzM0ODQ_0daad69d-0ac5-4b7e-af1c-898cf872d879">476,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTEtMS0xLTEtMzM0ODQ_79e75ea3-e28d-44bb-9b6f-a2595ee8e5cc">212,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTEtMy0xLTEtMzM0ODQ_d2a9b6c0-3335-4985-b151-629d1466c34c">206,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTEtNS0xLTEtMzM0ODQ_1ce03ebf-c30f-446c-b2ba-64a6fb1634b3">246,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTMtMS0xLTEtMzM0ODQ_2b233d0e-2a9d-4d4b-9c9a-31a230dae787">3,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTMtMy0xLTEtMzM0ODQ_3d20e90a-c4c4-49d3-b1b6-7964c9e922ea">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTMtNS0xLTEtMzM0ODQ_5ae6861c-1071-4ea2-be2b-6dd9ed1f1b2f">3,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTQtMS0xLTEtMzM0ODQ_2f00b82d-fefe-43cb-bcd8-0e8fc13da888">37,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTQtMy0xLTEtMzM0ODQ_79265994-8f27-409a-aedb-acef456fbf17">32,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTQtNS0xLTEtMzM0ODQ_1e9ec769-c231-4548-a3de-d80a8a74f32a">22,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTYtMS0xLTEtMzM0ODQ_dcb04c7f-2341-4def-8d93-a176e83903f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTYtMy0xLTEtMzM0ODQ_5fbc45cf-590a-4232-8114-c347fe96ebfc">257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTYtNS0xLTEtMzM0ODQ_d9897e39-200a-4ac3-8b3e-317eb4f01f25">7,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTctMS0xLTEtMzM0ODQ_7bb79202-58df-44bb-b52d-258c4d684900">4,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTctMy0xLTEtMzM0ODQ_47188334-e061-412f-9895-0bd349d87e37">2,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTctNS0xLTEtMzM0ODQ_66901e17-8505-4c84-bb6c-2eb7d5c2f208">781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTgtMS0xLTEtMzM0ODQ_4ae082ef-9559-43c9-bc8b-0d998d17393d">242,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTgtMy0xLTEtMzM0ODQ_1303c8ff-79bb-42d1-8b55-8377082da9df">241,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTgtNS0xLTEtMzM0ODQ_8e9297dc-21cb-4dd5-b31e-c6064259d518">274,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTktMS0xLTEtMzM0ODQ_460e76ab-d11f-46c1-891e-7dbecf171e0e">5,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTktMy0xLTEtMzM0ODQ_de812741-1d6b-449d-8aee-20535b447b90">8,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTktNS0xLTEtMzM0ODQ_58625f1f-ab9b-4b46-94ea-8a43ebb592fc">2,598</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjAtMS0xLTEtMzM0ODQ_31912635-4e4b-42fe-bf54-1da7e198e03b">236,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjAtMy0xLTEtMzM0ODQ_2986588f-afdf-41a5-a48f-0584aba577b5">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjAtNS0xLTEtMzM0ODQ_25165998-6a40-4506-b07c-90d9ba582d3b">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMS0xLTEtMzM0ODQ_926f3db3-5b20-480d-ba71-21e99f93648a"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMS0xLTEtMzM0ODQ_c26190ad-a13c-417f-a7a4-15a4b31a860a">0.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMy0xLTEtMzM0ODQ_48bd198e-37c1-4077-a2f1-e85924413957"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMy0xLTEtMzM0ODQ_6e159bb5-4598-40b9-88c5-77d78f72edd4">0.92</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtNS0xLTEtMzM0ODQ_3e97f924-c2ce-4021-ae8c-8ad94f4b1a35"><ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtNS0xLTEtMzM0ODQ_8110304d-e0d5-4367-a270-d22c8cdb4642">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMS0xLTEtMzM0ODQ_1c433790-e582-4274-9d40-d8d40070ee6d"><ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMS0xLTEtMzM0ODQ_976d7ef8-0948-41f0-86fe-6b67d7276185">289,057,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMy0xLTEtMzM0ODQ_9200c32c-e3b5-4763-84d7-eda3e10510eb"><ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMy0xLTEtMzM0ODQ_a4920a97-c93c-4f72-b5b9-1f79b627fc91">271,421,986</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItNS0xLTEtMzM0ODQ_886e1219-fdba-46d4-9fe2-6e66f0f50fae"><ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItNS0xLTEtMzM0ODQ_fd54a87e-c817-4f27-874d-4fbc4064a449">258,867,380</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-88-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfMi0xLTEtMS0zMzQ4NA_b137e190-00be-4ab7-a310-66cfa2d40429">236,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfMi0zLTEtMS0zMzQ4NA_80a853cc-d1d3-4c33-9da3-47889c0f347d">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfMi01LTEtMS0zMzQ4NA_86b27324-3c57-42a8-870b-cb84f9893970">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment (loss) gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNC0xLTEtMS0zMzQ4NA_73c2d101-9d91-49fb-8240-562180d03a80">17,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNC0zLTEtMS0zMzQ4NA_dd37173b-117c-42af-99be-82bd9306b734">3,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNC01LTEtMS0zMzQ4NA_c3415dca-9be9-4d0a-b9a4-3e8ccc430c42">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNS0xLTEtMS0zMzQ4NA_4ba57c58-b16c-4a65-bfd5-8a881f06894a">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNS0zLTEtMS0zMzQ4NA_44bd1485-b6d9-44b8-a129-3c27b8b03bf4">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNS01LTEtMS0zMzQ4NA_cf206f18-8aa9-4514-acec-88d64c6b09f3">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) gain</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNi0xLTEtMS0zMzQ4NA_067ea269-19c1-42ec-9fbb-772f4aa1fc5d">17,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNi0zLTEtMS0zMzQ4NA_2d92822b-183d-4ca0-9c80-008cc46b4d27">3,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNi01LTEtMS0zMzQ4NA_27f615ae-e446-4295-ae39-4a4a4f4957ae">5,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNy0xLTEtMS0zMzQ4NA_c7ea9194-575d-4007-a455-f063c617b792">253,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNy0zLTEtMS0zMzQ4NA_a0412609-7975-4bbb-b86c-5f97bbca4afb">253,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNy01LTEtMS0zMzQ4NA_93f5de3d-4cc2-4d20-ac02-8a5ccf7c30f6">271,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-89-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40d6b75012b24abc830ece41c6c75656_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMS0xLTEtMzM0ODQ_1808e56c-1f22-4edb-a966-74533efa7633">255,417,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d6b75012b24abc830ece41c6c75656_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMy0xLTEtMzM0ODQ_142e9616-9831-4061-a2ee-82d8a745c284">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98d799a4ea240c598fa644f12ddd44d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtNS0xLTEtMzM0ODQ_a1319aad-f82d-4adf-b405-1e8d35e4fd60">2,227,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida6ebb73d0a44583a25622bc2ff8bc70_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtNy0xLTEtMzM0ODQ_b86bc328-8688-43e6-ac8e-8b5fdfb5f594">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55cdc3ed7a544ad78b27effbad17252b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtOS0xLTEtMzM0ODQ_6e0f5293-93ce-4199-b929-a8427128235f">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i331f4737a70b494d8165d7ad00b4f89c_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMTEtMS0xLTMzNDg0_b8017908-3941-4d91-9195-c45fb2c91b61">1,768,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMTMtMS0xLTMzNDg0_6de1c21a-c459-497e-9fdc-203575acf7f9">476,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtMS0xLTEtMzM0ODQ_4ddd6d9a-5a41-44fa-9603-52bc2f1387f7">5,233,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtMy0xLTEtMzM0ODQ_4a102e53-9ea2-4b3f-9d60-e95b47ac7bd4">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtNS0xLTEtMzM0ODQ_a16084cc-6d52-49cb-ae9b-43f7b99cc915">42,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtMTMtMS0xLTMzNDg0_a9dce125-b1dc-41f1-b1f9-f8a939ee3b25">42,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTYtMS0xLTEtMzM0ODQ_543b0de2-92fc-4133-a274-0a68c826ca07">1,411,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTYtNS0xLTEtMzM0ODQ_95ce1acb-d9fb-4a5b-9f25-b74e4cd7527f">10,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTYtMTMtMS0xLTMzNDg0_b6893123-85f6-4410-9b30-0911251bf6a8">10,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTctNS0xLTEtMzM0ODQ_2afff49e-b709-495d-a2a6-22098a321a3a">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTctMTMtMS0xLTMzNDg0_4dfba46e-525a-420b-9bf8-5dfb54b12a98">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if20d67fb12e4438dbfce2517356c6668_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTgtOS0xLTEtMzM0ODQ_9278d359-0899-4c38-aa9d-63a9d7b6996a">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTgtMTMtMS0xLTMzNDg0_8e29db16-5300-46a0-aa66-dad16422a69f">225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20d67fb12e4438dbfce2517356c6668_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTktOS0xLTEtMzM0ODQ_67467b5d-42d5-49f6-9041-45e0f48a67e0">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTktMTMtMS0xLTMzNDg0_eead63c6-0137-4e96-a966-3af3b61014d7">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61a54e11bb144d7283f688389627911d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMTEtMS0xLTMzNDg0_88fbe4d3-569e-4a0a-b8ac-2fa52001771e">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMTMtMS0xLTMzNDg0_d6f94bfc-3e06-4995-9e20-e5f89480e23c">276,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2920a3c79ee544bfb57550e1524b3be6_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMS0xLTEtMzM0ODQ_89740f15-c626-4cd5-9339-4a86983fd2f9">262,063,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2920a3c79ee544bfb57550e1524b3be6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMy0xLTEtMzM0ODQ_b3c208ab-938e-4503-ae2b-e023752e1967">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ce7db741914e24aba11ec227d80098_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtNS0xLTEtMzM0ODQ_65f834dc-f447-4b6c-82d5-176d63af72a0">2,308,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1c8441149f45b193c288045bfccb67_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtNy0xLTEtMzM0ODQ_aaad9d43-0807-4de2-80b3-66b547f1eb79">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5867ad5312c144e38a3ba1be62b312de_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtOS0xLTEtMzM0ODQ_253d7132-33c5-4b07-a49d-0d28d25bfd1b">8,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15c8302234e443c5bca532c176601a9b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMTEtMS0xLTMzNDg0_9a65ad47-d1d9-4052-be03-8713a142cd2e">2,045,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMTMtMS0xLTMzNDg0_97645ff9-0c88-446c-87da-8be9e106a1ae">286,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMS0xLTEtMzM0ODQ_3e49013f-3490-48cd-8d52-db3eb3338a0a">1,461,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMy0xLTEtMzM0ODQ_5e4b19ad-782c-435a-a8d8-f17da2452e74">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItNS0xLTEtMzM0ODQ_a1bbb54e-838d-451b-b278-d179aaba0942">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMTMtMS0xLTMzNDg0_d419e274-8a74-4cfc-8a27-413b99199829">10,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued from equity financing and pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtMS0xLTEtMzM0ODQ_505c5079-31dd-40d1-9631-62146acb5aa1">11,296,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtMy0xLTEtMzM0ODQ_6c94d0e7-8157-4e83-b17e-fbab892a50b7">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtNS0xLTEtMzM0ODQ_f4d2491b-144a-47b5-8a31-376a886e9c58">199,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140a0265db284ab18fc85a7c566f5e3c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtNy0xLTEtMzM0ODQ_dc71b8ea-b951-47ef-b79f-c44b5ebc2e97">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtMTMtMS0xLTMzNDg0_63348c4d-0674-424a-a3de-707ca1b0b1bf">199,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtMS0xLTEtMzM0ODQ_7088c758-662a-4513-89f5-d907d3987cc3">1,064,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtNS0xLTEtMzM0ODQ_1aee02f0-7fd6-47cb-977d-9a162503c737">15,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtMTMtMS0xLTMzNDg0_5dc1f5dc-b41a-4bec-99e4-c8d4751b03a5">15,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtNS0xLTEtMzM0ODQ_4f41d2a1-aa62-4d91-8d6e-1a4d768f7fdc">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtMTMtMS0xLTMzNDg0_60d02930-32ab-48e0-a49a-9dad25ed13b2">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="INF" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMS0xLTEtMzM0ODQ_75f6ff51-1bda-498d-9b31-62c849b072a7">2,554,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMy0xLTEtMzM0ODQ_c8e80f66-9f13-4222-b2ad-e33c4d32c950">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtNS0xLTEtMzM0ODQ_99e94879-a126-4e28-a1e1-1fe9a4b2aff5">31,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140a0265db284ab18fc85a7c566f5e3c_D20210101-20211231" decimals="-3" sign="-" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtNy0xLTEtMzM0ODQ_ac27b4c0-762d-4c3b-8b7a-800325d82765">12,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMTMtMS0xLTMzNDg0_85bebc9d-cfac-4fd4-a15d-bc4a366c6f02">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity component of the convertible notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMS0xLTEtMzM0ODQ_a93f0f5a-7f84-4bc7-b6e1-867b35ce2dfe">472,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMy0xLTEtMzM0ODQ_c4dcc2ca-c675-4a59-9154-678fdd3acbfb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctNS0xLTEtMzM0ODQ_359af28a-8e72-4508-a108-416cbdfe52ce">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMTMtMS0xLTMzNDg0_305d3fa7-06c9-4a73-b6b6-79eadeb3e891">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia67c1c4115c1453abb07a9ff877be186_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjgtOS0xLTEtMzM0ODQ_fe8fce01-95c4-42f5-bdc3-d9cd2e63df1a">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjgtMTMtMS0xLTMzNDg0_df23dc95-2098-420e-9211-afd259659d62">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation Adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia67c1c4115c1453abb07a9ff877be186_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjktOS0xLTEtMzM0ODQ_a0f0732f-709c-4ae8-bb26-78c4ed1028cf">3,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjktMTMtMS0xLTMzNDg0_522afa99-6b9a-4ab1-86e4-31ef90391473">3,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedae25f2203048fdaca67cfcf5b407cd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzAtMTEtMS0xLTMzNDg0_2451cdc6-65fc-43e9-8be7-767c6debbdee">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzAtMTMtMS0xLTMzNDg0_ea25e462-398b-44f7-b5fb-e3205e8df48d">250,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8aefd971cde4f12941d682724a9a606_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMS0xLTEtMzM0ODQ_4fef31f4-283d-413a-b646-167e88b41830">278,912,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8aefd971cde4f12941d682724a9a606_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMy0xLTEtMzM0ODQ_5e1fbc8e-b1c7-40a2-93d2-cd27ccd5fcd1">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d57483c4a54eef8994b3bbaa7ffb31_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtNS0xLTEtMzM0ODQ_84b8b317-150f-4350-b62d-8a9ed312a2d4">2,595,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied530d85f0df4c79aa2114bf41baf122_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtNy0xLTEtMzM0ODQ_dd079865-a417-4609-840c-44425c6b95db">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e0d3884d4a4e348b28d2bf23c7218e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtOS0xLTEtMzM0ODQ_f30caa8a-93ff-4e68-b629-e5634ec36460">4,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47380801e43942c98bd579021cd66466_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMTEtMS0xLTMzNDg0_71751343-ddee-4862-88fc-6ebbe63c1b7f">2,295,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMTMtMS0xLTMzNDg0_a357c805-fc7d-4902-b49e-ed3f13c7c17e">307,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options exercised, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMS0xLTEtMzQwNjc_88ab4706-b78d-4dbf-8876-f15da62b31ad">656,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMy0xLTEtMzQwNjc_425ad5c6-9b22-4096-8b93-8131cb18f234">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtNS0xLTEtMzQwNjc_5d041d42-9b00-416f-81dd-3abff61c8231">4,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMTMtMS0xLTM0MDY3_124cb9f4-25c1-4b46-8fb6-75438d98be58">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMS0xLTEtMzQwNjc_15478e2d-331d-4cdb-a145-ab2c09ce733b">1,539,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtNS0xLTEtMzQwNjc_1e6e5bfc-46bc-46a0-85e6-3eb7e3b65c88">11,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMTMtMS0xLTM0MDY3_8f6279a5-93a9-4ac6-9436-8925db1bd343">11,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItNS0xLTEtMzQwNjc_1dceb666-ccb0-41c2-8712-08ce1d9f8b2d">76,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMTMtMS0xLTM0MDY3_38f21f02-ddba-454f-8f3b-40b06e43f4db">76,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafcc84ae1f04e7c9f6fe592d37ff72b_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtOS0xLTEtMzQwNjc_42ca1e2a-3bf5-4854-b9ab-b813c6cf2425">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtMTMtMS0xLTM0MDY3_6b6194e7-ae9d-4623-bc0f-7b847014b45d">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaafcc84ae1f04e7c9f6fe592d37ff72b_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtOS0xLTEtMzQwNjc_f934274a-0ab6-4352-ac8c-437c3961e86c">17,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtMTMtMS0xLTM0MDY3_a0a87a99-dce8-4f2b-a6a1-17031a15060a">17,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae02215294ea4a709fe26968153b5d93_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMTEtMS0xLTM0MDY3_79606733-d649-4676-99e4-02345ee7d160">236,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMTMtMS0xLTM0MDY3_e7cb510d-6c77-459e-9b9a-e1ef1c4674b6">236,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic04eb74993b34416ac4dae1ade133ddc_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMS0xLTEtMzQwNjc_31c38825-59ab-4507-af38-8e0dce0dc033">281,108,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04eb74993b34416ac4dae1ade133ddc_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMy0xLTEtMzQwNjc_c735a63f-7ff5-4773-b6d8-2ed9fa239c4d">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10fab736f36145b7ad0b9d9e1984f370_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctNS0xLTEtMzQwNjc_c3f2b1a3-af6c-449d-80ed-317384f7c47a">2,664,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed4526deb5b484388e6c5a3f6743677_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctNy0xLTEtMzQwNjc_6eae3d1b-3d77-4626-a326-b6474a8cc0b1">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i517924c9e42841189538479018e06f92_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctOS0xLTEtMzQwNjc_6b2df804-a0ac-4545-887f-526e0c175915">12,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b0d6f1aad064e62b2c5e3d60a822ed4_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMTEtMS0xLTM0MDY3_71f8b86a-127a-4089-8379-7a635476ff66">2,532,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMTMtMS0xLTM0MDY3_f21c8f65-29d0-4628-943d-369b80ad4aaf">123,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-90-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMy0xLTEtMS0zMzQ4NA_e00f706b-c68e-4c3c-a323-56afdf6833d5">236,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMy0zLTEtMS0zMzQ4NA_c673dd3a-65b8-4d8f-a9b7-e1e3f3b840a5">250,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMy01LTEtMS0zMzQ4NA_4b811d83-939b-4c79-bf11-359eb2173067">276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and deferred financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNS0xLTEtMS0zMzQ4NA_7354c563-a584-4bed-b19a-e8716a3b65a4">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNS0zLTEtMS0zMzQ4NA_5f4602cf-abe3-4571-866c-24b79fe54cf1">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNS01LTEtMS0zMzQ4NA_0a56ecd2-7e52-49b8-830c-169b089e12a7">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNi0xLTEtMS0zMzQ4NA_384d8404-0690-4513-86cf-ef6964ca9b9e">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNi0zLTEtMS0zMzQ4NA_f1f33a72-e8de-44f7-9114-c3eaab8b38f2">6,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNi01LTEtMS0zMzQ4NA_84d70f2b-55dc-4a74-93c9-0fcc7239cd9e">8,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNy0xLTEtMS0zMzQ4NA_6de80dc0-fe93-4e3c-be7d-a3af738d5abc">76,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNy0zLTEtMS0zMzQ4NA_039de454-5965-455e-be8d-841744ae5a66">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNy01LTEtMS0zMzQ4NA_efc01d95-7148-4fc5-aad3-a6e5a3653f53">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfOS0xLTEtMS0zMzQ4NA_01c7b696-6119-4177-9e34-9c90bf89958b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfOS0zLTEtMS0zMzQ4NA_c6159bcf-c4f8-437c-8bf1-7ecb350d1db2">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfOS01LTEtMS0zMzQ4NA_185ea3b7-3551-4083-a7d1-00eccbf93d22">7,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTEtMS0xLTEtMzM0ODQ_3336a8cd-012f-4497-ace1-277604049b94">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTEtMy0xLTEtMzM0ODQ_028aad59-8154-4dc5-b109-2228da6bea1d">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTEtNS0xLTEtMzM0ODQ_7e29cf02-3c29-49e0-96e7-e9cb9b41918c">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency remeasurement loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTItMS0xLTEtMzM0ODQ_1d13b582-8d80-44fa-8b54-c73ead0ec2c7">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTItMy0xLTEtMzM0ODQ_c05af45c-7b97-4789-90f8-293d1113bd76">3,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTItNS0xLTEtMzM0ODQ_169fd990-725b-4cc6-979e-8911b43fc741">5,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTMtMS0xLTEtMzM0ODQ_65491420-935b-4a44-8dd6-9b2695de6a9c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTMtMy0xLTEtMzM0ODQ_7b0e85cb-0e26-4e4b-a376-41f0f0a33ed6">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTMtNS0xLTEtMzM0ODQ_be738486-1b0c-4fc6-974c-d1739b8e99f1">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairment charges and other asset write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="fold:AssetImpairmentChargesAndOtherAssetWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTQtMS0xLTEtMzY3NzM_e9c50992-de88-4595-86b9-131f59afd508">18,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="fold:AssetImpairmentChargesAndOtherAssetWriteOffs" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTQtMy0xLTEtMzY3ODA_d3c74048-c202-475f-b33e-babd8e0f4cca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="fold:AssetImpairmentChargesAndOtherAssetWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTQtNS0xLTEtMzY3ODc_9af3966b-ee24-4de6-8dde-0838c9cbd2bb">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTYtMS0xLTEtMzM0ODQ_fdba9057-ee76-4105-b71e-ddd8f6e0205d">17,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTYtMy0xLTEtMzM0ODQ_8edacfff-3d73-45b0-831c-d449e9e6f3de">8,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTYtNS0xLTEtMzM0ODQ_c6e318ce-e555-4a1a-a454-56bebbd5f328">11,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTctMS0xLTEtMzM0ODQ_286a38a6-b234-4765-b6e9-3fee2f01fc69">5,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTctMy0xLTEtMzM0ODQ_2e2d81c9-383a-4ca2-bf9a-a99d339940b0">7,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTctNS0xLTEtMzM0ODQ_a4677300-a90c-4dc3-a89b-afba11ea80cd">4,639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTgtMS0xLTEtMzM0ODQ_bedbcf38-00cf-495f-8ade-07311c6d5788">6,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTgtMy0xLTEtMzM0ODQ_d1a47d0d-4a0c-4fb1-b952-ed8df91ed7f0">5,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTgtNS0xLTEtMzM0ODQ_ee943eff-5eed-4c75-aa99-fff75641494d">8,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses, and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTktMS0xLTEtMzM0ODQ_36c5e6ee-8c71-40eb-9ca6-dee1d45f263d">6,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTktMy0xLTEtMzM0ODQ_a82a394a-6345-4150-8e31-20371bf568bb">7,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTktNS0xLTEtMzM0ODQ_ec6a72bd-1ebc-42c7-b386-e3e5d1572c4a">10,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjAtMS0xLTEtMzM0ODQ_0c992237-78bf-4946-8eb0-26a97f8d42cd">4,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjAtMy0xLTEtMzM0ODQ_69eb3289-8b41-4d66-893c-4b737f71d239">4,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjAtNS0xLTEtMzM0ODQ_f7e73df6-6548-483c-bdc6-58897a908963">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjItMS0xLTEtMzM0ODQ_7d038eeb-aec0-487b-ae0b-23f7df0ffa79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjItMy0xLTEtMzM0ODQ_837ecf90-0e37-44f6-ab49-5246fa7c1583">10,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjItNS0xLTEtMzM0ODQ_2966739e-ac35-4842-b801-4b70506afca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjMtMS0xLTEtMzM0ODQ_24320e00-9e9a-4b32-bbf1-04cc70052e15">166,575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjMtMy0xLTEtMzM0ODQ_1f47e2f8-d6b9-4fda-8f90-ead4e13535d0">202,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjMtNS0xLTEtMzM0ODQ_0289ac3c-2d89-4e92-9ca0-02f4086ac7ef">233,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale and redemption of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjUtMS0xLTEtMzM0ODQ_940555ce-15e0-455a-a9fd-9ec00e99ec7d">335,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjUtMy0xLTEtMzM0ODQ_43ee87a9-a14f-4b54-a708-0ae20ea7f3fc">424,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjUtNS0xLTEtMzM0ODQ_b14d8634-c0db-4231-b34c-9e76561290f6">354,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjYtMS0xLTEtMzM0ODQ_b2fa3fc2-e7f0-4d94-acd0-8b463d74acb2">243,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjYtMy0xLTEtMzM0ODQ_b02f107e-53c9-4799-8d60-a92caa336d70">341,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjYtNS0xLTEtMzM0ODQ_69b4cc29-f784-45e2-be7a-b209632beacb">365,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMS0xLTEtMzM0ODQ_1dbdf552-2d39-4883-ab11-16de53b8dc35">3,766</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMy0xLTEtMzM0ODQ_2cfced85-a2b9-45d0-8b25-fdd8b302f7fb">3,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctNS0xLTEtMzM0ODQ_f824efdf-921c-4328-92d0-1beb146d2c9f">3,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMS0xLTEtMzg0MTk_0cb51a71-e444-416f-a360-955b76da03d2">3,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMy0xLTEtMzg0NDE_f6735103-29e3-4b5d-9575-440a92175d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctNS0xLTEtMzg0MzE_c479ac73-fb87-4c7a-88fd-baf79c00a7a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjgtMS0xLTEtMzM0ODQ_c02229ea-f8a2-465d-ae25-cb99565cb40a">92,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjgtMy0xLTEtMzM0ODQ_7025cac5-5b4f-456f-ae4f-a1df8c76154f">78,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjgtNS0xLTEtMzM0ODQ_ad43c601-cf40-4853-bbab-16569bca6c43">13,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzAtMS0xLTEtMzM0ODQ_5ebbca59-3db9-4c0c-9298-3d53c47cd42b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzAtMy0xLTEtMzM0ODQ_ede5886e-fbdb-48f7-97e4-5e796eae052a">199,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzAtNS0xLTEtMzM0ODQ_cce5470d-5c4a-4138-a8b0-f2e70ae03e7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzItMS0xLTEtMzM0ODQ_6975b54b-db89-4a7e-b739-1b17ec6eaa5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzItMy0xLTEtMzM0ODQ_43219ab6-251d-47cb-815b-7db1bba7a5be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzItNS0xLTEtMzM0ODQ_c80ee060-8c99-43cb-bc54-2e8d1043cbbc">155,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzMtMS0xLTEtMzM0ODQ_f79f9684-6c70-4d3b-828a-b821be9b54f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzMtMy0xLTEtMzM0ODQ_23156583-8635-46a5-bba9-1405b64fdb0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzMtNS0xLTEtMzM0ODQ_523f7a73-b4d8-4574-a511-b55c6903bbbb">385,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzQtMS0xLTEtMzM0ODQ_511159f0-d094-4fa2-8e84-70b0b823c6fb">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzQtMy0xLTEtMzM0ODQ_e0822e97-09a0-41d7-bc9e-ff464f246ddd">479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzQtNS0xLTEtMzM0ODQ_f001d9c5-572a-4495-bb14-4f4ba1855b6f">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of vested restricted stock units, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzUtMS0xLTEtMzM0ODQ_e5a2d7d0-88d6-452e-94f2-4a452f18bd42">11,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzUtMy0xLTEtMzM0ODQ_6a19fee2-8017-46e4-a91c-701fb44d3bef">15,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzUtNS0xLTEtMzM0ODQ_eeb4dcee-75b7-41d3-a761-cf016ed37624">10,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from stock options exercised, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzctMS0xLTEtMzM0ODQ_1b23aaf1-1189-4db0-837c-c1fb0d0bde8b">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzctMy0xLTEtMzM0ODQ_122a5185-10bb-445a-8f74-82df1dbac921">10,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzctNS0xLTEtMzM0ODQ_2cec4b3c-2d83-42da-8964-68ca0388aad6">42,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrants exercised, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzgtMS0xLTEtMzM0ODQ_cce7fe6f-dc2f-4c4f-972a-b8a5209552a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzgtMy0xLTEtMzM0ODQ_28785d59-9afa-493f-87a9-baac816548f5">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzgtNS0xLTEtMzM0ODQ_fabca615-84bd-4214-a662-2b0409df258d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzktMS0xLTEtMzM0ODQ_99d9e33a-bb13-4815-89f7-9089c89974e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzktMy0xLTEtMzM0ODQ_4b425776-51cb-419e-9fa7-1c1013d3c8fc">1,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzktNS0xLTEtMzM0ODQ_a1cfbb51-9486-4643-b35a-dcf1c05cfb47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDAtMS0xLTEtMzM0ODQ_7d1cea3a-5b21-4160-ad54-ab969a7c786b">7,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDAtMy0xLTEtMzM0ODQ_58f5b452-dc28-4ec2-a1d4-4b0bb7e60cfa">212,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDAtNS0xLTEtMzM0ODQ_1d52e970-8794-469b-81de-8705ccd3a374">262,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDEtMS0xLTEtMzM0ODQ_88331181-9148-4b88-8cd4-73146b4249ad">14,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDEtMy0xLTEtMzM0ODQ_63670e14-9a9b-402d-abac-f2bf0dcf26bf">5,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDEtNS0xLTEtMzM0ODQ_9812ff31-39b2-4bb9-88e3-f8b11215d153">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDItMS0xLTEtMzM0ODQ_25a5c18c-d19c-4813-9afe-41145507becb">96,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDItMy0xLTEtMzM0ODQ_ac315086-7e83-478e-96fb-a4ca8b9e4ae5">83,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDItNS0xLTEtMzM0ODQ_9c4e9eee-23d0-43ed-893b-5f542b718e60">19,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at the beginning of the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDMtMS0xLTEtMzM0ODQ_4f5bae04-4f6d-4700-8ef4-22e7903b63d2">249,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDMtMy0xLTEtMzM0ODQ_1335230b-ba20-4e1a-987b-9f143e37a137">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDMtNS0xLTEtMzM0ODQ_410ef0cf-8337-40ff-8ac4-a6363beb84b2">146,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at the end of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDQtMS0xLTEtMzM0ODQ_0280fe97-50e1-4a98-97b6-cbf362e57c9f">153,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDQtMy0xLTEtMzM0ODQ_e52522fb-4c9b-4269-9bf3-94a84dad6f04">249,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDQtNS0xLTEtMzM0ODQ_8d7aa7ba-c393-4edb-ac0b-8e2fd740a6bc">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-91-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements paid through lease incentive</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDctMS0xLTEtMzM0ODQ_784ac9cb-7e82-4ae4-acd8-0f116ee12a8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDctMy0xLTEtMzM0ODQ_c271cef2-175e-41dd-a769-2eeb5deb5289">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDctNS0xLTEtMzM0ODQ_e44064cf-fbf5-4aed-85bf-c0784736f19f">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDgtMS0xLTEtMzM0ODQ_c0dad387-bd4b-4385-95f3-a7bbd14e3ddf">34,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDgtMy0xLTEtMzM0ODQ_123bb58f-09a7-4a0b-802a-363e72298c19">30,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDgtNS0xLTEtMzM0ODQ_9c797797-a05f-485d-9b14-1950a40c1fc8">24,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures unpaid at the end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTAtMS0xLTEtMzM0ODQ_32586876-77a7-4394-94b3-ee35d3639b2a">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTAtMy0xLTEtMzM0ODQ_3eeb1a75-bc17-4e5b-8fe0-ac034987623d">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTAtNS0xLTEtMzM0ODQ_6cb58305-2080-4003-9dce-f19369e83f21">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTEtMS0xLTEtMzM0ODQ_1eb5baaa-c991-4805-9266-939003318e35">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTEtMy0xLTEtMzM0ODQ_f8f0a1c8-3989-4a97-a26d-eb7dc99184fa">20,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTEtNS0xLTEtMzM0ODQ_92408b2d-7779-42db-9a08-531d643ee3e4">10,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-92-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:36pt"><span><br/></span></div><div id="i60868bb9516a413c82303f6b0d1ba997_76"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183Ni9mcmFnOmZjMTg2YTQ5YzBiNzRmNDVhNGE2MzAzNThjNDZmMTk3L3RleHRyZWdpb246ZmMxODZhNDljMGI3NGY0NWE0YTYzMDM1OGM0NmYxOTdfNDcxNw_9cf6a675-13d0-47c2-a133-15a4d81e639e" continuedAt="i7efc00d30c0c4626bd256c20818cb499" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i7efc00d30c0c4626bd256c20818cb499"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), and the United Kingdom ("U.K.") Medicines and Healthcare products Regulatory Agency ("MHRA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), U.K., and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. In May 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. In October 2022, the FDA deferred action on the BLA for cipaglucosidase alfa, citing the inability to complete the manufacturing facility inspection prior to the PDUFA action date.  The Company is actively engaged with the FDA and an inspection has been scheduled</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Committee for Medicinal Products for Human Use ("CHMP") of the EMA adopted a positive opinion recommending market authorization of cipaglucosidase alfa, or Pombiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the novel coronavirus (&#8220;COVID-19&#8221;) pandemic. The Company's commercial operations have not been significantly impacted by the COVID-19 pandemic and the Company gradually continues to see an improvement in patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimum disruptions. The Company has been able to continue to meet required commercial demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as supply its ongoing Pompe disease clinical studies and access programs including the Early Access to Medicines Scheme ("EAMS") without interruption. In regard to the Company&#8217;s regulatory operations, the FDA deferred action on the pending BLA for cipaglucosidase alfa, as a facility inspection was necessary, however, could not be completed by the PDUFA action date due to COVID-19 related travel restrictions. The facility inspection has subsequently been scheduled. Per FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, receipt of a deferral action indicates no deficiencies have been identified and the application otherwise satisfies the requirements for approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183Ni9mcmFnOmZjMTg2YTQ5YzBiNzRmNDVhNGE2MzAzNThjNDZmMTk3L3RleHRyZWdpb246ZmMxODZhNDljMGI3NGY0NWE0YTYzMDM1OGM0NmYxOTdfMzk0MA_05e8df22-caad-47ae-a574-a507072c4972">2.5</ix:nonFraction> billion as of December 31, 2022 and anticipates incurring losses through the fiscal year ending December&#160;31, 2023. The Company has historically funded its operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuances, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs for at least the next 12 months. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-93-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MTY_a1a0e971-9869-4a25-acff-b26e6426ee7b" continuedAt="i78231d57189d486fb777b941234ec369" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i78231d57189d486fb777b941234ec369" continuedAt="idfbf93040fb74489a6587b5713d573ae"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDU_80548c9e-55e5-4dec-ad8c-87857d41d0e4" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4OTQ_944bb423-9209-47f2-a5c8-296970b23390" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDA_923cc282-81aa-439e-bd25-5a0fef6fa61e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDY_4b41f8ce-26a5-4222-8ccc-fbccc4821abe" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact the COVID-19 pandemic had on its operations and financial results as of December 31, 2022 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4Nzc_3a1effd3-8392-45d8-9b3b-9e700f2943d0" continuedAt="i8fc6ad85dc8e4139a2d070a8661205c3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive (loss) gain in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8fc6ad85dc8e4139a2d070a8661205c3">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-94-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="idfbf93040fb74489a6587b5713d573ae" continuedAt="idb5ceccb15d140f891212ba932a7b23e"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MTE_ac461f28-3f57-4c04-a3da-2dc7aa9d49fe" continuedAt="i93bda5373eeb47f8be1a02e53b444f70" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i93bda5373eeb47f8be1a02e53b444f70" continuedAt="ia15a3599752841c688bb0c95f4f8c429"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia15a3599752841c688bb0c95f4f8c429">. The Company's accounts receivable at December 31, 2022 have arisen from product sales primarily in Europe, the U.S., and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</ix:continuation> As of December 31, 2022, the Company's allowance for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDQyMA_2c6dbe55-561f-47cf-ab01-998142567a26">0.2</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDc_6fae1b80-25f0-464f-b35c-ea591cabd3c3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb">three</span> to <ix:nonNumeric contextRef="i0f3176f304064948be4451df697aa412_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyOQ_a38b4620-37b2-421f-b795-abbcb7bd8dbf">five years</ix:nonNumeric>, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDg_582b966a-032d-4144-a157-ff5ac18cf219" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist primarily of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for the years ended December 31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i3a136c7711d044a09a19e03c25fe39dd_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTA0NDUzNjA0OTQwNjA_8db90989-01b3-4a7e-aad6-e002c329a437">329.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5074d507bd1e4529aa53cc1be1409baf_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTA0NDUzNjA0OTQwODA_19ae113b-efd0-4b2c-8e3d-58ccd7ae89b2">305.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i508c824fb1844b0ca8a046ab3f8321c3_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTA0NDUzNjA0OTQwOTc_eee4295c-5559-4908-aa52-feee870645a5">260.9</ix:nonFraction> million, respectively. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2022, one customer accounted for <ix:nonFraction unitRef="number" contextRef="i71deb9575b294adb91ff789973f65bbf_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTYzNw_8465cc9c-74ee-4118-b908-411d4f836962">27</ix:nonFraction>% of net product sales and <ix:nonFraction unitRef="number" contextRef="ia738717e166c41c2a4392a1967ef4025_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTY2NQ_5187fb81-7d99-4197-b1bc-7cab9bc6c6d5">14</ix:nonFraction>% of accounts receivable from product sales. In 2021, one customer accounted for <ix:nonFraction unitRef="number" contextRef="id2c3883ff4d64b8e9595b3e84e9edfe4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTc0NQ_074b2945-7062-4a20-ac35-17f22838bfe1">24</ix:nonFraction>% of net product sales and <ix:nonFraction unitRef="number" contextRef="i102ca847ccf94fb3ac9a236e09d1fd19_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTc3Mw_afa4a7dc-b593-40ba-868b-cdccc2e247af">14</ix:nonFraction>% of accounts receivable from product sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzM_2d8264e3-42ef-484e-bc79-d76e92a5a69a" continuedAt="i423afd6becf54b7c929a219c7cfc13aa" escape="true">The following table summarizes the Company's net product sales disaggregated by geographic area:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-95-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="idb5ceccb15d140f891212ba932a7b23e" continuedAt="id37556b4e25545b6bc9f563eb660807e"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i423afd6becf54b7c929a219c7cfc13aa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:53.722%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b7fa862c79461ba0d440ef1d4f8431_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMi0yLTEtMS0zMzQ4NA_164f6477-61ee-4a27-bf4b-42b20bb7aef7">115,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3be0f0c66b2b4c8cbdda482aa8ee8d15_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMi00LTEtMS0zMzQ4NA_c94dbcd6-9dff-4f58-9e5a-b657c355900e">95,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc1cdb41092f4d06b127a3529fd12fa3_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMi02LTEtMS0zMzQ4NA_6c974f5e-11c2-4475-a623-288e29ec4632">80,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df5e946794844e891a2510cf44b7066_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMy0yLTEtMS0zMzQ4NA_f91089e5-fcc9-41f5-9052-91a1757dfbb2">213,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8a70346b0774591a4bd99dd9b48cdb5_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMy00LTEtMS0zMzQ4NA_cc1429d2-9e5d-409d-9e31-a90b51145c7d">210,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1d53e258e9423497806e3919e31742_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMy02LTEtMS0zMzQ4NA_82f1337d-1d30-4eca-b01b-237240b737ea">180,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfNC0yLTEtMS0zMzQ4NA_d29fb04a-308a-4dab-b5c8-5975a97847c2">329,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfNC00LTEtMS0zMzQ4NA_a4ac15e5-16ee-41e4-b1f4-fadcdd066d0a">305,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfNC02LTEtMS0zMzQ4NA_18eb0690-5c51-43d1-b7c8-f33f7b4175ba">260,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDk_66df39ec-47f3-41a1-aee2-9168ec855e5b" continuedAt="i30f5b1ae4f4b4657bfb259bd66fde82f" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i30f5b1ae4f4b4657bfb259bd66fde82f">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4ODE_e97da5f7-b144-4270-a144-cb42ce9335a5" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participant's assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4ODg_08840c60-7c3d-45d0-856e-fd836e785552" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="id37556b4e25545b6bc9f563eb660807e" continuedAt="id6df4479ca5142908e101b8c2320147b"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4ODQ_39228f7a-b642-4ea1-87f0-03a7ea07e21a" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="fold:InterestIncomeAndInterestExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4OTc_492a0587-d916-4202-8c3d-fade4d65a2c0" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDI_9b418db7-635e-417f-9059-71fc7e14c06a" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax returns are subject to examination by U.S. Federal, state, and foreign taxing jurisdictions. The impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more likely than not to be sustained. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not to be sustained.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="fold:OtherComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzQ_b950d34b-688f-48b1-9a8a-493eb28c5cf1" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive (Loss) Gain</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive (loss) gain include unrealized gains and losses on available-for-sale securities and (loss) gain on foreign currency transactions and are included in the Consolidated Statements of Comprehensive Loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4Njg_6d1b69d8-4e7b-4882-be18-9f1dc726763c" continuedAt="iddba763438704a78aa68d6d1a7977e09" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-97-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="id6df4479ca5142908e101b8c2320147b" continuedAt="i6e28b2e47ea6409998043944cc0d167c"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iddba763438704a78aa68d6d1a7977e09">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</ix:continuation></span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="fold:NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzE_57dcd490-480e-4660-b499-3208a82636ea" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NjA_a96b3cf7-603e-4fef-9aa8-d01dacfde60d" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had <ix:nonFraction unitRef="plan" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="fold:ShareBasedCompensationNumberOfPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTU3MjQ_d869993c-5f14-4851-b2a3-725de9f78101">one</ix:nonFraction> equity-based employee compensation plan, which is described more fully in "&#8212;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NTE_5921672f-2e3f-48de-94b4-85a4bac61dc9" continuedAt="ic01984edcec04abdb7aeafbbe7dca869" escape="true">Loss per Common Share</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic01984edcec04abdb7aeafbbe7dca869">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested restricted stock units, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.</ix:continuation> See "&#8212;&#160;Note&#160;15. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDM_3da62adf-dcb0-44e7-b70e-17b3dcc61fd3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTY3NTU_29df5999-b563-421e-8e45-d61183c2b3ec">one</ix:nonFraction> business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is <ix:nonFraction unitRef="unit" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTczNzQ_e6bb9daa-6657-4541-ba5e-dcb617145d74">one</ix:nonFraction> reporting unit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDQ_5cbbf921-c565-4eaf-b250-a4fc44cab807" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-98-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i6e28b2e47ea6409998043944cc0d167c"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NTY_af436921-d690-48d9-bd4f-5fe876e749d6" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. For contingent consideration payments in business combinations, the Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MTU_8e067c21-2c87-4875-91e4-986dcdab1735" continuedAt="i9c55a6e1b105401e9075b51fb30e112c" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9c55a6e1b105401e9075b51fb30e112c">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference.</ix:continuation> No indicators of impairment were noted during the years ended December 31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzI_89cf95c3-a3b3-4700-8a88-2efc283b53c7" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_82"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTQzMQ_512a0243-e83d-47c6-9cdb-2f788e5f9c16" continuedAt="i84eeabbdc8a94c0db24967e1ce69a311" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="i84eeabbdc8a94c0db24967e1ce69a311" continuedAt="i44f7a479d351406a9f35d7870f0c0392"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, in connection with the acquisitions, the Company had goodwill of $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTE0_b7dc4d37-a1b3-4e3c-a72e-e8442e866a84">197.8</ix:nonFraction> million and IPR&amp;D of $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTMw_f4102ea9-c5ad-4318-8f72-b168e2f8917f">23.0</ix:nonFraction> million, which are reported at fair value on the Company's Consolidated Balance Sheets. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value. An IPR&amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-99-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i44f7a479d351406a9f35d7870f0c0392"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTQzMg_f254d357-1468-4b7c-88e2-fd33b642647e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in IPR&amp;D for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:85.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfMS0yLTEtMS0zMzQ4NA_00baf766-3dd1-4802-b810-6188da54933d">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfMi0yLTEtMS0zMzQ4NA_541c84c8-3838-4902-800a-7d39b6e8630d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfMy0yLTEtMS0zMzQ4NA_784ad65c-f44a-4bc7-bc0c-6d65d1482222">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfNC0yLTEtMS0zMzQ4NA_10b6b2de-ac81-470c-8fdc-1a92afd4d42c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfNS0yLTEtMS0zMzQ4NA_436a999f-76b5-465f-b8de-cb89c9d3fff4">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTQyOA_ef4ecb82-c1e5-4dd3-a0f5-8fc340153da4" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in Goodwill for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:85.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfMS0yLTEtMS0zMzQ4NA_2c1e1ba7-07a5-4bd5-8ff1-1169afb8925d">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfMi0yLTEtMS0zMzQ4NA_c5b1cc78-018a-4d39-a69c-1be2b252a0cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfMy0yLTEtMS0zMzQ4NA_cee8a900-4ae8-423a-b2de-c410b2c05510">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfNC0yLTEtMS0zMzQ4NA_46ba3e09-34a7-46e1-bc37-3f4296948fb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfNS0yLTEtMS0zMzQ4NA_f01bc3e0-3af6-494c-8581-3e7a3d92ad91">197.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-100-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjgwMg_acbc120e-5d37-4da6-9728-6e54fb844513" continuedAt="i3ea19126710f4840b520f6b988622c42" escape="true">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="i3ea19126710f4840b520f6b988622c42" continuedAt="i0b7481649d3d417db7a161750290c3f8"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company held $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTAy_5a18b3c9-c56f-4e98-88df-43d401335d57">148.8</ix:nonFraction> million in cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTM4_a2cec948-8233-4a1a-a99f-93b6f1ca868c">144.8</ix:nonFraction> million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive (loss) gain in the Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjgwNA_e6e01c6c-5ed7-4084-9491-717b0d418cb0" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:46.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMi0yLTEtMS0zMzQ4NA_ba885f46-cd31-438b-b9eb-d780326213a4">148,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMi04LTEtMS0zMzQ4NA_0f5553fa-a092-49f6-ba12-69fd273a72a0">148,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy0yLTEtMS0zMzQ4NA_f5d554d0-59a5-4039-bdc4-8399ceaf4307">144,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy00LTEtMS0zMzQ4NA_f6531c09-60a2-4630-93f1-8e75ce016553">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy02LTEtMS0zMzQ4NA_c8be3704-02d6-433b-9bf6-5b8614fcee81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy04LTEtMS0zMzQ4NA_02a84e92-380c-4810-96ad-ae9134adcc14">144,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi0yLTEtMS0zMzQ4NA_bdd86b76-47ea-4543-b09f-7cbc20efeb26">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi00LTEtMS0zMzQ4NA_0ecba3c2-0481-4767-b4c1-2985ca68bf44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi02LTEtMS0zMzQ4NA_24b45492-41b2-4cf9-b5ec-22e0049974b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi04LTEtMS0zMzQ4NA_ab0ca5e7-ed8a-472b-a9b2-4efa035a627e">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy0yLTEtMS0zMzQ4NA_f6564130-8cf1-41eb-9e1d-56da9b17cbbf">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy00LTEtMS0zMzQ4NA_5f17e001-390d-49f4-a731-a1c876def2d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy02LTEtMS0zMzQ4NA_4faea1a9-d450-4026-848e-8c3c7df51003">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy04LTEtMS0zMzQ4NA_8a171c67-7879-4289-8230-eeb139053c60">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC0yLTEtMS0zMzQ4NA_d9b69b02-3012-4e84-8cce-a7381f3957be">293,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC00LTEtMS0zMzQ4NA_ff36e3fc-1c4f-4914-af7e-b898dbe9ef52">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC02LTEtMS0zMzQ4NA_3745bbfc-ff1f-4ecf-9842-d370397dfdd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC04LTEtMS0zMzQ4NA_736fe663-2f94-48ec-9979-feec0b0b18c9">293,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOS0yLTEtMS0zMzQ4NA_07a4dfce-38a4-44d5-86ee-ad57a11177b3">148,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOS04LTEtMS0zMzQ4NA_bbf084e9-e14d-4fda-88a6-24692a691afb">148,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtMi0xLTEtMzM0ODQ_402f5b95-e91e-482a-9df4-f77f02d71627">144,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtNC0xLTEtMzM0ODQ_367acb73-60f5-4cd3-b18f-d5be4f020151">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtNi0xLTEtMzM0ODQ_68892815-2b4e-47a6-946d-69597f3921cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtOC0xLTEtMzM0ODQ_5baeb24a-c59c-49ab-84e6-a2127d8f9ca8">144,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtMi0xLTEtMzM0ODQ_c1bd9732-63e9-42a5-bddf-349f4a06d26f">293,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtNC0xLTEtMzM0ODQ_491207f8-4410-4d20-8add-8bdeaa8b122d">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtNi0xLTEtMzM0ODQ_c8bc940a-b0ba-49c2-a333-a647bfd88e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtOC0xLTEtMzM0ODQ_c29b73a2-044b-4776-b1d7-e3b9b57fd3c3">293,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:46.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMi0yLTEtMS0zMzQ4NA_080a41f4-3f8f-46fe-b71f-3c3f556115e7">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMi04LTEtMS0zMzQ4NA_efa30b1c-bce8-4b7f-99ee-42773e8ae215">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy0yLTEtMS0zMzQ4NA_23fc2f98-fb84-42f0-a1ad-59396019b7f0">174,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy00LTEtMS0zMzQ4NA_7145bd14-108e-4e87-9a8b-4dda9433caec">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy02LTEtMS0zMzQ4NA_9bddf3a6-3233-49c1-bfa4-00732ae6a400">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy04LTEtMS0zMzQ4NA_0174099b-2bbe-4107-86e3-071ef9ea4798">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC0yLTEtMS0zMzQ4NA_d79daaf2-6547-47e4-9273-8cbeba9557a9">32,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC00LTEtMS0zMzQ4NA_ba5607f6-5dd8-4c3d-9695-e78e793eae83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC02LTEtMS0zMzQ4NA_8e00990d-0484-4a03-bacc-c8f3abdea82f">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC04LTEtMS0zMzQ4NA_24c43180-875c-4eba-8c19-80e3e58a3bc2">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS0yLTEtMS0zMzQ4NA_69b31100-cddf-4a7c-b639-54448783c010">30,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS00LTEtMS0zMzQ4NA_114c9057-50fb-4e6b-831f-0a6d2f3b42b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS02LTEtMS0zMzQ4NA_7b5d7df2-a62d-4312-a68a-cb8e94e743f2">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS04LTEtMS0zMzQ4NA_d1429964-d6e3-4e81-9e99-a8e4e0855981">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi0yLTEtMS0zMzQ4NA_f12882e3-859f-4a1b-9a48-e214d871d623">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi00LTEtMS0zMzQ4NA_e1c14384-f1e9-4d75-b306-1a4e6b25c6b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi02LTEtMS0zMzQ4NA_a61c3c50-9e91-41b1-9a16-a6ca12e62ba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi04LTEtMS0zMzQ4NA_42f6de71-4803-417e-b2ab-7ccdec0d41b3">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy0yLTEtMS0zMzQ4NA_30935db2-9077-4242-bcda-d203ad3f8723">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy00LTEtMS0zMzQ4NA_4a462b51-93f4-4707-8de6-35625f476087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy02LTEtMS0zMzQ4NA_954013cf-e1b2-4662-9118-3f3b055a22a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy04LTEtMS0zMzQ4NA_0bf67f96-2e9f-4e9a-9cd7-e36b1774bbe5">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS0yLTEtMS0zMzQ4NA_ec5679fa-82b8-4f6b-b6d7-8897b486763a">482,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS00LTEtMS0zMzQ4NA_4227cc65-e06d-4550-afc2-0210ae08fc58">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS02LTEtMS0zMzQ4NA_c42e7c5a-ce0b-4667-92d0-2f49e7760933">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS04LTEtMS0zMzQ4NA_c97adb51-bd3b-46bb-a87f-809760ea01fd">482,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTAtMi0xLTEtMzM0ODQ_edb74a2e-5b75-4f7a-b28b-0aa412eeeac4">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTAtOC0xLTEtMzM0ODQ_6f680846-60ea-4e3b-b98f-08e5d140d637">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtMi0xLTEtMzM0ODQ_7f225400-879c-4af1-ad4a-148f7ced1160">237,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtNC0xLTEtMzM0ODQ_033da3f1-7961-492c-afea-c852517cea3e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtNi0xLTEtMzM0ODQ_3e458125-2797-4bb4-9b19-d271db040846">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtOC0xLTEtMzM0ODQ_e0bd0ab5-fedf-4fd1-b952-5105da055ce0">237,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItMi0xLTEtMzM0ODQ_630459d1-a300-495d-8705-53d8e8a06bad">482,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItNC0xLTEtMzM0ODQ_2f96083c-1d5a-456a-91dc-5b2eb85019ce">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItNi0xLTEtMzM0ODQ_b9b9c812-6c69-4062-8dd8-22ea301adea8">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItOC0xLTEtMzM0ODQ_3d168964-511a-4a42-90b3-f0c6652171f4">482,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-101-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes To Consolidated Financial Statements &#8212; (Continued)</span></div></div><ix:continuation id="i0b7481649d3d417db7a161750290c3f8"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the years ended December 31, 2022 and 2021, there were <ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTkwMw_9c9f2584-01fb-4da6-abec-d109c043792e"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="INF" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTkwMw_f5965a99-eb9c-4e20-b720-d0c369d5de43">no</ix:nonFraction></ix:nonFraction> realized gains or losses. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfODI0NjMzNzIxMTU0Nw_f57d9932-4598-45e4-89fa-2623ee6733ba">no</ix:nonFraction> marketable securities in an unrealized loss position as of December 31, 2022. Unrealized loss positions in the marketable securities as of December 31, 2021 reflect temporary impairments and were not a result of credit loss. Additionally, as these positions were in a loss position for less than twelve months and the Company did not intend to sell these securities before recovery, the losses were recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjUyMw_7b2abb59-8c1c-4c4f-a141-52b81ed28216">173.4</ix:nonFraction> million as of December 31, 2021.  </span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjc5OQ_79be4a11-a473-4fa0-b550-982f1431f6c4" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:44.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMS0yLTEtMS0zMzQ4NA_1d087aea-111b-4aa2-a3b9-ca98eb8e81c8">148,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMS00LTEtMS0zMzQ4NA_91147616-f958-491f-a23a-155a8f801287">245,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMS02LTEtMS0zMzQ4NA_d7da6425-72b5-4b39-8e30-1ebeb95b93d9">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMi0yLTEtMS0zMzQ4NA_eb52abc9-d268-4621-9fa9-b998e6bad383">4,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMi00LTEtMS0zMzQ4NA_b70de7e0-0952-4f3a-80b2-43c7310974ae">4,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMi02LTEtMS0zMzQ4NA_287ab650-39e8-41f0-9dec-b3728d008a5a">2,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMy0yLTEtMS0zMzQ4NA_100cd97d-f2f3-4c94-a523-f7e5247a9934">153,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMy00LTEtMS0zMzQ4NA_226ccc89-52e8-4eec-a7c2-db63c9082852">249,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMy02LTEtMS0zMzQ4NA_c0158911-244c-4d5a-b61b-ed154dcdc7cd">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_88"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjg4_4c0a26fc-f27f-4765-a3e7-71ab793352ab" continuedAt="ifdd9882aa689459688ef581699315d9f" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="ifdd9882aa689459688ef581699315d9f"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjkx_7785ea22-60d9-4aa7-8797-d08a067434ee" continuedAt="iad245cee4e9a4dd89163a745dcb413b1" escape="true">The following table summarizes the components of inventories: </ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="iad245cee4e9a4dd89163a745dcb413b1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:66.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMS0yLTEtMS0zMzQ4NA_3681aa51-aae3-465c-baba-1005a6dab95c">10,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMS00LTEtMS0zMzQ4NA_dae47dc3-fd9d-4edf-b619-350ba33f57cf">12,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMi0yLTEtMS0zMzQ4NA_6947e993-7c64-400d-a4eb-b011ff32d441">9,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMi00LTEtMS0zMzQ4NA_c05bfa11-9865-47ee-83f5-9d4e94f46b8c">10,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMy0yLTEtMS0zMzQ4NA_fe4db831-c5c1-4fb7-9ff8-e2e8910c35df">4,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMy00LTEtMS0zMzQ4NA_b748f66b-764d-4668-9fac-8ea12fdb2e36">3,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfNC0yLTEtMS0zMzQ4NA_1cc8a515-7385-4f09-8ebe-307388635a68">23,816</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfNC00LTEtMS0zMzQ4NA_3595bea2-f902-433e-b9e1-328ac7cea0c8">26,818</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reserve for inventory was $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjQ4_93872883-163a-4f11-913e-23c70d2bd85c">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjU1_7907f932-9699-4887-b159-2f0ef0a3c482">1.1</ix:nonFraction> million as of December 31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-102-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTYy_08480277-55d8-46da-bb8e-286d72036188" continuedAt="i0ef7b89dbc1548599114010d45ba8d8f" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i0ef7b89dbc1548599114010d45ba8d8f"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTYz_88a06ff5-b10a-4f59-964d-8cd9675bc9c1" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd29482ac05d44c7ab8df32cee3dca44_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMi0yLTEtMS0zMzQ4NA_ccd75479-87cf-4be4-999b-c61247e293bf">24,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e615ec9f7c64a478d960eb4430d471b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMi00LTEtMS0zMzQ4NA_a5fe502a-bda9-47e1-9ef4-b4c6fcdfdae3">24,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ffd34918454b17a538f8040e16bd9b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMy0yLTEtMS0zMzQ4NA_8f2442e2-8b56-4742-b966-2a1a3c8c678f">16,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d1abcfa0ef48a8900c4f3cd89f734f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMy00LTEtMS0zMzQ4NA_9efa2939-e25c-40a6-923d-22a21db34b44">16,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e219ba46f9f454e81973029cbfee478_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNC0yLTEtMS0zMzQ4NA_d32ce071-60ae-46d0-9965-fd38e1b85c13">4,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3636fa399a0c4c1eba1f0545ca9be836_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNC00LTEtMS0zMzQ4NA_5d193483-4ccb-435d-bc50-c67d80157581">5,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e9bf5a1cc64621922ffe1980b7dac7_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNS0yLTEtMS0zMzQ4NA_f7af486f-10a9-4739-a3a7-507e713b090b">4,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676babb093b5444588a41929a2ea1306_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNS00LTEtMS0zMzQ4NA_79936b30-de7c-42d9-bed4-5951239c3515">8,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483ff1106b53432cbdf57bb9830bf8d2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNi0yLTEtMS0zMzQ4NA_6719d283-8548-4dc3-8c40-0edb9ea22be2">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628f96c5cfa5476392fcbe4410976f8d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNi00LTEtMS0zMzQ4NA_b1f7dfaa-5095-44b1-9d70-ef7989936d1d">3,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d7c1f78a2d4edfbd5dbd117237d2e8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNy0yLTEtMS0zMzQ4NA_1e5c1372-8637-44ab-b56c-5544726ba2ef">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia903203eb4da4bd3902cc71800cfbd03_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNy00LTEtMS0zMzQ4NA_4cc395d6-33eb-4916-b65f-3bf6bc8187b5">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe1f1cffd554a4b994d3edcc31500b4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOC0yLTEtMS0zMzQ4NA_88e5bc5f-9595-46e1-a347-c2e9f34f5b77">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf9b84e7254d4fec87bd8e31221e830a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOC00LTEtMS0zMzQ4NA_4ea2a648-b247-4d30-bc0c-06d494757760">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef01c16ab7e44bdb0fe14f5f6770e1d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOS0yLTEtMS0zMzQ4NA_8019d712-cf29-4e98-bc1e-f8d5847caa32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144d3b85e0f54b78b3e35a0ab3f69126_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOS00LTEtMS0zMzQ4NA_e31892bf-8c76-426b-bf77-f6399250314a">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTAtMi0xLTEtMzM0ODQ_9d45a0f0-1e44-4ead-9d73-317cd0dda4e6">53,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTAtNC0xLTEtMzM0ODQ_31840749-1377-45c5-83c5-644b55a49ae7">62,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTEtMi0xLTEtMzM0ODQ_c835e884-3964-4975-b535-a302a659a45a">22,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTEtNC0xLTEtMzM0ODQ_6fae3353-5204-4dac-974a-35f68a57d395">19,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTItMi0xLTEtMzM0ODQ_72fa51f2-2966-4975-ac7e-0a6894e134d2">30,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTItNC0xLTEtMzM0ODQ_676cb334-e577-48df-bf7d-c0f5a17d4f6f">42,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTA3_e82a7086-984d-43dc-ab13-072371e3563a">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTE0_e76fce7a-fee3-4ab9-b65d-9df8d040a3ce">5.7</ix:nonFraction> million for the years ended December 31, 2022 and 2021, respectively. Additionally, during the year ended December 31, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTA5OTUxMTYyNzgxNTU_bfaaa548-c289-4ada-a854-57270e90367a">6.6</ix:nonFraction>&#160;million</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_94"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RleHRyZWdpb246MjI2N2U2ZTYwN2I0NGIyYmFlZTg3MzUzZWRiMzJjMGRfMTMx_15fdcca6-d9af-452c-bfb4-0cd0c3265465" continuedAt="id06c1156c8ef48df92c255fe1675546f" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="id06c1156c8ef48df92c255fe1675546f"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RleHRyZWdpb246MjI2N2U2ZTYwN2I0NGIyYmFlZTg3MzUzZWRiMzJjMGRfMTMy_93dc2093-3743-4010-a609-3f13947e9c0f" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of the following: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMi0yLTEtMS0zMzQ4NA_009e9fe5-c00f-430a-b2cc-8eaa3dbe36a6">25,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMi00LTEtMS0zMzQ4NA_87f51064-2884-46ab-a752-0738375da10c">24,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales rebates and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:AccruedSalesRebatesAndChargebacksCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMy0yLTEtMS0zMzQ4NA_d4a3df67-2c83-4681-bbec-f08b766a90f5">21,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:AccruedSalesRebatesAndChargebacksCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMy00LTEtMS0zMzQ4NA_1b77f40d-8a71-4d4b-becd-6a9e0aa41479">15,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued program fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:AccruedProgramFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNC0yLTEtMS0zMzQ4NA_7b5c5467-9ae5-4ad6-9026-f8571d8afbf2">10,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:AccruedProgramFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNC00LTEtMS0zMzQ4NA_ae17ba4c-8f0d-420f-a507-9e63f9e3a5b8">13,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing&#160;&amp; contract research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:AccruedContractManufacturingAndContractResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNS0yLTEtMS0zMzQ4NA_d9d407e3-a525-4110-8353-5193e6393b03">8,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:AccruedContractManufacturingAndContractResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNS00LTEtMS0zMzQ4NA_f89f4dda-a488-47f4-a508-736e83f0e6c2">20,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNi0yLTEtMS0zMzQ4NA_3add20eb-24e4-421c-b6bf-6b751552edd3">6,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNi00LTEtMS0zMzQ4NA_d98b0760-5280-4ab0-b7fd-dfe6ea34a9ac">4,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNy0yLTEtMS0zMzQ4NA_47b231bd-14c3-4fff-a0e1-0ef61e4b148d">6,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNy00LTEtMS0zMzQ4NA_438afd17-6d99-4f45-8e5b-fd8cfafefe46">9,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC0yLTEtMS00MDg4OQ_9e6b9a78-3f76-457a-bbbb-620f4608d85a">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC00LTEtMS00MDg4OQ_79f0f86c-7266-4f7a-9ed9-9f190fed9cf6">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC0yLTEtMS0zMzQ4NA_563a03db-b8f9-489e-b68f-c2a0caa97a2d">7,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC00LTEtMS0zMzQ4NA_0dbd420c-0bec-4a5c-ba4e-6d6ff5b870d6">4,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMTAtMi0xLTEtMzM0ODQ_8c18fa0f-6c4b-46db-869d-9fc26cc98935">93,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMTAtNC0xLTEtMzM0ODQ_253ba8d8-e45f-4bed-86e8-6b5988cbb178">98,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_97"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNjAyOQ_43409ba3-994c-42b1-8d5b-f59a16eefa3a" continuedAt="i9f57a075d4294715bdd859a851afcd26" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i9f57a075d4294715bdd859a851afcd26" continuedAt="i813ec17232d9477e9221c24a07598073"><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Warrants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company was authorized to issue <ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTAx_6cbd67cc-350a-46b6-b3be-2c6e85b52a01">500</ix:nonFraction> million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to <ix:nonFraction unitRef="vote" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="INF" name="fold:CommonStockVotingRightsForEachShareHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMzQz_c69f1270-49c6-4aac-b6f0-41668b5c95e2">one</ix:nonFraction> vote for each share held.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-103-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="i813ec17232d9477e9221c24a07598073"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company entered into a Sales Agreement with The Goldman Sachs &amp; Co. LLC to create an at-the-market ("ATM") equity program, pursuant to which the Company may offer to sell shares of its common stock having an aggregate offering gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="icb2d2c63506847d38297b26fc2a46816_D20221101-20221130" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjc0ODc3OTA3ODEzNg_bc135f7b-e3b8-461e-ae57-6f4d3af11cc8">250.0</ix:nonFraction>&#160;million.  At December 31, 2022, no shares have been issued under the ATM equity program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a securities purchase agreement with certain entities, the (&#8220;Purchase Agreements&#8221;) for the private placement of an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1dbc7ec2bc82472e8d78a51e83eca27b_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ0_370a016d-b9ec-4ed6-814d-978d34944428">11,296,660</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0cc3b62495104669997b8f552c55251a_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNjA4_223c6de9-3997-4664-88eb-3fa8ac46be8e">10.18</ix:nonFraction> per share, and pre-funded warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0cc3b62495104669997b8f552c55251a_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNjc0_36fabbc9-b6c1-4447-9aee-1418d79f1f8a">8,349,705</ix:nonFraction> shares of common stock, at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i684e59baa0d248038199064182a492cf_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNzI0_7f258b73-6b48-4b63-acc7-498fb26a2a32">10.17</ix:nonFraction> per pre-funded warrant. Proceeds from the private placement, net of offering costs, were $<ix:nonFraction unitRef="usd" contextRef="i7b9f39dd6e7249298a92876de6b1e0e0_D20210901-20210930" decimals="-5" name="fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ5NzU1ODIxNjk4_1852f60c-e2a7-41fc-89be-2a058f55ebdd">199.8</ix:nonFraction> million. Each pre-funded warrant has an initial exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0cc3b62495104669997b8f552c55251a_I20210930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfODc3_37cf85d6-2b9f-4671-a7e4-a34e34f41721">0.01</ix:nonFraction> per share and is exercisable at any time after its original issuance, subject generally to the lock-up period, at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Certain of the Purchase Agreements provide for a lock-up period of either 60 days or nine months based on the individual agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of 2021, <ix:nonFraction unitRef="shares" contextRef="i6fb10a0ab84743b8a633a5e8af451568_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTU3NA_d1f1e847-f789-44ee-8c7e-38d7d9feeb07">1,294,999</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0c5e203f768a4aaf8bcf9130761b750a_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTU4MQ_5e594dca-691c-49b3-9fe6-e2fbcde1ae09">1,260,000</ix:nonFraction> warrants were exercised at $<ix:nonFraction unitRef="usdPerShare" contextRef="i7688b5af5be343ee94e09246b4b087c8_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTYxMQ_fffb1d53-1f90-412a-b3f6-d5a3b62e6444">7.98</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="idf13e1ea84ff4fe7aa83be773a9ca942_I20210331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTYxOA_ca9afe16-c50f-407f-a63d-1840b7043aef">7.06</ix:nonFraction> per share of common stock, respectively, resulting in gross cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9f2b79da371e47f782a538b4f4a5a21e_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ5NzU1ODIxNzA0_7ce8e567-62d6-4bd3-a0e4-5e73ffa69442">19.2</ix:nonFraction> million. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with the holders of the Convertible Notes (the "Holders"). Under the terms of the exchange agreements, the Holders agreed to exchange the remaining aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i434e5978cdfe47e2b88de10d3e704e27_D20210701-20210930" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjA0MQ_874540a9-928f-4354-8077-52a73bb61ab1">2.8</ix:nonFraction>&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjEyNA_a93f0f5a-7f84-4bc7-b6e1-867b35ce2dfe">472,356</ix:nonFraction> shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iebd9dd9985e24306a01c58683a8c7ab2_I20210930" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjE2OQ_8811374b-758a-4d19-9c13-cbeafb200f2c">0.01</ix:nonFraction> per share. This transaction resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i7a60c7a011cd48f384a926bf46f56bb5_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjIyNw_607ebed9-3189-48c5-8117-9659ab08f006">2.7</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjIzNA_9f82d6b9-5598-42a2-a334-eee861df4a58">five</ix:nonFraction> thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Deferral Plan provides certain key employees and members of the Board of Directors, as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a deferred compensation investment balance of $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNDQzMg_755f8583-1e1d-438f-8761-b58b2d74fe39">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-5" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNDQzOQ_0abd47c8-b133-4bbd-bfd3-e617b612825e">4.8</ix:nonFraction> million as of December 31, 2022 and 2021, respectively, with corresponding approximate amounts of liability. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral Plan investment assets are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plan </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. Under the provisions of the Plan, no option will have a term in excess of <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ0OA_3b7ac3d6-7b47-4923-9ba0-f680a914f2e1">10</ix:nonNumeric> years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest <ix:nonFraction unitRef="number" contextRef="i9f56a09188ad4413a91488ec17aa68c9_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTc0Mg_cb92dc6b-2e29-4667-b460-b06536fca674">25</ix:nonFraction>% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for <ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTg4Ng_3aca6099-9f5a-4a89-a421-ccbd936909ef">100</ix:nonFraction>% of the shares vested at any time after the date of grant. As of December 31, 2022, the Company has reserved up to <ix:nonFraction unitRef="shares" contextRef="i8462cf871c7a45aaa1430ee2bee44c64_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTk4OA_3ef33c7d-f33e-42e6-bcc0-d9fb293fb18c">15,472,672</ix:nonFraction> shares for issuance under the Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-104-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNTg_0d46ecbb-a0b9-4d45-b910-d2130c82d6d9" continuedAt="i2ddb81d0d5324e738cce5e4a0d50b4da" escape="true">Share based Compensation </ix:nonNumeric></span></div><ix:continuation id="i2ddb81d0d5324e738cce5e4a0d50b4da" continuedAt="ie0573082169745ef9e172e0c4ca2f911"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan provides for certain benefits to qualifying Plan participants who separate from service with the Company due to death, disability or "retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#8217;s separation and all vested options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#8217;s separation or the original expiration date of the option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the <ix:nonNumeric contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjg_0ed1ece5-78f6-4ae1-b4a2-5bcacbe0635b">two year</ix:nonNumeric> period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such <ix:nonNumeric contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjc_625338aa-b909-4162-8cd1-c9ac1c0ed52e">two year</ix:nonNumeric> period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#8217;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSUs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the fair value method of measuring share-based compensation, using the fair value of each equity award granted. The Company chose the &#8216;&#8216;straight-line&#8217;&#8217; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for share-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is based on the Company's historical volatility. The average expected life is determined using the Company's actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjU_db5118bd-f85b-43dd-9639-460987c1f331" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzItMi0xLTEtMzM0ODQ_ecd49944-1e6a-4014-a30c-517cdd749e04">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzItNC0xLTEtMzM0ODQ_c30e951c-13d0-42ea-a0bb-e5d106d616bf">65.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzItNi0xLTEtMzM0ODQ_0e0780f7-f775-4387-9f2c-c676443e547b">75.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzMtMi0xLTEtMzM0ODQ_6f3becaf-f9ef-4bdb-bbaf-f5c238ac04e3">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzMtNC0xLTEtMzM0ODQ_473575ea-6ca7-4e90-b341-d719a23c28b4">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzMtNi0xLTEtMzM0ODQ_6e5cf1ac-aeb6-46af-aa7e-1fab3af327ed">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life of options (years) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzQtMi0xLTEtMzM0ODQ_f4370168-2c0b-4f35-9ee9-4f98d16aa3e3">5.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzQtNC0xLTEtMzM0ODQ_19e91637-d48c-4b18-8e21-0ca5589242f7">5.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzQtNi0xLTEtMzM0ODQ_11720f40-ba89-4fc0-a384-b49eb792fc1f">5.67</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzUtMi0xLTEtMzM0ODQ_2c04ac8f-511a-4a7c-a7eb-5210f2dac102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzUtNC0xLTEtMzM0ODQ_e9f71309-0a3e-484f-bc48-37fe1b0a82ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231" decimals="INF" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzUtNi0xLTEtMzM0ODQ_5f018176-7119-4405-8e61-0991d823a307">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value per share of options granted during 2022, 2021, and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM0NjA_0480a80b-8ad3-4a10-ab6e-ab26a3dff2d5">6.11</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM0NjQ_9da6c62f-38b2-471f-be00-c5269aa8d897">9.08</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM0NzI_fe77bf0f-de1e-43b2-877d-53964dd9b36c">6.40</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-105-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="ie0573082169745ef9e172e0c4ca2f911" continuedAt="ida82ee5c5ec04f5bbbca8f511100ecc6"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNzA_ff61c3f8-d0ce-4619-88a9-ad78c6de9c54" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the year ended December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzItMS0xLTEtMzM0ODQ_d81545a9-3c26-4a8c-a203-cf6faf5a8736">16,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzItMy0xLTEtMzM0ODQ_e1378a04-31a8-4f74-ab32-84d209b36b30">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzMtMS0xLTEtMzM0ODQ_e6a71a28-78e8-47eb-a4b3-1ff032ac6dc0">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzMtMy0xLTEtMzM0ODQ_6bce596d-f6b5-4496-9242-32318aeba5d7">9.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzQtMS0xLTEtMzM0ODQ_a72f6aa3-3552-459b-833b-655224e977cf">5,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzQtMy0xLTEtMzM0ODQ_0668f7bf-0ecd-4bbb-ab93-1d00fe6a32c8">8.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzUtMS0xLTEtMzM0ODQ_a8447061-d351-4638-a5ac-3109b1128a4d">1,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzUtMy0xLTEtMzM0ODQ_97adb1d4-75e9-4ee9-869d-865b76122863">10.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzYtMS0xLTEtMzM0ODQ_1a28902c-46f2-4c99-a34b-9d42e0117ff5">435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzYtMy0xLTEtMzM0ODQ_be578d82-0f86-4095-9655-55379de31030">13.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzctMS0xLTEtMzM0ODQ_3d34ba8e-000a-43df-a576-0a7a11d514bf">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzctMy0xLTEtMzM0ODQ_6325760a-c6d6-4643-83e1-770a70101c05">9.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzgtMS0xLTEtMzM0ODQ_6612b37d-2124-4e52-b7a6-656362c3a343">3,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzgtMy0xLTEtMzM0ODQ_036f624f-9bcb-4c89-9f60-c9ba9d83c362">16.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzktMS0xLTEtMzM0ODQ_a366b72e-e3f4-4fdf-9663-8ed2fe74acf0">1,483</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzktMy0xLTEtMzM0ODQ_ad30b0bc-5f44-4a11-81a2-aa68107de4a3">7.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEwLTEtMS0xLTMzNDg0_7b3af838-92b7-4133-8ab7-7c92d31720b3">844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEwLTMtMS0xLTMzNDg0_719aa2bb-870f-4812-9f98-acc7f513d611">12.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzExLTEtMS0xLTMzNDg0_105cee67-fb3e-4137-89cc-783a288c0c0f">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzExLTMtMS0xLTMzNDg0_126260eb-91a4-4b45-a765-a209e80439e5">13.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEyLTEtMS0xLTMzNDg0_191b8bb7-157e-4101-90a2-7066d624c74c">14,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEyLTMtMS0xLTMzNDg0_15c440d6-bda4-4d60-9992-2022f4495a0a">11.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEzLTEtMS0xLTMzNDg0_30c5b6e4-94fb-46f9-9965-560714a0b4f5">5,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEzLTMtMS0xLTMzNDg0_52a45896-bf8b-42d4-843f-2017469c8a65">11.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE0LTEtMS0xLTMzNDg0_ed436892-95f4-4c9f-9d8d-581c3792eeb3">660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE0LTMtMS0xLTMzNDg0_e25cf858-33d0-4fce-983c-0c3be812387f">6.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE1LTEtMS0xLTMzNDg0_49428550-eeb3-4d84-bc5a-0a6c0d65c204">495</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE1LTMtMS0xLTMzNDg0_ad774a70-a7d1-4f13-9bb7-682b804831e9">12.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE2LTEtMS0xLTMzNDg0_d0812535-411a-43d3-8e72-25c5b5b3744d">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE2LTMtMS0xLTMzNDg0_5b92647a-9f70-476d-94bc-adba8cda6229">12.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTEtMS0xLTMzNDg0_9c0f2f8a-7d7f-48b8-8019-cb1f0fb33dd3">19,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTMtMS0xLTMzNDg0_1b345881-7f89-451c-848d-982d27df7804">11.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTUtMS0xLTMzNDg0_20a3e5ec-a431-4490-9fdf-e40871d9fd94">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTctMS0xLTMzNDg0_4b2afa94-6946-45b0-9808-4168f220b1ff">36.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTEtMS0xLTMzNDg0_75aa45a2-0ec0-4434-9659-20c044d0826c">17,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTMtMS0xLTMzNDg0_7b151666-0c35-44eb-a0b6-a97867145438">11.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTUtMS0xLTMzNDg0_42861fb4-782e-4372-9ea0-7f384a720722">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTctMS0xLTMzNDg0_fdf6e55c-eba3-43da-aa12-fa8071384fb0">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTEtMS0xLTMzNDg0_ac9ab6b9-08f4-4baa-9e3c-afbedcbf8a40">10,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTMtMS0xLTMzNDg0_ee867f54-0818-430d-9cb0-4c6816f2de5a">10.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTUtMS0xLTMzNDg0_cac53da6-65e5-47cd-ad41-173a2daf0d6e">5.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTctMS0xLTMzNDg0_a5d1cf2a-be1d-4cfd-a457-851448cffa18">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM2NjQ_b7ba9b59-271d-4be0-b83f-491c455c434a">2.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM2Njg_7812ed5f-f6b2-461b-b603-85c92300997e">8.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM2NzY_188b90f0-feab-43db-81fd-12749e9d3bb8">40.9</ix:nonFraction> million, respectively. Cash proceeds from stock options exercised during the years ended December 31, 2022, 2021, and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM3Nzk_54fa0a30-ed97-45b9-80e7-4ad2fac47242">4.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM3ODM_d49f61ee-fd63-42f4-9121-33faee563e1b">10.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM3OTE_84b31474-ebc5-4ef5-a73b-e7ced0af5d3c">42.3</ix:nonFraction> million, respectively. As of December 31, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM5MDg_36fbf301-04cc-422f-8018-8b9ec9742d0b">31.1</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM5Nzg_2e0c9004-ceb3-40df-8f2a-d01580dc17bf">three years</ix:nonNumeric>.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-106-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="ida82ee5c5ec04f5bbbca8f511100ecc6"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjA_cb8a6231-e51c-4f4c-8988-511de20fd6df" continuedAt="i4ec439096f604ff69bf89ad99e4b28f5" escape="true">A summary of non-vested RSU activity under the Plan for the year ended December 31, 2022 is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><ix:continuation id="i4ec439096f604ff69bf89ad99e4b28f5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc0df69ddff74c2089537bf0e99a1af4_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzItMS0xLTEtMzM0ODQ_0193fa40-0b53-4098-8ed6-fb65cf2eab3a">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc0df69ddff74c2089537bf0e99a1af4_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzItMy0xLTEtMzM0ODQ_7b81052a-28f8-43a0-abfd-95fc5adcead5">11.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzMtMS0xLTEtMzM0ODQ_723c5756-a2e3-4449-801c-de2e25061b3c">4,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzMtMy0xLTEtMzM0ODQ_98854c32-d9d2-437e-b14f-ddac61358cbd">11.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzQtMS0xLTEtMzM0ODQ_9c74594a-3344-4f8f-a9c5-7044da5882a7">2,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzQtMy0xLTEtMzM0ODQ_d7855c3d-8516-4d81-99d7-c2c639c915d8">10.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzUtMS0xLTEtMzM0ODQ_00601ac7-583c-4628-8f2c-97f8b2d46ed0">1,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzUtMy0xLTEtMzM0ODQ_a23d6616-98b3-4fc7-8063-fd45cde322cd">11.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbd0892a63d24555a0be7d1e129099a6_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzYtMS0xLTEtMzM0ODQ_2fb86938-7b4e-45bd-8aa3-d6e1fff52176">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idbd0892a63d24555a0be7d1e129099a6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzYtMy0xLTEtMzM0ODQ_3de9d66c-77ed-4a0a-b145-2d462294a141">11.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzctMS0xLTEtMzM0ODQ_7b483580-6089-4d01-beb8-d67c91e87664">3,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzctMy0xLTEtMzM0ODQ_3a1c9d8a-b613-4455-a41e-51d0f2bbb089">16.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzgtMS0xLTEtMzM0ODQ_4cfb0f45-228c-47db-abb8-1b25d6710935">1,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzgtMy0xLTEtMzM0ODQ_220f56dc-dcf9-4487-ad1f-131cb8ea8985">15.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzktMS0xLTEtMzM0ODQ_23230f9a-c100-4737-befd-8fe752198170">1,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzktMy0xLTEtMzM0ODQ_671f2411-466c-4141-9130-30f56f7ae271">12.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia25971519a474cb89a00ac0fe4405077_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEwLTEtMS0xLTMzNDg0_5f187bf3-1054-42fb-9409-3ce4ce4d0f5b">7,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia25971519a474cb89a00ac0fe4405077_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEwLTMtMS0xLTMzNDg0_44b1d2cb-3961-40c9-8cf9-590474c39e69">13.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzExLTEtMS0xLTMzNDg0_683dcc65-2612-455d-b14a-3f21de452899">5,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzExLTMtMS0xLTMzNDg0_5caf14f6-5029-45f5-aa6c-ddba5a9c74a9">11.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEyLTEtMS0xLTMzNDg0_c6dc2af2-d77b-4d67-af79-87c82150c7b4">2,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEyLTMtMS0xLTMzNDg0_25219180-9ec9-47ac-8efb-4bf971eaabac">12.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEzLTEtMS0xLTMzNDg0_5d43fea1-034d-4b15-bc53-6cfb83ac7cf8">421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEzLTMtMS0xLTMzNDg0_ba57b0a9-02d1-4a64-bd2b-000287003ec9">12.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTEtMS0xLTMzNDg0_fdc05969-f541-4e62-8175-a563614b879d">9,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTMtMS0xLTMzNDg0_7545fd18-0c13-4f9e-99e9-02286605823f">13.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTUtMS0xLTMzNDg0_c5d701f4-1917-4cc9-8f61-5a5fdbb39750">2.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTctMS0xLTMzNDg0_4a03d897-2b6f-492d-b616-8ae5b3135d48">118.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzQ3NjQ_4ddfe803-3584-43c1-b2c6-3be98e40ef08">50.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzQ5NDc_3a4ff0ab-1a25-4466-9761-8eac6fd54776">two years</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjE_c054d635-b8fb-497a-9cd6-c783c6785c50" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4aebf956783144d080e2da4950f36772_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzItMi0xLTEtMzM0ODQ_87ac7ede-8048-4bb9-b030-48ce3986b947">25,089</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7974cd6b41a844d691c4317454a8e713_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzItNC0xLTEtMzM0ODQ_2dfa7c4a-c6f6-45a8-9153-e9dc9464fcd6">17,340</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic11a83d2050e4006b0d4257abc62732d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzItNi0xLTEtMzM0ODQ_7d752b5f-c30e-4017-8f20-e7e8103e58d2">20,817</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bbbab375e34720aaff75d13f751ff3_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzMtMi0xLTEtMzM0ODQ_3d09556a-96dd-454c-9bdb-8e756bbdcc2b">51,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id791547accfd4c4ca3c15fd099f6a3c9_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzMtNC0xLTEtMzM0ODQ_73256d55-76d2-43c6-a318-592aebd6c245">40,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id344688a9ae545c792aa423f39c5e57d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzMtNi0xLTEtMzM0ODQ_8c158e2d-ad0e-4212-9ef3-d9813270174b">28,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzQtMi0xLTEtMzM0ODQ_5c7b3635-32ac-48d1-a6b5-fb59902c8fc5">76,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzQtNC0xLTEtMzM0ODQ_d8377047-1f12-4f61-8139-3d1d0456b334">57,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzQtNi0xLTEtMzM0ODQ_3c401f76-1569-4922-ad4f-acca771e15e8">49,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_106"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3NDE_99f6c69b-6b8b-4336-ba41-5f6ca2af1763" continuedAt="iab5be706ea974fd59e6169bbc3e771bb" escape="true">Assets and Liabilities Measured at Fair Value</ix:nonNumeric></span></div><ix:continuation id="iab5be706ea974fd59e6169bbc3e771bb" continuedAt="i4df1056857a64c519dbcddae05e8c48c"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-107-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="i4df1056857a64c519dbcddae05e8c48c" continuedAt="i513e1f39c89c4b43ba1c128c3003739b"><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3NDQ_83d87908-3261-476a-bca0-e3ab0a5f87f5" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2022 are identified in the following tables:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0583f7b3d714281b74c55de8631a291_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzItMi0xLTEtMzM0ODQ_1b81d5f4-3a14-4eb3-ad67-e88063659463">144,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzItNC0xLTEtMzM0ODQ_9a057391-3592-4813-9bd2-e15f3776f7d5">144,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c47266244c044308efa79fbb42126c1_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzUtMi0xLTEtMzM0ODQ_28b488ad-45fd-4cee-9602-056c83ad2088">5,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzUtNC0xLTEtMzM0ODQ_75830175-84cc-4d42-84c2-86f4f82eab8d">5,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzYtMi0xLTEtMzM0ODQ_f2b988e8-c10f-46ea-92ab-cf7204af726e">150,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzYtNC0xLTEtMzM0ODQ_40ae79d1-5ce6-48ef-ac9c-ed9d1cf6d11a">150,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzItMi0xLTEtMzM0ODQ_d3e385bc-9b17-42fd-9c63-bd9a5bcb62bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f66037dfaf441895506fef26bb3f6c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzItNC0xLTEtMzM0ODQ_e016aa3a-34cf-4d35-aab5-7daab94d3264">21,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzItNi0xLTEtMzM0ODQ_19a02ae4-6aa3-4327-9de3-721a6c0b02e6">21,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzMtMi0xLTEtMzM0ODQ_0ce08900-0ec6-4a04-8833-89a169c835af">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f66037dfaf441895506fef26bb3f6c_I20221231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzMtNC0xLTEtMzM0ODQ_b31a5fd9-66e7-4cae-a1e3-454f3e69e67e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzMtNi0xLTEtMzM0ODQ_30a8b084-f8c6-4795-8208-54d5efbfd42a">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzQtMi0xLTEtMzM0ODQ_88f1c614-5ee4-46d3-acc6-0e3efe4fb530">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f66037dfaf441895506fef26bb3f6c_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzQtNC0xLTEtMzM0ODQ_78c6e54f-d54c-4958-b32e-1e3d7f819d52">21,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzQtNi0xLTEtMzM0ODQ_7e2ae65c-26ef-49a0-a428-10a1787e8959">26,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"></td><td style="width:72.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73e550190f24545ba9da5442ddcbd4c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzItMi0xLTEtMzM0ODQ_8407d149-955c-4187-aabe-d2477d0d36a9">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzItNC0xLTEtMzM0ODQ_438ca6f0-0cf5-4b45-b293-9a0e73b74ca7">174,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea79d58e95c74a5991a23d4e79a1accb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzQtMi0xLTEtMzM0ODQ_8f301a5e-2b9e-48c2-a990-e2e41046b069">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7bc093340f94793b9356a4ad70fd286_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzQtNC0xLTEtMzM0ODQ_ad9a774e-343c-4002-b1d7-d050d426bcff">32,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c8c2cd061443e8b7635a574a7eb008_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzUtMi0xLTEtMzM0ODQ_2ea61f94-9874-4a91-8277-bdc7a7edf07a">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzUtNC0xLTEtMzM0ODQ_f836536c-6674-4b0f-9ffa-6fe722d73149">30,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief04e0e1c5f64e7ea10b52c1ac3b2b1b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzYtMi0xLTEtMzM0ODQ_db535b44-64fb-4770-b61e-86a6ed5413d2">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzYtNC0xLTEtMzM0ODQ_27c1a801-3d93-4f47-a89b-7741fa540ee4">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzctMi0xLTEtMzM0ODQ_4e6be8c9-cf82-4260-86b5-6143e4024a28">242,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzctNC0xLTEtMzM0ODQ_1332b477-9739-48b4-ae05-3226c61d905f">242,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzItMi0xLTEtMzM0ODQ_0661b5f0-7d08-4be6-926e-97c14d3ec323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11c64b571a447ccae1108601a456bd6_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzItNC0xLTEtMzM0ODQ_27ced4cc-faa5-4a61-aba6-72a8815350f7">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzItNi0xLTEtMzM0ODQ_da90cc2e-a49d-4c4b-bf4b-a310d70152e6">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzMtMi0xLTEtMzM0ODQ_bf700cc7-59a3-40bc-bf47-aec7780f8de9">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11c64b571a447ccae1108601a456bd6_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzMtNC0xLTEtMzM0ODQ_50fb4b23-f861-4c31-b63f-e0b15585ae64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzMtNi0xLTEtMzM0ODQ_b02aea91-ec60-4b22-8787-306c38c406fc">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzQtMi0xLTEtMzM0ODQ_54126ef1-c1fd-471e-b6c9-a65254bdee8e">4,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11c64b571a447ccae1108601a456bd6_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzQtNC0xLTEtMzM0ODQ_9a66c154-a37c-4a03-be5b-5433559bd622">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzQtNi0xLTEtMzM0ODQ_210112a7-0ae9-41d5-99e4-a337fa32cb23">25,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of December 31, 2022 or 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-108-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="i513e1f39c89c4b43ba1c128c3003739b" continuedAt="i6e490420067a411cae35abba637e4a54"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds and Marketable Securities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2022. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3MzY_13c492f0-c033-4d70-a76f-1b6a7ec272de" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ec9eab666f04c9ba3be68d4ffd794f2_I20221231" decimals="3" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzItOC0xLTEtMzM0ODQ_f65a33ec-d407-43d0-b700-c8ebbf225a77">10.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863463917abd46488618f36fe6140b3f_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzMtMi0xLTEtMzM0ODQ_b5e42e22-3893-4806-8e29-5f3492ea139a">21,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36478174e3aa4ca6a302830abc0b3fd0_I20221231" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzMtOC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiNzQ2ZmIzOGQ0OTc0Zjg5ODA2YTBjODMwMTBmY2M2NV80_b3be898d-791e-44d8-993a-490ca168fc0f">88</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i0914d34ae7a54148af314b77afd45e1d_I20221231" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzMtOC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiNzQ2ZmIzOGQ0OTc0Zjg5ODA2YTBjODMwMTBmY2M2NV83_6fa27180-73c0-4e12-83f3-c7af432dea71">98</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reached a regulatory milestone in September 2021 associated with FDA approval of the first BLA and in November 2021 associated with EMA validation of the MAA, both related to the contingent consideration of Callidus for the ATB200 Pompe disease program. The satisfaction of these milestones resulted in the collective milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzgyNDYzMzcyMTQxNjY_68752d6c-e2bb-442f-8d72-e3aafefa5272">12.0</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-109-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="i6e490420067a411cae35abba637e4a54"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3NDA_f8834e6a-fc01-4d78-a60f-b16ec53042b9" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2022 and 2021, respectively:  </span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:71.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzItMi0xLTEtMzM0ODQ_47abed7c-efe5-4fc9-a6d2-62c883196fe9">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzItNC0xLTEtMzM0ODQ_f645d125-86ea-4b93-943d-ef775c3f8051">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzMtMi0xLTEtMzM0ODQ_d9973eec-c49c-4cfc-9e84-3fde83c1c8db">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzMtNC0xLTEtMzM0ODQ_14f998e8-5fe0-4745-b626-222781f0d313">6,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration in cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzQtMi0xLTEtMzM0ODQ_12aa0166-0aa8-47ec-9358-50b5ddff769a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzQtNC0xLTEtMzM0ODQ_99ad23ba-1503-4eaa-b875-b11d165b28ea">12,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzUtMi0xLTEtMzM0ODQ_d27046d7-3ee7-4a59-a3e1-8046cf91fb65">21,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzUtNC0xLTEtMzM0ODQ_25fd64e5-2834-40f2-93dd-028bbb752098">20,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As certain milestones are expected to be reached within the next twelve months, the December 31, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.</span></div></ix:nonNumeric></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_109"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzY2NDI_5c91a4bb-786a-420f-a6c8-8444e8e87ba5" continuedAt="i92cbce3ecbee40d3ab94b457d3247bcb" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i92cbce3ecbee40d3ab94b457d3247bcb" continuedAt="id69ecb3cc42545d5b3f0fb139bf07718"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzY2NDM_94009178-062c-4376-a03e-e8613b1d82d3" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzItMi0xLTEtMzM0ODQ_424db012-4f45-4048-abe1-e9dec43c6377">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3c044f256444559188d07ee55b2357_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzItNC0xLTEtMzM0ODQ_e1e924ab-41a8-408a-93fb-15351ce24ad0">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzMtMi0xLTEtMzM0ODQ_028f4846-efb5-44fa-b157-9c72033cd191">4,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3c044f256444559188d07ee55b2357_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzMtNC0xLTEtMzM0ODQ_3ccde6fd-a5e1-408a-a239-27f9e01aac8b">6,074</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzQtMi0xLTEtMzM0ODQ_8e53c999-9612-4cbb-ab67-9f8374a0d778">3,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e3c044f256444559188d07ee55b2357_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzQtNC0xLTEtMzM0ODQ_534ca8c1-de66-4754-950c-bd31ae443594">4,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzUtMi0xLTEtMzM0ODQ_7e273c2c-bc36-4da2-a317-4cfe7e9b1cfe">391,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3c044f256444559188d07ee55b2357_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzUtNC0xLTEtMzM0ODQ_bd259414-7c51-481a-a775-7d7458fc80eb">389,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan using the effective interest rate method.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Term Loan due 2026</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a definitive agreement for a $<ix:nonFraction unitRef="usd" contextRef="i8b64c874c8c44ab193d9b7e4e27fc831_I20200731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzQyMA_db50c889-ea29-4c0a-8c44-ee8b551a3650">400</ix:nonFraction>&#160;million credit facility with Hayfin Capital Management (&#8220;Senior Secured Term Loan due 2026&#8221;) with an interest rate equal to 3-month LIBOR, subject to a <ix:nonFraction unitRef="number" contextRef="ib2b5d30d91b5477cb000659e1d65b4e9_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzU2Nw_83fd3181-029c-4cff-9e35-2f5218fc8991">1</ix:nonFraction>% floor, plus <ix:nonFraction unitRef="number" contextRef="ib2b5d30d91b5477cb000659e1d65b4e9_D20200701-20200731" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzU4Mg_70a830ac-7f35-4540-b024-9532d3b19e27">6.5</ix:nonFraction>% per annum and requires interest-only payments until mid-2024. The Senior Secured Term Loan due 2026 will be repaid in <ix:nonFraction unitRef="numberofpayments" contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentPeriodicPaymentNumberOfPayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzcwMw_c24362c0-645a-4e4c-9342-5a8f23af3157">nine</ix:nonFraction> quarterly payments of $<ix:nonFraction unitRef="usd" contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzcyOA_a4cfefe5-345f-43c7-b658-de93225f59dc">44.4</ix:nonFraction>&#160;million, starting on July 2024 with the final balance due on the maturity date in July 2026. This transaction resulted in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731" decimals="-5" name="us-gaap:ProceedsFromSecuredLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzg2MQ_9cf33124-9a3f-4933-89b4-11ef28c3bc20">385.9</ix:nonFraction>&#160;million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Company used the proceeds to voluntarily settle the Senior Secured Term Loan with BioPharma Credit PLC, which included the $<ix:nonFraction unitRef="usd" contextRef="i7ede13529d0c4d9b9a5b6711cd1a2495_I20200731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzExMzU_4a9d9a21-d469-4fa7-af23-f593043b395d">150</ix:nonFraction>&#160;million principal, $<ix:nonFraction unitRef="usd" contextRef="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzExNDk_3fa616bf-7bbd-4e03-b464-bb236fcb4269">1.1</ix:nonFraction>&#160;million accrued interest, and $<ix:nonFraction unitRef="usd" contextRef="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731" decimals="-5" name="fold:EarlySettlementPremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzExNzQ_12680404-fdf8-4c7c-b849-2d0ce83c872c">5.2</ix:nonFraction>&#160;million in early settlement premiums. As a result of this early extinguishment, the Company recognized a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzEzMDg_b75a9544-0b4f-4632-8ca6-179e6be1171a">7.3</ix:nonFraction>&#160;million in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Term Loan due 2026 is subject to mandatory prepayment provisions that require prepayment upon a change of control, the incurrence of certain additional indebtedness, asset sale, or an event of loss, subject to certain conditions set forth in the Senior Secured Term Loan due 2026. The Company may prepay the Senior Secured Term Loan due 2026 in whole, at its option at any time. Any prepayment of the Senior Secured Term Loan due 2026 is subject to certain make-whole premiums and prepayment premiums, the latter of which decrease until the fourth anniversary of the transaction date at which point no prepayment penalty shall exist. The obligations under the Senior Secured Term Loan due 2026 are secured by a first lien security interest in certain assets of the Company. The Senior Secured Term Loan due 2026 contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company. The Senior Secured Term Loan due 2026 also contains a minimum liquidity covenant of $<ix:nonFraction unitRef="usd" contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentLiquidityCovenantMinimumAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzI0MTY_942f6979-54bf-4b2f-b8f2-5ac8359d1fe6">75</ix:nonFraction>&#160;million, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $<ix:nonFraction unitRef="usd" contextRef="i4688884f4dfe4ebb993267308aba950f_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentConsolidatedRevenueCovenantAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzI1OTQ_ee6cd5a3-8eb5-4a64-84fd-74ad6befc920">140</ix:nonFraction>&#160;million, beginning March 31, 2021, and peaks at $<ix:nonFraction unitRef="usd" contextRef="if96cae15f3fe42258129198c088db297_D20200701-20200731" decimals="INF" name="fold:DebtInstrumentConsolidatedRevenueCovenantAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzI2Mzc_0d5d4835-b78c-4cee-a6b4-86569f2c73f4">225</ix:nonFraction>&#160;million by June 30, 2023, continuing at that level until the Senior Secured Term Loan due 2026 is repaid. If an event of default occurs and is continuing, Hayfin Capital Management may declare all amounts outstanding under the Senior Secured Term Loan due 2026 to be immediately due and payable.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-110-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="id69ecb3cc42545d5b3f0fb139bf07718"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzY2NDY_ac15ad20-3f45-47fa-b107-f22772989a43" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:73.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except interest rate amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzEtMi0xLTEtMzM0ODQ_cb16faee-4e92-4c02-aba7-46da80914b2b">34,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzEtNC0xLTEtMzM0ODQ_4d8a9a7d-19dc-4b1f-9009-3958c0f7d6ec">30,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzItMi0xLTEtMzM0ODQ_1f83f68e-abe7-4239-9db4-4e34c92ff985">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzItNC0xLTEtMzM0ODQ_401224ee-6562-4a77-8256-6d5dfc741cf8">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzMtMi0xLTEtMzM0ODQ_57d79e8c-6b80-4016-8769-e2f6175e2cd2">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzMtNC0xLTEtMzM0ODQ_b3300ff1-9279-43ed-9864-c392f8945c67">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Senior Secured Term Loan due 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib91a2c830ad742d79faac258a290765d_I20221231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzUtMi0xLTEtMzM0ODQ_c9904e9f-0f38-4ff0-a687-361e32ec9b4a">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i77e2344e04a24467a4594a535befc1ac_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzUtNC0xLTEtMzM0ODQ_a79f22e8-2347-4938-b89b-bb88f6b867c2">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_115"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEyMTk_6d46ae60-6b45-44f4-bf48-fcbe7fd847e5" continuedAt="iaf7fd1ba88bc48dfa9b15afe8e42cb45" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="iaf7fd1ba88bc48dfa9b15afe8e42cb45" continuedAt="i66813960c4a0405fa5fe82f8e804e88e"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, and 2021, operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzMzNw_d500d4a4-57ef-4a15-b6f8-ea9df0232969">9.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzM0NA_4a8586f1-f192-47f1-bc7f-af444c89fd48">10.0</ix:nonFraction>&#160;million and variable lease expense was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzM3OA_c8a7f623-cd62-4a6d-835d-bf06fc536b66">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzM4NQ_62f53650-52e3-4cd4-bcdd-1414534e4ec0">2.1</ix:nonFraction> million, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December 31, 2022, and 2021, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzQ1NA_fc54843c-050e-4c14-bf1d-0a5775d0f298">8.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzQ2MQ_1f6151ad-6665-4507-8b54-1eb7005d8ece">8.4</ix:nonFraction>&#160;million, respectively, for amounts included in the measurement of operating lease liabilities and recorded $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzU2Mw_4d3a06ab-3019-48cb-9034-fe7b43cd6299">8.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzU3MA_fb68b18f-178d-4373-a8b4-fff1facfd892">0.3</ix:nonFraction>&#160;million, respectively, of&#160;right-of-use assets. For the year ended December 31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="INF" name="us-gaap:PaymentsForTenantImprovements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEwNDQ1MzYwNDY1NTI5_d364bd01-4d2f-40ec-8f7a-c02212f582e1">no</ix:nonFraction> tenant improvements paid through lease incentives in exchange for new operating lease liabilities.  For the year ended December 31, 2021, there were $<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForTenantImprovements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzE2NDkyNjc0NDM2MzM_da4d83fd-06ee-4426-84fc-12bc91006102">0.3</ix:nonFraction>&#160;million of tenant improvements paid through lease incentives in exchange for new operating lease liabilities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments under finance leases are not significant for the year ended December 31, 2022.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-111-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="i66813960c4a0405fa5fe82f8e804e88e"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEyMTE_82b9f5c4-a1ec-4e3d-a468-b9936476f52e" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except year and discount rate amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzEtMi0xLTEtMzM0ODQ_73b2b4c2-a60f-427f-93cc-7c37a7bd1117">29,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzEtNC0xLTEtMzM0ODQ_0c9de150-8a75-4aac-a1f1-078bf816c2e0">20,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzMtMi0xLTEtMzM0ODQ_899a01d4-9173-4dec-9fe4-fdd965b55754">8,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzMtNC0xLTEtMzM0ODQ_afbe98c0-9080-4da1-9699-c9dd01204b8b">7,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzQtMi0xLTEtMzM0ODQ_97543071-7b5f-4b1b-83c0-f9364736e615">51,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzQtNC0xLTEtMzM0ODQ_ca142902-1e41-44da-a136-560a809e9fbc">43,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzUtMi0xLTEtMzM0ODQ_f9772e62-2296-4418-b9ea-9392a98d5d8a">60,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzUtNC0xLTEtMzM0ODQ_5c4be6ed-e164-4d07-9287-e0e1674b6873">50,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzctMi0xLTEtMzM0ODQ_4ea0eb59-71df-48a1-9ecc-25768ea326e4">17.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzctNC0xLTEtMzM0ODQ_a7c011de-d93d-4c80-ad06-89a1982ab977">19.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzgtMi0xLTEtMzM0ODQ_7bea2340-ae2a-4b5f-a342-934e47e9e851">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzgtNC0xLTEtMzM0ODQ_6c7405fd-7cc1-47c8-b10a-c054e3537ac1">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEyMTc_00c95e9b-b9a2-4432-8fd3-9533e577e79f" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the future minimum operating lease payments were as follows:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:83.355%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzEtMi0xLTEtMzM0ODQ_51ed2e83-04b1-4b44-8918-296670e05a4a">9,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzItMi0xLTEtMzM0ODQ_2432d159-7b93-4da5-b5db-7cf9e52d0ea7">8,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzMtMi0xLTEtMzM0ODQ_1a50503e-d8c6-423c-ad4a-855dbf0274aa">8,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzQtMi0xLTEtMzM0ODQ_23945a6e-664e-42a4-a6b6-e54590e32458">8,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzUtMi0xLTEtMzM0ODQ_88dced78-5064-4a40-b07a-d0e7befb47b5">8,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzYtMi0xLTEtMzM0ODQ_c7166298-e062-4536-8c6f-2ccb1d72c45f">124,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzctMi0xLTEtMzM0ODQ_bea586fe-cbf6-4328-af60-3e35fb2c161f">168,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less lease incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:LesseeOperatingLeaseLiabilityTenantIncentives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzgtMi0xLTEtMzM0ODQ_a6d280af-9a44-4734-b3e4-a2056d16a712">22,299</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzktMi0xLTEtMzM0ODQ_1e97f7db-71dc-487d-ab6c-7d9236f29201">86,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzEwLTItMS0xLTMzNDg0_2464da1e-c296-467a-a197-95e20f3a0ce1">60,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-112-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjI_49868de2-2b2a-439c-bc65-cc4ad40475f8" continuedAt="i465014da4b5a4e15923f65fc35dd9ee2" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i465014da4b5a4e15923f65fc35dd9ee2" continuedAt="i7f4e0b5557a24747ad4ad23d1239998a"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjM_bc809115-77f6-4e4a-82af-c5f65447a781" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzItMi0xLTEtMzM0ODQ_0978fe07-ba25-432b-a737-6aa4e4efaf75">343,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzItNC0xLTEtMzM0ODQ_869725b5-639f-4dea-86ad-f45668aaf5b2">333,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzItNi0xLTEtMzM0ODQ_0ad8f5f6-536a-494b-894a-c71bf623c145">365,332</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzMtMi0xLTEtMzM0ODQ_5b10db7c-f755-4c73-81a4-15ab4256a559">101,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzMtNC0xLTEtMzM0ODQ_c0e8b690-f2e5-4f57-a83e-704931a69aad">92,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzMtNi0xLTEtMzM0ODQ_c854bfca-8431-4112-bc7a-692d875f4b9f">91,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzQtMi0xLTEtMzM0ODQ_bc2219e3-abb7-4ede-b5f1-4ce4b125554d">242,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzQtNC0xLTEtMzM0ODQ_199b39c3-869d-4999-b775-4333ee86e4dd">241,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzQtNi0xLTEtMzM0ODQ_719b5087-48fe-47f2-ac9a-2bb3e04733b8">274,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjQ_f70f81ac-63fc-4bba-92ae-8f2c2e3c844f" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following were the components of income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzMtMi0xLTEtMzM0ODQ_bda365f6-48a6-4977-af5d-73ede3b0cfa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzMtNC0xLTEtMzM0ODQ_1610801e-1d99-4eee-ac89-58662e1375af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzMtNi0xLTEtMzM0ODQ_d7a1ffc2-35b3-4594-a8b4-2aa2563e9c4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzQtMi0xLTEtMzM0ODQ_2fe3d05a-6c3b-418b-bf53-86c81fb6d662">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzQtNC0xLTEtMzM0ODQ_15940e0e-699b-4ad6-851d-574cc799d197">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzQtNi0xLTEtMzM0ODQ_03b1d258-d37e-4808-bebe-3a16e3398b42">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzUtMi0xLTEtMzM0ODQ_c574f32a-b777-497b-8053-011826916a8c">5,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzUtNC0xLTEtMzM0ODQ_d4c7cb7c-be57-426c-9f6c-004806f66519">8,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzUtNi0xLTEtMzM0ODQ_2169bc2b-b50b-418a-8050-6b04c3dfb256">4,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzctMi0xLTEtMzM0ODQ_95a6994d-6fc8-4f69-98e9-97f680c3367c">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzctNC0xLTEtMzM0ODQ_462f6d1a-a6cb-41c4-b1f3-80cd8c03c4e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzctNi0xLTEtMzM0ODQ_fe71751f-ce0e-4511-921b-42e23448e478">1,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzgtMi0xLTEtMzM0ODQ_343bbc6d-5c37-404f-9a85-8f25eda84142">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzgtNC0xLTEtMzM0ODQ_a7c68717-9e2f-4410-9ed1-02df482a0b7e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzgtNi0xLTEtMzM0ODQ_bb583a44-b642-4a80-98ef-340b8018233d">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzktMi0xLTEtMzM0ODQ_904a1bd4-8b66-437f-9cbd-61a72b066a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzktNC0xLTEtMzM0ODQ_32320887-cc06-41b3-8e8f-59ae0fc91251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzktNi0xLTEtMzM0ODQ_e64db6d5-f9c7-410b-8d1f-6e91697abc20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzEwLTItMS0xLTMzNDg0_c6115db0-00bc-4319-9ccd-f1c892f3d648">5,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzEwLTQtMS0xLTMzNDg0_dd101d04-953c-4bce-8d07-2ed8777eb35d">8,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzEwLTYtMS0xLTMzNDg0_29c112d1-f27f-4179-96e9-f221c901b84f">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjU_b268cbf6-9180-42b8-90c8-a2dc3ac43836" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2022, 2021, and 2020 are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzItMi0xLTEtMzM0ODQ_3d6122f7-9bba-4e01-9a38-1dd7e950356e">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzItNC0xLTEtMzM0ODQ_55a91804-c29a-4026-8bbf-589224e0eb96">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzItNi0xLTEtMzM0ODQ_8945256b-f888-46be-be2c-dffadc596365">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzYtMi0xLTEtMzM0ODQ_f5837ac2-37c3-4f7a-9134-c64c19a4a3e0">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzYtNC0xLTEtMzM0ODQ_6e08db7c-42aa-4643-9f19-01cab3f491c0">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzYtNi0xLTEtMzM0ODQ_2db3383b-b467-4c09-9733-99407d2ab260">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzctMi0xLTEtMzM0ODQ_52a18680-1606-4de2-aeaa-2ad98707883f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzctNC0xLTEtMzM0ODQ_67ab8276-a3fb-4973-8fb3-63096426b7a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzctNi0xLTEtMzM0ODQ_ff8b3cb7-4797-464a-a598-85c1949dd8e4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEwLTItMS0xLTMzNDg0_4c95c8c2-cd75-4b8c-add6-01591e142dc3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEwLTQtMS0xLTMzNDg0_311fbfaa-85bd-4b0e-a563-d58b1f7af89b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEwLTYtMS0xLTMzNDg0_42cf99cf-836f-46d1-af38-848cd2ce20d6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzExLTItMS0xLTMzNDg0_fc53b6c7-73de-4e51-aa36-c62c1d3e5ad4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzExLTQtMS0xLTMzNDg0_0329eb63-3074-4691-bb9b-40bfb92e06d8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzExLTYtMS0xLTMzNDg0_e34f0d4e-4cc0-4644-a6a8-927eacd8d09c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEyLTItMS0xLTMzNDg0_18ffd659-468c-4926-acf0-615b0f88e249">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEyLTQtMS0xLTMzNDg0_b524e923-c474-473c-b12f-163eac0b0e6c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEyLTYtMS0xLTMzNDg0_4add76c5-d418-4268-ba56-356a97593f19">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act also introduced an additional U.S. tax on certain non-U.S. subsidiaries&#8217; earnings which are considered to be Global Intangible Low Taxed Income (referred to as "GILTI"). After consideration of the relevant guidance and completing the accounting for the tax effects of the Tax Act, the Company has elected to treat GILTI as a period cost. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-113-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="i7f4e0b5557a24747ad4ad23d1239998a" continuedAt="ia702bdcd7d53427e951681b1ca1558d3"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Tax Act eliminated the right to deduct research and development expenditures for tax purposes&#160;in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax returns for years 2017 through 2022 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNzU_4e5fc8ff-cfd7-4570-be1e-619b5123156c" continuedAt="i618388b81647454aa8d10b3d6aad2f6f" escape="true">The significant components of the deferred tax assets and liabilities are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i618388b81647454aa8d10b3d6aad2f6f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxAssetsIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzMtMi0xLTEtMzM0ODQ_cc85c611-7ef1-4f74-bfcc-86271c7856e1">68,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxAssetsIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzMtNC0xLTEtMzM0ODQ_6976fbae-6769-45a8-a0ef-7c9c336270bc">105,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzUtMi0xLTEtMzM0ODQ_c62eb1fd-2639-465b-ab8b-a9315e870f15">223,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzUtNC0xLTEtMzM0ODQ_d7a4800a-7b5b-4133-ac66-8a74d43f0359">205,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtMi0xLTEtNDA2NzY_15c54375-7ab1-47a8-8030-376057e091a9">29,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtNC0xLTEtNDA2ODY_c69692d4-5a08-4310-a5cc-5d00ef452455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtMi0xLTEtMzM0ODQ_f65fa247-c88d-49f0-9943-4692be52e497">315,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtNC0xLTEtMzM0ODQ_320e9055-cde1-47a9-848c-ad04edacfb0b">334,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxAssetsNonCashStockIssueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzgtMi0xLTEtMzM0ODQ_69fbe9d9-7882-4f82-97b6-df41b3e503e5">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxAssetsNonCashStockIssueNonCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzgtNC0xLTEtMzM0ODQ_b838734b-c8a9-4deb-adae-91c224f92934">11,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest carry forward limitation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxAssetsInterestCarryforwardLimitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzktMi0xLTEtMzM0ODQ_8bb94bf7-8bde-4d98-a0e5-b83c90b663d5">12,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxAssetsInterestCarryforwardLimitation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzktNC0xLTEtMzM0ODQ_f1d77cef-2ca9-445b-9c01-05cbe4b7f681">8,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEwLTItMS0xLTMzNDg0_3d688393-0533-4fe3-a2a8-de02c041d131">11,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEwLTQtMS0xLTMzNDg0_0d47dbfe-52a9-42dd-9de1-5d2b97ccdc92">9,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTItMS0xLTQwNjkz_1b706db1-2a7b-4b10-9b5d-7d7f12a7ddb6">10,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTQtMS0xLTQwNzAw_ea93f430-780f-43c6-98e2-1f1ed4290d6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzExLTItMS0xLTMzNDg0_6131f383-718a-42ef-ab15-3deeee8bbd36">20,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzExLTQtMS0xLTMzNDg0_68931713-f742-458c-9e63-ab2ef9c91bf3">17,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTItMS0xLTMzNDg0_52691b58-72c3-438a-adf1-9e7e06587f38">707,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTQtMS0xLTMzNDg0_426cf219-0532-4674-aafd-11324e990d3c">692,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxLiabilitiesBusinessAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE0LTItMS0xLTMzNDg0_d312a57b-25cd-4204-aace-16046ee21525">4,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxLiabilitiesBusinessAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE0LTQtMS0xLTMzNDg0_d175f6bb-c168-4ed5-bc57-b15ddb536145">4,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxLiabilitiesRoyaltyPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE1LTItMS0xLTMzNDg0_4f8ebf4d-249c-4e4a-910b-9e48fc9e4d1f">68,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxLiabilitiesRoyaltyPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE1LTQtMS0xLTMzNDg0_d9b1e345-78b2-47a0-bce7-140517392a09">105,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE3LTItMS0xLTMzNDg0_1feb39f8-79e0-4b23-8c00-da453fefcb9d">6,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE3LTQtMS0xLTMzNDg0_81bfc14b-fb50-4027-aeeb-4bdc6b03d016">4,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="fold:DeferredTaxAssetsLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE5LTItMS0xLTMzNDg0_20dfe3f5-81c0-4e26-9891-fbddf0ae487d">627,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="fold:DeferredTaxAssetsLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE5LTQtMS0xLTMzNDg0_79e46523-fba3-4fdd-aa05-e5945c12bcfa">576,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIwLTItMS0xLTMzNDg0_fde3f255-e05f-4023-82c8-f57b82e1c096">632,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIwLTQtMS0xLTMzNDg0_7bfe529e-98a5-4beb-b4d5-f96ab964d4ed">581,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIxLTItMS0xLTMzNDg0_cce43000-3587-4f7f-a1e6-80fa0ee13617">4,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIxLTQtMS0xLTMzNDg0_00f343a5-beff-4cef-b853-c27e5b60ba40">4,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2022 and 2021, the Company recorded valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzIyMjc_92f6f389-4653-440d-8f34-4565d7e9f80e">632.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzIyMzQ_2203fc1b-f835-497e-88cb-36f9382cfab9">581.8</ix:nonFraction> million, respectively, representing an increase in the valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzIzMDc_46c8fdc8-4170-420e-a190-d213300a38a0">50.4</ix:nonFraction> million in 2022, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-114-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><ix:continuation id="ia702bdcd7d53427e951681b1ca1558d3"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had federal and state net operating loss carry forwards ("NOLs") of approximately $<ix:nonFraction unitRef="usd" contextRef="ieeca2fca010445d2b6ac75145dc51d86_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzI5OTU_ab74f1c4-39f3-4a4c-9bbe-a892eb931ea1">1,183</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2ebce9bdfa62478e987dab4fc8cb80a4_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzMwMDI_6113693f-df61-4ddf-985a-87d68f9c91fb">992</ix:nonFraction> million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2022 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. The Company may experience ownership changes in the future as a result of shifts in the stock ownership some of which are outside the Company's control. The Company completed a detailed study of the NOLs for the tax year 2022 and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on the Company's ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has research and experimentation and orphan drug credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i79b2989cb3ff43f08613f1bb07e232a9_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzQ5MDI_b27a4cc3-a4ac-42c3-9c05-bd28b6bf6fdd">36.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib98e12399cbf4ef187963beeca3c3e2b_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzQ5MDk_18971ed2-eab8-40c6-9f06-79cdeeecdfa5">187.0</ix:nonFraction> million, respectively, which will expire in the years 2030 through 2040. Deferred tax assets for these carryforwards are subject to a full valuation allowance.</span></div></ix:continuation><div id="i60868bb9516a413c82303f6b0d1ba997_121"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzI2MjI_3c9f8a4d-5d67-4c9d-9dce-68342a138fd7" continuedAt="i62a2298ee0214c96a307869756eabe21" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="i62a2298ee0214c96a307869756eabe21" continuedAt="idcbfc0b256e4407fb714fab2e58f79e7"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease and other rare diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into a mutual termination agreement (the "Termination Agreement") pursuant to which the Company and Penn mutually agreed to terminate the collaboration agreement, as amended. In connection with the Termination Agreement, the Company agreed to pay Penn an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ib99cd8bfa1ce4661a32f07a098c4ad73_D20221201-20221231" decimals="-5" name="fold:PaymentsForCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzEwNDQ1MzYwNDY4Mzkz_eb7e47c1-a662-4b43-a839-f7bab301fcea">23.7</ix:nonFraction>&#160;million in connection with an unpaid portion of the discovery support payments, research program wind-down activities, and outstanding patent costs which was recorded as a component of research and development expense within the Consolidated Statements of Operations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, the Company entered into a license agreement with Penn pursuant to which it obtained a license with respect to the pre-clinical research and development of next generation parvovirus gene therapy products for the treatment of Pompe disease and Fabry disease. Under the agreement, the Company will be responsible for clinical development and commercialization of the licensed products for the indications and Penn is eligible to receive certain milestone and royalty payments with respect to licensed products for each indication, up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i9793bb80591f4cbe82d14a2f6ce6c5ef_I20221231" decimals="-5" name="fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzcxNDY4MjU1ODU5Njk_09ef389c-cf1f-44af-a2e3-d656fc0d16f0">86.5</ix:nonFraction>&#160;million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $<ix:nonFraction unitRef="usd" contextRef="i2a10a61a90a344cc83adebf491256426_I20131130" decimals="-6" name="fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzE4NTY_e73e2190-d1e3-4b9d-a620-286667ce80be">40</ix:nonFraction> million, as well as tiered royalties in the mid-teens in <ix:nonFraction unitRef="market" contextRef="i0c471c92318746a9b8b1e5af997f548b_D20131101-20131130" decimals="INF" name="fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzE5MDg_618eb778-8e67-4522-8cac-bf0b5c4c9c70">eight</ix:nonFraction> major markets outside the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent milestone payments due to GSK are recorded within the other current and other non-current liabilities accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-115-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idcbfc0b256e4407fb714fab2e58f79e7">For the year ended December 31, 2022, under the GSK collaboration agreements, the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="iba37a657d80947ab943a84d5c6b181e9_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzIzODc_2fc93470-2266-4b4f-b48b-487c9ae377eb">25.1</ix:nonFraction> million of royalty expenses. As of December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i5673e90eb6f14cadab1e4565ba42932c_I20221231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzI0MjE_b2976c78-2bd5-4e06-82c2-a82bd8aa2183">7.4</ix:nonFraction> million was recorded as deferred reimbursements and the Company recognized a liability of $<ix:nonFraction unitRef="usd" contextRef="i5673e90eb6f14cadab1e4565ba42932c_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzI1MDY_0f7841cc-0459-432c-9c53-be3033a20e1a">6.9</ix:nonFraction> million related to royalties payable to GSK within accrued expenses in the Consolidated Balance Sheets.</ix:continuation></span></div><div id="i60868bb9516a413c82303f6b0d1ba997_10445360465623"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDQ0NTM2MDQ2NTYyMy9mcmFnOjY0NjhlY2EzNGZjMjRlYmZhMDhjZDdhN2ZiNjdmN2NmL3RleHRyZWdpb246NjQ2OGVjYTM0ZmMyNGViZmEwOGNkN2E3ZmI2N2Y3Y2ZfMjc0ODc3OTA3MTUyMA_a3bf8cfc-4fdf-4b93-b27f-f19dcb88f468" continuedAt="ifcc4cb0ac8524785b4ec5a4c7da22956" escape="true">Legal Proceedings </ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="ifcc4cb0ac8524785b4ec5a4c7da22956"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, the Company received Paragraph IV Certification Notice Letters from Teva Pharmaceuticals USA, Inc. ("Teva"), Aurobindo Pharma Limited ("Aurobindo"), and Lupin Limited ("Lupin") in connection with Abbreviated New Drug Applications (&#8220;ANDA&#8221;) filed with the FDA requesting approval to market generic Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2022, the Company filed <ix:nonFraction unitRef="lawsuit" contextRef="if0862ce94c414f10953150dfe32fbbaf_I20221130" decimals="INF" name="fold:LossContingencyNumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDQ0NTM2MDQ2NTYyMy9mcmFnOjY0NjhlY2EzNGZjMjRlYmZhMDhjZDdhN2ZiNjdmN2NmL3RleHRyZWdpb246NjQ2OGVjYTM0ZmMyNGViZmEwOGNkN2E3ZmI2N2Y3Y2ZfMTY0OTI2NzQ0Mzc1OA_eccd570a-0534-42eb-9e29-4830b40cfc93">four</ix:nonFraction> lawsuits against Teva, Lupin, and Aurobindo in the U.S. District Court for the District of Delaware for infringement of its Orange Book-listed patents and will vigorously enforce its Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property rights.</span></ix:continuation></div><div id="i60868bb9516a413c82303f6b0d1ba997_124"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90ZXh0cmVnaW9uOjAzYjlhMjA0NjkwNTQ0YWY5ZGU0Mjc2YmY2OTZlMTcwXzcyNg_4acdac25-16de-424e-8bbb-016ada5e8368" continuedAt="i7a8f2538700a444095e8ae5b7b9daf6a" escape="true">Basic and Diluted Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="i7a8f2538700a444095e8ae5b7b9daf6a"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90ZXh0cmVnaW9uOjAzYjlhMjA0NjkwNTQ0YWY5ZGU0Mjc2YmY2OTZlMTcwXzcyMQ_169e6b22-4a51-42ad-b2f1-51cb90858a4a" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:56.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzMtMi0xLTEtMzM0ODQ_ebd856a9-106a-438d-bd92-8e1807581c34">236,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzMtNC0xLTEtMzM0ODQ_57da3075-6132-4ac6-99a6-454592b3152c">250,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzMtNi0xLTEtMzM0ODQ_523c5cb5-ba20-4dac-9728-63ed9255276a">276,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtMi0xLTEtMzM0ODQ_0f2f2046-2929-4c9a-8e5c-582537639b84"><ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtMi0xLTEtMzM0ODQ_5a66b666-540b-4994-9ee1-cc6364f25233">289,057,198</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNC0xLTEtMzM0ODQ_c89a777b-f2ca-45bd-95dc-33a228eaf64f"><ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNC0xLTEtMzM0ODQ_eb97c6fd-aac2-455d-92de-4face3c872af">271,421,986</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNi0xLTEtMzM0ODQ_989f6df0-f7df-40d6-805e-3257ddff5e42"><ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNi0xLTEtMzM0ODQ_b8f7b967-37bb-4cf3-9ce6-166442f46625">258,867,380</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of outstanding common stock options, unvested RSUs, outstanding warrants for common stock equivalents, and convertible debt units. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. </span></div><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90ZXh0cmVnaW9uOjAzYjlhMjA0NjkwNTQ0YWY5ZGU0Mjc2YmY2OTZlMTcwXzcyMg_8e359f54-5f96-4811-bed4-bd41618c3d61" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:58.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id13e58186fce456cb1f8099e4d16a816_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzItMi0xLTEtMzM0ODQ_180c5b91-092a-4e81-98f9-4c660622f607">19,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe76a53ea05f4538ab0428dc6a0d71ba_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzItNC0xLTEtMzM0ODQ_27852600-0463-40a4-bd9d-ddf4fb22611f">14,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i368b9dd19078410ea03a553d29d85a22_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzItNi0xLTEtMzM0ODQ_2c32673d-4a0d-42bd-9280-f5a6345ee85d">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b4ae1b3663f48dc81a42db36e0a2c47_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzMtMi0xLTEtMzM0ODQ_410f39f7-cd7c-4bf9-89af-35a55053cbb7">9,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8b18190ecdd4603980cfb4ea1d75b83_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzMtNC0xLTEtMzM0ODQ_e269a846-14a2-4395-bbf0-f2155b3e8ef3">7,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ac3baf5d87f4121b825257bdbd8cdfc_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzMtNi0xLTEtMzM0ODQ_d37c1f1d-2019-4953-824f-82e4bf350fd9">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c9f9812c5e347c0a7f7930aed8b7d7b_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzQtMi0xLTEtMzM0ODQ_f04bbe33-f7a4-43ea-9319-b9cafbb6fce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39d797c28b2c491eaa21d972d9a071a0_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzQtNC0xLTEtMzM0ODQ_ebf4d1cd-5e3d-48c5-b7da-c96713828d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i080e37076a644122a897798491e8bdd2_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzQtNi0xLTEtMzM0ODQ_f6ba1cec-e38d-4954-b48d-79a42c422305">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7edd439e87db45d786c45396af394cbd_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzUtMi0xLTEtMzM0ODQ_ab7a87d3-48aa-4cb9-b44d-de5ed85fa130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fc776c099cb497d877ef435b98b54e3_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzUtNC0xLTEtMzM0ODQ_6f88a4eb-7a14-4184-95e4-eafa3d7feb5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68a0f47df35a4dfa8f233290926fed7a_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzUtNi0xLTEtMzM0ODQ_be16c886-045c-44dc-bad2-4898f7f28d66">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzYtMi0xLTEtMzM0ODQ_376efe94-57d4-4217-8bee-03f0daafe0f3">28,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzYtNC0xLTEtMzM0ODQ_5f91b377-d150-4cb0-9658-6464c9e09ef3">22,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzYtNi0xLTEtMzM0ODQ_f89ae800-1ad6-4f56-8e4f-250f1831ce26">24,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div id="i60868bb9516a413c82303f6b0d1ba997_127"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-116-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term "disclosure controls and procedures," as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal controls over financial reporting during the fourth quarter of the year ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this section which includes the "Management's Report on Consolidated Financial Statements and Internal Control over Financial Reporting" and the "Report of Independent Registered Public Accounting Firm" are incorporated by reference from "Item&#160;8. Financial Statements and Supplementary Data."</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_133"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OTHER INFORMATION.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_136"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-117-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part&#160;III is omitted from this Annual Report on Form&#160;10-K as we intend to file our definitive proxy statement for our 2023 annual meeting of stockholders, pursuant to Regulation&#160;14A of the Securities Exchange Act, not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on Form&#160;10-K, and certain information to be included in the proxy statement is incorporated herein by reference.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_142"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the caption "Executive Officers," "Section&#160;16(a) Reports," "Proposal No.&#160;1&#160;&#8212; Election of Directors," "Committees of the Board and Meetings."</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Ethics and Conduct for Employees, Executive Officers and Directors that applies to our employees, officers and directors, including the principal executive officer, principal financial officer, and principal accounting officer, and incorporates guidelines designed to deter wrongdoing and to promote the honest and ethical conduct and compliance with applicable laws and regulations. In addition, the code of ethics incorporates our guidelines pertaining to topics such as conflicts of interest and workplace behavior. We have posted the text of our code on our website, where it is accessible for free, at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.amicusrx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in connection with "Investors/Corporate Governance" materials. In addition, we intend to promptly disclose (1)&#160;the nature of any amendment to our code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions and (2)&#160;the nature of any waiver, including an implicit waiver, from provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date the waiver on our website in the future.</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_145"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the caption "Compensation Discussion and Analysis," "Compensation and Leadership Development Committee Report," and "Compensation and Leadership Development Committee Interlocks and Insider Participation."</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_148"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters" and "Securities Authorized for Issuance under our Equity Compensation Plan."</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_151"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Policies and Procedures for Related Party Transactions," and "Director Independence."</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_154"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTING FEES AND SERVICES.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-118-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i60868bb9516a413c82303f6b0d1ba997_160"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EXHIBITS, FINANCIAL STATEMENT SCHEDULE</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Index to Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Consolidated Financial Statements are filed as part of this report:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_49">Management's Report on Consolidated Financial Statements and Internal Control over Financial Reporting</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_49">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_52">Report of Independent Registered Public Accounting Firm (PCAOB ID: </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xNjAvZnJhZzo3NjhkZmE5YTU4NDg0MTcxOWVmZTA5MzQ4Yjg4OWYxYi90YWJsZTphMzU3NjE2MzY0NmE0MWU0YmY2YWM4Zjk5NzM2ZjY3Mi90YWJsZXJhbmdlOmEzNTc2MTYzNjQ2YTQxZTRiZjZhYzhmOTk3MzZmNjcyXzEtMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjplM2NlYzA2YmNkOWY0MWQwYmIwNmE5MDRiYjhiZDg0MV83MQ_bb8d8b8f-0e31-45ae-920c-ea845d393928">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_52">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_52">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_58">Consolidated Balance Sheets as of December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_58">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_58"> and 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_58">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_58">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">Consolidated Statements of Operations for the years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61"> and 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_61">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">Consolidated Statements of Comprehensive Loss for the years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">, and 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_64">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">Consolidated Statements of Changes in Stockholders' Equity for the years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">, and 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_67">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">Consolidated Statements of Cash Flows for the years ended December 31, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">, and 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_70">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_73">Notes To Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_73">93</a></span></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2. Consolidated Financial Statement Schedules</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not required or because the required information is included in the Consolidated Financial Statements or notes thereto.</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3. Exhibits </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465922115125/tm2229838d1_ex1-1.htm">Equity Distribution Agreement, dated November 7, 2022, by and between Amicus Therapeutics, Inc. and Goldman Sachs &amp; Co. LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465914009064/a14-5772_1ex2d1.htm">Agreement and Plan of Merger, dated November&#160;19, 2013, by and among Amicus Therapeutics,&#160;Inc., CB Acquisition Corp., Callidus BioPharma,&#160;Inc., and Cuong&#160;Do</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915068317/a15-20301_1ex2d2.htm">Amendment to Agreement and Plan of Merger, dated September&#160;30, 2015, by and among the Registrant, Titan Merger Sub Corp. and Scioderm,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916131264/a16-14342_2ex2d1.htm">Agreement and Plan of Merger, dated July&#160;5, 2016, by and among MiaMed,&#160;Inc., the Registrant and Minervas Merger Sub,&#160;Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/6/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918058298/a18-35026_1ex2d1.htm#Exhibit2_1_042023">Agreement and Plan of Merger, dated as of September 19, 2018, by and among Amicus Therapeutics, Inc., Columbus Merger Sub Corp., Celenex, Inc. and Shareholder Representative Services LLC, solely in its capacity as the Shareholders&#8217; Representative</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/25/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000119312512085717/d299897dex31.htm">Restated Certificate of Incorporation of the Registrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv3w4.htm">Restated By-laws of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465915044580/a15-13880_1ex3d1.htm">Certificate of Amendment to the Registrant's Restated Certificate of Incorporation, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/10/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465918039068/a18-15070_1ex3d1.htm#Exhibit3_1_045312">Certificate of Amendment to the Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-119-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000095012307007596/y32191a2exv4w1.txt">Specimen Stock Certificate evidencing shares of common stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1 (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916116168/a16-9905_1ex4d7.htm">Form of Indenture</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;S-3ASR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/24/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit48descriptionof.htm">Description of the Registrant's securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-3.htm">Securities Purchase Agreement, dated September 29, 2021, by and between the Company and Redmile Group LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-4.htm">Securities Purchase Agreement, dated September 29, 2021, by and between the Company and Perceptive Life Sciences Master Fund, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-5.htm">Securities Purchase Agreement, dated September 29, 2021, by and among the Company and the Purchasers identified on the signature pages thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000095012307006223/y32191a1exv10w1.txt">2002 Equity Incentive Plan, as amended, and forms of option agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A (333-141700)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465922130567/tm2233572d1_ex10-1.htm">Form of Director and Officer Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000095012310059110/c02571exv10w2.htm">Amended and Restated 2007 Director Option Plan and form of option agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/18/2010</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465913086132/a13-24764_2ex10d1.htm">Securities Purchase Agreement, dated November&#160;20, 2013 by and among the Company and the purchasers identified therein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000104746914001702/a2218555zex-10_46.htm">Second Restated Agreement, dated November&#160;19, 2013 by and between the Registrant and Glaxo Group Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/3/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465917075420/a17-29011_1ex10d1.htm">Amicus Amicus Therapeutics, Inc. Amended and Restated Restricted Stock Unit Deferral Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000114036121014545/nc10021408x1_def14a.htm">Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/27/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465916152935/a16-20656_1ex10d1.htm">Amicus Therapeutics,&#160;Inc. Cash Deferral Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1178879/000110465916164572/a16-23950_1ex10d1.htm">Form of Performance-Based Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465914071932/a14-22497_1ex10d1.htm">Amendment #1 to the Amicus Therapeutics, Inc. Cash Deferral Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/26/2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887919000072/exhibit101.htm">Amendment #2 to the Amicus Therapeutics, Inc. Cash Deferral Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/19/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465922084778/tm2222250d1_10-1.htm">Employment Agreement, dated August 1, 2022, by and between the Registrant and Bradley L. Campbell.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465922026330/tm227309d2_ex10-2.htm">Employment Agreement, dated February 23, 2022, by and between the Registrant and John F. Crowley.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/24/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1045ellenrosenb.htm">Employment Agreement dated February 18, 2020 between the Registrant and Ellen S. Rosenberg </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1048daphnequimi.htm">Employment Agreement dated February 18, 2020, between the Registrant and Daphne Quimi</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000015/exhibit1049hungdo-empl.htm">Employment Agreement dated February 18, 2020 between the Registrant and Hung Do</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-120-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000110465921120517/tm2128671d1_ex10-8.htm">Amendment to Employment and Confidentiality Agreements dated September 28, 2021 by and between the Registrant and Hung Do.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1018_2022.htm">Employment Agreement dated February 18, 2020 between the Registrant and David Clark</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1019_2022.htm">Employment Agreement dated February 18, 2020 between the Registrant and Jeffrey Castelli</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887920000033/amicus-xloanagreemente.htm">Loan Agreement, dated as of July 17, 2020, by and among Amicus Therapeutics International Holding Ltd, as Borrower, Amicus Therapeutics, Inc. as Parent and a Guarantor, certain subsidiaries of Parent as additional Guarantors, and Hayfin Services LLP as Agent for certain lenders</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/10/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001178879/000117887921000004/formofboardrestrictedstock.htm">Form of Board Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001178879/000117887921000004/formofboardstockoptionawar.htm">Form of Board Stock Option Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001178879/000117887921000004/formofstockoptionawardagre.htm">Form of Stock Option Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1178879/000117887922000006/fold-12312021xex1025.htm">Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2007 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/24/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1025_2022.htm">License Agreement dated December 22, 2022, by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">++10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1026_2022.htm">Mutual Termination Agreement dated December 22, 2022, by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21_2022.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231_2022.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311_2022.htm">Certification of Principal Executive Officer Pursuant to Rule&#160;13a-14(a) of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312_2022.htm">Certification of Principal Financial Officer Pursuant to Rule&#160;13a-14(a) of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321_2022.htm">Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350 and Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322_2022.htm">Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350 and Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-121-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference<br/>to SEC Filing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed with this<br/>Form&#160;10-K</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from this Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021, formatted in Inline XBRL (Extensible Business Reporting Language) and filed electronically herewith: (i)&#160;the Consolidated Balance Sheets; (ii)&#160;the Consolidated Statements of Operations; (iii)&#160;the Consolidated Statements of Comprehensive Loss; (iv)&#160;the Consolidated Statements of Cash Flows; (v)&#160;and the Notes to the Consolidated Financial Statements.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Annual Report on Form 10-K for the year ended December 31, 2021 formatted in Inline XBRL (included in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________________________________________</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Confidential treatment has been granted as to certain portions of the document, which portions have been omitted and filed separately with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Subject to confidential treatment request.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Certain confidential portions of this exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the Proxy Statement under the captions "Certain Relationships and Related Transactions," "Director Independence," "Committee Compensation and Meetings of the Board of Directors," and "Compensation Committee Interlock and Insider Participation."</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-122-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FORM 10-K SUMMARY.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-123-</span></div></div></div><div id="i60868bb9516a413c82303f6b0d1ba997_169"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March&#160;1, 2023.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.508%"><tr><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMICUS THERAPEUTICS,&#160;INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ &#160;&#160;&#160;Bradley L. Campbell</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bradley L. Campbell</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ &#160;&#160;&#160;Bradley L. Campbell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Bradley L. Campbell)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;Daphne Quimi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principle Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Daphne Quimi)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;John F. Crowley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Chairman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(John F. Crowley)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;&#160;&#160;&#160;Margaret G. McGlynn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Margaret G. McGlynn)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael G. Raab</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Michael G. Raab)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Glenn Sblendorio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Glenn Sblendorio)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Craig Wheeler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Craig Wheeler)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; Lynn&#160;Bleil</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Lynn Bleil)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-124-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i60868bb9516a413c82303f6b0d1ba997_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Date</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Burke Whitman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Burke Whitman)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael A. Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Michael A. Kelly)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Eiry W. Roberts, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Eiry W. Roberts, M.D.)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-125-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>2
<FILENAME>exhibit1018_2022.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_1"></div><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:27.72pt;padding-right:27.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIS EMPLOYMENT AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 6400 Sanger Road, Orlando FL 32827 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and David Clark, an individual residing at &#91;&#8230;&#93;, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company wishes to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">continue to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employ Employee, and Employee wishes to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">continue to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be employed by Company, on the terms and conditions set forth herein&#59;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:23pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:23pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless otherwise defined herein, the following terms shall have the following respective meanings&#58;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Accrued Amounts&#8221; means, as of the termination of Employee&#8217;s employment&#58;</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination&#59; (b) the sum of</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination&#59; and (c) any accrued and unpaid Base Salary through and including the effective date of</font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:6.7pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Employee&#8217;s&#58; (i) willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate)&#59; (ii) violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance&#59; (iii) misappropriation of the funds or assets of the Company (or an Affiliate)&#59; (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to&#58; (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion&#59; (v) material breach of this Agreement&#59; (vi) material breach of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non- Disclosure and Non-Competition Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; (vii) breach of Employee&#8217;s duty of loyalty to the Company&#59; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement&#59; (ix) material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work)&#59; or (x) willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or Board of Directors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee). The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following&#58; (i) when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company&#59; (ii) when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction&#59; or (iii) when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs. Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">409</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:6.5pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18) months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel&#59; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination &#59; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination&#59; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination&#59; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion&#59; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 18 month period. Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;DC  </font></div><div style="height:59.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.446%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.5pt;padding-left:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></td></tr></table></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_7"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent&#58; (i) the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement&#59; or (ii) the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties. Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless&#58; (a) Employee had provided to the Company written notice within thirty</font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason&#59; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12) months, commencing within sixty</font></div><div style="padding-left:5pt;padding-right:8.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel&#59; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination&#59; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination&#59; (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination&#59; (v) the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s termination&#59; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing</font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_10"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:17.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Duties and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as Chief People Officer or in such other position as may be mutually agreed upon by the parties. A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C. Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position. Employee agrees to serve the Company faithfully and to the best</font></div><div style="padding-left:5pt;padding-right:6.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service. Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:7.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Full Time and Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests. During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so. Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:17.35pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Company Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:8.5pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $427,450 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:7.5pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 40% of base salary&#59; provided,</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_13"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:10.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year. Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less applicable withholding) on or before the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:10.5pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:8.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company. Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.05pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.2pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans. The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Reimbursement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in</font></div><div style="padding-left:5pt;padding-right:11.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the performance of Employee&#8217;s duties. Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions&#58; (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year&#59; (ii) the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred&#59; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:25.65pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:22pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duration of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company. At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination&#59; Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:17.15pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon. Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately. The parties agree that the notice requirements set</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:13.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates. Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates. In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts. The Accrued Amounts will be paid within the time required by applicable law. The impact of the</font></div><div style="padding-left:5pt;padding-right:23pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.05pt;text-decoration:underline">Termination by Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:12.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Resignation Independent of a Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason)&#58; (i) Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts&#59; and (ii) at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:12.75pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Good Reason Resignation Within 12 Months of a Change in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Employee resigns for Good Reason within twelve (12) months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, Change in Control Severance Benefits. All payments and benefits under this section, except for</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_16"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Accrued Amounts, shall&#58; (1) require Employee to execute and return (and not revoke) a separation agreement containing a general release, the form and substance of which are acceptable to the Company&#59; and (2) be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.05pt;text-decoration:underline">Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:19.85pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Without Cause Within 12 Months After a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts. All payments and benefits under this section, except for the Accrued Amounts, shall&#58; (1) require Employee to execute and return (and not revoke) a separation agreement containing a general release, the form and substance of which are acceptable to the Company&#59; and (2) be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:7.1pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Without Cause Not Within 12 Months After a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts. All payments and benefits under this section, except for the Accrued Amounts, shall&#58; (1) require Employee to execute and return (and not revoke) a separation agreement containing a general release, the form and substance of which are acceptable to the Company&#59; and (2) be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:14.6pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">For Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall&#58; (i) receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts&#59; and</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at</font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.05pt;text-decoration:underline">Termination upon Death or Inability to Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:8.1pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death. In the event of Employee&#8217;s death during the course of Employee&#8217;s</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:149.05pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.07pt;text-decoration:underline">Inability to Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Except as otherwise provided by applicable</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work. In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive&#58; (a) the Accrued Amounts, and (b) in the event that</font></div><div style="padding-left:5pt;padding-right:6.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:10.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">General Release and Compliance Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s receipt of any right, payment or benefit under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is subject to and conditioned upon&#58; (a) Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company&#59; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.05pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section 409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section 409A.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:6.4pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Amounts Payable On Account of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section 409A on or following termination of</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment. Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section 409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section 409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of&#58; (i) the date of Employee&#8217;s death&#59; or (ii) the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:13.25pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Series of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:18.4pt;text-align:justify;text-indent:107.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Interpretative Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In applying Section 409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:60.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Participation in Other Severance Plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="margin-top:4.5pt"><font><br></font></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:10.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Federal Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.2pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section 280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order&#58; (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero)&#59; (ii) second, any current cash payments shall be reduced (if necessary, to zero)&#59; (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero)&#59; and (iv) fourth, all equity or equity derivative payments shall be reduced. If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section 1274(b)(2)(B) of the Code. Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:31.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Exception</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:26.55pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The determination of whether the golden parachute penalties under Section 280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11.65pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Computers, Property and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures. Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited. All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:21.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resolution of Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-</font></div><div style="margin-top:4.5pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:21.85pt;text-indent:35.95pt"><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_19"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:8.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disclosure and Non-Competition Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:22.35pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:9.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:113pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.05pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall extend to and be binding upon</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:20pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business. Employee consents to that transfer. Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:10.65pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including all Employee&#8217;s prior Agreements, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B. Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company. No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:15.2pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:9.4pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_22"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:24.25pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows&#58;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.74pt">If to the Company to&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt;padding-right:235.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amicus Therapeutics, Inc. 1 Cedar Brook Drive</font></div><div style="padding-left:113pt;padding-right:209.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">Cranbury, New Jersey 08512 c&#47;o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="margin-top:0.05pt;padding-left:113pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.41pt">If to Employee to&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Clark</font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3) business days after the date so mailed or sent.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:14.6pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.05pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form 4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:21pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.05pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:11.05pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:7.05pt;text-decoration:underline">Knowing and Voluntary Nature of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else. Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176pt;padding-right:176.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_25"></div><hr style="page-break-after:always"><div style="min-height:43.2pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:5pt;padding-right:7.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%;text-decoration:underline">    &#47;s&#47; David Clark                                    </font></div><div style="padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Clark</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMICUS THERAPEUTICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Crowley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">                                    </font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; John Crowley Title&#58; Chairman &#38; CEO</font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:221.05pt;padding-right:130.95pt;text-indent:3pt"><font><br></font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:4.5pt"><font><br></font></div><div style="margin-top:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47;DC  </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idf6dd9ac9a1a45469dcbccaf0bff2f9f_28"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:27.75pt;padding-right:27.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:27.75pt;padding-right:27.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT </font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="padding-left:209.85pt;text-align:justify"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:20.6pt;padding-right:20.6pt;text-align:center"><font><br></font></div><div style="padding-right:14.05pt"><font><br></font></div><div style="margin-top:3.75pt;padding-left:27.72pt;padding-right:27.72pt;text-align:center"><font><br></font></div><div style="padding-left:14.18pt;padding-right:14.18pt;text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:14.18pt;padding-right:14.18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-top:4.5pt;padding-left:15.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:27.75pt;padding-right:27.75pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:27.75pt;padding-right:27.75pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:27.75pt;padding-right:27.75pt;text-align:center"><font><br></font></div><div style="padding-left:14.07pt;padding-right:14.07pt;text-align:center"><font><br></font></div><div style="padding-left:14.07pt;padding-right:14.07pt;text-align:center"><font><br></font></div><div style="padding-left:14.07pt;padding-right:14.07pt;text-align:center"><font><br></font></div><div style="padding-left:14.07pt;padding-right:14.07pt;text-align:center"><font><br></font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="padding-left:14.07pt;padding-right:14.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-top:4.5pt;padding-left:176.35pt;padding-right:176.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOB DESCRIPTION</font></div><div style="height:85.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>3
<FILENAME>exhibit1019_2022.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9d73d474fb0147d2b553d05b97974843_1"></div><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:30.2pt;padding-right:30.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:10.15pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THIS EMPLOYMENT AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), dated as of February 18, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), between AMICUS THERAPEUTICS, INC., a Delaware corporation having an office at 3675 Market Street, Philadelphia, PA 19104 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Jeffrey Castelli, an individual residing at &#91;&#8230;&#93;, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:10.15pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company wishes to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">continue to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employ Employee, and Employee wishes to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">continue to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">be employed by Company, on the terms and conditions set forth herein&#59;</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:12.3pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the sufficiency and receipt whereof is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:26.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless otherwise defined herein, the following terms shall have the following respective meanings&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:78pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Accrued Amounts&#8221; means, as of the termination of Employee&#8217;s employment&#58;</font></div><div style="padding-left:5.95pt;padding-right:11.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) the total of any expenses properly incurred by Employee under Section 3.4(b) that have not previously been reimbursed as of the effective date of the termination&#59; (b) the sum of Employee&#8217;s accrued, but unused, vacation time, if any, as of the effective date of the termination&#59; and (c) any accrued and unpaid Base Salary through and including the effective date of Employee&#8217;s termination.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any other company, directly or indirectly, controlling, controlled by or under common control with the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Employee&#8217;s&#58; (i) willful or deliberate misconduct that has or could reasonably be expected to have a materially adverse impact on the reputation or business of the Company (or an Affiliate), or that results in gain or personal enrichment of Employee to the detriment of the Company (or an Affiliate)&#59; (ii) violation of Company policy including, but not limited to, policies prohibiting harassment and other workplace misconduct, and policies governing corporate compliance&#59; (iii) misappropriation of the funds or assets of the Company (or an Affiliate)&#59; (iv) conviction, plea of guilty, admission to facts sufficient for a finding of guilt, or plea of no contest (or nolo contendere) to&#58; (a) any felony, or (b) any misdemeanor involving fraud, theft, dishonesty, wrongful taking of property, embezzlement, bribery, forgery or extortion&#59; (v) material breach of this Agreement&#59; (vi) material breach of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non- Disclosure and Non-Competition Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; (vii) breach of Employee&#8217;s duty of loyalty to the Company&#59; (viii) disqualification, bar or suspension by any governmental authority from performing any of the duties contemplated by this Agreement&#59; (ix) material failure to perform Employee&#8217;s duties or obligations hereunder (other than as a result of being Unable to Work)&#59; or (x) willful failure to adhere to or carry out lawful duties or directives of the Company&#8217;s Chief Executive Officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or Board of Directors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding anything to the contrary herein, the Company shall not be deemed to have terminated Employee for Cause for the events described above in subsections (ix) or (x) unless the CEO or Board, as</font></div><div style="text-align:justify"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d73d474fb0147d2b553d05b97974843_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:8.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, has determined that such events are amenable to cure and given Employee written notice of the occurrence of the claimed event(s) constituting Cause and Employee has failed to cure such event(s) within fourteen (14) calendar days after Employee&#8217;s receipt of such notice (or such other period as may be deemed reasonable by the CEO or Board under the circumstances and communicated to Employee). The other events described above are not subject to an opportunity to cure but the Company may, in its sole discretion, conduct an investigation into those events and provide the employee a full opportunity to participate.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any of the following&#58; (i) when any person or entity who is not currently a stockholder of the Company (as of the date of this Agreement) becomes the beneficial owner of greater than 50% of the then-outstanding voting power of the Company&#59; (ii) when a merger or consolidation with another entity occurs that causes the voting securities of the Company outstanding immediately before the transaction to constitute less than a majority of the voting power of the voting securities of the Company or the surviving entity outstanding immediately after the transaction&#59; or (iii) when a sale or disposition of all or substantially all of the Company&#8217;s assets occurs. Notwithstanding the foregoing, no event shall be deemed to be a Change in Control Event unless such event would also be a Change in Control under Section 409A and the rules and regulations promulgated thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">409</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or would otherwise be a permitted distribution event under Section 409A.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:10.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) payment of an amount equal to one and one-half (1.5) times Employee&#8217;s then current Base Salary, payable in installments over eighteen (18) months, commencing within sixty (60) calendar days after the resignation or termination (collectively, &#8220;termination&#8217;) of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices for its senior management personnel&#59; (ii) payment of an amount equal to 100% of the target Bonus for the calendar year in which such termination occurs (such amount being payable in a lump sum), payable within seventy five (75) calendar days following such termination &#59; (iii) the accelerated vesting of stock options held by Employee immediately prior to such termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such that all Options will become vested as of the date of Employee&#8217;s termination&#59; (iv) the accelerated vesting of restricted stock grants held by Employee immediately prior to such termination (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such that all Grants will become vested as of the date of Employee&#8217;s termination&#59; (v) the accelerated vesting of performance restricted stock units held by Employee immediately prior to such termination at the applicable performance targets or such greater amounts as determined by the Board of Directors in their sole discretion&#59; and (vi) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of eighteen (18) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 18 month period. Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Change in Control Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="padding-left:5.95pt;padding-right:10.65pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the occurrence of one or both of the following events without Employee&#8217;s consent&#58; (i) the Company&#8217;s material diminution of Employee&#8217;s authority, duties, or responsibilities as set forth in this Agreement&#59; or (ii) the Company&#8217;s change in the principal geographic location at which Employee provides services to the Company to a location more than thirty (30) miles from Employee&#8217;s assigned primary office location, unless such relocation is only temporary, for a reasonable period of time, or unless such relocation merely </font></div><div style="height:79.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">constitutes travel reasonably required in connection with the performance of Employee&#8217;s duties. Notwithstanding anything to the contrary herein, Employee shall not be deemed to have resigned for Good Reason unless&#58; (a) Employee had provided to the Company written notice within thirty</font></div><div style="padding-left:6pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(30) calendar days of the occurrence of the claimed event(s) constituting Good Reason, specifying in detail the basis for such Good Reason&#59; (b) the Company fails to cure the Good Reason within thirty (30) calendar days after its receipt of such notice, and (c) Employee terminates employment within sixty (60) calendar days after providing notice to Company of the claimed event(s) constituting Good Reason.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) payment of an amount equal to Employee&#8217;s then current Base Salary, payable in installments over twelve (12) months, commencing within sixty</font></div><div style="padding-left:6pt;padding-right:11.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(60) calendar days of the termination of Employee&#8217;s employment with the Company, in accordance with the Company&#8217;s customary payroll practices then in effect for its senior management personnel&#59; (ii) payment of a bonus equal to 100% of the target Bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the year of termination, payable within seventy five (75) calendar days following such termination&#59; (iii) the accelerated vesting of the Options, such that the portion of the Options that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination&#59; (iv) the accelerated vesting of RSUs, such that the portion of RSUs that was otherwise scheduled to vest during the twelve (12) month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination&#59; (v) the accelerated vesting of PRSUs, such that the portion of PRSUs that was otherwise scheduled to vest during the twelve month period immediately following such termination (had Employee remained employed with the Company for that period) will become vested as of the date of Employee&#8217;s termination&#59; and (vi)in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period. Notwithstanding any other provision of this Agreement, Employee&#8217;s receipt of Severance Benefits is conditioned on Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company.</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;Unable to Work&#8221; means the determination by the Company, following an interactive process, that Employee has become physically or mentally incapable of performing</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div><font><br></font></div><div style="height:79.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Employee&#8217;s essential job functions, with or without a reasonable accommodation, following any period during which such status would be protected under applicable law.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:12.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.05pt;text-decoration:underline">Duties and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Agreement, Employee will be employed by the Company as Chief Portfolio Officer and Head of Gene Therapy or in such other position as may be mutually agreed upon by the parties. A Job Description setting forth Employee&#8217;s duties and responsibilities is attached as Exhibit C. Employee accepts such employment, and agrees to perform all of the duties and accept all of the responsibilities accompanying such position. Employee agrees to serve the Company faithfully and to the best of Employee&#8217;s abilities, and to devote all of Employee&#8217;s business time, skill and attention to such service. Employee is expected to be available for meetings on a regular basis, upon request by the Company, at the Company&#8217;s Cranbury, New Jersey, and Philadelphia, Pennsylvania, locations or such other Company locations as needed including, but not limited to, the Company&#8217;s international offices.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:11.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Full Time and Attention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee shall devote Employee&#8217;s full business time and best efforts to the performance of Employee&#8217;s duties and to the furtherance of the Company&#8217;s interests. During Employee&#8217;s employment with the Company, Employee may not hold another position of employment, or be retained as a consultant, or engage in any other business activity (whether full-time or part-time, whether or not for compensation), unless the Company gives Employee prior written permission to do so. Notwithstanding anything stated in this provision to the contrary, Employee is permitted to engage in charitable activities, as long as they do not interfere with Employee&#8217;s employment obligations to the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:21.3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Company Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment with the Company, Employee will be subject to all applicable employment and other policies of the Company, as outlined in the Amicus Employee Handbook and as otherwise published by the Company in writing.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:12.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, the Company shall pay Employee a salary at the gross annual rate of $405,603 (less applicable withholding) or such greater amount as the Board or a committee thereof may from time to time establish pursuant to the terms hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Such Base Salary shall be reviewed annually and may be increased, but not decreased, by the Board or a committee thereof in its sole discretion. The Base Salary shall be payable in accordance with the Company&#8217;s customary payroll practices for its senior management personnel.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:11.45pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, Employee shall be eligible to participate in the Company&#8217;s bonus programs as may be in effect with respect to senior management personnel. Employee shall be eligible to earn an annual target bonus of 100% of the Base Salary in cash (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such actual amount determined by the Company Compensation Committee in its absolute discretion and at 40% of base salary&#59; provided,</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:26.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">however, that notwithstanding anything to the contrary herein or in any bonus program, Employee must be employed by the Company as of December 31 of the applicable calendar year, in order to be eligible to earn a Bonus for such calendar year. Any Bonus payment to which Employee becomes entitled hereunder shall be paid to Employee in a lump sum (less </font></div><div style="height:79.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:26.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable withholding) on or before the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the third month following the end of the calendar year in which the Bonus was earned.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:13pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of the Company&#8217;s Amended and Restated 2007 Equity Incentive Plan and such other equity plans as the Company may adopt from time to time including, but not limited to, an Employee Stock Purchase Plan, during Employee&#8217;s employment with the Company, Employee will be eligible to receive stock options, Restricted Stock Units and Performance Restricted Stock Units pursuant to any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company. Unless otherwise provided in this Agreement, the terms and conditions of the applicable equity plan will govern all equity grants to Employee (including vesting of options and units), including with regard to the impact of the end of Employee&#8217;s employment on such equity grants.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:13.15pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, Employee may participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior management personnel of the Company, including any equity plan, subject to the eligibility and contribution requirements, enrollment criteria and other terms and conditions of such plans. The Company reserves the right to modify, amend and eliminate any such plans, in its sole and absolute discretion.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Reimbursement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, the Company shall pay or promptly reimburse Employee, upon submission of proper invoices or other documentation in accordance with the Company&#8217;s policies and procedures, for all reasonable out-of-pocket business, entertainment and travel expenses incurred by Employee in the performance of Employee&#8217;s duties. Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following conditions&#58; (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year&#59; (ii) the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred&#59; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:29.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During Employee&#8217;s employment, Employee shall be entitled to vacation in accordance with the policies of the Company applicable to senior management personnel as may be in effect from time to time.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:25.9pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall withhold from all amounts payable or benefits accorded to Employee all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law.</font></div><div style="padding-left:6pt;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div style="height:79.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d73d474fb0147d2b553d05b97974843_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duration of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s employment with the Company shall begin on the Effective Date and continue until Employee&#8217;s employment is terminated by either Employee or the Company. At all times, Employee&#8217;s employment with the Company shall be &#8220;at-will,&#8221; meaning that either Employee or the Company may terminate the employment at any time, for no reason or any lawful reason.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination&#59; Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:12.2pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any termination of Employee&#8217;s employment by the Company or by Employee (other than on account of death) shall be communicated to the other party by written notice that indicates the specific termination provision in this Agreement relied upon. Except as otherwise expressly provided in this Agreement or the notice, the termination shall take effect immediately. The parties agree that the notice requirements set forth in this Agreement do not alter the &#8220;at will&#8221; nature of Employee&#8217;s employment, as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:17.7pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Upon termination of Employee&#8217;s employment for any reason, Employee shall be deemed simultaneously to have resigned as a member of the Board, if applicable, and from any other position or office Employee may at the time hold with the Company or any of its Affiliates. Employee agrees to cooperate with the Company by signing any necessary documents and taking any other steps necessary to effectuate Employee&#8217;s resignation from the Board, if applicable, and from any other position or office Employee may hold with the Company or any of its Affiliates. In addition, upon termination of Employee&#8217;s employment for any reason, the Company shall pay Employee the Accrued Amounts. The Accrued Amounts will be paid within the time required by applicable law. The impact of the termination of Employee&#8217;s employment on the Employee&#8217;s participation in the Company&#8217;s health plans is addressed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Termination by Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:16.5pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Resignation Independent of a Change in Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Employee resigns and a Change in Control Event has not occurred in the prior 12 months, then (irrespective of whether the resignation was with or without Good Reason)&#58; (i) Employee shall receive no further compensation or remuneration of any kind other than the Accrued Amounts&#59; and (ii) at the end of the month in which the resignation takes effect, Employee shall cease to be covered under or permitted to participate in or receive any of the benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:16.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Good Reason Resignation Within 12 Months of a Change in</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Control Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If Employee resigns for Good Reason within twelve (12) months after a Change in Control Event, Employee will be entitled to receive, in addition to the Accrued Amounts, Change in Control Severance Benefits. All payments and benefits under this section, except for</font></div><div style="padding-left:6pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Accrued Amounts, shall&#58; (1) require Employee to execute and return (and not revoke) a separation agreement containing a general release, the form and substance of which are acceptable to the Company&#59; and (2) be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:6pt;padding-right:23.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Without Cause Within 12 Months After a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If the Company terminates Employee&#8217;s employment without Cause within 12 months after a Change in Control Event, then in lieu of any other payments, rights or benefits under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Employee will be entitled to receive Change in Control Severance Benefits in addition to the Accrued Amounts. All payments and benefits under this section, except for the Accrued Amounts, shall&#58; (1) require Employee to execute and return (and not revoke) a separation agreement containing a general release, the form and substance of which are acceptable to the Company&#59; and (2) be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:11.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.07pt;text-decoration:underline">Without Cause Not Within 12 Months After a Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Company terminates Employee&#8217;s employment without Cause (other than within 12 months after a Change in Control Event), then Employee will be entitled to receive Severance Benefits in addition to the Accrued Amounts. All payments and benefits under this section, except for the Accrued Amounts, shall&#58; (1) require Employee to execute and return (and not revoke) a separation agreement containing a general release, the form and substance of which are acceptable to the Company&#59; and (2) be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:18.65pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">For Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Company terminates Employee&#8217;s employment for Cause at any time, Employee shall&#58; (i) receive no further compensation or remuneration of any kind (including any Base Salary or Bonus hereunder) other than the Accrued Amounts&#59; and</font></div><div style="padding-left:6pt;padding-right:8.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) at the end of the month in which the termination takes effect, cease to be covered under or be permitted to participate in or receive any of the benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, except that, if Employee is enrolled and participating in the Company&#8217;s health benefit plans at the time of termination, the Company will allow Employee to continue as a member of those plans at Employee&#8217;s expense in accordance with the terms of those plans and the Consolidated Omnibus Budget Reconciliation Act (COBRA) for the legally required benefit continuation period.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Termination upon Death or Inability to Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:12.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Death.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Employee&#8217;s employment shall terminate immediately upon Employee&#8217;s death. In the event of Employee&#8217;s death during the course of Employee&#8217;s employment with the Company, the Company will pay the Employee&#8217;s estate the Accrued Amounts.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:10.1pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Inability to Work.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Except as otherwise provided by applicable law, the Company may terminate Employee&#8217;s employment in the event Employee is Unable to Work. In the event of Employee&#8217;s death or termination by the Company due to Employee being Unable to Work, Employee shall receive&#58; (a) the Accrued Amounts, and (b) in the event that Employee is enrolled in any of the Company&#8217;s group health benefits plans as of the effective date of Employee&#8217;s termination, then Employee and Employee&#8217;s eligible dependents, if any, shall </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">remain eligible to continue their participation in such plans for a period of twelve (12) months after Employee&#8217;s date of termination, subject to the eligibility and other terms and conditions of such plans, except that the Company will pay the full premiums otherwise payable for such coverage during such 12 month period.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">General Release and Compliance Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s receipt of any right, payment or benefit under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is subject to and conditioned upon&#58; (a) Employee&#8217;s execution and delivery to the Company of a separation agreement (that Employee does not revoke) containing a general release, the form and substance of which are acceptable to the Company&#59; and (b) Employee&#8217;s reaffirmation of and continuing compliance with Employee&#8217;s contractual and legal obligations to the Company, as expressly set forth in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:11.7pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This section is intended to help ensure that compensation paid or delivered to Employee pursuant to this Agreement either is paid in compliance with, or is exempt from, IRC Section 409A. However, the Company does not warrant to Employee that all compensation paid or delivered to Employee for Employee&#8217;s services will be exempt from, or paid in compliance with, Section 409A.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:10.45pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Amounts Payable On Account of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For the purposes of determining when amounts otherwise payable on account of Employee&#8217;s termination of employment under this Agreement will be paid, which amounts become due because of Employee&#8217;s termination of employment, &#8220;termination of employment&#8221; or words of similar import, as used in this Agreement, shall be construed as the date that Employee first incurs a &#8220;separation from service&#8221; for purposes of Section 409A on or following termination of employment. Furthermore, if Employee is a &#8220;specified employee&#8221; of a public company as determined pursuant to Section 409A as of Employee&#8217;s termination of employment, any amounts payable on account of Employee&#8217;s termination of employment that constitute deferred compensation within the meaning of Section 409A and that are otherwise payable during the first six months following Employee&#8217;s termination (or prior to Employee&#8217;s death after termination) shall be paid to Employee in a cash lump-sum on the earlier of&#58; (i) the date of Employee&#8217;s death&#59; or (ii) the first business day of the seventh calendar month immediately following the month in which Employee&#8217;s termination occurs.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:17.25pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.7pt;text-decoration:underline">Series of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any right to a series of installment payments shall be treated as a right to a series of separate payments.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:22.4pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.02pt;text-decoration:underline">Interpretative Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In applying Section 409A to amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:64.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Participation in Other Severance Plans.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Employee agrees and acknowledges that Employee shall not be eligible to participate in or have any right to</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC   </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compensation or benefits pursuant to the Company&#8217;s Change in Control Severance Plan (or any successor plan thereto) or any other Severance Plan issued by the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:14.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event Employee&#8217;s employment is terminated for any reason, Employee (and Employee&#8217;s eligible dependents, if any) shall not be entitled to any payments or benefits from the Company or any of its Affiliates except as specifically set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Federal Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:11.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">General Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee&#8217;s payments and benefits under this Agreement and all other arrangements or programs related thereto shall not, in the aggregate, exceed the maximum amount that may be paid to Employee without triggering golden parachute penalties under Section 280G of the Code, and the provisions related thereto with respect to such payments. If Employee&#8217;s benefits must be cut back to avoid triggering such penalties, such reduction shall be made in the following order&#58; (i) first, any future cash payments (if any) shall be reduced (if necessary, to zero)&#59; (ii) second, any current cash payments shall be reduced (if necessary, to zero)&#59; (iii) third, all non-cash payments (other than equity or equity derivative related payments) shall be reduced (if necessary, to zero)&#59; and (iv) fourth, all equity or equity </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:6pt;padding-right:11.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">derivative payments shall be reduced. If an amount in excess of the limit set forth in this Section is paid to Employee, Employee must repay the excess amount to the Company upon demand, with interest at the rate provided in Section 1274(b)(2)(B) of the Code. Employee and the Company agree to cooperate with each other reasonably in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties on payments or benefits Employee receives.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Exception</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall apply only if it increases the net amount Employee would realize from payments and benefits subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> after payment of income and excise taxes by Employee on such payments and benefits.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:30.55pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The determination of whether the golden parachute penalties under Section 280G of the Code and the provisions related thereto shall be made by counsel chosen by Employee and reasonably acceptable to the Company. All other determinations needed to apply this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be made in good faith by the Company&#8217;s independent auditors.</font></div><div style="margin-top:0.45pt;text-align:justify"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:15.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Computers, Property and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee agrees to handle all Company property in accordance with the Company&#8217;s policies and procedures. Employee&#8217;s authorization to access the Company&#8217;s computer systems is limited and use of such systems to compete or prepare to compete with the Company constitutes unauthorized access that is strictly prohibited. All records received or created by Employee in the course of employment related to the Company&#8217;s business (such as but not limited to, email, notes, files, contact lists, agendas, drawings, maps, specifications, and calendars) are the property of the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:25.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resolution of Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee and the Company hereby agree that, except for disputes regarding alleged or anticipated violations of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-</font></div><div style="padding-left:6pt;padding-right:25.95pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC  </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d73d474fb0147d2b553d05b97974843_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:12.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disclosure and Non-Competition Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, any and all disputes between them shall be resolved solely in accordance with the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and, to the greatest extent permitted by law, Employee and the Company expressly waive their respective right to a trial by jury for any and all such disputes between them.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:26.25pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee represents and warrants that Employee has not entered, nor will Employee enter, into any other agreements that restrict Employee&#8217;s ability to fulfill Employee&#8217;s obligations under this Agreement.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:13.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be construed, interpreted and governed by the laws of the state of Employee&#8217;s assigned primary office location during the last six months of Employee&#8217;s employment with the Company, without regard to the conflicts of law principles.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:24.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall extend to and be binding upon Employee, Employee&#8217;s legal representatives, heirs and distributees and upon the Company, its successors and assigns regardless of any change in the business structure of the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:24.1pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company&#8217;s rights and obligations under this Agreement, including the restrictions in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, shall automatically transfer with any sale, transfer or other disposition of all or substantially all of its assets, stock or business. Employee consents to that transfer. Employee may not assign any rights or obligations under this Agreement without the Company&#8217;s prior written consent.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:5.95pt;padding-right:11.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.05pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties with respect thereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">including Employee&#8217;s prior Agreement, dated April 30, 2010, except this Agreement does not supersede the Confidentiality, Non-Disclosure and Non-Competition Agreement attached as Exhibit A or the Mutual Agreement to Arbitrate Disputes on an Individual Basis attached as Exhibit B. Nor does this Agreement supersede any Award Agreement (as that term is defined in the Company&#8217;s Equity Incentive Plan) between Employee and the Company. No waiver, modification or change of any provision of this Agreement shall be valid unless in writing and signed by both parties.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:19.25pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The waiver of any breach of any duty, term or condition of this Agreement shall not be deemed to constitute a waiver of any preceding or succeeding breach of the same or any other duty, term or condition of this Agreement.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:13.4pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of this Agreement shall be unenforceable in any jurisdiction in accordance with its terms, the provision shall be enforceable to the fullest extent permitted in that jurisdiction and shall continue to be enforceable in accordance with its</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC   </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">terms in any other jurisdiction and the validity, legality and enforceability of the remaining provisions contained herein shall not be affected thereby.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:28.25pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices pursuant to this Agreement shall be in writing and shall be sent by prepaid certified mail, return receipt requested or by recognized air courier service addressed as follows&#58;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">If to the Company to&#58;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:114pt;padding-right:239.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amicus Therapeutics, Inc. 1 Cedar Brook Drive</font></div><div style="padding-left:113.95pt;padding-right:213.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">Cranbury, New Jersey 08512 c&#47;o&#160;&#160;&#160;&#160;CEO or General Counsel</font></div><div style="padding-left:114pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">If to Employee to&#58;</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:114pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jeffrey Castelli</font></div><div style="padding-left:114pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at the address identified herein or in Employee&#8217;s personnel records,</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:26.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or to such other addresses as may hereinafter be specified by notice in writing by either of the parties, and shall be deemed given three (3) business days after the date so mailed or sent.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:18.65pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12pt;text-decoration:underline">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If reasonably requested in writing, Employee agrees within fifteen (15) business days to provide the Company with an executed IRS Form 4669 (Statement of Payments Received) with respect to any taxable amount paid to Employee by the Company.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:6pt;padding-right:25pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute one and the same agreement.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6pt;padding-right:15.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:6pt;text-decoration:underline">Knowing and Voluntary Nature of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Employee acknowledges and agrees that Employee is executing this Agreement knowingly and voluntarily and without any duress or undue influence by the Company or anyone else. Employee further acknowledges and agrees that Employee has carefully read this Agreement and fully understands it. Employee further agrees that Employee has been provided an opportunity to seek, and has received, the advice of an attorney of Employee&#8217;s choice (at Employee&#8217;s expense) before signing this Agreement.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:30.15pt;padding-right:30.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page Follows&#93;</font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt"><font><br></font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt"><font><br></font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt"><font><br></font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC   </font></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Agreement on the date first above written.</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%;text-decoration:underline">     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; JC                                                       </font></div><div style="margin-top:4.5pt;padding-left:222pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jeffrey Castelli</font></div><div><font><br></font></div><div style="padding-left:222pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AMICUS THERAPEUTICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:222pt;padding-right:45.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; DC&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Name&#58; David Clark</font></div><div style="padding-left:222pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; Chief People Officer</font></div><div><font><br></font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.45pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee&#8217;s Initials  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47;JC   </font></div><div style="height:77.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9d73d474fb0147d2b553d05b97974843_13"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIALITY, NON-DISCLOSURE AND NON-COMPETITION AGREEMENT </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:23.15pt;padding-right:23.15pt;text-align:center"><font><br></font></div><div style="padding-left:28.3pt;padding-right:18pt"><font><br></font></div><div style="padding-right:18pt"><font><br></font></div><div style="padding-left:23.15pt;padding-right:23.15pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:16.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MUTUAL AGREEMENT TO ARBITRATE DISPUTES ON AN INDIVIDUAL BASIS</font></div><div style="margin-top:0.1pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:3.95pt;padding-left:30.22pt;padding-right:30.22pt;text-align:center"><font><br></font></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font><br></font></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font><br></font></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font><br></font></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font><br></font></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font><br></font></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.04pt;padding-left:16.21pt;padding-right:16.21pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT C</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:30.17pt;padding-right:30.17pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOB DESCRIPTION</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:33.057%"><div style="margin-top:0.15pt"><font><br></font></div><div id="i9d73d474fb0147d2b553d05b97974843_94"></div></div><div style="display:inline-block;max-width:0.413%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:33.057%"></div><div style="display:inline-block;max-width:0.413%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:33.060%"></div></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>exhibit1025_2022.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9bc7ff1081344f6588412f3f599f4770_1"></div><div style="min-height:81.36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">CONFIDENTIAL</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">EXECUTION COPY</font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DATED AS OF DECEMBER 22, 2022</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BY AND BETWEEN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMICUS THERAPEUTICS, INC.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i9bc7ff1081344f6588412f3f599f4770_4"></div><hr style="page-break-after:always"><div style="min-height:87.84pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 1&#160;&#160;&#160;&#160;DEFINITIONS&#160;&#160;&#160;&#160;1</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 2&#160;&#160;&#160;&#160;COLLABORATION PROGRAMS&#160;&#160;&#160;&#160;15</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Overall Project&#160;&#160;&#160;&#160;15</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;Research&#160;&#160;&#160;&#160;16</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;Funding of the Research Program&#160;&#160;&#160;&#160;17</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;Discovery Program&#160;&#160;&#160;&#160;17</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;Data Ownership&#160;&#160;&#160;&#160;17</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;Manufacturing Technology Transfer&#160;&#160;&#160;&#160;18</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 3&#160;&#160;&#160;&#160;INFORMATION SHARING AND IP GOVERNANCE.&#160;&#160;&#160;&#160;18</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;Information Sharing Committee&#160;&#160;&#160;&#160;18</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;Joint Intellectual Property Committee&#160;&#160;&#160;&#160;19</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;Scope of Authority&#160;&#160;&#160;&#160;19</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 4&#160;&#160;&#160;&#160;LICENSES AND OTHER RIGHTS&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;Grant of License&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;Joint Patent Rights&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;Research License to Penn&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;Retained Rights&#160;&#160;&#160;&#160;21</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.5&#160;&#160;&#160;&#160;U.S. Government Rights&#160;&#160;&#160;&#160;21</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6&#160;&#160;&#160;&#160;Grant of Sublicense by Licensee&#160;&#160;&#160;&#160;21</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.7&#160;&#160;&#160;&#160;No Implied License&#160;&#160;&#160;&#160;23</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8&#160;&#160;&#160;&#160;DRG Technology License&#160;&#160;&#160;&#160;23</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 5&#160;&#160;&#160;&#160;FINANCIAL PROVISIONS&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;Payments&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;Milestone Payments&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;Royalties&#160;&#160;&#160;&#160;25</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;Penn Sublicense Income&#160;&#160;&#160;&#160;27</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;Discovery Product Proceeds&#160;&#160;&#160;&#160;28</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;Mode of Payment and Currency&#160;&#160;&#160;&#160;28</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;Royalty and Penn Sublicense Income Reports&#160;&#160;&#160;&#160;29</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.8&#160;&#160;&#160;&#160;Late Payments&#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.9&#160;&#160;&#160;&#160;Default Payment&#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.10&#160;&#160;&#160;&#160;Accounting&#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.11&#160;&#160;&#160;&#160;Books and Records&#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.12&#160;&#160;&#160;&#160;Audits&#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.13&#160;&#160;&#160;&#160;Taxes&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 6&#160;&#160;&#160;&#160;CLINICAL DEVELOPMENT, REGULATORY AFFAIRS&#59; COMMERCIALIZATION&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;Development Plan&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;Commercialization&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.3&#160;&#160;&#160;&#160;Manufacturing&#160;&#160;&#160;&#160;31</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.84pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Continued)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.4&#160;&#160;&#160;&#160;Regulatory&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.5&#160;&#160;&#160;&#160;Diligence&#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6&#160;&#160;&#160;&#160;Progress Reports&#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 7&#160;&#160;&#160;&#160;INTELLECTUAL PROPERTY&#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;Patent Filing Prosecution and Maintenance&#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;Patent Costs&#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;Infringement&#160;&#160;&#160;&#160;35</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.4&#160;&#160;&#160;&#160;Defense&#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5&#160;&#160;&#160;&#160;Patent Marking&#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.6&#160;&#160;&#160;&#160;Ownership of Inventions&#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;DRG Patent Filing Prosecution and Maintenance, Patent Costs, Infringement&#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 8&#160;&#160;&#160;&#160;CONFIDENTIALITY&#38; PUBLICATION&#160;&#160;&#160;&#160;39</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;Confidential Information&#160;&#160;&#160;&#160;39</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;Disclosures Required by Law&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;Penn Intellectual Property&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;Licensee Intellectual Property&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;Publications&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 9&#160;&#160;&#160;&#160;REPRESENTATIONS, WARRANTIES AND COVENANTS&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;Mutual Representations and Warranties&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;Representations of Penn&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;Disclaimer of Representations and Warranties&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;&#160;&#160;&#160;Covenants of Licensee&#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 10&#160;&#160;&#160;&#160;INDEMNIFICATION&#59; INSURANCE AND LIMITATION OF LIABILITY&#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;Indemnification by Licensee&#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;Insurance&#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;LIMITATION OF LIABILITY&#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 11&#160;&#160;&#160;&#160;TERM AND TERMINATION&#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;Term&#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;Termination of this Agreement for Convenience&#160;&#160;&#160;&#160;45</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;Termination For Cause&#160;&#160;&#160;&#160;45</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;Effects of Termination&#160;&#160;&#160;&#160;45</font></div><div style="margin-bottom:5pt;padding-left:86.4pt;padding-right:36pt;text-indent:-86.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ARTICLE 12&#160;&#160;&#160;&#160;ADDITIONAL PROVISIONS&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;Relationship of the Parties&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;Expenses&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;Use of Names&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;&#160;&#160;&#160;No Discrimination&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.5&#160;&#160;&#160;&#160;Successors and Assignment&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.6&#160;&#160;&#160;&#160;Further Actions&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.7&#160;&#160;&#160;&#160;Entire Agreement of the Parties&#59; Amendments&#160;&#160;&#160;&#160;47</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ii</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:87.84pt;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(Continued)</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page</font></div><div><font><br></font></div></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.8&#160;&#160;&#160;&#160;Governing Law&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.9&#160;&#160;&#160;&#160;Dispute Resolution&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.10&#160;&#160;&#160;&#160;Notices and Deliveries&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.11&#160;&#160;&#160;&#160;Waiver&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.12&#160;&#160;&#160;&#160;Severability&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.13&#160;&#160;&#160;&#160;Interpretation&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:5pt;padding-left:72pt;padding-right:9pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.14&#160;&#160;&#160;&#160;Counterparts&#160;&#160;&#160;&#160;48</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">iii</font></div><div><font><br></font></div></div></div><div id="i9bc7ff1081344f6588412f3f599f4770_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNIVERSITY OF PENNSYLVANIA</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This License Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is dated as of December 22, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Penn and Licensee may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Licensee is a biopharmaceutical company with expertise in the development, manufacture and commercialization of human therapeutic products for treatment of genetic disorders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Penn, through Dr. James Wilson and the Wilson Lab, have technology and expertise in the research and development of gene therapy products&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Penn and Licensee were parties to that certain Amended and Restated Research, Collaboration &#38; License Agreement dated as of May 28, 2019, as amended to date, pursuant to which the Parties collaborated regarding the research and development of gene therapy products for certain indications (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Penn and Licensee were parties to that certain Process Development Research &#38; License Agreement dated March 26, 2020, as amended to date, (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PD Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the development of process technologies relating to manufacturing in gene therapy&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as of the Effective Date, Penn and Licensee have entered into that certain Mutual Termination Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Mutual Termination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which the Parties have terminated the First Collaboration Agreement and the PD Agreement&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Penn and Licensee desire to enter into this Agreement for the grant of rights to Licensee with respect to the further research, development and commercialization of certain gene therapy products and candidates for Fabry and Pompe arising under the First Collaboration Agreement, all in accordance with the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.41pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Unless otherwise specifically provided herein, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AAV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means adeno-associated virus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to a Person, any corporation or other business entity that controls, is controlled by or is under common control with such Person, but only for so long as such control exists.  For the purposes of this Section 1.2, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under the common control with&#8221;) means the affirmative power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BLA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Biologics License Application as defined in the FD&#38;C Act and the regulations promulgated thereunder, (b) a Marketing Authorization Application in the European Union, or (c) any equivalent or comparable application, registration or certification in any other country or region.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 of each Calendar Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means those current practices, as amended from time to time, related to the manufacture of pharmaceutical products and any precursors thereto promulgated in guidelines and regulations of standard compilations including the GMP Rules of the World Health Organization, the United States Code of Federal Regulations, the Guide to Inspection of Bulk Pharmaceutical Chemicals (established by the United States Department of Health and Human Services), the Pharmaceutical Inspection Convention, and the European Community Guide to Good Manufacturing Practice in the production of pharmaceutical products, and equivalent guidelines, regulations and standards in the Territory, as such guidelines, regulations and standards may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Licensee or a Sublicensee will be deemed to have made a &#8220;Challenge&#8221; of the Penn Patent Rights if Licensee or a Sublicensee&#58;  (a) institutes or voluntarily joins as a party to, or causes its counsel to institute on Licensee&#8217;s or such Sublicensee&#8217;s behalf, any interference, opposition, re-examination, post-grant review or similar proceeding with respect to any Penn Patent Right with the U.S. Patent and Trademark Office or any foreign patent office&#59; or (b) files or voluntarily joins as a party to any legal proceeding, or causes its counsel to institute or voluntarily join as a party to any legal proceeding on Licensee&#8217;s or such Sublicensee&#8217;s behalf, with a court or other Governmental Body (including, without limitation, the U.S. Patent and Trademark Office or any foreign patent office) having authority to determine the validity, enforceability or scope of the Penn Patent Rights, in which one or more claims in such legal proceeding challenges the validity or enforceability of any Penn Patent Right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the occurrence of any of the following events&#58;  (a) any party becomes the owner, directly or indirectly, of more than fifty percent (50%) of the total voting power (on an as converted basis) of the equity units or other interests of Licensee then outstanding that are normally entitled to vote in the election of directors of Licensee other than in connection with a financing or series of financing transactions&#59; (b) the merger, consolidation or amalgamation of Licensee with or into any other party, other than any transaction in which the holders of the outstanding voting securities of Licensee immediately prior to the transaction own, directly or indirectly, not less than fifty percent (50%) of the total voting power (on an as converted basis) of the voting securities of the party surviving such merger, consolidation or amalgamation&#59; or (c) the sale of all or substantially all of the assets of Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Clinical Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Phase 1 Study, Phase 1&#47;2 Study, Phase 2 Study, or Phase 3 Study, or (b) such other study in humans that is conducted in accordance with good clinical practices and is designed to generate data in support or maintenance of an application for Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Compulsory License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a compulsory license under Penn Patent Rights obtained by a Third Party through the order, decree, or grant of a competent Governmental Body or court, authorizing such Third Party to develop, make, have made, use, sell, offer to sell or import a Licensed Product in any country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of a Party, means (i) confidential or proprietary information or materials relating to the business, operations, technology or products of a Party or any of its Affiliates, including any know-how, that such Party discloses to the other Party under this Agreement, or otherwise makes available to the other Party under this Agreement, and (ii) the terms of this Agreement&#59; provided that Confidential Information shall not include information that&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is or becomes generally available to the public other than as a result of disclosure by the recipient in breach of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">is already known by or in the possession of the recipient at the time of disclosure by the disclosing Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">is independently developed by recipient without use of or reference to the disclosing Party&#8217;s Confidential Information&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">is obtained by recipient from a Third Party that has not breached any obligations of confidentiality to the disclosing party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Information or materials of a Party or any of its Affiliates that was included in the Confidential Information of such Party pursuant to the First Collaboration Agreement shall be deemed Confidential Information of such Party under this Agreement and subject to the terms of Article 8 below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to intellectual property rights, that a Party or one of its Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide to, grant a license or sublicense to, or assign its right, title and interest in and to, such intellectual property rights as provided for in this Agreement without violating the terms of any other agreement or other arrangement with any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Designated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font><font style="background-color:#00ff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discovery Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discovery Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a product that is covered by a Discovery Patent Right and developed or sold by a Third Party, which Third Party has licensed such Discovery Patent Rights directly from Penn.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discovery Product Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discovery Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the discovery research conducted at Penn solely by the Wilson Lab during the Discovery Term to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discovery Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all any and all ideas, information, inventions, developments, animate and inanimate materials, including live animals, discoveries, software, know-how, methods, techniques, formulae, data, processes, methodologies, techniques, biological materials, software and works of authorship, whether patentable or copyrightable, that are first conceived, discovered, developed, reduced to practice, or generated in the performance of the Discovery Program by the Wilson Lab, including any unpatentable inventions discovered, developed or conceived in the conduct of the Discovery Program.  Discovery Results expressly excludes any such items covered by Penn Patent Rights and Joint Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Discovery Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period beginning January 1, 2016 and ending on May 28, 2024. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Exclusivity Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; and (b) any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues of any of the Patent Rights in (a), including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (c) any corresponding foreign Patent Rights to the foregoing&#59; provided, however, that the foregoing shall not include &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency and any successor entity thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Food and Drug Administration and any successor entity thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States Federal Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Field of Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all research, prophylactic, diagnostic and therapeutic uses in or for humans.  For clarity, except for any uses in non-humans intended to support development for prophylactic, diagnostic and&#47;or therapeutic use in humans, any and all uses in non-humans, including any and all veterinary uses in companion animals and livestock species, is excluded from the Field of Use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a country-by-country basis, the first commercial transfer or disposition for monetary value of Licensed Product in such country for use or consumption by a Third Party end user by Licensee, or any of its Affiliates or Sublicensees, in each case, after all Regulatory Approvals have been obtained for such country and where such disposition or transfer results in a recordable Net Sale in accordance with Licensee&#8217;s, or its Affiliate&#8217;s or Sublicensee&#8217;s, applicable accounting practices (consistently applied).  Sales prior to receipt of Regulatory Approval of a Licensed Product such as so-called &#8220;treatment IND sales,&#8221; &#8220;named patient sales,&#8221; &#8220;compassionate use sales&#8221; or expanded access programs, shall not be considered a First Commercial Sale.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FPFD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Licensed Product-by Licensed Product basis with respect to each Clinical Study, the first dosing of the first patient in such Clinical Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Funded Discovery Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means United States generally accepted accounting principles applied on a consistent basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Gene Editing Technologies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means nucleic acid polymers that encode proteins whose primary recognized enzymatic activity is to (a) selectively induce double or single stranded breaks in a DNA or RNA sequence, or (b) substitute, replace or delete a particular base or set of bases of a DNA or RNA sequence in the absence of a double or single stranded break in the DNA or RNA.  Gene Editing Technologies include, but are not limited to&#58;  CRISPR-Cas systems (including different Cas nucleases), Zinc finger nucleases, meganucleases, TALENS or base editors.  For clarity, &#8220;Gene Editing Technologies&#8221; does not include chromosomal integration of a transgene introduced by a parvovirus vector in the absence of exogenous nucleases.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Generic Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a particular Licensed Product in a country, a generic or biosimilar pharmaceutical product, that is not licensed or owned by Licensee, any of its Affiliates or Sublicensees, that is approved for use in such country by a Regulatory Authority by referencing the prior approval, in whole or part, or safety and efficacy data submitted in support of the prior approval, of such Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Governmental Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any&#58;  (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature&#59; (b) federal, provincial, state, local, municipal, foreign or other government&#59; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal)&#59; (d) multi- national or supranational organization or body&#59; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an Investigational New Drug Application as defined in the FD&#38;C Act and the regulations promulgated thereunder, or (b) an equivalent application to an equivalent Regulatory Authority in any other regulatory jurisdiction, including a Clinical Trial Authorization to the European </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Medicines Agency, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each of (a) Pompe disease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pompe Disease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (b) Fabry disease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Fabry Disease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in each case (a) and (b), (i) using a Parvovirus Gene Therapy Product &#91;***&#93; and (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) any Patent Rights covering an invention conceived and reduced to practice jointly by the Wilson Lab and Licensee in the conduct of a Research Program, (b) any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues of any of the Patent Rights in (a), including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (c) any corresponding Patent Rights to the foregoing outside of the United States.  Without limiting the foregoing, Joint Patent Rights existing as of the Effective Date are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit 1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means intellectual property, data, results, pre-clinical and clinical protocols and study data, chemical structures, chemical sequences, information, inventions, formulas, techniques, methods, processes, procedures and developments.  &#8220;Know-How&#8221; does not include any of the foregoing claimed in a Penn Patent Right or Patent Right Controlled by Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect of law of any Governmental Body.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Discovery Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How Controlled by Penn as of the Original Effective Date or during the Discovery Term and developed by the Wilson Lab under the Discovery Program and is necessary or reasonably useful to develop, make, use, sell, offer for sale or import a Designated Product for an Indication.  For clarity, Licensed Discovery Know-How does not include any DRG Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Know-How Controlled by Penn as of the Original Effective Date or during the Research Term and (a) developed by the Wilson Lab as of the Original Effective Date, or (b) developed by the Wilson Lab under a Research Program pursuant to the First Collaboration Agreement or this Agreement, and in each case (a) and (b) is necessary or reasonably useful to develop, make, use, sell, offer for sale or import a Licensed Product for an Indication in the Field of Use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any (a) article, composition, apparatus, substance, chemical or any other material covered by a Program Valid Claim or whose manufacture, import, use, offer for sale or sale would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Program Valid Claim or would infringe a Program Valid Claim once issued&#59; (b) article, composition, apparatus, substance, chemical or any other material&#160;made, used or sold by or utilizing or practicing a Method&#59; (c) article, composition, apparatus, substance, chemical or any other material that incorporates, uses or is made through the use of any Licensed Know-How and is a parvovirus gene therapy for an Indication&#59; or (d) any parvovirus gene therapy for an Indication conceived during, or test in, a Research Program.  Notwithstanding the foregoing, &#8220;Licensed Product&#8221; shall not include a product, to the extent it would have solely been a Licensed Product pursuant to subsection (c) above, that is, or was prior to the Effective Date, (i) acquired or licensed by Licensee or any of its Affiliates (including pursuant to a Change of Control) or (ii) controlled by a Third Party acquirer of Licensee or any of its Affiliates (whether by merger or acquisition of all or substantially all of the stock or assets of Licensee or its Affiliate or a similar transaction) and, in each case ((i) and (ii)), that has been independently developed by a Third Party and for which &#91;***&#93; prior to the closing of such acquisition or license by Licensee or any of its Affiliates (with respect to clause (i) above) or such merger, acquisition or similar transaction (with respect to clause (ii) above).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Major Markets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, (a)&#160;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and (b) any corresponding foreign Patent Rights to the foregoing.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means process or method covered by a Program Valid Claim or whose use or practice would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Program Valid Claim, or would infringe a Program Valid Claim once issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the gross amounts billed, invoiced or received by Licensee or any of its Affiliates or Sublicensees for Sales of Licensed Product (including any cash amounts plus the fair market value of any other forms of consideration), less the following deductions to the extent reasonable customary, and actually deducted&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Even if there is overlap between any of deductions described above, each individual item shall only be deducted once in the overall Net Sales calculation.  Net Sales shall not include sales or other transfers or dispositions of Licensed Products between or among Licensee, Sublicensees or their Affiliates.  The provision of a Licensed Product for the purposes of conducting research and development activities, for charitable purposes or for governmental purposes shall be deemed to give rise to a Net Sale solely to the extent Licensee or any of its Affiliates or Sublicensees receives a cash payment for such Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means October&#160;8, 2018, which was the effective date of the initial research, collaboration and license agreement between Licensee and Penn (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) relating to the Indications, among other matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Parvovirus Gene Therapy Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a product (or proposed or prospective product) that inserts one or more functional genes into a patient&#8217;s cells using a parvovirus vector to treat an indication, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) patents and patent applications, together with any unlisted patents and patent applications claiming priority thereto, and any continuations, continuations-in-part (to the extent related directly to the subject matter of the parent application or containing new information developed pursuant to a Research Program), reissues, reexamination certificates, substitutions, divisionals, supplementary protection certificates, renewals, registrations, extensions including all confirmations, revalidations, patents of addition, Patent Cooperation Treaty applications (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PCTs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and pediatric exclusivity periods and all foreign counterparts thereof, and any patents issued or issuing with respect to any of the foregoing and (b) all official correspondence relating to the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Party owed or receiving a payment under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Party owing or making a payment under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Penn Patent Rights A (including Penn&#8217;s interest in the Joint Patent Rights), Discovery Patent Rights (including Penn Patent Rights B), Penn Patent Rights C, and Manufacturing Patent Rights, collectively.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Patent Rights A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues of any of the Patent Rights in (a) or (b), including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (d) any corresponding foreign Patent Rights to the foregoing.  Without limiting the foregoing, the Penn Patent Rights&#160;A that are described in clauses (a) and&#160;(b) of this Section&#160;1.53 and are existing as of the Effective Date are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Patent Rights B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues thereof, including divisions, but excluding continuations-in-part except to the extent of claims entirely solely supported in the specification and entitled to the priority date of the parent application for any of the foregoing, and (c) any corresponding foreign Patent Rights to the foregoing.  Without limiting the foregoing, Penn Patent Rights&#160;B that are existing as of the Effective Date are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Patent Rights C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93; any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues thereof, including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of the parent application, and (c) any corresponding foreign Patent Rights to the foregoing.  Without limiting the foregoing, Penn Patent Rights&#160;C that are existing as of the Effective Date are listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 1 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a clinical study of a drug candidate in patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. 312.21(a), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United States.  The drug candidate can be administered to patients as a single agent or in combination with other investigational or marketed agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 1&#47;2 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a clinical study of a drug candidate in diseased patients that satisfies the requirements of a Phase 1 Study and a Phase 2 Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 2 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a clinical study of a drug candidate in patients with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information as described in 21 C.F.R. 312.21(b), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United States including a human clinical trial that is also designed to satisfy the requirements of 21 C.F.R. 312.21(a) or corresponding foreign regulations and is subsequently optimized or expanded to satisfy the requirements of 21 C.F.R. 312.21(b) (or corresponding foreign regulations) or otherwise to enable a Phase 3 Clinical Study (e.g., a phase 1&#47;2 trial).  The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phase 3 Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a clinical study of a drug candidate in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety in order to obtain Regulatory Approval in any country, as further described in 21 C.F.R. 312.21(c) with respect to the United States, or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States.  The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational or marketed agents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pivotal Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Phase 3 Study or other clinical study of a drug candidate in human patients with the disease being studied, in each case, the principal purpose of which is to achieve a determination of efficacy and safety and is designed and intended to provide the basis for obtaining </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Regulatory Approval to market the applicable product for patients with the indication being studied or where a Clinical Study subsequently is deemed to achieve efficacy and safety for the applicable product and indication for the purpose of obtaining Regulatory Approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Program Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a claim of (a) an issued and unexpired patent in Penn Patent Rights A or Penn Patent Rights B which claim has not been revoked or held unenforceable or invalid by a decision of a court of governmental agency of competent jurisdiction from which no further appeal can be taken or has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer&#59; or (b) a pending patent application that is included in Penn Patent Rights A or Penn Patent Rights B which was filed and is being prosecuted, and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application and has not been &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a product in any regulatory jurisdiction, approval from the applicable Regulatory Authority sufficient for the manufacture, distribution, use, marketing and sale of such pharmaceutical product in such jurisdiction in accordance with Laws (including, where applicable, any pricing or reimbursement approvals).  &#8220;Regulatory Approval&#8221; does not include authorization by a Regulatory Authority to conduct named patient, compassionate use or other similar activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any governmental authority, including the FDA or EMA, or any successor agency thereto, that has responsibility for granting any licenses or approvals or granting pricing or reimbursement approvals necessary for the marketing and sale of a pharmaceutical product in any country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to any country or jurisdiction, any exclusive marketing rights or data exclusivity protection conferred by an applicable Regulatory Authority or other Regulatory Authority in such country or jurisdiction with respect to a compound or bio-pharmaceutical product, including any regulatory data protection exclusivity (including any orphan drug designation or pediatric exclusivity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the research plan setting forth the Parties&#8217; roles and responsibilities for a Research Program, respectively, conducted pursuant to the First Collaboration Agreement or pursuant to this Agreement.  For clarity, &#8220;Research Plans&#8221; include solely those Research Plans in place pursuant to the First Collaboration Agreement (or the Original Collaboration Agreement) together with the Research Wind-Down Plans, which are set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereto, and any project outline entered into with respect to a New Research Project (if agreed to by the Parties in writing).   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font><font style="background-color:#00ffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all any and all ideas, information, inventions, developments, animate and inanimate materials, including live animals, discoveries, software, know-how, methods, techniques, formulae, data, processes, methodologies, techniques, biological materials, software and works of authorship, whether patentable or copyrightable, that are first conceived, discovered, developed, reduced to practice, or generated in the performance of a Research Program by the Wilson Lab, including any unpatentable inventions discovered, developed or conceived in the conduct of a Research Program.  Research Results expressly excludes any such items covered by Penn Patent Rights and Joint Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the period beginning on the Original Effective Date and ending on the completion of activities under the Research Plan for each Indication &#91;***&#93;, whichever occurs earlier</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any transaction for which consideration is received or expected by Licensee, its Affiliates or Sublicensees for sale, use, lease, transfer or other disposition of a Licensed Product to or for the benefit of a Third Party.  For clarity, sale, use, lease, transfer or other disposition of a Licensed Product by Licensee or any of its Affiliates or Sublicensees to another of these entities for resale by such entity to a Third Party shall not be deemed a Sale.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service Center Cores</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the following core laboratories at Penn that report directly to Dr. James Wilson, all science cores, including the Animal Models Core, the Vector Core, the Immunology Core, the Cell Morphology Core, the Biostatistics Core and the Integrated Technology Core.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Third Party to which a Sublicense is granted pursuant to the terms of Section 4.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicense Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all agreements, amendments or written understandings entered into with a Sublicensee (including any of its Affiliates) pertaining to a Sublicense, Penn Patent Rights or Licensed Product.  For clarity, a development agreement or distribution agreement for a Licensed Product is a Sublicense Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicense Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means payments received by Licensee or its Affiliates from a Sublicensee in consideration for a Sublicense or other agreement providing the right to negotiate or obtain a Sublicense.  Sublicense Income includes payments received from a Sublicensee in the form of license issue fees, milestone payments and the like, but specifically excludes &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Task</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all taxes, duties, fees, premiums, assessments, imposts, levies, rates, withholdings, dues, government contributions and other charges of any kind whatsoever, whether direct or indirect, together with all interest, penalties, fines, additions to tax or other additional amounts, imposed by any Governmental Body.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person other than Penn, Licensee or any of their respective Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">US</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the United States of America, its territories and possessions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">USD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the lawful currency of the United States of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a claim of (a) an issued and unexpired patent in Penn Patent Rights which claim has not been revoked or held unenforceable or invalid by a decision of a court of governmental agency of competent jurisdiction from which no further appeal can be taken or has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer&#59; or (b) a pending patent application that is included in Penn Patent Rights which was filed and is being prosecuted, and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application and has not &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vector Core</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the performance of the following activities by Vector Operations for and on behalf of personnel and departments of Penn (including the Wilson Lab) and&#47;or for other Third Parties&#58; (a) vector production services, and (b) characterization, release and stability testing of vectors, small scale through large scale, including for use in support of toxicology studies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vector Operations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a laboratory at Penn that reports to Dr. James M. Wilson and focuses on the development of AAV and other parvovirus vector manufacturing processes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Wilson Lab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Dr. James M. Wilson and all individuals who are under the direct supervision or control of Dr. James M. Wilson or his successor as Director of the Wilson Gene Therapy Program at Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that the Service Center Cores are not included in the Wilson Lab, including any personnel of the Service Center Cores.  For clarity, and notwithstanding the foregoing sentence, Vector Operations is a department of the Wilson Lab and is included in the Wilson Lab, but the performance of Vector Core activities is specifically excluded from the Wilson Lab.  It is understood that the activities of the Wilson Lab and&#47;or Vector Operations in the performance of a Research Program are not Vector Core activities.  For clarity, references to the Wilson Lab herein shall be deemed to refer to the Wilson Lab and&#47;or Vector Operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Other Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The definition of each of the following terms is set forth in the section of this Agreement indicated below&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Defined Term</font></td><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Section</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Abandoned Discovery Rights</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advance Payment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Introductory Clause</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amicus Technology</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial Milestone</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Commercial Milestone Payment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Development Milestone</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Development Milestone Payment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Disclosing Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Discovery Product Licenses</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRG Election Notice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7.2.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRG Patent Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRG Technology Improvement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">DRG Technology License</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.8.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Introductory Clause</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Election Notice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Excluded Penn IP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Existing Research Programs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Fabry Disease</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">First Collaboration Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Historic DRG Patent Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Historic Patent Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Information Sharing Committee (&#8220;ISC&#8221;)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Infringement Notice</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Joint Intellectual Property Committee (&#8220;JIPC&#8221;)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liabilities</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">License Maintenance Fee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Introductory Clause</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensee Data</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensee Financial Report</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Manufacturing Process</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Mutual Termination Agreement</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recitals</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">New Research Project</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ongoing DRG Patent Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ongoing Patent Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Paid Research Funding</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Party or Parties</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Introductory Clause</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patent Costs</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Patent Counsel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PCT</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.49</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PD Agreement</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Recitals</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Introductory Clause</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Data</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Discovery Results</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Financial Report</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5.3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Indemnitees</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Sublicense Income</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pompe Disease</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Progress Report</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6.1</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prosecution Request</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Receiving Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research Wind-Down Plans</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Royalty</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Royalty Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.2</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sale Transaction</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.74</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Service Provider Sublicensee</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6.4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sublicense</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.6.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Term</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party Candidate Patent Right</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.7.1(b)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Third Party IP</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.3(b)</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wilson Lab</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.83</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>COLLABORATION PROGRAMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Overall Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Pursuant to the First Collaboration Agreement, the Parties desired to, and did, collaborate with respect to the pre-clinical development of a parvovirus gene therapy product, for each Indication within the Field of Use, with the goal of designating one Licensed Product for clinical development and commercialization for each Indication in the Field of Use.  From and after the Effective Date and during the Research Term, the Parties desire to collaborate with the goal of the Wilson Lab completing those activities allocated to Penn and set forth in the Research Wind-Down Plan for the applicable Research Program for an Indication within the Field of Use &#91;***&#93; in order to enable a smooth and effective transition to Licensee (or its designee) of activities with respect to the further research, development, manufacture, and commercialization of Licensed Products for the relevant Indication.  After the Effective Date, Licensee will be responsible for those activities allocated to Licensee in a Research Plan and for any development activities performed outside of the Research Program during the Research Term as contemplated by this Agreement and&#47;or after expiration of the Research Term, as well as regulatory strategy and operations, clinical development, cGMP manufacture, and commercialization of all Licensed Product(s).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The Parties hereby acknowledge and agree that, as of the Effective Date, Penn is conducting certain Research Programs with respect to the Indications which commenced under the Original Collaboration Agreement and the First Collaboration Agreement (as amended through the Effective Date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Existing Research Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Penn will wind-down the Existing Research Programs by conducting the activities allocated to Penn with respect to each Existing Research Program to completion in accordance with the Research Plan attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Wind-Down Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the other terms and conditions of this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">After the Effective Date, Penn will conduct each Research Program in accordance with the Research Wind-Down Plan for such Research Program and the other terms and conditions of this Agreement. &#91;***&#93;. In the event Licensee desires that Penn conduct new or further </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">research for an Indication not covered by a Research Plan then in effect for such Indication, the Parties may agree in writing to a new project outline (including a budget therefor) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">New Research Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for such new or further research, and Penn shall conduct such research in accordance with such project outline and the other terms and conditions of this Agreement.  It is understood that Penn&#8217;s fees for any activities conducted by the Wilson Lab or Penn in connection with a New Research Project shall &#91;***&#93;.  In the event a New Research Project is implemented by the Parties, then the activities conducted under such New Research Project will be deemed to be activities under a Research Program and the Research Term will be deemed to recommence as of the date such project outline for such New Research Project was executed by both Parties and remain in effect until completion of the activities under such New Research Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Penn shall maintain records of the activities conducted under and the results of each Research Program (including the Research Results) in sufficient detail and in good scientific manner appropriate for patent purposes to properly reflect all work done and results achieved.  Penn will provide task-based, scientific reports of the progress and results of each Research Program on the schedule specified in the Research Plan for such Research Program or on another schedule to be agreed in writing by the Parties&#59; provided that, in any event, Penn shall have provided to Licensee the information and results included in the Final Deliverables (as defined in Section&#160;3.2 of the Mutual Termination Agreement) by no later than &#91;***&#93;.  Penn shall maintain reasonable and accurate records of the use of the funds provided by Licensee under this Agreement and shall make such records available to Licensee (or its designee) upon reasonable notice during Penn&#8217;s normal business hours, but not more frequently once each Calendar Year.  All Research Results shall be solely and exclusively owned by Penn.  For the avoidance of doubt, Research Results will constitute Licensed Know-How and will be included within the scope of the Licenses granted by Penn to Licensee under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Each Party will have the right to engage Third Party subcontractors to perform certain of its obligations under this Agreement.  Any subcontractor to be engaged by a Party to perform a Party&#8217;s obligations set forth in this Agreement will meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity and will enter into an appropriate agreement with such Party consistent with such Party&#8217;s standard practices which agreement shall be as least as protective as the nondisclosure and nonuse of confidential information obligations set forth herein and requiring the assignment or license of Know-How and other intellectual property generated in the course of the subcontracted work (including, with respect to any such Know-How and other intellectual property licensed to Penn, the right to grant and authorize Sublicenses under such Know-How and other intellectual property as contemplated herein in the same manner and of the same scope as required for intellectual property generated solely by the Wilson Lab).  Any Party engaging a subcontractor hereunder will remain responsible and obligated for the acts and omissions of such subcontractor and will not grant rights to such subcontractor that would interfere with, limit or diminish the rights of the other Party under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Funding of the Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The Parties acknowledge and agree that those portions of the Research Support Amount (as defined in the First Collaboration Agreement) provided by Licensee to Penn pursuant to the First Collaboration Agreement and the Research Program Wind-Down Payment (as defined in the Mutual Termination Agreement) to be provided by Licensee to Penn pursuant to the Mutual Termination Agreement, shall fund Penn&#8217;s conduct of the Existing Research Program in accordance with the Research Wind-Down Plans in effect as of the Effective Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Paid Research Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding anything in this Agreement to the contrary and for the avoidance of doubt, such funds shall be non-refundable and non-creditable and, subject to Penn using such funds first to support and fund each of the Research Wind-Down Plans, may be utilized and allocated by Penn in its sole discretion.  For clarity, other than payment of the Research Program Wind-Down Payment (as defined in the Mutual Termination Agreement) in accordance with the terms of the Mutual Termination Agreement, no additional amounts shall be paid by Licensee to Penn for Penn&#8217;s conduct of the Existing Research Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Title to any equipment, laboratory animals, or any other tangible materials made or acquired with funds provided under this Agreement will vest in Penn, and such equipment, animals, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">tangible materials will remain the property of Penn following termination or expiration of this Agreement (but subject to any license grants to Licensee hereunder).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Discovery Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that, as of the Effective Date, Licensee has provided, or is obligated to provide, pursuant to the Mutual Termination Agreement, the Remaining Discovery Support Amount (as defined in the Mutual Termination Agreement) to Penn which will be utilized by Penn to fund Penn&#8217;s performance of the Tasks.  For clarity, other than payment of the Remaining Discovery Support Amount (as defined in the Mutual Termination Agreement) and outstanding patents costs (as described in Section 3.4 of the Mutual Termination Agreement) in accordance with the terms of the Mutual Termination Agreement, no additional amounts shall be paid by Licensee to Penn for Penn&#8217;s conduct of the Discovery Program.  Notwithstanding anything in this Agreement to the contrary and for the avoidance of doubt, such funds are non-refundable and non-creditable and, subject to Penn using such funds for the Discovery Program, may be utilized and allocated by Penn in its sole discretion.  Penn shall maintain records of the activities conducted under and the results of the Discovery Program (including the Discovery Results) in sufficient detail and in good scientific manner appropriate for patent purposes to properly reflect all work done and results achieved.  At least once every &#91;***&#93; during the period beginning on the Effective Date and thereafter for the remainder of the Discovery Term, Penn will notify Licensee (via the ISC) of any available Discovery Patent Rights and&#47;or Discovery Results and will provide to Licensee updates and scientific reports of the progress and results of the Discovery Program for Tasks.  All Discovery Results shall be solely and exclusively owned by Penn (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Discovery Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, Penn Discovery Results will constitute Licensed Discovery Know-How and will be included within the scope of the Licenses granted by Penn to Licensee under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Data Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All data generated by Penn under a Research Program or the Discovery Program shall be owned by Penn including all rights, title and interest (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  All data generated by Licensee under a Research Program shall be owned by Licensee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensee Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  For the avoidance of doubt, Penn Data will constitute Research Results and Licensed Know-How and will be included within the scope of the License.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  On or prior to &#91;***&#93;, the Wilson Lab will transfer to Licensee additional Penn Know-How that has been qualified and undergone approval by and through the Wilson Lab PD Know-How (as defined in the PD Agreement immediately prior to the Effective Date) or Licensed Know-How, in each case, that is reasonably necessary to manufacture the Licensed Product for each Indication (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Manufacturing Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and that is existing as of the date of such transfer, including by providing copies or samples of relevant documentation and other embodiments of such Know-How (i.e. standard operating procedures and methods and training materials) to the extent reasonably necessary to perform the Manufacturing Process. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>INFORMATION SHARING AND IP GOVERNANCE.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Information Sharing Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Formation&#59; Composition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; after the Effective Date, the Parties shall establish and maintain (subject to Section&#160;3.1.6 below), an information sharing committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Information Sharing Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ISC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) comprised of at least one (1) representative from each Party.  Penn&#8217;s representative shall have sufficient knowledge of the Research Program and Discovery Program activities to share information regarding Penn&#8217;s activities, including any results and data obtained, with respect to the Research Program and&#47;or Discovery Program being conducted by Penn.  The ISC may change its size from time to time by mutual consent of the Parties, provided that the ISC will consist at all times of an equal number of representatives of each of Penn and Licensee.  Each Party may replace its ISC representatives at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Specific Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The ISC will&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">oversee the activities under the Research Wind-Down Plans&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">establish appropriate reporting procedures for the activities being conducted pursuant to the Research Wind-Down Plans and Penn&#8217;s performance of the Tasks, including the scope and content of reports to be provided by Penn to Licensee (including under Sections 2.2.3and 2.4) and in order to provide Licensee with sufficient information regarding the Research Results for each Indication, Discovery Results and the Discovery Program for Tasks&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">serve as a forum for Penn to share and the Parties to review and discuss any activities being conducted pursuant to the Research Wind-Down Plans&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">serve as a forum for Penn to share and the Parties to review and discuss Discovery Results and any available Discovery Patent Rights, provided by Penn to Licensee pursuant to Section&#160;2.4. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party shall keep the ISC informed on the status and progress of the activities under each Research Program then currently ongoing under a Research Plan, including delivering quarterly written updates of its progress under each Research Program to the ISC at least one (1) week in advance of each ISC meeting.  Penn shall also keep the ISC informed of the status and progress of the activities under the Discovery Program as provided in Section 2.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the performance of a Research Program by Penn, the ISC will meet at least monthly.  Following the Research Term and until the expiration of the Discovery Term, the ISC will meet at least quarterly.  Following the completion of Penn&#8217;s performance of all of the Research Programs, the Parties may agree to meet to discuss items with respect to a Research Plan or the Research Program previously addressed by the ISC.  The ISC may meet in person, by videoconference or by teleconference.  In-person ISC meetings (if any) will be held at locations alternately selected by Penn and by Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">No Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The ISC shall be a forum for sharing information only and shall have no decision-making power. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Termination of ISC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The ISC shall terminate effective as of the expiration of the Discovery Term.  Upon termination, the ISC shall disband and have no further obligations under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Joint Intellectual Property Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Formation&#59; Composition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As of the Effective Date, the Parties have established, and hereafter shall maintain, a joint intellectual property oversight committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Joint Intellectual Property Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JIPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) comprised of an equal number of representatives from each Party.  The JIPC may change its size from time to time by mutual consent of its members, provided that the JIPC will consist at all times of an equal number of representatives of each of Penn and Licensee, with at least one representative of Penn from the Penn Center for Innovation.  Each Party may replace its JIPC representatives at any time upon written notice to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Specific Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The JIPC will (a) discuss and make recommendations with respect to the intellectual property activities of the Parties related to Licensed Product research and development under each Research Plan in a manner that is consistent with the other terms of this Agreement, specifically with respect to the prosecution, maintenance, defense and enforcement of the Penn Patent Rights A and Joint Patent Rights, and prosecution and maintenance of Penn Patent Rights B (excluding Patent Rights listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and (b) conduct such other activities as specifically assigned to the JIPC under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The JIPC will meet at least quarterly, unless the Parties mutually agree in writing to a different frequency.  The JIPC may meet in person, by videoconference, or by teleconference.  In-person JIPC meetings (if any) will be held at locations alternately selected by Penn and by Licensee.  Meetings of the JIPC will be effective only if at least one representative of each Party is present or participating in such meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Decision-Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The representatives from each Party on the JIPC will have, collectively, one (1) vote on behalf of that party, and all decision making will be by unanimous consent by the Parties.  In the event of a dispute at the JIPC, such dispute will be escalated to Licensee&#8217;s Chief Executive Officer and Penn&#8217;s Dean of Medicine or his designee, for discussion in good faith&#59; provided, however, that, &#91;***&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Scope of Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the ISC (or the JIPC) unless expressly provided in this Agreement or otherwise agreed by the Parties in writing.  The ISC (and JIPC), including pursuant to any Party&#8217;s exercise of its final decision making authority, shall not have the power to amend, modify or waive this Agreement or compliance with the terms of this Agreement.  No decision of the JIPC shall conflict with the terms of this Agreement nor be in contravention of applicable law in any material respect.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>LICENSES AND OTHER RIGHTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Grant of License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Penn hereby grants to Licensee (the below rights under (a) through (d), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">(i) an exclusive, worldwide, royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 4.6), under Penn Patent Rights A and (ii) a non-exclusive, world-wide royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 4.6), under Licensed Know-How, in each case ((i) and (ii)), to make, have made, use, sell, offer for sale, and import Licensed Products for the Indications in the Field of Use during the Term&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">(i) an exclusive, worldwide, royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 4.6), under Penn Patent Rights B and (ii) a non-exclusive, world-wide royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 4.6), under Licensed Discovery Know-How, in each case ((i) and (ii)), to make, have made, use, sell, offer for sale, and import Designated Products for the Indications in the Field of Use during the Term&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">a non-exclusive, world-wide, royalty bearing right and license, with the right to sublicense (subject to the provisions of Section 4.6) under Penn Patent Rights C and Manufacturing Patent Rights, in each case, to make, have made, use, sell, offer for sale, and import Designated Products for the Indication (on an Indication-by-Indication basis) in the Field of Use during the Term&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">an exclusive, world-wide, royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 4.6) under Penn&#8217;s interest in Joint Patent Rights to make, have made, use, sell, offer for sale, and import products for any purposes within the Indications in the Field of Use during the Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Joint Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party hereby grants to the other Party a non-exclusive, world-wide, royalty-free, fully paid up, perpetual, irrevocable right and license, with the right to freely sublicense under the Joint Patent Rights, to make, have made, use, sell, offer for sale and import products and services, other than products and services for the Indications in the Field of Use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Research License to Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee will grant to Penn a non-exclusive, non-transferable, non- sublicensable license (a) under &#91;***&#93;, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amicus Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) solely for purposes of performing Penn&#8217;s obligations under a Research Program in accordance with the Research Plan for such Research Program and the terms of this Agreement and (b) under (i) the Licensee Data and (ii) new inventions reduced to practice by Licensee in the performance of a Research Program, in the case of each of (i) and (ii), to the extent Controlled by Licensee and solely during the Research Term and solely for purposes of performing internal, non-commercial research in the Wilson Lab. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, Amicus Technology expressly excludes any Joint Patent Rights.  For clarity, internal, non- </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">commercial research includes performance of activities funded by a government entity or non- commercial Third Party (so long as such non-commercial Third Party does not obtain any commercial right in or to any data, results, inventions or other intellectual property arising in connection with the relevant funded activities).  Amicus Technology will remain the exclusive property of Licensee.  Penn shall use the Amicus Technology solely in the conduct of the Research Program for which such Amicus Technology is provided in accordance with the Research Plan for such Research Program and the terms of this Agreement and, for clarity, shall not use any Amicus Technology in the conduct of the Discovery Program.  Penn shall not reverse engineer, decompile or disassemble any Amicus Technology, nor attempt or assist any Third Party to do the foregoing.  Amicus Technology is provided &#8220;as is&#8221; with no warranty, express, implied or statutory, including without limitation warranties of merchantability, title, non- infringement, exclusivity or fitness for a particular purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding the License or DRG Technology License, Penn retains the right under the Penn Patent Rights and the DRG Patent Rights to (a) conduct educational, research and clinical &#47; patient care activities itself (including sponsored research) and (b) authorize non-commercial third parties to conduct education, non- commercial research and clinical &#47; patient activities, in each case of subpart (a) and (b) related to the Indications in the Field of Use&#59; provided however that Penn shall not have the right to use or authorize the use of any Licensed Product for an Indication that is under active clinical testing or being sold by Licensee in the conduct of clinical or patient care activities without Licensee&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">U.S. Government Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The License and the DRG Technology License are expressly subject to all applicable provisions of any license to the United States Government executed by Penn and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. &#167;&#167;200-212, applicable governmental implementing regulations, and the U.S. Government sponsored research agreement or other guidelines, including that products that result from intellectual property funded by the United States Federal Government that are sold in the United States be substantially manufactured in the United States.  If so requested by Licensee, Penn shall reasonably cooperate with and assist Licensee to seek and obtain a waiver from the appropriate Regulatory Authorities with respect to such manufacturing requirement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Grant of Sublicense by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Penn grants to Licensee the right to grant and authorize sublicenses in whole or in part, under the License and, solely in connection with a sublicense under a License grant, the DRG Technology License (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) subject to the terms and conditions of this Agreement and specifically this Section 4.6.  The term Sublicense shall include any grant of rights under the License and, solely in connection with a sublicense under a License grant, the DRG Technology License by a Sublicensee to any downstream Third Party to develop, manufacture, use or sell a Licensed Product, such downstream Third Party shall also be considered a Sublicensee for the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will have the right to extend any and all of its rights under this Agreement to its Affiliate (subject to such Affiliate agreeing in writing with Licensee to be bound by the terms and conditions of this Agreement to the extent applicable to such Affiliate) without the consent of Penn&#59; provided that Licensee will be responsible for the conduct of any such Affiliate under this Agreement to the same extent as if such activities had been undertaken by Licensee itself.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will have the right to grant and authorize Sublicenses to Third Parties (and their Affiliates), without the consent of Penn.  For clarity, except for Sublicenses granted to Service Provider Sublicensees pursuant to Section 4.6.4 below, this provision permits only a single-tier of sublicensing to a Third Party (and its Affiliates) for Sale of a Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee, Sublicensee and each of their respective Affiliates may also, without Penn&#8217;s consent, engage Third Party service providers (and grant Sublicenses within the scope of the License and&#47;or DRG Technology License to such Persons) solely to perform activities for the benefit of or on behalf of Licensee or such Sublicensee or Affiliate, as the case may be (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Service Provider Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Licensee shall remain responsible to Penn for all activities of such Service Provider Sublicensee to the same extent as if such activities had been undertaken by Licensee itself.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Each Sublicense Document will (a) be issued in writing, (b) to the extent applicable, include all of the rights of Penn and require the performance of obligations due to Penn (and, if applicable, the U.S. Government under 35 U.S.C. &#167;&#167;200-212) contained in this Agreement and (c) to the extent applicable, include the following terms and conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Reasonable record keeping, audit and reporting obligations sufficient to enable Licensee and Penn to reasonably verify the payments due to Penn (if any) as a result of such Sublicense and to enable Licensee to reasonably monitor such Sublicensee&#8217;s progress in developing and&#47;or commercializing Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Infringement and enforcement provisions that do not conflict with the restrictions and procedural requirements imposed on Licensee and do not provide greater rights to Sublicensee than as provided in Sections 7.3 and 7.7.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Confidentiality provisions with respect to Confidential Information of Penn provided to a Sublicensee consistent with the obligations on Licensee in Article 8 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Covenants by Sublicensee that are equivalent to those made by Licensee in Section 9.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">A requirement of indemnification of Penn by Sublicensee that is equivalent to the indemnification of Penn by Licensee under Section 10.1 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">A requirement of obtaining and maintaining insurance by Sublicensee that is equivalent to the insurance requirement of Licensee under Section 10.2 of this Agreement, including coverage under such insurance of Penn as provided in Section 10.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Restriction on use of Penn&#8217;s names etc. consistent with Section 12.3 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">A requirement of antidiscrimination by Sublicensee no less stringent than that provided in Section 12.4 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">A requirement that Penn is a third party beneficiary of such Sublicense solely with respect to the rights of Penn and the performance obligations owed to Penn as required hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, with respect to Service Provider Sublicensees, the items set forth in subsections (a), (b), (d), (e), (f), (g), (h) and (i) may need not be included in the relevant Sublicense Document to the extent such is not applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Within thirty (30) days after of the execution of a Sublicense Document, Licensee shall provide a complete and accurate copy of such Sublicense Document (which may be redacted with respect to matters unnecessary to show compliance herewith, provided that in no event will any financial information be redacted) to Penn, in the English Language&#59; provided that Licensee shall not be required to provide any Sublicense Document solely with a Service Provider Sublicensee.  Penn&#8217;s receipt of a Sublicense Document, however, will constitute neither an approval nor disapproval of the Sublicense Document nor a waiver of any right of Penn or obligation of Licensee under this Agreement.  Notwithstanding the foregoing, upon Penn&#8217;s request, Licensee will provide an unredacted copy of any Sublicense Document to Penn&#8217;s outside counsel to confirm compliance herewith, and such outside counsel shall not provide such Sublicense Document to Penn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Implied License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party acknowledges that the rights and licenses granted in this Agreement are limited to the scope expressly granted.  Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.  All rights with respect to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any know-how, patent or other intellectual property right rights that are not specifically granted herein are reserved to the owner thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">DRG Technology License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Grant of DRG Technology License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Penn hereby grants to Licensee (the below rights, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Technology License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">(i) an exclusive, worldwide, royalty-bearing (solely to the extent provided in Section 5.3) right and license, with the right to sublicense only in conjunction with a Designated Product for such Indication subject to the provisions Section 4.6, under the DRG Patent Rights and (ii) a non-exclusive, worldwide, royalty-bearing right and license, with the right to sublicense only in conjunction with a Designated Product subject to the provisions Section 4.6 under the DRG Technology, in each case ((i) and (ii)), to make, have made, use, sell, offer for sale, and import Designated Products for the Indications in the Field of Use for the DRG Exclusivity Period.  Following the expiration of the DRG Exclusivity Period, the DRG Technology License granted under this Section 4.8.1(a) shall convert to a non-exclusive, worldwide, royalty-bearing right and license with the right to sublicense only in conjunction with a Designated Product subject to the provisions Section 4.6&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">a non-exclusive, worldwide, royalty-bearing (solely to the extent provided in Section 5.3) right and license, with the right to sublicense only in conjunction with a Licensed Product for such Indication subject to the provisions of Section 4.6, under DRG Patent Rights and the DRG Technology to make, have made, use, sell, offer for sale, and import Licensed Products for the Indications&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Limited Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event an IND is filed for a Designated Product for an Indication and such Designated Product does not utilize the DRG Technology, upon written notification by Penn, the exclusive license grant under Section 4.8.1(a) with respect to such Indication shall convert to a non-exclusive, worldwide, royalty-bearing right and license without the right to sublicense (except for sublicenses granted in conjunction with a sublicense to a Licensed Product subject to the provisions Section 4.6).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Indication Restriction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 4.8.3 and Penn&#8217;s retained rights set forth in Section 4.4 and Section 4.8.2, during the DRG Exclusivity Period, Penn shall not license to any Third Party the DRG Patent Rights for a product for an Indication.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>FINANCIAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">License Maintenance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Following expiration of the Research Term and until the expiration of the first Royalty Period in the first Major Market for a Licensed Product, Licensee shall pay Penn a non-refundable annual maintenance fee of &#91;***&#93; beginning on the &#91;***&#93; anniversary of the Research Term expiration date and on each anniversary thereafter (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License Maintenance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The License Maintenance Fee payment obligation shall only be creditable against royalties owed to Penn in the year such License Maintenance Fee was paid (there shall be no carry forward credit on License Maintenance Fees paid).  For clarity, the amount of the License Maintenance Fee will be paid only once per year (not once per Indication) and such payment obligation shall only commence on the &#91;***&#93; anniversary of the expiration date of Research Term (so long as this Agreement has not been terminated prior to such date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Development Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As partial consideration for the License, Licensee will pay Penn the following milestone payments (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) upon the achievement of the first Licensed Product to achieve the corresponding milestone for each Indication (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), whether achieved by Licensee or an Affiliate or Sublicensee.  Licensee shall promptly notify Penn in writing of the achievement of any such Development Milestone and Licensee shall pay Penn in full the corresponding Development Milestone Payment within &#91;***&#93; of such achievement.  For clarity, each Development Milestone Payment is non-refundable, non-creditable and is not an advance against Royalties due to Penn or any other amounts due to Penn.</font></div><div style="padding-left:30.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.019%"><tr><td style="width:1.0%"></td><td style="width:70.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Development Milestone (payable once per Indication)</font></td><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment (in U.S. dollars)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each time a Development Milestone &#91;***&#93; in the table above is achieved for a Licensed Product for an Indication, then any other Development Milestone Payments with respect to earlier Development Milestones (i.e., Development Milestones &#91;***&#93; in the table above, as applicable) for that Indication that have not yet been paid will be due and payable together with the Development Milestone Payment for the relevant Development Milestone that is actually achieved.  If Development Milestone &#91;***&#93; is achieved prior to the achievement any of Development Milestones &#91;***&#93;, then Milestone Payments for Development Milestones &#91;***&#93; shall be due to the extent not previously paid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">As additional consideration for the License, Licensee will pay Penn the following commercial milestone payments (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) upon the achievement of the corresponding milestone (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), whether achieved by Licensee or an Affiliate or Sublicensee, or a combination of Licensee, Affiliate or Sublicensee, when cumulative worldwide Net Sales of Licensed Product(s) for an Indication reach the respective thresholds indicated below.  Licensee shall notify Penn in writing of the achievement of any such Commercial Milestone within &#91;***&#93; following &#91;***&#93; in which such Commercial Milestone is achieved and Licensee shall pay Penn in full the corresponding Commercial Milestone Payment together with such notice.  For clarity, each Commercial Milestone Payment is non-refundable, non-creditable and is not an advance against Royalties due to Penn or any other amounts due to Penn.</font></div><div style="padding-left:30.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.019%"><tr><td style="width:1.0%"></td><td style="width:68.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commercial Milestone (payable once per Indication)</font></td><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cumulative Net Sales of Licensed Product for an Indication reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cumulative Net Sales of Licensed Product for an Indication reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cumulative Net Sales for Licensed Product for an Indication reaches &#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Total Commercial Milestone Payments to Penn for each Indication</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As further consideration for the License, on a Licensed Product-by-Licensed Product basis, during the applicable Royalty Period, Licensee shall pay to Penn a non-refundable, non-creditable royalty on worldwide Net Sales of Licensed Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as set forth below&#58;</font></div><div style="padding-left:30.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.019%"><tr><td style="width:1.0%"></td><td style="width:71.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual Worldwide Net Sales of a Licensed Product</font></td><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Rate</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Less than &#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Greater than or equal to &#91;***&#93; and less than or equal to &#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Greater than &#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For such purposes, &#8220;Annual Worldwide Net Sales&#8221; means the total Net Sales of the applicable Licensed Product in all countries in a particular Calendar Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee&#8217;s obligation to pay Penn the Royalty will continue on a country-by-country and Licensed Product-by-Licensed Product basis from the date of First Commercial Sale of such Licensed Product in a country until the latest of (a) the expiration or abandonment of the last Valid Claim within the Penn Patent Rights and, if applicable, DRG Patent Rights covering such Licensed Product in such country, (b) &#91;***&#93; after First Commercial Sale of such Licensed Product in such country, (c) the expiration of the Regulatory Exclusivity with respect to such Licensed Product&#59; provided that if both the &#91;***&#93; period described in subpart (b) and the applicable Regulatory Exclusivity described in subpart (c) have both expired and there are only pending Valid Claims, but not any issued Valid Claim, in such country covering such Licensed Product on the date that is &#91;***&#93; after the First Commercial Sale of such Licensed Product in such country, the royalty term with respect to such Licensed Product shall expire on such date (such royalty period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Royalty Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Royalty Reductions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.36pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.03pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Calculations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Licensee must pay Royalties owed to Penn on a Calendar Quarter basis on or before the following dates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#91;***&#93; for any Sales that took place on or before the last day of the Calendar Quarter ending December 31, of the prior Calendar Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; for any Sales that took place on or before the last day of the Calendar Quarter ending March 31 of such Calendar Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; for any Sales that took place on or before the last day of the Calendar Quarter ending June 30 of such Calendar Year&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; for any Sales that took place on or before the last day of the Calendar Quarter ending September 30.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Penn Sublicense Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Subject to the terms and conditions of this Agreement, on a Licensed Product-by-Licensed Product basis, Licensee will pay to Penn the following percentage of Sublicense Income (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Sublicense Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) received by Licensee from a Sublicensee&#58;</font></div><div style="padding-left:30.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.019%"><tr><td style="width:1.0%"></td><td style="width:67.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stage in Licensed Product development for the applicable Indication at which Sublicense is granted by Licensee</font></td><td colspan="3" style="background-color:#a6a6a6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Percent of Sublicense Income payable to Penn</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Prior to &#91;***&#93; for the first Licensed Product for such Indication</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After &#91;***&#93; for the first Licensed Product for such Indication and prior to &#91;***&#93; for the first Licensed Product for such Indication</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">After &#91;***&#93; for the first Licensed Product for an Indication</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will make such payment to Penn on or before the following dates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending December 31, of the prior Calendar Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending March 31 of such Calendar Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending June 30 of such Calendar Year&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter ending September 30 of such Calendar Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Discovery Product Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">During the Term of this Agreement and thereafter, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93; on or before the following dates&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#91;***&#93; for any Discovery Product Proceeds received by Penn that took place on or before the last day of the Calendar Quarter ending December 31, of the prior Calendar Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; for any Discovery Product Proceeds received by Penn that took place on or before the last day of the Calendar Quarter ending March 31 of such Calendar Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;***&#93; for any Discovery Product Proceeds received by Penn that took place on or before the last day of the Calendar Quarter ending June 30 of such Calendar Year&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;***&#93; for any Discovery Product Proceeds received by Penn that took place on or before the last day of the Calendar Quarter ending September 30.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Within &#91;***&#93; after &#91;***&#93; in which Penn receives Discovery Product Proceeds, Penn shall deliver to Licensee a report (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Financial Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) setting out sufficient details necessary to calculate the Discovery Product Proceeds received by Penn under this Article 5 in such Calendar Quarter, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Mode of Payment and Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">All payments to Penn hereunder shall be made by deposit of USD in the requisite amount to the &#8220;The Trustees of the University of Pennsylvania&#8221; and will be made by delivery to any one of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For funding of the performance of a Research Program by Penn (if applicable)&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">By ACH&#47;Wire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; (domestic wires)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(international wires only)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Account Number&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For all other payments to Penn under this Agreement&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">By ACH&#47;Wire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93; (domestic wires)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(international wires only)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Account Number&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">By Check (direct mail)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Trustees of the University of Pennsylvania</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c&#47;o Penn Center for Innovation</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Financial Coordinator</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3600 Civic Center Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia, PA 19104</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">By Check (lockbox)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Trustees of the University of Pennsylvania</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c&#47;o Penn Center for Innovation</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PO Box 785546</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia, PA 19178-5546</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">All payments to Licensee hereunder shall be made by deposit of USD in the requisite amount to such bank account as Licensee may from time to time designate by written notice to Penn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">All amounts stated in and payments due under this Agreement shall be in USD.  All Royalties, Sublicense Income and&#47;or &#91;***&#93; payable shall be calculated first in the currency of the jurisdiction in which payment was made, and if not in the United States, then converted into USD.  The exchange rate for such conversion shall be the average of the rate quoted in The Wall Street Journal for the last business day of each month in the Calendar Quarter for such Royalty, Sublicense Income and&#47;or &#91;***&#93; payment made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Royalty and Penn Sublicense Income Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;***&#93; after the end of each Calendar Quarter, Licensee shall deliver to Penn a report (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Licensee Financial Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) setting out sufficient details necessary to calculate the Royalty and Penn Sublicense Income due under this Article 5 for such Calendar Quarter, including&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Number of each Licensed Product Sold by Licensee, its Affiliates and Sublicensees in each country, the corresponding name of each such Licensed Product&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Gross sales, Net Sales of each Licensed Product made by Licensee, its Affiliates and Sublicensees&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Royalties due for the applicable period pursuant to Section 5.3&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Sublicense Income due for the applicable period pursuant to Section 5.4 and the calculation of Penn Sublicense Income&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The method and currency exchange rates (if any) used to calculate the Royalties and Penn Sublicense Income&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Date of First Commercial Sale of each Licensed Product in the United States (this need only be reported in the first royalty report following such First Commercial Sale in the United States).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to any other remedies available to Penn, including the right to terminate this Agreement, any failure by Licensee to make a payment within &#91;***&#93; after the date when due shall obligate Licensee to pay computed interest, the interest period commencing on the due date and ending on the actual payment date, to Penn at a rate per annum equal to &#91;***&#93;, or the highest rate allowed by Law, whichever is lower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Default Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of default in payment of any payment owing to Penn under the terms of this Agreement, and if it becomes necessary for Penn to undertake legal action to collect said payment, Licensee shall pay reasonable, documented legal fees and costs incurred in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Accounting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable to it in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee will keep accurate books and records of all Licensed Products developed, manufactured, used or sold and all Sublicenses entered into by Licensee with respect to Penn Patent Rights.  Licensee will preserve these books and records for at least &#91;***&#93; from the date of the Licensee Financial Report to which they pertain.  Penn will keep accurate books and records of all Discovery Product Licenses entered into by Penn and all Discovery Product Proceeds in connection therewith.  Penn will preserve these books and records for at least &#91;***&#93; from the date of the Penn Financial Report to which they pertain.  Upon reasonable notice, not less than &#91;***&#93; prior to the proposed date of review, books and records pertaining to the calculation of any Milestones, Royalties and Penn Sublicense Income due to Penn or (with respect to Penn as Payor) any Discovery Product Proceeds due to Licensee under this Agreement will be made reasonably available and will be open to examination by up to two (2) representatives or agents of Penn reasonably acceptable to Licensee (and, to the extent such are not employees of Penn, each of whom has executed an appropriate confidentiality agreement reasonably acceptable to Licensee that requires the representative or agent to keep any information learned by it confidential except as needed to report its audit conclusions to Penn) for no longer than &#91;***&#93; during regular office hours to determine the accuracy of such books and records and assess Licensee&#8217;s compliance with the terms of this Agreement, provided that Licensee shall not have an obligation to provide such access more than once in any given twelve (12) month period nor more than &#91;***&#93; after the date of any record to be audited.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Payee, at its own cost, through an independent auditor reasonably acceptable to Payor (and who has executed an appropriate confidentiality agreement reasonably acceptable to Payor that requires the auditor to keep any information learned by it confidential except as needed to report its audit conclusions to Payee), may inspect and audit the relevant records of Payor pertaining to the calculation of &#91;***&#93; any Milestones, Royalties and Penn Sublicense Income due to Penn &#91;***&#93;.  Payor shall provide such auditors with access to the records at Payor&#8217;s principal place of business during reasonable business hours.  Such access need not be given to any such set of records more often than once each Calendar Year nor more than &#91;***&#93; after the date of any report to be audited.  Payee shall provide Payor with written notice of its election to inspect and audit the records related to &#91;***&#93; the Milestones and Royalties &#91;***&#93; due hereunder not less than &#91;***&#93; prior to the proposed date of review of Payor&#8217;s records by Payee&#8217;s auditors.  Should the auditor establish any underpayment of Milestones, Royalties or Penn Sublicense Income by Licensee &#91;***&#93; Payor shall (a) promptly pay Payee the amount of such underpayment&#59; and (b) reimburse Payee for the cost of the audit, if such underpayment equals or exceeds &#91;***&#93; of amounts paid to Payee hereunder during the time period audited.  If the auditor finds </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">overpayment by Payor, then Payor shall have the right to deduct the overpayment from any future milestones or royalties due to Penn by Licensee &#91;***&#93; or deduct the overpayment from &#91;***&#93; or, if no such future milestones or royalties &#91;***&#93;, as applicable, are payable, then Payee shall refund the overpayment to Payor within &#91;***&#93; after Payee receives the audit report.  Payor may designate competitively sensitive information which such auditor may see and review but which it may not disclose to Payee&#59; provided, however, that such designation shall not restrict the auditor&#8217;s investigation or conclusions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All payments made by Licensee to Penn under this Agreement shall be made free and clear of and without any deduction for or on account of any Taxes on or with respect to such payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">In the event that a Licensed Product is Covered by a Penn PD Patent Right or a Joint PD Patent Right (each, as defined in the PD Agreement) in a particular country, and such Licensed Product is not Covered by any Penn Patent Rights, Joint Patent Rights, or Licensed Know-How, the royalty and milestone payments under this Agreement shall apply to such Licensed Product as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Solely with respect to such Licensed Product and such country and solely for purposes of subsections (b) and (c) below, the definition of &#8220;Program Valid Claim&#8221; shall be deemed to refer to such Penn PD Patent Rights or Joint PD Patent Rights (each, as defined in the PD Agreement immediately prior to the termination of such Agreement) instead of Penn Patent Rights A or Penn Patent Rights B&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Licensee will pay Penn milestone payments in accordance with the terms of Section 5.2 upon the achievement of the corresponding milestone event by such Licensed Product&#59; provided that such milestones have not previously been achieved by a Licensed Product for the same Indication&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Licensee will pay Penn royalties in accordance with the terms of Section 5.3 on Net Sales of such Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:31.41pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CLINICAL DEVELOPMENT, REGULATORY AFFAIRS&#59; COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Until the First Commercial Sale in a Major Market of the first Licensed Product for each Indication, Licensee shall provide Penn with a development plan for a Licensed Product for such Indication no later than December 1st of each year during the Term, commencing with the Calendar Year after the expiration of the Research Term.  The development plan shall include a good faith estimate of the timeline for material clinical activities to be conducted by Licensee, its Affiliates and Sublicensees to support obtaining Regulatory Approvals for a Licensed Product in the Major Markets in each Indication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As between the Parties, Licensee will have sole responsibility for and sole decision-making over all commercialization activities of the Licensed Products for the Indications in the Field of Use, and will be solely responsible for the associated costs of such commercialization activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Agreement or in a Research Plan, as between the Parties, Licensee will have responsibility for and decision-making authority over all manufacturing activities and associated costs for the clinical development (including cGMP manufacturing for clinical trials) and commercialization of the Licensed Products for the Indications in the Field of Use for each such Licensed Product.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Regulatory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">As between the Parties, Licensee will have responsibility for and decision-making over regulatory activities for the Licensed Products for the Indications in the Field of Use.  As between the Parties, Licensee will have the right to conduct all communications with Regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to Licensed Products for the Indications in the Field of Use.  Licensee will lead and have control over preparing and submitting all INDs, BLAs and other material regulatory filings related to the Licensed Products for the Indications in the Field of Use, including all applications for Regulatory Approval, provided, however, that, Licensee shall notify Penn in writing of any such application for Regulatory Approval reasonably in advance of filing to allow for Penn to request and, upon any such request, review such application.  Promptly following any such review request from Penn, Licensee shall provide Penn with a copy of such application for Regulatory Approval&#59; provided, however, that Licensee shall not be obligated to provide any particular application for Regulatory Approval more than once (unless Licensee materially changes such application other than to incorporate any comments provided by Penn).  As between the Parties, Licensee will own any and all applications for Regulatory Approvals (including INDs), Regulatory Approvals, and other regulatory filings related to the Licensed Products for the Indications in the Field of Use which will be held in the name of Licensee (or its designees).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">At Licensee&#8217;s reasonable request and expense, Penn (through Dr. Wilson and other Wilson Lab personnel) shall reasonably cooperate with and assist Licensee (or its designee) in connection with interactions with Regulatory Authorities relating to Licensed Products for the Indications in the Field of Use.  In addition, Licensee will keep Penn reasonably informed of the progress of such regulatory interactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and, upon request but not more than twice per Calendar Year, Licensee will provide to Dr. Wilson (or another designated Wilson Lab personnel), on a confidential basis, a copy of any material regulatory filings or correspondence to or from the FDA or EMA with respect to a Licensed Product for an Indication.  Licensee will consider any reasonable comments provided on a timely basis by Dr. Wilson (or such Wilson Lab personnel) with respect to such regulatory interactions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee (itself and&#47;or through its Affiliates or Sublicensees) shall use Commercially Reasonable Efforts to develop and, following Regulatory Approval, to commercialize, in the Major Markets one Licensed Product for each Indication in the Field of Use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Progress Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Prior to the First Commercial Sale of a Licensed Product for an Indication, Licensee on an annual basis, but in no event later than June 1st of each Calendar Year, shall submit to Penn a progress report (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Progress Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) summarizing Licensee&#8217;s (and any Affiliates&#8217; and Sublicensees&#8217;) material activities related to the development of all Licensed Products for each Indication directed to obtaining Regulatory Approvals necessary for commercialization of Licensed Products in the Major Markets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Each Progress Report must include all of the following for each annual period&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Update on the status of material pre-clinical work and Clinical Studies involving a Licensed Product, as well as the status of any IND and&#47;or BLA filings for a Licensed Product&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If known and relevant, anticipated dates for receipt of Regulatory Approval for a Licensed Product in the Major Markets.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Patent Filing Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Penn will use diligent efforts to file, and thereafter prosecute in good faith and maintain, a Patent Right(s), which would be included in Penn Patent Rights A, claiming the Designated Product for each Indication and the use of such Designated Product for the Indication.  Penn Patent Rights will be held in the name of Penn and obtained with counsel selected by Penn and reasonably acceptable to Licensee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Penn shall control all actions and decisions with respect to the filing, prosecution and maintenance of Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and Joint Patent Rights in close coordination with Licensee via discussions at the JIPC and, in any event, Penn will consider any reasonable comments or suggestions by Licensee with respect to same&#59; provided, however, that with respect to Penn Patent Rights A claiming solely a Designated Product applicable to the Indications in the Field of Use, Joint Patent Rights, and Discovery Patent Rights for which there is no Third Party licensee, Penn shall have an obligation to consider in good faith and implement any reasonable comments provided by Licensee.  Penn will instruct Patent Counsel to copy Licensee on all correspondence related to Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), Joint Patent Rights and any other Discovery Patent Rights for which there is no Third Party licensee (including copies of each patent application, office action, response to office action, request for terminal disclaimer, and request for reissue or reexamination of any patent or patent application) and to interact with Licensee with respect to the preparation, filing, prosecution and maintenance of Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and Joint Patent Rights.  Penn has the right to take action to preserve rights and minimize cost whether or not Licensee has commented, and will use reasonable efforts to not abandon or allow to lapse (a) any Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) or Joint Patent Rights for which Licensee is licensed and is underwriting its share of the Patent Costs nor (b) any other Discovery Patent Rights for which Licensee is underwriting its share of the Patent Costs, if any, in each case ((a) and (b)) without Licensee&#8217;s written authorization under this Agreement, except for filing of continuations, divisionals, or the like that substitute for the lapsed application, provided that, Penn shall have no requirement to file, prosecute, or maintain Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) or Joint Patent Rights if Licensee is not current with its Patent Cost obligations with respect to such Patent Right as set forth in this Agreement.  Upon Licensee&#8217;s reasonable request, the Parties shall cooperate and shall prepare updated versions of each of the exhibits pertaining to Penn Patent Rights.  For the purposes of this Agreement, &#8220;maintenance&#8221; of the Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and Joint Patent Rights includes inter parties patent review proceedings before the USPTO or a similar patent administration outside the US.  For further clarity, validity challenges raised in infringement litigation will be handled per Section 7.3, Infringement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The Parties shall discuss and agree at the JIPC the countries in which Patent Rights within the Penn Patent Rights A, Penn Patent Rights B (excluding Patent Rights on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) and Joint Patent Rights will be filed.  Licensee has the right to request any additional country filing for Penn Patent Rights A, Penn Patent Rights B and Joint Patent Rights via a written request to Penn &#91;***&#93; prior to the deadline set by the patent office in the territory in which filing is to take place (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prosecution Request</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The absence of a given Prosecution Request by such deadline will be considered an election not to secure the Patent Rights associated with the specific phase of patent prosecution in such country, and such patent application(s) and patent(s) in such country will not be part of Penn Patent Rights and therefore not subject to this Agreement, including the License, and Licensee will have no further rights or license to them.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">For Penn Patent Rights B listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and any other Discovery Patent Rights for which there is a Third Party licensee, Penn Patent Rights C and Manufacturing Patent Rights, Penn will instruct Patent Counsel to copy Licensee on all correspondence (including copies of each patent application, office action, response to office action, request for terminal disclaimer, and request for reissue or reexamination of any patent or patent application), to interact with Licensee with respect to the preparation, filing, prosecution and maintenance, and to consider any reasonable comments or suggestions by Licensee with respect to same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee shall also have the right, on a Penn Patent Right-by-Penn Patent Right and country-by-country basis, to (i) elect not to fund at the time of disclosure, or (ii) elect not to continue to fund, in each case (i) and (ii), its pro rata share (as determined pursuant to Section 7.2) of the Patent Costs with respect to any Penn Patent Right(s) in a particular country, which election may be made by Licensee upon &#91;***&#93; prior written notice to Penn (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Within &#91;***&#93; after receipt of an Election Notice from Licensee, Penn shall notify Licensee in writing whether (a) any Third Party is obligated to fund any portion of the Patent Costs with respect to any Penn Patent Right identified in such Election Notice in any country identified in such Election Notice or (b) Penn and&#47;or Dr. James Wilson will fund such Patent Costs or will allow such Penn Patent Right to lapse or become abandoned in such country.  Within &#91;***&#93; after receipt of any such notice from Penn, Licensee shall have the right to cancel its Election Notice and fund or continue to fund, as applicable, its pro rata share of the Patent Costs with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">respect to such Penn Patent Right in such country.  If Licensee delivers an Election Notice to Penn (and does not cancel such Election Notice, pursuant to the preceding sentence), following the expiration of such &#91;***&#93; period, Licensee shall have no further obligation to pay Ongoing Patent Costs with respect to any Penn Patent Right identified in such Election Notice in any country identified in such Election Notice and any such Patent Right in any such country shall thereafter be excluded from the Penn Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Notwithstanding the foregoing, on a Funded Discovery Patent Right-by-Funded Discovery Patent Right and country-by-country basis, if any Patent Right for which Licensee elects not to fund its share of Patent Costs in a country pursuant to Section 7.1.4, is a Funded Discovery Patent Right and Licensee has funded its share of the Patent Costs for such Funded Discovery Patent Right in such country through the expiration of the Discovery Term, such Patent Right in such country shall be treated as a Funded Discovery Patent Right in such country for the purpose of revenue sharing.  If Licensee chooses (pursuant to Section 7.1.4) not to fund its share of the Patent Costs for a Funded Discovery Patent Right in a country following completion of the Discovery Term (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Abandoned Discovery Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;***&#93;.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Subject to Section 7.2.3, within &#91;***&#93; after the Effective Date, Licensee will reimburse Penn for all documented out-of-pocket costs for the filing, prosecution and maintenance of Penn Patent Rights and Joint Patent Rights, including all accrued and documented attorney fees, expenses, official and filing fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), incurred prior to the Effective Date or the date at which such Patent Rights are added to the License (as applicable), which have not otherwise been reimbursed by Licensee or other licensees of such Penn Patent Rights (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Historic Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Historic Patent Costs for the Discovery Patent Rights that were incurred prior to the Effective Date shall be excluded from Licensee&#8217;s reimbursement obligation to Penn.  Notwithstanding the first sentence of this Section 7.2.1, for Penn Patent Rights or Joint Patent Rights licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata share of such documented Historic Patent Costs based on the number of licensees for such Penn Patent Rights or Joint Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will bear (a) all Patent Costs incurred during the Term, for Penn Patent Rights (other than Discovery Patent Rights) and Joint Patent Rights, (b) for Discovery Patent Rights, all Patent Costs incurred during the period beginning on the Effective Date and thereafter until the expiration of the last Discovery Patent Right (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ongoing Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding the foregoing, for Penn Patent Rights or Joint Patent Rights licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata share of such documented Ongoing Patent Costs based on the number of licensees for such Penn Patent Rights or Joint Patent Rights.  No later than &#91;***&#93; prior to the end of each Calendar Year during the Term, Penn shall provide to Licensee, a good faith estimate and budget for the Ongoing Patent Costs anticipated to be incurred for the next Calendar Year and, to the extent applicable, Licensee&#8217;s proportionate share of such Ongoing Patent Costs.  This Section 7.2.2 is subject to Section 7.1.4 above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee shall pay in advance the Patent Counsel&#8217;s estimated costs for undertaking material patent actions with respect to Penn Patent Rights and Joint Patent Rights before Penn authorizes the Patent Counsel to proceed (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Advance Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding whether Licensee makes an Advance Payment for any patent action, Licensee shall bear its pro rata share (based on the number of licensees for such Penn Patent Rights or Joint Patent Rights) of all Patent Costs with respect to Penn Patent Rights and Joint Patent Rights as set forth in Section 7.2.1 or Section 7.2.2 and shall pay such amounts within &#91;***&#93; of receipt of invoice for such patent actions.  For clarity, the term &#8220;Patent Costs&#8221; means and includes Historic Patent Costs and Ongoing Patent Costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If either Party believes that an infringement by a Third Party with respect to any Penn Patent Right is occurring or may potentially occur, the knowledgeable Party will provide the other Party with (a) written notice of such infringement or potential infringement and (b) evidence of such infringement or potential infringement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Infringement Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  During the period in which, and in the jurisdiction where, Licensee has exclusive rights under this Agreement, subject to Licensee&#8217;s right to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">institute suit for patent infringement pursuant to Section 7.3.2 if infringing activity of potential commercial significance has not been abated within &#91;***&#93; following the date the Infringement Notice for such activity was provided, neither Penn or Licensee will notify such a Third Party (including the infringer) of infringement or put such Third Party on notice of the existence of Penn Patent Rights without first obtaining the written consent of the other Party.  If Licensee puts such infringer on notice of the existence of any Penn Patent Right without the prior written consent of Penn prior to the expiration of such &#91;***&#93; period, then Licensee&#8217;s right to initiate a suit under Section 7.3.2 below will terminate immediately without the obligation of Penn to provide notice to Licensee.  Both Penn and Licensee will use their diligent efforts to cooperate with each other to terminate any such infringement without litigation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">With respect to Penn Patent Rights A, if infringing activity of potential commercial significance has not been abated within &#91;***&#93; following the date the Infringement Notice for such activity was provided, then during the period in which, and in the jurisdiction where, Licensee is the sole licensee for certain Penn Patent Rights A and the infringement is a competing product to a Licensed Product for an Indication, Licensee may institute suit for patent infringement of such Penn Patent Rights A against the infringer.  With respect to Penn Patent Rights B, if infringing activity of potential commercial significance has not been abated within &#91;***&#93; following the date the Infringement Notice for such activity was provided, then during the period in which, and in the jurisdiction where, Licensee is the sole licensee for certain Penn Patent Rights B and the infringement is a competing product to a Designated Product for an Indication, the JIPC shall discuss and recommend how to handle such infringement, including whether to institute suit for patent infringement of such Penn Patent Rights B against the infringer, which Party shall have the right to initiate and control such suit and making decisions with respect to litigation strategy.  If the JIPC (after escalation pursuant to Section 3.2.4) is unable to reach agreement, Penn shall have the final decision-making authority with respect to handling any infringement action related to Penn Patent Rights B&#59; provided that in any event, Penn will consider any reasonable comments or suggestions by Licensee with respect to same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Penn may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Licensee&#8217;s suit or any judgment rendered in such suit.  If in a suit initiated by Licensee, Penn is involuntarily joined other than by Licensee, then Licensee will pay any documented costs incurred by Penn arising out of such suit, including any documented legal fees of counsel that Penn selects and retains to represent it in the suit.  In any suit initiated by Licensee, Licensee shall be free to enter into a settlement, consent judgment or other voluntary disposition, provided that any settlement, consent judgment or other voluntary disposition that (i) limits the scope, validity or enforcement of Penn Patent Rights A or Penn Patent Rights B or (ii) admits fault or wrongdoing on the part of Penn must be approved in advance by Penn in writing (such approval not to be unreasonably withheld or delayed).  Licensee&#8217;s request for such approval shall include complete copies of proposed settlement documents, a summary of such settlement, and any other information material to such settlement that is reasonably requested by Penn.  Penn shall provide Licensee notice of its approval or denial within &#91;***&#93; of any request for such approval by Licensee, provided that (x) in the event Penn wishes to deny such approval, such notice shall include a detailed written description of Penn&#8217;s reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition and (y) Penn shall be deemed to have approved of such proposed settlement, consent judgment, or other voluntary disposition in the event it fails to provide such notice within such &#91;***&#93; period in accordance herewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If, within &#91;***&#93; following the date of a request to do so from Penn, infringing activity of potential commercial significance has not been abated and if Licensee has not brought suit against the infringer, then Penn may institute suit for patent infringement against the infringer.  If Penn institutes such suit, then Licensee may not join such suit without the prior written consent of Penn (which consent shall not be unreasonably withheld or delayed) and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Penn&#8217;s suit or any judgment rendered in such suit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Notwithstanding Sections 7.3.2, 7.3.3 and 7.3.4, in the event that any Penn Patent Rights A or Penn Patent Rights B are infringed by a Third Party and any of the infringed Penn Patent Rights A or Penn Patent Rights B are also licensed by Penn to a Third Party, prior to any enforcement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">action being taken by either Party regarding such infringement, the JIPC shall discuss and recommend how to handle such infringement by such Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Any recovery or settlement received in connection with any suit will first be shared by Penn and Licensee equally to cover any litigation costs each incurred (to the extent not previously reimbursed) and next shall be paid to Penn or Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other (to the extent not previously reimbursed).  Any remaining recoveries shall be allocated as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For any portion of the recovery or settlement, other than for amounts attributable and paid as enhanced damages for willful infringement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">for any suit that is initiated by Licensee and in which Penn was not a party in the litigation, Penn shall receive &#91;***&#93; of the recovery and the Licensee shall receive the remainder&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">for any suit that is initiated by the Licensee or Penn and that the other Party joins voluntarily (but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily, the non-initiating party&#8217;s percentage of the total litigation costs incurred by Penn and Licensee, but in no event shall the non-initiating Party receive less than &#91;***&#93; of such recovery, while the initiating party shall receive the remainder, and in no case shall Penn receive less than &#91;***&#93; of such recovery.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For any portion of the recovery or settlement paid as enhanced damages for willful infringement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">for any suit that is initiated by Licensee or Penn and the other Party voluntarily (but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily, the initiating party shall receive &#91;***&#93; and the non-initiating shall receive the remainder&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">for any suit that is initiated by Licensee and in which Penn was not a party in the litigation, Penn shall receive &#91;***&#93; and Licensee shall receive the remainder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For any portion of the recovery or settlement received in connection with any suit that is initiated by Penn and in which Licensee was not a party in the litigation, any recovery in excess of litigation costs will belong to Penn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Each Party will reasonably cooperate and assist with the other in litigation proceedings instituted hereunder but at the expense of the Party who initiated the suit (unless such suit is being jointly prosecuted by the Parties).  For clarity, such requirement does not require a Party to join a suit unless otherwise specifically required under this Agreement.  If Penn is subjected to third party discovery related to the Penn Patent Rights or Licensed Products licensed to Licensee hereunder, Licensee will pay Penn&#8217;s documented out-of- pocket expenses with respect to same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Penn shall keep Licensee reasonably informed of the initiation and status of any action to enforce any Penn Patent Rights A, Discovery Patent Rights (including Penn Patent Rights B), Penn Patent Rights C or Manufacturing Patent Rights pertaining to the Indications or a Licensed Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party shall have the right to defend any adversarial legal proceeding brought against it, and the Parties shall reasonably cooperate with one another regarding such defense, provided that such right of defense does not include any right to bring infringement actions (including counterclaims) with respect to Penn Patent Rights except as expressly set forth herein or as otherwise agreed by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Patent Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee shall place in a conspicuous location on any Licensed Product (or its packaging where appropriate and practicable) made or sold under this Agreement a patent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">notice in accordance with the Laws concerning the marking of patented articles where such Licensed Product is made or sold, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Ownership of Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Ownership of any inventions or other intellectual property generated in the conduct of a Research Program or otherwise under this Agreement will be determined in accordance with United States patent law or other applicable intellectual property law.  For clarity, (a) inventions conceived and reduced to practice solely by Penn inventors will be solely owned by Penn, (b) inventions conceived and reduced to practice solely by Licensee inventors will be solely owned by Licensee, and (c) inventions jointly conceived and reduced to practice by both Penn and Licensee inventors will be jointly owned by Penn and Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">DRG Patent Filing Prosecution and Maintenance, Patent Costs, Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patent Filing Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Penn will use diligent efforts to file, and thereafter prosecute in good faith and maintain DRG Patent Right(s).  DRG Patent Right(s) will be held in the name of Penn and obtained with Patent Counsel.  Penn shall control all actions and decisions with respect to the filing, prosecution and maintenance of DRG Patent Right(s).  For the purposes of this Agreement, &#8220;maintenance&#8221; of the DRG Patent Right(s) includes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">patent review proceedings before the USPTO or a similar patent administration outside the US.  For DRG Patent Rights, Penn will instruct Patent Counsel to provide Licensee copies of patent applications when filed, notices of allowance when received, office actions when issued and office action responses when filed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the event that DRG Technology is conceived and reduced to practice by the Wilson Lab and&#47;or Vector Operations during the Discovery Term without the use of any Licensee funding (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Technology Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and such DRG Technology Improvement is also incorporated into any clinical candidate of a Third Party with whom the Wilson Lab is collaborating, then Penn may file and prosecute a Patent Right that covers such clinical candidate of a Third Party with whom the Wilson Lab is collaborating incorporating such DRG Technology Improvement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Party Candidate Patent Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that if Penn files a Third Party Candidate Patent Right, Penn shall also separately file and prosecute a patent application specific for such DRG Technology Improvement distinct from such Third Party Candidate Patent Right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">Subject to Section 7.7.2.3, within &#91;***&#93; after the Effective Date, Licensee will reimburse Penn for all documented out-of-pocket costs for the filing, prosecution and maintenance of DRG Patent Right(s) for the filing, prosecution and maintenance of DRG Patent Rights, including all accrued and documented attorney fees, expenses, official and filing fees (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), incurred prior to the Effective Date, which have not otherwise been reimbursed by Licensee or other licensees of such DRG Patent Rights (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Historic DRG Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding the first sentence of this Section 7.7.2.1, for DRG Patent Right(s) licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata share of such documented Historic DRG Patent Costs based on the number of licensees for such Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">Licensee will bear (a) all documented out-of-pocket costs for the filing, prosecution and maintenance of DRG Patent Right(s) for the filing, prosecution and maintenance of DRG Patent Rights, including all attorney fees, expenses, official and filing fees incurred during the Term for DRG Patent Right(s) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ongoing DRG Patent Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding the foregoing, for DRG Patent Rights licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata share of such documented Ongoing DRG Patent Costs based on the number of licensees for such DRG Patent Rights.  No later than &#91;***&#93; prior to the end of each Calendar Year during the Term, Penn shall provide to Licensee, a good faith estimate and budget for the Ongoing DRG Patent Costs anticipated to be incurred for the next Calendar Year and, to the extent applicable, Licensee&#8217;s proportionate share of such Ongoing DRG Patent Costs.  This Section 7.7.2 is subject to Section 7.7.1 above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">With respect to DRG Patent Right(s), Licensee shall be subject to Advance Payment.  Notwithstanding whether Licensee makes an Advance Payment for any patent action, Licensee shall bear its pro rata share (based on the number of licensees for such DRG Patent Rights) of all DRG Patent Costs with respect to DRG Patent Right(s) as set forth in this Section 7.7.2, above, and shall pay such amounts within &#91;***&#93; of receipt of invoice for such patent actions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">Licensee shall also have the right, on a DRG Patent Right-by-DRG Patent Right and country-by-country basis, to (i) elect not to fund at the time of disclosure, or (ii) elect not to continue to fund, in each case (i) and (ii), its pro rata share (as determined pursuant to this Section 7.7 above) of the DRG Patent Costs with respect to any DRG Patent Right(s) in a particular country, which election may be made by Licensee upon &#91;***&#93; prior written notice to Penn (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DRG Election Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If Licensee delivers a DRG Election Notice to Penn, following the expiration of such &#91;***&#93; period, Licensee shall have no further obligation to pay Ongoing DRG Patent Costs with respect to any DRG Patent Right identified in such DRG Election Notice in any country identified in such DRG Election Notice and any such Patent Right in any such country shall thereafter be excluded from the DRG Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">If either Party believes that an infringement by a Third Party with respect to any DRG Patent Right is occurring or may potentially occur, the knowledgeable Party will provide the other Party with (a) written notice of such infringement or potential infringement and (b) evidence of such infringement or potential infringement.  With respect to DRG Patent Rights, Penn shall have the exclusive right to enforce such Patent Rights and institute suit for Patent Infringement.  If Penn institutes such suit, then Licensee may not join such suit without the prior written consent of Penn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">Any recovery or settlement received in connection with any suit will be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">Licensee will reasonably cooperate and assist Penn in litigation proceedings instituted hereunder at Penn&#8217;s request and expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.75pt">Penn shall keep Licensee reasonably informed of the initiation and status of any action to enforce any DRG Patent Rights to which Licensee has rights hereunder.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>CONFIDENTIALITY&#38; PUBLICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee shall not disclose Confidential Information to Penn unless it is reasonably necessary to the performance of a Research Program or otherwise required to perform Licensee&#8217;s obligations under this Agreement.  Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, during the Term and for &#91;***&#93; thereafter, the receiving Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and its Affiliates will keep confidential and will not publish or otherwise disclose or use for any purpose any Confidential Information, which is disclosed to it by the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or its Affiliates or otherwise made available to a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement.  A Receiving Party shall also have the right to disclose the disclosing Party&#8217;s Confidential Information to those of the Receiving Party&#8217;s and its Affiliates&#8217; employees, agents and&#47;or consultants who have a need to know such Confidential Information to perform its obligations or exercise its rights under this Agreement&#59; and who have entered into a written agreement with the Receiving Party (or its relevant Affiliate) to be bound by the obligations of confidentiality and non-use at least as protective of such Confidential Information as set forth in this Article 8.  In the case of Licensee as the Receiving Party, Licensee and its Affiliates shall have the right to use and disclose Confidential Information of Penn&#58;  for the purpose of developing, seeking and obtaining Regulatory Approval for, making, having made, using, selling, offering for sale and&#47;or otherwise commercializing Licensed Products under the License and, if applicable, also the DRG Technology License&#59; and to actual and potential Third Party service providers, sublicensees, other sources of financing and&#47;or acquirers or others on a need-to-know basis under appropriate conditions of confidentiality.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Disclosures Required by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event a Party is required to make a disclosure under Law or regulation, the order of a court of competent jurisdiction, or the rules of the U.S. Securities and Exchange Commission or other Governmental Body within or outside the United States (including by reason of any securities offering by Licensee), or any stock exchange or listing entity, a Receiving Party shall provide prompt written notice to the Disclosing Party and take all reasonable steps to limit the extent of the disclosure and obtain confidential treatment for any remaining required disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Penn Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In order to preserve the patentability of Penn intellectual property and to preserve Penn&#8217;s publication rights, Licensee shall maintain Penn Patent Rights, Research Results and Confidential Information provided by Penn pursuant to a Research Program (whether oral or written) as confidential and shall not disclose such Confidential Information to any Third Party except as permitted under this Article 8 until the publication of such information by Penn or until Penn provides Licensee with written verification that all desirable patentable inventions have been protected, whichever occurs sooner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Licensee Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In order to preserve the patentability of Licensee&#8217;s intellectual property and otherwise to preserve Licensee&#8217;s rights therein and thereto, Penn shall maintain Amicus Technology and Confidential Information provided by Licensee pursuant to a Research Program or otherwise under this Agreement as confidential and shall not disclose such information to any Third Party except as expressly permitted under this Agreement.  For the avoidance of doubt, for purposes of this Agreement, all records maintained by Licensee described in Section 5.11 and all Amicus Technology, Progress Reports and Licensee Financial Reports provided by Licensee to Penn under this Agreement, as well as the sequence of any Designated Product, shall be Confidential Information of Licensee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Penn shall have the first right to publish, present or otherwise disclose for any purpose Research Results, or other information and material resulting from a Research Program, to the extent any Research Results or other information to be included in any publication, presentation or disclosure exists or was generated by Penn personnel on or prior to &#91;***&#93;&#59; provided, however, that consistent with the Wilson Lab&#8217;s standard operating procedures for collaborations with commercial third parties, Penn shall provide Licensee the opportunity to review and comment on any proposed manuscripts or any other proposed public disclosure describing work developed under a Research Program that has not previously been disclosed, &#91;***&#93; prior to its submission for publication or first public disclosure for manuscripts and &#91;***&#93; prior to its submission or first public disclosure for abstracts and speaking engagements to (a) determine whether such contains any Licensee Confidential Information and (a) enable Licensee to identify any Penn intellectual property or joint intellectual property that it wishes Penn to file patent applications on or to seek other intellectual property protection for.  If within the &#91;***&#93; or &#91;***&#93; review period (i) Licensee notifies Penn in writing that the Licensee requires deletion from the publication or presentation of Licensee Confidential Information, the Parties will cooperate to modify the disclosure to ensure Licensee Confidential Information is not disclosed or (ii) if Licensee requests in writing that publication or presentation be delayed to allow for patent filings or other intellectual property protection on certain items in the proposed publication or presentation, Penn shall delay the publication or presentation for up to &#91;***&#93; to allow for the filing of applicable patent applications.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:31.41pt"><br>REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party represents and warrants to the other Party that, as of the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation or organization&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party has all right, power and authority to enter into this Agreement, to perform its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Representations of Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise disclosed by Penn to Licensee, Penn hereby represents&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">as of the Effective Date, to Penn&#8217;s knowledge, Penn&#8217;s performance of any Research Program and&#47;or the Discovery Program and&#47;or grant of rights to Licensee under this Agreement does not conflict with any agreement between Penn and a Third Party&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">other than licenses granted under the Excluded Penn IP, rights granted to Patent Rights set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or the arrangements with Third Parties described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, to Penn&#8217;s knowledge, Penn has not entered into any arrangement with any Third Party for any Indication prior to the Effective Date which is still in effect and pursuant to which a Third Party has license rights, or has an option to obtain rights, to any Patent Rights conceived or reduced to practice in the Wilson Lab for such Indication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Disclaimer of Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Other than the representations and warranties provided in Section 9.1 above, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PENN MAKES NO REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND EXPLICITLY DISCLAIMS ANY REPRESENTATION AND WARRANTY, INCLUDING WITH RESPECT TO ANY ACCURACY, COMPLETENESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE FOR THE INTELLECTUAL PROPERTY, PATENT RIGHTS, LICENSE AND ANY LICENSED PRODUCT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Furthermore, nothing in this Agreement will be construed as&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">A representation or warranty by Penn as to the validity or scope of any Penn Patent Right&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">A representation or warranty that anything made, used, sold or otherwise disposed of under the License is or will be free from infringement of patents, copyrights, trademarks or any other forms of intellectual property rights or tangible property rights of Third Parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Obligating Penn to bring or prosecute actions or suits against Third Parties for patent, copyright or trademark infringement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Conferring by implication, estoppel or otherwise any license or rights under any Patent Rights of Penn other than Penn Patent Rights as defined herein, regardless of whether such Patent Rights are dominant or subordinate to Penn Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Covenants of Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee and its Affiliates will not, directly or indirectly (including where such is done by a Third Party on behalf of Licensee or its Affiliates) make any Challenge&#59; provided, however, that if any Penn Patent Right is asserted against Licensee or its Affiliate, then such Licensee or its Affiliates is entitled to all and any defenses available to it including challenging the validity or enforceability of such Patent Right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will comply in all material respects with all Laws that apply to its activities or obligations under this Agreement.  For example, Licensee will comply with applicable United States export laws and regulations.  The transfer of certain technical data and commodities may require a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">license from the applicable agency of the United States Government and&#47;or written assurances by Licensee that Licensee will not export data or commodities to certain foreign countries without prior approval of the agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will not grant a security interest in the License or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.91pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INDEMNIFICATION&#59; INSURANCE AND LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Indemnification by Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee shall defend, indemnify and hold Penn and its respective trustees, officers, faculty, students, employees, contractors and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys&#8217; fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the extent arising out of Third Party claims or suits &#91;***&#93; including&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the gross negligence, recklessness or wrongful intentional acts or omissions of Licensee, its Affiliates or Sublicensees and its or their respective directors, officers, employees and agents, in the performance of the Licensee&#8217;s obligations or exercise of Licensee&#8217;s rights under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any material breach of this Agreement by Licensee&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">the development, manufacturing or commercialization of Licensed Products (including commercial manufacturing, packaging and labeling of Licensed Products, and all product liability losses of a Licensed Product by or on behalf of Licensee or its Affiliates or Sublicensees)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any enforcement action or suit brought by Licensee against a Third Party for infringement of Penn Patent Rights or Joint Patent Rights&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that Licensee&#8217;s obligations pursuant to this Section 10.1 shall not apply to the extent such Liabilities and Third Party claims or suits result or arise from &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">As a condition to a Penn Indemnitee&#8217;s right to receive indemnification under this Section 10.1, Penn shall&#58;  (a) promptly notify Licensee as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto&#59; (b) fully cooperate, and cause the individual Penn Indemnitees to fully cooperate, with Licensee in the defense, settlement or compromise of such claim or suit&#59; and (c) permit the Licensee to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel.  In no event, however, may Licensee compromise or settle any claim or suit in a manner which (i) admits fault or negligence on the part of Penn or any other Penn Indemnitee&#59; (ii) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action, without the prior written consent of Penn, or (iii) grant any rights under the Penn Patent Rights except for Sublicenses permitted under Article 4.  Penn shall fully cooperate, and cause the individual Penn Indemnitees to fully cooperate, with Licensee and its counsel in the course of the defense or settlement of any such suit, claim or demand, such cooperation to include without limitation providing or making available documents, information and witnesses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Notwithstanding Section 10.1.2 above, a Penn Indemnitee shall be entitled to participate in, but not control, the defense of a Third Party claim or suit subject to indemnification under Section 10.1.1 above and to engage counsel of its own choice for such purpose&#59; provided that such engagement shall be at such Penn Indemnitee&#8217;s own expense unless a bona fide conflict exists between Licensee and Penn or any other Penn Indemnitee with respect to a claim or suit subject to indemnification hereunder, such that representation by Licensee and Penn or such other Penn Indemnitee by the same legal counsel due to a misalignment of interests or would be prohibited under applicable law, ethical rules or equitable principles, in which case, Licensee will either pay any reasonable, documented out-of-pocket </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">attorney&#8217;s fees and litigation expenses of such Penn Indemnitee directly or reimburse Penn within &#91;***&#93; of Licensee&#8217;s receipt of invoices for such fees and expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">In no event shall Licensee be liable under this Section 10.1 for any settlement, compromise or other disposition of a Third Party claim or suit for which a Penn Indemnitee seeks indemnification hereunder and that is reached without the prior written consent of Licensee, such consent not to be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee, at its sole cost and expense, must insure its activities in connection with the exercise of its rights under this Agreement and keep in force and maintain Commercial Form General Liability Insurance (contractual liability included) with at least the following limits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Each occurrence&#160;&#160;&#160;&#160;&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">General aggregate&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Prior to the commencement of clinical trials, if applicable, involving Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Clinical trials liability insurance&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Prior to the First Commercial Sale of a Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Products liability insurance&#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn may review periodically the adequacy of the minimum amounts of insurance for each coverage required by this Section 10.2.1, and has the right to discuss with Licensee adjustments to such limits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination or expiration of this Agreement.  The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee expressly understands, however, that the coverages and limits in Section 10.2.1 do not in any way limit Licensee&#8217;s liability or indemnification obligations.  Licensee&#8217;s insurance will&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Be issued by an insurance carrier with an A.M. Best rating of &#8220;A&#8221; or better&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Provide for thirty (30) day advance written notice to Penn of any modification&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">State that Penn is endorsed as an additional insured with respect to the coverages in Section 10.2.1&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Include a provision that the coverages will be primary and will not participate with nor will be excess over any valid and collective insurance or program of self insurance carried or maintained by Penn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee must furnish to Penn with (a) valid certificate of insurance evidencing compliance with all requirements of this Agreement and (b) additional insured endorsements for Licensee&#8217;s applicable policies naming &#8220;The Trustees of the University of Pennsylvania&#8221; as an additional insured.  Licensee must furnish both documents within thirty (30) days of the Effective Date, once per year thereafter and at any time there is a modification in such insurance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">LIMITATION OF LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#91;***&#93;, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS OR OPPORTUNITY, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF&#59; PROVIDED THAT NOTHING IN THIS SECTION 10.3 SHALL BE DEEMED TO LIMIT LICENSEE&#8217;S INDEMNIFICATION OBLIGATIONS UNDER SECTION 10.1.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.91pt"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall commence on the Effective Date and, unless terminated sooner as provided below, shall continue in full force and effect on a country- by-country and Licensed Product-by-Licensed Product basis until &#91;***&#93;.  Following expiration of the &#91;***&#93; (but not earlier termination) in a particular country, the license to Licensed Know-How and Licensed Discovery Know-How in such country for Licensed Products for the applicable Indication in the Field of Use as set forth in Section 4.1 will become perpetual and fully paid-up.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination of this Agreement for Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 11.4, Licensee may, at its convenience, terminate this entire Agreement or on an Indication-by-Indication basis, by providing at least &#91;***&#93; prior written notice to Penn of such intention to terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination For Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">In addition to all other remedies available to it, Penn may terminate this Agreement upon &#91;***&#93; written notice if Licensee materially fails to comply with any Laws that apply to its activities or obligations under this Agreement and that can be remedied and Licensee fails to remedy such lack of compliance within such &#91;***&#93; period, (b) upon &#91;***&#93; written notice, if Licensee grants a security interest in this Agreement or any of the rights granted herein and does not revoke such grant prior to the expiration of such &#91;***&#93; period, or (d) upon written notice, if Licensee breaches Section 9.4.1 and does not withdraw or discontinue the applicable Challenge within &#91;***&#93; of such notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If either Party materially breaches any of its material obligations under this Agreement, the non-breaching Party may give to the breaching Party a written notice specifying the nature of the default, requiring it to cure such breach, and stating its intention to terminate this Agreement.  If such breach is not cured within &#91;***&#93; of such notice (for non-payment), and &#91;***&#93; of such notice for all other material breaches, such termination shall become effective upon a notice of termination by the terminating Party thereafter&#59; provide that if there is a good faith dispute as to the existence of a material breach, such &#91;***&#93; or &#91;***&#93; period may be extended by mutual agreement of the Parties to allow the Parties additional time to continue good faith discussions to resolve the dispute.  To the extent Licensee&#8217;s material breach relates solely to an Indication, Penn&#8217;s right to terminate the Licensee&#8217;s rights under this Agreement will be limited to such Indication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Either Party may terminate this Agreement, upon written notice if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such Party or of its assets, or if such Party proposes a written agreement of composition or extension of its debts, or if such Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within &#91;***&#93; after the filing thereof, or if such Party proposes or is a party to any dissolution or liquidation, or if such Party makes an assignment for the benefit of its creditors of all or substantially all its assets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Notwithstanding the termination or expiration of this Agreement, the following provisions shall survive&#58;  Sections &#91;***&#93; and Articles &#91;***&#93;.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Termination of this Agreement shall not relieve the Parties of any obligation or liability that, at the time of termination, has already accrued hereunder, or which is attributable to a period prior to the effective date of such termination.  Termination of this Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party&#8217;s right to obtain performance of any obligation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">If this Agreement is terminated for any reason, all outstanding Sublicenses (including all Sublicense Documents for each Sublicense) not in default shall survive, provided that each such Sublicensee agrees in writing to be bound by the applicable terms of this Agreement with respect to the activities of such Sublicensee under such Sublicense.  The duties and obligations of Penn under any surviving Sublicenses will not be greater than the duties of Penn under this Agreement, and the rights of Penn under any surviving Sublicenses will not be less than the rights of Penn under this Agreement, including all financial consideration and other rights of Penn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Upon termination of this Agreement and subject to Section 11.3.2, Licensee, its Affiliates and Sublicensees whose rights do not survive termination of this Agreement will promptly cease selling the Licensed Product(s) subject to such termination.  Each Party will return (or destroy, as directed by the other Party) all data, files, records and other materials containing or comprising the other Party&#8217;s Confidential Information with respect to this Agreement, except to the extent such Confidential Information is necessary or useful to conduct activities in connection with surviving portions of or rights pursuant to this Agreement.  Notwithstanding the foregoing, the Parties will be permitted to retain one copy of such data, files, records, and other materials for archival and legal compliance purposes.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.91pt"><br>ADDITIONAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement is intended or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture, fiduciary or employer-employee relationship between the Parties.  The Parties are independent contractors and at no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Agreement, each Party shall pay its own expenses and costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee, its Affiliates and Sublicensees may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative in any press release, advertising, promotional or sales literature, without the prior written consent of Penn.  Notwithstanding the foregoing, Licensee may use the name of Penn in a non-misleading and factual manner solely in (a) executive summaries, business plans, offering memoranda and other similar documents used by Licensee for the purpose of raising financing, including for the operations of Licensee as related to a Licensed Product, or entering into commercial contracts with Third Parties, but in such case only to the extent necessary to inform a reader that the Penn Patent Rights has been licensed by Licensee from Penn, and (b) any securities reports required to be filed with the Securities and Exchange Commission or any other disclosures required under applicable Laws (including securities regulations).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Discrimination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither Penn nor Licensee will discriminate against any employee or applicant for employment because of race, color, sex, sexual orientation, age, religion, national or ethnic origin, handicap, or veteran status.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Successors and Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The terms and provisions hereof shall inure to the benefit of, and be binding upon, the Parties and their respective successors and permitted assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Neither Party may assign or transfer this Agreement or any of its rights or obligations created hereunder, by operation of law or otherwise, without the prior written consent of the other Party.  Notwithstanding the foregoing, without the other Party&#8217;s consent, either Party shall have the right to assign any of its rights or obligations under this Agreement, or to transfer this Agreement, to&#58;  (a) any of its Affiliates, &#91;***&#93;&#59; or (b) a Third Party in connection with a merger, acquisition of all or substantially all of the business or assets of such Party (whether by sale of stock or assets), consolidation, change of control or other similar transaction&#59; provided that such third party is bound by the terms of this Agreement, by operation of law or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Any assignment not in accordance with this Section 12.5 shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement of the Parties&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement, the Exhibits and Appendices or Schedules hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter.  No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If a dispute arises between the Parties concerning this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute.  Prior to initiation of outside dispute resolution or termination of this Agreement for a material breach, each Party shall escalate such issue to the Chief Executive Officer of Licensee and Dean of Medicine for Penn and such parties will engage in good faith discussions with regard to the applicable dispute within fifteen (15) days.  If the Parties are unable to resolve such dispute amicably through good faith discussion and such escalation within thirty (30) days, then either Party may submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Notices and Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and directed to a Party at its address or, in the case of Penn providing notice to Licensee, email address shown below or such other address or email address as such Party shall have last given by notice to the other Party.  A notice will be deemed received&#58;  if delivered personally, on the date of delivery&#59; if mailed, five (5) days after deposit in the United States mail&#59; if sent via courier, one (1) business day after deposit with the courier service&#59; or, in the case of Penn providing notice to Licensee, if sent via email, upon receipt of confirmation of transmission (i.e., a read receipt e-mail is received by the sender) provided that a confirming copy of such notice is sent by certified mail, postage prepaid, return receipt requested.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">For Penn</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Center for Innovation University of Pennsylvania</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3600 Civic Center Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor Philadelphia, PA 19104</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Managing Director<br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">with a copy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">University of Pennsylvania Office of General Counsel</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2929 Walnut St., Suite 400</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia, PA 19104</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel<br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">For Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amicus Therapeutics, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3675 Market St.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia, PA 19104</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Chief Legal Officer<br>Email&#58; GCOffice&#64;amicusrx.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">with a copy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wilson Sonsini Goodrich &#38; Rosati</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12235 El Camino Real</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego CA 92130</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Miranda Biven</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; mbiven&#64;wsgr.com</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof.  All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under law, but if any provision of this Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.  The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation.&#8221;  All references herein to Articles, Sections, Schedules and Exhibits shall be deemed references to Articles and Sections of, Schedules and Exhibits to, this Agreement unless the context shall otherwise require.  Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect from time to time.  Unless the context otherwise requires, countries shall include territories.  References to any specific Law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement Law thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument.  A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39</font></div></div></div><div id="i9bc7ff1081344f6588412f3f599f4770_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Swartley&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">John Swartley&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AVP and Managing Director, PCI&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMICUS THERAPEUTICS, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Bradley Campbell&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bradley Campbell&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">President &#38; CEO&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Wilson&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Jim Wilson&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Professor&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">List of Exhibits</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit&#160;1.14A &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit&#160;1.14B&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.30</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.37</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.44 </font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.54</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 1.55</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;***&#93;</font></div><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit C </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit D</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit E</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit F</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit Y</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit Z</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>exhibit1026_2022.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i634735c98c0c4e6e9dacde56ed0f89f9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CONFIDENTIAL</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">EXECUTION COPY</font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">MUTUAL TERMINATION AGREEMENT</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;THIS MUTUAL TERMINATION AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Termination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;) is made and entered into as of December 22, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Termination Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221;). Penn and Licensee may be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">.&#8221;  Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Collaboration Agreement (as defined below).</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Parties entered into that certain Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019, as amended through the First Amendment dated December 20, 2019, the Second Amendment dated March 26, 2020, the Third Amendment dated December 3, 2020, the Fourth Amendment dated December 23, 2020, the Fifth Amendment dated April 6, 2021, the Sixth Amendment dated August 1, 2021, and the Seventh Amendment effective as of September 28, 2021 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which, among other things, Penn and Licensee were conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications&#59; </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Parties entered into that certain Process and Development Agreement dated March 26, 2020, as amended through the First Amendment dated September 28, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PD Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PD Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which, among other things, Penn and Licensee were conducting a research program for the development and&#47;or optimization of manufacturing technology for gene therapy products&#59;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Parties hereby agree to terminate the Collaboration Agreement and any further activities pursuant to the PD Agreement, in each case, effective as of the Termination Effective Date&#59; and</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, in conjunction with this Termination Agreement, the Parties are entering into that certain License Agreement, dated as of the date hereof, pursuant to which Licensee will have rights to research, develop and commercialize products for Pompe Disease and Fabry Disease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt"><br>TERMINATION OF THE COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Termination Agreement, the Collaboration Agreement and the PD Agreement are each hereby terminated as of the Termination Effective Date and, as a result of such termination, the Parties hereby acknowledge and agree that, except as expressly provided for under this Termination Agreement, their respective rights and obligations under each of the Collaboration Agreement and the PD Agreement are hereby terminated as of the Termination Effective Date and that both Parties shall have no further liability to each other under the Collaboration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement or the PD Agreement, respectively, nor with respect to the Collaboration Agreement or the PD Agreement, except as set forth in this Termination Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effect of Termination&#59; Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Upon the Termination Effective Date, all rights and obligations of the Parties under the Collaboration Agreement shall terminate, including all of those referenced in Section 12.4 of the Collaboration Agreement, except those described in the following Articles and Sections of the Collaboration Agreement and, to the extent applicable, for the period of time specified in the applicable provision&#58; Sections &#91;***&#93;.  Upon the Termination Effective Date, all rights and obligations of the Parties under the PD Agreement shall terminate, including all of those referenced in Section 10.4 of the PD Agreement, except those rights, licenses and obligations described in the following Articles and Sections of the PD Agreement&#58; Sections &#91;***&#93; and Articles &#91;***&#93;. The Parties acknowledge and agree that no Licensee PD Patent Rights, Licensee PD Know-How, and Joint PD Patent Rights were generated during the term of the PD Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Return of Penn Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee shall deliver to Penn all materials, reports and information listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by &#91;***&#93; or by such later date as may be specified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> with respect to particular items.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt"><br>LICENSES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination of License Grants under Collaboration Agreement and PD Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to any licenses granted by Penn to Licensee pursuant to that certain License Agreement, dated as of the Termination Effective Date, by and between the Parties for the completion of certain activities related to Pompe and Fabry diseases and the grant of rights by Penn to Licensee for continued research, development and commercialization of products for Pompe and Fabry, all licenses granted by Penn to Licensee in connection with the Collaboration Agreement and PD Agreement are hereby terminated effective as of the Termination Effective Date&#59; provided that this Section&#160;2.1 shall not be deemed to modify or limit those rights and obligations of each party under the Collaboration Agreement or the PD Agreement specified to survive termination pursuant to Section&#160;1.2 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Pilot Studies Reports and License Grants to Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The Parties acknowledge and agree that, as of the Termination Effective Date, Penn has completed under the Collaboration Agreement certain Pilot Studies (as defined in the Collaboration Agreement) funded by Licensee and related to Duchenne muscular dystrophy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DMD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Angelman Syndrome (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DMD Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Angelman Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Within &#91;***&#93; after the Termination Effective Date, and solely to the extent not already provided, Penn shall deliver to Licensee a complete and accurate, to the knowledge of Penn, copy of all datasets and reports arising out of, and detailing the results of, each of the DMD Study(ies) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DMD Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the Angelman Study(ies) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Angelman Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as further described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 3.2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Subject to the terms and conditions of this Termination Agreement (including Section 2.2.4 below), Penn hereby grants to Licensee (a) a non-exclusive, transferable (in accordance with Section 6.4), sublicensable (in accordance with this Section&#160;2.2), royalty-free, fully paid-up right and license under the DMD Results (and any intellectual property rights therein or arising therefrom (including Patent Rights)) for internal research purposes and (b) a non-exclusive, transferable (in accordance with Section 6.4), sublicensable (in accordance with this Section&#160;2.2), royalty-free, fully paid-up right and license under the Angelman Results (and any intellectual property rights therein or arising therefrom (including Patent Rights)) for internal research purposes.  Penn acknowledges and agrees that &#8220;internal research purposes&#8221; shall include the right for Licensee to extend the licenses in clauses (a) and&#47;or (b) of this Section&#160;2.2.2 to Licensee&#8217;s Affiliates and also to Third Party service providers who are performing activities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for and on behalf of Licensee and&#47;or its Affiliates for the purposes of such Affiliate or Third Party performing any such activities.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee will have the right to extend any and all of its rights and licenses under Section 2.2.2 above to its Affiliate(s), &#91;***&#93; provided that Licensee shall remain liable for all actions and omissions of its Affiliate and the terms of such extension shall contain a requirement for such Affiliate to comply with the terms contained herein relevant to such license grant.  In addition, Licensee will have the right to grant and authorize sublicenses under Licensee&#8217;s rights and licenses granted pursuant to Section&#160;2.2.2, as follows and &#91;***&#93;, to Third Parties (and their Affiliates) that are (i)&#160;Service Provider Sublicensees (as defined in the Collaboration Agreement) or (ii)&#160;if such Third Parties (and&#47;or their Affiliates) also obtain a license from Licensee or its Affiliate under other intellectual property owned or controlled by Licensee or its Affiliate to research, develop, manufacture and&#47;or commercialize gene therapy products for the treatment and&#47;or prevention of DMD or Angelman Syndrome, as applicable.  Each sublicense to a Third Party shall&#58; (x) be in writing&#59; and (y) be subject and subordinate to, and consistent with, the terms and conditions of this Termination Agreement (and Sections&#160;5.6.2, 5.6.3, 5.6.4, 5.6.5, and 5.6.6 of the Collaboration Agreement, as applicable).  Licensee shall remain responsible to Penn for all activities of its Affiliates and&#47;or any Third Parties (or their respective Affiliates) that obtain rights to the DMD Results and&#47;or the Angelman Results pursuant to this Section 2.2, to the same extent as if such activities had been undertaken by Licensee itself. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">For clarity, Confidential Information (as such term is defined in the Collaboration Agreement) of Penn included in the DMD Results and the Angelman Results shall be subject to the provisions of Publication and Confidentiality set forth in Article&#160;9 of the Collaboration Agreement&#59; it being understood that references in Article&#160;9 to the Collaboration Agreement shall be deemed to be references to this Agreement and accordingly, Licensee shall have the right to use and disclose the DMD results and Angelman Results for the purposes of exercising its rights and licenses with respect to the same under this Agreement, subject to Section 6.1 below (i.e., subject to the confidentiality and publication obligations set forth in Article 9 of the Collaboration Agreement incorporated herein by reference under Section 6.1).  Licensee shall not, and shall require that all sublicensees pursuant to Section&#160;2.2.3 above shall not, include any DMD Results or Angelman Results in any patent application or publication without Penn&#8217;s review and approval (such approval not to be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Intentionally Omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:14pt">Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:2pt;padding-left:153pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.75pt">Licensee shall defend, indemnify and hold Penn and its respective trustees, officers, faculty, students, employees, contractors and agents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Penn Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys&#8217; fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the extent arising out of Third Party claims or suits arising from (a) the gross negligence, recklessness or wrongful intentional acts or omissions of Licensee, its Affiliates or Sublicensees and its or their respective directors, officers, employees and agents, in the performance of the Licensee&#8217;s obligations or exercise of Licensee&#8217;s rights under this Agreement&#59; (b) the material breach of this Agreement by Licensee&#59; and (c) the development, manufacture and&#47;or commercialization by, or under the authority of, Licensee of any gene therapy products that are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:2pt;padding-left:153pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">intended for use in Angelman Syndrome or DMD and use the DMD Results and&#47;or Angelman Results licensed to Licensee hereunder&#59; provided that &#91;***&#93;. </font></div><div><font><br></font></div><div style="margin-top:2pt;padding-left:153pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.75pt">As a condition to a Penn Indemnitee&#8217;s right to receive indemnification under this Section 2.2.6.1, Penn shall&#58; (a) promptly notify Licensee as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto&#59; (b) fully cooperate, and cause the individual Penn Indemnitees to fully cooperate, with Licensee in the defense, settlement or compromise of such claim or suit&#59; and (c) permit the Licensee to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel. In no event, however, may Licensee compromise or settle any claim or suit in a manner which (i) admits fault or negligence on the part of Penn or any other Penn Indemnitee&#59; (ii) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action, without the prior written consent of Penn, or (iii) grant any rights under the Research Results except for Sublicenses permitted hereunder. Penn shall fully cooperate, and cause the individual Penn Indemnitees to fully cooperate, with Licensee and its counsel in the course of the defense or settlement of any such suit, claim or demand, such cooperation to include without limitation providing or making available documents, information and witnesses.</font></div><div style="margin-top:2pt;padding-left:153pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:2pt;padding-left:153pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.75pt">Notwithstanding the above, a Penn Indemnitee shall be entitled to participate in, but not control, the defense of a Third Party claim or suit subject to indemnification under this Section 2.2.6 and to engage counsel of its own choice for such purpose&#59; provided that such engagement shall be at such Penn Indemnitee&#8217;s own expense unless a bona fide conflict exists between Licensee and Penn or any other Penn Indemnitee with respect to a claim or suit subject to indemnification hereunder, such that representation by Licensee and Penn or such other Penn Indemnitee by the same legal counsel due to a misalignment of interests or would be prohibited under applicable law, ethical rules or equitable principles, in which case, Licensee will either pay any reasonable, documented out-of-pocket attorney&#8217;s fees and litigation expenses of such Penn Indemnitee directly or reimburse Penn within &#91;***&#93; of Licensee&#8217;s receipt of invoices for such fees and expenses. </font></div><div><font><br></font></div><div style="margin-top:2pt;padding-left:153pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.75pt">In no event shall Licensee be liable under this Section 2.2.6 for any settlement, compromise or other disposition of a Third Party claim or suit for which a Penn Indemnitee seeks indemnification hereunder and that is reached without the prior written consent of Licensee, such consent not to be unreasonably withheld, conditioned or delayed.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Option Grants to Penn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.   </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt;text-decoration:underline">CDKL5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that Licensee does not enter into an agreement granting a license, assignment or other rights to CDKL5 Technology &#91;***&#93; within &#91;***&#93; of the Termination Effective Date, Licensee shall provide written notice to Penn (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CDKL5 Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Penn shall have the right to obtain a license, assignment or other rights to such CDKL5 Technology on terms and conditions to be agreed upon&#59; provided that &#91;***&#93;.  Penn may exercise such option by providing written notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CDKL5 Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to Licensee within &#91;***&#93; of receipt of the CDKL5 Notice from Licensee.  If applicable, the Parties would negotiate in good faith for a period of &#91;***&#93; from Licensee&#8217;s receipt of Penn&#8217;s CDKL5 Exercise Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CDKL5 Negotiation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In the event the Parties do not enter </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">into an agreement with respect to the CDKL5 Technology prior to the expiration of the CDKL5 Negotiation Period, Licensee shall &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt;text-decoration:underline">MPS IIIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee hereby grants to Penn, subject to the terms and conditions of this Agreement (including without limitation Section&#160;2.4.5 below), an option to acquire &#91;***&#93; right and license, with the right to grant sublicenses (on equivalent terms to Licensee&#8217;s rights to sublicense under the License Agreement), under the MPS IIIA Technology to research, have researched, develop, have developed, make, have made, use, sell, offer for sale, import and export an Amicus MPS IIIA Candidate or another gene therapy product that contains the same transgene as the Amicus MPS IIIA Candidate for treatment and&#47;or prevention of MPS IIIA (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPS IIIA Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Penn may exercise such option by providing written notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPS IIIA Exercise Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to Licensee no later than the &#91;***&#93;.  Upon Penn&#8217;s exercise of the option in accordance with this Section&#160;2.3.2, the Parties would negotiate &#91;***&#93; in good faith for a period of &#91;***&#93;.  If Penn does not issue an MPS IIIA Exercise Notice in accordance with this Section 2.3.2 prior to the expiration of the &#91;***&#93; or, if Penn issues an MPS IIIA Exercise Notice in accordance with this Section 2.3.2 and the Parties do not enter into an MPS IIIA License with respect to the MPS IIIA Technology prior to the expiration of the &#91;***&#93;, then Licensee and its Affiliates shall have no further obligations to Penn, and Penn shall have no further rights with respect to, any MPS IIIA Technology.  For clarity, (a) certain intellectual property pertaining to the Amicus MPS IIIA Candidate is jointly owned by the Parties and nothing contained in this Section 2.3.2 shall waive, alter, amend or revise any Penn ownership rights in such intellectual property pertaining to the Amicus MPSIIIA Candidate, and (b) such MPS IIIA License shall not be effective until execution of an MPS IIIA Penn Sublicense contemporaneously with, or promptly after, execution of an MPS IIIA License (as such timing may be set forth in the MPS IIIA License).  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt;text-decoration:underline">Definitions</font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amicus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPS IIIA Candidate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Licensee&#8217;s gene therapy product as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.3.3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means with respect to an entity, any corporation or other business entity that controls, is controlled by or is under common control with such entity, but only for so long as such control exists.  For the purposes of this Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under the common control with&#8221;) means the affirmative power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.  </font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">CDKL5 Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;. The &#91;***&#93; included in the CDKL5 Technology are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;2.3.3(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to intellectual property rights, that Licensee or one of its Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide to, grant a license or sublicense to, or assign its right, title and interest in and to, such intellectual property rights as provided for in this Termination Agreement without violating the terms of any other agreement or other arrangement with any third party.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means intellectual property, data, results, pre-clinical and clinical protocols and study data, chemical structures, chemical sequences, information, inventions, formulas, techniques, methods, processes, procedures and developments. &#8220;Know-How&#8221; does not include any of the foregoing claimed in a Patent Right Controlled by Licensee.</font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPS IIIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Mucopolysaccharidosis Type IIIA.</font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPS IIIA Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;, as identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 2.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For clarity, MPS IIIA Technology includes &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:5.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MPS IIIA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Upstream Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:149.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.63pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) patents and patent applications, together with any unlisted patents and patent applications claiming priority thereto, and any continuations, continuations-in-part (to the extent related directly to the subject matter of the parent application), reissues, reexamination certificates, substitutions, divisionals, supplementary protection certificates, renewals, registrations, extensions including all confirmations, revalidations, patents of addition, PCTs, and pediatric exclusivity periods and all foreign counterparts thereof, and any patents issued or issuing with respect to any of the foregoing and (ii) all official correspondence relating to the foregoing. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee represents and warrants to Penn that, as of the Termination Effective Date, Licensee has the right, power and authority to grant to Penn the rights granted to Penn pursuant to Section 2.3 with respect to the MPS IIIA Upstream Agreement.  In particular, as of the Termination Effective Date, the grant of such rights requires no consent, waiver or other action by any party (other than Licensee) to the MPS IIIA Upstream Agreement and the rights and obligations of Penn set forth in Sections&#160;2.3.1 and 2.3.2 of this Termination Agreement do not contravene nor are they inconsistent with or conflict with the terms of the MPS IIIA Upstream Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Licensee represents and warrants to Penn that, as of the Termination Effective Date&#58; (a) the MPSIIIA Upstream Agreement constitutes all agreements between Licensee and a Third Party pursuant to which Licensee has licensed, or otherwise obtained rights with respect to, the Amicus MPS IIIA Candidate (b) Licensee has provided to Penn a redacted copy of the MPS IIIA Upstream Agreement, as amended as of the date hereof, containing those provisions of the MPS IIIA Upstream Agreement relevant to Penn&#8217;s rights and obligations under Section&#160;2.3 above, (c)&#160;the MPS IIIA Upstream Agreement is in full force and effect&#59; (d) Licensee is not in breach or default in the performance of its obligations under the MPS IIIA Upstream Agreement&#59; (e) Licensee has not received any notice from any third party of any breach, default or non-compliance of Licensee under the terms of the MPS IIIA Upstream Agreement relating to the MPS IIIA Technology&#59; and (f)&#160;there have been no amendments or other modification to the MPS IIIA Upstream Agreement relating to the MPS IIIA Technology, except as have been disclosed to Penn in writing.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">As of the Termination Effective Date, Licensee represents and warrants to Penn that (a) Licensee does not Control any Know-How or Patent Rights covering the Amicus MPS IIIA Candidate other than Patent Rights included in the MPS IIIA Technology and (b) Licensee is not actually aware of any intellectual property </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that is Controlled by Amicus and pertains to the Amicus MPS IIIA Candidate other than the MPS IIIA Technotelogy and any Joint Patent Rights. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">To the extent that Penn becomes aware of and&#47;or Licensee identifies, in either case, after the Termination Effective Date, any information or materials &#91;***&#93;, Penn will use &#91;***&#93;efforts to provide such information or materials to Licensee promptly following a written request by Licensee to do so.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">It is understood that the &#91;***&#93; may require that particular provisions be incorporated into an agreement pursuant to which &#91;***&#93;. The requirements of any such provisions in the &#91;***&#93; are set out on &#91;***&#93; attached hereto. In the event Licensee and Penn agree to the terms of a license as described in Section 2.3.2, Penn &#91;***&#93;. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Prior to the expiration of Penn&#8217;s option to the MPS IIIA Technology pursuant to Section&#160;2.3.2 above, Licensee shall not amend or waive, or take any action or omit to taking any action that would alter, in any material respect any of Licensee&#8217;s rights under the MPS IIIA Upstream Agreement in any manner that materially adversely affects, or would reasonably be expected to materially adversely affect, Penn&#8217;s rights and benefits under Section 2.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Mouse License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Commencing on the Termination Effective Date and continuing until the &#91;***&#93; anniversary thereof, Licensee hereby authorizes Penn and any Third Party acting for, or on behalf of, Penn to use for research purposes &#91;***&#93;. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt"><br>FINANCIALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Discovery Support Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In partial consideration for Penn agreeing to enter into this Termination Agreement and in satisfaction in full of Licensee&#8217;s obligation pursuant to Section 12.4.4(c) of the Collaboration Agreement, Licensee hereby agrees to, and shall, pay to Penn a certain unpaid portion of the Discovery Support Amount (as defined in the Collaboration Agreement) in the total amount of &#91;***&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Remaining Discovery Support Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which amount shall be payable by Licensee to Penn on or prior to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Research Program Wind-Down Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In partial consideration for Penn agreeing to enter into this Termination Agreement and in satisfaction in full of Licensee&#8217;s obligations pursuant to Section 12.4.4(a)-(b) of the Collaboration Agreement related to the Research Support Amount and wind-down costs related thereto, Licensee hereby agrees to, and shall, make a payment to Penn in the amount of &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research Program Wind-Down Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) in accordance with the following payment schedule&#58; &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Payment Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sections 6.6, 6.8, 6.9 and 6.13 of the Collaboration Agreement shall govern the payments to be made by Licensee to Penn pursuant to Sections 3.1, 3.2 and 3.4 of this Termination Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Outstanding Patent Costs and Alliance Management Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee shall&#58;  (a) within &#91;***&#93; after receipt of applicable invoice(s), pay Penn all unreimbursed Patent Costs incurred from November 1, 2022 through the Termination Effective Date&#59; (b) by &#91;***&#93;, pay all Patents Costs under &#91;***&#93;&#59; (c) by &#91;***&#93;, pay Penn the &#91;***&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">No Other Amounts Payable by Penn or Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Licensee hereby acknowledges and agrees that no amounts are due or payable by Penn to Licensee in connection with the Collaboration Agreement or the PD Agreement, including, without limitation, &#91;***&#93;.  Further, &#91;***&#93; except for those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">amounts specified in Sections&#160;3.1, 3.2 and 3.4 above and excluding any costs associated with any patent rights due under the License Agreement with respect to Penn Patent Rights pertaining to Fabry Disease or Pompe Disease, no amounts are due or payable by Licensee to Penn in connection with the Collaboration Agreement or the PD Agreement as of the Termination Effective Date.  Penn and Licensee mutually agree that this Section 3.5 does not include reference to any payments that come due under the License Agreement.    </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt"><br>GENERAL REPRESENTATIONS AND WARRANTIES&#59; DISCLAIMERS&#59; LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">Each Party represents and warrants to the other Party that, as of the Termination Effective Date&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party is duly organized and validly existing under the laws of the jurisdiction of its incorporation or organization&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party has taken all action necessary to authorize the execution and delivery of this Termination Agreement and the performance of its obligations under this Termination Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">this Termination Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Termination Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">such Party has all right, power and authority to enter into this Termination Agreement, to perform its obligations under this Termination Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 2.4 AND THIS ARTICLE 4, (A) NEITHER PARTY HERETO NOR ANY PERSON ON SUCH PARTY&#8217;S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WHATSOEVER, EITHER ORAL OR WRITTEN, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND (B) EACH PARTY HERETO ACKNOWLEDGES THAT, IN ENTERING INTO THIS TERMINATION AGREEMENT, IT HAS NOT RELIED UPON ANY REPRESENTATION OR WARRANTY MADE BY THE OTHER PARTY, OR ANY OTHER PERSON ON SUCH OTHER PARTY&#8217;S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN SECTION&#160;2.4 AND THIS ARTICLE 4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21pt">LIMITATION OF LIABILITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS OR OPPORTUNITY, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS TERMINATION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF&#59; PROVIDED THAT NOTHING IN THIS SECTION 4.3 SHALL BE DEEMED TO LIMIT (A) THE INDEMNIFICATION OBLIGATIONS UNDER SECTION 11.1 OF LICENSEE UNDER THE LICENSE AGREEMENT&#59; OR (B) THE INDEMNIFICATION OR OTHER OBLIGATIONS OF PENN (IF ANY) OR ANY (SUB)LICENSEE OF PENN IF PENN AND A (SUB)LICENSEE EXECUTE AN AGREEMENT(S) PURSUANT TO WHICH PENN OBTAINS RIGHTS TO THE CDKL5 TECHNOLOGY AND&#47;OR THE MPS IIIA TECHNOLOGY.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt"><br>TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term of this Termination Agreement shall commence on the Termination Effective Date and, unless terminated sooner as provided below, shall continue unless terminated in accordance with Section&#160;5.2 below.  Notwithstanding the foregoing, Penn&#8217;s option and rights to any CDKL5 Technology or MPS IIIA Technology shall expire within the time periods specified in Section&#160;2.3.1 or 2.3.2, as applicable, if &#91;***&#93;&#59; provided that the restrictions on Licensee shall survive for those periods set forth in Sections 2.3.1 in the event that Penn terminates this Agreement pursuant to Section 5.2 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If either Party materially breaches any of its material obligations under this Termination Agreement, the non-breaching Party may give the breaching Party a written notice specifying the nature of the default, requiring it to cure such breach, and stating its intention to terminate this Termination Agreement.  If such breach is not cured within &#91;***&#93; following such a notice for non-payment and &#91;***&#93; following such a notice for all other material breaches, such termination shall become effective upon a notice of termination by the other Party thereafter&#59; provided that if there is a good faith dispute as to the existence of such material breach, such &#91;***&#93; or &#91;***&#93; period, as applicable, may be extended by mutual agreement of the Parties to allow the Parties additional time to continue good faith discussions to resolve the dispute.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Notwithstanding the termination or expiration of this Termination Agreement, the following provisions shall survive (to the extent applicable, for the period of time specified)&#58; &#91;***&#93;.  Without limiting the foregoing, termination of the Termination Agreement by a Party shall not affect the rights and licenses granted to such Party by the other Party under this Termination Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Termination of this Termination Agreement shall not relieve the Parties of any obligation or liability that, at the time of termination, has already accrued hereunder, or which is attributable to a period prior to the effective date of such termination. Termination of this Termination Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Termination Agreement nor prejudice either Party&#8217;s right to obtain performance of any obligation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:13.66pt"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Article 9 of the Collaboration Agreement is hereby incorporated herein by reference (and references to &#8220;this Agreement&#8221; in Article 9 of the Collaboration Agreement and the Confidential Information definition in Section 1.14 of the Collaboration Agreement will be deemed to include this Termination Agreement and the License Agreement, as if this Termination Agreement and the License Agreement were expressly referenced therein) and shall govern the existence and terms of this Termination Agreement, each of which is hereby deemed Confidential Information thereunder and hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Nothing in this Termination Agreement is intended or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture, fiduciary or employer-employee relationship between the Parties. The Parties are independent contractors and at no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Except as otherwise provided in this Termination Agreement, each Party shall pay its own expenses and costs incidental to the preparation of this Termination Agreement and to the consummation of the transactions contemplated hereby.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Successors and Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The terms and provisions hereof shall inure to the benefit of, and be binding upon, the Parties and their respective successors and permitted assigns.  Neither Party may assign or transfer this Termination Agreement or any of its rights or obligations created hereunder, by operation of law or otherwise, without the prior written consent of the other Party. Notwithstanding the foregoing, without Penn&#8217;s consent, Licensee shall have the right to assign any of its rights or obligations under this Termination Agreement, or to transfer this Termination Agreement, to&#58; (a) any of its Affiliates, &#91;***&#93;&#59; or (b) a third party in connection with a merger, acquisition of all or substantially all of the business or assets of Licensee (whether by sale of stock or assets), consolidation, change of control or other similar transaction&#59; provided that, in each case (b), such third party is bound by the terms of this Termination Agreement, by operation of law or otherwise.  Any assignment not in accordance with this Section 6.4 shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Further Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Termination Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Entire Agreement of the Parties&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Termination Agreement, together with the Collaboration Agreement but only to the extent so incorporated or referenced herein and the License Agreement, contains the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter, including the Collaboration Agreement (except as expressly set forth herein). No waiver, modification or amendment of any provision of this Termination Agreement shall be valid or effective unless made in a writing referencing this Termination Agreement and signed by a duly authorized officer of each Party.  In the event of any conflict between the terms of this Termination Agreement and the terms of the License Agreement, then this Agreement shall control with respect to subject matter expressly addressed herein, except that the terms of the License Agreement shall control solely to the extent pertaining to Licensee&#8217;s and Penn&#8217;s rights, licenses and obligations with respect to patent rights and other intellectual property controlled by Penn and licensed to Licensee pursuant to the License Agreement for Fabry Disease and&#47;or Pompe Disease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Termination Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If a dispute arises between the Parties concerning this Termination Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. Prior to initiation of outside dispute resolution or termination of this Termination Agreement for a material breach, each Party shall escalate such issue to &#91;***&#93; and such parties will engage in good faith discussions with regard to the applicable dispute within &#91;***&#93;. If the Parties are unable to resolve such dispute amicably through good faith discussion and such escalation within &#91;***&#93;, then either Party may submit to the exclusive jurisdiction of, and venue in, the state and federal courts located in the Eastern District of Pennsylvania.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt">Notice and Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Any notice, request, approval or consent required or permitted to be given under this Termination Agreement shall be in writing and directed to a Party at its address or email address shown below or, in the case of Penn providing notice, such other address or email address as such Party shall have last given by notice to the other Party.  A notice will be deemed received&#58;  if delivered personally, on the date of delivery&#59; if mailed, &#91;***&#93; after deposit in the United States mail&#59; if sent via courier, &#91;***&#93; after deposit with the courier service&#59; or, in the case of Penn providing notice, if sent via email, upon receipt of confirmation of transmission (i.e., a read receipt e-mail is received by the sender) provided that a confirming copy of such notice is sent by certified mail, postage prepaid, return receipt requested.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">For Penn</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Penn Center for Innovation University of Pennsylvania</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3600 Civic Center Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor Philadelphia, PA 19104</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Managing Director</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">with a copy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">University of Pennsylvania Office of General Counsel</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2929 Walnut St., Suite 400</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia, PA 19104</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">For Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Amicus Therapeutics, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3675 Market Street</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philadelphia PA 19104</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Chief Legal Officer</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GCOffice&#64;amicusrx.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">with a copy to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Wilson Sonsini Goodrich &#38; Rosati</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12235 El Camino Real</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego CA 92130</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  Miranda Biven</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58; mbiven&#64;wsgr.com</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. A waiver by either Party of any of the terms and conditions of this Termination Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Termination Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. When possible, each provision of this Termination Agreement will be interpreted in such manner as to be effective and valid under law, but if any provision of this Termination Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Termination Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:16.75pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. This Termination Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Termination Agreement, including the signature pages, will be deemed an original.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><div id="i634735c98c0c4e6e9dacde56ed0f89f9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3.7pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have caused this Termination Agreement to be executed by their duly authorized representatives as of the Termination Effective Date.</font></div><div style="margin-top:3.7pt;padding-right:59.65pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:24.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:23.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AMICUS THERAPEUTICS, INC.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:-7.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; John Swartley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">___________________</font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:-2.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">John Swartley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">___________________</font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AVP and Managing Director, PCI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:-7.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Bradley Campbell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________</font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:-2.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bradley Campbell</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_______________</font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">President &#38; CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_________________</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:62.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Read and Acknowledged&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:62.4pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:-7.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Wilson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">_____________________</font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:-2.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Jim Wilson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">______________________</font></div><div style="margin-top:3.7pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Professor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">________________________</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3.7pt;padding-right:59.65pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Mutual Termination Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div></div></div><div id="i634735c98c0c4e6e9dacde56ed0f89f9_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 1.3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 2.3.3(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 2.3.3(c)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 2.3.3(g)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i634735c98c0c4e6e9dacde56ed0f89f9_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 2.4.5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div></div><div id="i634735c98c0c4e6e9dacde56ed0f89f9_13"></div><hr style="page-break-after:always"><div style="min-height:121.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule&#160;3.2(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:121.68pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule 3.2(b)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:87.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>6
<FILENAME>exhibit21_2022.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i72dcfafbe123487c816ee655bceffcd0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21</font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiaries of the Registrant&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Callidus Biopharma,&#160;Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Celenex, Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Scioderm,&#160;Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">MiaMed,&#160;Inc. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics International Holding Limited (UK)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics UK Limited (UK)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics UK Operations Limited (UK)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics SAS (France)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amicus Therapeutics&#160;B.V. (Netherlands)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics&#160;GmbH (Germany)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics S.L.U. (Spain)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics&#160;S.r.l. (Italy)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics K.K. (Japan)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics Canada&#160;Inc. (Canada)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics PTY&#160;LTD (Australia)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics US, LLC. (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Biologics, Inc. (Florida)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics ApS (Denmark)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics Europe Limited (Ireland)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics Switzerland GmbH (Switzerland)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus GT Holdings, LLC (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Caritas Therapeutics, LLC (Delaware)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Amicus Therapeutics France Services SAS (France)</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>exhibit231_2022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idadbdd4300024fdb8b6b15ceca4b03c5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 23.1&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-265531) pertaining to the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-262987) pertaining to the Amicus Therapeutics, Inc., Automatic shelf registration statement of securities of well-known seasoned issuers,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-260924) pertaining to the issuance of common stock and warrants in 2021,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-257289) pertaining to the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-252646) pertaining to the issuance of warrants in 2016,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-243779) pertaining to the&#58; 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-233153) pertaining to the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-212414), pertaining to the acquisition of MiaMed, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Registration Statement (Form S-3ASR No. 333-207210), pertaining to the acquisition of Scioderm, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-197202) pertaining to the Amicus Therapeutics, Inc. Cash Deferral Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-195194) pertaining to the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-192876), pertaining to the issuance of warrants,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-192747), pertaining to the acquisition of Callidus Biopharma, Inc.,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-174900) pertaining to the&#58; 1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. Amended and Restated 2007 Director Option Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-157219) pertaining to the&#58;  1) Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2) Amicus Therapeutics, Inc. 2007 Director Option Plan, and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">Registration Statement (Form S-8 No. 333-145305) pertaining to the&#58; 1) Amicus Therapeutics, Inc. 2002 Equity Incentive Plan, as Amended, 2) Amicus Therapeutics, Inc. 2007 Equity Incentive Plan, 3) Amicus Therapeutics, Inc. 2007 Director Option Plan, 4) Amicus Therapeutics, Inc. 2007 Employee Stock Purchase Plan</font></div><div style="text-indent:-18pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated March&#160;1, 2023 with respect to the consolidated financial statements of Amicus Therapeutics,&#160;Inc., and the effectiveness of internal control over financial reporting of Amicus Therapeutics,&#160;Inc. included in this Annual Report (Form&#160;10-K) of Amicus Therapeutics,&#160;Inc. for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst&#160;&#38; Young&#160;LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;1, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>exhibit311_2022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8b99d43dd23f42feadfec0a28a651008_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Bradley L. Campbell, certify that&#58;</font></div><div style="margin-bottom:12pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form&#160;10-K of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2023 </font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>exhibit312_2022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie4faea2d81364aa6b99292c3f4f9fbc1_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daphne Quimi, certify that&#58;</font></div><div style="margin-bottom:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this annual report on Form&#160;10-K of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;1, 2023</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>exhibit321_2022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2ff6f7e0898046bcb9d9bc24be5ee00f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Principal Executive Officer Pursuant to 18 U. S. C. Section&#160;1350, as</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U. S. C. Section&#160;1350, I, Bradley L. Campbell, hereby certify that, to the best of my knowledge, Amicus Therapeutics&#160;Inc., (the &#34;Company&#34;) Annual Report on Form&#160;10-K for the year ended December 31, 2022 (the &#34;Report&#34;), as filed with the Securities and Exchange Commission on March&#160;1, 2023, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Bradley L. Campbell</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bradley L. Campbell<br>President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>exhibit322_2022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i74b2c4c0581d4114937391362c9cd57d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification by the Principal Financial Officer Pursuant to 18 U. S. C. Section&#160;1350, as</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U. S. C. Section&#160;1350, I, Daphne Quimi, hereby certify that, to the best of my knowledge, the Amicus Therapeutics&#160;Inc. (the &#34;Company&#34;) Annual Report on Form&#160;10-K for the year ended December 31, 2022 (the &#34;Report&#34;), as filed with the Securities and Exchange Commission on March&#160;1, 2023, fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.432%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi<br>Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>fold-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:981bea1b-b87d-4677-ae2e-8728c40b94b3,g:80eaf27f-6f35-4ae6-9648-0cd9017af6e5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fold="http://www.amicustherapeutics.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amicustherapeutics.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amicustherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.amicustherapeutics.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness">
        <link:definition>0000009 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000011 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCash" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash">
        <link:definition>0000012 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amicustherapeutics.com/role/Inventories">
        <link:definition>0000013 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipment">
        <link:definition>0000014 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000015 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensation" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensation">
        <link:definition>0000017 - Disclosure - Share based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValue" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue">
        <link:definition>0000018 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.amicustherapeutics.com/role/Debt">
        <link:definition>0000019 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.amicustherapeutics.com/role/Leases">
        <link:definition>0000020 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements">
        <link:definition>0000022 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.amicustherapeutics.com/role/LegalProceedings">
        <link:definition>0000023 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShare" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare">
        <link:definition>0000024 - Disclosure - Basic and Diluted Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000027 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables">
        <link:definition>0000028 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amicustherapeutics.com/role/InventoriesTables">
        <link:definition>0000029 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentTables">
        <link:definition>0000030 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationTables" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationTables">
        <link:definition>0000032 - Disclosure - Share based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueTables" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables">
        <link:definition>0000033 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.amicustherapeutics.com/role/DebtTables">
        <link:definition>0000034 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.amicustherapeutics.com/role/LeasesTables">
        <link:definition>0000035 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables">
        <link:definition>0000036 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareTables" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables">
        <link:definition>0000037 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails">
        <link:definition>0000038 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails">
        <link:definition>0000039 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk and Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails">
        <link:definition>0000043 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>0000044 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsChangesinIPRDDetails" roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails">
        <link:definition>0000045 - Disclosure - Goodwill and Intangible Assets - Changes in IPR&amp;D (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails">
        <link:definition>0000046 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails">
        <link:definition>0000047 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1">
        <link:definition>0000047 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000048 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails">
        <link:definition>0000049 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails">
        <link:definition>0000050 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000051 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockandWarrantsDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails">
        <link:definition>0000052 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails">
        <link:definition>0000053 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails">
        <link:definition>0000054 - Disclosure - Share based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails">
        <link:definition>0000055 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationStockOptionActivityDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails">
        <link:definition>0000056 - Disclosure - Share based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationRSUsandPBRSUsSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails">
        <link:definition>0000057 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedCompensationExpenseSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails">
        <link:definition>0000058 - Disclosure - Share based Compensation - Expense Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails">
        <link:definition>0000059 - Disclosure - Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails">
        <link:definition>0000060 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails">
        <link:definition>0000061 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofLongTermDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails">
        <link:definition>0000062 - Disclosure - Debt - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails">
        <link:definition>0000063 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails">
        <link:definition>0000064 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/LeasesNarrativeDetails">
        <link:definition>0000065 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails">
        <link:definition>0000066 - Disclosure - Leases - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumOperatingLeasePaymentsDetails" roleURI="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails">
        <link:definition>0000067 - Disclosure - Leases - Future Minimum Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumOperatingLeasePaymentsDetails_1" roleURI="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1">
        <link:definition>0000067 - Disclosure - Leases - Future Minimum Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesStatutoryRateDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredandValuationDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Deferred and Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossCarryforwardsDetails" roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails">
        <link:definition>0000070 - Disclosure - Income Taxes - Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails">
        <link:definition>0000071 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.amicustherapeutics.com/role/LegalProceedingsDetails">
        <link:definition>0000072 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareDetails" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails">
        <link:definition>0000073 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="fold_AtTheMarketEquityProgramMember" abstract="true" name="AtTheMarketEquityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_GlaxoSmithKlinePLCMember" abstract="true" name="GlaxoSmithKlinePLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" abstract="false" name="NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_TB200PompeProgramMember" abstract="true" name="TB200PompeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="fold_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_OtherComprehensiveIncomePolicyPolicyTextBlock" abstract="false" name="OtherComprehensiveIncomePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_AmortizationDeferredFinancingCosts" abstract="false" name="AmortizationDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AssetImpairmentChargesAndOtherAssetWriteOffs" abstract="false" name="AssetImpairmentChargesAndOtherAssetWriteOffs" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationMeasurementInput" abstract="false" name="ContingentConsiderationMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" abstract="true" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_AccruedProgramFees" abstract="false" name="AccruedProgramFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_MeasurementInputProbabilityOfMilestoneAchievementMember" abstract="true" name="MeasurementInputProbabilityOfMilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_AccruedContractManufacturingAndContractResearchCostsCurrent" abstract="false" name="AccruedContractManufacturingAndContractResearchCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxLiabilitiesRoyaltyPayable" abstract="false" name="DeferredTaxLiabilitiesRoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ForeignCurrencyRemeasurementGainLossBeforeTax" abstract="false" name="ForeignCurrencyRemeasurementGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_GalafoldMember" abstract="true" name="GalafoldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DeferredTaxLiabilitiesBusinessAcquisition" abstract="false" name="DeferredTaxLiabilitiesBusinessAcquisition" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AccruedSalesRebatesAndChargebacksCurrent" abstract="false" name="AccruedSalesRebatesAndChargebacksCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_LossContingencyNumberOfLawsuits" abstract="false" name="LossContingencyNumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" abstract="false" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_DebtInstrumentVariableRate" abstract="false" name="DebtInstrumentVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_DebtInstrumentPeriodicPaymentNumberOfPayments" abstract="false" name="DebtInstrumentPeriodicPaymentNumberOfPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_TerminationAgreementMember" abstract="true" name="TerminationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentLiquidityCovenantMinimumAmount" abstract="false" name="DebtInstrumentLiquidityCovenantMinimumAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ConvertibleSeniorNotes2016Due2023Member" abstract="true" name="ConvertibleSeniorNotes2016Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_InterestIncomeAndInterestExpensePolicyTextBlock" abstract="false" name="InterestIncomeAndInterestExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_StockExercisesAt706Member" abstract="true" name="StockExercisesAt706Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" abstract="false" name="CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationNumberOfPlans" abstract="false" name="ShareBasedCompensationNumberOfPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_ProbabilityWeightedDiscountedCashFlowMember" abstract="true" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentConsolidatedRevenueCovenantAmount" abstract="false" name="DebtInstrumentConsolidatedRevenueCovenantAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_EarlySettlementPremiums" abstract="false" name="EarlySettlementPremiums" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CollaborativeArrangementDisclosureAbstract" abstract="true" name="CollaborativeArrangementDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" abstract="false" name="ProceedsFromIssuanceOfWarrantsAndEquityFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" abstract="false" name="DeferredTaxAssetsNonCashStockIssueNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_DeferredTaxAssetsIntellectualProperty" abstract="false" name="DeferredTaxAssetsIntellectualProperty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_LesseeOperatingLeaseLiabilityTenantIncentives" abstract="false" name="LesseeOperatingLeaseLiabilityTenantIncentives" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DeferredTaxAssetsInterestCarryforwardLimitation" abstract="false" name="DeferredTaxAssetsInterestCarryforwardLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fold_RevisedCollaborationAgreementMember" abstract="true" name="RevisedCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CallidusBiopharmaIncMember" abstract="true" name="CallidusBiopharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" abstract="false" name="CollaborativeAgreementConditionalAggregatePaymentsPerIndication" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" abstract="false" name="ContingentAcquisitionConsiderationPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fold_OrphanDrugTaxCreditCarryforwardMember" abstract="true" name="OrphanDrugTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_SeniorSecuredTermLoanDue2026Member" abstract="true" name="SeniorSecuredTermLoanDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_PaymentsForCollaborativeArrangement" abstract="false" name="PaymentsForCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockExercisesAt798Member" abstract="true" name="StockExercisesAt798Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" abstract="false" name="NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CommonStockVotingRightsForEachShareHeld" abstract="false" name="CommonStockVotingRightsForEachShareHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fold_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>fold-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:981bea1b-b87d-4677-ae2e-8728c40b94b3,g:80eaf27f-6f35-4ae6-9648-0cd9017af6e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5713576b-5d21-4b40-a892-051a661dcd18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:to="loc_us-gaap_CommonStockValue_5713576b-5d21-4b40-a892-051a661dcd18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54ed7502-9d91-4986-9c32-bdbb568d36b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_54ed7502-9d91-4986-9c32-bdbb568d36b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_6d057790-6600-4f91-bda2-3f9e12489cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_6d057790-6600-4f91-bda2-3f9e12489cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aa2b9b8a-e598-4b36-a0b4-39003c7dd452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aa2b9b8a-e598-4b36-a0b4-39003c7dd452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_6c5cd551-9722-4ee2-b161-19c65ca4e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_6c5cd551-9722-4ee2-b161-19c65ca4e1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2837263-5b25-4ccc-99a2-10f1f5d02436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_04a892d8-2301-4c53-944b-2bc034aa6c75" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2837263-5b25-4ccc-99a2-10f1f5d02436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0d7599b1-68aa-415f-a4e4-79599932d658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_29f2c4d4-415b-404d-9354-241bbb53d042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d7599b1-68aa-415f-a4e4-79599932d658" xlink:to="loc_us-gaap_AccountsPayableCurrent_29f2c4d4-415b-404d-9354-241bbb53d042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_da08eaea-34c8-4ae7-b341-83031865919c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d7599b1-68aa-415f-a4e4-79599932d658" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_da08eaea-34c8-4ae7-b341-83031865919c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_697e4fb1-4e88-4d55-98bf-0461da9d9b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d7599b1-68aa-415f-a4e4-79599932d658" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_697e4fb1-4e88-4d55-98bf-0461da9d9b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e7cdd96f-499c-46fd-b108-2566a1fd23a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_0d7599b1-68aa-415f-a4e4-79599932d658" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e7cdd96f-499c-46fd-b108-2566a1fd23a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_db2c139e-05ac-4b1a-bf0c-04ee2c154330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:to="loc_us-gaap_LiabilitiesCurrent_db2c139e-05ac-4b1a-bf0c-04ee2c154330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_beac41a5-bf24-43e0-a5d7-8315990829af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:to="loc_us-gaap_LongTermDebt_beac41a5-bf24-43e0-a5d7-8315990829af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_902f3810-0a54-4e85-adb8-b5fb723c3993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_902f3810-0a54-4e85-adb8-b5fb723c3993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_45253bfb-6458-4b7e-99ad-3fe65eda1dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_45253bfb-6458-4b7e-99ad-3fe65eda1dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_0ea283a1-ce6d-43c9-95a8-9bd803dad0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_0ea283a1-ce6d-43c9-95a8-9bd803dad0a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_eacc8cd1-bbc3-4192-8939-e6a349535a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_035c57ed-1c2c-4692-9089-0c8d07e52850" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_eacc8cd1-bbc3-4192-8939-e6a349535a31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c69e7ace-08a4-4de1-9e50-e4eef284578e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_96efe38a-7a2c-41db-8765-cf6ca3972817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c69e7ace-08a4-4de1-9e50-e4eef284578e" xlink:to="loc_us-gaap_Liabilities_96efe38a-7a2c-41db-8765-cf6ca3972817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1957947d-75c5-45a9-9147-5ed7ab1a71b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c69e7ace-08a4-4de1-9e50-e4eef284578e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1957947d-75c5-45a9-9147-5ed7ab1a71b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1aab0fd7-707d-4698-b0b5-0c6bdc676151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c69e7ace-08a4-4de1-9e50-e4eef284578e" xlink:to="loc_us-gaap_StockholdersEquity_1aab0fd7-707d-4698-b0b5-0c6bdc676151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f69476d5-111c-465d-9ec5-7afd60d1661c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_876dc5de-601d-47cc-be44-1b71434688c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f69476d5-111c-465d-9ec5-7afd60d1661c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_876dc5de-601d-47cc-be44-1b71434688c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ab4f39ed-8461-4e9c-acac-a83ea55135ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f69476d5-111c-465d-9ec5-7afd60d1661c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ab4f39ed-8461-4e9c-acac-a83ea55135ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ee3145b3-b4c1-4a23-95ec-0711c33d60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f69476d5-111c-465d-9ec5-7afd60d1661c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ee3145b3-b4c1-4a23-95ec-0711c33d60b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ac4b0b91-27a0-4150-a169-b9d563cddcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f69476d5-111c-465d-9ec5-7afd60d1661c" xlink:to="loc_us-gaap_InventoryNet_ac4b0b91-27a0-4150-a169-b9d563cddcbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a9467b3-b611-4561-98dc-37dc111423fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f69476d5-111c-465d-9ec5-7afd60d1661c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a9467b3-b611-4561-98dc-37dc111423fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cbaf8d4e-2867-4d3d-9730-0c58a531ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:to="loc_us-gaap_AssetsCurrent_cbaf8d4e-2867-4d3d-9730-0c58a531ca02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2cdd77cc-d92f-4a6d-b394-459da89328d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2cdd77cc-d92f-4a6d-b394-459da89328d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f6b2586d-ca9f-4a8b-b014-dfa6347d922b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f6b2586d-ca9f-4a8b-b014-dfa6347d922b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe4b2e8-2834-4567-a508-adfd7d3ba636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe4b2e8-2834-4567-a508-adfd7d3ba636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a1488212-d85a-4ae4-8ad5-4b03d2dcc596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:to="loc_us-gaap_Goodwill_a1488212-d85a-4ae4-8ad5-4b03d2dcc596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a62b9202-1caa-4e44-83ac-f7b4f5df6c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c1f0f5b5-1011-407f-991d-2eade4ecb761" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a62b9202-1caa-4e44-83ac-f7b4f5df6c1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bf177f08-4a00-49a0-b8f9-dd8cd386c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4fdb383b-732d-447b-a7da-c30ec7c54f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bf177f08-4a00-49a0-b8f9-dd8cd386c2c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4fdb383b-732d-447b-a7da-c30ec7c54f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_58a82915-16ee-4af6-a6d2-45ee104ce3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bf177f08-4a00-49a0-b8f9-dd8cd386c2c1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_58a82915-16ee-4af6-a6d2-45ee104ce3c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_563b3831-217d-4d45-906b-02bc28613e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bf177f08-4a00-49a0-b8f9-dd8cd386c2c1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_563b3831-217d-4d45-906b-02bc28613e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0448940c-e7aa-40df-9093-332492607981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bf177f08-4a00-49a0-b8f9-dd8cd386c2c1" xlink:to="loc_us-gaap_AssetImpairmentCharges_0448940c-e7aa-40df-9093-332492607981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a197f973-034e-44dd-b9f1-da03ba2bc289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_bf177f08-4a00-49a0-b8f9-dd8cd386c2c1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a197f973-034e-44dd-b9f1-da03ba2bc289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7f03b374-c0e8-4df5-8347-d4d4a37f234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_413134e9-ff76-4f7c-a828-280b74fa8d41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7f03b374-c0e8-4df5-8347-d4d4a37f234d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_413134e9-ff76-4f7c-a828-280b74fa8d41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_db53221d-adce-4b5b-8d61-6043f98a1bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7f03b374-c0e8-4df5-8347-d4d4a37f234d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_db53221d-adce-4b5b-8d61-6043f98a1bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f330939b-cac1-4317-9f25-1e90d9ae23da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e8571c6b-9614-4e31-9f58-52e5618ecfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f330939b-cac1-4317-9f25-1e90d9ae23da" xlink:to="loc_us-gaap_OperatingIncomeLoss_e8571c6b-9614-4e31-9f58-52e5618ecfe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9b253118-2b17-4da9-ae36-6e3f14d57b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f330939b-cac1-4317-9f25-1e90d9ae23da" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9b253118-2b17-4da9-ae36-6e3f14d57b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a72069f3-6405-452e-97c9-1e460f360ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f330939b-cac1-4317-9f25-1e90d9ae23da" xlink:to="loc_us-gaap_InterestExpense_a72069f3-6405-452e-97c9-1e460f360ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e0edb7d9-1071-4c6d-8f25-b568e043e65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f330939b-cac1-4317-9f25-1e90d9ae23da" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e0edb7d9-1071-4c6d-8f25-b568e043e65f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e925a24a-2a91-491c-b649-8378a544ab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f330939b-cac1-4317-9f25-1e90d9ae23da" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e925a24a-2a91-491c-b649-8378a544ab39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cdc861e5-bef3-4eb2-96d2-9ed12aa10a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_db823955-b283-4916-877e-726ab4a72837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cdc861e5-bef3-4eb2-96d2-9ed12aa10a18" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_db823955-b283-4916-877e-726ab4a72837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9829c4ac-74c9-4bc1-b192-3ee3a730fbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cdc861e5-bef3-4eb2-96d2-9ed12aa10a18" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9829c4ac-74c9-4bc1-b192-3ee3a730fbcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b30079b9-6082-471f-8e43-74342a8da446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8ba497ac-5f06-4f94-8068-0eaa159e7afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b30079b9-6082-471f-8e43-74342a8da446" xlink:to="loc_us-gaap_GrossProfit_8ba497ac-5f06-4f94-8068-0eaa159e7afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_34340e6c-bd71-42ee-8f5e-7170cd0cb7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b30079b9-6082-471f-8e43-74342a8da446" xlink:to="loc_us-gaap_OperatingExpenses_34340e6c-bd71-42ee-8f5e-7170cd0cb7d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d663c841-d024-4491-a6bb-6a63b1b2d80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9a9513d5-9507-452b-bb5d-6a26ce7238ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d663c841-d024-4491-a6bb-6a63b1b2d80b" xlink:to="loc_us-gaap_NetIncomeLoss_9a9513d5-9507-452b-bb5d-6a26ce7238ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bff93cc5-97e8-434b-87e4-68b94398fa01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d663c841-d024-4491-a6bb-6a63b1b2d80b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bff93cc5-97e8-434b-87e4-68b94398fa01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3f9bfa9-84c5-4e56-ae29-aad6dc7c1120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_697a0bba-a719-43a6-a6df-1393bfef56eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3f9bfa9-84c5-4e56-ae29-aad6dc7c1120" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_697a0bba-a719-43a6-a6df-1393bfef56eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_33333851-2d08-406b-bc73-93d04b04921e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e3f9bfa9-84c5-4e56-ae29-aad6dc7c1120" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_33333851-2d08-406b-bc73-93d04b04921e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c94343cb-6498-4817-b932-f2f91e2ae289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_ProfitLoss_c94343cb-6498-4817-b932-f2f91e2ae289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_33728ce1-cee7-4d9b-96e6-0373c17785a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_33728ce1-cee7-4d9b-96e6-0373c17785a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_12ce978f-1d79-456c-80f6-a3514a3d6ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_12ce978f-1d79-456c-80f6-a3514a3d6ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f581f657-540e-4f7e-b278-b5a38390d33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_ShareBasedCompensation_f581f657-540e-4f7e-b278-b5a38390d33c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_baa742a1-e5d3-41ae-9c30-6c4ea8bb289c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_baa742a1-e5d3-41ae-9c30-6c4ea8bb289c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_875d72ac-0da0-4c94-ba0a-fe18fea9004b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_875d72ac-0da0-4c94-ba0a-fe18fea9004b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_d369f1de-f516-49f3-aacc-84c03405034c" xlink:href="fold-20221231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_d369f1de-f516-49f3-aacc-84c03405034c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c2d371fe-b332-4e9e-bf9d-32e451b461bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c2d371fe-b332-4e9e-bf9d-32e451b461bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_2c943fdf-5a8c-4853-b2ef-a017d3a73856" xlink:href="fold-20221231.xsd#fold_AssetImpairmentChargesAndOtherAssetWriteOffs"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_2c943fdf-5a8c-4853-b2ef-a017d3a73856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bec30b38-8583-4f50-a33d-bff5c70cb3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bec30b38-8583-4f50-a33d-bff5c70cb3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2634dcd1-060b-4f92-8340-7448e2e8a17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2634dcd1-060b-4f92-8340-7448e2e8a17b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bef790dc-5467-4586-98de-cfaaf0dede4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bef790dc-5467-4586-98de-cfaaf0dede4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d85b95c5-24f5-4732-b608-f95d2646bbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d85b95c5-24f5-4732-b608-f95d2646bbc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_ff42bf69-3575-4c0a-a8e7-45a2fb29bf28" xlink:href="fold-20221231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_ff42bf69-3575-4c0a-a8e7-45a2fb29bf28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_7afb0ca9-e582-4d24-ae5e-674bac7e5c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a47c80ef-1b5c-4138-b994-7bb0370bdb79" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_7afb0ca9-e582-4d24-ae5e-674bac7e5c8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de6960c9-5814-4574-8f01-43d907a8c993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b071aae4-ee89-4b5b-9f06-f975af943071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de6960c9-5814-4574-8f01-43d907a8c993" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_b071aae4-ee89-4b5b-9f06-f975af943071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06aebb1e-d201-4e27-87be-6b1be482de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de6960c9-5814-4574-8f01-43d907a8c993" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_06aebb1e-d201-4e27-87be-6b1be482de0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e4b58b60-6d0c-416c-b533-ca811715758c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de6960c9-5814-4574-8f01-43d907a8c993" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e4b58b60-6d0c-416c-b533-ca811715758c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ee44f77c-aa34-46a1-b99c-1936be51055d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de6960c9-5814-4574-8f01-43d907a8c993" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ee44f77c-aa34-46a1-b99c-1936be51055d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_d05fc177-74b9-456a-944e-24153e3a5ff9" xlink:href="fold-20221231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_d05fc177-74b9-456a-944e-24153e3a5ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_004e0338-0117-4e77-a0f1-9d68357d916b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_004e0338-0117-4e77-a0f1-9d68357d916b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9ac200c3-261d-415d-bee9-85e9ce6834b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_9ac200c3-261d-415d-bee9-85e9ce6834b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_21eb8bb3-9d77-4f9e-b0d6-51c075cd72b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_21eb8bb3-9d77-4f9e-b0d6-51c075cd72b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_63e4cd7c-5338-469c-925c-a8f4375b6413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_63e4cd7c-5338-469c-925c-a8f4375b6413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_49791b08-0068-42a2-bb62-bf170047198f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_49791b08-0068-42a2-bb62-bf170047198f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_1dbf1ec9-071f-474e-a80c-1b933995a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_1dbf1ec9-071f-474e-a80c-1b933995a1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fe065e8-cd2d-49ef-abdb-272707c43e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b079c40e-54a0-4179-ae4d-ec4cff7a3fbc" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_3fe065e8-cd2d-49ef-abdb-272707c43e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f87fb64f-a01b-49e2-b7ef-07b780b0d8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c8d0603-bed8-4b2c-8321-95716b877fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f87fb64f-a01b-49e2-b7ef-07b780b0d8d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c8d0603-bed8-4b2c-8321-95716b877fc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_842c4247-6281-4d5a-8955-85e6d11f274d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f87fb64f-a01b-49e2-b7ef-07b780b0d8d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_842c4247-6281-4d5a-8955-85e6d11f274d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8599ab12-507a-4465-be7b-e8117764a6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f87fb64f-a01b-49e2-b7ef-07b780b0d8d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8599ab12-507a-4465-be7b-e8117764a6df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e86898e-7598-4d38-891a-6e437b86a62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f87fb64f-a01b-49e2-b7ef-07b780b0d8d6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e86898e-7598-4d38-891a-6e437b86a62b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_39e3aed5-cddc-4412-8577-3e124d975dc1" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_199bd412-0574-4297-9429-c18fb7ea2d02" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_39e3aed5-cddc-4412-8577-3e124d975dc1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_199bd412-0574-4297-9429-c18fb7ea2d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7dccad58-ffd4-4dbb-944c-ab9a84cd02af" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_39e3aed5-cddc-4412-8577-3e124d975dc1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7dccad58-ffd4-4dbb-944c-ab9a84cd02af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_58362b95-e62e-474b-bd51-8eda50ad47a8" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_39e3aed5-cddc-4412-8577-3e124d975dc1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_58362b95-e62e-474b-bd51-8eda50ad47a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_944fee6d-7e2e-4d03-a400-c3b122597636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_2816b1b0-e5c0-4076-9602-df53447f9a1e" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_944fee6d-7e2e-4d03-a400-c3b122597636" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_2816b1b0-e5c0-4076-9602-df53447f9a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_49312f46-4108-4b4d-ad60-0c5c49ccb46f" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_944fee6d-7e2e-4d03-a400-c3b122597636" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_49312f46-4108-4b4d-ad60-0c5c49ccb46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fd539029-7d17-4f8a-a474-44049927dbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_944fee6d-7e2e-4d03-a400-c3b122597636" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fd539029-7d17-4f8a-a474-44049927dbb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_022f3483-dfd9-4a35-ba57-88ca8c6a0029" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2159d8dc-3e54-4072-a334-8e1e3db1649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_022f3483-dfd9-4a35-ba57-88ca8c6a0029" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2159d8dc-3e54-4072-a334-8e1e3db1649c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_daaca54e-e160-4f0c-8f0f-0300a1015105" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_022f3483-dfd9-4a35-ba57-88ca8c6a0029" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_daaca54e-e160-4f0c-8f0f-0300a1015105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7f40aa5-22c7-47ed-b0b0-e9ab4d1e40d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11e92b7f-b510-4c33-bcb3-a6d76437e292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7f40aa5-22c7-47ed-b0b0-e9ab4d1e40d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11e92b7f-b510-4c33-bcb3-a6d76437e292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_cc625061-5646-44f6-aeef-0b8068304a9a" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f5552d40-568c-4b94-a030-4ed89d383a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_cc625061-5646-44f6-aeef-0b8068304a9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f5552d40-568c-4b94-a030-4ed89d383a9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5a4fea67-eafa-4f07-956f-5b50beb0284a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_cc625061-5646-44f6-aeef-0b8068304a9a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5a4fea67-eafa-4f07-956f-5b50beb0284a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af3e5584-031d-4c19-8345-9027bc373b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_cc625061-5646-44f6-aeef-0b8068304a9a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af3e5584-031d-4c19-8345-9027bc373b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea3f1893-e4ff-49f2-9a6e-6c0a34e6a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cab64b3-72ac-4ed1-86d1-6d369480bb38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea3f1893-e4ff-49f2-9a6e-6c0a34e6a7fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4cab64b3-72ac-4ed1-86d1-6d369480bb38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2452ae60-0add-4d68-ad40-2b4ba859291e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea3f1893-e4ff-49f2-9a6e-6c0a34e6a7fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2452ae60-0add-4d68-ad40-2b4ba859291e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5e13bf09-44e0-4a6d-9ed7-8466eeb6d560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea3f1893-e4ff-49f2-9a6e-6c0a34e6a7fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5e13bf09-44e0-4a6d-9ed7-8466eeb6d560" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e3775620-da7f-4481-9fc3-e2ffcb9bb2b1" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41448f47-917c-4a1d-b118-d93b8c859dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e3775620-da7f-4481-9fc3-e2ffcb9bb2b1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41448f47-917c-4a1d-b118-d93b8c859dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_464981d7-af83-4b45-adda-9b0e12f52929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_e3775620-da7f-4481-9fc3-e2ffcb9bb2b1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_464981d7-af83-4b45-adda-9b0e12f52929" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f122488c-812d-4a96-8905-2cc83ac06a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd88eca0-198b-4dc8-b0b0-5b830af60cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f122488c-812d-4a96-8905-2cc83ac06a1b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fd88eca0-198b-4dc8-b0b0-5b830af60cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_91029f80-2fca-4216-bfb8-8fdbde5ad2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f122488c-812d-4a96-8905-2cc83ac06a1b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_91029f80-2fca-4216-bfb8-8fdbde5ad2fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_516df408-dce3-4c61-9c97-232f824a98fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_24932a77-adfa-4773-80e8-fc8b7dec4297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_516df408-dce3-4c61-9c97-232f824a98fa" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_24932a77-adfa-4773-80e8-fc8b7dec4297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_973643d5-a27f-4bfa-aa2b-60da77be312a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_516df408-dce3-4c61-9c97-232f824a98fa" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_973643d5-a27f-4bfa-aa2b-60da77be312a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_09dae8bf-2bb6-4144-941f-607788cf5a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_516df408-dce3-4c61-9c97-232f824a98fa" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_09dae8bf-2bb6-4144-941f-607788cf5a1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14a65b0c-540d-49bf-96c3-469e06f7394d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_feed8027-1681-4f45-b9ee-0dbba30b8950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_14a65b0c-540d-49bf-96c3-469e06f7394d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_feed8027-1681-4f45-b9ee-0dbba30b8950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e0b90969-cc3e-41ee-bab4-4830e925bde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_14a65b0c-540d-49bf-96c3-469e06f7394d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e0b90969-cc3e-41ee-bab4-4830e925bde9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_07916c77-bd7a-4b7d-bdc4-5c5689807be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_07916c77-bd7a-4b7d-bdc4-5c5689807be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_888a3cae-08d4-4e3b-8544-ae142e093062" xlink:href="fold-20221231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_888a3cae-08d4-4e3b-8544-ae142e093062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedProgramFees_6dd239bc-6ea2-4381-a443-ed1837cb0c76" xlink:href="fold-20221231.xsd#fold_AccruedProgramFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_fold_AccruedProgramFees_6dd239bc-6ea2-4381-a443-ed1837cb0c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_28768abb-7c56-497f-b913-f197249957bb" xlink:href="fold-20221231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_28768abb-7c56-497f-b913-f197249957bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cbdcb5b0-dbf8-403a-83a1-e59e91411f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cbdcb5b0-dbf8-403a-83a1-e59e91411f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d8282c5b-0ab4-43d7-9e03-ea784ea3b980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d8282c5b-0ab4-43d7-9e03-ea784ea3b980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_77ea07c9-a820-4215-a574-6148185fa72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_us-gaap_TaxesPayableCurrent_77ea07c9-a820-4215-a574-6148185fa72b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cee1aeef-a733-4583-864f-b5368ab11fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc742238-e96d-4fc1-a3b2-7862d79da6ba" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cee1aeef-a733-4583-864f-b5368ab11fdf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_aea26690-0d7d-4938-aab5-0c922eb1e3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43bcbb5b-38a2-44a4-94d5-c927e7483b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_aea26690-0d7d-4938-aab5-0c922eb1e3c9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_43bcbb5b-38a2-44a4-94d5-c927e7483b4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_ead94e45-c903-4b6f-abb9-8a4270314af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_aea26690-0d7d-4938-aab5-0c922eb1e3c9" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_ead94e45-c903-4b6f-abb9-8a4270314af3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32899a63-811a-45ef-9cf1-3f0a2c9614a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f8f53a0f-f6ce-4dd5-b0c1-99369e0260b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_32899a63-811a-45ef-9cf1-3f0a2c9614a1" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f8f53a0f-f6ce-4dd5-b0c1-99369e0260b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6b2981b3-5768-482a-8806-2e00c2d2a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_32899a63-811a-45ef-9cf1-3f0a2c9614a1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6b2981b3-5768-482a-8806-2e00c2d2a70b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_a7d683e5-b175-43cf-8f0a-5fc32ad15df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_32899a63-811a-45ef-9cf1-3f0a2c9614a1" xlink:to="loc_us-gaap_DeferredOfferingCosts_a7d683e5-b175-43cf-8f0a-5fc32ad15df4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_543de299-382d-4ecc-b820-beb9930190dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f476ada9-fbe2-430b-80ba-a26b79d3be4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_543de299-382d-4ecc-b820-beb9930190dd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f476ada9-fbe2-430b-80ba-a26b79d3be4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa23b352-f9ed-4913-8e43-d32cac181a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_543de299-382d-4ecc-b820-beb9930190dd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa23b352-f9ed-4913-8e43-d32cac181a20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesFutureMinimumOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b54c0d0e-5054-42ec-9874-c77f1af99149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5877f230-323c-44b2-8a9a-b006bdb3f856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b54c0d0e-5054-42ec-9874-c77f1af99149" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5877f230-323c-44b2-8a9a-b006bdb3f856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7eb294af-9429-4937-a445-c89fd93e2192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b54c0d0e-5054-42ec-9874-c77f1af99149" xlink:to="loc_us-gaap_OperatingLeaseLiability_7eb294af-9429-4937-a445-c89fd93e2192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_af0bdd33-1967-46d1-b521-514966f1a3c2" xlink:href="fold-20221231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b54c0d0e-5054-42ec-9874-c77f1af99149" xlink:to="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_af0bdd33-1967-46d1-b521-514966f1a3c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesFutureMinimumOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac6fcab4-de3a-429a-9c14-4bca4e7fccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ac6fcab4-de3a-429a-9c14-4bca4e7fccbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1fe4ea96-c2d6-454a-8ef3-cdd31e6aafa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1fe4ea96-c2d6-454a-8ef3-cdd31e6aafa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_28b5576d-6076-488f-910c-c8b26fd3107a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_28b5576d-6076-488f-910c-c8b26fd3107a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_765d8073-b548-4b67-9cef-5852457e9e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_765d8073-b548-4b67-9cef-5852457e9e37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5c0eb3bd-937a-4e47-a48f-75d807f3b2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5c0eb3bd-937a-4e47-a48f-75d807f3b2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fa6ea1a3-6a16-4a5e-8b65-325d7a550034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_63054b75-baa4-40f2-910d-cc47c8776653" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fa6ea1a3-6a16-4a5e-8b65-325d7a550034" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d8d9df80-7dbf-4e36-afdc-708e5acd8e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_d8d9df80-7dbf-4e36-afdc-708e5acd8e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d8d464ab-070c-41f1-8f35-32e6d3aa7b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d8d464ab-070c-41f1-8f35-32e6d3aa7b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_eb3277fb-cfda-4326-b8a2-649e8940e5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_eb3277fb-cfda-4326-b8a2-649e8940e5d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cacbbb74-267b-4600-92c3-decfc160a902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_cacbbb74-267b-4600-92c3-decfc160a902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_17ae6a2b-e3cc-47a4-845e-868849b4c581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_17ae6a2b-e3cc-47a4-845e-868849b4c581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c2ea0ff6-c06b-4f82-b61f-6632e89b018e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fa59f9e7-fb70-4039-9991-67690ebfe535" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c2ea0ff6-c06b-4f82-b61f-6632e89b018e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e8d7f01-3fc9-4bb6-bde2-42f88f41ffcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_17012646-71e8-4d0e-9998-83f89fa49818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e8d7f01-3fc9-4bb6-bde2-42f88f41ffcb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_17012646-71e8-4d0e-9998-83f89fa49818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a0eb6525-af47-404f-bfa7-fe32c02adfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e8d7f01-3fc9-4bb6-bde2-42f88f41ffcb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a0eb6525-af47-404f-bfa7-fe32c02adfb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d33de7c9-919d-4a91-b3c5-55afcfbaed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cbd535fa-68a8-4ced-8527-771d62b02438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d33de7c9-919d-4a91-b3c5-55afcfbaed48" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cbd535fa-68a8-4ced-8527-771d62b02438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_34869c9d-1c32-4243-80c2-e1bbed9bcc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d33de7c9-919d-4a91-b3c5-55afcfbaed48" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_34869c9d-1c32-4243-80c2-e1bbed9bcc8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e4593a79-4a46-432a-a850-6ff4e2b4e465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d33de7c9-919d-4a91-b3c5-55afcfbaed48" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e4593a79-4a46-432a-a850-6ff4e2b4e465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fbd90f63-735b-430b-9d2d-2ed6a43bd99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d33de7c9-919d-4a91-b3c5-55afcfbaed48" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fbd90f63-735b-430b-9d2d-2ed6a43bd99e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_759e4825-3572-4dfe-8255-f12eb8004918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d33de7c9-919d-4a91-b3c5-55afcfbaed48" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_759e4825-3572-4dfe-8255-f12eb8004918" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesDeferredandValuationDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_a0663416-8520-4b33-bddc-61ba900ea82e" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_464c51b9-cf9a-4ea5-a0f4-cc0f6962a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_a0663416-8520-4b33-bddc-61ba900ea82e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_464c51b9-cf9a-4ea5-a0f4-cc0f6962a53a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_50f15988-42a2-49a0-8785-2f65364d6066" xlink:href="fold-20221231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_a0663416-8520-4b33-bddc-61ba900ea82e" xlink:to="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_50f15988-42a2-49a0-8785-2f65364d6066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_415e3247-f3d8-4eda-a955-67a928634f6f" xlink:href="fold-20221231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_a0663416-8520-4b33-bddc-61ba900ea82e" xlink:to="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_415e3247-f3d8-4eda-a955-67a928634f6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_769b5d64-bbbc-4399-b74d-0e3f863905a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross_a0663416-8520-4b33-bddc-61ba900ea82e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_769b5d64-bbbc-4399-b74d-0e3f863905a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_eb028fd9-0149-416b-bc73-981036ca3041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_1f4cccf0-e861-4ad5-bdfa-248bae6597e3" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_eb028fd9-0149-416b-bc73-981036ca3041" xlink:to="loc_fold_DeferredTaxAssetsLiabilitiesGross_1f4cccf0-e861-4ad5-bdfa-248bae6597e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_be65fd2d-0f0d-4abb-bcb3-3be168486825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_eb028fd9-0149-416b-bc73-981036ca3041" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_be65fd2d-0f0d-4abb-bcb3-3be168486825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_924db676-9222-4b07-8401-7711ba8f6770" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsIntellectualProperty"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_fold_DeferredTaxAssetsIntellectualProperty_924db676-9222-4b07-8401-7711ba8f6770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_af3670fe-0d13-47e9-98a0-2cccb755d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_af3670fe-0d13-47e9-98a0-2cccb755d59a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4b11b441-c685-4d3f-a7f3-451197ab1c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4b11b441-c685-4d3f-a7f3-451197ab1c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_24d7cb43-dabb-4e2d-b1fa-838abcf67ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_24d7cb43-dabb-4e2d-b1fa-838abcf67ab4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_2376b48d-d6f6-4411-b7c8-ffbc8407fcc8" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_2376b48d-d6f6-4411-b7c8-ffbc8407fcc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_d3d1517b-f4b0-44ec-aa5b-9da91d3e227f" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_d3d1517b-f4b0-44ec-aa5b-9da91d3e227f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLeasingArrangements_7449238c-5ec0-4152-948e-93b4d7092698" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_fold_DeferredTaxAssetsLeasingArrangements_7449238c-5ec0-4152-948e-93b4d7092698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_9472aa38-aac8-4630-b40b-3f4ca2e54391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_9472aa38-aac8-4630-b40b-3f4ca2e54391" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b77ee257-5251-4510-a4bb-407e3a4a4ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_277ac8b2-4c78-46d7-bd2f-b8964cee3fed" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b77ee257-5251-4510-a4bb-407e3a4a4ae7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>fold-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:981bea1b-b87d-4677-ae2e-8728c40b94b3,g:80eaf27f-6f35-4ae6-9648-0cd9017af6e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="ie77e16650484435b974a480e20490ac9_ConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_911bd5c2-051e-4776-aff3-1240c7951990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_911bd5c2-051e-4776-aff3-1240c7951990" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13204bb3-3890-4a5a-a9a6-ab01531c1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13204bb3-3890-4a5a-a9a6-ab01531c1bd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_666be3ed-2fe8-43e6-8262-23081c3015a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockholdersEquity_666be3ed-2fe8-43e6-8262-23081c3015a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3155e4d6-134c-4584-ad47-b0a4b279d096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3155e4d6-134c-4584-ad47-b0a4b279d096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1562e785-1d35-4750-967b-b82f0665f2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1562e785-1d35-4750-967b-b82f0665f2cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ebdcd47-7056-4177-9be4-d363b4bff47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ebdcd47-7056-4177-9be4-d363b4bff47c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_289f0f17-a3a4-4bfe-aa4f-9f2cdf3af191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_289f0f17-a3a4-4bfe-aa4f-9f2cdf3af191" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7a08b73f-f6b2-44d6-bafb-f63ef35d089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7a08b73f-f6b2-44d6-bafb-f63ef35d089a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ea3407db-4c9b-4ca8-8558-3e3dcf6d1e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ea3407db-4c9b-4ca8-8558-3e3dcf6d1e7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6ac57c0-3234-4bdd-bf53-d2ccc18bdbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6ac57c0-3234-4bdd-bf53-d2ccc18bdbf8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2962d30b-2ee9-4dc8-af55-c56d11b758a2" xlink:href="fold-20221231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2962d30b-2ee9-4dc8-af55-c56d11b758a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_6780b164-9edd-4ee4-8f0f-604f0923323a" xlink:href="fold-20221231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_6780b164-9edd-4ee4-8f0f-604f0923323a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a240f8a5-715e-46c3-9780-44a24f04b968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a240f8a5-715e-46c3-9780-44a24f04b968" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_939f5f15-f5eb-4d03-8fc6-f957381ab488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_939f5f15-f5eb-4d03-8fc6-f957381ab488" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dc85b4cb-7e5a-43fe-af68-13ac02ae8158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dc85b4cb-7e5a-43fe-af68-13ac02ae8158" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5afe6616-546b-42a5-870c-4ebb86a04391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5afe6616-546b-42a5-870c-4ebb86a04391" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_24c7b0bd-0f93-423a-8ae2-bd7eb7d73c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_NetIncomeLoss_24c7b0bd-0f93-423a-8ae2-bd7eb7d73c2c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2fa50cef-e1f2-4f09-9396-6e8acb8ca369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_865116ca-f169-454a-968a-3dffe2278fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_911bd5c2-051e-4776-aff3-1240c7951990" xlink:to="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fcdf34d4-e514-4fb8-a697-9e364742419d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:to="loc_us-gaap_EquityComponentDomain_fcdf34d4-e514-4fb8-a697-9e364742419d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:to="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d974f056-ad3e-4212-badc-6927c1509b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_CommonStockMember_d974f056-ad3e-4212-badc-6927c1509b93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eb9b5f11-87bd-4b95-ac0a-8470cc86732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eb9b5f11-87bd-4b95-ac0a-8470cc86732b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9bfd2558-68ff-45e6-aa8a-8fffa0cc1712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_WarrantMember_9bfd2558-68ff-45e6-aa8a-8fffa0cc1712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_cb38fe96-c2e4-41e3-b0f4-f34919615d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_cb38fe96-c2e4-41e3-b0f4-f34919615d50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_966004e4-9058-4b91-bc99-9ed9750efb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_RetainedEarningsMember_966004e4-9058-4b91-bc99-9ed9750efb21" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails" xlink:type="extended" id="iaee09376977e47d58934c9b13caa9b59_SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3bae0d09-bdfd-44d7-b256-a6b33de27f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3bae0d09-bdfd-44d7-b256-a6b33de27f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ebc91312-11d5-44b8-b462-4d44f7aed12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ebc91312-11d5-44b8-b462-4d44f7aed12f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76d93506-ff12-436b-b55f-4855cf029f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76d93506-ff12-436b-b55f-4855cf029f07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_55d46d7d-00d7-4e55-aeb5-a70e7b0e4b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:to="loc_us-gaap_SalesRevenueNetMember_55d46d7d-00d7-4e55-aeb5-a70e7b0e4b1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8b5de741-dc4d-49b4-bf41-e55c8f2961cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:to="loc_us-gaap_AccountsReceivableMember_8b5de741-dc4d-49b4-bf41-e55c8f2961cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_99bf2d8d-59d3-47e8-85ca-a833c3148c9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_99bf2d8d-59d3-47e8-85ca-a833c3148c9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3520bcb7-1cbd-4f60-9c5d-c60f319ed486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3520bcb7-1cbd-4f60-9c5d-c60f319ed486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e5abba22-37e2-4949-adcd-e98b9403f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3520bcb7-1cbd-4f60-9c5d-c60f319ed486" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e5abba22-37e2-4949-adcd-e98b9403f2f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_51faf403-aad1-42c5-ab75-c8b3f1dca95a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:to="loc_srt_NameOfMajorCustomerDomain_51faf403-aad1-42c5-ab75-c8b3f1dca95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GalafoldMember_7926e57c-35c9-4346-9fa5-59a6e6d7a0b8" xlink:href="fold-20221231.xsd#fold_GalafoldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:to="loc_fold_GalafoldMember_7926e57c-35c9-4346-9fa5-59a6e6d7a0b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CustomerOneMember_57a4d299-f8de-4efb-8fd0-d67af2d46658" xlink:href="fold-20221231.xsd#fold_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:to="loc_fold_CustomerOneMember_57a4d299-f8de-4efb-8fd0-d67af2d46658" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i09a44b2d311348f0b2b630fc42301ea9_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13e7ed62-b17e-4b2f-b072-79a1377e0a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ffaa2812-6fde-4867-a600-613ae8cc0c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13e7ed62-b17e-4b2f-b072-79a1377e0a05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ffaa2812-6fde-4867-a600-613ae8cc0c64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13e7ed62-b17e-4b2f-b072-79a1377e0a05" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:to="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ab38721-89ed-42d2-b21a-bb68c031f50f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:to="loc_srt_RangeMember_3ab38721-89ed-42d2-b21a-bb68c031f50f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:to="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eabbc288-a762-45e6-aa12-e4e8b22a3e5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:to="loc_srt_MinimumMember_eabbc288-a762-45e6-aa12-e4e8b22a3e5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_074b368b-a938-4054-a49f-c6369587c372" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:to="loc_srt_MaximumMember_074b368b-a938-4054-a49f-c6369587c372" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="extended" id="i674a13080d2c4a4a889eb0899cc8755b_SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8ad435e6-a675-4b8e-bc68-7fd8bb1ad247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_307b3982-185e-4e43-bc0b-7c5089318280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8ad435e6-a675-4b8e-bc68-7fd8bb1ad247" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_307b3982-185e-4e43-bc0b-7c5089318280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8ad435e6-a675-4b8e-bc68-7fd8bb1ad247" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:to="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e717edbe-1243-405e-a238-94b5f9852561_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:to="loc_srt_SegmentGeographicalDomain_e717edbe-1243-405e-a238-94b5f9852561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:to="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3f61e39c-fb92-44cc-84e0-237544c20855" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:to="loc_country_US_3f61e39c-fb92-44cc-84e0-237544c20855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1ae5e186-623c-4506-9b0e-75cd23f72377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:to="loc_us-gaap_NonUsMember_1ae5e186-623c-4506-9b0e-75cd23f72377" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i916b5c83e1074f329056e75c60a2f615_CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a352ad4-d436-4064-8645-c9e9959d3eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a352ad4-d436-4064-8645-c9e9959d3eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_341b98d4-f2db-4cd1-9c11-f626eeaa0368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_341b98d4-f2db-4cd1-9c11-f626eeaa0368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4ef01e60-e003-46fe-a5b0-6d0fde463429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4ef01e60-e003-46fe-a5b0-6d0fde463429" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_453719e8-c1c1-4cf3-9d14-86b244804294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_453719e8-c1c1-4cf3-9d14-86b244804294" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_05a68d25-2737-46f2-94c9-39ee35c95c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_05a68d25-2737-46f2-94c9-39ee35c95c49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d59b1776-946e-4ecb-918f-51ffe38902bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d59b1776-946e-4ecb-918f-51ffe38902bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_766daf02-62ed-4f0f-a4a5-2ccc0cbef709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_766daf02-62ed-4f0f-a4a5-2ccc0cbef709" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_cea60211-1a2e-4a09-afde-fa750663c382" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_cea60211-1a2e-4a09-afde-fa750663c382" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ef3e8f07-8ec9-46ee-a5f8-c4bb2acf1c0c" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ef3e8f07-8ec9-46ee-a5f8-c4bb2acf1c0c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5e8b517c-fb42-4d51-8d7d-e990331d9ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5e8b517c-fb42-4d51-8d7d-e990331d9ed9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_4a1b332f-9106-4c00-a2e2-aeedf16f4076" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_4a1b332f-9106-4c00-a2e2-aeedf16f4076" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70a07cd2-134b-4d91-a95b-1f777cc074b7" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70a07cd2-134b-4d91-a95b-1f777cc074b7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_733191ab-438d-459b-b55b-d7e57402991b" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_733191ab-438d-459b-b55b-d7e57402991b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_192f9147-08cb-4e9e-8dd8-ce468099bed2" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_192f9147-08cb-4e9e-8dd8-ce468099bed2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f3acccd-941e-4e8a-a226-a2051ed86b92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f3acccd-941e-4e8a-a226-a2051ed86b92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_690b9be4-b4f2-4729-aaed-fc07f094270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_690b9be4-b4f2-4729-aaed-fc07f094270c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_846a6383-7e60-4373-8a20-4dcfa8b8fa16" xlink:href="fold-20221231.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_846a6383-7e60-4373-8a20-4dcfa8b8fa16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_74cb868d-3bcb-4324-8fad-d2f3ae461c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_74cb868d-3bcb-4324-8fad-d2f3ae461c0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ca7f1a05-0ade-4cda-b8d3-8bafdb425e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ca7f1a05-0ade-4cda-b8d3-8bafdb425e33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d1338632-7806-4b4e-9866-edaf9fc72bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d1338632-7806-4b4e-9866-edaf9fc72bec" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i65c81972ded546829986306604320a39_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_acd230bb-6d1c-4b82-98a3-817ac51c0ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_acd230bb-6d1c-4b82-98a3-817ac51c0ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31b978d5-7673-4da9-a99b-5c4893ed47de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31b978d5-7673-4da9-a99b-5c4893ed47de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_034335fd-2076-420d-a1b7-cfb96d6ab085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_034335fd-2076-420d-a1b7-cfb96d6ab085" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2c3a2fca-b9cd-458b-b4b7-5a80912e1bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_Depreciation_2c3a2fca-b9cd-458b-b4b7-5a80912e1bb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_24a12f84-8866-45eb-a8c3-983597678014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_AssetImpairmentCharges_24a12f84-8866-45eb-a8c3-983597678014" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9249dece-455c-4c8f-be8c-34134a5d6c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9249dece-455c-4c8f-be8c-34134a5d6c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_465156c1-db10-45ea-a5da-15e5429ecc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_465156c1-db10-45ea-a5da-15e5429ecc0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ResearchEquipmentMember_1959ded0-69ac-496c-8a25-cdae556fdab9" xlink:href="fold-20221231.xsd#fold_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_fold_ResearchEquipmentMember_1959ded0-69ac-496c-8a25-cdae556fdab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ad946873-dfba-46b9-9c1c-728d978e68db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_ComputerEquipmentMember_ad946873-dfba-46b9-9c1c-728d978e68db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6c50b9b1-b47e-428b-bc96-417c88090515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_ConstructionInProgressMember_6c50b9b1-b47e-428b-bc96-417c88090515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9b1c3b91-84f9-4661-8334-7b54fcbd9dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9b1c3b91-84f9-4661-8334-7b54fcbd9dba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1cbe7dcf-5f40-4c6e-890d-cc861b873158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1cbe7dcf-5f40-4c6e-890d-cc861b873158" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_f886fc91-dae2-49f7-abf7-e2f8e702dc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_VehiclesMember_f886fc91-dae2-49f7-abf7-e2f8e702dc1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_b65900e6-2e88-4771-95a3-cefc985ae5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_LandMember_b65900e6-2e88-4771-95a3-cefc985ae5bc" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended" id="i43ea3ab1e11540278ca911c4a388574d_StockholdersEquityCommonStockandWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4ea93ae-639c-4d3c-ae35-6c266379cf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4ea93ae-639c-4d3c-ae35-6c266379cf2e" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0f6ab527-db8f-4e4a-9ef8-5697300d5758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0f6ab527-db8f-4e4a-9ef8-5697300d5758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_7d056d2c-a232-4725-917f-2e108adbcd48" xlink:href="fold-20221231.xsd#fold_CommonStockVotingRightsForEachShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_fold_CommonStockVotingRightsForEachShareHeld_7d056d2c-a232-4725-917f-2e108adbcd48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09ffdd9d-a913-41b0-9cb9-ede48964f901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09ffdd9d-a913-41b0-9cb9-ede48964f901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1f768c9-ca78-40d4-a08f-7f3f96121d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1f768c9-ca78-40d4-a08f-7f3f96121d4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b2096bbc-6782-4d86-89c2-3242ecb7254e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b2096bbc-6782-4d86-89c2-3242ecb7254e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ebbe4181-a0bd-4392-bd38-86577b362f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ebbe4181-a0bd-4392-bd38-86577b362f22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_4d46254d-e210-4101-ad5f-1da050b0358a" xlink:href="fold-20221231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_4d46254d-e210-4101-ad5f-1da050b0358a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41a67f40-543e-495f-b6cc-f3e923a16a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41a67f40-543e-495f-b6cc-f3e923a16a33" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_28f5e41e-0dd8-45ed-81e4-549f29281f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_28f5e41e-0dd8-45ed-81e4-549f29281f78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6f8b27b6-3ce9-4c01-ba1a-f0378630870f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6f8b27b6-3ce9-4c01-ba1a-f0378630870f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1916523b-9937-4aa3-851a-49de709d5bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1916523b-9937-4aa3-851a-49de709d5bf0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_acbdce07-7c9a-421e-b7c2-890bb8e454b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_acbdce07-7c9a-421e-b7c2-890bb8e454b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8bcda718-ff3c-4837-b128-78326827aa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8bcda718-ff3c-4837-b128-78326827aa8f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4ea93ae-639c-4d3c-ae35-6c266379cf2e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:to="loc_us-gaap_ClassOfStockDomain_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b2bc6d6-9b0c-4141-8d85-52e75fe96cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:to="loc_us-gaap_ClassOfStockDomain_4b2bc6d6-9b0c-4141-8d85-52e75fe96cf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2563b4e5-db19-4b3c-8fd4-c56267cb843c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b2bc6d6-9b0c-4141-8d85-52e75fe96cf5" xlink:to="loc_us-gaap_CommonStockMember_2563b4e5-db19-4b3c-8fd4-c56267cb843c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4939f3ec-2d9d-47d7-8b4f-5649d810b240_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4939f3ec-2d9d-47d7-8b4f-5649d810b240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1ee14a39-d9b0-4e06-af08-7a6622b57ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1ee14a39-d9b0-4e06-af08-7a6622b57ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_54d94840-6c2a-447e-b783-e5365b11d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ee14a39-d9b0-4e06-af08-7a6622b57ddc" xlink:to="loc_us-gaap_WarrantMember_54d94840-6c2a-447e-b783-e5365b11d5d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1588a313-838e-4f83-b321-d065f5559849_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:to="loc_us-gaap_EquityComponentDomain_1588a313-838e-4f83-b321-d065f5559849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:to="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_88590031-9a59-4bd1-929d-44c07034c257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:to="loc_us-gaap_CommonStockMember_88590031-9a59-4bd1-929d-44c07034c257" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_728a1b19-ebf9-4f46-b781-0dbb0a3a2133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_728a1b19-ebf9-4f46-b781-0dbb0a3a2133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AtTheMarketEquityProgramMember_5f90a386-36bb-4cef-8432-be27f94dde00" xlink:href="fold-20221231.xsd#fold_AtTheMarketEquityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_fold_AtTheMarketEquityProgramMember_5f90a386-36bb-4cef-8432-be27f94dde00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e8a6ea24-4b64-4f71-a5b5-d3435709013e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_us-gaap_PrivatePlacementMember_e8a6ea24-4b64-4f71-a5b5-d3435709013e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member_bb85c7e6-c2d4-4b62-82a4-35e59063e445" xlink:href="fold-20221231.xsd#fold_StockExercisesAt798Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_fold_StockExercisesAt798Member_bb85c7e6-c2d4-4b62-82a4-35e59063e445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member_fdd78b6f-f8ec-46a5-9592-edfdb7d16328" xlink:href="fold-20221231.xsd#fold_StockExercisesAt706Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_fold_StockExercisesAt706Member_fdd78b6f-f8ec-46a5-9592-edfdb7d16328" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ed801c2-e4d7-4752-b62f-6a73efa19ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ed801c2-e4d7-4752-b62f-6a73efa19ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_d05cf11c-f727-4582-9553-221ee3fa775f" xlink:href="fold-20221231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ed801c2-e4d7-4752-b62f-6a73efa19ace" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_d05cf11c-f727-4582-9553-221ee3fa775f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a28198a1-959f-4c7d-9393-cf623b6bdabb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a28198a1-959f-4c7d-9393-cf623b6bdabb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7aae4ac4-7d74-4014-8478-c87184624071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7aae4ac4-7d74-4014-8478-c87184624071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1c0165cf-4f00-43a5-99b1-753eea0e6400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7aae4ac4-7d74-4014-8478-c87184624071" xlink:to="loc_us-gaap_ConvertibleDebtMember_1c0165cf-4f00-43a5-99b1-753eea0e6400" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="extended" id="ic694a09e027346179fea65199c0875b1_StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_8b43bb15-1a48-403c-a0ff-0688abb59c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_TradingSecurities_8b43bb15-1a48-403c-a0ff-0688abb59c60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0702a676-0521-492d-b5f0-596741303208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0702a676-0521-492d-b5f0-596741303208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9cb774bb-b627-4e1e-ac68-cf54a433956f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9cb774bb-b627-4e1e-ac68-cf54a433956f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_0036525f-14e5-48d9-afed-7df9ed69e746" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_0036525f-14e5-48d9-afed-7df9ed69e746" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fdc1d733-7586-4d27-a42a-c43a3bebce50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fdc1d733-7586-4d27-a42a-c43a3bebce50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9ebd4050-f3c0-4584-8988-45060d51f93f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:to="loc_us-gaap_VestingDomain_9ebd4050-f3c0-4584-8988-45060d51f93f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4c6a07e5-94ba-4942-8050-66342646252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:to="loc_us-gaap_VestingDomain_4c6a07e5-94ba-4942-8050-66342646252f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70c1b240-1b7e-41b8-8399-b2bc0d78435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_4c6a07e5-94ba-4942-8050-66342646252f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70c1b240-1b7e-41b8-8399-b2bc0d78435e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12ce7ed5-6339-441b-ac2e-928798914bf0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:to="loc_srt_RangeMember_12ce7ed5-6339-441b-ac2e-928798914bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc57e136-761e-4c64-85a6-2c240f2e26d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:to="loc_srt_RangeMember_cc57e136-761e-4c64-85a6-2c240f2e26d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e181f37e-37c6-4ba0-9aab-290654524596" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cc57e136-761e-4c64-85a6-2c240f2e26d9" xlink:to="loc_srt_MaximumMember_e181f37e-37c6-4ba0-9aab-290654524596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c63f4841-b577-4ac2-938f-ed53b4a9f7bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c63f4841-b577-4ac2-938f-ed53b4a9f7bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f13eb8-256b-497b-8c43-630225458a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f13eb8-256b-497b-8c43-630225458a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec8b6a28-4446-43eb-9054-1e97634bd00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f13eb8-256b-497b-8c43-630225458a4e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec8b6a28-4446-43eb-9054-1e97634bd00a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended" id="i7b5067e80fc14a798e7c6df510cfd6f1_SharebasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_e2c3a6b8-747f-44ae-963c-2d033e655488" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_e2c3a6b8-747f-44ae-963c-2d033e655488" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa782fcc-f207-4713-ae19-c6932e1df7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa782fcc-f207-4713-ae19-c6932e1df7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2036d084-2a1b-4f1f-a1c3-241489e0ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2036d084-2a1b-4f1f-a1c3-241489e0ec51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_13debdbd-0044-43da-8704-397c7251981a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_13debdbd-0044-43da-8704-397c7251981a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1f03a5c7-5f98-46ab-bcbc-bdbacbfd6233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1f03a5c7-5f98-46ab-bcbc-bdbacbfd6233" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b2b216b-2d7c-4ac8-b0fa-04a129077dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b2b216b-2d7c-4ac8-b0fa-04a129077dbe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_89c5bf81-c3fa-4fe9-95a7-1a8cb40afb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_89c5bf81-c3fa-4fe9-95a7-1a8cb40afb0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:to="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d66e4bd-ad24-424e-accd-d96f0977c72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d66e4bd-ad24-424e-accd-d96f0977c72c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10a5dfe7-e232-4015-b1aa-1dfe46222b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10a5dfe7-e232-4015-b1aa-1dfe46222b55" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="ib676ab1e029e430c85acae42ca34e409_SharebasedCompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd7db15d-33c5-4a4c-8373-9d65bdd4f1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd7db15d-33c5-4a4c-8373-9d65bdd4f1b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce12c1eb-e151-4dc2-a658-da4de620b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce12c1eb-e151-4dc2-a658-da4de620b1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_368f6634-77d5-41f7-8124-268d4e160aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_368f6634-77d5-41f7-8124-268d4e160aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_c2abbd43-cdcc-4144-8c39-39d28ff1abb4" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_c2abbd43-cdcc-4144-8c39-39d28ff1abb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:to="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c95a35f8-a751-4ec6-ab87-0562277a13a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c95a35f8-a751-4ec6-ab87-0562277a13a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_165d4b56-115b-48ca-a947-871a782b9a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_165d4b56-115b-48ca-a947-871a782b9a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_973aca24-57d3-4dde-8769-a890df9f5ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_165d4b56-115b-48ca-a947-871a782b9a64" xlink:to="loc_us-gaap_EmployeeStockOptionMember_973aca24-57d3-4dde-8769-a890df9f5ecc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended" id="i01236a27b00f45f18b2855095abaa173_SharebasedCompensationRSUsandPBRSUsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5457f35-726d-48e5-bbd9-bf02d8763811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5457f35-726d-48e5-bbd9-bf02d8763811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5a5d32b-1109-4614-a1ef-4d8fb9f6684b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5a5d32b-1109-4614-a1ef-4d8fb9f6684b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ed1efa8c-df59-47f2-89d7-b52b0ecbe3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ed1efa8c-df59-47f2-89d7-b52b0ecbe3d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5dfd0fc-c2e2-40b9-b095-f36e82bf767f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5dfd0fc-c2e2-40b9-b095-f36e82bf767f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd6f14d5-5d1b-41b7-b710-0a053c06edab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eede50f-e413-41be-a3c2-14d40723690b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eede50f-e413-41be-a3c2-14d40723690b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_283d4f59-033a-4e84-a91f-40d327b21b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_283d4f59-033a-4e84-a91f-40d327b21b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12a01c63-228a-41c2-b95c-19e9c18b0b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12a01c63-228a-41c2-b95c-19e9c18b0b04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8d5fa038-8cd4-459a-90ba-37ad884f685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8d5fa038-8cd4-459a-90ba-37ad884f685a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6a40d04-b4e1-43c3-98af-75e9ae9aac56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4da94142-36d9-49fd-ac54-c8c9b819668f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4da94142-36d9-49fd-ac54-c8c9b819668f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6892d56c-8e10-44bb-bb2b-2d287634224a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6892d56c-8e10-44bb-bb2b-2d287634224a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:to="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b11fa3-2906-425a-8a80-da92bfda81c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7b11fa3-2906-425a-8a80-da92bfda81c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d8dca04-af6e-4e08-9f62-18d191111008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d8dca04-af6e-4e08-9f62-18d191111008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_53448a23-2b79-4d92-84dd-54c953b78e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d8dca04-af6e-4e08-9f62-18d191111008" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_53448a23-2b79-4d92-84dd-54c953b78e23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationExpenseSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="extended" id="i22c6c994d1bb4608b607f5a724bf776c_SharebasedCompensationExpenseSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c44b7599-47a1-40cc-9bc8-f643966d5eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ce3d192-7ebf-4eaf-b8b5-c54637af4f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c44b7599-47a1-40cc-9bc8-f643966d5eb3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ce3d192-7ebf-4eaf-b8b5-c54637af4f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c44b7599-47a1-40cc-9bc8-f643966d5eb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc3e0d75-0253-4e13-8d8f-bbe290192b85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc3e0d75-0253-4e13-8d8f-bbe290192b85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_651138ce-60b3-485d-97e3-7ccac0ab94e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_651138ce-60b3-485d-97e3-7ccac0ab94e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_82a40303-2cd6-4611-96a8-6aa9e27e741c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_82a40303-2cd6-4611-96a8-6aa9e27e741c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="extended" id="i3d6cf0929f5549d7a137fc5a249f9698_AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_127546da-5c92-49c9-a756-dfe7f89e8386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_127546da-5c92-49c9-a756-dfe7f89e8386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_eabcc13b-bbf5-4be2-bf02-1c90f8d99a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_127546da-5c92-49c9-a756-dfe7f89e8386" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_eabcc13b-bbf5-4be2-bf02-1c90f8d99a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2736aac-6f71-48f4-b2a7-9089659b1b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2736aac-6f71-48f4-b2a7-9089659b1b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_625082df-8e4f-4d97-80aa-6e6785a05273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_625082df-8e4f-4d97-80aa-6e6785a05273" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_77aa7eff-ecfe-4c97-90e9-1f64f894deed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_77aa7eff-ecfe-4c97-90e9-1f64f894deed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32c6bcc6-cd77-475e-83bc-033705db1d1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32c6bcc6-cd77-475e-83bc-033705db1d1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c6b21f87-5f88-4b71-a754-f888a34d6f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c6b21f87-5f88-4b71-a754-f888a34d6f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_186ca98f-56dd-432f-82f9-575020b8d180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_186ca98f-56dd-432f-82f9-575020b8d180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f355ce5b-ef33-4355-9137-e70538000c88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f355ce5b-ef33-4355-9137-e70538000c88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7d27816d-7598-435f-be13-cf659d4ba2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7d27816d-7598-435f-be13-cf659d4ba2a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6d7eb2df-2c02-4473-bfc1-dbfd30b5bb53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6d7eb2df-2c02-4473-bfc1-dbfd30b5bb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c24857ad-7f57-4541-9b04-121f04d72e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c24857ad-7f57-4541-9b04-121f04d72e73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e7ef77c0-b461-4801-a91f-45b689277c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e7ef77c0-b461-4801-a91f-45b689277c7d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended" id="i4ae7f0e100024047bfca6931da0f97ed_AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3466fee9-54b0-4305-ad34-0cd4da6b86ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3466fee9-54b0-4305-ad34-0cd4da6b86ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_227d79ec-2f6a-4c3a-ab0d-1a00baa3330a" xlink:href="fold-20221231.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_227d79ec-2f6a-4c3a-ab0d-1a00baa3330a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f357d60-1800-4ee0-b6b5-60d502c8614f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3f357d60-1800-4ee0-b6b5-60d502c8614f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696b092f-9b34-4976-abc7-22626ee4aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696b092f-9b34-4976-abc7-22626ee4aa09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_cd9f58d9-0c9a-44b1-a7a3-1f180f1cf859" xlink:href="fold-20221231.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696b092f-9b34-4976-abc7-22626ee4aa09" xlink:to="loc_fold_CallidusBiopharmaIncMember_cd9f58d9-0c9a-44b1-a7a3-1f180f1cf859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b5cf3417-cc64-4a36-a183-4fa4dfd6add3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b5cf3417-cc64-4a36-a183-4fa4dfd6add3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_506140a0-0585-4cc4-9ff5-fe98953c45ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_506140a0-0585-4cc4-9ff5-fe98953c45ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_60fbdf72-8366-4071-9968-d918d6b19667" xlink:href="fold-20221231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_506140a0-0585-4cc4-9ff5-fe98953c45ee" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_60fbdf72-8366-4071-9968-d918d6b19667" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e262ada1-c52b-45ac-aa9f-a5b6f520baba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e262ada1-c52b-45ac-aa9f-a5b6f520baba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_124d6897-b339-45a1-8f6c-db73b7f375e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_124d6897-b339-45a1-8f6c-db73b7f375e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_8a04a407-e799-4be0-80f1-b2189a31a7c7" xlink:href="fold-20221231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_8a04a407-e799-4be0-80f1-b2189a31a7c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92e94206-2036-47f8-807b-3c47b21aff4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92e94206-2036-47f8-807b-3c47b21aff4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d29d97-7264-40d0-9e81-d2b5e4bb54f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d29d97-7264-40d0-9e81-d2b5e4bb54f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TB200PompeProgramMember_f1f6b348-bcf9-4236-b22f-7fbb27f5c4a8" xlink:href="fold-20221231.xsd#fold_TB200PompeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d29d97-7264-40d0-9e81-d2b5e4bb54f4" xlink:to="loc_fold_TB200PompeProgramMember_f1f6b348-bcf9-4236-b22f-7fbb27f5c4a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_6c722eab-a5e4-46ae-b379-4fb0fd51479a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:to="loc_us-gaap_ValuationTechniqueDomain_6c722eab-a5e4-46ae-b379-4fb0fd51479a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9f064031-f3d9-422c-b7a1-3801057c489c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9f064031-f3d9-422c-b7a1-3801057c489c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_33fab0f0-3fd2-4b32-a88b-e2b95161ad25" xlink:href="fold-20221231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9f064031-f3d9-422c-b7a1-3801057c489c" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_33fab0f0-3fd2-4b32-a88b-e2b95161ad25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_12f7cdce-7922-4e45-bc1b-2dfe09dca46d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:to="loc_srt_RangeMember_12f7cdce-7922-4e45-bc1b-2dfe09dca46d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:to="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aac7cff4-47bf-4882-a1fa-f58c0c423b03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:to="loc_srt_MinimumMember_aac7cff4-47bf-4882-a1fa-f58c0c423b03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a68b36fc-ccef-4661-a569-46e426584093" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:to="loc_srt_MaximumMember_a68b36fc-ccef-4661-a569-46e426584093" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended" id="i037314d038a74e92a74ecfc474626c6d_DebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c4a452b-6be4-4454-9eec-8cd372f34e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c4a452b-6be4-4454-9eec-8cd372f34e26" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b272ebdb-59a2-4088-9552-670d49c5468f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b272ebdb-59a2-4088-9552-670d49c5468f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_501c3b22-1d28-4ecf-b87e-b8ef8cc6d470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_501c3b22-1d28-4ecf-b87e-b8ef8cc6d470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_af393ac8-4ce5-4f46-8b33-e43305fd4b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_DeferredOfferingCosts_af393ac8-4ce5-4f46-8b33-e43305fd4b36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_769698a4-8131-4cea-af77-6bea992a607e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_LongTermDebt_769698a4-8131-4cea-af77-6bea992a607e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c4a452b-6be4-4454-9eec-8cd372f34e26" xlink:to="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c8ebf763-1baa-4ac6-b1d7-66618907c434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c8ebf763-1baa-4ac6-b1d7-66618907c434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_589abd77-5568-4ecf-ac1e-5c917fae1c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_589abd77-5568-4ecf-ac1e-5c917fae1c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_28fb5952-e4d6-4cb0-83ed-7c2699c5d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_589abd77-5568-4ecf-ac1e-5c917fae1c74" xlink:to="loc_us-gaap_SeniorLoansMember_28fb5952-e4d6-4cb0-83ed-7c2699c5d4c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:to="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a4ce9e49-f67d-4953-b3bc-3cf16f3989b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a4ce9e49-f67d-4953-b3bc-3cf16f3989b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_a949f410-d621-48f4-b836-64fc22395e54" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a4ce9e49-f67d-4953-b3bc-3cf16f3989b5" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_a949f410-d621-48f4-b836-64fc22395e54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended" id="ia3244a7658704c5d8c323fca15099695_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c73a51ed-86ca-4a73-bc95-bf759a80f56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c73a51ed-86ca-4a73-bc95-bf759a80f56d" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0b05381e-c361-4596-a17e-a7b4827f700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0b05381e-c361-4596-a17e-a7b4827f700e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentVariableRate_8bc2bed5-d126-47f6-9b04-3498fd0c56b7" xlink:href="fold-20221231.xsd#fold_DebtInstrumentVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentVariableRate_8bc2bed5-d126-47f6-9b04-3498fd0c56b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d0dc38d-9f2a-46ab-bbab-60ef7e856fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d0dc38d-9f2a-46ab-bbab-60ef7e856fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_3b47876b-8cca-4869-abf2-4ea3ed5de523" xlink:href="fold-20221231.xsd#fold_DebtInstrumentPeriodicPaymentNumberOfPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_3b47876b-8cca-4869-abf2-4ea3ed5de523" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_9da74d39-fdac-46af-8139-8c02383249e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_9da74d39-fdac-46af-8139-8c02383249e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_ec210a1a-4b7c-4c3f-9563-b33359b19a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_ec210a1a-4b7c-4c3f-9563-b33359b19a34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9f60e8e4-c6f6-4b64-9452-a004977512a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_InterestExpenseDebt_9f60e8e4-c6f6-4b64-9452-a004977512a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EarlySettlementPremiums_eaa70c0c-efad-42b7-ad3d-c7db60cb3aef" xlink:href="fold-20221231.xsd#fold_EarlySettlementPremiums"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_EarlySettlementPremiums_eaa70c0c-efad-42b7-ad3d-c7db60cb3aef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db0f4e70-583b-456f-b867-e4bac5fbcfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db0f4e70-583b-456f-b867-e4bac5fbcfec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_23912380-6ca6-414a-9195-289232b78c46" xlink:href="fold-20221231.xsd#fold_DebtInstrumentLiquidityCovenantMinimumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_23912380-6ca6-414a-9195-289232b78c46" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_01169318-7925-4cf6-a9f4-2cd35baf02a1" xlink:href="fold-20221231.xsd#fold_DebtInstrumentConsolidatedRevenueCovenantAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_01169318-7925-4cf6-a9f4-2cd35baf02a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c73a51ed-86ca-4a73-bc95-bf759a80f56d" xlink:to="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8afb7032-fd6b-45fd-bdfc-e06e11d529b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:to="loc_us-gaap_CreditFacilityDomain_8afb7032-fd6b-45fd-bdfc-e06e11d529b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:to="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2b409084-cdc1-4704-9b97-c1f3952192fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:to="loc_us-gaap_SecuredDebtMember_2b409084-cdc1-4704-9b97-c1f3952192fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_17deeb64-7a53-4a00-bb06-a93c8a915f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:to="loc_us-gaap_LineOfCreditMember_17deeb64-7a53-4a00-bb06-a93c8a915f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_da9005c9-deaf-4fda-af6e-81dd6f347f14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_da9005c9-deaf-4fda-af6e-81dd6f347f14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b10139d4-5296-48dd-a575-3078c75f8b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b10139d4-5296-48dd-a575-3078c75f8b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_fd740f56-2d2d-410e-8e2f-e2835ec6fc5c" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b10139d4-5296-48dd-a575-3078c75f8b97" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_fd740f56-2d2d-410e-8e2f-e2835ec6fc5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d253e508-9935-4c18-ae22-f35ba75d4d46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d253e508-9935-4c18-ae22-f35ba75d4d46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1935b51f-7e8e-4c00-9b0e-976312be1e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1935b51f-7e8e-4c00-9b0e-976312be1e9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_b1b4218e-707d-465a-84ee-69466b5a61f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1935b51f-7e8e-4c00-9b0e-976312be1e9c" xlink:to="loc_us-gaap_SeniorLoansMember_b1b4218e-707d-465a-84ee-69466b5a61f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f15037e2-ff1e-4209-966f-a12555220458_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:to="loc_us-gaap_VariableRateDomain_f15037e2-ff1e-4209-966f-a12555220458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4d7eea27-24a2-4b30-8386-a28d0a0513f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:to="loc_us-gaap_VariableRateDomain_4d7eea27-24a2-4b30-8386-a28d0a0513f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6fa787e1-7f82-4cd3-9aa7-fe61cfa23e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4d7eea27-24a2-4b30-8386-a28d0a0513f1" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6fa787e1-7f82-4cd3-9aa7-fe61cfa23e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ad32d7a-b367-4b3c-a577-8249216c628d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:to="loc_srt_RangeMember_2ad32d7a-b367-4b3c-a577-8249216c628d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:to="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1608660e-f170-48be-8742-55832e497c26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:to="loc_srt_MinimumMember_1608660e-f170-48be-8742-55832e497c26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c295344-9654-4292-aaba-eedd5b446a98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:to="loc_srt_MaximumMember_6c295344-9654-4292-aaba-eedd5b446a98" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended" id="icd735b026b49483fac351cea41baa044_DebtInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_de15d1c4-3277-435f-87e7-7c4eba0c70f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de15d1c4-3277-435f-87e7-7c4eba0c70f7" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ace55273-0cf7-46c7-ba08-b57a88def678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ace55273-0cf7-46c7-ba08-b57a88def678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cffb9354-d150-4c32-a1d8-a3adffc7b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cffb9354-d150-4c32-a1d8-a3adffc7b3af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_f2646106-34aa-4a33-ba9d-0e4d41e6fa07" xlink:href="fold-20221231.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_f2646106-34aa-4a33-ba9d-0e4d41e6fa07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_deed18c0-5a63-4cf8-8566-f2f065ed7f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_deed18c0-5a63-4cf8-8566-f2f065ed7f60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de15d1c4-3277-435f-87e7-7c4eba0c70f7" xlink:to="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94157aa5-aef6-4c40-96fa-d9dd5da2e391_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94157aa5-aef6-4c40-96fa-d9dd5da2e391_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_81b7f79c-37b7-43ea-8ca6-1d189dc62104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_81b7f79c-37b7-43ea-8ca6-1d189dc62104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6b40080f-9aa2-4c02-a24d-665a54d3f919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81b7f79c-37b7-43ea-8ca6-1d189dc62104" xlink:to="loc_us-gaap_SeniorNotesMember_6b40080f-9aa2-4c02-a24d-665a54d3f919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:to="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_99a26d72-fa23-445b-a372-9ea50dfc4369_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_99a26d72-fa23-445b-a372-9ea50dfc4369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29990d19-c8ad-4d55-8d2a-e6a2b6ce691a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29990d19-c8ad-4d55-8d2a-e6a2b6ce691a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_814ed8a2-c734-4736-96f5-09be7f576cdc" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29990d19-c8ad-4d55-8d2a-e6a2b6ce691a" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_814ed8a2-c734-4736-96f5-09be7f576cdc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended" id="id3d96cd36ef24aaf9ae88f28ec80c542_IncomeTaxesLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9a79ddd4-6c64-4db4-89bc-e92ef04c276f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9a79ddd4-6c64-4db4-89bc-e92ef04c276f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7a8d4284-1ddc-4efc-96c4-17e4f97573ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7a8d4284-1ddc-4efc-96c4-17e4f97573ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5b762666-5229-4268-8543-1e3ee3aee398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5b762666-5229-4268-8543-1e3ee3aee398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_48bf121f-e98d-4cd6-bcd7-199e336305f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:to="loc_us-gaap_DomesticCountryMember_48bf121f-e98d-4cd6-bcd7-199e336305f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d6b2d443-33bc-4f71-bc1e-c6c703dafd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d6b2d443-33bc-4f71-bc1e-c6c703dafd51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6076c6a0-4114-4229-aae6-4427eb0c0c6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6076c6a0-4114-4229-aae6-4427eb0c0c6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_ac323afa-1e75-4401-8f0b-845992c2efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:to="loc_us-gaap_ResearchMember_ac323afa-1e75-4401-8f0b-845992c2efe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_5da57b83-0155-4ad7-975a-a497211b4e04" xlink:href="fold-20221231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:to="loc_fold_OrphanDrugTaxCreditCarryforwardMember_5da57b83-0155-4ad7-975a-a497211b4e04" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="i0889479dd4604c90a318c512ed374ad8_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_ea2cbec3-4310-4b8c-b6ee-42649363ce5e" xlink:href="fold-20221231.xsd#fold_PaymentsForCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_PaymentsForCollaborativeArrangement_ea2cbec3-4310-4b8c-b6ee-42649363ce5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_8d2aa89d-9783-4ef2-a76f-8ffd4bb5d98e" xlink:href="fold-20221231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_8d2aa89d-9783-4ef2-a76f-8ffd4bb5d98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_df0a5c42-b919-4426-8015-20958ffc1c83" xlink:href="fold-20221231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_df0a5c42-b919-4426-8015-20958ffc1c83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_4b79ee67-6f73-4f2d-b0f6-1b171513cd6e" xlink:href="fold-20221231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_4b79ee67-6f73-4f2d-b0f6-1b171513cd6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcdf682-aacf-41e1-8988-a6228ece19a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcdf682-aacf-41e1-8988-a6228ece19a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_0e02b3a4-deab-4173-bea9-21bc02212504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_0e02b3a4-deab-4173-bea9-21bc02212504" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4523cd26-806d-4d6a-bd03-99d87934fcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4523cd26-806d-4d6a-bd03-99d87934fcd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505f5319-b1ff-4fbe-83e9-5ead95d1fba2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_505f5319-b1ff-4fbe-83e9-5ead95d1fba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TerminationAgreementMember_cc3f9962-3db3-4818-b5f0-8898f41613ef" xlink:href="fold-20221231.xsd#fold_TerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:to="loc_fold_TerminationAgreementMember_cc3f9962-3db3-4818-b5f0-8898f41613ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_db8deabf-2c5a-4b1d-aab8-eca7ad99e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:to="loc_us-gaap_CollaborativeArrangementMember_db8deabf-2c5a-4b1d-aab8-eca7ad99e70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_RevisedCollaborationAgreementMember_12ef630f-c8d4-4f82-8941-57fa8399a050" xlink:href="fold-20221231.xsd#fold_RevisedCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:to="loc_fold_RevisedCollaborationAgreementMember_12ef630f-c8d4-4f82-8941-57fa8399a050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:to="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fe4f9d4-0a99-42a4-af3a-32a0f6c5e1b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fe4f9d4-0a99-42a4-af3a-32a0f6c5e1b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_54687603-30df-4ccc-9378-b36b766df854" xlink:href="fold-20221231.xsd#fold_GlaxoSmithKlinePLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fe4f9d4-0a99-42a4-af3a-32a0f6c5e1b6" xlink:to="loc_fold_GlaxoSmithKlinePLCMember_54687603-30df-4ccc-9378-b36b766df854" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended" id="i6cd4a1464086423c8582726f8578d6bc_BasicandDilutedNetLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b956178a-da0e-44ad-984e-7c8e1459e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a26dc2f-dc5c-4c2b-bd4a-728f4adedf85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b956178a-da0e-44ad-984e-7c8e1459e0fd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a26dc2f-dc5c-4c2b-bd4a-728f4adedf85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b956178a-da0e-44ad-984e-7c8e1459e0fd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bb25b209-771a-4780-b67c-3b2c2af3a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bb25b209-771a-4780-b67c-3b2c2af3a1e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a588f8ae-3860-4995-9047-aaf515f19663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a588f8ae-3860-4995-9047-aaf515f19663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_115c30c7-19ea-469f-a203-412e7ba936cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_WarrantMember_115c30c7-19ea-469f-a203-412e7ba936cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_2f656e28-ebce-442f-b6a4-ee2e956873b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_2f656e28-ebce-442f-b6a4-ee2e956873b6" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>fold-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:981bea1b-b87d-4677-ae2e-8728c40b94b3,g:80eaf27f-6f35-4ae6-9648-0cd9017af6e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_ea1fae22-d953-4995-a184-f156156eb3c5_terseLabel_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026:</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_label_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Due2026 [Member]</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_documentation_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Due2026 Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:to="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_071739e5-500b-458d-9387-b4eb763aec43_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_ae88aeef-f335-4757-86d2-db7ee9d0946a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fa86c03-0c98-4a75-ba00-1e092c55f6f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_efe4e601-7113-4fdb-b3ae-48bbb3c6a479_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_771b4567-edd6-4bae-abf0-f4e536199c9f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0d3a2863-83d0-4e9d-b65a-2a6e91d569ae_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_bb3e5564-b201-451d-9dbe-1d8e93dbf601_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_LossContingencyNumberOfLawsuits_88ddfe18-6aeb-4d75-87f6-816771084a67_terseLabel_en-US" xlink:label="lab_fold_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_fold_LossContingencyNumberOfLawsuits_label_en-US" xlink:label="lab_fold_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits</link:label>
    <link:label id="lab_fold_LossContingencyNumberOfLawsuits_documentation_en-US" xlink:label="lab_fold_LossContingencyNumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LossContingencyNumberOfLawsuits" xlink:href="fold-20221231.xsd#fold_LossContingencyNumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_LossContingencyNumberOfLawsuits" xlink:to="lab_fold_LossContingencyNumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_8b7f522b-b18b-484c-a09b-2b597b359001_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1794ffd4-7057-4aed-852b-6d8c7db9de51_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_365efd86-89da-4ea3-a264-8a5868560fb1_terseLabel_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:href="fold-20221231.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_c3296099-571e-48a2-a665-a6ae9cdf41c0_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation investment</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_c2e3d712-4040-47bf-affa-66e849856f28_terseLabel_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing&#160;&amp; contract research costs</link:label>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_label_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing and Contract Research Costs Current</link:label>
    <link:label id="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_documentation_en-US" xlink:label="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:href="fold-20221231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:to="lab_fold_AccruedContractManufacturingAndContractResearchCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_28124b78-b3f6-47b6-a928-95425c46eb6c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_cfa5fd71-10ec-4ba6-8c5c-701011edb824_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_748c07a2-ee9a-4a12-a92b-5d4ea08c711c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ab1da80f-e3a4-4fe4-8f11-bfa0e287fe9a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_10600b83-8d51-444c-b91e-91d455d60a74_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_label_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput" xlink:href="fold-20221231.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMeasurementInput" xlink:to="lab_fold_ContingentConsiderationMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_246dba15-9247-45c7-bc6b-8b07fb0ce3ed_terseLabel_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability weighted discounted cash flow</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_label_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Weighted Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_documentation_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:href="fold-20221231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:to="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bf8ce13a-79e1-41c5-a673-7478c2cf9939_negatedTerseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_2616c058-6c04-43e8-b2df-7e22fdbfd464_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e629335a-4853-4db5-8d40-46b0b138b6a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_2aec946d-b8c7-4d21-ba48-77d382192a10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_31a30bad-cefc-41e2-b62e-a75d04f1fd91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_a8a7e255-d15f-4a8f-be41-43be399db1d8_terseLabel_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones</link:label>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_label_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones</link:label>
    <link:label id="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_documentation_en-US" xlink:label="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:href="fold-20221231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:to="lab_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5b763a2f-a72b-4ca2-afff-7b757ce956a9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_0bd07f2c-e1fe-4ec7-b012-d1c13085cad6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_b1817c0b-a838-4bbe-8852-6c2bd9fab2f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f662edd8-933a-4b54-bb9c-30d82d2e3112_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7a301c5f-cc75-4fcb-bdef-0066757d05c1_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f4ca39b8-304c-4417-a231-3db9ae315ff2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0f8051a4-2118-4bb2-a12e-df9d3fa2727e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_a1c6a722-cacb-40fa-bd69-5d74e2ac6d42_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5f61394f-5da4-456c-ad9c-9164af34101e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_83ba9e26-c5d1-48cc-9389-8e4346338066_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_16a05390-8940-4508-a597-7861122bd5c7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ee5e0174-565b-45a2-a392-76b3d7bc66f8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, net of taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_8a73a56d-8d04-476d-b875-583f45539030_terseLabel_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense</link:label>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense [Policy Text Block]</link:label>
    <link:label id="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for interest income and interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:href="fold-20221231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:to="lab_fold_InterestIncomeAndInterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6d3cd6cb-f49f-429b-8713-011ab9f749f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_3120f6c8-52a6-46ea-890b-13a9c1ecba83_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_13c879a5-1af3-4776-971e-dfc28aa6eb9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96e73d91-76ea-4682-acc2-125db970d859_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2d15da69-dbb7-464c-ae42-258cc125a619_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_92a8bb07-915e-4228-953a-7fbced65ce2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_adfacea1-9a7b-4515-b7a8-5323136fc0f0_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6d9de9bf-b94a-4bc5-a2e7-a9b75ed9bc20_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_1d7e46bb-4a3f-4307-86d0-f170b484cc87_terseLabel_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Gain</link:label>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Policy [Policy Text Block]</link:label>
    <link:label id="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for other comprehensive income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:href="fold-20221231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_fold_OtherComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0773503c-57ed-4f62-97ce-31e6c219d1d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_794116ba-a53d-4e4f-9f09-c11adb2c8801_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ddf9e4a4-902b-40c4-9ce3-ea43ec77d314_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_05fd2537-5e4c-4229-9c57-3166573d8ee9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f7f3e037-da98-4475-9c0c-9ef071596e6d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8b605ac-c4cc-4caa-8325-9804a7e8911e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_07679cf2-9a99-4828-a35f-136e9c25f8da_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_ab9c5af7-ad1f-4638-ae6b-0298bbef7e91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_cb31530e-12c0-4553-8186-02054d9b3419_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_3aa4ba07-2cfa-46ab-ad33-fc061c2c8fae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0393bc53-41eb-4d79-a804-8b8bff563445_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_35ce5902-0101-4ffa-bf93-d9c62d6e002e_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_e7313a04-8898-4bdf-9cf3-9df90a36fa15_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_30caf7e6-620e-4848-ba19-78f8fd0aa935_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_46a05200-f226-4e55-9b82-290686ce153f_terseLabel_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised Agreement</link:label>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_label_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised Collaboration Agreement [Member]</link:label>
    <link:label id="lab_fold_RevisedCollaborationAgreementMember_documentation_en-US" xlink:label="lab_fold_RevisedCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_RevisedCollaborationAgreementMember" xlink:href="fold-20221231.xsd#fold_RevisedCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_RevisedCollaborationAgreementMember" xlink:to="lab_fold_RevisedCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_10e29d34-f48f-4ee8-8ddc-5dba85c239b3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f3f6e5ae-6938-4890-97fd-d608d3655963_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9fd14095-aeb2-45b4-a4ce-6ed230a42d8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_246c91b5-cc80-4b66-92a6-ea0706948dff_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_eaadb3a8-b936-410b-893b-114a35c15dfc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the statutory tax rates and the effective tax rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_7d3b59bb-d48a-4d89-ad9a-45361f301743_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payable</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Royalty Payable</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:href="fold-20221231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:to="lab_fold_DeferredTaxLiabilitiesRoyaltyPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c168261b-942c-4754-a3cc-b133d0b1d0ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_26c8bdcf-bd69-4944-9aa0-8c2cb3b3008e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_1ed95fa2-4c4d-42ee-a9af-cf4c264b018a_terseLabel_en-US" xlink:label="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges and other asset write-offs</link:label>
    <link:label id="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_label_en-US" xlink:label="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges And Other Asset Write-Offs</link:label>
    <link:label id="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_documentation_en-US" xlink:label="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges And Other Asset Write-Offs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:href="fold-20221231.xsd#fold_AssetImpairmentChargesAndOtherAssetWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:to="lab_fold_AssetImpairmentChargesAndOtherAssetWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5983f20d-ddd9-448b-b19b-fd9cc824b95b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c777df9f-14a0-469e-ae66-a415417394d4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_749f03b1-472e-4bcf-a17d-700b1b857a15_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_48e739c2-9223-4ad6-b228-226743451502_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_324c3c36-21c9-436a-b800-bfca79e88c03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_bda02e8b-28ab-40bf-8d24-34ccfe411211_negatedTerseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, gross unrealized loss</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_dc97d6c5-23a7-4dc0-8613-743185b38ea7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_b6a462af-19c0-44fb-8d8f-6eb2bc589cb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements paid through lease incentive</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ddeccfb4-8671-4e70-a190-eac462e17cd1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e260b196-99b1-47f1-b44d-836dc1a2ebba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_77cf9626-d54a-427c-8339-7307d624d4ca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f4e17d28-1460-4c4a-86c0-466dd0fde406_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c1b02da2-0057-42f2-8122-cdb684bf8de1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_c129a093-b0b4-470e-8d57-f82c67751c61_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7df26d51-2eb8-4406-b0cb-b7a77d4d4199_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c579c697-53a0-4c97-bb12-216285a392e1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a94fea40-77a1-4916-bd85-5922da2f1e28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of the operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7e79e424-4c0e-41e2-a5bb-738a19fc0273_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_146bad01-2d1f-40ef-a582-135c9008f9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested RSU Activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_85b5c314-26fe-4a2f-9a46-5ebd2b7615a2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration in cash</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_abcba667-97b4-48a4-9e8d-a44b2372e480_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets and liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Operating Liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:href="fold-20221231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:to="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_b8db3e44-0db6-4e5a-8066-73e6e9582cc8_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly vesting percentage</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_761c1661-e7c1-450b-8191-0086e0c34a4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9c3127b2-041d-4a04-89e9-d7b82295b721_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_1c73f5ec-f50d-40f9-876e-c3ec294f653b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_6f5a60f9-9d8f-4eb5-b30b-d27c8d5ba8c1_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d8f02f02-f683-46af-af5d-1019d3c0502f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e6a9a873-f4e0-4cef-b207-0ec23e5de25e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease terms (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_92137f1b-be04-46c8-924d-466f182e5185_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d03d8482-10b6-475f-b85e-c1f3d92936af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_5fec8838-faa5-4596-9222-21695058f1e0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c061627a-3356-43d6-a5f7-e1f602892c7f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0e5d0d8b-f240-41b3-8bde-a0c52662c54d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued from equity financing and pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2af65c68-9822-4ab7-b520-4ea52304d93e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_6c63af5f-28eb-4ca8-b17e-e9b1b4b0fde0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentsAbstract_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentsAbstract" xlink:to="lab_us-gaap_DebtInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3da35725-9344-456e-97d7-baa62210fef8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_24ed7ed3-3794-41d4-963f-d33852bcec33_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a62f6421-2352-4403-b847-7b84a30b1438_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_1088e8fa-2eee-4444-8429-70bf68504d46_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtAbstract_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract" xlink:to="lab_us-gaap_InterestExpenseDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7937bcd2-9cf3-4049-9972-b1f5777b07b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c303f1b0-7686-4938-841a-91b3bbac7486_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_dc1a8ea2-666a-42e2-b4f6-2333feaebfb5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d13e389b-8969-43b4-b886-2debdd836feb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_323c56c0-7f53-4149-8f0a-0852972f458e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_40e564a9-a146-4c83-82e9-86714a566917_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_83ecaec9-6361-4e6c-8979-12d408c4e278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_be0d07f6-df64-4f64-85bf-fcd23c9cecba_terseLabel_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales rebates and discounts</link:label>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_label_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Rebates And Chargebacks, Current</link:label>
    <link:label id="lab_fold_AccruedSalesRebatesAndChargebacksCurrent_documentation_en-US" xlink:label="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Rebates And Chargebacks, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:href="fold-20221231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:to="lab_fold_AccruedSalesRebatesAndChargebacksCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_42c85636-45d1-46ca-8ffc-71e5c79766de_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b6d48bd3-e84b-4b2b-a85b-af1f7dd01bdb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40ebeb41-fcee-4578-9e3a-8c5f7ceab4bf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bdcadde6-2ff1-43a5-bcd5-0dbd48847f4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_0a5c1dc7-0f34-41b6-a8da-f205952c541e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c7f2393c-0169-4604-8a42-658c79c70365_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_72219b96-9cf0-4e80-a9dd-f3ca70cc3a86_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_a95b0c6d-49e3-460d-8045-c742c233d3a5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_96c6b94c-2e8e-4024-a9de-5b3563896e7d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ee882d96-6739-4e29-86e5-e9095932bcad_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_fe02804e-3f50-4c36-968d-cdbdfa251d03_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_1e0ef960-53eb-4c0c-ba12-66823028b8f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross cash proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_bf352138-2a8e-467e-ad3b-6291c79de94a_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_05322826-af01-44d8-a3b0-f9723a4fb472_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d8a63e14-de9a-404b-8698-51e7e9fed682_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4bb2be03-9ffd-4222-ba1d-71a7c52bc4b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Anniversary</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_b96cff07-fea1-460a-b864-6c094242a276_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7f22ae0a-a0a9-4a7f-9e52-5443631160dc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5b983486-650b-4136-a7df-e0a274c4e21f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_cd4b72a3-f23e-43ff-9c95-3b6fe6ee85ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bc24c54e-2d7f-48e4-95f3-f63167f87b2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5a3c7572-2f81-448f-8f57-e12da15de527_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Assets and Liabilities Subject to Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6710eb0c-e538-48f0-a6ce-15513dd7108d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_092930de-b61d-46e7-bef2-cd33b8bfd3bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_1e02a0af-4412-4249-8e0d-d6fc05ce645f_terseLabel_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Convertible Notes</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_label_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes2016 Due2023 [Member]</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_documentation_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:href="fold-20221231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:to="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_76dd862c-96a7-4aa2-9a4b-cb1ceb5d6036_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_21ce91f2-253b-4caa-b268-2235c40017ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5c499574-bcf4-4a9f-a3b4-4fdb9627b05f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e97b8046-896d-4a6a-97f1-dfee64b569f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_91f09646-15c5-45cb-9bcf-66b2b3ee3cf7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7a808aac-24e4-42ce-815b-7394b7536d9c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_5a40380f-9347-45d1-83f1-ce36a5c873ef_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_09ec9839-35a8-49a7-a3da-84b5913bc910_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_c0113021-03ef-4d61-832c-94f7918fcc0e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d15aa2a6-c4d2-437c-927e-30b2db5ba2a0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7ae9d03a-5cfa-43bb-a4d6-00fd579204f5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_66cffc25-b1ee-4f0d-8641-ef3357f6429a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c474b80b-0cfb-46a6-a962-3d892667eea6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1687f980-d83a-4978-9bbe-df29076279c2_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and deferred financing</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e73f3bbc-3cb3-4986-a673-6e1173c2817d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_543b89c8-e18d-493c-af38-bb749322be22_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c1f53896-d257-456c-bc39-ba670644444e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_752d58e4-2227-4db0-9b8e-9e7a818627f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ef60fff1-fcfd-4cfd-aadd-b505bae59ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1d92ca8-a262-4c7d-bb18-851febe0120c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_93a8d04f-cea5-4b97-a608-e326f5f9beaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41122608-94a0-4ff8-a9e4-f47cc84d90bd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_df6c9ac6-be22-48f6-859f-31e223a059f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0b2b8c13-2dc5-4f20-a0e0-920f8516250b_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c492309-fd76-48c5-b215-f817b0705a95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_04fe4e33-a471-4feb-bc16-874a615c1266_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_acf3b893-abcd-4b89-a772-f45332393fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_79d2d121-a5b8-46db-8db2-3f335edc96f9_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e266d806-a575-4f27-ac77-f6d6eb3cb5a3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1254702a-b8ed-4175-8d14-8730e3e1a497_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued from equity financing and pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_291038a5-eb8c-4c19-97cf-9fec5ab53a35_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from equity financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_0bfc23ae-af7e-4b4d-b179-bfc83adcdafd_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_523006de-db3d-472d-a452-1198bae282a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_615b13fe-7e0c-459f-860e-5308b60165cb_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_bca62745-c4b4-40dd-8402-abbc7aa1bfdf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_3a108b4d-65a1-41a7-9af2-959398bacb13_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, net of taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bf711876-8c46-4446-bf79-144e0923e284_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b7232a6e-4308-45f0-8f39-6c0f8c10e772_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b8112172-e0a2-4694-9d32-b02d4b0fbbff_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_065ff68e-f09e-4113-bfef-69a71a589569_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_4378e527-c499-4087-9cb9-0baf78ab06f8_terseLabel_en-US" xlink:label="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_label_en-US" xlink:label="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Warrants And Equity Financing</link:label>
    <link:label id="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_documentation_en-US" xlink:label="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Warrants And Equity Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:href="fold-20221231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:to="lab_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bc7266ba-953b-4bf1-a6b0-cf693e56a32d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cdf8b882-97b9-43da-884c-e415b9bc903c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9519b0a1-b47a-40f5-bfab-ae7e7b4d474a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_6b62266e-ebf6-424e-aaec-5adbaca6fc15_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_8b3f524e-a8e7-492e-a64b-8b416998a5c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockExercisesAt798Member_4750668f-f4f2-4925-8128-d3df0f79bfe8_terseLabel_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98</link:label>
    <link:label id="lab_fold_StockExercisesAt798Member_label_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98 [Member]</link:label>
    <link:label id="lab_fold_StockExercisesAt798Member_documentation_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member" xlink:href="fold-20221231.xsd#fold_StockExercisesAt798Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockExercisesAt798Member" xlink:to="lab_fold_StockExercisesAt798Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_74ac115c-5f05-431e-956d-4dc2f7fcc7a0_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5aa1b79a-78ac-48e6-97ab-17878b923989_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_11e68ff0-38b9-49b0-aa8f-d5dca9dd4dbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ca91fdd8-1d6c-4bb7-8dde-7b854bddb4c9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ef168dd5-2dae-4bde-b9af-c23d5cde625c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_85eb9fdc-bc5e-4943-85ba-e573827a7d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AuditInformationAbstract_label_en-US" xlink:label="lab_fold_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_fold_AuditInformationAbstract_documentation_en-US" xlink:label="lab_fold_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AuditInformationAbstract" xlink:href="fold-20221231.xsd#fold_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AuditInformationAbstract" xlink:to="lab_fold_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_692200fe-386e-47c4-8735-bcb8c6c7bd80_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Non Cash Stock Issue Non Current</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:to="lab_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_8241a842-ecde-4f1e-8501-897a0de7a105_terseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, gross unrealized gain</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_82c639ba-2097-4ba0-b755-0f1c95e71fb0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_eee395dd-3081-4f7b-a467-af3852b892d5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_7784cbdc-0f55-45de-b30b-af9805dc8b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and experimentation tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_191ab473-fb42-4b0f-8b74-72b8337f3af8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bfc87f90-331b-477e-92d3-b0a64999b16f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_485bf940-cb83-47c4-b9bb-a9e90dfa8f26_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_990eb6ae-c581-4cb5-bcb3-7edb6f55abc9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_80232f9e-b7c9-45c7-992f-4c977be8b54d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest as of the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_87df9116-c5f9-47be-8422-9faf8d5dcece_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8d15f339-1ada-4ae9-b4b5-32ff6f66c6c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, cash balances</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_15cf1208-116b-48aa-993f-51ab69f35c77_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_4058a4ea-5e32-42d2-b3a1-f31dcafa6db7_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7a7d3653-8e20-467a-be93-b47f2f7edfb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c287eb8e-f972-4e42-b80f-4c5a8a000124_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4732a6ac-cbf8-42d9-95d5-d64180a9ff4b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_924e650a-e16f-4b96-aabc-c6835f2d60d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0f52db5a-fffa-4c9b-8834-ad9228aa2867_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_c2da0a96-7817-42eb-9e94-83f3d0a0bcb5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a3d2f752-b2b0-463b-a6c6-34e12c538ee8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_890d03ef-b9e2-4d7f-adfd-b6a173686ed8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_9ac446d3-bd00-4380-96bf-ddfc98ba165f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6ab2ac00-0232-4a75-b397-d6539a317d71_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_a9d7bb87-2634-41b9-bd49-4947f9dcc163_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_c6d575ca-139f-4ca8-bce4-6e25b4e4b710_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_13e41025-d3cd-4262-b009-d96e28d0f326_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d0273f1d-7a9d-4a2c-8d9b-42ff301f63f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f6d1bc0b-0e9d-44cd-8539-cc4b09bd0ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_dd620132-af4a-45d8-a3db-78ff636dc804_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_b5aa7d1f-3925-4541-9ac0-905ccda4dfea_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3107401b-b244-497c-950d-0056bcd6712e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6f7f928a-338a-4041-8389-995fd7087d46_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_03931053-65f8-42aa-aaad-e4f41067a2f8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1a776b89-01a0-4f2d-8afc-32685ad6cc7c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_c9d3181e-a8ee-47bc-81df-fec83af118f3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_034783cc-faa0-41fb-a0ed-9c1dfaf37329_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_c3742129-6e69-4122-8a3a-58cde38fbeee_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_76840741-5031-406b-9057-cea0cf819624_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fbe877c5-c2fe-4c04-9e18-1321036b7ddd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_11ba2bbc-364d-495a-a312-5275e8a22aed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f12b4e8e-a2f1-48ba-b55c-c97230e49b8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_1422a44c-7b3f-4637-a9f1-41850caee6af_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_54e459f0-bc77-44ed-9b8d-dbca62c0f01c_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_a1aa1319-4815-4d12-916a-3ab3756328df_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend per share (in dollars per share)</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9d277d56-cd43-4ca1-bbe7-70c1fe6c83c8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_29bac43b-0f30-4b82-80d7-abc54bb3d6d4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ccaf4af0-1507-4c94-88fa-0db49866ee39_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2cdf6b82-6542-4391-a000-5e8feefde8d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_16b31edf-42d4-44c5-9f9d-9bcfa2805c46_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2d944129-4ef1-419a-bcf7-ef6c92accb2f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_c5a1aef5-090f-4fe8-a45d-334e89389587_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3b6492c8-1f1b-4a1c-ac1e-0e2ddceaf067_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ca2a3f87-880d-4a49-94c5-ecd6058b9ee7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_411e3f06-0a7b-48c4-9e4d-a855fd43708a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_TB200PompeProgramMember_d763ac94-1722-4a42-90a7-d474562276f9_terseLabel_en-US" xlink:label="lab_fold_TB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB-200 Pompe Program</link:label>
    <link:label id="lab_fold_TB200PompeProgramMember_label_en-US" xlink:label="lab_fold_TB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">T B200 Pompe Program [Member]</link:label>
    <link:label id="lab_fold_TB200PompeProgramMember_documentation_en-US" xlink:label="lab_fold_TB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to ATB-200 Pompe program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TB200PompeProgramMember" xlink:href="fold-20221231.xsd#fold_TB200PompeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_TB200PompeProgramMember" xlink:to="lab_fold_TB200PompeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cb63925d-bb9c-4355-9280-72955ba5a682_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_460c5a3a-f4f5-4b22-9cdd-0da321067eae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate of the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6aa91557-4412-436e-811e-64595779c017_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_e1d2b988-7fb9-4a8b-91c3-9fa6690bb82c_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_77b1586e-62db-46f7-b78f-8395133a3c66_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9a4ebe77-4887-4aee-9d01-2c0d11795547_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7fd6b887-7016-4299-b5f8-7dcddb29c126_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_afd05a27-0441-4046-be69-1d4bfc82e101_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of the operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_bae806e0-a47c-44fb-a3a9-2d2e3079dee9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_d6e3e548-6710-470b-a5e1-ebcb89ef9eca_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_77e5c4aa-9f0e-4177-a3e8-0b3e9d1bed5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3858c8eb-8acc-4b72-b61a-494a308dde04_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_15f6bf14-050b-4289-806b-3db6802936eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_94ae048a-2714-4189-8115-956ba5a0f02a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_3085970f-2ca6-4ec2-bb03-2496f712d3b3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Disaggregated by Geographical Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_30fff11b-f1c2-4c7b-aa43-c4e15f64a305_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8aafb048-9674-436d-989a-6371d4abd181_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5412a63b-76ca-458b-86cf-3c4295d882cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_4d293661-bed6-4f0e-b0fa-899a9ca9a568_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_865fce3f-0d3c-407e-81ea-bc3662c52eac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3b9c176d-866e-4126-a8ad-2725539ed23c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_fb69ac3b-65e8-4d2f-b17d-c1927005f175_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_76c52b0f-3f8f-432c-8f07-cf3dd3df50ea_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b03f19fd-7ccb-48aa-a41e-bb29275d4853_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ca379dc3-e29e-4dd6-b512-121748f52dfb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_819eb464-7081-4529-a4b2-a50b4fdd6261_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_ab8f3110-b726-4a31-90dd-fe06344e0089_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3285a38-722f-499c-96bb-f637713121a9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5fd9a19e-fb05-48ff-b173-e2ba81a130a9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_6e9a1263-6a14-4f68-b8d5-99559e0d70f3_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fe6eb1e0-eb64-430c-b133-fcb27a7ba09d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15492b6c-1e04-42b4-9ef1-257b2695d8c4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cdd651ee-46dd-4b87-a41e-91f757e76f8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units as of the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8c49e580-2766-42e5-97f2-69875b89d163_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_8327c485-1051-4b46-b392-e4a7613f84e3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_71bf37e0-25cd-47bf-9658-30ab850207ad_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities [Policy Text Block]</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="lab_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_2226925c-3540-4472-8c3e-1636945533c6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_a7e9707c-0e99-4e06-98a0-38c03feb3372_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) gain:</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_50430411-a352-4841-b572-5cfe32a0eb7a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7e233471-1ef1-42e5-a5fa-6d340baf5a2f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_52236760-91bd-464e-8cef-781c28e8d7ee_terseLabel_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conditional aggregate payments per indication</link:label>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_label_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Conditional Aggregate Payments Per Indication</link:label>
    <link:label id="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_documentation_en-US" xlink:label="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Conditional Aggregate Payments Per Indication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:href="fold-20221231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:to="lab_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2532f2d5-a122-4494-84f0-cbdc92d32522_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_0e1e575f-863c-40f0-9b9a-dcb9c948f698_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fd852f56-0073-41a0-b57c-f1fc88d7dc01_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6a4a14d5-6f90-4869-bf2b-6c0d64bc5d2e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b0835b69-248e-435d-ab91-afe0c3999910_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_64488ca0-3069-452c-abb3-5cbebbf3cfca_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_2e77a547-cd6d-48e3-9983-f9913b2f319e_negatedLabel_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_label_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_documentation_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:href="fold-20221231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:to="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_d75a544b-36bf-40f9-a56b-98ed95dddc51_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_a1123088-e653-4053-b0bb-6f2e00d21419_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c2c845dc-f504-4cf0-8d0c-1232e9f20467_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest as of the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_484e2b09-0576-42fd-a2fa-60b8b900b58f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f5d15970-853a-43a3-8b43-1815bd9fab1e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_66f529b9-d576-41c3-99f4-a7f1f6ffe52f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_974f83ed-a3ea-4ebe-a539-03d8c2504999_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred financing</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_9ab6d9cc-79f5-407d-9f39-824d948e3b0f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f08fd778-734d-4858-bd8d-198bf5787203_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f05827a3-1a72-43d6-a0a7-8728c964dac1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_9aef5b0f-c316-4750-8de8-801d5f3d427f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_55017d92-2e31-4610-9c8b-aa5a7eb882fc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a1b1322b-a0b5-43f8-8290-e71e64dedb80_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_abebf053-98be-46d9-980d-3bff4171eef9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_7c3ed952-3c8f-4ead-ad95-fabc9fda26e8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_27ff1695-828e-43d3-a083-8821627255e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_af626732-f57a-4418-b0bf-483c1019ae2e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6bce4b6f-2ef2-4099-ae84-1c614606c0ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cf741cf6-4ee6-45a6-b90c-faf129a62da7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2d190eb9-98b6-4789-9163-fe7840db6545_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_55113c96-74e4-4627-8d75-ee3389ef51ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_b1bf5133-9413-467b-bcbe-4039495a9564_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_14e3e174-2e04-41b7-ad44-7a56a85bd1d8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95ab2335-6da9-4858-b350-518c4f9a7d42_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_621b5944-060a-46f8-bf3a-ecc7945fa08f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_51e80c2f-0b7b-472d-a4e8-530362c664f5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7c42826b-6090-4f37-8017-cd69765ba2bd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ad88cf0c-06f5-4069-8537-473dcaf3e0c8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9ae79ca4-06ea-4311-b72c-8a2935334c09_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b8f3eb86-7f53-4bd3-897c-178316ce32f4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2bc4ac2b-e566-4b37-bbab-ed4ecd4e18b2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_599c5b06-5e17-4f66-96a3-cbcb66cc7dff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8641316b-d50d-4390-83a2-a5f1173b33fb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_3bad6267-d8ca-45bf-8db4-81261fae44e0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b65bca43-be60-47fd-a7d7-86597de517f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b486cce8-8af4-44d3-80c3-87b744bfd376_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_8d033a6a-6687-4d2b-89ac-d8c42c73eee2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6936bcd-8445-4d4b-a23f-d323ade8737c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e704a090-0159-4606-8687-a217a0edeb72_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_12a5202e-923b-4430-9470-671249e1deaf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_86855d84-b87e-48f5-a129-5170f6d8112e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_711a3fa6-295a-4a83-b97f-921e3ee5b786_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_6a64d800-5ceb-4cd7-a33d-ea703eeddda1_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="fold-20221231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1398ef01-743b-43df-9d8b-d0ab035e3728_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_bcce74db-969a-4fcd-9c19-c0a011bc782b_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b178cb56-f60d-4478-b62e-f91f85358a51_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ba5fac77-bc72-4b78-a7a8-8f86fd0dc00b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_08599401-0880-46f5-9c00-5b76d88c72a0_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_38192207-0043-4523-9351-8f87ded6b0eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c85ca52f-f6e0-4700-91cd-7e3ea9dfd46d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_605cb3b4-acee-448b-919d-1004ad8e74a2_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period following separation for accelerated vesting</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b01fe33-cd5b-4b2a-9c33-631517b60845_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_58b8881e-4f80-4c27-9d55-f6afdfaab8b8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42b7c025-ff77-4bc7-81af-0bd5237ec0f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_e543fef9-c965-402c-974f-6bc77a168346_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_5c026ea3-fa36-4504-9677-d97577d50085_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_dab74344-4167-44e6-beb7-c1b8ca54a207_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b00b792b-0c45-4759-b246-19259b03b394_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_20d60f6e-2496-444c-9f54-6de9c09308bf_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 500,000,000 shares authorized, 281,108,273 and 278,912,800 shares issued and outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2df090ce-2cad-42b4-9cc7-229840866c19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_720ea24f-d8f2-4f41-a0bf-9ba86ac0fabe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_68682fae-0cf9-4c75-b032-54ae538e9a7c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_d2153425-8048-4a85-afe0-6b52a840488c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a1d1c359-570a-4a74-a7a1-ebd87a17765a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_384bfaf7-0688-4e2a-acc8-3e7078010fa3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_897ec9b8-c5b9-4bf3-9ba3-27fe37c02608_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_55dc83ac-cc01-4d61-8750-2642aa221809_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_fafbab4e-457d-4058-b6b4-8bb2262b2af9_terseLabel_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_label_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Deferred Financing Costs</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_documentation_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts" xlink:href="fold-20221231.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AmortizationDeferredFinancingCosts" xlink:to="lab_fold_AmortizationDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49933230-c1c8-420b-ac1e-f657e0df2b0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b10516c-d0d3-466d-8646-5a277cb943fe_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d058ae5-56b8-4665-bc97-1516f2d7f6d3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e0c3c79f-c3ed-433f-9617-817958b5839f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3fe3eea2-4caf-461d-956c-a5f94ea309c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7eaa50b3-99ea-4997-aec1-920e1c7c4278_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d566713d-be70-4755-8830-a3c58fc7fc76_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6cb42821-c253-4995-bb1b-c8743d621980_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_039324a8-a056-4b18-bb15-3aa6f8336bad_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and unvested expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_1cdacc43-3e00-4ede-b7e0-ac9fbd44d5e6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_88307a29-c7fb-4499-9c92-328e81fb1b41_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_eadd9d86-e0f8-4d01-b287-78615daecf71_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures unpaid at the end of period</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_ba98cc90-1863-4486-9886-765602013428_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_52292a45-0bb3-4059-9b05-8a1950837cfc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_91f65dd5-4387-4552-a2aa-e81301f1a215_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_6a3f211a-cb13-4b99-b6b0-a5c1b42060c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, weighted average remaining years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_f276db48-95e5-4210-9c45-de843f394aa5_terseLabel_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan drug tax credit carryforwards</link:label>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orphan Drug Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_fold_OrphanDrugTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent the information pertaining to orphan drug tax credit carryforward.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:href="fold-20221231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:to="lab_fold_OrphanDrugTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd7f3537-2e94-49a2-9d6b-28761609ad6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of available-for-sale debt securities in unrealized loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_000a12d9-ce49-4855-bf71-7de267c35671_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8ae12aa-756f-4482-809c-66e7521703f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6a78181a-7039-4c9d-8c8c-9fb91738be1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_af193de6-6522-4f3a-90d4-af950fb3390e_terseLabel_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achievement of milestones</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_label_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_documentation_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:href="fold-20221231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:to="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9267b7a5-e2f5-495d-8414-80d212b996fb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_029b7d1c-35a5-4f58-9785-0c8ceef53268_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4c6fa18-13bc-4473-bf23-c93527836050_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_44cf79f9-ce43-4188-a48a-72fbe87fed26_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_37c7b311-1d9e-4ad2-a3c1-d99dc673e81e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b1c351fe-3bb1-41ca-94c9-c4254aa228a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_413ea5c6-595c-4fc8-91b9-f8a233984379_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b00ad991-f6f1-4c03-aa7c-38640fe3684c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b7a232db-5a50-429c-b82e-2a45526b3697_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f4775765-e8cf-4a8b-9792-7109efe0b33f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_674275bf-0289-4a65-bacb-778e8b7a7b40_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and Regulatory Approval Milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to clinical and regulatory contingent consideration milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:href="fold-20221231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_d764febf-0f58-400a-9bc1-ba4eff6acb40_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest carry forward limitation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Carryforward Limitation</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Carryforward Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:to="lab_fold_DeferredTaxAssetsInterestCarryforwardLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_4398397e-eef3-4e86-8af2-e3168040f3bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9262b8ff-f0a2-4a63-b1bb-453d8c21e0ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_df48be20-aa26-4e18-9544-661016643862_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25812db4-ff83-472d-bb5c-741885f6a304_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20541260-cf2d-46dd-807a-f1702e022770_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_72ca16ff-5f89-4ef0-bdee-ffb146de2dc7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Total Interest Expense Recognized Related to the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_793e7065-1c28-4358-9434-884c0a50b752_totalLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Liabilities Gross</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLiabilitiesGross_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsLiabilitiesGross" xlink:to="lab_fold_DeferredTaxAssetsLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a2a64571-a0ee-49cf-abcb-875435e602e0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_b7306a85-a358-46ec-92d7-0fc2b7cc1733_terseLabel_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments upon achievement of post-approval and sales-based milestones</link:label>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_label_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments</link:label>
    <link:label id="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_documentation_en-US" xlink:label="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:href="fold-20221231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:to="lab_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_276a56ad-71fb-4070-ad00-1b2e24c7d8c6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of the deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_56417dbb-3018-47a8-9d9d-ede2a6ed4596_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d572f414-2768-43e0-9a10-6d6fa4f298e1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7fae9ff9-03f4-4345-811c-5af5abf7c6e6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_86035cd7-32c6-48a8-8e59-63fb30b9c457_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, less accumulated depreciation of $22,281 and $19,882 at December 31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_46e4eab8-051f-44f9-9b66-deb135106c1e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_7498b11c-6cea-4d77-b73d-cc380f83b812_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_TerminationAgreementMember_38fadb02-c236-462a-9e86-a2a52e2defa2_terseLabel_en-US" xlink:label="lab_fold_TerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Agreement</link:label>
    <link:label id="lab_fold_TerminationAgreementMember_label_en-US" xlink:label="lab_fold_TerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Agreement [Member]</link:label>
    <link:label id="lab_fold_TerminationAgreementMember_documentation_en-US" xlink:label="lab_fold_TerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TerminationAgreementMember" xlink:href="fold-20221231.xsd#fold_TerminationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_TerminationAgreementMember" xlink:to="lab_fold_TerminationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_006e89c6-5d3a-491b-a839-ac5d0336bb56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_6beeb500-2926-4d23-b717-2af7a6ac7d79_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value during the period, included in the Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1b8f95ca-087f-4fed-95e5-90e9bac5c8be_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8c7ce00e-1f57-4730-b529-088de3bdd03a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ResearchEquipmentMember_9d009709-f257-4610-804d-2b253d4e4c8d_terseLabel_en-US" xlink:label="lab_fold_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_fold_ResearchEquipmentMember_label_en-US" xlink:label="lab_fold_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_fold_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_fold_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents tangible property used for research.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ResearchEquipmentMember" xlink:href="fold-20221231.xsd#fold_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ResearchEquipmentMember" xlink:to="lab_fold_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a4d964d0-382c-4c85-9170-374501f79673_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e470bddb-2a1f-4aac-a082-1883cbb810bc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5545f0e0-b89f-45a0-8dad-d34901c2dde9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_80736531-c9cf-4ff7-aa59-6c781f429bce_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_229661a6-2920-4a17-a94e-71f4bac0cf34_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value of Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_e20db539-462d-4850-a2aa-aaadf9c0664e_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants (in shares).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="fold-20221231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount_d4844404-d70f-4165-93bb-cf3ac4659a62_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount_label_en-US" xlink:label="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Liquidity Covenant, Minimum Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount_documentation_en-US" xlink:label="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Liquidity Covenant, Minimum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:href="fold-20221231.xsd#fold_DebtInstrumentLiquidityCovenantMinimumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:to="lab_fold_DebtInstrumentLiquidityCovenantMinimumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_acffc98d-2115-48d1-8126-ab0a69edf76c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f42fd20c-212d-4702-9d67-7ac385b6c352_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_c06592d1-74b4-48df-895a-99906faef1a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e30b2aa8-2155-41e8-b121-6a13575d8cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f72620ab-ffee-40bc-a208-f23dbdd72a17_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5b6268ff-b4a6-4aac-ac67-4e032844ced0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_5673ed0e-0cfb-4889-9f32-76202d147692_terseLabel_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_label_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline P L C [Member]</link:label>
    <link:label id="lab_fold_GlaxoSmithKlinePLCMember_documentation_en-US" xlink:label="lab_fold_GlaxoSmithKlinePLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GlaxoSmithKlinePLCMember" xlink:href="fold-20221231.xsd#fold_GlaxoSmithKlinePLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GlaxoSmithKlinePLCMember" xlink:to="lab_fold_GlaxoSmithKlinePLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f12a3bb3-7f7e-4793-a2e4-a455a571e4ca_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ce11402a-9bb6-414a-bca2-c8e9d22af622_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bcec4454-6e41-419b-8928-3ee8a62db59f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_fe9d5746-b8aa-419b-aa6a-8912c52f24ce_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_6e58acda-77dc-4575-841a-0ced69a82fb8_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payments</link:label>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_label_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Number Of Payments</link:label>
    <link:label id="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_documentation_en-US" xlink:label="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Number Of Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:href="fold-20221231.xsd#fold_DebtInstrumentPeriodicPaymentNumberOfPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:to="lab_fold_DebtInstrumentPeriodicPaymentNumberOfPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_45ca17bb-1e01-4a4c-8a9f-77aa22b0560c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_52fea9c5-ac85-4272-9f79-61cb4a46d65a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_fbcb8236-bad3-4465-b851-7897e4b7a63b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3b1f075b-d694-49e9-a26c-5ec8828819f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_f8657056-5d05-4036-9c92-3495eaa7824e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9fbb5c58-b265-4afb-8899-2a94f514506f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c7c9ec33-fddb-4fc5-9265-e11cf9f11f5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8903a763-1cfb-4d8c-8141-44513f751fc3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_02c27a21-0b71-45e2-be21-56186e3e7012_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_0122003e-43c1-430b-8477-bd7f0707f93d_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Intellectual Property</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsIntellectualProperty_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsIntellectualProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsIntellectualProperty" xlink:to="lab_fold_DeferredTaxAssetsIntellectualProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fb7b7d83-6cc6-4f0a-a65a-77e54f688285_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_043885aa-824e-41ef-9d38-76eb6e348666_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4a230342-f975-4093-b683-9a292023d8fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_313424dd-e387-49ec-833a-034f7931ed4a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ab07d75a-7c29-4ffa-b635-c367dc88e80b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_42283aa8-d79d-4bda-b8b6-5c405dce167b_negatedLabel_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_label_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Business Acquisition</link:label>
    <link:label id="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition_documentation_en-US" xlink:label="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Business Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:href="fold-20221231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:to="lab_fold_DeferredTaxLiabilitiesBusinessAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_a254a71c-3304-4501-8f6c-582db54c9239_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_72aacc07-d565-4698-937b-1c4cc56bf62c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1a9b7445-90b2-439a-9fc8-95acfbc855b4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f3379f0e-9b8e-4cf9-8e2b-0b6278f1c6b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3883f543-f069-42f9-8dfc-b637f45a2682_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f027b404-64a9-4cc6-a97e-c100c0d20da9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c5a5661f-f6e2-4a98-bfa3-9ea981be675f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_8aa2e3b2-4f8f-481e-b539-bb66790feae4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4251da38-76b6-4947-a632-35754ca87a93_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_825188db-4754-40e7-96db-58a226df69b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_feb5e019-5c4c-4131-9e51-558917099082_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_387d4a07-9526-4047-985a-f5ddc280aa88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0d3866b1-2565-4ea7-afc8-9ea21673872b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_794ffc5c-3d91-4f99-83bb-dd00067b24a4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dde4505c-47b4-4764-a36f-c3463c6f55e8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_537ea18a-91f6-4c1a-8d34-5c84ce677ebf_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_529155f0-dd53-4cdc-bae1-edc79c75a35b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_24622753-8b8a-48db-b638-117c0523dea0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b34737e3-e74a-4d9a-9513-111094b2c535_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_84a3a5a7-7b28-4968-87d7-dfba89b467df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_3f8311a7-8cf1-41a4-aa2d-76b2120fd346_terseLabel_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Payable</link:label>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_label_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Acquisition Consideration Payable [Policy Text Block]</link:label>
    <link:label id="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:href="fold-20221231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:to="lab_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_7c28e27b-974c-413f-b66f-289966cbfed2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CollaborativeArrangementDisclosureAbstract_2106ce59-2e9a-4215-a8ff-28aca4a5efb4_terseLabel_en-US" xlink:label="lab_fold_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_fold_CollaborativeArrangementDisclosureAbstract_label_en-US" xlink:label="lab_fold_CollaborativeArrangementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract" xlink:href="fold-20221231.xsd#fold_CollaborativeArrangementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract" xlink:to="lab_fold_CollaborativeArrangementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_8079e627-3f06-4f2d-9d11-eea311c70184_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DeferredTaxAssetsLeasingArrangements_a197748f-fadd-4a41-9cd9-48ac6c4b8389_terseLabel_en-US" xlink:label="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_fold_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLeasingArrangements" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_fold_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_42cb68d4-26ff-4429-9b7b-5dbcc1192879_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_47563125-395d-4691-951c-95b8de24261a_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding warrants, convertible to common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_91680773-88ab-420c-a0f1-504483c92789_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4e7e5815-6c5f-4af2-8236-f310f5226a69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e0545bd7-3d02-447f-971b-0c8136da3cf0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_6dca248a-a6a8-429c-8d40-00e3c72581ac_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8ee64e57-8931-408e-b262-4219ea08c1e6_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_d202cc57-3e41-4c23-8288-499f79bc74e7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_EarlySettlementPremiums_fede0982-3eab-4f87-95e5-034c83a61d88_terseLabel_en-US" xlink:label="lab_fold_EarlySettlementPremiums" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early settlement premiums</link:label>
    <link:label id="lab_fold_EarlySettlementPremiums_label_en-US" xlink:label="lab_fold_EarlySettlementPremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Settlement Premiums</link:label>
    <link:label id="lab_fold_EarlySettlementPremiums_documentation_en-US" xlink:label="lab_fold_EarlySettlementPremiums" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Settlement Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EarlySettlementPremiums" xlink:href="fold-20221231.xsd#fold_EarlySettlementPremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EarlySettlementPremiums" xlink:to="lab_fold_EarlySettlementPremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_16bf08c9-f36c-47bd-8f84-9d3003cb764b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0da0d2e2-d1b5-423e-ab58-add69472267b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_65b85fc8-bdc7-46d1-933b-f38b48ac2b79_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_007c2b24-efa0-47c5-9e25-660db952eab9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c24008ed-45de-494b-a535-4212629b187d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_4855f026-625b-49df-a25f-68d4f4678db3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_cbf74146-d800-40e9-b528-c55c79ab607a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ea640e05-933d-4c7c-8e8d-f297ae3bed09_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_8d99afd5-e36a-4261-bf60-0f0de1c008c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a05a1714-38b9-4bd6-b63c-c9798bc2be06_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_df4e9ddd-d7e8-4468-9515-a1b63e0365b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_485d9d12-92e9-4c2a-bc86-492794aecda7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AtTheMarketEquityProgramMember_3ffa3cda-661e-4605-8473-8e5730252d1a_terseLabel_en-US" xlink:label="lab_fold_AtTheMarketEquityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Program</link:label>
    <link:label id="lab_fold_AtTheMarketEquityProgramMember_label_en-US" xlink:label="lab_fold_AtTheMarketEquityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Program [Member]</link:label>
    <link:label id="lab_fold_AtTheMarketEquityProgramMember_documentation_en-US" xlink:label="lab_fold_AtTheMarketEquityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AtTheMarketEquityProgramMember" xlink:href="fold-20221231.xsd#fold_AtTheMarketEquityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AtTheMarketEquityProgramMember" xlink:to="lab_fold_AtTheMarketEquityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_af27ed82-2281-452b-8334-517d1a8c334f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_e5d0b992-2ce5-40d3-9e90-e4ad9a9f0b35_terseLabel_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting right for each share held, number</link:label>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_label_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Voting Rights for Each Share Held</link:label>
    <link:label id="lab_fold_CommonStockVotingRightsForEachShareHeld_documentation_en-US" xlink:label="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of votes entitled for each share held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld" xlink:href="fold-20221231.xsd#fold_CommonStockVotingRightsForEachShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CommonStockVotingRightsForEachShareHeld" xlink:to="lab_fold_CommonStockVotingRightsForEachShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a3ce8244-7c2c-405f-8e83-bb8e3fffd89e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6647ec3a-7f76-4524-b7dc-c87accf08936_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f45e9c33-9101-4b1f-9958-399c08ab7627_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f11a653f-5dfb-404f-82f5-912dcd41825f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_28e65fae-1f18-4c53-8f88-77a5dd9aebd7_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_eae85a04-a115-4bae-a281-1d4c7e01b23a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3f30a6d2-6013-426e-99a5-4334835015e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_babf668c-33b5-49e7-ac34-73e4b80fb5da_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_94552681-723a-497e-9743-46069cd58842_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentVariableRate_ecb00acb-8714-4971-bcac-16df70941496_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_fold_DebtInstrumentVariableRate_label_en-US" xlink:label="lab_fold_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:label id="lab_fold_DebtInstrumentVariableRate_documentation_en-US" xlink:label="lab_fold_DebtInstrumentVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentVariableRate" xlink:href="fold-20221231.xsd#fold_DebtInstrumentVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentVariableRate" xlink:to="lab_fold_DebtInstrumentVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_577c6b46-df01-4f74-9efe-b9c7487186d4_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0ca0196b-33ba-4c23-b59a-7745ba1a950c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d4c70c65-393a-4bed-b453-71414a669657_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_68e508e8-e419-405d-81f2-6275c87de6f3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of vested restricted stock units, net of taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4fc2e0f3-d60e-4fa8-874f-a3242c5dbedd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_606b2ac5-4153-484d-b3be-36057a1ced6d_negatedTerseLabel_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less lease incentives</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_label_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Incentives</link:label>
    <link:label id="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives_documentation_en-US" xlink:label="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Incentives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:href="fold-20221231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:to="lab_fold_LesseeOperatingLeaseLiabilityTenantIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_555a2c84-19a5-4f0d-9be9-7381fe42eb62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2df51ee4-d5b9-49bb-b899-84c50e7a2a7f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_08aebc65-c1b6-4ac3-8103-10e32b846f3f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_44e09cdc-c1c7-41cd-955a-75f3cdb303dd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_5ef3d6ee-548c-4048-9f34-afca73a3d65d_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_f7c7be59-cc0d-4b24-8815-d0c29429d03d_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ex-U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89668fe0-15ca-4dc4-a762-b4b49cf31f7f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_506811c4-4841-4780-b748-e4d99271e667_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_b349d4f8-e7d9-4c77-bd71-86dd2818b092_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_77ef750e-03a5-4858-8fc0-fd664506e1a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_8fa533dc-c12a-4203-a4dd-f5c01eb60911_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember" xlink:to="lab_us-gaap_ComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1ed0fdbd-0195-48e5-ad5d-97be368b7715_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_63f6c407-b629-4c14-9226-3a6c99d05842_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8cadded9-e974-4d89-8909-85bac69e8e9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_9f2fc1e8-0d58-4686-92ad-2156b31f42bb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_f391df12-e6a0-4c53-a4eb-744bdae1b68f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cd95718e-800d-4a8f-85a3-dd839f91fd5b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_105721c4-add9-4926-99ae-26bed360e203_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research&#160;&amp; development</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_94ccb226-eb77-446e-a8a8-456f879d8cf4_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_fc730bfd-bca8-4150-924f-f964b96c4428_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockExercisesAt706Member_20063125-1b84-4605-9c79-80fd80f3cfb8_terseLabel_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06</link:label>
    <link:label id="lab_fold_StockExercisesAt706Member_label_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06 [Member]</link:label>
    <link:label id="lab_fold_StockExercisesAt706Member_documentation_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member" xlink:href="fold-20221231.xsd#fold_StockExercisesAt706Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockExercisesAt706Member" xlink:to="lab_fold_StockExercisesAt706Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1005cb14-b00f-47d3-a1fe-709276afb39d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ecef3076-859a-4bf5-9269-1fd3bf06fcac_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_981c4e01-0428-43aa-8499-78ef4946ce99_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_5347f771-e8b2-4ea3-b64b-4a578ab2aa76_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7af1ac88-01a1-4b74-8fcd-7399d4e3daa0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLoansMember_8a613a59-26db-49ea-8704-2c4ecf4ad81d_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember" xlink:to="lab_us-gaap_SeniorLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c526f561-fbe4-4ef3-bb0e-24f4e5ecad00_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_c91aea7c-5863-450e-8038-361e84117c8f_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated revenue covenant, amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_label_en-US" xlink:label="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Consolidated Revenue Covenant, Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Consolidated Revenue Covenant, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:href="fold-20221231.xsd#fold_DebtInstrumentConsolidatedRevenueCovenantAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:to="lab_fold_DebtInstrumentConsolidatedRevenueCovenantAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSecuredLinesOfCredit_df0a9d57-f685-465a-89e2-13110cba796a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from secured lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSecuredLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Secured Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromSecuredLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_96c0b03e-f56e-4b62-a7ac-b4e0c6e5c25f_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_5e478151-d0e2-4144-b2ee-8e951e911866_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4b21098a-d8d8-4fdc-affc-2edadcf8b164_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_eb8ddd5b-cc65-49e6-8d28-1a6d0c6dd71a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_513edb60-1e9e-4ed8-b301-f3021af0568d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_75696404-0254-443d-aacb-6ff19639271e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_079276d5-8525-4804-a021-b2341283a34e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_529164fc-50ff-489d-82e2-dd3d9f648696_terseLabel_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Cash Deferral Plan</link:label>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_label_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Cash Deferral Plans Policy [Policy Text Block]</link:label>
    <link:label id="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:href="fold-20221231.xsd#fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:to="lab_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5941adff-cd8b-4f5d-bc27-2faa1f03eedd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CustomerOneMember_cbde43a6-864e-43bb-bcbb-7845f5e02b9c_terseLabel_en-US" xlink:label="lab_fold_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_fold_CustomerOneMember_label_en-US" xlink:label="lab_fold_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_fold_CustomerOneMember_documentation_en-US" xlink:label="lab_fold_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CustomerOneMember" xlink:href="fold-20221231.xsd#fold_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CustomerOneMember" xlink:to="lab_fold_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_7e8a684c-dd5a-48f1-ba62-3d197fa0322b_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a0d4c04a-0690-4560-b36e-9182482d1a83_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8d3ccc08-b0d7-4ba1-ad3d-514ba73c73f1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in the valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_4f8a8e34-814e-4951-bcdd-d6b25a9f8dfa_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liabilities</link:label>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a687d634-7263-4794-9652-02180a12be8e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_bb7518d1-cb1f-4476-a172-ee19fcac1f7e_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_effa4296-d5df-4d19-954c-d3bede9259e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_20efb4e2-c543-4e88-8a22-9aabbf232844_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_3e2726c8-3e4e-41ed-b38c-45ca48ccfc5e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_a9bb07e6-64fd-4152-9775-c0a9db7308f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_7a01c05a-0719-4449-864e-3b3d9a7ecc2a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1f1bb9a3-175b-4e91-a57d-3e9617241df7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_242df954-3d5a-4391-a35a-3443542f31e9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_50b38e83-734b-4cec-bd6f-5a026ae84da6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GalafoldMember_77175aab-3b69-4063-81fc-51696ce77175_terseLabel_en-US" xlink:label="lab_fold_GalafoldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galafold</link:label>
    <link:label id="lab_fold_GalafoldMember_label_en-US" xlink:label="lab_fold_GalafoldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galafold [Member]</link:label>
    <link:label id="lab_fold_GalafoldMember_documentation_en-US" xlink:label="lab_fold_GalafoldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Galafold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GalafoldMember" xlink:href="fold-20221231.xsd#fold_GalafoldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GalafoldMember" xlink:to="lab_fold_GalafoldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_c27e3731-c700-4045-9280-5a8df647b5e4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_98eac06a-6741-4390-9bae-9579910142f5_terseLabel_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_label_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc [Member]</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_documentation_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Callidus Biopharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember" xlink:href="fold-20221231.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CallidusBiopharmaIncMember" xlink:to="lab_fold_CallidusBiopharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_028a6eaa-22f6-46f9-b527-dcea22ff4983_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_39de2399-fc4f-4e6e-9141-397533574364_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_b13159af-9958-4540-9e78-196e35d6cec9_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity-based employee compensation plans</link:label>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_label_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Number of Plans</link:label>
    <link:label id="lab_fold_ShareBasedCompensationNumberOfPlans_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of plans under the equity-based arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationNumberOfPlans" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationNumberOfPlans" xlink:to="lab_fold_ShareBasedCompensationNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccruedProgramFees_27cdc71d-a9b7-44ee-b944-436cf740852a_terseLabel_en-US" xlink:label="lab_fold_AccruedProgramFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued program fees</link:label>
    <link:label id="lab_fold_AccruedProgramFees_label_en-US" xlink:label="lab_fold_AccruedProgramFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Program Fees</link:label>
    <link:label id="lab_fold_AccruedProgramFees_documentation_en-US" xlink:label="lab_fold_AccruedProgramFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedProgramFees" xlink:href="fold-20221231.xsd#fold_AccruedProgramFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccruedProgramFees" xlink:to="lab_fold_AccruedProgramFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6b375929-2145-4888-812a-11709c483f95_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ae1f0cf8-72c2-4091-9b9c-a5cdba3a8996_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b114deb1-8222-4243-ba7e-72209b4a8630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a632e714-521b-4f7e-8b4d-51cd0bc0a31a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0475d057-37fb-4889-912e-2b08cf53c367_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e97b6834-d601-469c-a082-62b8b3c625b6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_fe8d8b48-697f-4cc6-bc78-ab7c06e1a773_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_593d0173-a37b-4930-9833-5b2965a8c37c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7d5c99cf-5bb2-4f82-9b24-717fb5b8a08a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c6fea27f-7ce8-4a07-8ded-7ead7531c684_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2b8d2d3d-b733-4776-b865-5495f5a45564_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_7fcfdef1-7614-4e1a-81bd-2f97dcb016e5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9a28d275-73cc-49ba-9e28-e78ff3372647_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7b132c52-fbfb-4cb4-8a73-0705750db486_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_831b78ed-4ce9-4aa8-9c8e-4e5e9197d91f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8ab9ac3a-932b-47d9-b454-1f3627cfc11c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9b50f77d-8269-498a-8200-4c72272312cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_eb24a453-86ca-4e90-a75b-a4ea183623da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d5b223b4-e250-4bff-b9d9-0116e1960a97_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4553c648-0fa2-4118-89cf-e5c6c98d6814_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3c9fd248-87fb-476b-bed8-c9923afac433_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec96c50a-cb9d-40fd-88b7-2557215f0ce4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_bd6fc516-d64b-4883-abdd-e54f5fede5dd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_31cd1ff6-af4d-4dcb-b2cb-fe0579b367cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4987dacb-136a-4738-9814-72d37ae66876_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_afe1f59e-2031-4563-a32a-76a376f428ca_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b5e027b5-b9e0-4139-8ce7-53dfac484e30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_f7392d6c-2e9a-40c4-a622-15b77cb30016_terseLabel_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for collaborative agreement</link:label>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_label_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:label id="lab_fold_PaymentsForCollaborativeArrangement_documentation_en-US" xlink:label="lab_fold_PaymentsForCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForCollaborativeArrangement" xlink:href="fold-20221231.xsd#fold_PaymentsForCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForCollaborativeArrangement" xlink:to="lab_fold_PaymentsForCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d961db0e-a3d1-4811-b427-6ea118a9df0d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_24f0adf5-c215-434f-819c-1ad977f036b7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on impairment of assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_9aaf231a-110f-4b1a-a503-ec59b604ca24_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c1addb59-8336-4797-95ce-dcfec9863dc2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_ff69b284-1cf3-4023-84ee-81bac2e7a93b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ccc737b4-dbda-4521-9dcb-77c081b5bf17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a76de7ed-a233-448a-8dc9-5efac7c8cc5d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_3bf93456-05d1-4725-b88e-3349734723ec_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability Components of the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f8cc7af6-ed4f-4a56-8767-c377a633e162_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>fold-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:981bea1b-b87d-4677-ae2e-8728c40b94b3,g:80eaf27f-6f35-4ae6-9648-0cd9017af6e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Cover" xlink:type="simple" xlink:href="fold-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_07fea3d1-42ae-40d9-9446-375e3cc02ec5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentType_07fea3d1-42ae-40d9-9446-375e3cc02ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3d28ba25-940d-4eba-8c2f-fec1205d92b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentAnnualReport_3d28ba25-940d-4eba-8c2f-fec1205d92b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_85e0809a-b3e3-4cae-9a19-f933ed16d0a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentPeriodEndDate_85e0809a-b3e3-4cae-9a19-f933ed16d0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dfa849d9-8e4f-40e6-b72b-2560fce4ede7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_CurrentFiscalYearEndDate_dfa849d9-8e4f-40e6-b72b-2560fce4ede7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4492a759-5e0a-43e9-abbb-d4d47912c545" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentTransitionReport_4492a759-5e0a-43e9-abbb-d4d47912c545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e4cab3ca-4b80-40ad-9354-ee414aa11f23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityFileNumber_e4cab3ca-4b80-40ad-9354-ee414aa11f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9658844d-4962-4d1d-9479-35001faa8856" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityRegistrantName_9658844d-4962-4d1d-9479-35001faa8856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0abaa455-3c6b-4860-b79d-39a14e4e5337" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0abaa455-3c6b-4860-b79d-39a14e4e5337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_58362908-155e-42c9-9f56-e999dbbc1e8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityTaxIdentificationNumber_58362908-155e-42c9-9f56-e999dbbc1e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0d9a8cf2-a1bc-49e7-8ae1-e83717f44d8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityAddressAddressLine1_0d9a8cf2-a1bc-49e7-8ae1-e83717f44d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7e9f7dc8-e347-4857-989d-199b6eb76213" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityAddressCityOrTown_7e9f7dc8-e347-4857-989d-199b6eb76213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_70f568fa-39bd-4bda-a4f1-ec20f2b496d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityAddressStateOrProvince_70f568fa-39bd-4bda-a4f1-ec20f2b496d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_14a55b13-99e6-4c44-bf9c-8217f4f30c8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityAddressPostalZipCode_14a55b13-99e6-4c44-bf9c-8217f4f30c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4f4d0c61-82d0-4d86-8dd4-366b357d27c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_CityAreaCode_4f4d0c61-82d0-4d86-8dd4-366b357d27c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e9653d19-2393-4304-93e1-62743f17fa50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_LocalPhoneNumber_e9653d19-2393-4304-93e1-62743f17fa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a7552a81-dacc-475e-90c1-a6dd7884b5cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_Security12bTitle_a7552a81-dacc-475e-90c1-a6dd7884b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_84df225c-9258-4f4d-aa6e-3acd561dadc2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_TradingSymbol_84df225c-9258-4f4d-aa6e-3acd561dadc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_19c2ed47-4424-4e61-812e-edcdcfe8aea3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_SecurityExchangeName_19c2ed47-4424-4e61-812e-edcdcfe8aea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a5a3b766-b9ee-4617-92d0-43306948122a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a5a3b766-b9ee-4617-92d0-43306948122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_849a60ca-f25c-4f66-9938-2a041f7409d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityVoluntaryFilers_849a60ca-f25c-4f66-9938-2a041f7409d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f4bcb274-d30b-4d63-9456-af3cca6237ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityCurrentReportingStatus_f4bcb274-d30b-4d63-9456-af3cca6237ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b5a007d3-754b-4d5e-ba78-c0539bd124cf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityInteractiveDataCurrent_b5a007d3-754b-4d5e-ba78-c0539bd124cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c4effbf1-6c66-4948-9eec-1b9041c613c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityFilerCategory_c4effbf1-6c66-4948-9eec-1b9041c613c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8e39972b-fb4b-42b1-8254-d0886a2951ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntitySmallBusiness_8e39972b-fb4b-42b1-8254-d0886a2951ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0512857a-2712-4009-b94a-c9ed3f5a8764" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityEmergingGrowthCompany_0512857a-2712-4009-b94a-c9ed3f5a8764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_291409aa-7254-4cee-b89a-594a1c3bc256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_IcfrAuditorAttestationFlag_291409aa-7254-4cee-b89a-594a1c3bc256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f0c78da1-40f0-4326-9fb5-30b5f004329c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityShellCompany_f0c78da1-40f0-4326-9fb5-30b5f004329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5e42cead-a134-4cf2-9943-0312e37232cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityPublicFloat_5e42cead-a134-4cf2-9943-0312e37232cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c599e582-1b28-4cda-a6e1-b35cf0e4e047" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c599e582-1b28-4cda-a6e1-b35cf0e4e047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b107db4b-4e18-44a1-9bdc-1d4f5c4f4280" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b107db4b-4e18-44a1-9bdc-1d4f5c4f4280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_99e367f9-c812-41b9-8242-9d623850f490" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_EntityCentralIndexKey_99e367f9-c812-41b9-8242-9d623850f490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_37cda16f-67f8-4c77-85fe-7227a55013bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_AmendmentFlag_37cda16f-67f8-4c77-85fe-7227a55013bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_89b071f1-2227-4bf6-8acc-ae4036d56de8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentFiscalYearFocus_89b071f1-2227-4bf6-8acc-ae4036d56de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f27d938d-58d3-4786-967f-570444bb3c2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1485388f-b6bc-4195-92df-d0ec91261861" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f27d938d-58d3-4786-967f-570444bb3c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AuditInformation" xlink:type="simple" xlink:href="fold-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_AuditInformationAbstract_b3218392-58b2-44d7-be2c-398c5d87aef7" xlink:href="fold-20221231.xsd#fold_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d4dc1ab8-2b15-4aba-a90a-6a0bde7bdbc3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AuditInformationAbstract_b3218392-58b2-44d7-be2c-398c5d87aef7" xlink:to="loc_dei_AuditorFirmId_d4dc1ab8-2b15-4aba-a90a-6a0bde7bdbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_1ddbd0fe-b64c-458b-89f9-e8d795ac5eae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AuditInformationAbstract_b3218392-58b2-44d7-be2c-398c5d87aef7" xlink:to="loc_dei_AuditorName_1ddbd0fe-b64c-458b-89f9-e8d795ac5eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f26ee01e-efae-4110-8db8-e5d9f7eda60d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_AuditInformationAbstract_b3218392-58b2-44d7-be2c-398c5d87aef7" xlink:to="loc_dei_AuditorLocation_f26ee01e-efae-4110-8db8-e5d9f7eda60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6d8c3933-efec-44c3-a2fc-20208f08b71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d8c3933-efec-44c3-a2fc-20208f08b71a" xlink:to="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01f3b37c-a48d-44ac-8ce3-3e07af524dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_01f3b37c-a48d-44ac-8ce3-3e07af524dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ab085ccb-5691-4245-9d5b-bb83f23a5bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ab085ccb-5691-4245-9d5b-bb83f23a5bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aad846eb-9b2a-4c9f-b253-9a0bb10b47fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aad846eb-9b2a-4c9f-b253-9a0bb10b47fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0d9b3edd-1ed1-4cb9-b84d-32615e855284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:to="loc_us-gaap_InventoryNet_0d9b3edd-1ed1-4cb9-b84d-32615e855284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_96f3afdb-1811-473f-8cd2-6eb141a7f47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_96f3afdb-1811-473f-8cd2-6eb141a7f47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b6a57e18-0071-407c-ae58-c9addb6dc481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3f88c1b5-bdc2-4159-a945-eadc987fb7e8" xlink:to="loc_us-gaap_AssetsCurrent_b6a57e18-0071-407c-ae58-c9addb6dc481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b8ba0ddc-9d8f-45d2-9299-7f76d897aa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b8ba0ddc-9d8f-45d2-9299-7f76d897aa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b4cb95fc-0272-430c-861e-6a58bb951bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b4cb95fc-0272-430c-861e-6a58bb951bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a298c47b-8ed4-45a2-b46c-1ecfced6b23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a298c47b-8ed4-45a2-b46c-1ecfced6b23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eb4d3df1-de1e-4e46-b8da-a02710bce936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_Goodwill_eb4d3df1-de1e-4e46-b8da-a02710bce936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_34e16674-7389-478e-a5e5-e5390af874e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_34e16674-7389-478e-a5e5-e5390af874e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_035c06a4-76e6-4339-8550-b4285ac87adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea402bd8-fe20-4f44-b18f-38a2287162f1" xlink:to="loc_us-gaap_Assets_035c06a4-76e6-4339-8550-b4285ac87adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6d8c3933-efec-44c3-a2fc-20208f08b71a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_084d624c-d412-4423-bc00-12032e1d3027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:to="loc_us-gaap_AccountsPayableCurrent_084d624c-d412-4423-bc00-12032e1d3027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ad1842d0-c085-44a5-8ad5-313809fd37ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_ad1842d0-c085-44a5-8ad5-313809fd37ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bc234aab-6d26-4b6d-9c28-d9d24454c62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_bc234aab-6d26-4b6d-9c28-d9d24454c62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_361bbe17-25e6-41de-a0be-265a840bfe37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_361bbe17-25e6-41de-a0be-265a840bfe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5a784cac-8302-4af6-9685-243bab243cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f37c1c6a-743d-4593-bd56-eeff93968647" xlink:to="loc_us-gaap_LiabilitiesCurrent_5a784cac-8302-4af6-9685-243bab243cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_73925587-d543-4a7c-8b5d-fa4f2ecd842c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_LongTermDebt_73925587-d543-4a7c-8b5d-fa4f2ecd842c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83537082-d525-4043-9555-b381cae70b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83537082-d525-4043-9555-b381cae70b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_48930dab-b02b-48a8-9969-13e4dd51e5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_48930dab-b02b-48a8-9969-13e4dd51e5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_428a1a0a-216a-436a-a2b8-8945f9c3d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_428a1a0a-216a-436a-a2b8-8945f9c3d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_90c722fc-411b-467a-8176-625b255d8cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_90c722fc-411b-467a-8176-625b255d8cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_64e213d7-e056-4e97-aa67-db9386d93517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_Liabilities_64e213d7-e056-4e97-aa67-db9386d93517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8b5c3af9-9727-43a3-86d3-0ce6217feff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8b5c3af9-9727-43a3-86d3-0ce6217feff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_701d4774-402f-4adc-bf0f-e5e5873d2ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:to="loc_us-gaap_CommonStockValue_701d4774-402f-4adc-bf0f-e5e5873d2ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f6eff502-1c3b-4359-9db0-3d4bed4f7236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f6eff502-1c3b-4359-9db0-3d4bed4f7236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_151f52c0-8604-4774-9c13-bffb55f5ed83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_151f52c0-8604-4774-9c13-bffb55f5ed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_aaf46209-69c8-424f-8432-0ad3308ebf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_151f52c0-8604-4774-9c13-bffb55f5ed83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_aaf46209-69c8-424f-8432-0ad3308ebf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636f4619-c212-4fcd-b5fd-f24cf9fed053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_151f52c0-8604-4774-9c13-bffb55f5ed83" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_636f4619-c212-4fcd-b5fd-f24cf9fed053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1996b4ff-d27f-4e69-bc4d-9042c060d877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1996b4ff-d27f-4e69-bc4d-9042c060d877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ae6b4ab-20d4-4da1-b657-1436f2ede418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ae6b4ab-20d4-4da1-b657-1436f2ede418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a3df8d07-65dc-4ff4-8419-867c1fbd9442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_34f45bf1-7b86-497a-aedc-8fba40703f14" xlink:to="loc_us-gaap_StockholdersEquity_a3df8d07-65dc-4ff4-8419-867c1fbd9442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_061bc56f-e524-4408-8807-69a28fefe812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c42badce-6c55-4dfe-a9df-fc423bcbbccc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_061bc56f-e524-4408-8807-69a28fefe812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3152edcc-0755-4ff5-886e-43a188132725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7eb3a37b-11cf-4aa4-8d69-ad8497d4d5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3152edcc-0755-4ff5-886e-43a188132725" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7eb3a37b-11cf-4aa4-8d69-ad8497d4d5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_87a28fb9-476c-4bb9-8112-e97bc0e16677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3152edcc-0755-4ff5-886e-43a188132725" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_87a28fb9-476c-4bb9-8112-e97bc0e16677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1e28fe4c-ab39-42b7-86af-a3f8e2293e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3152edcc-0755-4ff5-886e-43a188132725" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1e28fe4c-ab39-42b7-86af-a3f8e2293e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e635e2d7-5491-43bc-93e0-c07f754182a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3152edcc-0755-4ff5-886e-43a188132725" xlink:to="loc_us-gaap_CommonStockSharesIssued_e635e2d7-5491-43bc-93e0-c07f754182a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bfa72b0c-5df5-4163-8e28-28f706807c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3152edcc-0755-4ff5-886e-43a188132725" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bfa72b0c-5df5-4163-8e28-28f706807c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d45fe6cb-2827-43d2-bb6d-421aad4d6952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d45fe6cb-2827-43d2-bb6d-421aad4d6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ca7efed5-1425-4940-8f4a-a15876452ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ca7efed5-1425-4940-8f4a-a15876452ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_81aedf9f-b275-4f75-87e5-96e9fd9bd8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_GrossProfit_81aedf9f-b275-4f75-87e5-96e9fd9bd8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f0e7a6a1-ef73-451b-9c5f-ac4966403e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f0e7a6a1-ef73-451b-9c5f-ac4966403e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0804497d-dac0-4460-aa09-819151b54f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0804497d-dac0-4460-aa09-819151b54f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_46afc54d-a561-4ddb-adad-ef5032856cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_46afc54d-a561-4ddb-adad-ef5032856cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fd581d0b-0e5a-4318-9cf9-189b832ce5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:to="loc_us-gaap_AssetImpairmentCharges_fd581d0b-0e5a-4318-9cf9-189b832ce5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2e832105-d2d8-4e44-9fde-c07ca58f3a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2e832105-d2d8-4e44-9fde-c07ca58f3a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5af60dda-1069-4542-b3c8-2722efcaef48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a5c71a79-772e-44df-b4ab-14a2eb943ed9" xlink:to="loc_us-gaap_OperatingExpenses_5af60dda-1069-4542-b3c8-2722efcaef48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_46204dca-c106-4858-b3b8-2677d3616764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_OperatingIncomeLoss_46204dca-c106-4858-b3b8-2677d3616764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f5136933-f5b3-4073-b226-d6217f070448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f5136933-f5b3-4073-b226-d6217f070448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cbf98881-1f35-4296-bed4-65de692ca76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f5136933-f5b3-4073-b226-d6217f070448" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cbf98881-1f35-4296-bed4-65de692ca76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_405907b9-c3be-445c-b0bd-f12110007768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f5136933-f5b3-4073-b226-d6217f070448" xlink:to="loc_us-gaap_InterestExpense_405907b9-c3be-445c-b0bd-f12110007768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07aa71a5-e104-4266-b8c5-ebb076dddcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f5136933-f5b3-4073-b226-d6217f070448" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_07aa71a5-e104-4266-b8c5-ebb076dddcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_43e85800-836a-43dc-a7ec-a1372d2532b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_f5136933-f5b3-4073-b226-d6217f070448" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_43e85800-836a-43dc-a7ec-a1372d2532b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ab51285-42fb-424f-ad2c-1ac49dae20a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6ab51285-42fb-424f-ad2c-1ac49dae20a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f6d39eb7-965c-4103-bc37-3f29083fc873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f6d39eb7-965c-4103-bc37-3f29083fc873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_552c4678-4caa-4691-a74d-0f04946d81cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_NetIncomeLoss_552c4678-4caa-4691-a74d-0f04946d81cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e084b5b0-addb-4afd-8c60-49bc704b4e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_EarningsPerShareBasic_e084b5b0-addb-4afd-8c60-49bc704b4e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5aa7c699-c380-4c43-a832-89485951895b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5aa7c699-c380-4c43-a832-89485951895b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5738a4cb-d2bf-441b-9699-0360855a8b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5738a4cb-d2bf-441b-9699-0360855a8b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90661b7e-17f4-44b8-b5f3-82e461f369f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3eaa6447-c322-4b63-8148-ed2155a19a2b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90661b7e-17f4-44b8-b5f3-82e461f369f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_99f07e81-a388-49e7-b98f-116dc5d24664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eebe2ef8-84ff-4aa3-a00b-ca8cd4d8cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_99f07e81-a388-49e7-b98f-116dc5d24664" xlink:to="loc_us-gaap_NetIncomeLoss_eebe2ef8-84ff-4aa3-a00b-ca8cd4d8cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0f830d24-105d-4afc-acf0-3357d473fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_99f07e81-a388-49e7-b98f-116dc5d24664" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0f830d24-105d-4afc-acf0-3357d473fb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7cb6b3bc-07d6-4d86-9e83-64b962618fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0f830d24-105d-4afc-acf0-3357d473fb69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_7cb6b3bc-07d6-4d86-9e83-64b962618fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_83ee7906-f3b7-4a0f-98e5-e28ee617bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0f830d24-105d-4afc-acf0-3357d473fb69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_83ee7906-f3b7-4a0f-98e5-e28ee617bff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4693070f-a4d0-41c9-ba00-fbddf375a2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0f830d24-105d-4afc-acf0-3357d473fb69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4693070f-a4d0-41c9-ba00-fbddf375a2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a66728c5-8b66-4b75-afb7-c4373b0a24e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_99f07e81-a388-49e7-b98f-116dc5d24664" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a66728c5-8b66-4b75-afb7-c4373b0a24e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5429bb2d-ba61-4572-a9e8-4dee0c60950c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5429bb2d-ba61-4572-a9e8-4dee0c60950c" xlink:to="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fcdf34d4-e514-4fb8-a697-9e364742419d" xlink:to="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d974f056-ad3e-4212-badc-6927c1509b93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_CommonStockMember_d974f056-ad3e-4212-badc-6927c1509b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eb9b5f11-87bd-4b95-ac0a-8470cc86732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eb9b5f11-87bd-4b95-ac0a-8470cc86732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9bfd2558-68ff-45e6-aa8a-8fffa0cc1712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_WarrantMember_9bfd2558-68ff-45e6-aa8a-8fffa0cc1712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_cb38fe96-c2e4-41e3-b0f4-f34919615d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_cb38fe96-c2e4-41e3-b0f4-f34919615d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_966004e4-9058-4b91-bc99-9ed9750efb21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_07fd040c-197a-4fce-9206-d00bd4c1837d" xlink:to="loc_us-gaap_RetainedEarningsMember_966004e4-9058-4b91-bc99-9ed9750efb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_911bd5c2-051e-4776-aff3-1240c7951990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ccbcad95-a889-4e53-82ae-32333ab35bf7" xlink:to="loc_us-gaap_StatementLineItems_911bd5c2-051e-4776-aff3-1240c7951990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_911bd5c2-051e-4776-aff3-1240c7951990" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13204bb3-3890-4a5a-a9a6-ab01531c1bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13204bb3-3890-4a5a-a9a6-ab01531c1bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_666be3ed-2fe8-43e6-8262-23081c3015a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockholdersEquity_666be3ed-2fe8-43e6-8262-23081c3015a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3155e4d6-134c-4584-ad47-b0a4b279d096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3155e4d6-134c-4584-ad47-b0a4b279d096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1562e785-1d35-4750-967b-b82f0665f2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1562e785-1d35-4750-967b-b82f0665f2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ebdcd47-7056-4177-9be4-d363b4bff47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ebdcd47-7056-4177-9be4-d363b4bff47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_289f0f17-a3a4-4bfe-aa4f-9f2cdf3af191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_289f0f17-a3a4-4bfe-aa4f-9f2cdf3af191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7a08b73f-f6b2-44d6-bafb-f63ef35d089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_7a08b73f-f6b2-44d6-bafb-f63ef35d089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ea3407db-4c9b-4ca8-8558-3e3dcf6d1e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ea3407db-4c9b-4ca8-8558-3e3dcf6d1e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6ac57c0-3234-4bdd-bf53-d2ccc18bdbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6ac57c0-3234-4bdd-bf53-d2ccc18bdbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2962d30b-2ee9-4dc8-af55-c56d11b758a2" xlink:href="fold-20221231.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2962d30b-2ee9-4dc8-af55-c56d11b758a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_6780b164-9edd-4ee4-8f0f-604f0923323a" xlink:href="fold-20221231.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_6780b164-9edd-4ee4-8f0f-604f0923323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a240f8a5-715e-46c3-9780-44a24f04b968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a240f8a5-715e-46c3-9780-44a24f04b968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_939f5f15-f5eb-4d03-8fc6-f957381ab488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_939f5f15-f5eb-4d03-8fc6-f957381ab488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dc85b4cb-7e5a-43fe-af68-13ac02ae8158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_dc85b4cb-7e5a-43fe-af68-13ac02ae8158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5afe6616-546b-42a5-870c-4ebb86a04391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5afe6616-546b-42a5-870c-4ebb86a04391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_24c7b0bd-0f93-423a-8ae2-bd7eb7d73c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_NetIncomeLoss_24c7b0bd-0f93-423a-8ae2-bd7eb7d73c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2fa50cef-e1f2-4f09-9396-6e8acb8ca369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2fa50cef-e1f2-4f09-9396-6e8acb8ca369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_865116ca-f169-454a-968a-3dffe2278fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f5dc8466-d17c-4241-9b25-8ff6d3dc69e7" xlink:to="loc_us-gaap_StockholdersEquity_865116ca-f169-454a-968a-3dffe2278fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c077b0c-f796-40e0-aa78-e85b864b92b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c077b0c-f796-40e0-aa78-e85b864b92b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b18072fa-ee12-4dd7-bb76-ea1aeca32f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c077b0c-f796-40e0-aa78-e85b864b92b4" xlink:to="loc_us-gaap_ProfitLoss_b18072fa-ee12-4dd7-bb76-ea1aeca32f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c077b0c-f796-40e0-aa78-e85b864b92b4" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1268448d-2db4-4db5-a7ab-fe5620ba6c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1268448d-2db4-4db5-a7ab-fe5620ba6c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_737a3076-725a-438d-a8b7-45aa1108c6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_737a3076-725a-438d-a8b7-45aa1108c6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e49cee11-7d84-4ec2-a5eb-fe9c3eb57c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_us-gaap_ShareBasedCompensation_e49cee11-7d84-4ec2-a5eb-fe9c3eb57c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a970d26f-b142-4b94-acef-891fac493c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a970d26f-b142-4b94-acef-891fac493c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2f268abc-c361-4859-863d-b9610572221b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2f268abc-c361-4859-863d-b9610572221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_a3480f61-36d3-452a-ac0e-7251745e0fee" xlink:href="fold-20221231.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_a3480f61-36d3-452a-ac0e-7251745e0fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bde58e19-954d-4424-a7fc-408fdc28755c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bde58e19-954d-4424-a7fc-408fdc28755c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_8357e2ed-a9de-4905-a661-c406bb5cf466" xlink:href="fold-20221231.xsd#fold_AssetImpairmentChargesAndOtherAssetWriteOffs"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a61eb178-3b08-42ab-8091-512e3c720a73" xlink:to="loc_fold_AssetImpairmentChargesAndOtherAssetWriteOffs_8357e2ed-a9de-4905-a661-c406bb5cf466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c077b0c-f796-40e0-aa78-e85b864b92b4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9186da83-4170-4b09-b745-e643449bbf4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9186da83-4170-4b09-b745-e643449bbf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_99a77c26-a959-4c96-9934-b7261210fd04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_99a77c26-a959-4c96-9934-b7261210fd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64f047eb-3a90-4469-8c3d-81bb5a13dd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_64f047eb-3a90-4469-8c3d-81bb5a13dd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4cc52bc0-6376-40ed-83a3-24357d397546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4cc52bc0-6376-40ed-83a3-24357d397546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_f8f90bed-0fcf-4720-8893-def4d106ce99" xlink:href="fold-20221231.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_f8f90bed-0fcf-4720-8893-def4d106ce99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_c431981d-672f-4306-9831-32de4bdc8e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96cc3496-fcf8-4ea8-bc4c-2189b0c4e329" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_c431981d-672f-4306-9831-32de4bdc8e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8bd8f24-43df-4f2e-84a6-295ad5b718e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2c077b0c-f796-40e0-aa78-e85b864b92b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a8bd8f24-43df-4f2e-84a6-295ad5b718e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_32558d04-6fbf-477b-b7d6-b840a9082d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_32558d04-6fbf-477b-b7d6-b840a9082d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8c2035c4-45bd-4a50-98bd-065d913bc824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8c2035c4-45bd-4a50-98bd-065d913bc824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_744911c6-3e34-4899-afae-a5d602216d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_744911c6-3e34-4899-afae-a5d602216d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_df128640-b338-4d5b-9a5b-b0997e202656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_df128640-b338-4d5b-9a5b-b0997e202656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5b52f6b-ebfa-494a-92d9-20fc06d43434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c59577de-ea74-4cef-bd79-006fd49c02c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5b52f6b-ebfa-494a-92d9-20fc06d43434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_1ed6a002-6c9e-4f21-bb18-00ff49cecb1c" xlink:href="fold-20221231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_1ed6a002-6c9e-4f21-bb18-00ff49cecb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5b3e8548-9d24-49e9-afb0-617ca1cfb06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5b3e8548-9d24-49e9-afb0-617ca1cfb06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b753f8a2-0f13-4d86-9e88-54d2d2cc5bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b753f8a2-0f13-4d86-9e88-54d2d2cc5bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7d29ab5f-ca14-469f-8dfb-2620939179fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7d29ab5f-ca14-469f-8dfb-2620939179fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aa090980-5c5d-4f33-aeb1-bc2317cadbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aa090980-5c5d-4f33-aeb1-bc2317cadbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0d25cb2b-46b4-4a69-8b78-859ac2196345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0d25cb2b-46b4-4a69-8b78-859ac2196345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_acc59848-74ea-4b66-80ae-563c9f530859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_acc59848-74ea-4b66-80ae-563c9f530859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_72c89478-8bf1-44fa-8005-a978954ef038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_72c89478-8bf1-44fa-8005-a978954ef038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5dda42d2-4985-4263-b6aa-1d7bdf850b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8408116e-4d2f-4a58-a020-5b988f5ae303" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5dda42d2-4985-4263-b6aa-1d7bdf850b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_741c8ffe-6e23-4d23-87c3-f4d29ca9775c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_741c8ffe-6e23-4d23-87c3-f4d29ca9775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbcad91a-039d-42d5-9515-2da17b484992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbcad91a-039d-42d5-9515-2da17b484992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dfe8bb9-8e0d-4cd4-8eaf-edee5b922bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dfe8bb9-8e0d-4cd4-8eaf-edee5b922bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db8562a0-ee6b-44e6-86e7-dfeb524309d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db8562a0-ee6b-44e6-86e7-dfeb524309d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1a9629a-7a7c-4387-ad1a-945e2c24eca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a800f0e4-5a70-498e-80fb-65149c6aa640" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1a9629a-7a7c-4387-ad1a-945e2c24eca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_4b23dc00-f598-4dd2-8137-5776ff8b1fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1a9629a-7a7c-4387-ad1a-945e2c24eca9" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_4b23dc00-f598-4dd2-8137-5776ff8b1fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_91c762e3-9b9b-4492-b591-7956727bf451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1a9629a-7a7c-4387-ad1a-945e2c24eca9" xlink:to="loc_us-gaap_InterestPaidNet_91c762e3-9b9b-4492-b591-7956727bf451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1699ce0e-f37f-478b-975f-df97c7c99227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1a9629a-7a7c-4387-ad1a-945e2c24eca9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1699ce0e-f37f-478b-975f-df97c7c99227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_957f14c6-795b-4445-94e4-e4d93002c7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a1a9629a-7a7c-4387-ad1a-945e2c24eca9" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_957f14c6-795b-4445-94e4-e4d93002c7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20221231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_904b3d6f-07f1-403c-9846-1bb65a156804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0e7a72c2-cf20-41bc-85c6-19028c8c76c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_904b3d6f-07f1-403c-9846-1bb65a156804" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0e7a72c2-cf20-41bc-85c6-19028c8c76c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c8e3dd71-b4cb-4345-ba95-373c2d4b6c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ee9208f6-513f-4152-addb-b5fb77173404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8e3dd71-b4cb-4345-ba95-373c2d4b6c6c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_ee9208f6-513f-4152-addb-b5fb77173404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="fold-20221231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b3354a-7884-44c0-a2e9-828637f0115c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5fcf956b-bb5c-4bf9-8acd-66e5b9c9ba25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64b3354a-7884-44c0-a2e9-828637f0115c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5fcf956b-bb5c-4bf9-8acd-66e5b9c9ba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_92a46aa4-6478-4a64-812c-797e6ddaf10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_17dac2c4-51ef-43fe-97a7-b7699ba5fb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_92a46aa4-6478-4a64-812c-797e6ddaf10d" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_17dac2c4-51ef-43fe-97a7-b7699ba5fb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20221231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_61ed253b-0886-451b-8f0b-975b5023b12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_332fb133-c3e2-4588-ba10-57802cb7ce98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_61ed253b-0886-451b-8f0b-975b5023b12a" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_332fb133-c3e2-4588-ba10-57802cb7ce98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="fold-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5d9e9067-4781-41e6-ae53-9c5db2832b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4c20d0f3-1dc7-4da5-ae2f-a23acc4ce559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5d9e9067-4781-41e6-ae53-9c5db2832b6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4c20d0f3-1dc7-4da5-ae2f-a23acc4ce559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="fold-20221231.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f378a080-2644-481b-b3b6-5e95573c031c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_58b2fd47-82b0-46ba-8168-a2bd702cbb79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f378a080-2644-481b-b3b6-5e95573c031c" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_58b2fd47-82b0-46ba-8168-a2bd702cbb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="fold-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_55609599-324e-40f5-bec4-72cb2259976a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0dd04604-f550-4051-be35-f515a7a47bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_55609599-324e-40f5-bec4-72cb2259976a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0dd04604-f550-4051-be35-f515a7a47bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensation" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09b4f337-b629-41ba-a869-8e639256e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_193097fe-0a85-465e-a8f7-b2a1bea4d26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09b4f337-b629-41ba-a869-8e639256e66f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_193097fe-0a85-465e-a8f7-b2a1bea4d26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_73f236b5-c8e5-40d4-8c61-a7c17b6d3d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9efd700d-edbd-4ed3-9700-2ac7f72e4c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_73f236b5-c8e5-40d4-8c61-a7c17b6d3d31" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9efd700d-edbd-4ed3-9700-2ac7f72e4c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d8032ba-f2fc-451e-b5b6-45e84897cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f300e06a-ce5c-486c-af34-5e63b3ddc6df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d8032ba-f2fc-451e-b5b6-45e84897cf6e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f300e06a-ce5c-486c-af34-5e63b3ddc6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Leases" xlink:type="simple" xlink:href="fold-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_96204ab1-3338-4762-8e05-5f51c39fd1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8ba1982b-8e6c-46f9-bce9-734939bdd3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_96204ab1-3338-4762-8e05-5f51c39fd1db" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8ba1982b-8e6c-46f9-bce9-734939bdd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d8cc2bea-c793-4941-9d70-3616ff6f8f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_38c51b74-c140-4fda-b074-76a4e43d11f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d8cc2bea-c793-4941-9d70-3616ff6f8f3d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_38c51b74-c140-4fda-b074-76a4e43d11f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="fold-20221231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_41810cf0-082a-4c0e-9461-fce459b4dd4c" xlink:href="fold-20221231.xsd#fold_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8b1765ca-4b6d-45d4-b42d-4468990f8ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_41810cf0-082a-4c0e-9461-fce459b4dd4c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8b1765ca-4b6d-45d4-b42d-4468990f8ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LegalProceedings" xlink:type="simple" xlink:href="fold-20221231.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e085521d-db02-4eea-b397-dfce56545f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4ded1864-6407-48ea-8c5a-816cbdc52376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e085521d-db02-4eea-b397-dfce56545f56" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4ded1864-6407-48ea-8c5a-816cbdc52376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20221231.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b3c56e8c-876d-4151-84e4-065d1e34256e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c357ad5d-831a-4b95-b5f4-cbb945eeabd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b3c56e8c-876d-4151-84e4-065d1e34256e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c357ad5d-831a-4b95-b5f4-cbb945eeabd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8e69ae93-8633-4ca9-8283-07d9469581a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8e69ae93-8633-4ca9-8283-07d9469581a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2f6828b6-8a2f-4016-9a0a-734f4c3a955c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2f6828b6-8a2f-4016-9a0a-734f4c3a955c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ed3e339e-cbb6-4210-a0e9-b7601fd39ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ed3e339e-cbb6-4210-a0e9-b7601fd39ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f30ee415-6081-4b6b-a628-775896985b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_UseOfEstimates_f30ee415-6081-4b6b-a628-775896985b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_056b9a23-a3f1-4ea7-9354-04ebf93c42d3" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_056b9a23-a3f1-4ea7-9354-04ebf93c42d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_299743ab-0546-4da8-87c1-81fcb0eacc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_299743ab-0546-4da8-87c1-81fcb0eacc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0d556ec9-f654-430c-8b75-afa160f0804c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0d556ec9-f654-430c-8b75-afa160f0804c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c1be4621-4215-498b-af07-d12de0ffbbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c1be4621-4215-498b-af07-d12de0ffbbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_29011c7f-59bc-4e5a-8d77-f4fdd4ef7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_29011c7f-59bc-4e5a-8d77-f4fdd4ef7aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ce458138-b91f-4081-8133-04fe1d40e5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ce458138-b91f-4081-8133-04fe1d40e5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_fc392636-52b8-41ff-b851-01780b410088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_fc392636-52b8-41ff-b851-01780b410088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_75d3fdf6-6680-4fd7-8631-a5cf70248092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_75d3fdf6-6680-4fd7-8631-a5cf70248092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_1e357f60-7d71-487c-bcac-03af5b98832a" xlink:href="fold-20221231.xsd#fold_InterestIncomeAndInterestExpensePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_fold_InterestIncomeAndInterestExpensePolicyTextBlock_1e357f60-7d71-487c-bcac-03af5b98832a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1788c418-0a8f-4ec7-98d4-e15b5dd7daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1788c418-0a8f-4ec7-98d4-e15b5dd7daf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_278cc6a1-6e59-457f-a19b-5b4e109aa5d1" xlink:href="fold-20221231.xsd#fold_OtherComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_fold_OtherComprehensiveIncomePolicyPolicyTextBlock_278cc6a1-6e59-457f-a19b-5b4e109aa5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b5f1f25d-7654-420c-bb1d-74853c9898e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b5f1f25d-7654-420c-bb1d-74853c9898e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_ebbccc19-5650-4644-8564-867f56bf6398" xlink:href="fold-20221231.xsd#fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock_ebbccc19-5650-4644-8564-867f56bf6398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_83a3ae93-1a2b-435f-b0de-2b5c76a27f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_83a3ae93-1a2b-435f-b0de-2b5c76a27f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_599e10ef-6952-48f8-9cae-8ee0ca1c1b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_599e10ef-6952-48f8-9cae-8ee0ca1c1b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_bd4837b6-c8db-4731-ae81-e8bf2a1c9927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_bd4837b6-c8db-4731-ae81-e8bf2a1c9927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_7706672b-c917-47fc-8b52-d3971755e7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_7706672b-c917-47fc-8b52-d3971755e7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7c146ced-61a7-46e7-824d-e58502a1068e" xlink:href="fold-20221231.xsd#fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock_7c146ced-61a7-46e7-824d-e58502a1068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_81bdd40b-72ac-4378-82a2-898f7c5b025e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_81bdd40b-72ac-4378-82a2-898f7c5b025e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9361d605-b12d-4f21-b451-076ded05dd36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0e223e97-f9d7-4569-8671-5b8b59f1459d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9361d605-b12d-4f21-b451-076ded05dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89c1009e-1afe-4178-9175-256b6f9b93b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_cbd757ac-5844-4e72-8a17-297a79bf05d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89c1009e-1afe-4178-9175-256b6f9b93b6" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_cbd757ac-5844-4e72-8a17-297a79bf05d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="fold-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad4b5c8b-f481-40d0-a75a-774d5bc992aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b2f1696f-0134-45be-83f9-643d89ecabd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad4b5c8b-f481-40d0-a75a-774d5bc992aa" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b2f1696f-0134-45be-83f9-643d89ecabd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_fc9941eb-ab75-425e-9dc8-3fd9ac86abf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad4b5c8b-f481-40d0-a75a-774d5bc992aa" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_fc9941eb-ab75-425e-9dc8-3fd9ac86abf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2a96a210-f94d-4376-b4d5-0fdd24cebde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fe530566-279e-46f9-9c54-2a7c188ddbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2a96a210-f94d-4376-b4d5-0fdd24cebde2" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_fe530566-279e-46f9-9c54-2a7c188ddbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_55c482d6-1459-4616-b763-7fdc47c42920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2a96a210-f94d-4376-b4d5-0fdd24cebde2" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_55c482d6-1459-4616-b763-7fdc47c42920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20221231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a599f3ce-ff87-4606-b134-b8529f40b4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_86fc2540-a3ed-42ec-9e34-cf5807319788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a599f3ce-ff87-4606-b134-b8529f40b4ea" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_86fc2540-a3ed-42ec-9e34-cf5807319788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="fold-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ed1914a-4039-4e9b-969d-e7a9ef0943cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f92b63ca-a7c8-4274-8763-801b3860c874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ed1914a-4039-4e9b-969d-e7a9ef0943cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f92b63ca-a7c8-4274-8763-801b3860c874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="fold-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ef989429-d5a6-4c91-9e6f-c9f73798bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6fc05652-c7ec-412b-a6d8-e3584abc8b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ef989429-d5a6-4c91-9e6f-c9f73798bfa0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6fc05652-c7ec-412b-a6d8-e3584abc8b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationTables" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c23cc6-9185-47dc-8f43-1fd13455fa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_753bc583-e13d-4424-8f7d-2dfc6fa77fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c23cc6-9185-47dc-8f43-1fd13455fa50" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_753bc583-e13d-4424-8f7d-2dfc6fa77fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2362b870-bcca-4d0c-b05a-e288c5e0f5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c23cc6-9185-47dc-8f43-1fd13455fa50" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2362b870-bcca-4d0c-b05a-e288c5e0f5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9dbd994f-1fe1-49ab-b4b5-83cb3b2b498a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c23cc6-9185-47dc-8f43-1fd13455fa50" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_9dbd994f-1fe1-49ab-b4b5-83cb3b2b498a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d36150c-bd4f-4b4a-9309-f74949fe824f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_77c23cc6-9185-47dc-8f43-1fd13455fa50" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d36150c-bd4f-4b4a-9309-f74949fe824f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6ef84b8d-7b42-4c9a-954d-b7fd48175c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d21fd046-be11-4572-b622-9af7709205dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ef84b8d-7b42-4c9a-954d-b7fd48175c32" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d21fd046-be11-4572-b622-9af7709205dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9066aa3a-aa74-40cb-a3a3-03e8ae0dd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ef84b8d-7b42-4c9a-954d-b7fd48175c32" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9066aa3a-aa74-40cb-a3a3-03e8ae0dd61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4d59d838-317e-4f04-a7e2-5ce126d17f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ef84b8d-7b42-4c9a-954d-b7fd48175c32" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_4d59d838-317e-4f04-a7e2-5ce126d17f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f417f84f-01d5-495d-9152-3594898e6a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_46e67667-81ce-4041-9f4a-a6c295fd1293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f417f84f-01d5-495d-9152-3594898e6a4f" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_46e67667-81ce-4041-9f4a-a6c295fd1293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_261a1bd2-b212-4ab1-9ee6-b8dc97422d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f417f84f-01d5-495d-9152-3594898e6a4f" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_261a1bd2-b212-4ab1-9ee6-b8dc97422d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0f8e51c5-c3dc-42d8-ba77-6865eda3235a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_99eec1ee-708e-4e4b-9637-1e20f29272bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f8e51c5-c3dc-42d8-ba77-6865eda3235a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_99eec1ee-708e-4e4b-9637-1e20f29272bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5eac6edc-1eb2-446d-ae2e-36f46babb79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f8e51c5-c3dc-42d8-ba77-6865eda3235a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5eac6edc-1eb2-446d-ae2e-36f46babb79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_875f4416-8b61-42f4-83b5-37d924355f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_141841ee-f8ed-4dfc-8cdf-d9aa135a9f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_875f4416-8b61-42f4-83b5-37d924355f9a" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_141841ee-f8ed-4dfc-8cdf-d9aa135a9f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0df017cb-25d6-4e23-83a2-a1810949197a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_875f4416-8b61-42f4-83b5-37d924355f9a" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0df017cb-25d6-4e23-83a2-a1810949197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3d6081ff-1d46-4b39-80d5-4e04728e4c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_875f4416-8b61-42f4-83b5-37d924355f9a" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3d6081ff-1d46-4b39-80d5-4e04728e4c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f1cd68d2-9ea6-47e6-890c-0f595ac154c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_875f4416-8b61-42f4-83b5-37d924355f9a" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f1cd68d2-9ea6-47e6-890c-0f595ac154c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20221231.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c62b60ee-be59-4636-8dcf-f5c003ba18d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_06b62a7d-ff1c-45dc-a13a-5891548cc7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c62b60ee-be59-4636-8dcf-f5c003ba18d6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_06b62a7d-ff1c-45dc-a13a-5891548cc7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b4ae73be-3709-43dd-8e17-9d04213e0765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c62b60ee-be59-4636-8dcf-f5c003ba18d6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b4ae73be-3709-43dd-8e17-9d04213e0765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4406344a-563e-4c6f-82be-029b3463b14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa9df580-02d4-404d-b5e5-df22f6a027cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4406344a-563e-4c6f-82be-029b3463b14e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aa9df580-02d4-404d-b5e5-df22f6a027cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9144107d-a258-482f-8309-a9fda40b71ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9144107d-a258-482f-8309-a9fda40b71ac" xlink:to="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_beaf1679-4aa3-47ad-a86c-b05fdb37bcfa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_55d46d7d-00d7-4e55-aeb5-a70e7b0e4b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:to="loc_us-gaap_SalesRevenueNetMember_55d46d7d-00d7-4e55-aeb5-a70e7b0e4b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8b5de741-dc4d-49b4-bf41-e55c8f2961cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb516b92-0903-4981-9fba-df9b4e042152" xlink:to="loc_us-gaap_AccountsReceivableMember_8b5de741-dc4d-49b4-bf41-e55c8f2961cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3520bcb7-1cbd-4f60-9c5d-c60f319ed486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_99bf2d8d-59d3-47e8-85ca-a833c3148c9e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3520bcb7-1cbd-4f60-9c5d-c60f319ed486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e5abba22-37e2-4949-adcd-e98b9403f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3520bcb7-1cbd-4f60-9c5d-c60f319ed486" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e5abba22-37e2-4949-adcd-e98b9403f2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_51faf403-aad1-42c5-ab75-c8b3f1dca95a" xlink:to="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GalafoldMember_7926e57c-35c9-4346-9fa5-59a6e6d7a0b8" xlink:href="fold-20221231.xsd#fold_GalafoldMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:to="loc_fold_GalafoldMember_7926e57c-35c9-4346-9fa5-59a6e6d7a0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CustomerOneMember_57a4d299-f8de-4efb-8fd0-d67af2d46658" xlink:href="fold-20221231.xsd#fold_CustomerOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_6c91145e-5e15-4ac6-a5e6-09fe1f2d9621" xlink:to="loc_fold_CustomerOneMember_57a4d299-f8de-4efb-8fd0-d67af2d46658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2b3022ea-dead-4207-ae8a-a25f0b5e3846" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3bae0d09-bdfd-44d7-b256-a6b33de27f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3bae0d09-bdfd-44d7-b256-a6b33de27f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ebc91312-11d5-44b8-b462-4d44f7aed12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ebc91312-11d5-44b8-b462-4d44f7aed12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76d93506-ff12-436b-b55f-4855cf029f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f2c894e4-18b1-4c46-af94-24eb8df2bad5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76d93506-ff12-436b-b55f-4855cf029f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e95ad9a6-1e42-47ec-97bc-a5b903618989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e95ad9a6-1e42-47ec-97bc-a5b903618989" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:to="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ab38721-89ed-42d2-b21a-bb68c031f50f" xlink:to="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eabbc288-a762-45e6-aa12-e4e8b22a3e5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:to="loc_srt_MinimumMember_eabbc288-a762-45e6-aa12-e4e8b22a3e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_074b368b-a938-4054-a49f-c6369587c372" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_350965a6-dc7d-4b60-a0ce-67ea3d152e2c" xlink:to="loc_srt_MaximumMember_074b368b-a938-4054-a49f-c6369587c372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13e7ed62-b17e-4b2f-b072-79a1377e0a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08161f69-6ec2-4e85-852b-d3fa1f54e89f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13e7ed62-b17e-4b2f-b072-79a1377e0a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ffaa2812-6fde-4867-a600-613ae8cc0c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_13e7ed62-b17e-4b2f-b072-79a1377e0a05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ffaa2812-6fde-4867-a600-613ae8cc0c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9cea12f4-96a9-4daf-ade2-3eab81dc2d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9cea12f4-96a9-4daf-ade2-3eab81dc2d8c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:to="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e717edbe-1243-405e-a238-94b5f9852561" xlink:to="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3f61e39c-fb92-44cc-84e0-237544c20855" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:to="loc_country_US_3f61e39c-fb92-44cc-84e0-237544c20855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1ae5e186-623c-4506-9b0e-75cd23f72377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_256e3e55-559f-438e-a528-96016b764a39" xlink:to="loc_us-gaap_NonUsMember_1ae5e186-623c-4506-9b0e-75cd23f72377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8ad435e6-a675-4b8e-bc68-7fd8bb1ad247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c0a9cb9b-fc67-40bf-8268-0962f3fff20a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8ad435e6-a675-4b8e-bc68-7fd8bb1ad247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_307b3982-185e-4e43-bc0b-7c5089318280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8ad435e6-a675-4b8e-bc68-7fd8bb1ad247" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_307b3982-185e-4e43-bc0b-7c5089318280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1fbd483c-c330-43ad-9529-59b767d51c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_4a4289b4-8de7-45fd-9f5b-f060868cdd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1fbd483c-c330-43ad-9529-59b767d51c7a" xlink:to="loc_us-gaap_ShareBasedCompensationAbstract_4a4289b4-8de7-45fd-9f5b-f060868cdd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationNumberOfPlans_151dbbe1-c25b-4f25-ae25-ffadcbec3788" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4a4289b4-8de7-45fd-9f5b-f060868cdd0a" xlink:to="loc_fold_ShareBasedCompensationNumberOfPlans_151dbbe1-c25b-4f25-ae25-ffadcbec3788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8917c87d-ec23-4ed4-b33d-1977fe30d59f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_06fc5ad2-9e56-40d3-8826-5d90640db3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8917c87d-ec23-4ed4-b33d-1977fe30d59f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_06fc5ad2-9e56-40d3-8826-5d90640db3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_c32dab3c-65eb-4e0c-ab70-0638bf39d090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8917c87d-ec23-4ed4-b33d-1977fe30d59f" xlink:to="loc_us-gaap_NumberOfReportingUnits_c32dab3c-65eb-4e0c-ab70-0638bf39d090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_02c64b36-57bb-4a20-bfe3-afd43d2f2f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6778ca12-7e85-439d-bbf6-16e0abaa51bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_02c64b36-57bb-4a20-bfe3-afd43d2f2f60" xlink:to="loc_us-gaap_Goodwill_6778ca12-7e85-439d-bbf6-16e0abaa51bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52c4075e-a8e2-4067-aab4-5fdee6a4840b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_02c64b36-57bb-4a20-bfe3-afd43d2f2f60" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_52c4075e-a8e2-4067-aab4-5fdee6a4840b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#GoodwillandIntangibleAssetsChangesinIPRDDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b519d6b-3d0b-4559-8e21-cdb6c569d828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_aa367228-da46-495f-aadd-c682e92d0340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b519d6b-3d0b-4559-8e21-cdb6c569d828" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_aa367228-da46-495f-aadd-c682e92d0340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b209a173-83e9-4768-839d-09b8ab421567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_aa367228-da46-495f-aadd-c682e92d0340" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b209a173-83e9-4768-839d-09b8ab421567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3b75ac69-9c43-4595-8599-407820b0dd93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_aa367228-da46-495f-aadd-c682e92d0340" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3b75ac69-9c43-4595-8599-407820b0dd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_19bc8b51-63f3-4dc7-b55d-b2f96ed298f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_aa367228-da46-495f-aadd-c682e92d0340" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_19bc8b51-63f3-4dc7-b55d-b2f96ed298f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7b5bc40b-6581-4625-b903-0f051b6b1bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9b519d6b-3d0b-4559-8e21-cdb6c569d828" xlink:to="loc_us-gaap_GoodwillRollForward_7b5bc40b-6581-4625-b903-0f051b6b1bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8510d188-276e-4e95-b2dc-97f4f1b4559c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5bc40b-6581-4625-b903-0f051b6b1bce" xlink:to="loc_us-gaap_Goodwill_8510d188-276e-4e95-b2dc-97f4f1b4559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_b885059f-eb50-4a6c-a233-877a3a166209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5bc40b-6581-4625-b903-0f051b6b1bce" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_b885059f-eb50-4a6c-a233-877a3a166209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_77ca5ccd-3924-4ab4-9bb2-9c18477558c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7b5bc40b-6581-4625-b903-0f051b6b1bce" xlink:to="loc_us-gaap_Goodwill_77ca5ccd-3924-4ab4-9bb2-9c18477558c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_ef4e3b39-104f-4a55-adc5-56d68828302a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cedc3a8-31b5-4831-8f70-19e6f84c7e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_ef4e3b39-104f-4a55-adc5-56d68828302a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cedc3a8-31b5-4831-8f70-19e6f84c7e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a072cdbe-6803-47e6-89d7-0668d18941b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_ef4e3b39-104f-4a55-adc5-56d68828302a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a072cdbe-6803-47e6-89d7-0668d18941b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_d1c89e64-22c6-49f1-b6e0-cad9130e8f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_ef4e3b39-104f-4a55-adc5-56d68828302a" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_d1c89e64-22c6-49f1-b6e0-cad9130e8f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6e656f9c-2659-4bfd-8198-ce84dcaad896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_ef4e3b39-104f-4a55-adc5-56d68828302a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6e656f9c-2659-4bfd-8198-ce84dcaad896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_84976834-dd2e-4b15-bd32-dfb42f2f5513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_84976834-dd2e-4b15-bd32-dfb42f2f5513" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f3acccd-941e-4e8a-a226-a2051ed86b92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_690b9be4-b4f2-4729-aaed-fc07f094270c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_690b9be4-b4f2-4729-aaed-fc07f094270c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_846a6383-7e60-4373-8a20-4dcfa8b8fa16" xlink:href="fold-20221231.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_846a6383-7e60-4373-8a20-4dcfa8b8fa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_74cb868d-3bcb-4324-8fad-d2f3ae461c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_74cb868d-3bcb-4324-8fad-d2f3ae461c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_ca7f1a05-0ade-4cda-b8d3-8bafdb425e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_ca7f1a05-0ade-4cda-b8d3-8bafdb425e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d1338632-7806-4b4e-9866-edaf9fc72bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bfbd668b-67dd-48c0-80c2-d9ee81540dc9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d1338632-7806-4b4e-9866-edaf9fc72bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1650214f-b934-45f4-a556-d53fc4cd4dd9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a352ad4-d436-4064-8645-c9e9959d3eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a352ad4-d436-4064-8645-c9e9959d3eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_341b98d4-f2db-4cd1-9c11-f626eeaa0368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_341b98d4-f2db-4cd1-9c11-f626eeaa0368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4ef01e60-e003-46fe-a5b0-6d0fde463429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4ef01e60-e003-46fe-a5b0-6d0fde463429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_453719e8-c1c1-4cf3-9d14-86b244804294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_453719e8-c1c1-4cf3-9d14-86b244804294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_05a68d25-2737-46f2-94c9-39ee35c95c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_05a68d25-2737-46f2-94c9-39ee35c95c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d59b1776-946e-4ecb-918f-51ffe38902bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d59b1776-946e-4ecb-918f-51ffe38902bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_766daf02-62ed-4f0f-a4a5-2ccc0cbef709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_766daf02-62ed-4f0f-a4a5-2ccc0cbef709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_cea60211-1a2e-4a09-afde-fa750663c382" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_cea60211-1a2e-4a09-afde-fa750663c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ef3e8f07-8ec9-46ee-a5f8-c4bb2acf1c0c" xlink:href="fold-20221231.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ef3e8f07-8ec9-46ee-a5f8-c4bb2acf1c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5e8b517c-fb42-4d51-8d7d-e990331d9ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5e8b517c-fb42-4d51-8d7d-e990331d9ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_4a1b332f-9106-4c00-a2e2-aeedf16f4076" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_4a1b332f-9106-4c00-a2e2-aeedf16f4076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70a07cd2-134b-4d91-a95b-1f777cc074b7" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_70a07cd2-134b-4d91-a95b-1f777cc074b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_733191ab-438d-459b-b55b-d7e57402991b" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_733191ab-438d-459b-b55b-d7e57402991b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_192f9147-08cb-4e9e-8dd8-ce468099bed2" xlink:href="fold-20221231.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0d2d16a0-5e19-4d86-82a8-b80b6315fbe1" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_192f9147-08cb-4e9e-8dd8-ce468099bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_99a91a2a-0611-4e37-a104-8fe231160e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b9419b1-3a85-47c7-b750-6de48499b86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_99a91a2a-0611-4e37-a104-8fe231160e6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b9419b1-3a85-47c7-b750-6de48499b86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3b385966-1f35-4501-a5e4-fd118e74a98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_99a91a2a-0611-4e37-a104-8fe231160e6a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3b385966-1f35-4501-a5e4-fd118e74a98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8eae3ff-d5b7-4f32-b64a-3712873ddba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_99a91a2a-0611-4e37-a104-8fe231160e6a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8eae3ff-d5b7-4f32-b64a-3712873ddba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1a17455d-9ca1-4162-9abf-fe7cb3a683c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5829904b-9fa2-4f81-a81b-548fd792c30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1a17455d-9ca1-4162-9abf-fe7cb3a683c0" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5829904b-9fa2-4f81-a81b-548fd792c30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9a593dc5-b64c-4c86-a2a3-b4fcf616ed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1a17455d-9ca1-4162-9abf-fe7cb3a683c0" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_9a593dc5-b64c-4c86-a2a3-b4fcf616ed12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_82c3cd0f-194d-4024-8622-66bd9d3fdcb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1a17455d-9ca1-4162-9abf-fe7cb3a683c0" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_82c3cd0f-194d-4024-8622-66bd9d3fdcb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8c974ead-868f-4bcc-96b0-55564b230bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1a17455d-9ca1-4162-9abf-fe7cb3a683c0" xlink:to="loc_us-gaap_InventoryNet_8c974ead-868f-4bcc-96b0-55564b230bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_58036ff7-4988-4203-81b8-4b4a8dca7f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1a17455d-9ca1-4162-9abf-fe7cb3a683c0" xlink:to="loc_us-gaap_InventoryValuationReserves_58036ff7-4988-4203-81b8-4b4a8dca7f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2e1a490e-5f29-4d81-97fa-e11f140d93d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2e1a490e-5f29-4d81-97fa-e11f140d93d6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9249dece-455c-4c8f-be8c-34134a5d6c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_465156c1-db10-45ea-a5da-15e5429ecc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_465156c1-db10-45ea-a5da-15e5429ecc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ResearchEquipmentMember_1959ded0-69ac-496c-8a25-cdae556fdab9" xlink:href="fold-20221231.xsd#fold_ResearchEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_fold_ResearchEquipmentMember_1959ded0-69ac-496c-8a25-cdae556fdab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ad946873-dfba-46b9-9c1c-728d978e68db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_ComputerEquipmentMember_ad946873-dfba-46b9-9c1c-728d978e68db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6c50b9b1-b47e-428b-bc96-417c88090515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_ConstructionInProgressMember_6c50b9b1-b47e-428b-bc96-417c88090515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9b1c3b91-84f9-4661-8334-7b54fcbd9dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9b1c3b91-84f9-4661-8334-7b54fcbd9dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1cbe7dcf-5f40-4c6e-890d-cc861b873158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1cbe7dcf-5f40-4c6e-890d-cc861b873158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_f886fc91-dae2-49f7-abf7-e2f8e702dc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_VehiclesMember_f886fc91-dae2-49f7-abf7-e2f8e702dc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_b65900e6-2e88-4771-95a3-cefc985ae5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc4384b1-7fbd-4d33-bb3b-0c1f373bc4a4" xlink:to="loc_us-gaap_LandMember_b65900e6-2e88-4771-95a3-cefc985ae5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_296444ee-a428-4aab-8eaa-9ef8aad98a5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_acd230bb-6d1c-4b82-98a3-817ac51c0ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_acd230bb-6d1c-4b82-98a3-817ac51c0ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31b978d5-7673-4da9-a99b-5c4893ed47de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31b978d5-7673-4da9-a99b-5c4893ed47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_034335fd-2076-420d-a1b7-cfb96d6ab085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_034335fd-2076-420d-a1b7-cfb96d6ab085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2c3a2fca-b9cd-458b-b4b7-5a80912e1bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_Depreciation_2c3a2fca-b9cd-458b-b4b7-5a80912e1bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_24a12f84-8866-45eb-a8c3-983597678014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b8dbf5-934b-444f-8179-6386cc60dc05" xlink:to="loc_us-gaap_AssetImpairmentCharges_24a12f84-8866-45eb-a8c3-983597678014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0a59819e-bf22-467e-b645-d75d9c1a88ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0a59819e-bf22-467e-b645-d75d9c1a88ba" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_18c696e8-9e3f-4826-a1c9-a7a348f51595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_18c696e8-9e3f-4826-a1c9-a7a348f51595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_cc20ee22-9cb2-4569-897b-1e78b08c79ce" xlink:href="fold-20221231.xsd#fold_AccruedSalesRebatesAndChargebacksCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_fold_AccruedSalesRebatesAndChargebacksCurrent_cc20ee22-9cb2-4569-897b-1e78b08c79ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedProgramFees_a7d0383a-f8f4-4232-8e5f-81b035405efd" xlink:href="fold-20221231.xsd#fold_AccruedProgramFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_fold_AccruedProgramFees_a7d0383a-f8f4-4232-8e5f-81b035405efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6b3132a0-e0ae-4615-b679-1e4097f245ff" xlink:href="fold-20221231.xsd#fold_AccruedContractManufacturingAndContractResearchCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_fold_AccruedContractManufacturingAndContractResearchCostsCurrent_6b3132a0-e0ae-4615-b679-1e4097f245ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_203115d7-d2fa-4563-9d41-4a0b14358540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_203115d7-d2fa-4563-9d41-4a0b14358540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5e7d93d0-03f9-4385-b401-b805317d7b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5e7d93d0-03f9-4385-b401-b805317d7b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_e875ddfa-a9bd-4e2d-9472-b287dc6b30eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_us-gaap_TaxesPayableCurrent_e875ddfa-a9bd-4e2d-9472-b287dc6b30eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_08e9df4d-165b-463a-bf33-1e0a11ef3f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_08e9df4d-165b-463a-bf33-1e0a11ef3f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8f884109-37c6-496f-bd96-0d5b9bc8a903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_89574dac-5288-4761-b412-4cb4ecd27296" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8f884109-37c6-496f-bd96-0d5b9bc8a903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c7dab288-d9bf-46dc-af12-a871c656d76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c7dab288-d9bf-46dc-af12-a871c656d76c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b2bc6d6-9b0c-4141-8d85-52e75fe96cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8fa39107-e7eb-42e7-99e8-fadc6f8b17e0" xlink:to="loc_us-gaap_ClassOfStockDomain_4b2bc6d6-9b0c-4141-8d85-52e75fe96cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2563b4e5-db19-4b3c-8fd4-c56267cb843c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b2bc6d6-9b0c-4141-8d85-52e75fe96cf5" xlink:to="loc_us-gaap_CommonStockMember_2563b4e5-db19-4b3c-8fd4-c56267cb843c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1ee14a39-d9b0-4e06-af08-7a6622b57ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4939f3ec-2d9d-47d7-8b4f-5649d810b240" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1ee14a39-d9b0-4e06-af08-7a6622b57ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_54d94840-6c2a-447e-b783-e5365b11d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1ee14a39-d9b0-4e06-af08-7a6622b57ddc" xlink:to="loc_us-gaap_WarrantMember_54d94840-6c2a-447e-b783-e5365b11d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1588a313-838e-4f83-b321-d065f5559849" xlink:to="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_88590031-9a59-4bd1-929d-44c07034c257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:to="loc_us-gaap_CommonStockMember_88590031-9a59-4bd1-929d-44c07034c257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_728a1b19-ebf9-4f46-b781-0dbb0a3a2133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_656df52e-83a3-4224-b2b1-cf51629dd553" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_728a1b19-ebf9-4f46-b781-0dbb0a3a2133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ac55fff7-4cd1-4e73-8dee-cd3580c0c3ac" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AtTheMarketEquityProgramMember_5f90a386-36bb-4cef-8432-be27f94dde00" xlink:href="fold-20221231.xsd#fold_AtTheMarketEquityProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_fold_AtTheMarketEquityProgramMember_5f90a386-36bb-4cef-8432-be27f94dde00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e8a6ea24-4b64-4f71-a5b5-d3435709013e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_us-gaap_PrivatePlacementMember_e8a6ea24-4b64-4f71-a5b5-d3435709013e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member_bb85c7e6-c2d4-4b62-82a4-35e59063e445" xlink:href="fold-20221231.xsd#fold_StockExercisesAt798Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_fold_StockExercisesAt798Member_bb85c7e6-c2d4-4b62-82a4-35e59063e445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member_fdd78b6f-f8ec-46a5-9592-edfdb7d16328" xlink:href="fold-20221231.xsd#fold_StockExercisesAt706Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12c6c4d9-1641-4239-aad3-75fec618cb2a" xlink:to="loc_fold_StockExercisesAt706Member_fdd78b6f-f8ec-46a5-9592-edfdb7d16328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2ed801c2-e4d7-4752-b62f-6a73efa19ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_633f5e9f-03c3-4bcc-a6d6-c07cfe5c0fe3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2ed801c2-e4d7-4752-b62f-6a73efa19ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_d05cf11c-f727-4582-9553-221ee3fa775f" xlink:href="fold-20221231.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2ed801c2-e4d7-4752-b62f-6a73efa19ace" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_d05cf11c-f727-4582-9553-221ee3fa775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7aae4ac4-7d74-4014-8478-c87184624071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a28198a1-959f-4c7d-9393-cf623b6bdabb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7aae4ac4-7d74-4014-8478-c87184624071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1c0165cf-4f00-43a5-99b1-753eea0e6400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7aae4ac4-7d74-4014-8478-c87184624071" xlink:to="loc_us-gaap_ConvertibleDebtMember_1c0165cf-4f00-43a5-99b1-753eea0e6400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4ea93ae-639c-4d3c-ae35-6c266379cf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_faaab0b7-d3ab-4f8b-b566-f710c2d1bfd3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4ea93ae-639c-4d3c-ae35-6c266379cf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4ea93ae-639c-4d3c-ae35-6c266379cf2e" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0f6ab527-db8f-4e4a-9ef8-5697300d5758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0f6ab527-db8f-4e4a-9ef8-5697300d5758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CommonStockVotingRightsForEachShareHeld_7d056d2c-a232-4725-917f-2e108adbcd48" xlink:href="fold-20221231.xsd#fold_CommonStockVotingRightsForEachShareHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_fold_CommonStockVotingRightsForEachShareHeld_7d056d2c-a232-4725-917f-2e108adbcd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09ffdd9d-a913-41b0-9cb9-ede48964f901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09ffdd9d-a913-41b0-9cb9-ede48964f901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1f768c9-ca78-40d4-a08f-7f3f96121d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a1f768c9-ca78-40d4-a08f-7f3f96121d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b2096bbc-6782-4d86-89c2-3242ecb7254e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b2096bbc-6782-4d86-89c2-3242ecb7254e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ebbe4181-a0bd-4392-bd38-86577b362f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ebbe4181-a0bd-4392-bd38-86577b362f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_4d46254d-e210-4101-ad5f-1da050b0358a" xlink:href="fold-20221231.xsd#fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing_4d46254d-e210-4101-ad5f-1da050b0358a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41a67f40-543e-495f-b6cc-f3e923a16a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41a67f40-543e-495f-b6cc-f3e923a16a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_28f5e41e-0dd8-45ed-81e4-549f29281f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_28f5e41e-0dd8-45ed-81e4-549f29281f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6f8b27b6-3ce9-4c01-ba1a-f0378630870f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6f8b27b6-3ce9-4c01-ba1a-f0378630870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1916523b-9937-4aa3-851a-49de709d5bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1916523b-9937-4aa3-851a-49de709d5bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_acbdce07-7c9a-421e-b7c2-890bb8e454b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_acbdce07-7c9a-421e-b7c2-890bb8e454b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8bcda718-ff3c-4837-b128-78326827aa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_b705425a-fc4d-43e9-a44e-eee8d5d3ec46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8bcda718-ff3c-4837-b128-78326827aa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_01597f74-67cd-4e37-bf0c-4b53152587e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_01597f74-67cd-4e37-bf0c-4b53152587e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_4c6a07e5-94ba-4942-8050-66342646252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9ebd4050-f3c0-4584-8988-45060d51f93f" xlink:to="loc_us-gaap_VestingDomain_4c6a07e5-94ba-4942-8050-66342646252f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70c1b240-1b7e-41b8-8399-b2bc0d78435e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_4c6a07e5-94ba-4942-8050-66342646252f" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_70c1b240-1b7e-41b8-8399-b2bc0d78435e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc57e136-761e-4c64-85a6-2c240f2e26d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_12ce7ed5-6339-441b-ac2e-928798914bf0" xlink:to="loc_srt_RangeMember_cc57e136-761e-4c64-85a6-2c240f2e26d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e181f37e-37c6-4ba0-9aab-290654524596" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cc57e136-761e-4c64-85a6-2c240f2e26d9" xlink:to="loc_srt_MaximumMember_e181f37e-37c6-4ba0-9aab-290654524596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f13eb8-256b-497b-8c43-630225458a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c63f4841-b577-4ac2-938f-ed53b4a9f7bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f13eb8-256b-497b-8c43-630225458a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec8b6a28-4446-43eb-9054-1e97634bd00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f13eb8-256b-497b-8c43-630225458a4e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec8b6a28-4446-43eb-9054-1e97634bd00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ae147d51-5f92-424b-a450-83327f73b022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_8b43bb15-1a48-403c-a0ff-0688abb59c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_TradingSecurities_8b43bb15-1a48-403c-a0ff-0688abb59c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0702a676-0521-492d-b5f0-596741303208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0702a676-0521-492d-b5f0-596741303208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9cb774bb-b627-4e1e-ac68-cf54a433956f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_9cb774bb-b627-4e1e-ac68-cf54a433956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_0036525f-14e5-48d9-afed-7df9ed69e746" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage_0036525f-14e5-48d9-afed-7df9ed69e746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fdc1d733-7586-4d27-a42a-c43a3bebce50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d48d1309-50a7-4291-b373-98455b4fc4d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fdc1d733-7586-4d27-a42a-c43a3bebce50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1fc9d94f-f1f1-45f5-bb71-2494d34a53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1fc9d94f-f1f1-45f5-bb71-2494d34a53f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:to="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_baba3cae-c940-4ab3-8b2f-38bb8ef20f2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5d66e4bd-ad24-424e-accd-d96f0977c72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5d66e4bd-ad24-424e-accd-d96f0977c72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_10a5dfe7-e232-4015-b1aa-1dfe46222b55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16de29ac-c9d3-4547-9aad-6d4e45d7ba9b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_10a5dfe7-e232-4015-b1aa-1dfe46222b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9c3a11e-f976-4525-960a-37b0a5edeb91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_e2c3a6b8-747f-44ae-963c-2d033e655488" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting_e2c3a6b8-747f-44ae-963c-2d033e655488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa782fcc-f207-4713-ae19-c6932e1df7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa782fcc-f207-4713-ae19-c6932e1df7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2036d084-2a1b-4f1f-a1c3-241489e0ec51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2036d084-2a1b-4f1f-a1c3-241489e0ec51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_13debdbd-0044-43da-8704-397c7251981a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_13debdbd-0044-43da-8704-397c7251981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1f03a5c7-5f98-46ab-bcbc-bdbacbfd6233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1f03a5c7-5f98-46ab-bcbc-bdbacbfd6233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b2b216b-2d7c-4ac8-b0fa-04a129077dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b2b216b-2d7c-4ac8-b0fa-04a129077dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_89c5bf81-c3fa-4fe9-95a7-1a8cb40afb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f649609-0032-4ac0-b7cf-8f656e9e2bf2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_89c5bf81-c3fa-4fe9-95a7-1a8cb40afb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c68f6e52-f2bb-4553-a3bd-742dce3fb87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c68f6e52-f2bb-4553-a3bd-742dce3fb87c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:to="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_165d4b56-115b-48ca-a947-871a782b9a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c95a35f8-a751-4ec6-ab87-0562277a13a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_165d4b56-115b-48ca-a947-871a782b9a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_973aca24-57d3-4dde-8769-a890df9f5ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_165d4b56-115b-48ca-a947-871a782b9a64" xlink:to="loc_us-gaap_EmployeeStockOptionMember_973aca24-57d3-4dde-8769-a890df9f5ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_182fe9b9-bc0e-4a5d-bd5f-3d63d0d068a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd7db15d-33c5-4a4c-8373-9d65bdd4f1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cd7db15d-33c5-4a4c-8373-9d65bdd4f1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce12c1eb-e151-4dc2-a658-da4de620b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ce12c1eb-e151-4dc2-a658-da4de620b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_368f6634-77d5-41f7-8124-268d4e160aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_368f6634-77d5-41f7-8124-268d4e160aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_c2abbd43-cdcc-4144-8c39-39d28ff1abb4" xlink:href="fold-20221231.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9d22be1d-cb53-4a9c-9673-a36465dde1b9" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_c2abbd43-cdcc-4144-8c39-39d28ff1abb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d151b16f-902f-4e4e-9309-7403d4a73669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d151b16f-902f-4e4e-9309-7403d4a73669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_874c874d-3e6c-44f1-8880-fa83f965280d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_874c874d-3e6c-44f1-8880-fa83f965280d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7244b88-d336-4ffd-b25d-b6b77f7e21d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f7244b88-d336-4ffd-b25d-b6b77f7e21d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c184245-5339-4a71-a026-91541fa6a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0c184245-5339-4a71-a026-91541fa6a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e69f3736-0516-47fa-98d9-c24645e3982d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e69f3736-0516-47fa-98d9-c24645e3982d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3b55ed5d-2c97-497b-8a15-805e498d3686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_914cfd4d-cd8b-40d8-ab00-d99a84221a84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3b55ed5d-2c97-497b-8a15-805e498d3686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17c1f4cc-7ac8-43e4-9edd-bfd51408d4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17c1f4cc-7ac8-43e4-9edd-bfd51408d4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_75491a1e-8d44-4563-a6a9-50d942f1323e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_75491a1e-8d44-4563-a6a9-50d942f1323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e67c61f-120a-4d27-8150-2ffafb45de80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e67c61f-120a-4d27-8150-2ffafb45de80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2c58dca7-b5bb-41ea-ae7f-0492e040bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2c58dca7-b5bb-41ea-ae7f-0492e040bb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b591b0d3-3063-4295-9152-de2864bf3170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b591b0d3-3063-4295-9152-de2864bf3170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1acc001f-0d08-4bf1-8c77-9a13336bfb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1acc001f-0d08-4bf1-8c77-9a13336bfb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3f9ea113-bd2e-4625-83c7-b76122326ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3f9ea113-bd2e-4625-83c7-b76122326ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98f27d61-3d05-4750-82c4-70d9b9fa9ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbb1fbc1-d2ba-47cb-b0d5-21caf0d7d9ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_98f27d61-3d05-4750-82c4-70d9b9fa9ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_61502cb7-4af5-41bb-a48a-74b0746b37ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_61502cb7-4af5-41bb-a48a-74b0746b37ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a885942-adc1-45a4-a24e-1d3a59daa314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6a885942-adc1-45a4-a24e-1d3a59daa314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6102a779-12e3-4f18-9a3a-4b0ee95080aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e74c8545-254c-4e61-b345-360038c07879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e74c8545-254c-4e61-b345-360038c07879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bd6e4907-2bba-45fa-bd35-0780b75e74c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bd6e4907-2bba-45fa-bd35-0780b75e74c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_72eb0efd-36cc-4bc2-8a4d-1eff1b81047b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_72eb0efd-36cc-4bc2-8a4d-1eff1b81047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bbee39bf-e4ce-4098-95ac-36e1f4503587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bbee39bf-e4ce-4098-95ac-36e1f4503587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b1f0a612-b1d8-4081-a1ee-b803efda39ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b1f0a612-b1d8-4081-a1ee-b803efda39ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f9f35c39-232b-4e91-a836-be02047a6e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_35db6be4-d102-4a0c-a63e-ee0d0fe01649" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f9f35c39-232b-4e91-a836-be02047a6e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4948180a-5358-4d5b-8e62-50763cd085de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4948180a-5358-4d5b-8e62-50763cd085de" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:to="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d8dca04-af6e-4e08-9f62-18d191111008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c7b11fa3-2906-425a-8a80-da92bfda81c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d8dca04-af6e-4e08-9f62-18d191111008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_53448a23-2b79-4d92-84dd-54c953b78e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d8dca04-af6e-4e08-9f62-18d191111008" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_53448a23-2b79-4d92-84dd-54c953b78e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_83a6d6d7-fbbb-4d02-96e1-aec1fa20afee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5457f35-726d-48e5-bbd9-bf02d8763811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d5457f35-726d-48e5-bbd9-bf02d8763811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5a5d32b-1109-4614-a1ef-4d8fb9f6684b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5a5d32b-1109-4614-a1ef-4d8fb9f6684b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ed1efa8c-df59-47f2-89d7-b52b0ecbe3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ed1efa8c-df59-47f2-89d7-b52b0ecbe3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5dfd0fc-c2e2-40b9-b095-f36e82bf767f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b5dfd0fc-c2e2-40b9-b095-f36e82bf767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd6f14d5-5d1b-41b7-b710-0a053c06edab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcab3436-54be-442a-aeb1-1c470b07de57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd6f14d5-5d1b-41b7-b710-0a053c06edab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eede50f-e413-41be-a3c2-14d40723690b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9eede50f-e413-41be-a3c2-14d40723690b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_283d4f59-033a-4e84-a91f-40d327b21b82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_283d4f59-033a-4e84-a91f-40d327b21b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12a01c63-228a-41c2-b95c-19e9c18b0b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12a01c63-228a-41c2-b95c-19e9c18b0b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8d5fa038-8cd4-459a-90ba-37ad884f685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8d5fa038-8cd4-459a-90ba-37ad884f685a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6a40d04-b4e1-43c3-98af-75e9ae9aac56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7792d5c1-33dd-4fc5-a8e3-f2f977ec0fdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6a40d04-b4e1-43c3-98af-75e9ae9aac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f36fa6a3-d6db-4540-9b00-41b6a4112390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4da94142-36d9-49fd-ac54-c8c9b819668f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4da94142-36d9-49fd-ac54-c8c9b819668f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6892d56c-8e10-44bb-bb2b-2d287634224a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8837b7e4-f08d-48b5-85fd-e9b370681a88" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6892d56c-8e10-44bb-bb2b-2d287634224a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#SharebasedCompensationExpenseSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dbcafad5-85c3-4d1e-b59d-eaf12f66adee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dbcafad5-85c3-4d1e-b59d-eaf12f66adee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc3e0d75-0253-4e13-8d8f-bbe290192b85" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_651138ce-60b3-485d-97e3-7ccac0ab94e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_651138ce-60b3-485d-97e3-7ccac0ab94e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_82a40303-2cd6-4611-96a8-6aa9e27e741c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ee6c3918-4ddb-42d8-ad3e-f58e778e1bc1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_82a40303-2cd6-4611-96a8-6aa9e27e741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c44b7599-47a1-40cc-9bc8-f643966d5eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e2fbca9-8f81-406a-b7ca-10b2fc0a8b7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c44b7599-47a1-40cc-9bc8-f643966d5eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ce3d192-7ebf-4eaf-b8b5-c54637af4f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c44b7599-47a1-40cc-9bc8-f643966d5eb3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5ce3d192-7ebf-4eaf-b8b5-c54637af4f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0735b39a-f738-49b0-98e5-818120568250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0735b39a-f738-49b0-98e5-818120568250" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32c6bcc6-cd77-475e-83bc-033705db1d1f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c6b21f87-5f88-4b71-a754-f888a34d6f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c6b21f87-5f88-4b71-a754-f888a34d6f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_186ca98f-56dd-432f-82f9-575020b8d180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53e17051-f9ba-489f-a826-7c75f0aba09c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_186ca98f-56dd-432f-82f9-575020b8d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f355ce5b-ef33-4355-9137-e70538000c88" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7d27816d-7598-435f-be13-cf659d4ba2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_7d27816d-7598-435f-be13-cf659d4ba2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6d7eb2df-2c02-4473-bfc1-dbfd30b5bb53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6d7eb2df-2c02-4473-bfc1-dbfd30b5bb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c24857ad-7f57-4541-9b04-121f04d72e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c24857ad-7f57-4541-9b04-121f04d72e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_e7ef77c0-b461-4801-a91f-45b689277c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bae2f6f7-1ff0-49f8-92a7-511e5cad8766" xlink:to="loc_us-gaap_MoneyMarketFundsMember_e7ef77c0-b461-4801-a91f-45b689277c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_96621dd7-e72f-4277-b1dc-ba813186d5a8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_127546da-5c92-49c9-a756-dfe7f89e8386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_127546da-5c92-49c9-a756-dfe7f89e8386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_eabcc13b-bbf5-4be2-bf02-1c90f8d99a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_127546da-5c92-49c9-a756-dfe7f89e8386" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_eabcc13b-bbf5-4be2-bf02-1c90f8d99a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76c2122a-c7e7-4c8e-b1ed-10b55c52862d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2736aac-6f71-48f4-b2a7-9089659b1b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c2736aac-6f71-48f4-b2a7-9089659b1b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_625082df-8e4f-4d97-80aa-6e6785a05273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_625082df-8e4f-4d97-80aa-6e6785a05273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_77aa7eff-ecfe-4c97-90e9-1f64f894deed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f38f8dfb-c48e-41f4-9376-cc403b9f6653" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_77aa7eff-ecfe-4c97-90e9-1f64f894deed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc832c79-543e-4a97-8871-e8d68f5d38b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc832c79-543e-4a97-8871-e8d68f5d38b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696b092f-9b34-4976-abc7-22626ee4aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3f357d60-1800-4ee0-b6b5-60d502c8614f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696b092f-9b34-4976-abc7-22626ee4aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_cd9f58d9-0c9a-44b1-a7a3-1f180f1cf859" xlink:href="fold-20221231.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_696b092f-9b34-4976-abc7-22626ee4aa09" xlink:to="loc_fold_CallidusBiopharmaIncMember_cd9f58d9-0c9a-44b1-a7a3-1f180f1cf859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_506140a0-0585-4cc4-9ff5-fe98953c45ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b5cf3417-cc64-4a36-a183-4fa4dfd6add3" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_506140a0-0585-4cc4-9ff5-fe98953c45ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_60fbdf72-8366-4071-9968-d918d6b19667" xlink:href="fold-20221231.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_506140a0-0585-4cc4-9ff5-fe98953c45ee" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_60fbdf72-8366-4071-9968-d918d6b19667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e262ada1-c52b-45ac-aa9f-a5b6f520baba" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_124d6897-b339-45a1-8f6c-db73b7f375e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_124d6897-b339-45a1-8f6c-db73b7f375e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_8a04a407-e799-4be0-80f1-b2189a31a7c7" xlink:href="fold-20221231.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1356a64d-7477-42e5-8ce2-62e90c17db39" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_8a04a407-e799-4be0-80f1-b2189a31a7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d29d97-7264-40d0-9e81-d2b5e4bb54f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_92e94206-2036-47f8-807b-3c47b21aff4d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d29d97-7264-40d0-9e81-d2b5e4bb54f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TB200PompeProgramMember_f1f6b348-bcf9-4236-b22f-7fbb27f5c4a8" xlink:href="fold-20221231.xsd#fold_TB200PompeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_24d29d97-7264-40d0-9e81-d2b5e4bb54f4" xlink:to="loc_fold_TB200PompeProgramMember_f1f6b348-bcf9-4236-b22f-7fbb27f5c4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9f064031-f3d9-422c-b7a1-3801057c489c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_6c722eab-a5e4-46ae-b379-4fb0fd51479a" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9f064031-f3d9-422c-b7a1-3801057c489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_33fab0f0-3fd2-4b32-a88b-e2b95161ad25" xlink:href="fold-20221231.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9f064031-f3d9-422c-b7a1-3801057c489c" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_33fab0f0-3fd2-4b32-a88b-e2b95161ad25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_12f7cdce-7922-4e45-bc1b-2dfe09dca46d" xlink:to="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aac7cff4-47bf-4882-a1fa-f58c0c423b03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:to="loc_srt_MinimumMember_aac7cff4-47bf-4882-a1fa-f58c0c423b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a68b36fc-ccef-4661-a569-46e426584093" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_da53bc77-7a07-42e8-8b52-4a54ff475ff1" xlink:to="loc_srt_MaximumMember_a68b36fc-ccef-4661-a569-46e426584093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa4bdd00-6615-4eeb-8425-58c95fd0adb1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3466fee9-54b0-4305-ad34-0cd4da6b86ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3466fee9-54b0-4305-ad34-0cd4da6b86ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_227d79ec-2f6a-4c3a-ab0d-1a00baa3330a" xlink:href="fold-20221231.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2ed9040-031d-4a68-a530-625e97ab0911" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_227d79ec-2f6a-4c3a-ab0d-1a00baa3330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_040c14ac-76eb-4fa2-8273-793102ce0b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a0aea9a-9cba-4192-9531-e0cb1be9e675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_040c14ac-76eb-4fa2-8273-793102ce0b15" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a0aea9a-9cba-4192-9531-e0cb1be9e675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_864a0418-838d-4254-99cf-84d927e63e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a0aea9a-9cba-4192-9531-e0cb1be9e675" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_864a0418-838d-4254-99cf-84d927e63e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0d6289ff-1f1c-4cc0-a5ec-5ba28793731c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a0aea9a-9cba-4192-9531-e0cb1be9e675" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_0d6289ff-1f1c-4cc0-a5ec-5ba28793731c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8ccb876a-474e-45fb-891a-6b4cdfafa67a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a0aea9a-9cba-4192-9531-e0cb1be9e675" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8ccb876a-474e-45fb-891a-6b4cdfafa67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d1a21c4f-f490-4fdb-af9d-2b252d279dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1a0aea9a-9cba-4192-9531-e0cb1be9e675" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d1a21c4f-f490-4fdb-af9d-2b252d279dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9f7e8e3f-6769-45f5-96be-55ee004f7f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9f7e8e3f-6769-45f5-96be-55ee004f7f23" xlink:to="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_589abd77-5568-4ecf-ac1e-5c917fae1c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c8ebf763-1baa-4ac6-b1d7-66618907c434" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_589abd77-5568-4ecf-ac1e-5c917fae1c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_28fb5952-e4d6-4cb0-83ed-7c2699c5d4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_589abd77-5568-4ecf-ac1e-5c917fae1c74" xlink:to="loc_us-gaap_SeniorLoansMember_28fb5952-e4d6-4cb0-83ed-7c2699c5d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:to="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a4ce9e49-f67d-4953-b3bc-3cf16f3989b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6b91c51f-a3a2-4078-bd0c-d4f4b67070ef" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a4ce9e49-f67d-4953-b3bc-3cf16f3989b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_a949f410-d621-48f4-b836-64fc22395e54" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a4ce9e49-f67d-4953-b3bc-3cf16f3989b5" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_a949f410-d621-48f4-b836-64fc22395e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4c4a452b-6be4-4454-9eec-8cd372f34e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b686508c-279b-49d3-afae-42d2b4c8b39b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4c4a452b-6be4-4454-9eec-8cd372f34e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4c4a452b-6be4-4454-9eec-8cd372f34e26" xlink:to="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b272ebdb-59a2-4088-9552-670d49c5468f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b272ebdb-59a2-4088-9552-670d49c5468f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_501c3b22-1d28-4ecf-b87e-b8ef8cc6d470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_501c3b22-1d28-4ecf-b87e-b8ef8cc6d470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_af393ac8-4ce5-4f46-8b33-e43305fd4b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_DeferredOfferingCosts_af393ac8-4ce5-4f46-8b33-e43305fd4b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_769698a4-8131-4cea-af77-6bea992a607e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentsAbstract_e21f801b-d7d6-4d35-ac1d-5be8ca59f2d2" xlink:to="loc_us-gaap_LongTermDebt_769698a4-8131-4cea-af77-6bea992a607e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_20ed9a07-2d22-403a-8d4a-45dd18405278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_20ed9a07-2d22-403a-8d4a-45dd18405278" xlink:to="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8afb7032-fd6b-45fd-bdfc-e06e11d529b1" xlink:to="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2b409084-cdc1-4704-9b97-c1f3952192fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:to="loc_us-gaap_SecuredDebtMember_2b409084-cdc1-4704-9b97-c1f3952192fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_17deeb64-7a53-4a00-bb06-a93c8a915f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8b408106-dcd2-40c2-810d-39a649ecba15" xlink:to="loc_us-gaap_LineOfCreditMember_17deeb64-7a53-4a00-bb06-a93c8a915f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b10139d4-5296-48dd-a575-3078c75f8b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_da9005c9-deaf-4fda-af6e-81dd6f347f14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b10139d4-5296-48dd-a575-3078c75f8b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_fd740f56-2d2d-410e-8e2f-e2835ec6fc5c" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b10139d4-5296-48dd-a575-3078c75f8b97" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_fd740f56-2d2d-410e-8e2f-e2835ec6fc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1935b51f-7e8e-4c00-9b0e-976312be1e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d253e508-9935-4c18-ae22-f35ba75d4d46" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1935b51f-7e8e-4c00-9b0e-976312be1e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_b1b4218e-707d-465a-84ee-69466b5a61f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1935b51f-7e8e-4c00-9b0e-976312be1e9c" xlink:to="loc_us-gaap_SeniorLoansMember_b1b4218e-707d-465a-84ee-69466b5a61f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4d7eea27-24a2-4b30-8386-a28d0a0513f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f15037e2-ff1e-4209-966f-a12555220458" xlink:to="loc_us-gaap_VariableRateDomain_4d7eea27-24a2-4b30-8386-a28d0a0513f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6fa787e1-7f82-4cd3-9aa7-fe61cfa23e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4d7eea27-24a2-4b30-8386-a28d0a0513f1" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_6fa787e1-7f82-4cd3-9aa7-fe61cfa23e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2ad32d7a-b367-4b3c-a577-8249216c628d" xlink:to="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1608660e-f170-48be-8742-55832e497c26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:to="loc_srt_MinimumMember_1608660e-f170-48be-8742-55832e497c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c295344-9654-4292-aaba-eedd5b446a98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c223adb-9992-4ffc-8e0f-bb8a656555c1" xlink:to="loc_srt_MaximumMember_6c295344-9654-4292-aaba-eedd5b446a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c73a51ed-86ca-4a73-bc95-bf759a80f56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_812d895a-0331-465c-bf5d-37300774737e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c73a51ed-86ca-4a73-bc95-bf759a80f56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c73a51ed-86ca-4a73-bc95-bf759a80f56d" xlink:to="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0b05381e-c361-4596-a17e-a7b4827f700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0b05381e-c361-4596-a17e-a7b4827f700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentVariableRate_8bc2bed5-d126-47f6-9b04-3498fd0c56b7" xlink:href="fold-20221231.xsd#fold_DebtInstrumentVariableRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentVariableRate_8bc2bed5-d126-47f6-9b04-3498fd0c56b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d0dc38d-9f2a-46ab-bbab-60ef7e856fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5d0dc38d-9f2a-46ab-bbab-60ef7e856fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_3b47876b-8cca-4869-abf2-4ea3ed5de523" xlink:href="fold-20221231.xsd#fold_DebtInstrumentPeriodicPaymentNumberOfPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentPeriodicPaymentNumberOfPayments_3b47876b-8cca-4869-abf2-4ea3ed5de523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_9da74d39-fdac-46af-8139-8c02383249e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_9da74d39-fdac-46af-8139-8c02383249e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_ec210a1a-4b7c-4c3f-9563-b33359b19a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSecuredLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_ProceedsFromSecuredLinesOfCredit_ec210a1a-4b7c-4c3f-9563-b33359b19a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_9f60e8e4-c6f6-4b64-9452-a004977512a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_InterestExpenseDebt_9f60e8e4-c6f6-4b64-9452-a004977512a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EarlySettlementPremiums_eaa70c0c-efad-42b7-ad3d-c7db60cb3aef" xlink:href="fold-20221231.xsd#fold_EarlySettlementPremiums"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_EarlySettlementPremiums_eaa70c0c-efad-42b7-ad3d-c7db60cb3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db0f4e70-583b-456f-b867-e4bac5fbcfec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db0f4e70-583b-456f-b867-e4bac5fbcfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_23912380-6ca6-414a-9195-289232b78c46" xlink:href="fold-20221231.xsd#fold_DebtInstrumentLiquidityCovenantMinimumAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentLiquidityCovenantMinimumAmount_23912380-6ca6-414a-9195-289232b78c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_01169318-7925-4cf6-a9f4-2cd35baf02a1" xlink:href="fold-20221231.xsd#fold_DebtInstrumentConsolidatedRevenueCovenantAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_267ccfe9-f058-4d0c-a3f4-5399133369f3" xlink:to="loc_fold_DebtInstrumentConsolidatedRevenueCovenantAmount_01169318-7925-4cf6-a9f4-2cd35baf02a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d73a7bad-fa6c-4768-8d57-aa73de734876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d73a7bad-fa6c-4768-8d57-aa73de734876" xlink:to="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_81b7f79c-37b7-43ea-8ca6-1d189dc62104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94157aa5-aef6-4c40-96fa-d9dd5da2e391" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_81b7f79c-37b7-43ea-8ca6-1d189dc62104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_6b40080f-9aa2-4c02-a24d-665a54d3f919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81b7f79c-37b7-43ea-8ca6-1d189dc62104" xlink:to="loc_us-gaap_SeniorNotesMember_6b40080f-9aa2-4c02-a24d-665a54d3f919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:to="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29990d19-c8ad-4d55-8d2a-e6a2b6ce691a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_99a26d72-fa23-445b-a372-9ea50dfc4369" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29990d19-c8ad-4d55-8d2a-e6a2b6ce691a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_814ed8a2-c734-4736-96f5-09be7f576cdc" xlink:href="fold-20221231.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29990d19-c8ad-4d55-8d2a-e6a2b6ce691a" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_814ed8a2-c734-4736-96f5-09be7f576cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_de15d1c4-3277-435f-87e7-7c4eba0c70f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef474efd-ea52-474c-b204-0bd9173e2d89" xlink:to="loc_us-gaap_DebtInstrumentLineItems_de15d1c4-3277-435f-87e7-7c4eba0c70f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_de15d1c4-3277-435f-87e7-7c4eba0c70f7" xlink:to="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ace55273-0cf7-46c7-ba08-b57a88def678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_ace55273-0cf7-46c7-ba08-b57a88def678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_cffb9354-d150-4c32-a1d8-a3adffc7b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_cffb9354-d150-4c32-a1d8-a3adffc7b3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_f2646106-34aa-4a33-ba9d-0e4d41e6fa07" xlink:href="fold-20221231.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_f2646106-34aa-4a33-ba9d-0e4d41e6fa07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_deed18c0-5a63-4cf8-8566-f2f065ed7f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestExpenseDebtAbstract_627a1456-08a9-46fd-b863-42069a5f4102" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_deed18c0-5a63-4cf8-8566-f2f065ed7f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_da099a06-9de5-44b1-aec8-9e3c5bfc7aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e2195e6c-db5f-40d3-8e85-07770bef9890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da099a06-9de5-44b1-aec8-9e3c5bfc7aff" xlink:to="loc_us-gaap_OperatingLeaseExpense_e2195e6c-db5f-40d3-8e85-07770bef9890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e1f3eb37-47d6-47bc-9d9d-223cd879e868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da099a06-9de5-44b1-aec8-9e3c5bfc7aff" xlink:to="loc_us-gaap_VariableLeaseCost_e1f3eb37-47d6-47bc-9d9d-223cd879e868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f949ca34-1247-4678-8fc3-c172299f234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da099a06-9de5-44b1-aec8-9e3c5bfc7aff" xlink:to="loc_us-gaap_OperatingLeaseCost_f949ca34-1247-4678-8fc3-c172299f234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9d436f58-b82a-466e-b60b-29c709dcd78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da099a06-9de5-44b1-aec8-9e3c5bfc7aff" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9d436f58-b82a-466e-b60b-29c709dcd78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_6bc64101-4338-4d51-8b7c-29d089a18018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_da099a06-9de5-44b1-aec8-9e3c5bfc7aff" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_6bc64101-4338-4d51-8b7c-29d089a18018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e64c038e-ccac-47f4-9e49-809aafcf4974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e64c038e-ccac-47f4-9e49-809aafcf4974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_31783620-de94-4474-82e3-8ea6353a8e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_31783620-de94-4474-82e3-8ea6353a8e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_28e7f902-a155-498c-afc2-1fcffc9fc6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_28e7f902-a155-498c-afc2-1fcffc9fc6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_532d21ff-6b86-48f8-b6d2-c1434b74b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:to="loc_us-gaap_OperatingLeaseLiability_532d21ff-6b86-48f8-b6d2-c1434b74b5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_403f0213-bf8e-428a-928b-63cd68fed12b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_403f0213-bf8e-428a-928b-63cd68fed12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1431ead3-d639-43bf-b878-a671f75ee63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d7dac36-72ae-447d-b6ad-e880ba8e643c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1431ead3-d639-43bf-b878-a671f75ee63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesFutureMinimumOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ede057a3-8ded-4644-b7ce-5216c5d6a212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ede057a3-8ded-4644-b7ce-5216c5d6a212" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_26451d58-f90e-474b-8903-0efe874f59b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_26451d58-f90e-474b-8903-0efe874f59b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_38511689-12c6-4ab1-bd01-0f09aa6283d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_38511689-12c6-4ab1-bd01-0f09aa6283d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7efd62b0-ea25-4fc4-aa88-57f6ff03d218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7efd62b0-ea25-4fc4-aa88-57f6ff03d218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_89b245ee-9cbf-4eab-835c-ab107606f97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_89b245ee-9cbf-4eab-835c-ab107606f97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c2a35a8f-d8bb-4190-850a-ad3fa21da62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c2a35a8f-d8bb-4190-850a-ad3fa21da62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a50854fb-ff81-4604-a678-8e0d09291ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a50854fb-ff81-4604-a678-8e0d09291ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_152b0e5b-feab-481a-8ec4-223304f5f3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_152b0e5b-feab-481a-8ec4-223304f5f3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_f857f339-b89a-42af-865d-411456f85f21" xlink:href="fold-20221231.xsd#fold_LesseeOperatingLeaseLiabilityTenantIncentives"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_fold_LesseeOperatingLeaseLiabilityTenantIncentives_f857f339-b89a-42af-865d-411456f85f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ee6188ff-1c4b-4bea-a09a-5970d39d31d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ee6188ff-1c4b-4bea-a09a-5970d39d31d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bbcd1d3c-6c9d-496a-97d2-c1438d89b402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3826e996-e2d0-4eef-b04a-f4fb5bdcec4c" xlink:to="loc_us-gaap_OperatingLeaseLiability_bbcd1d3c-6c9d-496a-97d2-c1438d89b402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="fold-20221231.xsd#LeasesFutureMinimumOperatingLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0a7042e0-0b6c-408f-a7f8-a007cf581457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_a2d7a278-32a9-4878-9451-f49a4eed1a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a7042e0-0b6c-408f-a7f8-a007cf581457" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_a2d7a278-32a9-4878-9451-f49a4eed1a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_68356d85-5289-4fcc-8358-9435e881a76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_a2d7a278-32a9-4878-9451-f49a4eed1a22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_68356d85-5289-4fcc-8358-9435e881a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_31a71eef-423d-43fe-8855-ac987ed3c405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_a2d7a278-32a9-4878-9451-f49a4eed1a22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_31a71eef-423d-43fe-8855-ac987ed3c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c3d2cbd2-86d7-49fe-b7e7-b1ca531d5a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract_a2d7a278-32a9-4878-9451-f49a4eed1a22" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c3d2cbd2-86d7-49fe-b7e7-b1ca531d5a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12eb0e0b-8c17-4246-a8e9-b73a681e49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a7042e0-0b6c-408f-a7f8-a007cf581457" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12eb0e0b-8c17-4246-a8e9-b73a681e49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_92b7f0c2-c2ee-4823-a0ae-dddbfc28a334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12eb0e0b-8c17-4246-a8e9-b73a681e49e0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_92b7f0c2-c2ee-4823-a0ae-dddbfc28a334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4474567f-bb9e-47b4-8d08-74d96aaba17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12eb0e0b-8c17-4246-a8e9-b73a681e49e0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4474567f-bb9e-47b4-8d08-74d96aaba17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4275c1b1-53dc-43ec-b073-5fd4002bbaea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_12eb0e0b-8c17-4246-a8e9-b73a681e49e0" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_4275c1b1-53dc-43ec-b073-5fd4002bbaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b9d9a78-71f2-457f-8fcd-eea05225f8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a7042e0-0b6c-408f-a7f8-a007cf581457" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b9d9a78-71f2-457f-8fcd-eea05225f8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e2ea36f9-dc88-49ab-8d0c-1a77879d3db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b9d9a78-71f2-457f-8fcd-eea05225f8c6" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e2ea36f9-dc88-49ab-8d0c-1a77879d3db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_dcf49f25-10d4-4009-be0e-39aed82b640c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b9d9a78-71f2-457f-8fcd-eea05225f8c6" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_dcf49f25-10d4-4009-be0e-39aed82b640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_75a93eac-eb23-4bd7-a4d5-a7ec3550848c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1b9d9a78-71f2-457f-8fcd-eea05225f8c6" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_75a93eac-eb23-4bd7-a4d5-a7ec3550848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_db738cc2-73d2-4a79-ae1e-e11f1883b6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a7042e0-0b6c-408f-a7f8-a007cf581457" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_db738cc2-73d2-4a79-ae1e-e11f1883b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a7042e0-0b6c-408f-a7f8-a007cf581457" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_578396d1-e249-447e-9c54-9b8eece5cd03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_578396d1-e249-447e-9c54-9b8eece5cd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_650c4bed-8daa-46cd-ab05-f41481bd63e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_650c4bed-8daa-46cd-ab05-f41481bd63e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2ae12efe-1c57-48c2-a6a7-c108145b5ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2ae12efe-1c57-48c2-a6a7-c108145b5ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5cff7864-049b-4ad0-83b6-e3e079bfb2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5cff7864-049b-4ad0-83b6-e3e079bfb2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bfba5b64-a82a-42c1-85eb-58439c076967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bfba5b64-a82a-42c1-85eb-58439c076967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_78dc2492-633b-4da0-8b4f-ccdbf082fb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_06042681-cc64-4117-ad55-aa74d1ae2250" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_78dc2492-633b-4da0-8b4f-ccdbf082fb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesDeferredandValuationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3c35e7f0-2315-47d1-902c-3a64051b4419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c35e7f0-2315-47d1-902c-3a64051b4419" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsIntellectualProperty_2e9c5d2c-e721-4f8c-98c7-4a32018f6125" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsIntellectualProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_fold_DeferredTaxAssetsIntellectualProperty_2e9c5d2c-e721-4f8c-98c7-4a32018f6125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ae378ea5-531c-4eb2-9c66-8b6b3369248d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ae378ea5-531c-4eb2-9c66-8b6b3369248d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a6c0ad9a-8dab-44e1-8cf7-273f5a19dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a6c0ad9a-8dab-44e1-8cf7-273f5a19dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1db3c72b-0c46-479e-8867-f79c0de6e32f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1db3c72b-0c46-479e-8867-f79c0de6e32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_d1794e97-1ca4-4a8e-9b7b-c7bcad4e42ed" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsNonCashStockIssueNonCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent_d1794e97-1ca4-4a8e-9b7b-c7bcad4e42ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_ed17af3e-b1e8-464b-9972-cc71a4e52b14" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsInterestCarryforwardLimitation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_fold_DeferredTaxAssetsInterestCarryforwardLimitation_ed17af3e-b1e8-464b-9972-cc71a4e52b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLeasingArrangements_0a7c7c96-2527-4280-a94f-f849274cd06f" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_fold_DeferredTaxAssetsLeasingArrangements_0a7c7c96-2527-4280-a94f-f849274cd06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0298b875-0197-4d06-b2a2-95c10c539db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_0298b875-0197-4d06-b2a2-95c10c539db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c7a96356-2087-4162-ba32-799f855b7de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c7a96356-2087-4162-ba32-799f855b7de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b80ad342-fef6-4794-85fe-4b94d069c86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_7ff7b347-4a17-4947-a1c5-14fcf0c45703" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b80ad342-fef6-4794-85fe-4b94d069c86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6393d65c-ee96-4e13-a67e-9e59bcb5e761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6393d65c-ee96-4e13-a67e-9e59bcb5e761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_eb5e5fc7-ae22-4198-b733-cec89f0e02c2" xlink:href="fold-20221231.xsd#fold_DeferredTaxLiabilitiesBusinessAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6393d65c-ee96-4e13-a67e-9e59bcb5e761" xlink:to="loc_fold_DeferredTaxLiabilitiesBusinessAcquisition_eb5e5fc7-ae22-4198-b733-cec89f0e02c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_e974a80a-b31e-47ae-a5e5-c48fe5e28f60" xlink:href="fold-20221231.xsd#fold_DeferredTaxLiabilitiesRoyaltyPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6393d65c-ee96-4e13-a67e-9e59bcb5e761" xlink:to="loc_fold_DeferredTaxLiabilitiesRoyaltyPayable_e974a80a-b31e-47ae-a5e5-c48fe5e28f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_3e0186e4-837e-4cb7-8bfa-726ef46b30e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6393d65c-ee96-4e13-a67e-9e59bcb5e761" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_3e0186e4-837e-4cb7-8bfa-726ef46b30e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DeferredTaxAssetsLiabilitiesGross_9251911e-de8c-4f59-8717-d1d16ea842f7" xlink:href="fold-20221231.xsd#fold_DeferredTaxAssetsLiabilitiesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_6393d65c-ee96-4e13-a67e-9e59bcb5e761" xlink:to="loc_fold_DeferredTaxAssetsLiabilitiesGross_9251911e-de8c-4f59-8717-d1d16ea842f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c2bd1071-f211-49b3-9618-331c317f41e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c2bd1071-f211-49b3-9618-331c317f41e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1135f2f4-bf6f-4234-b94b-5383451fa38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1135f2f4-bf6f-4234-b94b-5383451fa38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19f37b2c-f356-46e2-ab7a-b9006be9ded8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19f37b2c-f356-46e2-ab7a-b9006be9ded8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_70124fe4-f4f7-49fa-b424-4119a8e048e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_9e77bc1f-2b93-463c-b3c9-1cb085d0eec6" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_70124fe4-f4f7-49fa-b424-4119a8e048e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#IncomeTaxesLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a16d6c2e-b78d-4b16-a200-8ffd156d1214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a16d6c2e-b78d-4b16-a200-8ffd156d1214" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5b762666-5229-4268-8543-1e3ee3aee398" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_48bf121f-e98d-4cd6-bcd7-199e336305f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:to="loc_us-gaap_DomesticCountryMember_48bf121f-e98d-4cd6-bcd7-199e336305f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d6b2d443-33bc-4f71-bc1e-c6c703dafd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_967a4888-d59f-464b-b3e0-50dd51c43825" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d6b2d443-33bc-4f71-bc1e-c6c703dafd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6076c6a0-4114-4229-aae6-4427eb0c0c6f" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_ac323afa-1e75-4401-8f0b-845992c2efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:to="loc_us-gaap_ResearchMember_ac323afa-1e75-4401-8f0b-845992c2efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_OrphanDrugTaxCreditCarryforwardMember_5da57b83-0155-4ad7-975a-a497211b4e04" xlink:href="fold-20221231.xsd#fold_OrphanDrugTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_10c85a2b-7804-46fd-bc36-9bb3111f38b0" xlink:to="loc_fold_OrphanDrugTaxCreditCarryforwardMember_5da57b83-0155-4ad7-975a-a497211b4e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_42d42d62-3f92-486c-8a54-f3a6c9c0dcaa" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9a79ddd4-6c64-4db4-89bc-e92ef04c276f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9a79ddd4-6c64-4db4-89bc-e92ef04c276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_7a8d4284-1ddc-4efc-96c4-17e4f97573ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3a9f87dc-42e8-447d-93e4-0d4db9328551" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_7a8d4284-1ddc-4efc-96c4-17e4f97573ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementDisclosureAbstract_675cbccd-9737-41a8-8c9f-0d1b50690fd3" xlink:href="fold-20221231.xsd#fold_CollaborativeArrangementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fold_CollaborativeArrangementDisclosureAbstract_675cbccd-9737-41a8-8c9f-0d1b50690fd3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_505f5319-b1ff-4fbe-83e9-5ead95d1fba2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_TerminationAgreementMember_cc3f9962-3db3-4818-b5f0-8898f41613ef" xlink:href="fold-20221231.xsd#fold_TerminationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:to="loc_fold_TerminationAgreementMember_cc3f9962-3db3-4818-b5f0-8898f41613ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_db8deabf-2c5a-4b1d-aab8-eca7ad99e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:to="loc_us-gaap_CollaborativeArrangementMember_db8deabf-2c5a-4b1d-aab8-eca7ad99e70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_RevisedCollaborationAgreementMember_12ef630f-c8d4-4f82-8941-57fa8399a050" xlink:href="fold-20221231.xsd#fold_RevisedCollaborationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0697015-6ac2-4ac3-a3cb-8eee2cdc3f5b" xlink:to="loc_fold_RevisedCollaborationAgreementMember_12ef630f-c8d4-4f82-8941-57fa8399a050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:to="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fe4f9d4-0a99-42a4-af3a-32a0f6c5e1b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b2761fb6-4cc2-42ca-aa2d-a50bc5cb524c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fe4f9d4-0a99-42a4-af3a-32a0f6c5e1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GlaxoSmithKlinePLCMember_54687603-30df-4ccc-9378-b36b766df854" xlink:href="fold-20221231.xsd#fold_GlaxoSmithKlinePLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fe4f9d4-0a99-42a4-af3a-32a0f6c5e1b6" xlink:to="loc_fold_GlaxoSmithKlinePLCMember_54687603-30df-4ccc-9378-b36b766df854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_706129ca-cddb-40d5-905b-335c902113a0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForCollaborativeArrangement_ea2cbec3-4310-4b8c-b6ee-42649363ce5e" xlink:href="fold-20221231.xsd#fold_PaymentsForCollaborativeArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_PaymentsForCollaborativeArrangement_ea2cbec3-4310-4b8c-b6ee-42649363ce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_8d2aa89d-9783-4ef2-a76f-8ffd4bb5d98e" xlink:href="fold-20221231.xsd#fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication_8d2aa89d-9783-4ef2-a76f-8ffd4bb5d98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_df0a5c42-b919-4426-8015-20958ffc1c83" xlink:href="fold-20221231.xsd#fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments_df0a5c42-b919-4426-8015-20958ffc1c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_4b79ee67-6f73-4f2d-b0f6-1b171513cd6e" xlink:href="fold-20221231.xsd#fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones_4b79ee67-6f73-4f2d-b0f6-1b171513cd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcdf682-aacf-41e1-8988-a6228ece19a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adcdf682-aacf-41e1-8988-a6228ece19a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_0e02b3a4-deab-4173-bea9-21bc02212504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_0e02b3a4-deab-4173-bea9-21bc02212504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4523cd26-806d-4d6a-bd03-99d87934fcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ae43926c-25d5-4bc7-9730-600f211a4d90" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4523cd26-806d-4d6a-bd03-99d87934fcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b37d91db-9b8c-4a6e-bded-b38ea01e8cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_LossContingencyNumberOfLawsuits_be848cb5-59ff-4bde-834d-fa8f32b423aa" xlink:href="fold-20221231.xsd#fold_LossContingencyNumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b37d91db-9b8c-4a6e-bded-b38ea01e8cf6" xlink:to="loc_fold_LossContingencyNumberOfLawsuits_be848cb5-59ff-4bde-834d-fa8f32b423aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20221231.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_369f062a-7033-4509-adc5-38f2113ca734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_0c73dc08-a33c-42c0-a9f4-5c21cb59e81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_369f062a-7033-4509-adc5-38f2113ca734" xlink:to="loc_us-gaap_NetIncomeLossAbstract_0c73dc08-a33c-42c0-a9f4-5c21cb59e81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23f82eec-3bdb-4b33-93cb-ed49e6a1ef32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_0c73dc08-a33c-42c0-a9f4-5c21cb59e81a" xlink:to="loc_us-gaap_NetIncomeLoss_23f82eec-3bdb-4b33-93cb-ed49e6a1ef32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6da7e689-a426-4834-8882-5f244a4204d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_369f062a-7033-4509-adc5-38f2113ca734" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6da7e689-a426-4834-8882-5f244a4204d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a49b1790-13d4-4a48-8fd7-b3c664cb5053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6da7e689-a426-4834-8882-5f244a4204d4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a49b1790-13d4-4a48-8fd7-b3c664cb5053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1d5dcb0-57c0-4000-ae7f-7abf9c1eff0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6da7e689-a426-4834-8882-5f244a4204d4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1d5dcb0-57c0-4000-ae7f-7abf9c1eff0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_369f062a-7033-4509-adc5-38f2113ca734" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1ef84d0f-ad18-4908-b67a-cfa3e7e20fa3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bb25b209-771a-4780-b67c-3b2c2af3a1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bb25b209-771a-4780-b67c-3b2c2af3a1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a588f8ae-3860-4995-9047-aaf515f19663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a588f8ae-3860-4995-9047-aaf515f19663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_115c30c7-19ea-469f-a203-412e7ba936cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_WarrantMember_115c30c7-19ea-469f-a203-412e7ba936cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_2f656e28-ebce-442f-b6a4-ee2e956873b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_62ee9a1e-00b6-47b3-9cc7-b1a3cadeee4a" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_2f656e28-ebce-442f-b6a4-ee2e956873b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b956178a-da0e-44ad-984e-7c8e1459e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9b1e42cd-cf0e-464c-b7bf-eb0a48eff8b0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b956178a-da0e-44ad-984e-7c8e1459e0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a26dc2f-dc5c-4c2b-bd4a-728f4adedf85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b956178a-da0e-44ad-984e-7c8e1459e0fd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6a26dc2f-dc5c-4c2b-bd4a-728f4adedf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>fold-20221231_g1.jpg
<TEXT>
begin 644 fold-20221231_g1.jpg
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M>/O^"5__  4J\(^$9OB)X7\&1^,O"'C[P!!+!IOB30FN(K=G>&4DQRK+,JY
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MQW-C>6[AHYX9%#I(I'564@@]P: +5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^PCKFA7>J>"?$.B7]AXBEU"X#WVISWTDDUYJ$LP4#[7+<S27)E50!*VY54
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M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
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M10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\
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M &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44 8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XUL44
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M4/#$LC,;;@@_C5K[%XW_ .@W9?\ @,?\:++_ )'>]_Z\HOYFMB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\
MH-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L7C?_ *#=
ME_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:JQ7'C&;5I=(75[4/#$LC,;;@@_C715
MCV7_ ".][_UY1?S- !]B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:UXPXC42L"VT;B!P32T4 %%%% !1110
M4444 %%%% !1110 4444 %>%_P#!/?\ Y(GJW_8]ZS_Z4FO=*\+_ .">_P#R
M1/5O^Q[UG_TI- 'NE%%% !1110 4444 %%%% !1110 5C^)?^0OH_P#U^G_T
M$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?
M_036Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CV7_([WO_
M %Y1?S-;%8]E_P CO>_]>47\S6Q0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6/9?\CO>_P#7E%_,UL5CV7_([WO_ %Y1
M?S- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S-;% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?_  3W
M_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DT >Z4444 %%%% !1
M110 4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!- &Q1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XE_Y"^C_P#7Z?\
MT$UL5C^)?^0OH_\ U^G_ -!- &Q1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &/9?\ ([WO_7E%_,UL5CV7_([WO_7E
M%_,UL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C
M^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!-;% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B
M7_D+Z/\ ]?I_]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S-;% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'=W=I
M86LE]?7,<$$,9>::9PJ(H&2Q)X  Y)-?,?Q-_P""J?P2L_%4_P *?V7?">N_
M&[QM'\IT7X>V_GV5JW0-<Z@08(8\@@NIDVD<@5SXC%8?"I.K)*^W=^BW?R/3
MRW)LTSBHXX.DY\NK>T8KO*3M&*\Y-+S/S\_X.'?VO?''B_\ :(B_9$T36I[3
MPQX2L+6[UFQAD*K?ZC<1"='DQ]Y8X9(MBGHSN>XQ^<5?;7_!83]F#]M&W^(G
M_#;/[1WPHT'0X/&SPV]Y8^%=0DOH]%D@@C@@AO)2-OFO'&N'0F-BA P>*^):
M_&\^GB*F;5954U=Z733Y?LZ/R/[T\-L/EF$X+P='!2A)1BE-P:DG4_Y>>\M&
M^:^O:UM+'Z._\&\7[7OCCPA^T1+^R)K>M3W?ACQ;875WHUC-(66PU&WB,[O'
MG[JR0QR[U'5D0]CG]HZ_!;_@A_8>"OAM^VCX5^-7QTO[KPUHEW9ZEIW@?7M2
ML9(]/U+67C6!K47+ 1JPAGEZG[Q5>K ']Z:_0>#JE6>4<LW>TG;NE9-?K;R/
MY?\ ';"82AQO[7#PY54IQ<FE92FG)2:>S:2BI6^U>^H4445]6?C 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]E_P CO>_]>47\
MS6Q6/9?\CO>_]>47\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5X7_P3W_Y(GJW_ &/>L_\ I2:]TKPO_@GO
M_P D3U;_ +'O6?\ TI- 'NE%%% !1110 4444 %%%% !1110 5C^)?\ D+Z/
M_P!?I_\ 036Q6/XE_P"0OH__ %^G_P!!- &Q1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XE_Y"^C_P#7Z?\ T$UL
M5C^)?^0OH_\ U^G_ -!-;% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?
MI_\ 030!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!CV7_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4444
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M10 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444
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M_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4444 %%%% !1110 4444
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MR/Q$LPQ*+L6VFA]^><Y!_'/O7YU?M6V'C?6/V O^"JFO^%8YW\-M^V)9K<-
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C6Q10!C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
MT&[+_P !C_C6Q10!RFN6OBE=1TU;K5+9W:Y(@98" K;>I]:T_L7C?_H-V7_@
M,?\ &CQ+_P A?1_^OT_^@FMB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
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M$^LW?Q9\=DE8O"'PSTAM2EC8'!,\Z'R854\/EBR<DKQ62O[ O[3/[4K#5/\
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M=E_X#'_&MBB@#'^Q>-_^@W9?^ Q_QK,M;7Q2?%-U''JEL+@6T9DD,!VE<G
MKJZQ[+_D=[W_ *\HOYF@ ^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#
M'^Q>-_\ H-V7_@,?\:/L7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:/L
M7C?_ *#=E_X#'_&MBB@#'^Q>-_\ H-V7_@,?\:Y;XS_ C1?VA/ASJ/PG^,>D
M:/KN@ZI%LNK&[LSP?X9$8$-'(IY5U(93R"*]!HJ9PC4BXR5T]T:T:U;#5HU:
M4G&46FFG9IK9IK5-=SX4TGXC?M&_\$KM4T_X;?M >*[WQE\"+FX2U\-?$N6U
M:YOO"6XA8[/4PHW/;C(5)P#C@="L:?9&AW^N^)]&M/$?AOQEI.H:??VZ3V5]
M9*)8;B)P&61'4D,I!!!!P0:U_$/A[0?%NA7GA?Q3HMKJ.FZA;/;WUA?6ZRPW
M$3@JT;HP(92"001@U\7:W\/?C5_P2@UJZ\?? G2=6\=?L]W%P]SXC^'R2-<:
MGX*#,6DN].+G,UJ,EGA)RO+9Y>0>7^]RSO*C][A^KC^,?-;?86PG%^W+2QWR
MC"N_P4*S^4*C_EG\?V+]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XU1^#_
M ,8OAG\?/AYIOQ6^$'C&SUW0-6A\RSU"R?(/JC*<-&ZGAD8!E(((!%=-7J1E
M&<5*+NF?'5J-7#U94JL7&46TTU9IK=-/5-=C'^Q>-_\ H-V7_@,?\:/L7C?_
M *#=E_X#'_&MBBJ,S'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?
M_H-V7_@,?\:/L7C?_H-V7_@,?\:V** ,?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X
M#'_&MBB@#'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QK8HH Q_L7C?_H-V7_@,
M?\:/L7C?_H-V7_@,?\:V** .4M;7Q2?%-U''JEL+@6T9DD,!VE<G  K3^Q>-
M_P#H-V7_ (#'_&BR_P"1WO?^O*+^9K8H Q_L7C?_ *#=E_X#'_&C[%XW_P"@
MW9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_
M *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@
MW9?^ Q_QK8HH Q_L7C?_ *#=E_X#'_&C[%XW_P"@W9?^ Q_QK8HH Q_L7C?_
M *#=E_X#'_&M>,.(U$K MM&X@<$TM% !1110 4444 %%%% !1110 4444 %%
M%% !7A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DT >Z
M4444 %%%% !1110 4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\
MU^G_ -!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/XE_
MY"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!- &Q1110 4444 %%%% !1110
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M_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4F@#W2BBB@ HHHH ****
M"BBB@ HHHH *Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@F@#8HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\
M(7T?_K]/_H)K8K'\2_\ (7T?_K]/_H)K8H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%
M]'_Z_3_Z": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)H ]THHHH **** "BBB@ HHHH
M**** "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z": -BBBB@ HHHH
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MCHO^O--_#Y5)WGUC&FSEO@Y\$OA-^SYX$M/AG\%_ 6G>'-#LA^YL-.@VAFP
M9'8Y:60X&7<LS=R:ZFBBO1A"-.*C%62Z(^5K5JV)JRJU9.4I.[;;;;?5MZMA
M1115&04444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1110
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MVO'=0_:T_:C_ &];^?P7_P $^- ?PCX#\UH-4^.OBW3&"S*#AQI%G( UPW!
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MN-M=VZ3Q9QQG9(M '2T444 %>%_\$]_^2)ZM_P!CWK/_ *4FO=*\+_X)[_\
M)$]6_P"Q[UG_ -*30![I1110 4444 %%%% !1110 4444 %8_B7_ )"^C_\
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MJ)6%J<-()L.1SP"VX@=@17T?7A?_  3W_P"2)ZM_V/>L_P#I2: /7/L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
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M_@I'_I'Q2FUCX$_!>ZYC\*6,P3Q5XEMSVO)>EA"XZQ ;B"RL'!5Q]0? _P"
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
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MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !K\+_\ @OG\)?'?@/\ ;ZU+Q_XJC:2Q\::'87FDWJ1D
M1.+>VCM)8@?[RM"&*]0)5/\ $*_>BO+_ -K']CWX$_MI_#-OA=\=?"[7EK'*
M9M-U&TE\J\TV?&/-@EP=IQP00R,.&5A7BY_E<\VR]T8.TDTU?:ZOH_DV?H'A
MIQC1X)XGCCJ\'*E*+A.VZC)IW7=IQ3MU5T?S'U]L?\$#/A+X[\>?M]:;X_\
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MBBB@ HHHH **** "BBB@ HHHH *\+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
M!/?_ )(GJW_8]ZS_ .E)H ]THHHH **** "BBB@ HHHH **** "L?Q+_ ,A?
M1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\ H)H V**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$O_(7T?\ Z_3_ .@F
MMBL?Q+_R%]'_ .OT_P#H)K8H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K'\2_P#(7T?_ *_3_P"@FMBL?Q+_ ,A?1_\
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M?=0_6B'U>I_S]E_Y+_\ (GFQ^)'[147W_P!FN*7/_//QE;#'YK1_PL[]H?\
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M)^1S_6XS_A1<O3;[W9?=<[?Q5X\\%^![;[7XN\46.G(1E1=7"JS_ .ZO5OH
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MRSNDE'YJ37HX/-LJS#_=:\*G^&2?Y,UIUZ-7X))^C+E%%%>@:A1110 4444
M8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%_,UL4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%_\ !/?_ )(GJW_8
M]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*30![I1110 4444 %%%% !1110
M4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1110
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M0;HM MVX*(1]ZY89 4'*^Q!9)/C3\8?&7C/QD_[-_P"SO=+_ ,)#)&#XE\2
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MQ.I)!(.55^L^"'P1\*_ SPD?#^A22WE[=RFXUO6KP[KG4KIN6FD8Y/4G"Y.
M>Y))^BPN&H93AXXW&14IRUI4WU[5)K^3^6/VW_=3O\WB\37SC$RP.#DXTXNU
M6HNG>G!_S_S2^PO[[5I?@M\%_"/P-\&IX3\+))-+)(9]4U2Z.ZXU"Y;[\TK=
M2Q/;L.!77445XF)Q-?&5Y5JTG*<G=M[MGNX;#8?!X>-"A%1A%626R04445@;
MA1110 4444 %%%% &/9?\CO>_P#7E%_,UL5CV7_([WO_ %Y1?S-;% !1110
M4444 %%%% !1110 4444 >7_ !T_9X?Q[JMM\4?ACKH\-^/=)3_B6ZW$OR72
M#_EVNE _>Q-TY!*^XRI=\"_VAU^(FH77PU^(NA'PWX\T=/\ B;:!.WRS*/\
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M* "L>R_Y'>]_Z\HOYFMBL>R_Y'>]_P"O*+^9H V**** "BBB@ HHHH ****
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MI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>%_\$]_^2)ZM_V/>L_^E)KW2O"_^">__)$]6_['O6?_ $I- 'NE%%% !111
M0 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &Q111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]@[Q)8_\%BOC?^T9\>OC9KOB"[^'7@/XG77PV^$GAG2?$M[IMK81Z?#&]WK
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MR&(^(UM3H_AZ!P<'??7:C)!R=H0;@#M;O4/_  RC_P %"_VG/])_:U_:^C\
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M/9P>#PV PT</0CRQCLOS;>[;>K;U;U>H4445S'2%%%% !1110 4444 %%%%
M!1110!CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S6Q0 4444 %%%% !1110
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ME%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1110
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MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
M,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^
MQ>-_^@W9?^ Q_P :V** ,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :V**
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M_P""77BB,C@_8/&FEW0S]5(R,=_PKWO_ (9C\,VO.A?$3QII?]W[!XC=0/\
MOH&C_A1_Q!L?^0#^T7XFCQ]W^T(XKK\]P&:?MN)J?QT9O_#.A+_TJ%,?^LF
M?QY+0_[=J8C]<1;\#P(_\%#?VL;#G7/^":OQ@C Y/V#2K6Z..W"RC)SV].::
M?^"G_P 4+'C7/^">/[2<)'#&S^% N5![\K<CCWKW_P#X03]I/3O^/'X[:=J
M'W5U#PS''^9C:C_C+73O^A$U)!_U]PR'_P!EI?VIFE/^)1KQ]:=*?_IN<@_U
M@R!_'E%O2K4_^3F?/_\ P]FT>U_Y#W[,7QYTL#[QU#X/SK@=B=LK=3Q1_P /
MB/@!:_\ (?LOB#I6/O?VC\+=07;C[V=JM]WO_6OH#_A._P!I33O^/[X$Z;J
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M&?QHY^*,5\,*5!?WG*K+_P !7LXI_P#;\A7QD]DH_>_\OS/,H/C#\;?$K;?
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MQK,URU\4KJ.FK=:I;.[7)$#+ 0%;;U/K75UC^)?^0OH__7Z?_030 ?8O&_\
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!REK:^*3X
MINHX]4MA<"VC,DA@.TKDX %:?V+QO_T&[+_P&/\ C19?\CO>_P#7E%_,UL4
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XUL44 8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C6Q10!C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^-;%% &/]B\;_ /0;LO\ P&/^-'V+QO\
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M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M10 4444 %%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444
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MBW;YV/"RCB_AO/L0Z&!Q"G-=+-/Y*25_E<["BBBOG3Z0**** "BBB@ HHHH
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M?$#1(L'!\S585P?3EJ\^MOV$/V2[7'E?!FR..GF7UR__ *%*:O6W[&7[+=J
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M7T?_ *_3_P"@FMBL?Q+_ ,A?1_\ K]/_ *": -BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"&_T^PU6SDT[5+*&YMYEVS07$0='7
MT*G@CZUY+XF_8J^$UQJK^*/A?>:KX"UIN?[0\(7S6R.>P>#F-E]5 7/K7L%%
M=V"S/,,NDWAJKC?=)Z/U6S7DTT<&.RO+LRBEB:2G;9M:KSB]XOS33/$/MO[;
M'P>XOM/T/XI:1%_RVM2-+U4*.Y0YA? [+EF->*?M>?\ !0KQ8^C0_#KX7:!K
M_A#5I%)\02:S9_9[VT_NQ1#)V[A\WF#!P5QC)Q]M5^<'_!33P9K7A[]IN\\3
MWT#_ &/7].MI[&8CY3Y4*0.@/J#'DCT<'O7Z3X??V1Q!Q%&GCL-3YXQ<HN*Y
M5*2MHX+W'9-R]V,=M;GYGXB?VQP[PW*I@,34Y)249*3YG&+OK&HUSJ[2C[TI
M;Z6/"3XK\4'6/^$B/B2_.H;]_P!N^V/YV[UWYW9]\U]P_P#!.S]L'Q9\3]0G
M^"WQ4U9[_4K>T:XT;5ISF:XC3&^&0_QL =P8\D!LDX&?@^O:OV$/@_XM^+/Q
ML'_",^+-4\/QZ1I\UQ=ZYI) EM]ZF-44L",N6(QW4-Z5^Q<<91E&/X<KO%J,
M.2+<9M:Q:VM;6S>C2WO:U['XOP)G&<9?Q+06$<I^TDE*%])I[WOI=+5-[6WM
M<_3JBO%O^&5/B1_T>'\0O_ B'_XBC_ADGQB>3^UY\3\]\:Q'_P#&Z_F/^S<G
M_P"@Z/\ X!4_^1/ZD_M/.>F E_X,I_\ R1[317BW_#(GB:7Y;K]KGXJ%1T\G
MQ D9S]1'1_PQ[K'_ $=K\7/_  JE_P#C5']G9-_T&K_P7/\ R#^TL[_Z 7_X
M,A_F>TT5XM_PQG(_S2_M8?&<L?O%/'&T9]AY/%'_  Q? _RW'[4OQEF3O'+X
MY)!_**G_ &?DG_0;_P"4Y?YA_:&>_P#0#_Y5C_D>TT5XM_PQ3H__ $<;\7/_
M  MV_P#C='_#$GA9_FN/CK\4YG[R2^-7)/Y)1]1R+_H,?_@I_P#R0?7\_P#^
M@)?^#5_\B>TT5XM_PQ!X+;Y9?C/\39%/WD?QG)AAZ'Y:/^&&OAO_ -%+^(7_
M (6$W^%'U+(/^@R7_@I__)A]>X@?_,''_P &_P#VA[317BW_  PK\*'YN_&W
MCJ=NS3>+YR0/3C%+_P ,)?![OXG\:'V/BVX_QI?4^'_^@N?_ ()_^Z!]=XB_
MZ X?^#O_ +F>T45XM_PP3\!?^>OB?_PJKK_XNC_A@;]GJ3_C[M?$,X'W1-XH
MNSCZ8<4_JG#G_074_P#!*_\ EP?6^)/^@2G_ .#G_P#*3VFBO%O^& ?V;?\
MH!ZU_P"%->?_ !RC_AWU^RN>7\"WS-W9O$=]DGU/[ZCZKPWUQ57_ ,$Q_P#E
MX?6N)O\ H%I?^#Y?_*#VFBO%O^'>_P"R:_RW/PWN9U_N2^(K\C/KQ.*/^'>7
M['O_ $2#_P N#4/_ )(H^K\,_P#036_\$0_^: ^L\4?] M'_ ,'S_P#F<]DD
MOK*)S'+>1*PZJT@!%,DU;2HD,DNIVZJ.K-,H _6O(X_^"?W[(4:!%^#T1 _O
M:Q>D_F9Z?'^P)^R-&X=?@Y;DC^]JMX1^1FI>PX9_Z"*W_@F'_P O#V_%/_0/
M1_\ !T__ )0>J?\ "2>'?^@_9?\ @4G^-1R^,/"4#;)_%.G(V,X>^C!_G7FG
M_#"'[)?_ $1FR_\  ZY_^.U)%^PW^RA"NQ/@OIQ&?X[B=C^9DH]CPS_S_K?^
M"H?_ "X/;<4?\^*/_@V?_P I/EC_ (*;?'_5/%WQ(B^#GA[6P="T>VBFO$M9
M@R7=U(H<,Q7A@B,@ [$L?3'RU7TI_P %"_V5+3X->*K3Q]\-O"OV3PIJ%ND,
MR6P9DLKM<@AB22H<;2"3RP8>F?FNOZCX'65+A?#++W>'+KHD^;[7,DW:5]U=
M]+.UC^5..WFSXJQ+S!6GS::MKE^SRMI7C;9V76ZO<^A_^";VLZ+J/[1FD>%O
M&5H^HQQ6-Y)X:AN9F:+3[P*)7E2,G:&,<;\XSD ]0#7Z.U\"_P#!+SX'>(M<
M^*#_ !PU"PDATC1+::"PN70@7-U*AC94]0L;/N/8LH]<??5?A7BO7PU7BIQH
MRORPBI*^BE>3:7;1IOS;OK<_>_"2ABJ/":E7C;FG)Q=M7&T4F^^J:7DE;2P4
M445^:'Z>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S-;% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8]E_R.][_ ->47\S6Q6/9
M?\CO>_\ 7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%_,UL4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*30![I1
M110 4444 %%%% !1110 4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7
MZ?\ T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5Q_QJ^!?PY^/WA(^#_B-HYGA5_,M+J!]D]I)C&^-\'!]000>X-=A
M16^&Q.(P=>->A-QG%W33LT_)F&)PN'QN'E0KP4H25FFKIKS1\8ZI_P $H?"V
MG>)+.,?&74'T^[N=AMSI""95QG_6>9M)]]GX5]/?!7X%_#GX ^$AX/\ ASHY
M@A9_,N[J=]\]W)C&^1\#)]   .P%;'B7_D+Z/_U^G_T$UL5[>;<6<19Y05#&
MXAS@NEDE\U%*_P [GA91PAPWD.(=? X=0F^MVW\G)NWRL%%%%?.GT@4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5]5TG2]=TZ;1]
M;TVWO+2YC*7%K=0K)'*IZJRL"&'L:\;UW]B?]EFT\4Z;JMO\'=/62>\/FQ"X
MG\EAC./*\SR\>VW%>V5C^)?^0OH__7Z?_037=A,SS+ *2PM:=-2WY9.-_6S5
MSAQF5Y9F$HO%4(5'';FC&5O2Z=C0TK2=+T+3H='T33;>SM+:,);VMK"L<<2C
MHJJH 4>PJQ117%*3DVV[MG;&,8Q22LD%%%%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 8]E_R.][_UY1?S-;%8]E_R.][_ ->4
M7\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6/9?\ ([WO_7E%_,UL5CV7_([WO_7E%_,T ;%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]E_R.][_UY1?S
M-;%8]E_R.][_ ->47\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444
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M\A?1_P#K]/\ Z":V*Q_$O_(7T?\ Z_3_ .@F@#8HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'LO\ D=[W_KRB_F:V
M*Q[+_D=[W_KRB_F:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Q[+_D=[W_ *\HOYFMBL>R_P"1WO?^O*+^9H V****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOGH_X=U? _\ Z&[QW_X5\]>]44 >"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O'?\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O'?\
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M4 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\ X5\]>]44 >"_\.ZO@?\
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M=U? _P#Z&[QW_P"%?/1_P[J^!_\ T-WCO_PKYZ]ZHH \%_X=U? __H;O'?\
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MQ)&OZI8:;%#<:EY.A0&(SR(H:4IYTNTL21O;'6ONS]H3]F7X7?M16'AWPO\
M&K1(=<\-:%XBCUJY\+:A LUAJ]Q#%(MNEW$X*SPQ22"<1,"IEAA8@[ * .:_
M9C_X*)?L,_MG:UJ/AG]EG]JCP7XXU328O-U#2]#UE)+J*+<%\[R3AVBW$#S
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M7\_8"\=>%O ND:;K/B.Z^)(U_5+#38H;C4O)T* Q&>1%#2E/.EVEB2-[8ZT
M?HQX[\>^!_A=X.U+XA_$KQAI?A_0-'M'NM6UK6K^.UM+.!1EI)99"$C4=RQ
MKR[]F/\ X*)?L,_MG:UJ/AG]EG]JCP7XXU328O-U#2]#UE)+J*+<%\[R3AVB
MW$#S "F2!G)%=+^T)^S+\+OVHK#P[X7^-6B0ZYX:T+Q%'K5SX6U"!9K#5[B&
M*1;=+N)P5GABDD$XB8%3+#"Q!V 5\$_MY_L6_"S0/^"RW[&/CS]C[X<:1X/^
M(0UO7;_Q_<>$=.CLDN/"-G:Q"XDOD@55*EIQ:1NPR[76S)VJ% /T;^*/Q,\#
M?!;X;:_\7_B=X@CTKPYX7T:YU77=2DB>06MI;Q-++)LC5G?"*QVHK,QX4$D"
MO.OVE_\ @H-^Q1^QM'HY_:G_ &F/"G@.;7XO-T>Q\2:D+>ZN8QUD6W(\T(#P
MS%0%/!(/%<Y^W5_Q=+Q)\*?V0+;]XGQ"\=0ZIXIB';P[H;)J=WN'>.:ZCTVQ
M<=UU$BJ/[:6I?\$VOV2?ASX]_:6_;9TOP9#I_BFR\KQ+>>+K&*_N]:AB@6*/
M3;:&4,\J!1\MK$-F^620J&DD<@'OG@'Q_P"!?BIX+TSXC?#+QCIGB'P_K5FE
MUI&MZ+?1W-I>P.,K)%+&2KJ>Q!(K%U#]H7X%Z5\9]._9TOOBYX>3Q[JNGS7]
MAX.&JQ-J4EK$H9Y_LX)=8P"/G8!3T!)KY0_X-V/A1X!^$7_!*7P%I/PU^+VE
M^,-)UB^U/6H)-$U,W5KH_P!KO))O[+1V^8/;AA'*& /G"4XY%>8_%/X9_#OP
M%_P<^_!?6? _@72-&NM=_9X\1W6M3:5IL5NU_<?;)B9IC&H\V0[CEVRQ[F@#
M]+J\L\6?MM?LG?#_ .#NK?M!?$+X\:!X=\%:)XAO]"U#Q+XAN386HU&RNYK.
MYMHVG">>ZW%O-$/+W!VB;86Q5S]KSXWW?[./[,_C/XRZ1IBW^K:/HL@\.:6W
M_,1U:8B#3[,>\]W+!"/>05YY\,_^";?P)T;P;\*?#WQE\/V'CN3X4^#O[-T:
MV\16$=U9MJTX1M0UIH95*/>3NA(E9=T8EGV8\Y\@'?\ [,G[97[*O[9OA:[\
M:?LK?'[POX\T[3[@0:C-X<U5)WLY""52:,'?"6 )4.HW 9&15GXV?M7?LY?L
MY7FGZ7\;/C!HWA^^U6&6?3M-NK@O=W$$6/.G6",-(88\C?+MV)N&YAD5\)_!
MW]DGP-\)/^#DWQ#XT_9 \(67A7PI#^SE#<?&K3/#ELMOIDFM7FI2+81O#&!'
M'=2PVPN" !E86D/S2L7M_P#!$CXAZI^U?^V[^VM^V1XVD-Y?P?&(?#KPK-/\
MQT[0=&$HAMX0?]4DAF6>15P'E)8Y/- 'Z)>$?%_A/X@>%]/\<>!/$^GZUHNK
M6<=WI>KZ3>)<6UY ZADEBEC)61&!!#*2"#Q7/Z=^T+\"]8^-=U^S?H_Q<\/7
MGCZPT1M8U'P?::K%+J%G8K)%%]HFA4EH4+S1*"X&[=QG!Q\)_P#!#7XBZEX0
M_:N_;4_8'M+@CPK\)?C;_:_@?3\_N]*L-<:\N7L(!T2"*6W=E0< SMZUG? G
MX9?#KX7?\'1OQ$TSX;>!=(\/VNH?L?6M]>VNBZ;%:Q37+>(+5&F9(U4%RL:
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M#7XBZEX0_:N_;4_8'M+@CPK\)?C;_:_@?3\_N]*L-<:\N7L(!T2"*6W=E0<
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M9/VROV5?VS?"UWXT_96^/WA?QYIVGW @U&;PYJJ3O9R$$JDT8.^$L 2H=1N
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M?PSX2M)K#PKX=L=,@N;ZXO;B#3[1(4EN;B5IIYV" !I))7>1W/S.[LQ)))H
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M_3-3N?B1XQC'*FUT@QQ:9"_HSZK=VETGK_94N.A(]0U+]FW]G76=;G\3:O\
M /P5=:E<W+7-SJ%SX6M))Y9F;<TC2-&69RQR6)R3S73Q>%_#,'B:?QK#X=L$
MUFZL(K*YU9;1!<RVT3R21P-+C>T:/-*RH3M5I7( +'(!\Y?\%(/^"HW[.'_!
M.[PYHNA_$GXI>%]+\;>-)C;>#M)\2:F8+:/J'U"]9 7BLH<%G907D($40:1@
M!YI^P9_P4*_X)<Q>,=,_9V_9O_:UT_XN?%?XG^(;C5/%6JZ'8RRWNNZD+8RW
M6HW1V"*TMH;>W$<<9<+%###!$'(56^OO&OP0^"WQ)U5-=^(OPA\+Z_?16X@C
MO=:\/VUU*D09F$8>5&(4%F.,XRQ/<TSP?\!_@=\/=9'B+P#\&?"FAZ@L;1B^
MT?P[;6TP1OO+OC0-@XY&>: /@K_@E%X1L?V _P!NS]L']DWXO:M::#:^*OB)
M)\6OA]?ZK<I!!JVA:BK_ &IX7<@,+*6..";/W"58_*P8Z/\ P0M^#^O:[\7O
MVK/^"C&H:?-;Z%^T%\9))OA[+<1%#J7AO2WNH;+4D!Y$5S]IE9,_>1%<95E)
M^Z_B1\&OA!\9+.TT[XO_  I\-^*[?3[G[180>)-"M[Y+:;_GI&LZ,$?C[PP:
MZ*&&*WB6"")41%"HB+@*!P  .@H _-_P%XK\,2?\'5?CC24\0V1NA^QS:6OV
M<72;_/&OV\IBQG.\1L'V]=ISC'-?HWJ>IZ=HNFW&LZO>Q6UI:0/-=7,[A4BC
M52S.Q/   ))/0"N1MOV;?V=;/7(_$]G\ _!46I178NHM1C\+6BSI.&WB42"/
M<'#?-NSG/.<UUFM:+HWB71KOP[XBTFUU#3]0M9+:_L+V!98;F%U*O'(C JZ,
MI*E2"""0: /E/_@CQI6H>.O@!XI_;=\4V,L6L_M%_$#4?'<0ND(FAT-REGH5
MN2>2JZ5:6;@< &9\#FOK6JF@Z#H?A70[+PQX8T:TTW3=-M([73M.L+988+6"
M-0D<4<: *B*H"JJ@    8%6Z "BBB@ HHHH **** "BBB@ K\W?^"G_BKPSI
MG_!=K_@G=9ZCXALH)K>[^(_GQ372*T?VC1;6*#<">/,D5D3/WF! R17Z15QO
MB/\ 9T_9\\8ZW<>)?%WP)\&ZKJ5VP:ZU#4O#%I//,P  +R/&68X ')Z 4 <5
M^W7^WG^SG_P3P^!ES\=?VC?&UKIEF9UL]#TQ[J..YUF_?_5VL D8#<3RSL0D
M2!I)&5%+#Y+_ &9/^"KG_!+?1O'5Y\6?%'[:'A'XB_'?XHWFGZ.-(\$17-]*
M@:8QZ=X;TE&B4BVCEG.99/+$T\TMQ+Y08)%]]>,?A'\*/B):6=A\0/ACX>UV
M#3@PT^'6=%@NDM00H(C$B,$R%4'&/NCT%9>A_LV?LZ>&-8MO$/AKX!>"M.O[
M.42VE]8^%;2&:"0='1TC#*P]0<T >7_ K_B\_P"W)\6/CS+^]TOP#96?PV\*
M2=5\]5CU/6IXSW#SW&GVK>DFD,.U=#??MM?L(>,/&?C3]GSQ#^TK\.+C6_"B
M/:^.?">M^(;1)+.-HP76>&=@&CV-AS@J,E6(/%>K>'_"_AGPE:36'A7P[8Z9
M!<WUQ>W$&GVB0I+<W$K33SL$ #222N\CN?F=W9B2237)^)/V7_V:/&7CX?%;
MQ?\ L[^!=5\4J4*^)=2\)6<^H H $/VAXC)\H  ^;@#B@#Y&_P""#W[,&F_L
M\^#/CSXK^%^CS:/\*/B'\>]7U[X/Z,86B@&A^5!"EY;QL 4MIGC?R.!OMXH)
M!E74GD/VAO%?ABU_X.?/@#HMSXALH[P_LZ>((?LSW2"3S)+F=T3;G.YE1R!U
M(4D=*_2*N*U+]FW]G76=;G\3:O\  /P5=:E<W+7-SJ%SX6M))Y9F;<TC2-&6
M9RQR6)R3S0!Y?^T__P 7B_:M^#'[,D'[W3],U.Y^)'C&,<J;72#'%ID+^C/J
MMW:72>O]E2XZ$C)_X*0?\%1OV</^"=WAS1=#^)/Q2\+Z7XV\:3&V\':3XDU,
MP6T?4/J%ZR O%90X+.R@O(0(H@TC #Z-B\+^&8/$T_C6'P[8)K-U8165SJRV
MB"YEMHGDDC@:7&]HT>:5E0G:K2N0 6.<7QK\$/@M\2=537?B+\(?"^OWT5N(
M([W6O#]M=2I$&9A&'E1B%!9CC.,L3W- 'R!^P9_P4*_X)<Q>,=,_9V_9O_:T
MT_XN?%?XG^(;C5/%6K:'8RRWVNZD+8RW6HW3;!%:6T-O;B..,N%BAAA@B#D*
MK<-_P2B\(V/[ ?[=G[8/[)OQ>U:TT&U\5?$23XM?#Z_U6Y2"#5M"U%7^U/"[
MD!A92QQP39^X2K'Y6#'[U\'_  '^!WP]UD>(O /P9\*:'J"QM&+[1_#MM;3!
M&^\N^- V#CD9YJ?XD?!KX0?&2SM-.^+_ ,*?#?BNWT^Y^T6$'B30K>^2VF_Y
MZ1K.C!'X^\,&@#X4_P""%OP?U[7?B]^U9_P48U#3YK?0OV@OC))-\/9;B(H=
M2\-Z6]U#9:D@/(BN?M,K)G[R(KC*LI.9X"\5^&)/^#JOQQI*>(;(W0_8YM+7
M[.+I-_GC7[>4Q8SG>(V#[>NTYQCFOT@AABMXE@@B5$10J(BX"@<  #H*XRV_
M9M_9UL]<C\3V?P#\%1:E%=BZBU&/PM:+.DX;>)1((]P<-\V[.<\YS0!\G_\
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M?#V6XB*'4O#>EO=0V6I(#R(KG[3*R9^\B*XRK*3]U_$CX-?"#XR6=IIWQ?\
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MA>7PW\";KQ?J6H7VL>-;N998[OQ'-/J<LMX]GY4TD%KYSG>FR9 @^]^I%%%
M!1110 4444 %%%% !1110 5^;O\ P4_\5>&=,_X+M?\ !.ZSU'Q#9036]W\1
M_/BFND5H_M&BVL4&X$\>9(K(F?O,"!DBOTBKC?$?[.G[/GC'6[CQ+XN^!/@W
M5=2NV#76H:EX8M)YYF  !>1XRS'  Y/0"@#BOVZ_V\_V<_\ @GA\#+GXZ_M&
M^-K73+,SK9Z'ICW4<=SK-^_^KM8!(P&XGEG8A(D#22,J*6'R7^S)_P %7/\
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MQVKE?^&3_P!EG_HVKX?_ /A&V/\ \:H \'_;4_X+!?LN_L@_!;P/XQ\7^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&_MP?LB_#W]K#P(8UL/''AFWU"2UCDW?8[K&RZM2>[0W"2PGWC- 'JM%%%
M!117E7[*'@#]J_X?:'XOM?VM/C_I'Q!OM1\>ZC?^#[O2/#$6EKI.@2%/LFG2
M+'_KI(L.3*V6.\ N^W<0#U6BBB@ HHHH ***_.[]I_\ :1_X+ ?LR_\ !//Q
MW^WSX[^*'P8TV\\.Z)-KFG?#.;X/:H]Q!:-< 6]O=7KZY&5N/)DC,H%L D@=
M<-C- 'Z(T5\,_!;XK?\ !6_XF?LR? []K_1?BK\'O$FE>/K3P9KGC7P%8_"'
M4[.^M-&U5[*2_P#L=Z-:G5YK:WN97!>W"L(2Q ^X9/V OVK?VN?B5_P54_:V
M_9&_:(^*&B:_X?\ A%:^#7\'V^@>%$TR"W&J6$U[*Q#233NQ5X4/F3NN8=RJ
MFXB@#[BHHHH **** "BBB@ HHHH ***Y+X\_'#X:?LT_!GQ-\??C'XE@T?PQ
MX1T:?4]:U"X< 1PQ*3M4$C<['"(@Y=V51DD"@#K:*\E^."_'_P#:!_8\O;W]
MCWXKV7PY\>^*O#5G>^$/%&N:)%J46DR2^5,?,MW#1R$Q%X\E6"LX;:VW:?2/
M!MCXFTSPAI6F^--=AU36;?38(M6U.WM!;QWERL:B698@3Y:NX9@F3M!QDXH
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MDO\ 4+R[BN!9+]EDB36[=%97NV/F X*QCY 6R #]'**_/C]L+_@H_P#MW?\
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M%.HW?A.2ZM[G3Y=7CACEMD2>,J?*,*R1S[LAP,H>H *6L_\ !*33?VC?V/\
MX2?$SX&?M,ZUX$^-MJF@^++C]H*-9=3UC7)7@66[CNF-Q%]HM;CSG(MF;[/&
MHC18_+796+XOLH/!'_!S=X!T+P7=7&FZ7XG_ &9=5U?7=)L;R1+.^U :I*GV
MQX WEM,4"@R;=S8&2:@_9&_X)A_\%:/@7X"L/V(/B=_P4/\ !VL_L\:'"=-L
M;S2_",\?C.[T(':-(^T.WDV49B_<^<AFFCC)6)D*QLGJ/[;_ /P3]_:C\9?M
MQ?"O_@H1^PI\3/ &A^,_ OA.^\(ZYX=^(^EW<NDZGHMS)Y@V&R998Y8G9V51
MA6)3+*%*N >9_L9V-QX-_P"#@7]K#X8^";Z>PT*'X5^%=0T[0?M4K:?9WEQ$
MK2RQ6^[9%O?YF"!<DD]2:^:/V9_CW\!]&\:^ _V(/^"KOPM\2_ S]JO1_B=I
M.L6GQIUB*5K+XEW-IK<-V0NKQLHN+>Z1#;?9YB;6/S$6/:R)$GV;^SM_P3/_
M &O?A1_P4D^*'[=/C_\ :H\):]9_$SP'IFA:SI<?@V:*>::W@0%[;9<(FGPQ
MR!DB1C>.T6/,D:0F0X/Q:_X)E?MB?MD_L5^"_P!@3]M_Q/\ "[6M*\.:AH<V
MJ?&#0KB_.OW$.G2Q/_HUA-;".UO)XXC;R7@NV&R:9A;_ #!  ?H)7QY_P<!?
M\H:/V@_^Q#?_ -*(:^PZ^<_^"J'[+/QL_;@_8P\9?LB_!K7?"^B-X\TO^S]5
M\1^)9KAO[/A$T4A\JWAC/G,ZHZY:2,)P</G  -'_ ()5?\HO?V;O^R">#_\
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M12HCB"X^SPNR8?RVC4'SD#+( >E_"+_@FO9?LX?M[7'[4?[.WQAE\%_#?7/
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MOQBL[.P\+7_Q.U@"9&M96C^T7BW(O;E85.V.*2<Q#[S([K&R?0_[#G_!._\
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M/@31OC3X8^(^I^)M.T06.IZCI7@B[O8+KR'>&.03H")6:-$+-UWEL\YKU?\
MX?'?LN?]$\^+'_AM+W_XFOH+X"?!GPG^SQ\&/#/P0\#J_P#9?AC1X;"VDE W
MS;%^:5\<;W?<[8XRQKKJ_8\-A<TIX>$)5E=))^Y?IWYM?4_@_-<XX-Q6:5ZU
M+ 5.64Y-6K**LY-JT?9/ETZ7=MKL^3_^'QW[+G_1//BQ_P"&TO?_ (FC_A\=
M^RY_T3SXL?\ AM+W_P")KZPHK?V&9?\ /Z/_ (!_]L<']H<)?] %3_PH7_RD
MJ:!K-KXCT*R\0V,<R07]I'<0I<1%)%1U# ,IY5L'D'H:^.OCO^S'\&/VR/\
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M1M;LA+JJNT/[*O[-W_!4_P#8J^"EA\#_  W\4?@_\6]+LO-?1Y?%[ZIX?N]
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MH_Q&M=4FT[7?#6G0@+;KK5C%!.+Y(H@$^V0-"K"(&58F(9P#B_VC].U35/\
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MXPOK/6FTTZ9J-SIMO=7EM+'+=&#[("ZR,RNLJHRLBJ!]:?"+_@G;^TO^P?\
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M&ATZ[^UVMI*\\A>"622,K$JQ1Q"(!5)=B>=_;G_X))?'37?VHO 7[?7_  3
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MP^TS3_@98:W"/"][J=]+-K+:OIXM+O\ TA;55@$0)\L^6^[8&8+NV+4\.?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792099312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amicus Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,979,823,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,714,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Proxy Statement for the registrant's 2022 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789332352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792254672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 148,813<span></span>
</td>
<td class="nump">$ 245,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">144,782<span></span>
</td>
<td class="nump">237,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">66,196<span></span>
</td>
<td class="nump">52,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">23,816<span></span>
</td>
<td class="nump">26,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">40,209<span></span>
</td>
<td class="nump">34,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">423,816<span></span>
</td>
<td class="nump">596,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">29,534<span></span>
</td>
<td class="nump">20,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $22,281 and $19,882 at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">30,778<span></span>
</td>
<td class="nump">42,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">19,242<span></span>
</td>
<td class="nump">24,427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">724,167<span></span>
</td>
<td class="nump">905,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,413<span></span>
</td>
<td class="nump">21,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">93,636<span></span>
</td>
<td class="nump">98,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable</a></td>
<td class="nump">21,417<span></span>
</td>
<td class="nump">18,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">8,552<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">139,018<span></span>
</td>
<td class="nump">145,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">391,990<span></span>
</td>
<td class="nump">389,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">51,578<span></span>
</td>
<td class="nump">43,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">4,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">5,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">8,939<span></span>
</td>
<td class="nump">8,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">601,120<span></span>
</td>
<td class="nump">597,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 500,000,000 shares authorized, 281,108,273 and 278,912,800 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">2,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,664,744<span></span>
</td>
<td class="nump">2,595,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(11,989)<span></span>
</td>
<td class="nump">5,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,532,490)<span></span>
</td>
<td class="num">(2,295,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">123,047<span></span>
</td>
<td class="nump">307,369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 724,167<span></span>
</td>
<td class="nump">$ 905,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594809&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792017584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment</a></td>
<td class="nump">$ 22,281<span></span>
</td>
<td class="nump">$ 19,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">281,108,273<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">281,108,273<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789238768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 329,233<span></span>
</td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">38,599<span></span>
</td>
<td class="nump">34,466<span></span>
</td>
<td class="nump">31,044<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">290,634<span></span>
</td>
<td class="nump">271,048<span></span>
</td>
<td class="nump">229,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">276,677<span></span>
</td>
<td class="nump">272,049<span></span>
</td>
<td class="nump">308,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">213,041<span></span>
</td>
<td class="nump">192,710<span></span>
</td>
<td class="nump">156,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">6,514<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Loss on impairment of assets</a></td>
<td class="nump">6,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">8,846<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">502,754<span></span>
</td>
<td class="nump">477,482<span></span>
</td>
<td class="nump">476,840<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(212,120)<span></span>
</td>
<td class="num">(206,434)<span></span>
</td>
<td class="num">(246,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3,024<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">3,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(37,119)<span></span>
</td>
<td class="num">(32,471)<span></span>
</td>
<td class="num">(22,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="num">(7,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">4,176<span></span>
</td>
<td class="num">(2,901)<span></span>
</td>
<td class="num">(781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(242,039)<span></span>
</td>
<td class="num">(241,554)<span></span>
</td>
<td class="num">(274,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">5,471<span></span>
</td>
<td class="num">(8,906)<span></span>
</td>
<td class="num">(2,598)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (236,568)<span></span>
</td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss attributable to common stockholders per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss attributable to common stockholders per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">289,057,198<span></span>
</td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">289,057,198<span></span>
</td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638793486640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (236,568)<span></span>
</td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment (loss) gain</a></td>
<td class="num">(17,240)<span></span>
</td>
<td class="num">(3,161)<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">154<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) gain</a></td>
<td class="num">(17,086)<span></span>
</td>
<td class="num">(3,246)<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (253,654)<span></span>
</td>
<td class="num">$ (253,706)<span></span>
</td>
<td class="num">$ (271,450)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788659744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 476,425<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="nump">$ 2,227,225<span></span>
</td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="nump">$ 2,825<span></span>
</td>
<td class="num">$ (1,768,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">5,243,000<span></span>
</td>
<td class="nump">5,233,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 42,282<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">42,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(10,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">49,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">5,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(276,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276,852)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 286,380<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">2,308,578<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">8,227<span></span>
</td>
<td class="num">(2,045,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">1,483,000<span></span>
</td>
<td class="nump">1,461,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 10,228<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">10,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from equity financing and pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,296,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued from equity financing and pre-funded warrants</a></td>
<td class="nump">199,747<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">199,552<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(15,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">57,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">31,591<span></span>
</td>
<td class="num">(12,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,460)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">278,912,800<span></span>
</td>
<td class="nump">278,912,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 307,369<span></span>
</td>
<td class="nump">$ 2,808<span></span>
</td>
<td class="nump">2,595,419<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">4,981<span></span>
</td>
<td class="num">(2,295,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised, net (in shares)</a></td>
<td class="nump">660,000<span></span>
</td>
<td class="nump">656,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised, net</a></td>
<td class="nump">$ 4,310<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">4,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,539,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, net of taxes</a></td>
<td class="num">(11,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">76,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(17,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (236,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236,568)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">281,108,273<span></span>
</td>
<td class="nump">281,108,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 123,047<span></span>
</td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="nump">$ 2,664,744<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="num">$ (12,105)<span></span>
</td>
<td class="num">$ (2,532,490)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792287696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (236,568,000)<span></span>
</td>
<td class="num">$ (250,460,000)<span></span>
</td>
<td class="num">$ (276,852,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing</a></td>
<td class="nump">2,634,000<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="nump">1,794,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,342,000<span></span>
</td>
<td class="nump">6,209,000<span></span>
</td>
<td class="nump">8,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">76,512,000<span></span>
</td>
<td class="nump">57,838,000<span></span>
</td>
<td class="nump">49,151,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="nump">7,276,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="nump">1,078,000<span></span>
</td>
<td class="nump">6,514,000<span></span>
</td>
<td class="nump">3,144,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">6,121,000<span></span>
</td>
<td class="nump">3,565,000<span></span>
</td>
<td class="nump">5,471,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Non-cash deferred taxes</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_AssetImpairmentChargesAndOtherAssetWriteOffs', window );">Asset impairment charges and other asset write-offs</a></td>
<td class="nump">18,177,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(17,330,000)<span></span>
</td>
<td class="num">(8,189,000)<span></span>
</td>
<td class="num">(11,219,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,343,000)<span></span>
</td>
<td class="num">(7,790,000)<span></span>
</td>
<td class="num">(4,639,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,194,000)<span></span>
</td>
<td class="num">(5,919,000)<span></span>
</td>
<td class="num">(8,766,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="num">(6,377,000)<span></span>
</td>
<td class="nump">7,430,000<span></span>
</td>
<td class="num">(10,610,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Other non-current assets and liabilities</a></td>
<td class="num">(4,636,000)<span></span>
</td>
<td class="num">(4,117,000)<span></span>
</td>
<td class="nump">3,170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payment of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,353,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(166,575,000)<span></span>
</td>
<td class="num">(202,491,000)<span></span>
</td>
<td class="num">(233,290,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">335,926,000<span></span>
</td>
<td class="nump">424,043,000<span></span>
</td>
<td class="nump">354,826,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(243,255,000)<span></span>
</td>
<td class="num">(341,398,000)<span></span>
</td>
<td class="num">(365,178,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(3,766,000)<span></span>
</td>
<td class="num">(3,884,000)<span></span>
</td>
<td class="num">(3,227,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of assets</a></td>
<td class="nump">3,411,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">92,316,000<span></span>
</td>
<td class="nump">78,761,000<span></span>
</td>
<td class="num">(13,579,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing', window );">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">199,750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(155,249,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">385,929,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance leases</a></td>
<td class="num">(283,000)<span></span>
</td>
<td class="num">(479,000)<span></span>
</td>
<td class="num">(76,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of vested restricted stock units, net of taxes</a></td>
<td class="num">(11,490,000)<span></span>
</td>
<td class="num">(15,009,000)<span></span>
</td>
<td class="num">(10,028,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised, net</a></td>
<td class="nump">4,310,000<span></span>
</td>
<td class="nump">10,228,000<span></span>
</td>
<td class="nump">42,282,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,230,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,647,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(7,463,000)<span></span>
</td>
<td class="nump">212,073,000<span></span>
</td>
<td class="nump">262,858,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(14,619,000)<span></span>
</td>
<td class="num">(5,049,000)<span></span>
</td>
<td class="nump">3,830,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(96,341,000)<span></span>
</td>
<td class="nump">83,294,000<span></span>
</td>
<td class="nump">19,819,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the beginning of the year</a></td>
<td class="nump">249,456,000<span></span>
</td>
<td class="nump">166,162,000<span></span>
</td>
<td class="nump">146,343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the end of the year</a></td>
<td class="nump">153,115,000<span></span>
</td>
<td class="nump">249,456,000<span></span>
</td>
<td class="nump">166,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentive</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">34,358,000<span></span>
</td>
<td class="nump">30,468,000<span></span>
</td>
<td class="nump">24,683,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures unpaid at the end of period</a></td>
<td class="nump">1,141,000<span></span>
</td>
<td class="nump">1,448,000<span></span>
</td>
<td class="nump">985,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 1,609,000<span></span>
</td>
<td class="nump">$ 20,032,000<span></span>
</td>
<td class="nump">$ 10,371,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AssetImpairmentChargesAndOtherAssetWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges And Other Asset Write-Offs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AssetImpairmentChargesAndOtherAssetWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Remeasurement Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ForeignCurrencyRemeasurementGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Warrants And Equity Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792044384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), and the United Kingdom ("U.K.") Medicines and Healthcare products Regulatory Agency ("MHRA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), U.K., and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#8220;MAA&#8221;) in the fourth quarter of 2021. In May 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. In October 2022, the FDA deferred action on the BLA for cipaglucosidase alfa, citing the inability to complete the manufacturing facility inspection prior to the PDUFA action date.  The Company is actively engaged with the FDA and an inspection has been scheduled</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Committee for Medicinal Products for Human Use ("CHMP") of the EMA adopted a positive opinion recommending market authorization of cipaglucosidase alfa, or Pombiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the novel coronavirus (&#8220;COVID-19&#8221;) pandemic. The Company's commercial operations have not been significantly impacted by the COVID-19 pandemic and the Company gradually continues to see an improvement in patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimum disruptions. The Company has been able to continue to meet required commercial demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as supply its ongoing Pompe disease clinical studies and access programs including the Early Access to Medicines Scheme ("EAMS") without interruption. In regard to the Company&#8217;s regulatory operations, the FDA deferred action on the pending BLA for cipaglucosidase alfa, as a facility inspection was necessary, however, could not be completed by the PDUFA action date due to COVID-19 related travel restrictions. The facility inspection has subsequently been scheduled. Per FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, receipt of a deferral action indicates no deficiencies have been identified and the application otherwise satisfies the requirements for approval.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $2.5 billion as of December 31, 2022 and anticipates incurring losses through the fiscal year ending December&#160;31, 2023. The Company has historically funded its operations through stock offerings, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, debt issuances, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs for at least the next 12 months. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790845472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact the COVID-19 pandemic had on its operations and financial results as of December 31, 2022 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive (loss) gain in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's accounts receivable at December 31, 2022 have arisen from product sales primarily in Europe, the U.S., and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of December 31, 2022, the Company's allowance for doubtful accounts was $0.2 million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb">three</span> to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist primarily of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for the years ended December 31, 2022, 2021 and 2020 were $329.0 million, $305.5 million and $260.9 million, respectively. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2022, one customer accounted for 27% of net product sales and 14% of accounts receivable from product sales. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales disaggregated by geographic area:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"/><td style="width:53.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participant's assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax returns are subject to examination by U.S. Federal, state, and foreign taxing jurisdictions. The impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more likely than not to be sustained. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not to be sustained.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive (Loss) Gain</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive (loss) gain include unrealized gains and losses on available-for-sale securities and (loss) gain on foreign currency transactions and are included in the Consolidated Statements of Comprehensive Loss.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had one equity-based employee compensation plan, which is described more fully in "&#8212;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss per Common Share</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested restricted stock units, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#8212;&#160;Note&#160;15. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. For contingent consideration payments in business combinations, the Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference. No indicators of impairment were noted during the years ended December 31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790917568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, in connection with the acquisitions, the Company had goodwill of $197.8 million and IPR&amp;D of $23.0 million, which are reported at fair value on the Company's Consolidated Balance Sheets. Intangible assets related to IPR&amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D assets below their respective carrying amounts.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value. An IPR&amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in IPR&amp;D for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in Goodwill for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790939728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company held $148.8 million in cash and cash equivalents and $144.8 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive (loss) gain in the Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the years ended December 31, 2022 and 2021, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no marketable securities in an unrealized loss position as of December 31, 2022. Unrealized loss positions in the marketable securities as of December 31, 2021 reflect temporary impairments and were not a result of credit loss. Additionally, as these positions were in a loss position for less than twelve months and the Company did not intend to sell these securities before recovery, the losses were recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $173.4 million as of December 31, 2021.  </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:44.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638794610624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table summarizes the components of inventories: </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:66.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,816&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reserve for inventory was $0.4 million and $1.1 million as of December 31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638877500672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $4.8 million and $5.7 million for the years ended December 31, 2022 and 2021, respectively. Additionally, during the year ended December 31, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6&#160;million</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638877592448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of the following: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales rebates and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued program fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing&#160;&amp; contract research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790952768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock and Warrants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company was authorized to issue 500 million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company entered into a Sales Agreement with The Goldman Sachs &amp; Co. LLC to create an at-the-market ("ATM") equity program, pursuant to which the Company may offer to sell shares of its common stock having an aggregate offering gross proceeds of up to $250.0&#160;million.  At December 31, 2022, no shares have been issued under the ATM equity program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into a securities purchase agreement with certain entities, the (&#8220;Purchase Agreements&#8221;) for the private placement of an aggregate of 11,296,660 shares of the Company&#8217;s common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. Proceeds from the private placement, net of offering costs, were $199.8 million. Each pre-funded warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance, subject generally to the lock-up period, at the option of each holder, in such holder&#8217;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Certain of the Purchase Agreements provide for a lock-up period of either 60 days or nine months based on the individual agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of 2021, 1,294,999 and 1,260,000 warrants were exercised at $7.98 and $7.06 per share of common stock, respectively, resulting in gross cash proceeds of $19.2 million. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with the holders of the Convertible Notes (the "Holders"). Under the terms of the exchange agreements, the Holders agreed to exchange the remaining aggregate principal amount of $2.8&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 472,356 shares of Company common stock, par value $0.01 per share. This transaction resulted in an increase of $2.7&#160;million and five thousand dollars to additional paid-in-capital and common stock, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Deferral Plan provides certain key employees and members of the Board of Directors, as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a deferred compensation investment balance of $5.5 million and $4.8 million as of December 31, 2022 and 2021, respectively, with corresponding approximate amounts of liability. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral Plan investment assets are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plan </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. Under the provisions of the Plan, no option will have a term in excess of 10 years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. As of December 31, 2022, the Company has reserved up to 15,472,672 shares for issuance under the Plan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638791689280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share based Compensation</a></td>
<td class="text">Share based Compensation <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan provides for certain benefits to qualifying Plan participants who separate from service with the Company due to death, disability or "retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#8217;s separation and all vested options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#8217;s separation or the original expiration date of the option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the two year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such two year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#8217;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSUs.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the fair value method of measuring share-based compensation, using the fair value of each equity award granted. The Company chose the &#8216;&#8216;straight-line&#8217;&#8217; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for share-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is based on the Company's historical volatility. The average expected life is determined using the Company's actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life of options (years) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value per share of options granted during 2022, 2021, and 2020 were $6.11, $9.08, and $6.40, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the year ended December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,483)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,492&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $2.5 million, $8.5 million, and $40.9 million, respectively. Cash proceeds from stock options exercised during the years ended December 31, 2022, 2021, and 2020 were $4.3 million, $10.2 million, and $42.3 million, respectively. As of December 31, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $31.1 million and is expected to be recognized over a weighted average period of three years.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the year ended December 31, 2022 is as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, there was $50.4 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.</span></div><div style="margin-bottom:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,089&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,340&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,817&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,151&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638791010096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">Assets and Liabilities Measured at Fair Value<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2022 are identified in the following tables:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"/><td style="width:72.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of December 31, 2022 or 2021.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds and Marketable Securities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2022. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.386%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%-98%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reached a regulatory milestone in September 2021 associated with FDA approval of the first BLA and in November 2021 associated with EMA validation of the MAA, both related to the contingent consideration of Callidus for the ATB200 Pompe disease program. The satisfaction of these milestones resulted in the collective milestone payment of $12.0 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2022 and 2021, respectively:  </span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:71.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration in cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As certain milestones are expected to be reached within the next twelve months, the December 31, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638794610624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan using the effective interest rate method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Term Loan due 2026</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a definitive agreement for a $400&#160;million credit facility with Hayfin Capital Management (&#8220;Senior Secured Term Loan due 2026&#8221;) with an interest rate equal to 3-month LIBOR, subject to a 1% floor, plus 6.5% per annum and requires interest-only payments until mid-2024. The Senior Secured Term Loan due 2026 will be repaid in nine quarterly payments of $44.4&#160;million, starting on July 2024 with the final balance due on the maturity date in July 2026. This transaction resulted in net proceeds of $385.9&#160;million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Company used the proceeds to voluntarily settle the Senior Secured Term Loan with BioPharma Credit PLC, which included the $150&#160;million principal, $1.1&#160;million accrued interest, and $5.2&#160;million in early settlement premiums. As a result of this early extinguishment, the Company recognized a loss on extinguishment of debt of $7.3&#160;million in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Term Loan due 2026 is subject to mandatory prepayment provisions that require prepayment upon a change of control, the incurrence of certain additional indebtedness, asset sale, or an event of loss, subject to certain conditions set forth in the Senior Secured Term Loan due 2026. The Company may prepay the Senior Secured Term Loan due 2026 in whole, at its option at any time. Any prepayment of the Senior Secured Term Loan due 2026 is subject to certain make-whole premiums and prepayment premiums, the latter of which decrease until the fourth anniversary of the transaction date at which point no prepayment penalty shall exist. The obligations under the Senior Secured Term Loan due 2026 are secured by a first lien security interest in certain assets of the Company. The Senior Secured Term Loan due 2026 contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company. The Senior Secured Term Loan due 2026 also contains a minimum liquidity covenant of $75&#160;million, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $140&#160;million, beginning March 31, 2021, and peaks at $225&#160;million by June 30, 2023, continuing at that level until the Senior Secured Term Loan due 2026 is repaid. If an event of default occurs and is continuing, Hayfin Capital Management may declare all amounts outstanding under the Senior Secured Term Loan due 2026 to be immediately due and payable.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:73.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except interest rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Senior Secured Term Loan due 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638794610624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, and 2021, operating lease expense was $9.8 million and $10.0&#160;million and variable lease expense was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7&#160;million and $2.1 million, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the years ended December 31, 2022, and 2021, the Company paid $8.3 million and $8.4&#160;million, respectively, for amounts included in the measurement of operating lease liabilities and recorded $8.9 million and $0.3&#160;million, respectively, of&#160;right-of-use assets. For the year ended December 31, 2022, there were no tenant improvements paid through lease incentives in exchange for new operating lease liabilities.  For the year ended December 31, 2021, there were $0.3&#160;million of tenant improvements paid through lease incentives in exchange for new operating lease liabilities. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments under finance leases are not significant for the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except year and discount rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the future minimum operating lease payments were as follows:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:83.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less lease incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638791010096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,039)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,254)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following were the components of income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,471)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2022, 2021, and 2020 are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act also introduced an additional U.S. tax on certain non-U.S. subsidiaries&#8217; earnings which are considered to be Global Intangible Low Taxed Income (referred to as "GILTI"). After consideration of the relevant guidance and completing the accounting for the tax effects of the Tax Act, the Company has elected to treat GILTI as a period cost. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2022, the Tax Act eliminated the right to deduct research and development expenditures for tax purposes&#160;in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax returns for years 2017 through 2022 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest carry forward limitation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,939)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2022 and 2021, the Company recorded valuation allowances of $632.2 million and $581.8 million, respectively, representing an increase in the valuation allowance of $50.4 million in 2022, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had federal and state net operating loss carry forwards ("NOLs") of approximately $1,183 million and $992 million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2022 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. The Company may experience ownership changes in the future as a result of shifts in the stock ownership some of which are outside the Company's control. The Company completed a detailed study of the NOLs for the tax year 2022 and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on the Company's ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has research and experimentation and orphan drug credit carryforwards of approximately $36.4 million and $187.0 million, respectively, which will expire in the years 2030 through 2040. Deferred tax assets for these carryforwards are subject to a full valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792064496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CollaborativeArrangementDisclosureAbstract', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">University of Pennsylvania</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease and other rare diseases.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company entered into a mutual termination agreement (the "Termination Agreement") pursuant to which the Company and Penn mutually agreed to terminate the collaboration agreement, as amended. In connection with the Termination Agreement, the Company agreed to pay Penn an aggregate of $23.7&#160;million in connection with an unpaid portion of the discovery support payments, research program wind-down activities, and outstanding patent costs which was recorded as a component of research and development expense within the Consolidated Statements of Operations. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently, the Company entered into a license agreement with Penn pursuant to which it obtained a license with respect to the pre-clinical research and development of next generation parvovirus gene therapy products for the treatment of Pompe disease and Fabry disease. Under the agreement, the Company will be responsible for clinical development and commercialization of the licensed products for the indications and Penn is eligible to receive certain milestone and royalty payments with respect to licensed products for each indication, up to an aggregate of $86.5&#160;million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent milestone payments due to GSK are recorded within the other current and other non-current liabilities accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations.</span></div>For the year ended December 31, 2022, under the GSK collaboration agreements, the Company incurred approximately $25.1 million of royalty expenses. As of December 31, 2022, $7.4 million was recorded as deferred reimbursements and the Company recognized a liability of $6.9 million related to royalties payable to GSK within accrued expenses in the Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638877585808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal Proceedings <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, the Company received Paragraph IV Certification Notice Letters from Teva Pharmaceuticals USA, Inc. ("Teva"), Aurobindo Pharma Limited ("Aurobindo"), and Lupin Limited ("Lupin") in connection with Abbreviated New Drug Applications (&#8220;ANDA&#8221;) filed with the FDA requesting approval to market generic Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2022, the Company filed four lawsuits against Teva, Lupin, and Aurobindo in the U.S. District Court for the District of Delaware for infringement of its Orange Book-listed patents and will vigorously enforce its Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property rights.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638877572272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text">Basic and Diluted Net Loss per Common Share<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:56.241%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,057,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,421,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,867,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of outstanding common stock options, unvested RSUs, outstanding warrants for common stock equivalents, and convertible debt units. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789208240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact the COVID-19 pandemic had on its operations and financial results as of December 31, 2022 and through the issuance of these financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive (loss) gain in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div>Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>. The Company's accounts receivable at December 31, 2022 have arisen from product sales primarily in Europe, the U.S., and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb">three</span> to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product sales consist primarily of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales for the years ended December 31, 2022, 2021 and 2020 were $329.0 million, $305.5 million and $260.9 million, respectively. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2022, one customer accounted for 27% of net product sales and 14% of accounts receivable from product sales. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories and Cost of Goods Sold</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div>Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participant's assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Liabilities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock', window );">Interest Income and Interest Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s tax returns are subject to examination by U.S. Federal, state, and foreign taxing jurisdictions. The impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more likely than not to be sustained. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not to be sustained.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive (Loss) Gain</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive (Loss) Gain</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive (loss) gain include unrealized gains and losses on available-for-sale securities and (loss) gain on foreign currency transactions and are included in the Consolidated Statements of Comprehensive Loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div>Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock', window );">Nonqualified Cash Deferral Plan</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had one equity-based employee compensation plan, which is described more fully in "&#8212;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Common Share</a></td>
<td class="text">Loss per Common ShareThe Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested restricted stock units, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock', window );">Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. For contingent consideration payments in business combinations, the Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and GoodwillThe Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Developments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_InterestIncomeAndInterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest income and interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_InterestIncomeAndInterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_OtherComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_OtherComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638791791424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue Disaggregated by Geographical Area</a></td>
<td class="text">The following table summarizes the Company's net product sales disaggregated by geographic area:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"/><td style="width:53.722%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.646%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,514&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792097088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Changes in IPR&amp;D</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in IPR&amp;D for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the changes in Goodwill for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:85.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792000784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash and Available for Sale Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,595&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:46.670%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:44.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.138%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790759248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories for the Period</a></td>
<td class="text">The following table summarizes the components of inventories: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:66.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,816&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,818&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790749840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,882)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790788816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consist of the following: </span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales rebates and discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued program fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued contract manufacturing&#160;&amp; contract research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788456224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected life of options (years) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the year ended December 31, 2022 were as follows:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,483)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,492&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested RSU Activity under the Plan</a></td>
<td class="text">A summary of non-vested RSU activity under the Plan for the year ended December 31, 2022 is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,067)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity Compensation Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,089&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,340&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,817&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,838&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,151&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790891152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Subject to Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2022 are identified in the following tables:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"/><td style="width:72.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.623%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.929%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.331%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.386%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88%-98%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Changes in Contingent Consideration Payable</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2022 and 2021, respectively:  </span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:71.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.831%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration in cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of the period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,417&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As certain milestones are expected to be reached within the next twelve months, the December 31, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788466144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Liability Components of the Convertible Notes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,569)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan using the effective interest rate method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of Total Interest Expense Recognized Related to the Convertible Notes</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2022 and 2021, respectively:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:73.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.952%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except interest rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest rate of the liability component, Senior Secured Term Loan due 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790110464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except year and discount rate amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of the operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the future minimum operating lease payments were as follows:</span></div><div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"/><td style="width:83.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less lease incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,299)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,130&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792096176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For financial reporting purposes, income (loss) before income taxes includes the following components:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343,424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(365,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242,039)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,554)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,254)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following were the components of income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,760)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,471)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2022, 2021, and 2020 are as follows:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Deferred Tax Assets and Liabilities</a></td>
<td class="text">The significant components of the deferred tax assets and liabilities are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carry forwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest carry forward limitation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">707,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,932)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576,912&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,939)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,930)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790916416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:56.241%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.660%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(236,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,057,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,421,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,867,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:58.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,072&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,129&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788638944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (2,532,490)<span></span>
</td>
<td class="num">$ (2,295,922)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789034704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk and Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">329,233<span></span>
</td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=fold_GalafoldMember', window );">Galafold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 329,000<span></span>
</td>
<td class="nump">$ 305,500<span></span>
</td>
<td class="nump">$ 260,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net product sales | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts receivable | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fold_GalafoldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fold_GalafoldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=fold_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=fold_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792099312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789209408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Geographical Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 329,233<span></span>
</td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">115,946<span></span>
</td>
<td class="nump">95,387<span></span>
</td>
<td class="nump">80,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 213,287<span></span>
</td>
<td class="nump">$ 210,127<span></span>
</td>
<td class="nump">$ 180,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638790809232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>plan</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Equity-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ShareBasedCompensationNumberOfPlans', window );">Number of equity-based employee compensation plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of plans under the equity-based arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792046880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>unit </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788536848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792273856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Changes in IPR&amp;D (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Changes in IPR&amp;D</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Change in IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Change in goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 197,797<span></span>
</td>
<td class="nump">$ 197,797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788474544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 148,813,000<span></span>
</td>
<td class="nump">$ 245,197,000<span></span>
</td>
<td class="nump">$ 163,240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">144,782,000<span></span>
</td>
<td class="nump">237,299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Debt securities, realized gain (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of available-for-sale debt securities in unrealized loss positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 173,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788857376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 148,813<span></span>
</td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value, cash balances</a></td>
<td class="nump">148,813<span></span>
</td>
<td class="nump">245,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">144,700<span></span>
</td>
<td class="nump">237,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">144,782<span></span>
</td>
<td class="nump">237,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities', window );">Cost, cash balances and available-for-sale securities</a></td>
<td class="nump">293,513<span></span>
</td>
<td class="nump">482,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, cash balances and available-for-sale securities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, cash balances and available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure', window );">Fair value, cash balances and available-for-sale securities</a></td>
<td class="nump">293,595<span></span>
</td>
<td class="nump">482,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">144,299<span></span>
</td>
<td class="nump">174,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">144,381<span></span>
</td>
<td class="nump">174,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789308480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 148,813<span></span>
</td>
<td class="nump">$ 245,197<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">4,259<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 153,115<span></span>
</td>
<td class="nump">$ 249,456<span></span>
</td>
<td class="nump">$ 166,162<span></span>
</td>
<td class="nump">$ 146,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789244016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 10,054<span></span>
</td>
<td class="nump">$ 12,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">9,615<span></span>
</td>
<td class="nump">10,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">23,816<span></span>
</td>
<td class="nump">26,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788898272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 53,059<span></span>
</td>
<td class="nump">$ 62,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(22,281)<span></span>
</td>
<td class="num">(19,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">30,778<span></span>
</td>
<td class="nump">42,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">6,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24,162<span></span>
</td>
<td class="nump">24,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,345<span></span>
</td>
<td class="nump">16,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,486<span></span>
</td>
<td class="nump">5,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">3,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fold_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788524112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">$ 25,701<span></span>
</td>
<td class="nump">$ 24,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_AccruedSalesRebatesAndChargebacksCurrent', window );">Accrued sales rebates and discounts</a></td>
<td class="nump">21,886<span></span>
</td>
<td class="nump">15,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_AccruedProgramFees', window );">Accrued program fees</a></td>
<td class="nump">10,515<span></span>
</td>
<td class="nump">13,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent', window );">Accrued contract manufacturing&#160;&amp; contract research costs</a></td>
<td class="nump">8,230<span></span>
</td>
<td class="nump">20,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">6,908<span></span>
</td>
<td class="nump">4,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">6,868<span></span>
</td>
<td class="nump">9,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Accrued taxes</a></td>
<td class="nump">5,938<span></span>
</td>
<td class="nump">6,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">7,590<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 93,636<span></span>
</td>
<td class="nump">$ 98,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedContractManufacturingAndContractResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedContractManufacturingAndContractResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedProgramFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedProgramFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccruedSalesRebatesAndChargebacksCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Rebates And Chargebacks, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccruedSalesRebatesAndChargebacksCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788253632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock and Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CommonStockVotingRightsForEachShareHeld', window );">Voting right for each share held, number | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing', window );">Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199,750<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross cash proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,230<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member', window );">2016 Convertible Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_AtTheMarketEquityProgramMember', window );">At The Market Equity Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,349,705<span></span>
</td>
<td class="nump">8,349,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member', window );">Stock Exercises at $7.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member', window );">Stock Exercises at $7.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,296,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,296,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Equity component of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="nump">$ 10.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Stock Exercises at $7.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants | Stock Exercises at $7.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CommonStockVotingRightsForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes entitled for each share held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CommonStockVotingRightsForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Warrants And Equity Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_AtTheMarketEquityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_AtTheMarketEquityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789049808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Deferred compensation investment</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">15,472,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage', window );">Monthly vesting percentage</a></td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788603152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="nump">$ 9.08<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised, net</a></td>
<td class="nump">4,310<span></span>
</td>
<td class="nump">$ 10,228<span></span>
</td>
<td class="nump">$ 42,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting', window );">Period following separation for accelerated vesting</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 50,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788974880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">62.10%<span></span>
</td>
<td class="nump">65.40%<span></span>
</td>
<td class="nump">75.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788700368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">14,731<span></span>
</td>
<td class="nump">14,032<span></span>
</td>
<td class="nump">16,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted (in shares)</a></td>
<td class="nump">5,733<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
<td class="nump">4,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="num">(660)<span></span>
</td>
<td class="num">(1,483)<span></span>
</td>
<td class="num">(5,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="num">(495)<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="num">(1,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(245)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">19,064<span></span>
</td>
<td class="nump">14,731<span></span>
</td>
<td class="nump">14,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and unvested expected to vest as of the end of the period (in shares)</a></td>
<td class="nump">17,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">10,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 11.08<span></span>
</td>
<td class="nump">$ 9.54<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">11.53<span></span>
</td>
<td class="nump">16.53<span></span>
</td>
<td class="nump">9.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">6.58<span></span>
</td>
<td class="nump">7.05<span></span>
</td>
<td class="nump">8.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">12.57<span></span>
</td>
<td class="nump">12.97<span></span>
</td>
<td class="nump">10.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">12.84<span></span>
</td>
<td class="nump">13.28<span></span>
</td>
<td class="nump">13.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">11.31<span></span>
</td>
<td class="nump">$ 11.08<span></span>
</td>
<td class="nump">$ 9.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and unvested expected to vest as of the end of the period (in dollars per share)</a></td>
<td class="nump">11.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 10.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and unvested expected to vest at the end of the period</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 36.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options vested and unvested expected to vest</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788212992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - RSUs and PBRSUs Summary (Details) - Unvested restricted stock units - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the beginning of the period (in shares)</a></td>
<td class="nump">7,341<span></span>
</td>
<td class="nump">7,080<span></span>
</td>
<td class="nump">5,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">5,048<span></span>
</td>
<td class="nump">3,191<span></span>
</td>
<td class="nump">4,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(2,251)<span></span>
</td>
<td class="num">(1,863)<span></span>
</td>
<td class="num">(2,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(421)<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(1,240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units as of the end of the period (in shares)</a></td>
<td class="nump">9,717<span></span>
</td>
<td class="nump">7,341<span></span>
</td>
<td class="nump">7,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 13.90<span></span>
</td>
<td class="nump">$ 11.35<span></span>
</td>
<td class="nump">$ 11.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.93<span></span>
</td>
<td class="nump">16.94<span></span>
</td>
<td class="nump">11.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">12.48<span></span>
</td>
<td class="nump">15.77<span></span>
</td>
<td class="nump">10.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">12.06<span></span>
</td>
<td class="nump">12.82<span></span>
</td>
<td class="nump">11.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units as of the end of the period (in dollars per share)</a></td>
<td class="nump">$ 13.07<span></span>
</td>
<td class="nump">$ 13.90<span></span>
</td>
<td class="nump">$ 11.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units, weighted average remaining years</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Non-vested units, aggregate intrinsic value</a></td>
<td class="nump">$ 118.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788885440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Expense Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 76,512<span></span>
</td>
<td class="nump">$ 57,838<span></span>
</td>
<td class="nump">$ 49,151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">25,089<span></span>
</td>
<td class="nump">17,340<span></span>
</td>
<td class="nump">20,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 51,423<span></span>
</td>
<td class="nump">$ 40,498<span></span>
</td>
<td class="nump">$ 28,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788754736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 150,189<span></span>
</td>
<td class="nump">$ 242,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">21,417<span></span>
</td>
<td class="nump">20,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">26,875<span></span>
</td>
<td class="nump">25,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">144,381<span></span>
</td>
<td class="nump">174,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">5,808<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">150,189<span></span>
</td>
<td class="nump">242,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">144,381<span></span>
</td>
<td class="nump">174,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">5,808<span></span>
</td>
<td class="nump">5,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">21,417<span></span>
</td>
<td class="nump">20,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">$ 21,417<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788197840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 21,417<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | ATB-200 Pompe Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 21,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | Discount rate | ATB-200 Pompe Program | Probability weighted discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus | Clinical and Regulatory Approval Milestones | Probability of achievement of milestones | ATB-200 Pompe Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Financial assets and liabilities subject to fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788193600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 20,339<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value during the period, included in the Consolidated Statements of Operations</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">6,514<span></span>
</td>
<td class="nump">$ 3,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment of contingent consideration in cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 21,417<span></span>
</td>
<td class="nump">$ 20,339<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788858656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long Term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of Long-term debt</a></td>
<td class="nump">$ 391,990<span></span>
</td>
<td class="nump">$ 389,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans | Senior Secured Term Loan due 2026:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentsAbstract', window );"><strong>Debt Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(4,571)<span></span>
</td>
<td class="num">(6,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(3,439)<span></span>
</td>
<td class="num">(4,569)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value of Long-term debt</a></td>
<td class="nump">$ 391,990<span></span>
</td>
<td class="nump">$ 389,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638784561136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>numberOfPayments</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (257,000)<span></span>
</td>
<td class="num">$ (7,276,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtInstrumentPeriodicPaymentNumberOfPayments', window );">Number of payments | numberOfPayments</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 44,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSecuredLinesOfCredit', window );">Proceeds from secured lines of credit</a></td>
<td class="nump">385,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtInstrumentLiquidityCovenantMinimumAmount', window );">Minimum liquidity covenant</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtInstrumentConsolidatedRevenueCovenantAmount', window );">Consolidated revenue covenant, amount</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtInstrumentConsolidatedRevenueCovenantAmount', window );">Consolidated revenue covenant, amount</a></td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Loans | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DebtInstrumentVariableRate', window );">Variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Senior Secured Term Loan due 2026:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_EarlySettlementPremiums', window );">Early settlement premiums</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(7,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConsolidatedRevenueCovenantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Consolidated Revenue Covenant, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConsolidatedRevenueCovenantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentLiquidityCovenantMinimumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Liquidity Covenant, Minimum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentLiquidityCovenantMinimumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentPeriodicPaymentNumberOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Number Of Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentPeriodicPaymentNumberOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_EarlySettlementPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Settlement Premiums</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_EarlySettlementPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSecuredLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSecuredLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788798560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 34,446<span></span>
</td>
<td class="nump">$ 30,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing</a></td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Senior Secured Term Loan due 2026:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate of the liability component</a></td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638784443600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 9,800,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Cash paid for amounts included in operating lease liabilities</a></td>
<td class="nump">8,300,000<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">8,900,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentive</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 470,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788523680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets, net</a></td>
<td class="nump">$ 29,534<span></span>
</td>
<td class="nump">$ 20,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of the operating lease liabilities</a></td>
<td class="nump">8,552<span></span>
</td>
<td class="nump">7,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of the operating lease liabilities</a></td>
<td class="nump">51,578<span></span>
</td>
<td class="nump">43,363<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 60,130<span></span>
</td>
<td class="nump">$ 50,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease terms (years)</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">19 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788433632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Operating Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 9,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">8,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">8,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">8,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">124,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">168,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_LesseeOperatingLeaseLiabilityTenantIncentives', window );">Less lease incentives</a></td>
<td class="num">(22,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(86,384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 60,130<span></span>
</td>
<td class="nump">$ 50,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LesseeOperatingLeaseLiabilityTenantIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Incentives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LesseeOperatingLeaseLiabilityTenantIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638784549632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Statutory Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract', window );"><strong>Income (loss) before income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (343,424)<span></span>
</td>
<td class="num">$ (333,571)<span></span>
</td>
<td class="num">$ (365,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">101,385<span></span>
</td>
<td class="nump">92,017<span></span>
</td>
<td class="nump">91,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(242,039)<span></span>
</td>
<td class="num">(241,554)<span></span>
</td>
<td class="num">(274,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(5,760)<span></span>
</td>
<td class="nump">8,857<span></span>
</td>
<td class="nump">4,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (5,471)<span></span>
</td>
<td class="nump">$ 8,906<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory tax rates and the effective tax rates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Impact of foreign operations</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788216624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred and Valuation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxAssetsIntellectualProperty', window );">Intellectual property</a></td>
<td class="nump">$ 68,567<span></span>
</td>
<td class="nump">$ 105,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credit</a></td>
<td class="nump">223,366<span></span>
</td>
<td class="nump">205,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">29,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">315,444<span></span>
</td>
<td class="nump">334,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent', window );">Share-based compensation</a></td>
<td class="nump">16,417<span></span>
</td>
<td class="nump">11,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxAssetsInterestCarryforwardLimitation', window );">Interest carry forward limitation</a></td>
<td class="nump">12,558<span></span>
</td>
<td class="nump">8,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxAssetsLeasingArrangements', window );">Lease liability</a></td>
<td class="nump">11,428<span></span>
</td>
<td class="nump">9,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">10,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">20,109<span></span>
</td>
<td class="nump">17,748<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">707,606<span></span>
</td>
<td class="nump">692,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesBusinessAcquisition', window );">Business acquisition</a></td>
<td class="num">(4,939)<span></span>
</td>
<td class="num">(4,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxLiabilitiesRoyaltyPayable', window );">Royalty payable</a></td>
<td class="num">(68,567)<span></span>
</td>
<td class="num">(105,453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(6,806)<span></span>
</td>
<td class="num">(4,932)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_DeferredTaxAssetsLiabilitiesGross', window );">Total net deferred tax assets</a></td>
<td class="nump">627,294<span></span>
</td>
<td class="nump">576,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(632,233)<span></span>
</td>
<td class="num">(581,842)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">(4,939)<span></span>
</td>
<td class="num">(4,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">632,233<span></span>
</td>
<td class="nump">$ 581,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in the valuation allowance</a></td>
<td class="num">$ (50,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsInterestCarryforwardLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Carryforward Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsInterestCarryforwardLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxAssetsNonCashStockIssueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxAssetsNonCashStockIssueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesBusinessAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Business Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesBusinessAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DeferredTaxLiabilitiesRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from royalty payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DeferredTaxLiabilitiesRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792271584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Loss Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and experimentation tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 36.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember', window );">Orphan drug tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">187.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">1,183.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Amount of net operating loss carry forwards</a></td>
<td class="nump">$ 992.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=fold_OrphanDrugTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638789021104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2013 </div>
<div>USD ($) </div>
<div>market</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,233<span></span>
</td>
<td class="nump">$ 305,514<span></span>
</td>
<td class="nump">$ 260,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">$ 4,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">5,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">93,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,636<span></span>
</td>
<td class="nump">$ 98,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_TerminationAgreementMember', window );">Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_PaymentsForCollaborativeArrangement', window );">Payments for collaborative agreement</a></td>
<td class="nump">23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication', window );">Conditional aggregate payments per indication</a></td>
<td class="nump">86,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember', window );">Revised Agreement | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments', window );">Potential milestone payments upon achievement of post-approval and sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones', window );">Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones | market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Conditional Aggregate Payments Per Indication</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_RevisedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fold_GlaxoSmithKlinePLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638792214976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_fold_LossContingencyNumberOfLawsuits', window );">Number of lawsuits</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_LossContingencyNumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_LossContingencyNumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139638788728672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (236,568)<span></span>
</td>
<td class="num">$ (250,460)<span></span>
</td>
<td class="num">$ (276,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">289,057,198<span></span>
</td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">289,057,198<span></span>
</td>
<td class="nump">271,421,986<span></span>
</td>
<td class="nump">258,867,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">28,781,000<span></span>
</td>
<td class="nump">22,072,000<span></span>
</td>
<td class="nump">24,129,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">19,064,000<span></span>
</td>
<td class="nump">14,731,000<span></span>
</td>
<td class="nump">14,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">9,717,000<span></span>
</td>
<td class="nump">7,341,000<span></span>
</td>
<td class="nump">7,080,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>fold-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:fold="http://www.amicustherapeutics.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fold-20221231.xsd" xlink:type="simple"/>
    <context id="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8346990c1864a19a63bcc7bbf6367c7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id6fffb5d4f854f989389548059d508dc_I20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2023-02-13</instant>
        </period>
    </context>
    <context id="id6fb65dbd72b492e80987a09a840570c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2fe03ce4e8348beb3ff495315b993c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40d6b75012b24abc830ece41c6c75656_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib98d799a4ea240c598fa644f12ddd44d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida6ebb73d0a44583a25622bc2ff8bc70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55cdc3ed7a544ad78b27effbad17252b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i331f4737a70b494d8165d7ad00b4f89c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica44d8bb33204fffa5ffdcad376a613c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if20d67fb12e4438dbfce2517356c6668_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61a54e11bb144d7283f688389627911d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2920a3c79ee544bfb57550e1524b3be6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8ce7db741914e24aba11ec227d80098_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a1c8441149f45b193c288045bfccb67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5867ad5312c144e38a3ba1be62b312de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15c8302234e443c5bca532c176601a9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i140a0265db284ab18fc85a7c566f5e3c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia67c1c4115c1453abb07a9ff877be186_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iedae25f2203048fdaca67cfcf5b407cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8aefd971cde4f12941d682724a9a606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25d57483c4a54eef8994b3bbaa7ffb31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied530d85f0df4c79aa2114bf41baf122_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49e0d3884d4a4e348b28d2bf23c7218e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47380801e43942c98bd579021cd66466_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaafcc84ae1f04e7c9f6fe592d37ff72b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iae02215294ea4a709fe26968153b5d93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic04eb74993b34416ac4dae1ade133ddc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10fab736f36145b7ad0b9d9e1984f370_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ed4526deb5b484388e6c5a3f6743677_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i517924c9e42841189538479018e06f92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b0d6f1aad064e62b2c5e3d60a822ed4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5e5211df4e48468b80d3325414933d9f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0f3176f304064948be4451df697aa412_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3a136c7711d044a09a19e03c25fe39dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:GalafoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5074d507bd1e4529aa53cc1be1409baf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:GalafoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i508c824fb1844b0ca8a046ab3f8321c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:GalafoldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71deb9575b294adb91ff789973f65bbf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia738717e166c41c2a4392a1967ef4025_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id2c3883ff4d64b8e9595b3e84e9edfe4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i102ca847ccf94fb3ac9a236e09d1fd19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">fold:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16b7fa862c79461ba0d440ef1d4f8431_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3be0f0c66b2b4c8cbdda482aa8ee8d15_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc1cdb41092f4d06b127a3529fd12fa3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4df5e946794844e891a2510cf44b7066_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib8a70346b0774591a4bd99dd9b48cdb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e1d53e258e9423497806e3919e31742_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ee0584c009d47bdb038931ceca9c5e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79ec32aa3cf74295bf4d454eeeda3370_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e6e594e389f4523b7a7c9bab80844f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9fbcc912009f4550a0f6de763f637746_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i877c2edcab8a4345bf7101d61ccf2c15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f9e1d0ccde74a5397233b019d1d1666_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeff130df8d84f32801b649c773d0d55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if837fc4ce0e8435692a6f567914b6ed3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd29482ac05d44c7ab8df32cee3dca44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e615ec9f7c64a478d960eb4430d471b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89ffd34918454b17a538f8040e16bd9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36d1abcfa0ef48a8900c4f3cd89f734f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fold:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e219ba46f9f454e81973029cbfee478_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3636fa399a0c4c1eba1f0545ca9be836_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1e9bf5a1cc64621922ffe1980b7dac7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i676babb093b5444588a41929a2ea1306_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i483ff1106b53432cbdf57bb9830bf8d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i628f96c5cfa5476392fcbe4410976f8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04d7c1f78a2d4edfbd5dbd117237d2e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia903203eb4da4bd3902cc71800cfbd03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfe1f1cffd554a4b994d3edcc31500b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf9b84e7254d4fec87bd8e31221e830a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ef01c16ab7e44bdb0fe14f5f6770e1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i144d3b85e0f54b78b3e35a0ab3f69126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb2d2c63506847d38297b26fc2a46816_D20221101-20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:AtTheMarketEquityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i1dbc7ec2bc82472e8d78a51e83eca27b_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0cc3b62495104669997b8f552c55251a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i684e59baa0d248038199064182a492cf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7b9f39dd6e7249298a92876de6b1e0e0_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fb10a0ab84743b8a633a5e8af451568_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0c5e203f768a4aaf8bcf9130761b750a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7688b5af5be343ee94e09246b4b087c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idf13e1ea84ff4fe7aa83be773a9ca942_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9f2b79da371e47f782a538b4f4a5a21e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i434e5978cdfe47e2b88de10d3e704e27_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iebd9dd9985e24306a01c58683a8c7ab2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7a60c7a011cd48f384a926bf46f56bb5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f56a09188ad4413a91488ec17aa68c9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8462cf871c7a45aaa1430ee2bee44c64_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0893f89fb16742748936ee83717865e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb57920f3b814e169748405b9928e37d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i69703642df9a437496988406ce21d664_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i270475db6676442a85109f9df17c710f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc0df69ddff74c2089537bf0e99a1af4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbd0892a63d24555a0be7d1e129099a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia25971519a474cb89a00ac0fe4405077_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4aebf956783144d080e2da4950f36772_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7974cd6b41a844d691c4317454a8e713_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic11a83d2050e4006b0d4257abc62732d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62bbbab375e34720aaff75d13f751ff3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id791547accfd4c4ca3c15fd099f6a3c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id344688a9ae545c792aa423f39c5e57d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0583f7b3d714281b74c55de8631a291_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c47266244c044308efa79fbb42126c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia6f66037dfaf441895506fef26bb3f6c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if73e550190f24545ba9da5442ddcbd4c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea79d58e95c74a5991a23d4e79a1accb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7bc093340f94793b9356a4ad70fd286_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20c8c2cd061443e8b7635a574a7eb008_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief04e0e1c5f64e7ea10b52c1ac3b2b1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i050f1ac85c0b486fb9e3931da07d4215_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia11c64b571a447ccae1108601a456bd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ec9eab666f04c9ba3be68d4ffd794f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i863463917abd46488618f36fe6140b3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36478174e3aa4ca6a302830abc0b3fd0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0914d34ae7a54148af314b77afd45e1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e3c044f256444559188d07ee55b2357_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b64c874c8c44ab193d9b7e4e27fc831_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="ib2b5d30d91b5477cb000659e1d65b4e9_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i7ede13529d0c4d9b9a5b6711cd1a2495_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i4688884f4dfe4ebb993267308aba950f_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="if96cae15f3fe42258129198c088db297_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ib91a2c830ad742d79faac258a290765d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77e2344e04a24467a4594a535befc1ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieeca2fca010445d2b6ac75145dc51d86_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ebce9bdfa62478e987dab4fc8cb80a4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79b2989cb3ff43f08613f1bb07e232a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib98e12399cbf4ef187963beeca3c3e2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fold:OrphanDrugTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib99cd8bfa1ce4661a32f07a098c4ad73_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9793bb80591f4cbe82d14a2f6ce6c5ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a10a61a90a344cc83adebf491256426_I20131130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-30</instant>
        </period>
    </context>
    <context id="i0c471c92318746a9b8b1e5af997f548b_D20131101-20131130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-11-01</startDate>
            <endDate>2013-11-30</endDate>
        </period>
    </context>
    <context id="iba37a657d80947ab943a84d5c6b181e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5673e90eb6f14cadab1e4565ba42932c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fold:GlaxoSmithKlinePLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:RevisedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0862ce94c414f10953150dfe32fbbaf_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="id13e58186fce456cb1f8099e4d16a816_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe76a53ea05f4538ab0428dc6a0d71ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i368b9dd19078410ea03a553d29d85a22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3b4ae1b3663f48dc81a42db36e0a2c47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8b18190ecdd4603980cfb4ea1d75b83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ac3baf5d87f4121b825257bdbd8cdfc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c9f9812c5e347c0a7f7930aed8b7d7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i39d797c28b2c491eaa21d972d9a071a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i080e37076a644122a897798491e8bdd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7edd439e87db45d786c45396af394cbd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0fc776c099cb497d877ef435b98b54e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68a0f47df35a4dfa8f233290926fed7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>fold:plan</measure>
    </unit>
    <unit id="segment">
        <measure>fold:segment</measure>
    </unit>
    <unit id="unit">
        <measure>fold:unit</measure>
    </unit>
    <unit id="vote">
        <measure>fold:vote</measure>
    </unit>
    <unit id="numberofpayments">
        <measure>fold:numberOfPayments</measure>
    </unit>
    <unit id="market">
        <measure>fold:market</measure>
    </unit>
    <unit id="lawsuit">
        <measure>fold:lawsuit</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV8zLTEtMS0xLTMzNDg0_8711408a-c382-468e-8f17-cf9c4fa726e8">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV80LTEtMS0xLTMzNDg0_3cb4b284-6987-45ae-acde-292955d48a2b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV81LTEtMS0xLTMzNDg0_c1168db6-d983-4617-9889-f4b25e1b0953">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N180L2ZyYWc6YTkyNjgxNjk3YWEwNDk2OGE1MDA5MDIwMWZiYTg5MjgvdGFibGU6ODc2NTk5ODJlYmNjNDgxZGIzNTdiNzNiMzMyOTE5NWEvdGFibGVyYW5nZTo4NzY1OTk4MmViY2M0ODFkYjM1N2I3M2IzMzI5MTk1YV82LTEtMS0xLTMzNDg0_8e45c8c2-503b-446d-8e81-1f0809d5ff57">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5e5211df4e48468b80d3325414933d9f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage
      contextRef="i9f56a09188ad4413a91488ec17aa68c9_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDAvZnJhZzo5NjI1OTliMmVmOTI0NDc0YTBmOTY0OTdiMWMyNTJhMy90YWJsZTo5NTIwMzc2YmI1NzY0NGEyOGU1YTg3OTcwNTZiNTJhNC90YWJsZXJhbmdlOjk1MjAzNzZiYjU3NjQ0YTI4ZTVhODc5NzA1NmI1MmE0XzAtMS0xLTEtMzM0ODQ_a4541521-3307-4c25-bf8a-dcf0de38c5ce"
      unitRef="number">0.0208</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage>
    <dei:DocumentType
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU3_34247cee-fb3e-4281-8f01-b899acc15faf">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjY2_7f41bd09-33a5-4d89-b86b-4520202be786">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8yMjE_8010d765-08ce-4ab8-a344-c5d7289e1b84">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8yMjE_bb80fbdd-43f1-46bb-b9b1-7a56215c9bb2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYz_c8c6e852-020c-4421-b549-d3d6fa1c0f22">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU4_84f084b3-1bd6-4847-a8ae-95fc9a0567bc">001-33497</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU0_0cd5372c-e496-420c-aa2b-2909affa2cc4">Amicus Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl8wLTAtMS0xLTMzNDg0_eb2825db-065d-433e-a040-b8c91efbcb56">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl8wLTQtMS0xLTMzNDg0_975d93cb-fd92-4774-b3d1-033c0c19746c">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTAtMS0xLTMzNDg0_2e225512-eb8f-4fb7-a117-45d3a6fd2cb7">3675 Market Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTEtMS0xLTMzNDg0_c3b76afb-4a8e-40a4-9973-33a73c004642">Philadelphia,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTItMS0xLTMzNDg0_81b501fa-211b-4ee6-96fe-ae18cff036f3">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl80LTQtMS0xLTMzNDg0_a3acc602-9acf-4fb6-9311-21f566d39edf">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl83LTAtMS0xLTMzNDg0_3a708f34-b47d-4472-9201-1070e5e23236">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZGUxMWJlMTIxOTRiNDhkM2IxOWM1MWQ2YTZlM2NjYmIvdGFibGVyYW5nZTpkZTExYmUxMjE5NGI0OGQzYjE5YzUxZDZhNmUzY2NiYl83LTMtMS0xLTMzNDg0_a03a098f-18eb-4ee0-b4e6-7d65bbc868f5">921-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6M2YwZjk5YWYxZThkNDNhMTk2NDJjNjY0OGI1YWIzNWQvdGFibGVyYW5nZTozZjBmOTlhZjFlOGQ0M2ExOTY0MmM2NjQ4YjVhYjM1ZF8xLTAtMS0xLTMzNDg0_afd8a757-951b-48d9-bd30-9ba2e3e4469b">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6M2YwZjk5YWYxZThkNDNhMTk2NDJjNjY0OGI1YWIzNWQvdGFibGVyYW5nZTozZjBmOTlhZjFlOGQ0M2ExOTY0MmM2NjQ4YjVhYjM1ZF8xLTEtMS0xLTMzNDg0_245904a9-33a0-44b8-9f1c-62681159471c">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6M2YwZjk5YWYxZThkNDNhMTk2NDJjNjY0OGI1YWIzNWQvdGFibGVyYW5nZTozZjBmOTlhZjFlOGQ0M2ExOTY0MmM2NjQ4YjVhYjM1ZF8xLTItMS0xLTMzNDg0_2be7bc2f-3aff-45ac-bf5b-2cf8b9d6a34b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjY1_50526d45-0455-47ab-8ae4-a36ee5b3a3e7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU5_28a369fc-ecbc-429c-9f90-80a13497fbce">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYw_ba30cb5d-9df0-4f7e-85d5-a5d2290674c2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjU1_bf9baa9f-a4bb-488e-b475-e23da218132c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZjA2MTk5MDMxNTAwNGQ3NjkzNDY2OWU4ZDhlNmI1MzcvdGFibGVyYW5nZTpmMDYxOTkwMzE1MDA0ZDc2OTM0NjY5ZThkOGU2YjUzN18wLTAtMS0xLTMzNDg0_14a758a3-32af-4468-ba41-6b1306f76ce9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZjA2MTk5MDMxNTAwNGQ3NjkzNDY2OWU4ZDhlNmI1MzcvdGFibGVyYW5nZTpmMDYxOTkwMzE1MDA0ZDc2OTM0NjY5ZThkOGU2YjUzN18xLTQtMS0xLTMzNDg0_98c6c46c-2985-436d-9601-610392401b44">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGFibGU6ZjA2MTk5MDMxNTAwNGQ3NjkzNDY2OWU4ZDhlNmI1MzcvdGFibGVyYW5nZTpmMDYxOTkwMzE1MDA0ZDc2OTM0NjY5ZThkOGU2YjUzN18yLTQtMS0xLTMzNDg0_ce5fa66d-9e42-4670-a2a5-46843c0ad5fb">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYx_a11ec5ab-e15b-4d41-a318-13686988cf22">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjYy_36805ad3-41cc-43f1-8835-b8ff517f2448">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ia8346990c1864a19a63bcc7bbf6367c7_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8xMDQ0NTM2MDQ2NzY0OA_5d895dc1-3b13-4f78-b874-c0974757520f"
      unitRef="usd">2979823386</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id6fffb5d4f854f989389548059d508dc_I20230213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zMzg1_c2ce02c6-f719-4e0d-9ee1-ed2254a2f5dc"
      unitRef="shares">282714738</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xL2ZyYWc6ZWUzN2ZjNDViMzNiNGY1ZDkxOWRhZjFiZGY5NjY5NjUvdGV4dHJlZ2lvbjplZTM3ZmM0NWIzM2I0ZjVkOTE5ZGFmMWJkZjk2Njk2NV8zNjY3_6d9a4fc7-b260-462b-8843-a4dca57aeb82">Portions of the Proxy Statement for the registrant's 2022 Annual Meeting of Stockholders which is to be filed subsequent to the date hereof are incorporated by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181NS9mcmFnOmIxOThjOTI3MThlNDRiNWNhYmQ0ZmJkNjA0MmYwOGE3L3RhYmxlOjg1ZDBiY2YxZDFkMzRhYjc4Y2Y5MzI1NTg2Y2I5ODU5L3RhYmxlcmFuZ2U6ODVkMGJjZjFkMWQzNGFiNzhjZjkzMjU1ODZjYjk4NTlfMC0wLTEtMS0zMzQ4NC90ZXh0cmVnaW9uOjMxMjNjMTJjYWFlZjQyZjliMGU5ZTJlOWFjYjc4YjgxXzk_d48c3a0c-678e-4f2a-915f-c03bb73aa5c9">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181NS9mcmFnOmIxOThjOTI3MThlNDRiNWNhYmQ0ZmJkNjA0MmYwOGE3L3RleHRyZWdpb246YjE5OGM5MjcxOGU0NGI1Y2FiZDRmYmQ2MDQyZjA4YTdfMzQzOQ_f6e5f871-a51e-41ae-bb17-2eaa94557704">Iselin, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNC0xLTEtMS0zMzQ4NA_e0b35bdd-1bc3-4502-a35c-2ad302f94a18"
      unitRef="usd">148813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNC0zLTEtMS0zMzQ4NA_c3cc282e-9baa-4281-8fc5-1e5433621775"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNS0xLTEtMS0zMzQ4NA_cde497d7-9c58-45cc-bc1b-85187d141a0f"
      unitRef="usd">144782000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNS0zLTEtMS0zMzQ4NA_ba1f2ab6-c23f-4761-8839-fe62cd107adc"
      unitRef="usd">237299000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNi0xLTEtMS0zMzQ4NA_e0fa8574-4c49-423a-a863-b17a64e092f4"
      unitRef="usd">66196000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNi0zLTEtMS0zMzQ4NA_9707df5b-e54d-42be-a706-e54d076a23a6"
      unitRef="usd">52672000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNy0xLTEtMS0zMzQ4NA_293f39ca-350e-490a-bcb8-0d2d67ad49ce"
      unitRef="usd">23816000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNy0zLTEtMS0zMzQ4NA_aa430f4e-74c0-48d5-9dbc-b8175984ddce"
      unitRef="usd">26818000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOC0xLTEtMS0zMzQ4NA_54d52069-606d-44d4-8af5-187623261345"
      unitRef="usd">40209000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOC0zLTEtMS0zMzQ4NA_a984fd77-74f6-458c-9c95-6ae90cf92672"
      unitRef="usd">34848000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOS0xLTEtMS0zMzQ4NA_42dd43aa-7c76-4c0f-b7a9-43fe267e7ff8"
      unitRef="usd">423816000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfOS0zLTEtMS0zMzQ4NA_7e950689-2465-4207-9ad9-9b55634216c9"
      unitRef="usd">596834000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTAtMS0xLTEtMzM0ODQ_aa639658-4e7f-4f94-a097-d631f9989352"
      unitRef="usd">29534000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTAtMy0xLTEtMzM0ODQ_f4004a8c-9fbb-4e79-bf83-9f36be730074"
      unitRef="usd">20586000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjowMjg0ZDMyMzYxYTA0OGU0OWJlZDE0ZTY3NjdhOWJmNV82MQ_9dbe595f-1401-463f-b512-118ec76d9349"
      unitRef="usd">22281000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjowMjg0ZDMyMzYxYTA0OGU0OWJlZDE0ZTY3NjdhOWJmNV82OA_aabf6636-40c5-40b0-9926-8cd99c300b5d"
      unitRef="usd">19882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMS0xLTEtMzM0ODQ_2df47375-11cf-400b-a52b-52cf7cbf4f0f"
      unitRef="usd">30778000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTEtMy0xLTEtMzM0ODQ_f77a434c-bca6-457b-a2e9-4dc08435d4b0"
      unitRef="usd">42496000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTItMS0xLTEtMzM0ODQ_93314b6e-b796-4cfe-a17d-243d3c30a41e"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTItMy0xLTEtMzM0ODQ_529a523d-d5b8-4d68-b627-efd5df6166b7"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTMtMS0xLTEtMzM0ODQ_45fc8156-8c24-452e-a964-78c50e4f2d4e"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTMtMy0xLTEtMzM0ODQ_4ef8e7da-aedc-492c-8dab-b8d86f2e2946"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTQtMS0xLTEtMzM0ODQ_e20ab0bf-8037-4763-b51a-0ab9c2632b44"
      unitRef="usd">19242000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTQtMy0xLTEtMzM0ODQ_f9724e85-4752-48c3-a3f5-fee16ff587ca"
      unitRef="usd">24427000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTUtMS0xLTEtMzM0ODQ_9f9e7b81-efca-42e5-9a4e-c075bbb6521b"
      unitRef="usd">724167000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTUtMy0xLTEtMzM0ODQ_05f8bec7-9215-4533-a8e7-a7b2ec88361d"
      unitRef="usd">905140000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTgtMS0xLTEtMzM0ODQ_465f3fde-c944-4a7d-bc62-3488413846cf"
      unitRef="usd">15413000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTgtMy0xLTEtMzM0ODQ_86f23e4d-31ac-43fc-9466-4293bebc59ff"
      unitRef="usd">21513000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTktMS0xLTEtMzM0ODQ_52669fef-fd05-4542-b75e-bfdf752bc92b"
      unitRef="usd">93636000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMTktMy0xLTEtMzM0ODQ_2dc20a38-0d86-429a-ac9f-914a9b560028"
      unitRef="usd">98153000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjAtMS0xLTEtMzM0ODQ_d21b6c5d-936c-417b-81b1-e16cf4b7be74"
      unitRef="usd">21417000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjAtMy0xLTEtMzM0ODQ_30dd32a9-3b7c-4b81-bde1-3d5c2c55401f"
      unitRef="usd">18900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjEtMS0xLTEtMzM0ODQ_495542b3-4ce7-4344-be21-94c2587be30d"
      unitRef="usd">8552000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjEtMy0xLTEtMzM0ODQ_89790829-aa9e-4b5f-836b-e59f505e287d"
      unitRef="usd">7409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjItMS0xLTEtMzM0ODQ_e2e26cf2-7476-4fbd-b1dd-3244c38651bd"
      unitRef="usd">139018000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjItMy0xLTEtMzM0ODQ_e8738b0a-c19a-45d1-8232-3b67c1273893"
      unitRef="usd">145975000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMS0xLTEtMzY1NzE_83e5a4dc-c733-4563-86bc-263b5a8c4b40"
      unitRef="usd">391990000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMy0xLTEtMzY1NzE_a5ba31d0-94ff-4fe2-9c28-deed8c5f8b76"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjQtMS0xLTEtMzY1Nzg_d973b853-3638-4e9e-8a0c-39b12e467b21"
      unitRef="usd">51578000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjQtMy0xLTEtMzY1Nzg_fa1e0777-b95e-45e0-9cdb-1c988357172e"
      unitRef="usd">43363000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjUtMS0xLTEtNDAxNjc_769e3af3-28cb-47fc-96da-8badfe01e49c"
      unitRef="usd">4939000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjUtMy0xLTEtNDAxNjc_b8b2a0c5-6698-42a2-9a42-e1684ae3ccf6"
      unitRef="usd">4930000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMS0xLTEtMzM0ODQ_b412a83f-2214-46a3-9521-91479ea652fc"
      unitRef="usd">4656000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjMtMy0xLTEtMzM0ODQ_dd20b774-f043-487d-80f3-05dc5ceef507"
      unitRef="usd">5906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjgtMS0xLTEtMzM0ODQ_a20c1c23-9e44-4288-afdf-6bbf1cc23725"
      unitRef="usd">8939000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjgtMy0xLTEtMzM0ODQ_29a2933e-ff93-4346-8ba2-5a9a3e9d441f"
      unitRef="usd">8240000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjktMS0xLTEtMzM0ODQ_da789686-b976-4814-b903-e56e5d359799"
      unitRef="usd">601120000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMjktMy0xLTEtMzM0ODQ_46484c2f-ab5c-4628-897d-777c1c55549e"
      unitRef="usd">597771000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzAtMS0xLTEtMzM0ODQ_3e7c1942-9d55-4eb9-a734-d2f26e2b9da7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzAtMy0xLTEtMzM0ODQ_69fb141f-e134-4433-a2ca-9c05850f2894"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8xOA_1d1164fe-e625-4842-a073-f74a071d93be"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8xOA_c1f1f0fb-6a93-46fb-9149-8dcfcdafde7c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8zMg_5c275367-540c-4f2d-a7b4-a49af084d086"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV8zMg_88121304-0622-48a3-938c-a70320bbea01"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV81NA_09713280-82a8-4a7e-a419-10a5957374a9"
      unitRef="shares">281108273</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV81NA_a53b67bf-0e4d-4466-b6d5-0c2c9de5e612"
      unitRef="shares">281108273</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV82MQ_2ab2ae72-d059-4474-819a-183613931e59"
      unitRef="shares">278912800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiOGIzZDlhYzYxYzE0OTc1OGVlNjlkNGZhMTE0NDNkMV82MQ_9261f9c5-c16a-458e-9e8c-cade8ea5b4c6"
      unitRef="shares">278912800</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMS0xLTEtMzM0ODQ_dcb7dc09-faae-4cf5-a4c4-301f296a399d"
      unitRef="usd">2815000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzItMy0xLTEtMzM0ODQ_8f95a0fd-73b0-4458-aaf0-06285ac1f78c"
      unitRef="usd">2808000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzMtMS0xLTEtMzM0ODQ_ca1dcf3c-59e3-4371-be86-8af5b3e447c6"
      unitRef="usd">2664744000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzMtMy0xLTEtMzM0ODQ_ead0e5d3-deda-4c9c-a358-3cb2169d6c58"
      unitRef="usd">2595419000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzUtMS0xLTEtMzM0ODQ_7030cd0c-f0ab-488b-90b5-b532159dd7b9"
      unitRef="usd">-11989000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzUtMy0xLTEtMzM0ODQ_d235ad0d-b027-4d88-a261-b0996c468c97"
      unitRef="usd">5251000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzYtMS0xLTEtMzM0ODQ_94d6ca12-d010-4a35-a15f-07bdb20621f3"
      unitRef="usd">-116000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzYtMy0xLTEtMzM0ODQ_a5115124-a31b-480b-9c84-69678a1f7abe"
      unitRef="usd">-270000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzctMS0xLTEtMzM0ODQ_64b19cb4-4aca-4186-9c68-197fdd7ed1e8"
      unitRef="usd">83000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzctMy0xLTEtMzM0ODQ_101ef394-9db3-49ef-bf57-5a34fa392afd"
      unitRef="usd">83000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzgtMS0xLTEtMzM0ODQ_67f417cf-4dfd-4c05-9960-5dd19583c0d3"
      unitRef="usd">-2532490000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzgtMy0xLTEtMzM0ODQ_c2512754-0f5e-4be5-8539-ff9018a48ba7"
      unitRef="usd">-2295922000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzktMS0xLTEtMzM0ODQ_9dd23619-d20f-4bb5-8158-68ab15a2bd25"
      unitRef="usd">123047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfMzktMy0xLTEtMzM0ODQ_00c49b07-ce95-414a-b35b-a4a0a08beae3"
      unitRef="usd">307369000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNDAtMS0xLTEtMzM0ODQ_fe47d58d-05bc-4d98-92a2-778adc98f640"
      unitRef="usd">724167000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N181OC9mcmFnOmRlN2E1MDU0MzIyZDQyNDBhNzA0MmVkMDUzMzJiYjVkL3RhYmxlOmM2ZjVhYTY5ODI3ZDQ0NzNhMTc2MDBhYjkwZTA2MTc3L3RhYmxlcmFuZ2U6YzZmNWFhNjk4MjdkNDQ3M2ExNzYwMGFiOTBlMDYxNzdfNDAtMy0xLTEtMzM0ODQ_2ea62abc-8043-426b-974c-7e502d4adab6"
      unitRef="usd">905140000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMi0xLTEtMS0zMzQ4NA_d591b5a5-9c11-4491-9054-15f7ef62577d"
      unitRef="usd">329233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMi0zLTEtMS0zMzQ4NA_e9df2e14-24a6-4d01-bb75-960c7af5660b"
      unitRef="usd">305514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMi01LTEtMS0zMzQ4NA_e5056927-fd4f-46e8-bc9c-ee5decba5ae7"
      unitRef="usd">260886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMy0xLTEtMS0zMzQ4NA_218ce292-5c25-4c01-98e7-dfd0001bacc7"
      unitRef="usd">38599000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMy0zLTEtMS0zMzQ4NA_9c1e6f49-801a-4330-a9c6-09e872991a16"
      unitRef="usd">34466000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMy01LTEtMS0zMzQ4NA_1979fa72-c314-4717-9383-7e661786e3e8"
      unitRef="usd">31044000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNC0xLTEtMS0zMzQ4NA_f94566a7-a14a-4f48-80d9-d01410f916fd"
      unitRef="usd">290634000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNC0zLTEtMS0zMzQ4NA_4fdcc392-d1b5-4a66-8815-f6a2e7fe69f1"
      unitRef="usd">271048000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNC01LTEtMS0zMzQ4NA_893c9afd-e2cd-4659-a9f5-fec4cc5259ab"
      unitRef="usd">229842000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNi0xLTEtMS0zMzQ4NA_d7004e9b-debc-4c28-b43a-7a876fcec3dd"
      unitRef="usd">276677000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNi0zLTEtMS0zMzQ4NA_45c6dd63-f64a-49a0-9259-cc88b05c7aea"
      unitRef="usd">272049000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNi01LTEtMS0zMzQ4NA_7dfd3c3d-2dd0-4e51-a526-c1df284e4349"
      unitRef="usd">308443000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNy0xLTEtMS0zMzQ4NA_6a868185-1146-4bac-ac5a-4c7a27395e9a"
      unitRef="usd">213041000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNy0zLTEtMS0zMzQ4NA_334926a4-ac4a-41fb-8910-cce002eacf9c"
      unitRef="usd">192710000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfNy01LTEtMS0zMzQ4NA_4303b871-759a-4917-a04a-af8848230cd3"
      unitRef="usd">156407000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOC0xLTEtMS0zMzQ4NA_30fd46cf-6fdd-4832-8556-7d39891ba8d6"
      unitRef="usd">-1078000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOC0zLTEtMS0zMzQ4NA_bc137bfe-3852-442e-a796-76fa066026d2"
      unitRef="usd">-6514000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOC01LTEtMS0zMzQ4NA_424ceb7d-5ad1-4fc2-b9a6-9e848024d38c"
      unitRef="usd">-3144000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0xLTEtMS0zNjY0NQ_cef65ca6-a38f-4470-9a52-1f6fe1c56856"
      unitRef="usd">6616000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0zLTEtMS0zNjY1Mw_ac273bbb-fbcf-43da-9877-81b6db49d637"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS01LTEtMS0zNjY2Mg_27b6a77e-02a1-471c-ab0c-77d6dac1b939"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0xLTEtMS0zMzQ4NA_610bd037-06c5-4cd6-b3fe-1175f900649c"
      unitRef="usd">5342000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS0zLTEtMS0zMzQ4NA_dea730ec-db15-4f15-9991-4b80dcb0c7b2"
      unitRef="usd">6209000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfOS01LTEtMS0zMzQ4NA_500248fd-7205-4eed-a61b-335117b61f6c"
      unitRef="usd">8846000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTAtMS0xLTEtMzM0ODQ_e46dc9bb-87ef-482b-93f2-8f6ce980da9f"
      unitRef="usd">502754000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTAtMy0xLTEtMzM0ODQ_a55920fb-b664-46e0-8b6e-6777c21292fa"
      unitRef="usd">477482000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTAtNS0xLTEtMzM0ODQ_0daad69d-0ac5-4b7e-af1c-898cf872d879"
      unitRef="usd">476840000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTEtMS0xLTEtMzM0ODQ_79e75ea3-e28d-44bb-9b6f-a2595ee8e5cc"
      unitRef="usd">-212120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTEtMy0xLTEtMzM0ODQ_d2a9b6c0-3335-4985-b151-629d1466c34c"
      unitRef="usd">-206434000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTEtNS0xLTEtMzM0ODQ_1ce03ebf-c30f-446c-b2ba-64a6fb1634b3"
      unitRef="usd">-246998000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTMtMS0xLTEtMzM0ODQ_2b233d0e-2a9d-4d4b-9c9a-31a230dae787"
      unitRef="usd">3024000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTMtMy0xLTEtMzM0ODQ_3d20e90a-c4c4-49d3-b1b6-7964c9e922ea"
      unitRef="usd">509000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTMtNS0xLTEtMzM0ODQ_5ae6861c-1071-4ea2-be2b-6dd9ed1f1b2f"
      unitRef="usd">3226000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTQtMS0xLTEtMzM0ODQ_2f00b82d-fefe-43cb-bcd8-0e8fc13da888"
      unitRef="usd">37119000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTQtMy0xLTEtMzM0ODQ_79265994-8f27-409a-aedb-acef456fbf17"
      unitRef="usd">32471000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTQtNS0xLTEtMzM0ODQ_1e9ec769-c231-4548-a3de-d80a8a74f32a"
      unitRef="usd">22425000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTYtMS0xLTEtMzM0ODQ_dcb04c7f-2341-4def-8d93-a176e83903f1"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTYtMy0xLTEtMzM0ODQ_5fbc45cf-590a-4232-8114-c347fe96ebfc"
      unitRef="usd">-257000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTYtNS0xLTEtMzM0ODQ_d9897e39-200a-4ac3-8b3e-317eb4f01f25"
      unitRef="usd">-7276000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTctMS0xLTEtMzM0ODQ_7bb79202-58df-44bb-b52d-258c4d684900"
      unitRef="usd">4176000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTctMy0xLTEtMzM0ODQ_47188334-e061-412f-9895-0bd349d87e37"
      unitRef="usd">-2901000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTctNS0xLTEtMzM0ODQ_66901e17-8505-4c84-bb6c-2eb7d5c2f208"
      unitRef="usd">-781000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTgtMS0xLTEtMzM0ODQ_4ae082ef-9559-43c9-bc8b-0d998d17393d"
      unitRef="usd">-242039000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTgtMy0xLTEtMzM0ODQ_1303c8ff-79bb-42d1-8b55-8377082da9df"
      unitRef="usd">-241554000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTgtNS0xLTEtMzM0ODQ_8e9297dc-21cb-4dd5-b31e-c6064259d518"
      unitRef="usd">-274254000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTktMS0xLTEtMzM0ODQ_460e76ab-d11f-46c1-891e-7dbecf171e0e"
      unitRef="usd">-5471000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTktMy0xLTEtMzM0ODQ_de812741-1d6b-449d-8aee-20535b447b90"
      unitRef="usd">8906000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMTktNS0xLTEtMzM0ODQ_58625f1f-ab9b-4b46-94ea-8a43ebb592fc"
      unitRef="usd">2598000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjAtMS0xLTEtMzM0ODQ_31912635-4e4b-42fe-bf54-1da7e198e03b"
      unitRef="usd">-236568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjAtMy0xLTEtMzM0ODQ_2986588f-afdf-41a5-a48f-0584aba577b5"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjAtNS0xLTEtMzM0ODQ_25165998-6a40-4506-b07c-90d9ba582d3b"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMS0xLTEtMzM0ODQ_926f3db3-5b20-480d-ba71-21e99f93648a"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMS0xLTEtMzM0ODQ_c26190ad-a13c-417f-a7a4-15a4b31a860a"
      unitRef="usdPerShare">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMy0xLTEtMzM0ODQ_48bd198e-37c1-4077-a2f1-e85924413957"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtMy0xLTEtMzM0ODQ_6e159bb5-4598-40b9-88c5-77d78f72edd4"
      unitRef="usdPerShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtNS0xLTEtMzM0ODQ_3e97f924-c2ce-4021-ae8c-8ad94f4b1a35"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjEtNS0xLTEtMzM0ODQ_8110304d-e0d5-4367-a270-d22c8cdb4642"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMS0xLTEtMzM0ODQ_1c433790-e582-4274-9d40-d8d40070ee6d"
      unitRef="shares">289057198</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMS0xLTEtMzM0ODQ_976d7ef8-0948-41f0-86fe-6b67d7276185"
      unitRef="shares">289057198</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMy0xLTEtMzM0ODQ_9200c32c-e3b5-4763-84d7-eda3e10510eb"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItMy0xLTEtMzM0ODQ_a4920a97-c93c-4f72-b5b9-1f79b627fc91"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItNS0xLTEtMzM0ODQ_886e1219-fdba-46d4-9fe2-6e66f0f50fae"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182MS9mcmFnOmNlY2M3NWUxNWU5OTQ4YmZhNzgyZjkyMWE3YmJiNzdjL3RhYmxlOjk3NTVjZGI0NzdmNzQ4MzVhMjFjMWNjZDRlYTRlZGFlL3RhYmxlcmFuZ2U6OTc1NWNkYjQ3N2Y3NDgzNWEyMWMxY2NkNGVhNGVkYWVfMjItNS0xLTEtMzM0ODQ_fd54a87e-c817-4f27-874d-4fbc4064a449"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfMi0xLTEtMS0zMzQ4NA_b137e190-00be-4ab7-a310-66cfa2d40429"
      unitRef="usd">-236568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfMi0zLTEtMS0zMzQ4NA_80a853cc-d1d3-4c33-9da3-47889c0f347d"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfMi01LTEtMS0zMzQ4NA_86b27324-3c57-42a8-870b-cb84f9893970"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNC0xLTEtMS0zMzQ4NA_73c2d101-9d91-49fb-8240-562180d03a80"
      unitRef="usd">-17240000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNC0zLTEtMS0zMzQ4NA_dd37173b-117c-42af-99be-82bd9306b734"
      unitRef="usd">-3161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNC01LTEtMS0zMzQ4NA_c3415dca-9be9-4d0a-b9a4-3e8ccc430c42"
      unitRef="usd">5627000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNS0xLTEtMS0zMzQ4NA_4ba57c58-b16c-4a65-bfd5-8a881f06894a"
      unitRef="usd">154000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNS0zLTEtMS0zMzQ4NA_44bd1485-b6d9-44b8-a129-3c27b8b03bf4"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNS01LTEtMS0zMzQ4NA_cf206f18-8aa9-4514-acec-88d64c6b09f3"
      unitRef="usd">-225000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNi0xLTEtMS0zMzQ4NA_067ea269-19c1-42ec-9fbb-772f4aa1fc5d"
      unitRef="usd">-17086000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNi0zLTEtMS0zMzQ4NA_2d92822b-183d-4ca0-9c80-008cc46b4d27"
      unitRef="usd">-3246000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNi01LTEtMS0zMzQ4NA_27f615ae-e446-4295-ae39-4a4a4f4957ae"
      unitRef="usd">5402000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNy0xLTEtMS0zMzQ4NA_c7ea9194-575d-4007-a455-f063c617b792"
      unitRef="usd">-253654000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNy0zLTEtMS0zMzQ4NA_a0412609-7975-4bbb-b86c-5f97bbca4afb"
      unitRef="usd">-253706000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182NC9mcmFnOjViMmQ4NTJlZTE4YTRjYzU5M2Q0ZGJlODUxZDZjZjg1L3RhYmxlOjY0MjY1Yjc1ODI2YjQ5NTViZjliYjA3YTI2ODQwNjc1L3RhYmxlcmFuZ2U6NjQyNjViNzU4MjZiNDk1NWJmOWJiMDdhMjY4NDA2NzVfNy01LTEtMS0zMzQ4NA_93f5de3d-4cc2-4d20-ac02-8a5ccf7c30f6"
      unitRef="usd">-271450000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i40d6b75012b24abc830ece41c6c75656_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMS0xLTEtMzM0ODQ_1808e56c-1f22-4edb-a966-74533efa7633"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i40d6b75012b24abc830ece41c6c75656_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMy0xLTEtMzM0ODQ_142e9616-9831-4061-a2ee-82d8a745c284"
      unitRef="usd">2598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib98d799a4ea240c598fa644f12ddd44d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtNS0xLTEtMzM0ODQ_a1319aad-f82d-4adf-b405-1e8d35e4fd60"
      unitRef="usd">2227225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida6ebb73d0a44583a25622bc2ff8bc70_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtNy0xLTEtMzM0ODQ_b86bc328-8688-43e6-ac8e-8b5fdfb5f594"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55cdc3ed7a544ad78b27effbad17252b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtOS0xLTEtMzM0ODQ_6e0f5293-93ce-4199-b929-a8427128235f"
      unitRef="usd">2825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i331f4737a70b494d8165d7ad00b4f89c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMTEtMS0xLTMzNDg0_b8017908-3941-4d91-9195-c45fb2c91b61"
      unitRef="usd">-1768610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTQtMTMtMS0xLTMzNDg0_6de1c21a-c459-497e-9fdc-203575acf7f9"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtMS0xLTEtMzM0ODQ_4ddd6d9a-5a41-44fa-9603-52bc2f1387f7"
      unitRef="shares">5233672</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtMy0xLTEtMzM0ODQ_4a102e53-9ea2-4b3f-9d60-e95b47ac7bd4"
      unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtNS0xLTEtMzM0ODQ_a16084cc-6d52-49cb-ae9b-43f7b99cc915"
      unitRef="usd">42230000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTUtMTMtMS0xLTMzNDg0_a9dce125-b1dc-41f1-b1f9-f8a939ee3b25"
      unitRef="usd">42282000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i996d7c3f335e442eaf4bd3c5a1ece598_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTYtMS0xLTEtMzM0ODQ_543b0de2-92fc-4133-a274-0a68c826ca07"
      unitRef="shares">1411920</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTYtNS0xLTEtMzM0ODQ_95ce1acb-d9fb-4a5b-9f25-b74e4cd7527f"
      unitRef="usd">-10028000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTYtMTMtMS0xLTMzNDg0_b6893123-85f6-4410-9b30-0911251bf6a8"
      unitRef="usd">-10028000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5b8c1f2ce9e548fd896c7a906e2e3b0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTctNS0xLTEtMzM0ODQ_2afff49e-b709-495d-a2a6-22098a321a3a"
      unitRef="usd">49151000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTctMTMtMS0xLTMzNDg0_4dfba46e-525a-420b-9bf8-5dfb54b12a98"
      unitRef="usd">49151000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if20d67fb12e4438dbfce2517356c6668_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTgtOS0xLTEtMzM0ODQ_9278d359-0899-4c38-aa9d-63a9d7b6996a"
      unitRef="usd">-225000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTgtMTMtMS0xLTMzNDg0_8e29db16-5300-46a0-aa66-dad16422a69f"
      unitRef="usd">-225000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if20d67fb12e4438dbfce2517356c6668_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTktOS0xLTEtMzM0ODQ_67467b5d-42d5-49f6-9041-45e0f48a67e0"
      unitRef="usd">5627000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMTktMTMtMS0xLTMzNDg0_eead63c6-0137-4e96-a966-3af3b61014d7"
      unitRef="usd">5627000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i61a54e11bb144d7283f688389627911d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMTEtMS0xLTMzNDg0_88fbe4d3-569e-4a0a-b8ac-2fa52001771e"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMTMtMS0xLTMzNDg0_d6f94bfc-3e06-4995-9e20-e5f89480e23c"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2920a3c79ee544bfb57550e1524b3be6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMS0xLTEtMzM0ODQ_89740f15-c626-4cd5-9339-4a86983fd2f9"
      unitRef="shares">262063461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2920a3c79ee544bfb57550e1524b3be6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMy0xLTEtMzM0ODQ_b3c208ab-938e-4503-ae2b-e023752e1967"
      unitRef="usd">2650000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8ce7db741914e24aba11ec227d80098_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtNS0xLTEtMzM0ODQ_65f834dc-f447-4b6c-82d5-176d63af72a0"
      unitRef="usd">2308578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a1c8441149f45b193c288045bfccb67_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtNy0xLTEtMzM0ODQ_aaad9d43-0807-4de2-80b3-66b547f1eb79"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5867ad5312c144e38a3ba1be62b312de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtOS0xLTEtMzM0ODQ_253d7132-33c5-4b07-a49d-0d28d25bfd1b"
      unitRef="usd">8227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15c8302234e443c5bca532c176601a9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMTEtMS0xLTMzNDg0_9a65ad47-d1d9-4052-be03-8713a142cd2e"
      unitRef="usd">-2045462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMTMtMS0xLTMzNDg0_97645ff9-0c88-446c-87da-8be9e106a1ae"
      unitRef="usd">286380000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMS0xLTEtMzM0ODQ_3e49013f-3490-48cd-8d52-db3eb3338a0a"
      unitRef="shares">1461189</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMy0xLTEtMzM0ODQ_5e4b19ad-782c-435a-a8d8-f17da2452e74"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItNS0xLTEtMzM0ODQ_a1bbb54e-838d-451b-b278-d179aaba0942"
      unitRef="usd">10213000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMTMtMS0xLTMzNDg0_d419e274-8a74-4cfc-8a27-413b99199829"
      unitRef="usd">10228000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtMS0xLTEtMzM0ODQ_505c5079-31dd-40d1-9631-62146acb5aa1"
      unitRef="shares">11296660</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtMy0xLTEtMzM0ODQ_6c94d0e7-8157-4e83-b17e-fbab892a50b7"
      unitRef="usd">112000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtNS0xLTEtMzM0ODQ_f4d2491b-144a-47b5-8a31-376a886e9c58"
      unitRef="usd">199552000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i140a0265db284ab18fc85a7c566f5e3c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtNy0xLTEtMzM0ODQ_dc71b8ea-b951-47ef-b79f-c44b5ebc2e97"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjMtMTMtMS0xLTMzNDg0_63348c4d-0674-424a-a3de-707ca1b0b1bf"
      unitRef="usd">199747000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtMS0xLTEtMzM0ODQ_7088c758-662a-4513-89f5-d907d3987cc3"
      unitRef="shares">1064135</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtNS0xLTEtMzM0ODQ_1aee02f0-7fd6-47cb-977d-9a162503c737"
      unitRef="usd">-15009000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtMTMtMS0xLTMzNDg0_5dc1f5dc-b41a-4bec-99e4-c8d4751b03a5"
      unitRef="usd">-15009000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtNS0xLTEtMzM0ODQ_4f41d2a1-aa62-4d91-8d6e-1a4d768f7fdc"
      unitRef="usd">57838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtMTMtMS0xLTMzNDg0_60d02930-32ab-48e0-a49a-9dad25ed13b2"
      unitRef="usd">57838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMS0xLTEtMzM0ODQ_75f6ff51-1bda-498d-9b31-62c849b072a7"
      unitRef="shares">2554999</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMy0xLTEtMzM0ODQ_c8e80f66-9f13-4222-b2ad-e33c4d32c950"
      unitRef="usd">26000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtNS0xLTEtMzM0ODQ_99e94879-a126-4e28-a1e1-1fe9a4b2aff5"
      unitRef="usd">31591000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i140a0265db284ab18fc85a7c566f5e3c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtNy0xLTEtMzM0ODQ_ac27b4c0-762d-4c3b-8b7a-800325d82765"
      unitRef="usd">-12387000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMTMtMS0xLTMzNDg0_85bebc9d-cfac-4fd4-a15d-bc4a366c6f02"
      unitRef="usd">19230000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMS0xLTEtMzM0ODQ_a93f0f5a-7f84-4bc7-b6e1-867b35ce2dfe"
      unitRef="shares">472356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iab9f654cd7f84de0996b086422a009f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMy0xLTEtMzM0ODQ_c4dcc2ca-c675-4a59-9154-678fdd3acbfb"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4a285a9aee3e41fb9eec7b510edb8fc2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctNS0xLTEtMzM0ODQ_359af28a-8e72-4508-a108-416cbdfe52ce"
      unitRef="usd">2656000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMTMtMS0xLTMzNDg0_305d3fa7-06c9-4a73-b6b6-79eadeb3e891"
      unitRef="usd">2661000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia67c1c4115c1453abb07a9ff877be186_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjgtOS0xLTEtMzM0ODQ_fe8fce01-95c4-42f5-bdc3-d9cd2e63df1a"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjgtMTMtMS0xLTMzNDg0_df23dc95-2098-420e-9211-afd259659d62"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia67c1c4115c1453abb07a9ff877be186_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjktOS0xLTEtMzM0ODQ_a0f0732f-709c-4ae8-bb26-78c4ed1028cf"
      unitRef="usd">-3161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjktMTMtMS0xLTMzNDg0_522afa99-6b9a-4ab1-86e4-31ef90391473"
      unitRef="usd">-3161000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="iedae25f2203048fdaca67cfcf5b407cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzAtMTEtMS0xLTMzNDg0_2451cdc6-65fc-43e9-8be7-767c6debbdee"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzAtMTMtMS0xLTMzNDg0_ea25e462-398b-44f7-b5fb-e3205e8df48d"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic8aefd971cde4f12941d682724a9a606_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMS0xLTEtMzM0ODQ_4fef31f4-283d-413a-b646-167e88b41830"
      unitRef="shares">278912800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic8aefd971cde4f12941d682724a9a606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMy0xLTEtMzM0ODQ_5e1fbc8e-b1c7-40a2-93d2-cd27ccd5fcd1"
      unitRef="usd">2808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25d57483c4a54eef8994b3bbaa7ffb31_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtNS0xLTEtMzM0ODQ_84b8b317-150f-4350-b62d-8a9ed312a2d4"
      unitRef="usd">2595419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied530d85f0df4c79aa2114bf41baf122_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtNy0xLTEtMzM0ODQ_dd079865-a417-4609-840c-44425c6b95db"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49e0d3884d4a4e348b28d2bf23c7218e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtOS0xLTEtMzM0ODQ_f30caa8a-93ff-4e68-b629-e5634ec36460"
      unitRef="usd">4981000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47380801e43942c98bd579021cd66466_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMTEtMS0xLTMzNDg0_71751343-ddee-4862-88fc-6ebbe63c1b7f"
      unitRef="usd">-2295922000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMzEtMTMtMS0xLTMzNDg0_a357c805-fc7d-4902-b49e-ed3f13c7c17e"
      unitRef="usd">307369000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMS0xLTEtMzQwNjc_88ab4706-b78d-4dbf-8876-f15da62b31ad"
      unitRef="shares">656377</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMy0xLTEtMzQwNjc_425ad5c6-9b22-4096-8b93-8131cb18f234"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtNS0xLTEtMzQwNjc_5d041d42-9b00-416f-81dd-3abff61c8231"
      unitRef="usd">4303000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjAtMTMtMS0xLTM0MDY3_124cb9f4-25c1-4b46-8fb6-75438d98be58"
      unitRef="usd">4310000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="icd9d5374305f44ffabea8f31925735e3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMS0xLTEtMzQwNjc_15478e2d-331d-4cdb-a145-ab2c09ce733b"
      unitRef="shares">1539096</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtNS0xLTEtMzQwNjc_1e6e5bfc-46bc-46a0-85e6-3eb7e3b65c88"
      unitRef="usd">-11490000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjEtMTMtMS0xLTM0MDY3_8f6279a5-93a9-4ac6-9436-8925db1bd343"
      unitRef="usd">-11490000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i67ea2bc7a7ad401187d512dc1f4eff03_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItNS0xLTEtMzQwNjc_1dceb666-ccb0-41c2-8712-08ce1d9f8b2d"
      unitRef="usd">76512000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjItMTMtMS0xLTM0MDY3_38f21f02-ddba-454f-8f3b-40b06e43f4db"
      unitRef="usd">76512000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaafcc84ae1f04e7c9f6fe592d37ff72b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtOS0xLTEtMzQwNjc_42ca1e2a-3bf5-4854-b9ab-b813c6cf2425"
      unitRef="usd">154000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjQtMTMtMS0xLTM0MDY3_6b6194e7-ae9d-4623-bc0f-7b847014b45d"
      unitRef="usd">154000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaafcc84ae1f04e7c9f6fe592d37ff72b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtOS0xLTEtMzQwNjc_f934274a-0ab6-4352-ac8c-437c3961e86c"
      unitRef="usd">-17240000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjUtMTMtMS0xLTM0MDY3_a0a87a99-dce8-4f2b-a6a1-17031a15060a"
      unitRef="usd">-17240000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="iae02215294ea4a709fe26968153b5d93_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMTEtMS0xLTM0MDY3_79606733-d649-4676-99e4-02345ee7d160"
      unitRef="usd">-236568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjYtMTMtMS0xLTM0MDY3_e7cb510d-6c77-459e-9b9a-e1ef1c4674b6"
      unitRef="usd">-236568000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic04eb74993b34416ac4dae1ade133ddc_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMS0xLTEtMzQwNjc_31c38825-59ab-4507-af38-8e0dce0dc033"
      unitRef="shares">281108273</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic04eb74993b34416ac4dae1ade133ddc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMy0xLTEtMzQwNjc_c735a63f-7ff5-4773-b6d8-2ed9fa239c4d"
      unitRef="usd">2815000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i10fab736f36145b7ad0b9d9e1984f370_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctNS0xLTEtMzQwNjc_c3f2b1a3-af6c-449d-80ed-317384f7c47a"
      unitRef="usd">2664744000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ed4526deb5b484388e6c5a3f6743677_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctNy0xLTEtMzQwNjc_6eae3d1b-3d77-4626-a326-b6474a8cc0b1"
      unitRef="usd">83000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i517924c9e42841189538479018e06f92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctOS0xLTEtMzQwNjc_6b2df804-a0ac-4545-887f-526e0c175915"
      unitRef="usd">-12105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b0d6f1aad064e62b2c5e3d60a822ed4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMTEtMS0xLTM0MDY3_71f8b86a-127a-4089-8379-7a635476ff66"
      unitRef="usd">-2532490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N182Ny9mcmFnOjRiMjAzMTkxNGVlNzRmMjNhMjNlOGM1N2U5Nzk3ZjYyL3RhYmxlOmY2YTg4NGEyZDZlZTQ5YTU4ZTRjOTk0OTM1OWU1NzA2L3RhYmxlcmFuZ2U6ZjZhODg0YTJkNmVlNDlhNThlNGM5OTQ5MzU5ZTU3MDZfMjctMTMtMS0xLTM0MDY3_f21c8f65-29d0-4628-943d-369b80ad4aaf"
      unitRef="usd">123047000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMy0xLTEtMS0zMzQ4NA_e00f706b-c68e-4c3c-a323-56afdf6833d5"
      unitRef="usd">-236568000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMy0zLTEtMS0zMzQ4NA_c673dd3a-65b8-4d8f-a9b7-e1e3f3b840a5"
      unitRef="usd">-250460000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMy01LTEtMS0zMzQ4NA_4b811d83-939b-4c79-bf11-359eb2173067"
      unitRef="usd">-276852000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNS0xLTEtMS0zMzQ4NA_7354c563-a584-4bed-b19a-e8716a3b65a4"
      unitRef="usd">2634000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNS0zLTEtMS0zMzQ4NA_5f4602cf-abe3-4571-866c-24b79fe54cf1"
      unitRef="usd">2490000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNS01LTEtMS0zMzQ4NA_0a56ecd2-7e52-49b8-830c-169b089e12a7"
      unitRef="usd">1794000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNi0xLTEtMS0zMzQ4NA_384d8404-0690-4513-86cf-ef6964ca9b9e"
      unitRef="usd">5342000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNi0zLTEtMS0zMzQ4NA_f1f33a72-e8de-44f7-9114-c3eaab8b38f2"
      unitRef="usd">6209000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNi01LTEtMS0zMzQ4NA_84d70f2b-55dc-4a74-93c9-0fcc7239cd9e"
      unitRef="usd">8846000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNy0xLTEtMS0zMzQ4NA_6de80dc0-fe93-4e3c-be7d-a3af738d5abc"
      unitRef="usd">76512000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNy0zLTEtMS0zMzQ4NA_039de454-5965-455e-be8d-841744ae5a66"
      unitRef="usd">57838000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNy01LTEtMS0zMzQ4NA_efc01d95-7148-4fc5-aad3-a6e5a3653f53"
      unitRef="usd">49151000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfOS0xLTEtMS0zMzQ4NA_01c7b696-6119-4177-9e34-9c90bf89958b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfOS0zLTEtMS0zMzQ4NA_c6159bcf-c4f8-437c-8bf1-7ecb350d1db2"
      unitRef="usd">-257000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfOS01LTEtMS0zMzQ4NA_185ea3b7-3551-4083-a7d1-00eccbf93d22"
      unitRef="usd">-7276000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTEtMS0xLTEtMzM0ODQ_3336a8cd-012f-4497-ace1-277604049b94"
      unitRef="usd">1078000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTEtMy0xLTEtMzM0ODQ_028aad59-8154-4dc5-b109-2228da6bea1d"
      unitRef="usd">6514000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTEtNS0xLTEtMzM0ODQ_7e29cf02-3c29-49e0-96e7-e9cb9b41918c"
      unitRef="usd">3144000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTItMS0xLTEtMzM0ODQ_1d13b582-8d80-44fa-8b54-c73ead0ec2c7"
      unitRef="usd">-6121000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTItMy0xLTEtMzM0ODQ_c05af45c-7b97-4789-90f8-293d1113bd76"
      unitRef="usd">-3565000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTItNS0xLTEtMzM0ODQ_169fd990-725b-4cc6-979e-8911b43fc741"
      unitRef="usd">-5471000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTMtMS0xLTEtMzM0ODQ_65491420-935b-4a44-8dd6-9b2695de6a9c"
      unitRef="usd">9000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTMtMy0xLTEtMzM0ODQ_7b0e85cb-0e26-4e4b-a376-41f0f0a33ed6"
      unitRef="usd">34000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTMtNS0xLTEtMzM0ODQ_be738486-1b0c-4fc6-974c-d1739b8e99f1"
      unitRef="usd">-155000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <fold:AssetImpairmentChargesAndOtherAssetWriteOffs
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTQtMS0xLTEtMzY3NzM_e9c50992-de88-4595-86b9-131f59afd508"
      unitRef="usd">18177000</fold:AssetImpairmentChargesAndOtherAssetWriteOffs>
    <fold:AssetImpairmentChargesAndOtherAssetWriteOffs
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTQtMy0xLTEtMzY3ODA_d3c74048-c202-475f-b33e-babd8e0f4cca"
      unitRef="usd">0</fold:AssetImpairmentChargesAndOtherAssetWriteOffs>
    <fold:AssetImpairmentChargesAndOtherAssetWriteOffs
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTQtNS0xLTEtMzY3ODc_9af3966b-ee24-4de6-8dde-0838c9cbd2bb"
      unitRef="usd">99000</fold:AssetImpairmentChargesAndOtherAssetWriteOffs>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTYtMS0xLTEtMzM0ODQ_fdba9057-ee76-4105-b71e-ddd8f6e0205d"
      unitRef="usd">17330000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTYtMy0xLTEtMzM0ODQ_8edacfff-3d73-45b0-831c-d449e9e6f3de"
      unitRef="usd">8189000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTYtNS0xLTEtMzM0ODQ_c6e318ce-e555-4a1a-a454-56bebbd5f328"
      unitRef="usd">11219000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTctMS0xLTEtMzM0ODQ_286a38a6-b234-4765-b6e9-3fee2f01fc69"
      unitRef="usd">5343000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTctMy0xLTEtMzM0ODQ_2e2d81c9-383a-4ca2-bf9a-a99d339940b0"
      unitRef="usd">7790000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTctNS0xLTEtMzM0ODQ_a4677300-a90c-4dc3-a89b-afba11ea80cd"
      unitRef="usd">4639000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTgtMS0xLTEtMzM0ODQ_bedbcf38-00cf-495f-8ade-07311c6d5788"
      unitRef="usd">6194000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTgtMy0xLTEtMzM0ODQ_d1a47d0d-4a0c-4fb1-b952-ed8df91ed7f0"
      unitRef="usd">5919000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTgtNS0xLTEtMzM0ODQ_ee943eff-5eed-4c75-aa99-fff75641494d"
      unitRef="usd">8766000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTktMS0xLTEtMzM0ODQ_36c5e6ee-8c71-40eb-9ca6-dee1d45f263d"
      unitRef="usd">-6377000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTktMy0xLTEtMzM0ODQ_a82a394a-6345-4150-8e31-20371bf568bb"
      unitRef="usd">7430000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMTktNS0xLTEtMzM0ODQ_ec6a72bd-1ebc-42c7-b386-e3e5d1572c4a"
      unitRef="usd">-10610000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjAtMS0xLTEtMzM0ODQ_0c992237-78bf-4946-8eb0-26a97f8d42cd"
      unitRef="usd">-4636000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjAtMy0xLTEtMzM0ODQ_69eb3289-8b41-4d66-893c-4b737f71d239"
      unitRef="usd">-4117000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjAtNS0xLTEtMzM0ODQ_f7e73df6-6548-483c-bdc6-58897a908963"
      unitRef="usd">3170000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjItMS0xLTEtMzM0ODQ_7d038eeb-aec0-487b-ae0b-23f7df0ffa79"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjItMy0xLTEtMzM0ODQ_837ecf90-0e37-44f6-ab49-5246fa7c1583"
      unitRef="usd">10353000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjItNS0xLTEtMzM0ODQ_2966739e-ac35-4842-b801-4b70506afca4"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjMtMS0xLTEtMzM0ODQ_24320e00-9e9a-4b32-bbf1-04cc70052e15"
      unitRef="usd">-166575000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjMtMy0xLTEtMzM0ODQ_1f47e2f8-d6b9-4fda-8f90-ead4e13535d0"
      unitRef="usd">-202491000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjMtNS0xLTEtMzM0ODQ_0289ac3c-2d89-4e92-9ca0-02f4086ac7ef"
      unitRef="usd">-233290000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjUtMS0xLTEtMzM0ODQ_940555ce-15e0-455a-a9fd-9ec00e99ec7d"
      unitRef="usd">335926000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjUtMy0xLTEtMzM0ODQ_43ee87a9-a14f-4b54-a708-0ae20ea7f3fc"
      unitRef="usd">424043000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjUtNS0xLTEtMzM0ODQ_b14d8634-c0db-4231-b34c-9e76561290f6"
      unitRef="usd">354826000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjYtMS0xLTEtMzM0ODQ_b2fa3fc2-e7f0-4d94-acd0-8b463d74acb2"
      unitRef="usd">243255000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjYtMy0xLTEtMzM0ODQ_b02f107e-53c9-4799-8d60-a92caa336d70"
      unitRef="usd">341398000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjYtNS0xLTEtMzM0ODQ_69b4cc29-f784-45e2-be7a-b209632beacb"
      unitRef="usd">365178000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMS0xLTEtMzM0ODQ_1dbdf552-2d39-4883-ab11-16de53b8dc35"
      unitRef="usd">3766000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMy0xLTEtMzM0ODQ_2cfced85-a2b9-45d0-8b25-fdd8b302f7fb"
      unitRef="usd">3884000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctNS0xLTEtMzM0ODQ_f824efdf-921c-4328-92d0-1beb146d2c9f"
      unitRef="usd">3227000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMS0xLTEtMzg0MTk_0cb51a71-e444-416f-a360-955b76da03d2"
      unitRef="usd">3411000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctMy0xLTEtMzg0NDE_f6735103-29e3-4b5d-9575-440a92175d83"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjctNS0xLTEtMzg0MzE_c479ac73-fb87-4c7a-88fd-baf79c00a7a6"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjgtMS0xLTEtMzM0ODQ_c02229ea-f8a2-465d-ae25-cb99565cb40a"
      unitRef="usd">92316000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjgtMy0xLTEtMzM0ODQ_7025cac5-5b4f-456f-ae4f-a1df8c76154f"
      unitRef="usd">78761000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMjgtNS0xLTEtMzM0ODQ_ad43c601-cf40-4853-bbab-16569bca6c43"
      unitRef="usd">-13579000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzAtMS0xLTEtMzM0ODQ_5ebbca59-3db9-4c0c-9298-3d53c47cd42b"
      unitRef="usd">0</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzAtMy0xLTEtMzM0ODQ_ede5886e-fbdb-48f7-97e4-5e796eae052a"
      unitRef="usd">199750000</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzAtNS0xLTEtMzM0ODQ_cce5470d-5c4a-4138-a8b0-f2e70ae03e7b"
      unitRef="usd">0</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzItMS0xLTEtMzM0ODQ_6975b54b-db89-4a7e-b739-1b17ec6eaa5a"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzItMy0xLTEtMzM0ODQ_43219ab6-251d-47cb-815b-7db1bba7a5be"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzItNS0xLTEtMzM0ODQ_c80ee060-8c99-43cb-bc54-2e8d1043cbbc"
      unitRef="usd">155249000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzMtMS0xLTEtMzM0ODQ_f79f9684-6c70-4d3b-828a-b821be9b54f8"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzMtMy0xLTEtMzM0ODQ_23156583-8635-46a5-bba9-1405b64fdb0b"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzMtNS0xLTEtMzM0ODQ_523f7a73-b4d8-4574-a511-b55c6903bbbb"
      unitRef="usd">385929000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzQtMS0xLTEtMzM0ODQ_511159f0-d094-4fa2-8e84-70b0b823c6fb"
      unitRef="usd">283000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzQtMy0xLTEtMzM0ODQ_e0822e97-09a0-41d7-bc9e-ff464f246ddd"
      unitRef="usd">479000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzQtNS0xLTEtMzM0ODQ_f001d9c5-572a-4495-bb14-4f4ba1855b6f"
      unitRef="usd">76000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzUtMS0xLTEtMzM0ODQ_e5a2d7d0-88d6-452e-94f2-4a452f18bd42"
      unitRef="usd">11490000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzUtMy0xLTEtMzM0ODQ_6a19fee2-8017-46e4-a91c-701fb44d3bef"
      unitRef="usd">15009000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzUtNS0xLTEtMzM0ODQ_eeb4dcee-75b7-41d3-a761-cf016ed37624"
      unitRef="usd">10028000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzctMS0xLTEtMzM0ODQ_1b23aaf1-1189-4db0-837c-c1fb0d0bde8b"
      unitRef="usd">4310000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzctMy0xLTEtMzM0ODQ_122a5185-10bb-445a-8f74-82df1dbac921"
      unitRef="usd">10228000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzctNS0xLTEtMzM0ODQ_2cec4b3c-2d83-42da-8964-68ca0388aad6"
      unitRef="usd">42282000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzgtMS0xLTEtMzM0ODQ_cce7fe6f-dc2f-4c4f-972a-b8a5209552a6"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzgtMy0xLTEtMzM0ODQ_28785d59-9afa-493f-87a9-baac816548f5"
      unitRef="usd">19230000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzgtNS0xLTEtMzM0ODQ_fabca615-84bd-4214-a662-2b0409df258d"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzktMS0xLTEtMzM0ODQ_99d9e33a-bb13-4815-89f7-9089c89974e1"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzktMy0xLTEtMzM0ODQ_4b425776-51cb-419e-9fa7-1c1013d3c8fc"
      unitRef="usd">1647000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfMzktNS0xLTEtMzM0ODQ_a1cfbb51-9486-4643-b35a-dcf1c05cfb47"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDAtMS0xLTEtMzM0ODQ_7d1cea3a-5b21-4160-ad54-ab969a7c786b"
      unitRef="usd">-7463000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDAtMy0xLTEtMzM0ODQ_58f5b452-dc28-4ec2-a1d4-4b0bb7e60cfa"
      unitRef="usd">212073000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDAtNS0xLTEtMzM0ODQ_1d52e970-8794-469b-81de-8705ccd3a374"
      unitRef="usd">262858000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDEtMS0xLTEtMzM0ODQ_88331181-9148-4b88-8cd4-73146b4249ad"
      unitRef="usd">-14619000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDEtMy0xLTEtMzM0ODQ_63670e14-9a9b-402d-abac-f2bf0dcf26bf"
      unitRef="usd">-5049000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDEtNS0xLTEtMzM0ODQ_9812ff31-39b2-4bb9-88e3-f8b11215d153"
      unitRef="usd">3830000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDItMS0xLTEtMzM0ODQ_25a5c18c-d19c-4813-9afe-41145507becb"
      unitRef="usd">-96341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDItMy0xLTEtMzM0ODQ_ac315086-7e83-478e-96fb-a4ca8b9e4ae5"
      unitRef="usd">83294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDItNS0xLTEtMzM0ODQ_9c4e9eee-23d0-43ed-893b-5f542b718e60"
      unitRef="usd">19819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDMtMS0xLTEtMzM0ODQ_4f5bae04-4f6d-4700-8ef4-22e7903b63d2"
      unitRef="usd">249456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDMtMy0xLTEtMzM0ODQ_1335230b-ba20-4e1a-987b-9f143e37a137"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDMtNS0xLTEtMzM0ODQ_410ef0cf-8337-40ff-8ac4-a6363beb84b2"
      unitRef="usd">146343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDQtMS0xLTEtMzM0ODQ_0280fe97-50e1-4a98-97b6-cbf362e57c9f"
      unitRef="usd">153115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDQtMy0xLTEtMzM0ODQ_e52522fb-4c9b-4269-9bf3-94a84dad6f04"
      unitRef="usd">249456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDQtNS0xLTEtMzM0ODQ_8d7aa7ba-c393-4edb-ac0b-8e2fd740a6bc"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDctMS0xLTEtMzM0ODQ_784ac9cb-7e82-4ae4-acd8-0f116ee12a8c"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDctMy0xLTEtMzM0ODQ_c271cef2-175e-41dd-a769-2eeb5deb5289"
      unitRef="usd">300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDctNS0xLTEtMzM0ODQ_e44064cf-fbf5-4aed-85bf-c0784736f19f"
      unitRef="usd">470000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:InterestPaidNet
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDgtMS0xLTEtMzM0ODQ_c0dad387-bd4b-4385-95f3-a7bbd14e3ddf"
      unitRef="usd">34358000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDgtMy0xLTEtMzM0ODQ_123bb58f-09a7-4a0b-802a-363e72298c19"
      unitRef="usd">30468000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNDgtNS0xLTEtMzM0ODQ_9c797797-a05f-485d-9b14-1950a40c1fc8"
      unitRef="usd">24683000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTAtMS0xLTEtMzM0ODQ_32586876-77a7-4394-94b3-ee35d3639b2a"
      unitRef="usd">1141000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTAtMy0xLTEtMzM0ODQ_3eeb1a75-bc17-4e5b-8fe0-ac034987623d"
      unitRef="usd">1448000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTAtNS0xLTEtMzM0ODQ_6cb58305-2080-4003-9dce-f19369e83f21"
      unitRef="usd">985000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTEtMS0xLTEtMzM0ODQ_1eb5baaa-c991-4805-9266-939003318e35"
      unitRef="usd">1609000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTEtMy0xLTEtMzM0ODQ_f8f0a1c8-3989-4a97-a26d-eb7dc99184fa"
      unitRef="usd">20032000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183MC9mcmFnOmQ1NzQwYzhhNDdjZjRkNjk4MjlhZDIyNzIzMjZmZTFiL3RhYmxlOjI2NGUwNDUxM2M3NTQ0ZDY4YjgzZmNiNGUxM2FiMmFjL3RhYmxlcmFuZ2U6MjY0ZTA0NTEzYzc1NDRkNjhiODNmY2I0ZTEzYWIyYWNfNTEtNS0xLTEtMzM0ODQ_92408b2d-7779-42db-9a08-531d643ee3e4"
      unitRef="usd">10371000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183Ni9mcmFnOmZjMTg2YTQ5YzBiNzRmNDVhNGE2MzAzNThjNDZmMTk3L3RleHRyZWdpb246ZmMxODZhNDljMGI3NGY0NWE0YTYzMDM1OGM0NmYxOTdfNDcxNw_9cf6a675-13d0-47c2-a133-15a4d81e639e">Description of Business&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio including the first, oral monotherapy for Fabry disease that has achieved widespread global approval and a differentiated biologic for Pompe disease, that is under review with the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA"), and the United Kingdom ("U.K.") Medicines and Healthcare products Regulatory Agency ("MHRA"). The Company is committed to discovering and developing next generation therapies in Fabry and Pompe diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cornerstone of the Company's portfolio is Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States ("U.S."), European Union ("E.U."), U.K., and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, two-component, potential best-in-class treatment for Pompe disease. In February 2019, the FDA granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In September 2021, the FDA set the Prescription Drug User Fee Act ("PDUFA") target action date of May 29, 2022 for the New Drug Application ("NDA") for miglustat and July 29, 2022 for the Biologics License Application ("BLA") for cipaglucosidase alfa. The EMA validated the Marketing Authorization Application (&#x201c;MAA&#x201d;) in the fourth quarter of 2021. In May 2022, the FDA extended the review period for the NDA for miglustat and the BLA for cipaglucosidase alfa resulting in revised PDUFA action dates of August 29, 2022 and October 29, 2022, respectively. In October 2022, the FDA deferred action on the BLA for cipaglucosidase alfa, citing the inability to complete the manufacturing facility inspection prior to the PDUFA action date.  The Company is actively engaged with the FDA and an inspection has been scheduled&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Committee for Medicinal Products for Human Use ("CHMP") of the EMA adopted a positive opinion recommending market authorization of cipaglucosidase alfa, or Pombiliti&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The regulatory submission process for AT-GAA in the U.K. was initiated in December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic. The Company's commercial operations have not been significantly impacted by the COVID-19 pandemic and the Company gradually continues to see an improvement in patient identification and Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; initiation. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, as well as maintained the operational integrity of its clinical trials, with minimum disruptions. The Company has been able to continue to meet required commercial demand for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as supply its ongoing Pompe disease clinical studies and access programs including the Early Access to Medicines Scheme ("EAMS") without interruption. In regard to the Company&#x2019;s regulatory operations, the FDA deferred action on the pending BLA for cipaglucosidase alfa, as a facility inspection was necessary, however, could not be completed by the PDUFA action date due to COVID-19 related travel restrictions. The facility inspection has subsequently been scheduled. Per FDA guidance relating to pre-approval inspections during the COVID-19 pandemic, receipt of a deferral action indicates no deficiencies have been identified and the application otherwise satisfies the requirements for approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had an accumulated deficit of $2.5 billion as of December 31, 2022 and anticipates incurring losses through the fiscal year ending December&#160;31, 2023. The Company has historically funded its operations through stock offerings, Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues, debt issuances, collaborations, and other financing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on its current operating model, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs for at least the next 12 months. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183Ni9mcmFnOmZjMTg2YTQ5YzBiNzRmNDVhNGE2MzAzNThjNDZmMTk3L3RleHRyZWdpb246ZmMxODZhNDljMGI3NGY0NWE0YTYzMDM1OGM0NmYxOTdfMzk0MA_05e8df22-caad-47ae-a574-a507072c4972"
      unitRef="usd">-2500000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MTY_a1a0e971-9869-4a25-acff-b26e6426ee7b">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact the COVID-19 pandemic had on its operations and financial results as of December 31, 2022 and through the issuance of these financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive (loss) gain in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company's accounts receivable at December 31, 2022 have arisen from product sales primarily in Europe, the U.S., and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of December 31, 2022, the Company's allowance for doubtful accounts was $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb"&gt;three&lt;/span&gt; to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist primarily of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; sales for the years ended December 31, 2022, 2021 and 2020 were $329.0 million, $305.5 million and $260.9 million, respectively. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2022, one customer accounted for 27% of net product sales and 14% of accounts receivable from product sales. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participant's assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Income and Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s tax returns are subject to examination by U.S. Federal, state, and foreign taxing jurisdictions. The impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more likely than not to be sustained. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not to be sustained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive (Loss) Gain&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive (loss) gain include unrealized gains and losses on available-for-sale securities and (loss) gain on foreign currency transactions and are included in the Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the Company had one equity-based employee compensation plan, which is described more fully in "&#x2014;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested restricted stock units, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same. See "&#x2014;&#160;Note&#160;15. Basic and Diluted Net Loss per Common Share" for further discussion on net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. For contingent consideration payments in business combinations, the Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference. No indicators of impairment were noted during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDU_80548c9e-55e5-4dec-ad8c-87857d41d0e4">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S.&#160;GAAP") and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4OTQ_944bb423-9209-47f2-a5c8-296970b23390">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDA_923cc282-81aa-439e-bd25-5a0fef6fa61e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDY_4b41f8ce-26a5-4222-8ccc-fbccc4821abe">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact the COVID-19 pandemic had on its operations and financial results as of December 31, 2022 and through the issuance of these financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4Nzc_3a1effd3-8392-45d8-9b3b-9e700f2943d0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within other comprehensive (loss) gain in the Company's Consolidated Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</fold:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MTE_ac461f28-3f57-4c04-a3da-2dc7aa9d49fe">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;. The Company's accounts receivable at December 31, 2022 have arisen from product sales primarily in Europe, the U.S., and Japan. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDQyMA_2c6dbe55-561f-47cf-ab01-998142567a26"
      unitRef="usd">200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDc_6fae1b80-25f0-464f-b35c-ea591cabd3c3">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated over the estimated useful lives of the respective assets, which range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyMw_116c61d6-7699-442e-a625-eecf0a2ea0bb"&gt;three&lt;/span&gt; to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements, and additions are capitalized in accordance with Company policy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If indications of impairment exist, projected future undiscounted cash flows associated with the asset or asset group are compared to the carrying value of the asset to determine whether the asset or asset group's value is recoverable. If impairment is determined, the Company writes down the asset to its estimated fair value and records an impairment loss equal to the excess of the carrying value of the long-lived asset over its estimated fair value in the period at which such a determination is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0f3176f304064948be4451df697aa412_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNDYyOQ_a38b4620-37b2-421f-b795-abbcb7bd8dbf">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDg_582b966a-032d-4144-a157-ff5ac18cf219">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product sales consist primarily of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; sales for the years ended December 31, 2022, 2021 and 2020 were $329.0 million, $305.5 million and $260.9 million, respectively. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program. Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies, with the ultimate payor often a government authority. In 2022, one customer accounted for 27% of net product sales and 14% of accounts receivable from product sales. In 2021, one customer accounted for 24% of net product sales and 14% of accounts receivable from product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a136c7711d044a09a19e03c25fe39dd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTA0NDUzNjA0OTQwNjA_8db90989-01b3-4a7e-aad6-e002c329a437"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5074d507bd1e4529aa53cc1be1409baf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTA0NDUzNjA0OTQwODA_19ae113b-efd0-4b2c-8e3d-58ccd7ae89b2"
      unitRef="usd">305500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i508c824fb1844b0ca8a046ab3f8321c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTA0NDUzNjA0OTQwOTc_eee4295c-5559-4908-aa52-feee870645a5"
      unitRef="usd">260900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i71deb9575b294adb91ff789973f65bbf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTYzNw_8465cc9c-74ee-4118-b908-411d4f836962"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia738717e166c41c2a4392a1967ef4025_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTY2NQ_5187fb81-7d99-4197-b1bc-7cab9bc6c6d5"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id2c3883ff4d64b8e9595b3e84e9edfe4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTc0NQ_074b2945-7062-4a20-ac35-17f22838bfe1"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i102ca847ccf94fb3ac9a236e09d1fd19_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfNTc3Mw_afa4a7dc-b593-40ba-868b-cdccc2e247af"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzM_2d8264e3-42ef-484e-bc79-d76e92a5a69a">The following table summarizes the Company's net product sales disaggregated by geographic area:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16b7fa862c79461ba0d440ef1d4f8431_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMi0yLTEtMS0zMzQ4NA_164f6477-61ee-4a27-bf4b-42b20bb7aef7"
      unitRef="usd">115946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3be0f0c66b2b4c8cbdda482aa8ee8d15_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMi00LTEtMS0zMzQ4NA_c94dbcd6-9dff-4f58-9e5a-b657c355900e"
      unitRef="usd">95387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc1cdb41092f4d06b127a3529fd12fa3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMi02LTEtMS0zMzQ4NA_6c974f5e-11c2-4475-a623-288e29ec4632"
      unitRef="usd">80046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4df5e946794844e891a2510cf44b7066_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMy0yLTEtMS0zMzQ4NA_f91089e5-fcc9-41f5-9052-91a1757dfbb2"
      unitRef="usd">213287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8a70346b0774591a4bd99dd9b48cdb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMy00LTEtMS0zMzQ4NA_cc1429d2-9e5d-409d-9e31-a90b51145c7d"
      unitRef="usd">210127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e1d53e258e9423497806e3919e31742_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfMy02LTEtMS0zMzQ4NA_82f1337d-1d30-4eca-b01b-237240b737ea"
      unitRef="usd">180840000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfNC0yLTEtMS0zMzQ4NA_d29fb04a-308a-4dab-b5c8-5975a97847c2"
      unitRef="usd">329233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfNC00LTEtMS0zMzQ4NA_a4ac15e5-16ee-41e4-b1f4-fadcdd066d0a"
      unitRef="usd">305514000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RhYmxlOmQ0MGUwNWY4NTRjNTRlOTk5NmVjODM3ZGZiYzYyMjM4L3RhYmxlcmFuZ2U6ZDQwZTA1Zjg1NGM1NGU5OTk2ZWM4MzdkZmJjNjIyMzhfNC02LTEtMS0zMzQ4NA_18eb0690-5c51-43d1-b7c8-f33f7b4175ba"
      unitRef="usd">260886000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDk_66df39ec-47f3-41a1-aee2-9168ec855e5b">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4ODE_e97da5f7-b144-4270-a144-cb42ce9335a5">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records certain asset and liability balances under the fair value measurements as defined by the Financial Accounting Standard Board ("FASB") guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels&#160;1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participant's assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level&#160;3 of the hierarchy).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level&#160;2 inputs are inputs other than quoted prices included in Level&#160;1 that are observable for the asset or liability, either directly or indirectly. Level&#160;2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level&#160;3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4ODg_08840c60-7c3d-45d0-856e-fd836e785552">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company may be involved in various claims and legal proceedings. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals will be based on the Company's best estimates based on available information. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation or settlement of claims, the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in material adverse adjustments to the Company's operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4ODQ_39228f7a-b642-4ea1-87f0-03a7ea07e21a">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expense consist primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees, and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <fold:InterestIncomeAndInterestExpensePolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4OTc_492a0587-d916-4202-8c3d-fade4d65a2c0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Income and Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income consists of interest earned on the Company's cash, cash equivalents, and marketable securities. Interest expense consists of interest incurred on debt and finance leases.&lt;/span&gt;&lt;/div&gt;</fold:InterestIncomeAndInterestExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDI_9b418db7-635e-417f-9059-71fc7e14c06a">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s tax returns are subject to examination by U.S. Federal, state, and foreign taxing jurisdictions. The impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more likely than not to be sustained. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not to be sustained.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <fold:OtherComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzQ_b950d34b-688f-48b1-9a8a-493eb28c5cf1">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive (Loss) Gain&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive (loss) gain include unrealized gains and losses on available-for-sale securities and (loss) gain on foreign currency transactions and are included in the Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/div&gt;</fold:OtherComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4Njg_6d1b69d8-4e7b-4882-be18-9f1dc726763c">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</us-gaap:LesseeLeasesPolicyTextBlock>
    <fold:NonqualifiedCashDeferralPlansPolicyPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzE_57dcd490-480e-4660-b499-3208a82636ea">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Cash Deferral Plan (the "Deferral Plan"), provides certain key employees and members of the Board of Directors as selected by the Compensation Committee of the Board of Directors of the Company (the "Compensation Committee"), with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</fold:NonqualifiedCashDeferralPlansPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NjA_a96b3cf7-603e-4fef-9aa8-d01dacfde60d">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the Company had one equity-based employee compensation plan, which is described more fully in "&#x2014;&#160;Note&#160;8. Stockholders' Equity." The Company applies the fair value method of measuring equity-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <fold:ShareBasedCompensationNumberOfPlans
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTU3MjQ_d869993c-5f14-4851-b2a3-725de9f78101"
      unitRef="plan">1</fold:ShareBasedCompensationNumberOfPlans>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NTE_5921672f-2e3f-48de-94b4-85a4bac61dc9">Loss per Common ShareThe Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options, unvested restricted stock units, and certain warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDM_3da62adf-dcb0-44e7-b70e-17b3dcc61fd3">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently operates in one business segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines, and thus there is one reporting unit.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTY3NTU_29df5999-b563-421e-8e45-d61183c2b3ec"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportingUnits
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMTczNzQ_e6bb9daa-6657-4541-ba5e-dcb617145d74"
      unitRef="unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MDQ_5cbbf921-c565-4eaf-b250-a4fc44cab807">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assigns fair value to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date from acquired businesses. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development ("IPR&amp;amp;D"). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NTY_af436921-d690-48d9-bd4f-5fe876e749d6">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable. This does not apply in circumstances when the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. For contingent consideration payments in business combinations, the Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. The short term and long term portions of the contingent consideration payable is shown on the Company's Consolidated Balance Sheets. The fair value of the contingent consideration payable will be determined each period end and the resulting change will be recorded on the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</fold:ContingentAcquisitionConsiderationPayablePolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE5MTU_8e067c21-2c87-4875-91e4-986dcdab1735">Intangible Assets and GoodwillThe Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased IPR&amp;amp;D is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. The Company first assesses the qualitative factors to determine if a quantitative test is necessary.  If required, or if the Company elects to bypass the qualitative assessment, a quantitative goodwill or IPR&amp;amp;D impairment test is conducted. If it is determined the full carrying amount of IPR&amp;amp;D is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. If it is determined the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value, an impairment loss is recorded for the difference.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N183OS9mcmFnOjdmYzRjNzgyM2NkYjQ3MDg4MDhlNDkxMWY3YTBmNjczL3RleHRyZWdpb246N2ZjNGM3ODIzY2RiNDcwODgwOGU0OTExZjdhMGY2NzNfMjE4NzI_89cf95c3-a3b3-4700-8a88-2efc283b53c7">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTQzMQ_512a0243-e83d-47c6-9cdb-2f788e5f9c16">Goodwill and Intangible Assets&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, in connection with the acquisitions, the Company had goodwill of $197.8 million and IPR&amp;amp;D of $23.0 million, which are reported at fair value on the Company's Consolidated Balance Sheets. Intangible assets related to IPR&amp;amp;D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D assets below their respective carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and intangible assets are assessed annually for impairment on October&#160;1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. A goodwill impairment loss, if any, is measured as the amount by which the Company's single reporting unit's carrying value, including goodwill, exceeds its fair value. An IPR&amp;amp;D impairment loss, if any, is measured as the amount by which the carrying amount of the asset exceeds its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in IPR&amp;amp;D for the years ended December 31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in Goodwill for the years ended December 31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTE0_b7dc4d37-a1b3-4e3c-a72e-e8442e866a84"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTMw_f4102ea9-c5ad-4318-8f72-b168e2f8917f"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTQzMg_f254d357-1468-4b7c-88e2-fd33b642647e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in IPR&amp;amp;D for the years ended December 31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfMS0yLTEtMS0zMzQ4NA_00baf766-3dd1-4802-b810-6188da54933d"
      unitRef="usd">23000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfMi0yLTEtMS0zMzQ4NA_541c84c8-3838-4902-800a-7d39b6e8630d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfMy0yLTEtMS0zMzQ4NA_784ad65c-f44a-4bc7-bc0c-6d65d1482222"
      unitRef="usd">23000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfNC0yLTEtMS0zMzQ4NA_10b6b2de-ac81-470c-8fdc-1a92afd4d42c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU5Mzk3MWIyYmFkNTQ0NjliMWNjMjJjNzZhNzZhNTRlL3RhYmxlcmFuZ2U6NTkzOTcxYjJiYWQ1NDQ2OWIxY2MyMmM3NmE3NmE1NGVfNS0yLTEtMS0zMzQ4NA_436a999f-76b5-465f-b8de-cb89c9d3fff4"
      unitRef="usd">23000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RleHRyZWdpb246ZTNkNjIwOTA0MzhiNDViN2IzMWE0MTljNWM3MDFlNDJfMTQyOA_ef4ecb82-c1e5-4dd3-a0f5-8fc340153da4">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the changes in Goodwill for the years ended December 31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfMS0yLTEtMS0zMzQ4NA_2c1e1ba7-07a5-4bd5-8ff1-1169afb8925d"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfMi0yLTEtMS0zMzQ4NA_c5b1cc78-018a-4d39-a69c-1be2b252a0cb"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfMy0yLTEtMS0zMzQ4NA_cee8a900-4ae8-423a-b2de-c410b2c05510"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfNC0yLTEtMS0zMzQ4NA_46ba3e09-34a7-46e1-bc37-3f4296948fb3"
      unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184Mi9mcmFnOmUzZDYyMDkwNDM4YjQ1YjdiMzFhNDE5YzVjNzAxZTQyL3RhYmxlOjU0MzNmZDUwZTU4ZTQ0MWRhYTc5NTkzMWQyMmI5M2Q3L3RhYmxlcmFuZ2U6NTQzM2ZkNTBlNThlNDQxZGFhNzk1OTMxZDIyYjkzZDdfNS0yLTEtMS0zMzQ4NA_f01bc3e0-3af6-494c-8581-3e7a3d92ad91"
      unitRef="usd">197800000</us-gaap:Goodwill>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjgwMg_acbc120e-5d37-4da6-9728-6e54fb844513">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company held $148.8 million in cash and cash equivalents and $144.8 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within other comprehensive (loss) gain in the Consolidated Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#x2019;s fair value is determined to be less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both the years ended December 31, 2022 and 2021, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no marketable securities in an unrealized loss position as of December 31, 2022. Unrealized loss positions in the marketable securities as of December 31, 2021 reflect temporary impairments and were not a result of credit loss. Additionally, as these positions were in a loss position for less than twelve months and the Company did not intend to sell these securities before recovery, the losses were recognized in other comprehensive (loss) gain. The fair value of these marketable securities in unrealized loss positions was $173.4 million as of December 31, 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTAy_5a18b3c9-c56f-4e98-88df-43d401335d57"
      unitRef="usd">148800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTM4_a2cec948-8233-4a1a-a99f-93b6f1ca868c"
      unitRef="usd">144800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjgwNA_e6e01c6c-5ed7-4084-9491-717b0d418cb0">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMi0yLTEtMS0zMzQ4NA_ba885f46-cd31-438b-b9eb-d780326213a4"
      unitRef="usd">148813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMi04LTEtMS0zMzQ4NA_0f5553fa-a092-49f6-ba12-69fd273a72a0"
      unitRef="usd">148813000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy0yLTEtMS0zMzQ4NA_f5d554d0-59a5-4039-bdc4-8399ceaf4307"
      unitRef="usd">144299000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy00LTEtMS0zMzQ4NA_f6531c09-60a2-4630-93f1-8e75ce016553"
      unitRef="usd">82000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy02LTEtMS0zMzQ4NA_c8be3704-02d6-433b-9bf6-5b8614fcee81"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMy04LTEtMS0zMzQ4NA_02a84e92-380c-4810-96ad-ae9134adcc14"
      unitRef="usd">144381000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi0yLTEtMS0zMzQ4NA_bdd86b76-47ea-4543-b09f-7cbc20efeb26"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi00LTEtMS0zMzQ4NA_0ecba3c2-0481-4767-b4c1-2985ca68bf44"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi02LTEtMS0zMzQ4NA_24b45492-41b2-4cf9-b5ec-22e0049974b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNi04LTEtMS0zMzQ4NA_ab0ca5e7-ed8a-472b-a9b2-4efa035a627e"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy0yLTEtMS0zMzQ4NA_f6564130-8cf1-41eb-9e1d-56da9b17cbbf"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy00LTEtMS0zMzQ4NA_5f17e001-390d-49f4-a731-a1c876def2d2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy02LTEtMS0zMzQ4NA_4faea1a9-d450-4026-848e-8c3c7df51003"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e6e594e389f4523b7a7c9bab80844f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfNy04LTEtMS0zMzQ4NA_8a171c67-7879-4289-8230-eeb139053c60"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC0yLTEtMS0zMzQ4NA_d9b69b02-3012-4e84-8cce-a7381f3957be"
      unitRef="usd">293513000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC00LTEtMS0zMzQ4NA_ff36e3fc-1c4f-4914-af7e-b898dbe9ef52"
      unitRef="usd">82000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC02LTEtMS0zMzQ4NA_3745bbfc-ff1f-4ecf-9842-d370397dfdd2"
      unitRef="usd">0</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOC04LTEtMS0zMzQ4NA_736fe663-2f94-48ec-9979-feec0b0b18c9"
      unitRef="usd">293595000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOS0yLTEtMS0zMzQ4NA_07a4dfce-38a4-44d5-86ee-ad57a11177b3"
      unitRef="usd">148813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfOS04LTEtMS0zMzQ4NA_bbf084e9-e14d-4fda-88a6-24692a691afb"
      unitRef="usd">148813000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtMi0xLTEtMzM0ODQ_402f5b95-e91e-482a-9df4-f77f02d71627"
      unitRef="usd">144700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtNC0xLTEtMzM0ODQ_367acb73-60f5-4cd3-b18f-d5be4f020151"
      unitRef="usd">82000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtNi0xLTEtMzM0ODQ_68892815-2b4e-47a6-946d-69597f3921cf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTAtOC0xLTEtMzM0ODQ_5baeb24a-c59c-49ab-84e6-a2127d8f9ca8"
      unitRef="usd">144782000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtMi0xLTEtMzM0ODQ_c1bd9732-63e9-42a5-bddf-349f4a06d26f"
      unitRef="usd">293513000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtNC0xLTEtMzM0ODQ_491207f8-4410-4d20-8add-8bdeaa8b122d"
      unitRef="usd">82000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtNi0xLTEtMzM0ODQ_c8bc940a-b0ba-49c2-a333-a647bfd88e95"
      unitRef="usd">0</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOmYwOGQ0YzUxODY0YjRhOWM4NTM0ZGM4N2ZiNjdlOGNlL3RhYmxlcmFuZ2U6ZjA4ZDRjNTE4NjRiNGE5Yzg1MzRkYzg3ZmI2N2U4Y2VfMTEtOC0xLTEtMzM0ODQ_c29b73a2-044b-4776-b1d7-e3b9b57fd3c3"
      unitRef="usd">293595000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMi0yLTEtMS0zMzQ4NA_080a41f4-3f8f-46fe-b71f-3c3f556115e7"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMi04LTEtMS0zMzQ4NA_efa30b1c-bce8-4b7f-99ee-42773e8ae215"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy0yLTEtMS0zMzQ4NA_23fc2f98-fb84-42f0-a1ad-59396019b7f0"
      unitRef="usd">174578000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy00LTEtMS0zMzQ4NA_7145bd14-108e-4e87-9a8b-4dda9433caec"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy02LTEtMS0zMzQ4NA_9bddf3a6-3233-49c1-bfa4-00732ae6a400"
      unitRef="usd">54000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMy04LTEtMS0zMzQ4NA_0174099b-2bbe-4107-86e3-071ef9ea4798"
      unitRef="usd">174531000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC0yLTEtMS0zMzQ4NA_d79daaf2-6547-47e4-9273-8cbeba9557a9"
      unitRef="usd">32322000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC00LTEtMS0zMzQ4NA_ba5607f6-5dd8-4c3d-9695-e78e793eae83"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC02LTEtMS0zMzQ4NA_8e00990d-0484-4a03-bacc-c8f3abdea82f"
      unitRef="usd">11000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i877c2edcab8a4345bf7101d61ccf2c15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNC04LTEtMS0zMzQ4NA_24c43180-875c-4eba-8c19-80e3e58a3bc2"
      unitRef="usd">32311000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS0yLTEtMS0zMzQ4NA_69b31100-cddf-4a7c-b639-54448783c010"
      unitRef="usd">30070000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS00LTEtMS0zMzQ4NA_114c9057-50fb-4e6b-831f-0a6d2f3b42b5"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS02LTEtMS0zMzQ4NA_7b5d7df2-a62d-4312-a68a-cb8e94e743f2"
      unitRef="usd">14000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNS04LTEtMS0zMzQ4NA_d1429964-d6e3-4e81-9e99-a8e4e0855981"
      unitRef="usd">30056000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi0yLTEtMS0zMzQ4NA_f12882e3-859f-4a1b-9a48-e214d871d623"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi00LTEtMS0zMzQ4NA_e1c14384-f1e9-4d75-b306-1a4e6b25c6b3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi02LTEtMS0zMzQ4NA_a61c3c50-9e91-41b1-9a16-a6ca12e62ba4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNi04LTEtMS0zMzQ4NA_42f6de71-4803-417e-b2ab-7ccdec0d41b3"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy0yLTEtMS0zMzQ4NA_30935db2-9077-4242-bcda-d203ad3f8723"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy00LTEtMS0zMzQ4NA_4a462b51-93f4-4707-8de6-35625f476087"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy02LTEtMS0zMzQ4NA_954013cf-e1b2-4662-9118-3f3b055a22a7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if837fc4ce0e8435692a6f567914b6ed3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfNy04LTEtMS0zMzQ4NA_0bf67f96-2e9f-4e9a-9cd7-e36b1774bbe5"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS0yLTEtMS0zMzQ4NA_ec5679fa-82b8-4f6b-b6d7-8897b486763a"
      unitRef="usd">482568000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS00LTEtMS0zMzQ4NA_4227cc65-e06d-4550-afc2-0210ae08fc58"
      unitRef="usd">7000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS02LTEtMS0zMzQ4NA_c42e7c5a-ce0b-4667-92d0-2f49e7760933"
      unitRef="usd">79000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfOS04LTEtMS0zMzQ4NA_c97adb51-bd3b-46bb-a87f-809760ea01fd"
      unitRef="usd">482496000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTAtMi0xLTEtMzM0ODQ_edb74a2e-5b75-4f7a-b28b-0aa412eeeac4"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTAtOC0xLTEtMzM0ODQ_6f680846-60ea-4e3b-b98f-08e5d140d637"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtMi0xLTEtMzM0ODQ_7f225400-879c-4af1-ad4a-148f7ced1160"
      unitRef="usd">237371000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtNC0xLTEtMzM0ODQ_033da3f1-7961-492c-afea-c852517cea3e"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtNi0xLTEtMzM0ODQ_3e458125-2797-4bb4-9b19-d271db040846"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTEtOC0xLTEtMzM0ODQ_e0bd0ab5-fedf-4fd1-b952-5105da055ce0"
      unitRef="usd">237299000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItMi0xLTEtMzM0ODQ_630459d1-a300-495d-8705-53d8e8a06bad"
      unitRef="usd">482568000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItNC0xLTEtMzM0ODQ_2f96083c-1d5a-456a-91dc-5b2eb85019ce"
      unitRef="usd">7000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItNi0xLTEtMzM0ODQ_b9b9c812-6c69-4062-8dd8-22ea301adea8"
      unitRef="usd">79000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjA2MGVhNDNjYWM0MTQ3ODhiOGYxN2JjMDNmYjE2MWMzL3RhYmxlcmFuZ2U6MDYwZWE0M2NhYzQxNDc4OGI4ZjE3YmMwM2ZiMTYxYzNfMTItOC0xLTEtMzM0ODQ_3d168964-511a-4a42-90b3-f0c6652171f4"
      unitRef="usd">482496000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTkwMw_9c9f2584-01fb-4da6-abec-d109c043792e"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMTkwMw_f5965a99-eb9c-4e20-b720-d0c369d5de43"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfODI0NjMzNzIxMTU0Nw_f57d9932-4598-45e4-89fa-2623ee6733ba"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjUyMw_7b2abb59-8c1c-4c4f-a141-52b81ed28216"
      unitRef="usd">173400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RleHRyZWdpb246MzczYzhjNGRhYmY3NDFmODk1YWMwODc5MTM4MjEwMjBfMjc5OQ_79be4a11-a473-4fa0-b550-982f1431f6c4">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMS0yLTEtMS0zMzQ4NA_1d087aea-111b-4aa2-a3b9-ca98eb8e81c8"
      unitRef="usd">148813000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMS00LTEtMS0zMzQ4NA_91147616-f958-491f-a23a-155a8f801287"
      unitRef="usd">245197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMS02LTEtMS0zMzQ4NA_d7da6425-72b5-4b39-8e30-1ebeb95b93d9"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMi0yLTEtMS0zMzQ4NA_eb52abc9-d268-4621-9fa9-b998e6bad383"
      unitRef="usd">4302000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMi00LTEtMS0zMzQ4NA_b70de7e0-0952-4f3a-80b2-43c7310974ae"
      unitRef="usd">4259000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMi02LTEtMS0zMzQ4NA_287ab650-39e8-41f0-9dec-b3728d008a5a"
      unitRef="usd">2922000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMy0yLTEtMS0zMzQ4NA_100cd97d-f2f3-4c94-a523-f7e5247a9934"
      unitRef="usd">153115000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMy00LTEtMS0zMzQ4NA_226ccc89-52e8-4eec-a7c2-db63c9082852"
      unitRef="usd">249456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184NS9mcmFnOjM3M2M4YzRkYWJmNzQxZjg5NWFjMDg3OTEzODIxMDIwL3RhYmxlOjBhZWM1NDc2NWRkNjRhY2Q4YjRlYzc0MTcxZTUwMTZmL3RhYmxlcmFuZ2U6MGFlYzU0NzY1ZGQ2NGFjZDhiNGVjNzQxNzFlNTAxNmZfMy02LTEtMS0zMzQ4NA_c0158911-244c-4d5a-b61b-ed154dcdc7cd"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjg4_4c0a26fc-f27f-4765-a3e7-71ab793352ab">Inventories&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of raw materials, work in process, and finished goods related to the manufacture of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table summarizes the components of inventories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reserve for inventory was $0.4 million and $1.1 million as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjkx_7785ea22-60d9-4aa7-8797-d08a067434ee">The following table summarizes the components of inventories: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMS0yLTEtMS0zMzQ4NA_3681aa51-aae3-465c-baba-1005a6dab95c"
      unitRef="usd">10054000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMS00LTEtMS0zMzQ4NA_dae47dc3-fd9d-4edf-b619-350ba33f57cf"
      unitRef="usd">12289000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMi0yLTEtMS0zMzQ4NA_6947e993-7c64-400d-a4eb-b011ff32d441"
      unitRef="usd">9615000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMi00LTEtMS0zMzQ4NA_c05bfa11-9865-47ee-83f5-9d4e94f46b8c"
      unitRef="usd">10699000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMy0yLTEtMS0zMzQ4NA_fe4db831-c5c1-4fb7-9ff8-e2e8910c35df"
      unitRef="usd">4147000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfMy00LTEtMS0zMzQ4NA_b748f66b-764d-4668-9fac-8ea12fdb2e36"
      unitRef="usd">3830000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfNC0yLTEtMS0zMzQ4NA_1cc8a515-7385-4f09-8ebe-307388635a68"
      unitRef="usd">23816000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RhYmxlOmZiY2I3NmYyNzNkYzRjYjg4ZDkyM2EyOTQ2MTYxMmZjL3RhYmxlcmFuZ2U6ZmJjYjc2ZjI3M2RjNGNiODhkOTIzYTI5NDYxNjEyZmNfNC00LTEtMS0zMzQ4NA_3595bea2-f902-433e-b9e1-328ac7cea0c8"
      unitRef="usd">26818000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjQ4_93872883-163a-4f11-913e-23c70d2bd85c"
      unitRef="usd">400000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N184OC9mcmFnOmJhYmE2MzA1NzBjODQxNzhhM2NkODAyZjlhZmJhZDBkL3RleHRyZWdpb246YmFiYTYzMDU3MGM4NDE3OGEzY2Q4MDJmOWFmYmFkMGRfMjU1_7907f932-9699-4887-b159-2f0ef0a3c482"
      unitRef="usd">1100000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTYy_08480277-55d8-46da-bb8e-286d72036188">Property and Equipment&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $4.8 million and $5.7 million for the years ended December 31, 2022 and 2021, respectively. Additionally, during the year ended December 31, 2022, in connection with the strategic prioritization of its gene therapy portfolio, the Company performed an assessment of its fixed assets. As a result, the Company recognized an impairment charge of $6.6&#160;million&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTYz_88a06ff5-b10a-4f59-964d-8cd9675bc9c1">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,882)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifd29482ac05d44c7ab8df32cee3dca44_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMi0yLTEtMS0zMzQ4NA_ccd75479-87cf-4be4-999b-c61247e293bf"
      unitRef="usd">24162000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1e615ec9f7c64a478d960eb4430d471b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMi00LTEtMS0zMzQ4NA_a5fe502a-bda9-47e1-9ef4-b4c6fcdfdae3"
      unitRef="usd">24168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i89ffd34918454b17a538f8040e16bd9b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMy0yLTEtMS0zMzQ4NA_8f2442e2-8b56-4742-b966-2a1a3c8c678f"
      unitRef="usd">16345000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i36d1abcfa0ef48a8900c4f3cd89f734f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMy00LTEtMS0zMzQ4NA_9efa2939-e25c-40a6-923d-22a21db34b44"
      unitRef="usd">16663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e219ba46f9f454e81973029cbfee478_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNC0yLTEtMS0zMzQ4NA_d32ce071-60ae-46d0-9965-fd38e1b85c13"
      unitRef="usd">4486000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3636fa399a0c4c1eba1f0545ca9be836_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNC00LTEtMS0zMzQ4NA_5d193483-4ccb-435d-bc50-c67d80157581"
      unitRef="usd">5720000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib1e9bf5a1cc64621922ffe1980b7dac7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNS0yLTEtMS0zMzQ4NA_f7af486f-10a9-4739-a3a7-507e713b090b"
      unitRef="usd">4160000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i676babb093b5444588a41929a2ea1306_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNS00LTEtMS0zMzQ4NA_79936b30-de7c-42d9-bed4-5951239c3515"
      unitRef="usd">8229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i483ff1106b53432cbdf57bb9830bf8d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNi0yLTEtMS0zMzQ4NA_6719d283-8548-4dc3-8c40-0edb9ea22be2"
      unitRef="usd">2734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i628f96c5cfa5476392fcbe4410976f8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNi00LTEtMS0zMzQ4NA_b1f7dfaa-5095-44b1-9d70-ef7989936d1d"
      unitRef="usd">3163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i04d7c1f78a2d4edfbd5dbd117237d2e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNy0yLTEtMS0zMzQ4NA_1e5c1372-8637-44ab-b56c-5544726ba2ef"
      unitRef="usd">1106000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia903203eb4da4bd3902cc71800cfbd03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfNy00LTEtMS0zMzQ4NA_4cc395d6-33eb-4916-b65f-3bf6bc8187b5"
      unitRef="usd">1174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibfe1f1cffd554a4b994d3edcc31500b4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOC0yLTEtMS0zMzQ4NA_88e5bc5f-9595-46e1-a347-c2e9f34f5b77"
      unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaf9b84e7254d4fec87bd8e31221e830a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOC00LTEtMS0zMzQ4NA_4ea2a648-b247-4d30-bc0c-06d494757760"
      unitRef="usd">71000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5ef01c16ab7e44bdb0fe14f5f6770e1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOS0yLTEtMS0zMzQ4NA_8019d712-cf29-4e98-bc1e-f8d5847caa32"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i144d3b85e0f54b78b3e35a0ab3f69126_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfOS00LTEtMS0zMzQ4NA_e31892bf-8c76-426b-bf77-f6399250314a"
      unitRef="usd">3190000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTAtMi0xLTEtMzM0ODQ_9d45a0f0-1e44-4ead-9d73-317cd0dda4e6"
      unitRef="usd">53059000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTAtNC0xLTEtMzM0ODQ_31840749-1377-45c5-83c5-644b55a49ae7"
      unitRef="usd">62378000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTEtMi0xLTEtMzM0ODQ_c835e884-3964-4975-b535-a302a659a45a"
      unitRef="usd">22281000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTEtNC0xLTEtMzM0ODQ_6fae3353-5204-4dac-974a-35f68a57d395"
      unitRef="usd">19882000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTItMi0xLTEtMzM0ODQ_72fa51f2-2966-4975-ac7e-0a6894e134d2"
      unitRef="usd">30778000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RhYmxlOmNjYzNlODIxMDNmZDRmOTk4YzY0YjBlNmZhNTA1NTA1L3RhYmxlcmFuZ2U6Y2NjM2U4MjEwM2ZkNGY5OThjNjRiMGU2ZmE1MDU1MDVfMTItNC0xLTEtMzM0ODQ_676cb334-e577-48df-bf7d-c0f5a17d4f6f"
      unitRef="usd">42496000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTA3_e82a7086-984d-43dc-ab13-072371e3563a"
      unitRef="usd">4800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTE0_e76fce7a-fee3-4ab9-b65d-9df8d040a3ce"
      unitRef="usd">5700000</us-gaap:Depreciation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185MS9mcmFnOmJiYmRhOTA1ZjFhOTQzNWI4OTU3ZWE2N2MwNmQwMWZkL3RleHRyZWdpb246YmJiZGE5MDVmMWE5NDM1Yjg5NTdlYTY3YzA2ZDAxZmRfMTA5OTUxMTYyNzgxNTU_bfaaa548-c289-4ada-a854-57270e90367a"
      unitRef="usd">6600000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RleHRyZWdpb246MjI2N2U2ZTYwN2I0NGIyYmFlZTg3MzUzZWRiMzJjMGRfMTMx_15fdcca6-d9af-452c-bfb4-0cd0c3265465">Accrued Expenses and Other Current Liabilities&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued program fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract manufacturing&#160;&amp;amp; contract research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RleHRyZWdpb246MjI2N2U2ZTYwN2I0NGIyYmFlZTg3MzUzZWRiMzJjMGRfMTMy_93dc2093-3743-4010-a609-3f13947e9c0f">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales rebates and discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued program fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued contract manufacturing&#160;&amp;amp; contract research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMi0yLTEtMS0zMzQ4NA_009e9fe5-c00f-430a-b2cc-8eaa3dbe36a6"
      unitRef="usd">25701000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMi00LTEtMS0zMzQ4NA_87f51064-2884-46ab-a752-0738375da10c"
      unitRef="usd">24258000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fold:AccruedSalesRebatesAndChargebacksCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMy0yLTEtMS0zMzQ4NA_d4a3df67-2c83-4681-bbec-f08b766a90f5"
      unitRef="usd">21886000</fold:AccruedSalesRebatesAndChargebacksCurrent>
    <fold:AccruedSalesRebatesAndChargebacksCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMy00LTEtMS0zMzQ4NA_1b77f40d-8a71-4d4b-becd-6a9e0aa41479"
      unitRef="usd">15989000</fold:AccruedSalesRebatesAndChargebacksCurrent>
    <fold:AccruedProgramFees
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNC0yLTEtMS0zMzQ4NA_7b5c5467-9ae5-4ad6-9026-f8571d8afbf2"
      unitRef="usd">10515000</fold:AccruedProgramFees>
    <fold:AccruedProgramFees
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNC00LTEtMS0zMzQ4NA_ae17ba4c-8f0d-420f-a507-9e63f9e3a5b8"
      unitRef="usd">13294000</fold:AccruedProgramFees>
    <fold:AccruedContractManufacturingAndContractResearchCostsCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNS0yLTEtMS0zMzQ4NA_d9d407e3-a525-4110-8353-5193e6393b03"
      unitRef="usd">8230000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
    <fold:AccruedContractManufacturingAndContractResearchCostsCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNS00LTEtMS0zMzQ4NA_f89f4dda-a488-47f4-a508-736e83f0e6c2"
      unitRef="usd">20361000</fold:AccruedContractManufacturingAndContractResearchCostsCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNi0yLTEtMS0zMzQ4NA_3add20eb-24e4-421c-b6bf-6b751552edd3"
      unitRef="usd">6908000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNi00LTEtMS0zMzQ4NA_d98b0760-5280-4ab0-b7fd-dfe6ea34a9ac"
      unitRef="usd">4522000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNy0yLTEtMS0zMzQ4NA_47b231bd-14c3-4fff-a0e1-0ef61e4b148d"
      unitRef="usd">6868000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfNy00LTEtMS0zMzQ4NA_438afd17-6d99-4f45-8e5b-fd8cfafefe46"
      unitRef="usd">9377000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC0yLTEtMS00MDg4OQ_9e6b9a78-3f76-457a-bbbb-620f4608d85a"
      unitRef="usd">5938000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC00LTEtMS00MDg4OQ_79f0f86c-7266-4f7a-9ed9-9f190fed9cf6"
      unitRef="usd">6154000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC0yLTEtMS0zMzQ4NA_563a03db-b8f9-489e-b68f-c2a0caa97a2d"
      unitRef="usd">7590000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfOC00LTEtMS0zMzQ4NA_0dbd420c-0bec-4a5c-ba4e-6d6ff5b870d6"
      unitRef="usd">4198000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMTAtMi0xLTEtMzM0ODQ_8c18fa0f-6c4b-46db-869d-9fc26cc98935"
      unitRef="usd">93636000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185NC9mcmFnOjIyNjdlNmU2MDdiNDRiMmJhZWU4NzM1M2VkYjMyYzBkL3RhYmxlOmUwNDc1NmU4MzU1YzRiOGI4ZTUyMmRmNTdlZWY0ZjI4L3RhYmxlcmFuZ2U6ZTA0NzU2ZTgzNTVjNGI4YjhlNTIyZGY1N2VlZjRmMjhfMTAtNC0xLTEtMzM0ODQ_253ba8d8-e45f-4bed-86e8-6b5988cbb178"
      unitRef="usd">98153000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNjAyOQ_43409ba3-994c-42b1-8d5b-f59a16eefa3a">Stockholders' Equity&lt;div style="margin-bottom:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company was authorized to issue 500 million shares of common stock. Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for stockholder voting and is entitled to one vote for each share held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company entered into a Sales Agreement with The Goldman Sachs &amp;amp; Co. LLC to create an at-the-market ("ATM") equity program, pursuant to which the Company may offer to sell shares of its common stock having an aggregate offering gross proceeds of up to $250.0&#160;million.  At December 31, 2022, no shares have been issued under the ATM equity program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company entered into a securities purchase agreement with certain entities, the (&#x201c;Purchase Agreements&#x201d;) for the private placement of an aggregate of 11,296,660 shares of the Company&#x2019;s common stock, at a purchase price of $10.18 per share, and pre-funded warrants to purchase an aggregate of 8,349,705 shares of common stock, at a purchase price of $10.17 per pre-funded warrant. Proceeds from the private placement, net of offering costs, were $199.8 million. Each pre-funded warrant has an initial exercise price of $0.01 per share and is exercisable at any time after its original issuance, subject generally to the lock-up period, at the option of each holder, in such holder&#x2019;s discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of common stock purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the pre-funded warrant. Certain of the Purchase Agreements provide for a lock-up period of either 60 days or nine months based on the individual agreements.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the first quarter of 2021, 1,294,999 and 1,260,000 warrants were exercised at $7.98 and $7.06 per share of common stock, respectively, resulting in gross cash proceeds of $19.2 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; During the first and third quarters of 2021, the Company entered into separate, privately negotiated exchange agreements with the holders of the Convertible Notes (the "Holders"). Under the terms of the exchange agreements, the Holders agreed to exchange the remaining aggregate principal amount of $2.8&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 472,356 shares of Company common stock, par value $0.01 per share. This transaction resulted in an increase of $2.7&#160;million and five thousand dollars to additional paid-in-capital and common stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nonqualified Cash Deferral Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Deferral Plan provides certain key employees and members of the Board of Directors, as selected by the Compensation Committee, with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section&#160;409A of the Internal Revenue Code of 1986 as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a deferred compensation investment balance of $5.5 million and $4.8 million as of December 31, 2022 and 2021, respectively, with corresponding approximate amounts of liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral Plan investment assets are classified as trading securities and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. Deferred compensation liability amounts under the Deferral Plan are included in other long-term liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. Under the provisions of the Plan, no option will have a term in excess of 10 years. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to the Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. As of December 31, 2022, the Company has reserved up to 15,472,672 shares for issuance under the Plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTAx_6cbd67cc-350a-46b6-b3be-2c6e85b52a01"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <fold:CommonStockVotingRightsForEachShareHeld
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMzQz_c69f1270-49c6-4aac-b6f0-41668b5c95e2"
      unitRef="vote">1</fold:CommonStockVotingRightsForEachShareHeld>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="icb2d2c63506847d38297b26fc2a46816_D20221101-20221130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjc0ODc3OTA3ODEzNg_bc135f7b-e3b8-461e-ae57-6f4d3af11cc8"
      unitRef="usd">250000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1dbc7ec2bc82472e8d78a51e83eca27b_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ0_370a016d-b9ec-4ed6-814d-978d34944428"
      unitRef="shares">11296660</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0cc3b62495104669997b8f552c55251a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNjA4_223c6de9-3997-4664-88eb-3fa8ac46be8e"
      unitRef="usdPerShare">10.18</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i0cc3b62495104669997b8f552c55251a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNjc0_36fabbc9-b6c1-4447-9aee-1418d79f1f8a"
      unitRef="shares">8349705</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i684e59baa0d248038199064182a492cf_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNzI0_7f258b73-6b48-4b63-acc7-498fb26a2a32"
      unitRef="usdPerShare">10.17</us-gaap:SaleOfStockPricePerShare>
    <fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing
      contextRef="i7b9f39dd6e7249298a92876de6b1e0e0_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ5NzU1ODIxNjk4_1852f60c-e2a7-41fc-89be-2a058f55ebdd"
      unitRef="usd">199800000</fold:ProceedsFromIssuanceOfWarrantsAndEquityFinancing>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0cc3b62495104669997b8f552c55251a_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfODc3_37cf85d6-2b9f-4671-a7e4-a34e34f41721"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6fb10a0ab84743b8a633a5e8af451568_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTU3NA_d1f1e847-f789-44ee-8c7e-38d7d9feeb07"
      unitRef="shares">1294999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0c5e203f768a4aaf8bcf9130761b750a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTU4MQ_5e594dca-691c-49b3-9fe6-e2fbcde1ae09"
      unitRef="shares">1260000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7688b5af5be343ee94e09246b4b087c8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTYxMQ_fffb1d53-1f90-412a-b3f6-d5a3b62e6444"
      unitRef="usdPerShare">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idf13e1ea84ff4fe7aa83be773a9ca942_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMTYxOA_ca9afe16-c50f-407f-a63d-1840b7043aef"
      unitRef="usdPerShare">7.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i9f2b79da371e47f782a538b4f4a5a21e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ5NzU1ODIxNzA0_7ce8e567-62d6-4bd3-a0e4-5e73ffa69442"
      unitRef="usd">19200000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i434e5978cdfe47e2b88de10d3e704e27_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjA0MQ_874540a9-928f-4354-8077-52a73bb61ab1"
      unitRef="usd">2800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjEyNA_a93f0f5a-7f84-4bc7-b6e1-867b35ce2dfe"
      unitRef="shares">472356</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iebd9dd9985e24306a01c58683a8c7ab2_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjE2OQ_8811374b-758a-4d19-9c13-cbeafb200f2c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7a60c7a011cd48f384a926bf46f56bb5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjIyNw_607ebed9-3189-48c5-8117-9659ab08f006"
      unitRef="usd">2700000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i063885fc29274fc29121ffc03adfdd69_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfMjIzNA_9f82d6b9-5598-42a2-a334-eee861df4a58"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:TradingSecurities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNDQzMg_755f8583-1e1d-438f-8761-b58b2d74fe39"
      unitRef="usd">5500000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNDQzOQ_0abd47c8-b133-4bbd-bfd3-e617b612825e"
      unitRef="usd">4800000</us-gaap:TradingSecurities>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTQ0OA_3b7ac3d6-7b47-4923-9ba0-f680a914f2e1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9f56a09188ad4413a91488ec17aa68c9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTc0Mg_cb92dc6b-2e29-4667-b460-b06536fca674"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTg4Ng_3aca6099-9f5a-4a89-a421-ccbd936909ef"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8462cf871c7a45aaa1430ee2bee44c64_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N185Ny9mcmFnOjkyMWFlODg5NGM0MDQ4YzE5ZWUwNjU2ODI5MWYxNDM1L3RleHRyZWdpb246OTIxYWU4ODk0YzQwNDhjMTllZTA2NTY4MjkxZjE0MzVfNTk4OA_3ef33c7d-f33e-42e6-bcc0-d9fb293fb18c"
      unitRef="shares">15472672</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNTg_0d46ecbb-a0b9-4d45-b910-d2130c82d6d9">Share based Compensation &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors. advisors, and consultants at a price to be determined by the Company&#x2019;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#x2019;s business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan provides for certain benefits to qualifying Plan participants who separate from service with the Company due to death, disability or "retirement" (as such term is defined under the Plan) ("Qualified Participants"). Options granted under the Plan to a Qualified Participant shall continue to vest until the 2nd anniversary of the Qualified Participant&#x2019;s separation and all vested options held by such Qualified Participant shall remain exercisable until the earlier of the 4th anniversary of the Qualified Participant&#x2019;s separation or the original expiration date of the option. Options that are not exercised during this exercise period shall be forfeited. Time-based restricted stock units and restricted stock granted to a Qualified Participant under the Plan that was scheduled to vest within the two year period following the Qualified Participant's separation shall accelerate and be delivered upon such separation. Any time-based restricted stock units or restricted stock that would have vested after such two year period will be forfeited upon the Qualified Participant's separation. Also, per the Amendment, any performance-based restricted stock units under the Plan ("PRSUs") received by the Qualified Participant, shall remain eligible to vest after the Qualified Participant&#x2019;s separation based on the actual performance of the Company through the end of the performance period applicable to any such PRSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the fair value method of measuring share-based compensation, using the fair value of each equity award granted. The Company chose the &#x2018;&#x2018;straight-line&#x2019;&#x2019; attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model when estimating the grant date fair value for share-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is based on the Company's historical volatility. The average expected life is determined using the Company's actual historical data. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life of options (years) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value per share of options granted during 2022, 2021, and 2020 were $6.11, $9.08, and $6.40, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock options for the year ended December 31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $2.5 million, $8.5 million, and $40.9 million, respectively. Cash proceeds from stock options exercised during the years ended December 31, 2022, 2021, and 2020 were $4.3 million, $10.2 million, and $42.3 million, respectively. As of December 31, 2022, the total unrecognized compensation cost related to non-vested stock options granted was $31.1 million and is expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units and Performance-Based Restricted Stock Units (collectively "RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the year ended December 31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, there was $50.4 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation Expense Related to Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjg_0ed1ece5-78f6-4ae1-b4a2-5bcacbe0635b">P2Y</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjc_625338aa-b909-4162-8cd1-c9ac1c0ed52e">P2Y</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjU_db5118bd-f85b-43dd-9639-460987c1f331">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected life of options (years) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzItMi0xLTEtMzM0ODQ_ecd49944-1e6a-4014-a30c-517cdd749e04"
      unitRef="number">0.621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzItNC0xLTEtMzM0ODQ_c30e951c-13d0-42ea-a0bb-e5d106d616bf"
      unitRef="number">0.654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzItNi0xLTEtMzM0ODQ_0e0780f7-f775-4387-9f2c-c676443e547b"
      unitRef="number">0.751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzMtMi0xLTEtMzM0ODQ_6f3becaf-f9ef-4bdb-bbaf-f5c238ac04e3"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzMtNC0xLTEtMzM0ODQ_473575ea-6ca7-4e90-b341-d719a23c28b4"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzMtNi0xLTEtMzM0ODQ_6e5cf1ac-aeb6-46af-aa7e-1fab3af327ed"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzQtMi0xLTEtMzM0ODQ_f4370168-2c0b-4f35-9ee9-4f98d16aa3e3">P5Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzQtNC0xLTEtMzM0ODQ_19e91637-d48c-4b18-8e21-0ca5589242f7">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzQtNi0xLTEtMzM0ODQ_11720f40-ba89-4fc0-a384-b49eb792fc1f">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzUtMi0xLTEtMzM0ODQ_2c04ac8f-511a-4a7c-a7eb-5210f2dac102"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i69703642df9a437496988406ce21d664_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzUtNC0xLTEtMzM0ODQ_e9f71309-0a3e-484f-bc48-37fe1b0a82ec"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i270475db6676442a85109f9df17c710f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MzA0ZDA5OWFmYmM0OGRmOWUzYWNiMDY5OWIzN2E0Yy90YWJsZXJhbmdlOjgzMDRkMDk5YWZiYzQ4ZGY5ZTNhY2IwNjk5YjM3YTRjXzUtNi0xLTEtMzM0ODQ_5f018176-7119-4405-8e61-0991d823a307"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM0NjA_0480a80b-8ad3-4a10-ab6e-ab26a3dff2d5"
      unitRef="usdPerShare">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM0NjQ_9da6c62f-38b2-471f-be00-c5269aa8d897"
      unitRef="usdPerShare">9.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM0NzI_fe77bf0f-de1e-43b2-877d-53964dd9b36c"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNzA_ff61c3f8-d0ce-4619-88a9-ad78c6de9c54">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock options for the year ended December 31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzItMS0xLTEtMzM0ODQ_d81545a9-3c26-4a8c-a203-cf6faf5a8736"
      unitRef="shares">16724000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ica44d8bb33204fffa5ffdcad376a613c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzItMy0xLTEtMzM0ODQ_e1378a04-31a8-4f74-ab32-84d209b36b30"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzMtMS0xLTEtMzM0ODQ_e6a71a28-78e8-47eb-a4b3-1ff032ac6dc0"
      unitRef="shares">4362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzMtMy0xLTEtMzM0ODQ_6bce596d-f6b5-4496-9242-32318aeba5d7"
      unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzQtMS0xLTEtMzM0ODQ_a72f6aa3-3552-459b-833b-655224e977cf"
      unitRef="shares">5243000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzQtMy0xLTEtMzM0ODQ_0668f7bf-0ecd-4bbb-ab93-1d00fe6a32c8"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzUtMS0xLTEtMzM0ODQ_a8447061-d351-4638-a5ac-3109b1128a4d"
      unitRef="shares">1376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzUtMy0xLTEtMzM0ODQ_97adb1d4-75e9-4ee9-869d-865b76122863"
      unitRef="usdPerShare">10.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzYtMS0xLTEtMzM0ODQ_1a28902c-46f2-4c99-a34b-9d42e0117ff5"
      unitRef="shares">435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzYtMy0xLTEtMzM0ODQ_be578d82-0f86-4095-9655-55379de31030"
      unitRef="usdPerShare">13.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzctMS0xLTEtMzM0ODQ_3d34ba8e-000a-43df-a576-0a7a11d514bf"
      unitRef="shares">14032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzctMy0xLTEtMzM0ODQ_6325760a-c6d6-4643-83e1-770a70101c05"
      unitRef="usdPerShare">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzgtMS0xLTEtMzM0ODQ_6612b37d-2124-4e52-b7a6-656362c3a343"
      unitRef="shares">3262000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzgtMy0xLTEtMzM0ODQ_036f624f-9bcb-4c89-9f60-c9ba9d83c362"
      unitRef="usdPerShare">16.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzktMS0xLTEtMzM0ODQ_a366b72e-e3f4-4fdf-9663-8ed2fe74acf0"
      unitRef="shares">1483000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzktMy0xLTEtMzM0ODQ_ad30b0bc-5f44-4a11-81a2-aa68107de4a3"
      unitRef="usdPerShare">7.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEwLTEtMS0xLTMzNDg0_7b3af838-92b7-4133-8ab7-7c92d31720b3"
      unitRef="shares">844000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEwLTMtMS0xLTMzNDg0_719aa2bb-870f-4812-9f98-acc7f513d611"
      unitRef="usdPerShare">12.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzExLTEtMS0xLTMzNDg0_105cee67-fb3e-4137-89cc-783a288c0c0f"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzExLTMtMS0xLTMzNDg0_126260eb-91a4-4b45-a765-a209e80439e5"
      unitRef="usdPerShare">13.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEyLTEtMS0xLTMzNDg0_191b8bb7-157e-4101-90a2-7066d624c74c"
      unitRef="shares">14731000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEyLTMtMS0xLTMzNDg0_15c440d6-bda4-4d60-9992-2022f4495a0a"
      unitRef="usdPerShare">11.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEzLTEtMS0xLTMzNDg0_30c5b6e4-94fb-46f9-9965-560714a0b4f5"
      unitRef="shares">5733000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzEzLTMtMS0xLTMzNDg0_52a45896-bf8b-42d4-843f-2017469c8a65"
      unitRef="usdPerShare">11.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE0LTEtMS0xLTMzNDg0_ed436892-95f4-4c9f-9d8d-581c3792eeb3"
      unitRef="shares">660000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE0LTMtMS0xLTMzNDg0_e25cf858-33d0-4fce-983c-0c3be812387f"
      unitRef="usdPerShare">6.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE1LTEtMS0xLTMzNDg0_49428550-eeb3-4d84-bc5a-0a6c0d65c204"
      unitRef="shares">495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE1LTMtMS0xLTMzNDg0_ad774a70-a7d1-4f13-9bb7-682b804831e9"
      unitRef="usdPerShare">12.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE2LTEtMS0xLTMzNDg0_d0812535-411a-43d3-8e72-25c5b5b3744d"
      unitRef="shares">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE2LTMtMS0xLTMzNDg0_5b92647a-9f70-476d-94bc-adba8cda6229"
      unitRef="usdPerShare">12.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTEtMS0xLTMzNDg0_9c0f2f8a-7d7f-48b8-8019-cb1f0fb33dd3"
      unitRef="shares">19064000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTMtMS0xLTMzNDg0_1b345881-7f89-451c-848d-982d27df7804"
      unitRef="usdPerShare">11.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTUtMS0xLTMzNDg0_20a3e5ec-a431-4490-9fdf-e40871d9fd94">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE3LTctMS0xLTMzNDg0_4b2afa94-6946-45b0-9808-4168f220b1ff"
      unitRef="usd">36700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTEtMS0xLTMzNDg0_75aa45a2-0ec0-4434-9659-20c044d0826c"
      unitRef="shares">17492000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTMtMS0xLTMzNDg0_7b151666-0c35-44eb-a0b6-a97867145438"
      unitRef="usdPerShare">11.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTUtMS0xLTMzNDg0_42861fb4-782e-4372-9ea0-7f384a720722">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE4LTctMS0xLTMzNDg0_fdf6e55c-eba3-43da-aa12-fa8071384fb0"
      unitRef="usd">35100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTEtMS0xLTMzNDg0_ac9ab6b9-08f4-4baa-9e3c-afbedcbf8a40"
      unitRef="shares">10938000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTMtMS0xLTMzNDg0_ee867f54-0818-430d-9cb0-4c6816f2de5a"
      unitRef="usdPerShare">10.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTUtMS0xLTMzNDg0_cac53da6-65e5-47cd-ad41-173a2daf0d6e">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTo4MjhhMGZlNDc5MGU0NmQwYThlZjFjY2VjZDIxMWExNC90YWJsZXJhbmdlOjgyOGEwZmU0NzkwZTQ2ZDBhOGVmMWNjZWNkMjExYTE0XzE5LTctMS0xLTMzNDg0_a5d1cf2a-be1d-4cfd-a457-851448cffa18"
      unitRef="usd">29000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM2NjQ_b7ba9b59-271d-4be0-b83f-491c455c434a"
      unitRef="usd">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM2Njg_7812ed5f-f6b2-461b-b603-85c92300997e"
      unitRef="usd">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM2NzY_188b90f0-feab-43db-81fd-12749e9d3bb8"
      unitRef="usd">40900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM3Nzk_54fa0a30-ed97-45b9-80e7-4ad2fac47242"
      unitRef="usd">4300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM3ODM_d49f61ee-fd63-42f4-9121-33faee563e1b"
      unitRef="usd">10200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM3OTE_84b31474-ebc5-4ef5-a73b-e7ced0af5d3c"
      unitRef="usd">42300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM5MDg_36fbf301-04cc-422f-8018-8b9ec9742d0b"
      unitRef="usd">31100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ieb57920f3b814e169748405b9928e37d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzM5Nzg_2e0c9004-ceb3-40df-8f2a-d01580dc17bf">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjA_cb8a6231-e51c-4f4c-8988-511de20fd6df">A summary of non-vested RSU activity under the Plan for the year ended December 31, 2022 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,240)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifc0df69ddff74c2089537bf0e99a1af4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzItMS0xLTEtMzM0ODQ_0193fa40-0b53-4098-8ed6-fb65cf2eab3a"
      unitRef="shares">5792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifc0df69ddff74c2089537bf0e99a1af4_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzItMy0xLTEtMzM0ODQ_7b81052a-28f8-43a0-abfd-95fc5adcead5"
      unitRef="usdPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzMtMS0xLTEtMzM0ODQ_723c5756-a2e3-4449-801c-de2e25061b3c"
      unitRef="shares">4692000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzMtMy0xLTEtMzM0ODQ_98854c32-d9d2-437e-b14f-ddac61358cbd"
      unitRef="usdPerShare">11.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzQtMS0xLTEtMzM0ODQ_9c74594a-3344-4f8f-a9c5-7044da5882a7"
      unitRef="shares">2164000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzQtMy0xLTEtMzM0ODQ_d7855c3d-8516-4d81-99d7-c2c639c915d8"
      unitRef="usdPerShare">10.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzUtMS0xLTEtMzM0ODQ_00601ac7-583c-4628-8f2c-97f8b2d46ed0"
      unitRef="shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3585d06e78404ca8b11a1dadafac9ada_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzUtMy0xLTEtMzM0ODQ_a23d6616-98b3-4fc7-8063-fd45cde322cd"
      unitRef="usdPerShare">11.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idbd0892a63d24555a0be7d1e129099a6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzYtMS0xLTEtMzM0ODQ_2fb86938-7b4e-45bd-8aa3-d6e1fff52176"
      unitRef="shares">7080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idbd0892a63d24555a0be7d1e129099a6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzYtMy0xLTEtMzM0ODQ_3de9d66c-77ed-4a0a-b145-2d462294a141"
      unitRef="usdPerShare">11.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzctMS0xLTEtMzM0ODQ_7b483580-6089-4d01-beb8-d67c91e87664"
      unitRef="shares">3191000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzctMy0xLTEtMzM0ODQ_3a1c9d8a-b613-4455-a41e-51d0f2bbb089"
      unitRef="usdPerShare">16.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzgtMS0xLTEtMzM0ODQ_4cfb0f45-228c-47db-abb8-1b25d6710935"
      unitRef="shares">1863000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzgtMy0xLTEtMzM0ODQ_220f56dc-dcf9-4487-ad1f-131cb8ea8985"
      unitRef="usdPerShare">15.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzktMS0xLTEtMzM0ODQ_23230f9a-c100-4737-befd-8fe752198170"
      unitRef="shares">1067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i38d88c548d6c4659bdc75c6a29f07233_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzktMy0xLTEtMzM0ODQ_671f2411-466c-4141-9130-30f56f7ae271"
      unitRef="usdPerShare">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia25971519a474cb89a00ac0fe4405077_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEwLTEtMS0xLTMzNDg0_5f187bf3-1054-42fb-9409-3ce4ce4d0f5b"
      unitRef="shares">7341000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia25971519a474cb89a00ac0fe4405077_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEwLTMtMS0xLTMzNDg0_44b1d2cb-3961-40c9-8cf9-590474c39e69"
      unitRef="usdPerShare">13.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzExLTEtMS0xLTMzNDg0_683dcc65-2612-455d-b14a-3f21de452899"
      unitRef="shares">5048000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzExLTMtMS0xLTMzNDg0_5caf14f6-5029-45f5-aa6c-ddba5a9c74a9"
      unitRef="usdPerShare">11.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEyLTEtMS0xLTMzNDg0_c6dc2af2-d77b-4d67-af79-87c82150c7b4"
      unitRef="shares">2251000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEyLTMtMS0xLTMzNDg0_25219180-9ec9-47ac-8efb-4bf971eaabac"
      unitRef="usdPerShare">12.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEzLTEtMS0xLTMzNDg0_5d43fea1-034d-4b15-bc53-6cfb83ac7cf8"
      unitRef="shares">421000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzEzLTMtMS0xLTMzNDg0_ba57b0a9-02d1-4a64-bd2b-000287003ec9"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTEtMS0xLTMzNDg0_fdc05969-f541-4e62-8175-a563614b879d"
      unitRef="shares">9717000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTMtMS0xLTMzNDg0_7545fd18-0c13-4f9e-99e9-02286605823f"
      unitRef="usdPerShare">13.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTUtMS0xLTMzNDg0_c5d701f4-1917-4cc9-8f61-5a5fdbb39750">P2Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTplNTgxZjFmMmU3MTg0MzdkYjFjNTgwMzlmMGI3MmZiNi90YWJsZXJhbmdlOmU1ODFmMWYyZTcxODQzN2RiMWM1ODAzOWYwYjcyZmI2XzE0LTctMS0xLTMzNDg0_4a03d897-2b6f-492d-b616-8ae5b3135d48"
      unitRef="usd">118600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="idd2e7ab3b96b476daec9f665f0ce53a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzQ3NjQ_4ddfe803-3584-43c1-b2c6-3be98e40ef08"
      unitRef="usd">50400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0893f89fb16742748936ee83717865e9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzQ5NDc_3a4ff0ab-1a25-4466-9761-8eac6fd54776">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90ZXh0cmVnaW9uOjFiNjJjNDE0OTgyMjQ0YzJiZmJhMmE0YTZmMGExMjAyXzUxNjE_c054d635-b8fb-497a-9cd6-c783c6785c50">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify;text-indent:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4aebf956783144d080e2da4950f36772_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzItMi0xLTEtMzM0ODQ_87ac7ede-8048-4bb9-b030-48ce3986b947"
      unitRef="usd">25089000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7974cd6b41a844d691c4317454a8e713_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzItNC0xLTEtMzM0ODQ_2dfa7c4a-c6f6-45a8-9153-e9dc9464fcd6"
      unitRef="usd">17340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic11a83d2050e4006b0d4257abc62732d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzItNi0xLTEtMzM0ODQ_7d752b5f-c30e-4017-8f20-e7e8103e58d2"
      unitRef="usd">20817000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i62bbbab375e34720aaff75d13f751ff3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzMtMi0xLTEtMzM0ODQ_3d09556a-96dd-454c-9bdb-8e756bbdcc2b"
      unitRef="usd">51423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id791547accfd4c4ca3c15fd099f6a3c9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzMtNC0xLTEtMzM0ODQ_73256d55-76d2-43c6-a318-592aebd6c245"
      unitRef="usd">40498000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id344688a9ae545c792aa423f39c5e57d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzMtNi0xLTEtMzM0ODQ_8c158e2d-ad0e-4212-9ef3-d9813270174b"
      unitRef="usd">28334000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzQtMi0xLTEtMzM0ODQ_5c7b3635-32ac-48d1-a6b5-fb59902c8fc5"
      unitRef="usd">76512000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzQtNC0xLTEtMzM0ODQ_d8377047-1f12-4f61-8139-3d1d0456b334"
      unitRef="usd">57838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDMvZnJhZzoxYjYyYzQxNDk4MjI0NGMyYmZiYTJhNGE2ZjBhMTIwMi90YWJsZTowMDg4MTQ0Y2RmZTM0YWIzODdjNDUzNzFkMDNjNGVjOC90YWJsZXJhbmdlOjAwODgxNDRjZGZlMzRhYjM4N2M0NTM3MWQwM2M0ZWM4XzQtNi0xLTEtMzM0ODQ_3c401f76-1569-4922-ad4f-acca771e15e8"
      unitRef="usd">49151000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3NDE_99f6c69b-6b8b-4336-ba41-5f6ca2af1763">Assets and Liabilities Measured at Fair Value&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:63pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2022 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets as of December 31, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Money Market Funds and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2022. No transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable for Callidus has been classified as a Level&#160;3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%-98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reached a regulatory milestone in September 2021 associated with FDA approval of the first BLA and in November 2021 associated with EMA validation of the MAA, both related to the contingent consideration of Callidus for the ATB200 Pompe disease program. The satisfaction of these milestones resulted in the collective milestone payment of $12.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2022 and 2021, respectively:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; As certain milestones are expected to be reached within the next twelve months, the December 31, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3NDQ_83d87908-3261-476a-bca0-e3ab0a5f87f5">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2022 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0583f7b3d714281b74c55de8631a291_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzItMi0xLTEtMzM0ODQ_1b81d5f4-3a14-4eb3-ad67-e88063659463"
      unitRef="usd">144381000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7ee0584c009d47bdb038931ceca9c5e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzItNC0xLTEtMzM0ODQ_9a057391-3592-4813-9bd2-e15f3776f7d5"
      unitRef="usd">144381000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c47266244c044308efa79fbb42126c1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzUtMi0xLTEtMzM0ODQ_28b488ad-45fd-4cee-9602-056c83ad2088"
      unitRef="usd">5808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79ec32aa3cf74295bf4d454eeeda3370_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzUtNC0xLTEtMzM0ODQ_75830175-84cc-4d42-84c2-86f4f82eab8d"
      unitRef="usd">5808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzYtMi0xLTEtMzM0ODQ_f2b988e8-c10f-46ea-92ab-cf7204af726e"
      unitRef="usd">150189000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo2ODRlN2MxMjRjZjI0OWEwOTM3NzhiZTA1MTIzZjExMS90YWJsZXJhbmdlOjY4NGU3YzEyNGNmMjQ5YTA5Mzc3OGJlMDUxMjNmMTExXzYtNC0xLTEtMzM0ODQ_40ae79d1-5ce6-48ef-ac9c-ed9d1cf6d11a"
      unitRef="usd">150189000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzItMi0xLTEtMzM0ODQ_d3e385bc-9b17-42fd-9c63-bd9a5bcb62bb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia6f66037dfaf441895506fef26bb3f6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzItNC0xLTEtMzM0ODQ_e016aa3a-34cf-4d35-aab5-7daab94d3264"
      unitRef="usd">21417000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzItNi0xLTEtMzM0ODQ_19a02ae4-6aa3-4327-9de3-721a6c0b02e6"
      unitRef="usd">21417000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzMtMi0xLTEtMzM0ODQ_0ce08900-0ec6-4a04-8833-89a169c835af"
      unitRef="usd">5458000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ia6f66037dfaf441895506fef26bb3f6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzMtNC0xLTEtMzM0ODQ_b31a5fd9-66e7-4cae-a1e3-454f3e69e67e"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzMtNi0xLTEtMzM0ODQ_30a8b084-f8c6-4795-8208-54d5efbfd42a"
      unitRef="usd">5458000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib7aa7b36b3cd4afa8f711a716528a93d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzQtMi0xLTEtMzM0ODQ_88f1c614-5ee4-46d3-acc6-0e3efe4fb530"
      unitRef="usd">5458000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia6f66037dfaf441895506fef26bb3f6c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzQtNC0xLTEtMzM0ODQ_78c6e54f-d54c-4958-b32e-1e3d7f819d52"
      unitRef="usd">21417000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTpkNzc2OGM1YTJlMTg0ZjczYmIyOGIzYzkxODQ5MGMxMi90YWJsZXJhbmdlOmQ3NzY4YzVhMmUxODRmNzNiYjI4YjNjOTE4NDkwYzEyXzQtNi0xLTEtMzM0ODQ_7e2ae65c-26ef-49a0-a428-10a1787e8959"
      unitRef="usd">26875000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if73e550190f24545ba9da5442ddcbd4c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzItMi0xLTEtMzM0ODQ_8407d149-955c-4187-aabe-d2477d0d36a9"
      unitRef="usd">174531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9fbcc912009f4550a0f6de763f637746_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzItNC0xLTEtMzM0ODQ_438ca6f0-0cf5-4b45-b293-9a0e73b74ca7"
      unitRef="usd">174531000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea79d58e95c74a5991a23d4e79a1accb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzQtMi0xLTEtMzM0ODQ_8f301a5e-2b9e-48c2-a990-e2e41046b069"
      unitRef="usd">32311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7bc093340f94793b9356a4ad70fd286_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzQtNC0xLTEtMzM0ODQ_ad9a774e-343c-4002-b1d7-d050d426bcff"
      unitRef="usd">32311000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20c8c2cd061443e8b7635a574a7eb008_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzUtMi0xLTEtMzM0ODQ_2ea61f94-9874-4a91-8277-bdc7a7edf07a"
      unitRef="usd">30056000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0f9e1d0ccde74a5397233b019d1d1666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzUtNC0xLTEtMzM0ODQ_f836536c-6674-4b0f-9ffa-6fe722d73149"
      unitRef="usd">30056000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief04e0e1c5f64e7ea10b52c1ac3b2b1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzYtMi0xLTEtMzM0ODQ_db535b44-64fb-4770-b61e-86a6ed5413d2"
      unitRef="usd">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifeff130df8d84f32801b649c773d0d55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzYtNC0xLTEtMzM0ODQ_27c1a801-3d93-4f47-a89b-7741fa540ee4"
      unitRef="usd">5150000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzctMi0xLTEtMzM0ODQ_4e6be8c9-cf82-4260-86b5-6143e4024a28"
      unitRef="usd">242048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZToxZTM0ZWNhYmM3ZDg0MTJlOWM0MmEzYWUzZjNjMDg0MS90YWJsZXJhbmdlOjFlMzRlY2FiYzdkODQxMmU5YzQyYTNhZTNmM2MwODQxXzctNC0xLTEtMzM0ODQ_1332b477-9739-48b4-ae05-3226c61d905f"
      unitRef="usd">242048000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzItMi0xLTEtMzM0ODQ_0661b5f0-7d08-4be6-926e-97c14d3ec323"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia11c64b571a447ccae1108601a456bd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzItNC0xLTEtMzM0ODQ_27ced4cc-faa5-4a61-aba6-72a8815350f7"
      unitRef="usd">20339000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzItNi0xLTEtMzM0ODQ_da90cc2e-a49d-4c4b-bf4b-a310d70152e6"
      unitRef="usd">20339000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzMtMi0xLTEtMzM0ODQ_bf700cc7-59a3-40bc-bf47-aec7780f8de9"
      unitRef="usd">4800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ia11c64b571a447ccae1108601a456bd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzMtNC0xLTEtMzM0ODQ_50fb4b23-f861-4c31-b63f-e0b15585ae64"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzMtNi0xLTEtMzM0ODQ_b02aea91-ec60-4b22-8787-306c38c406fc"
      unitRef="usd">4800000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i050f1ac85c0b486fb9e3931da07d4215_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzQtMi0xLTEtMzM0ODQ_54126ef1-c1fd-471e-b6c9-a65254bdee8e"
      unitRef="usd">4800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia11c64b571a447ccae1108601a456bd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzQtNC0xLTEtMzM0ODQ_9a66c154-a37c-4a03-be5b-5433559bd622"
      unitRef="usd">20339000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTphNGMwMjYzZDQ4Zjc0M2Q0YWJhZDg5MjBhYjU2ZjRiNC90YWJsZXJhbmdlOmE0YzAyNjNkNDhmNzQzZDRhYmFkODkyMGFiNTZmNGI0XzQtNi0xLTEtMzM0ODQ_210112a7-0ae9-41d5-99e4-a337fa32cb23"
      unitRef="usd">25139000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3MzY_13c492f0-c033-4d70-a76f-1b6a7ec272de">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe disease program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.331%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88%-98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i2ec9eab666f04c9ba3be68d4ffd794f2_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzItOC0xLTEtMzM0ODQ_f65a33ec-d407-43d0-b700-c8ebbf225a77"
      unitRef="number">0.102</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i863463917abd46488618f36fe6140b3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzMtMi0xLTEtMzM0ODQ_b5e42e22-3893-4806-8e29-5f3492ea139a"
      unitRef="usd">21417000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i36478174e3aa4ca6a302830abc0b3fd0_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzMtOC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiNzQ2ZmIzOGQ0OTc0Zjg5ODA2YTBjODMwMTBmY2M2NV80_b3be898d-791e-44d8-993a-490ca168fc0f"
      unitRef="number">0.88</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i0914d34ae7a54148af314b77afd45e1d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTowMWMwNjUxNWNmYzU0YWI3Yjg3NTUyNzhiODdlYWQ3MC90YWJsZXJhbmdlOjAxYzA2NTE1Y2ZjNTRhYjdiODc1NTI3OGI4N2VhZDcwXzMtOC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjpiNzQ2ZmIzOGQ0OTc0Zjg5ODA2YTBjODMwMTBmY2M2NV83_6fa27180-73c0-4e12-83f3-c7af432dea71"
      unitRef="number">0.98</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzgyNDYzMzcyMTQxNjY_68752d6c-e2bb-442f-8d72-e3aafefa5272"
      unitRef="usd">-12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90ZXh0cmVnaW9uOjZjOGY1ZDQ4NmUxMjRmODc4NzkxNmEwNjRlOWFlM2Y3XzQ3NDA_f8834e6a-fc01-4d78-a60f-b16ec53042b9">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the year ended December 31, 2022 and 2021, respectively:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of contingent consideration in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of the period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; As certain milestones are expected to be reached within the next twelve months, the December 31, 2022 balance was recorded as a current liability in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzItMi0xLTEtMzM0ODQ_47abed7c-efe5-4fc9-a6d2-62c883196fe9"
      unitRef="usd">20339000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3dabe0822cd541628f0bfa8cbeb3e8e2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzItNC0xLTEtMzM0ODQ_f645d125-86ea-4b93-943d-ef775c3f8051"
      unitRef="usd">25825000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzMtMi0xLTEtMzM0ODQ_d9973eec-c49c-4cfc-9e84-3fde83c1c8db"
      unitRef="usd">-1078000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzMtNC0xLTEtMzM0ODQ_14f998e8-5fe0-4745-b626-222781f0d313"
      unitRef="usd">-6514000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzQtMi0xLTEtMzM0ODQ_12aa0166-0aa8-47ec-9358-50b5ddff769a"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzQtNC0xLTEtMzM0ODQ_99ad23ba-1503-4eaa-b875-b11d165b28ea"
      unitRef="usd">-12000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzUtMi0xLTEtMzM0ODQ_d27046d7-3ee7-4a59-a3e1-8046cf91fb65"
      unitRef="usd">21417000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDYvZnJhZzo2YzhmNWQ0ODZlMTI0Zjg3ODc5MTZhMDY0ZTlhZTNmNy90YWJsZTo1MDgwNDk4ZmE2YmM0ZmZmYjMyYWMwNzViYzYwYTI5OC90YWJsZXJhbmdlOjUwODA0OThmYTZiYzRmZmZiMzJhYzA3NWJjNjBhMjk4XzUtNC0xLTEtMzM0ODQ_25fd64e5-2834-40f2-93dd-028bbb752098"
      unitRef="usd">20339000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzY2NDI_5c91a4bb-786a-420f-a6c8-8444e8e87ba5">Debt &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Secured Term Loan due 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a definitive agreement for a $400&#160;million credit facility with Hayfin Capital Management (&#x201c;Senior Secured Term Loan due 2026&#x201d;) with an interest rate equal to 3-month LIBOR, subject to a 1% floor, plus 6.5% per annum and requires interest-only payments until mid-2024. The Senior Secured Term Loan due 2026 will be repaid in nine quarterly payments of $44.4&#160;million, starting on July 2024 with the final balance due on the maturity date in July 2026. This transaction resulted in net proceeds of $385.9&#160;million, after deducting fees and expenses. There were no warrants or equity conversion features associated with the Senior Secured Term Loan due 2026. The Company used the proceeds to voluntarily settle the Senior Secured Term Loan with BioPharma Credit PLC, which included the $150&#160;million principal, $1.1&#160;million accrued interest, and $5.2&#160;million in early settlement premiums. As a result of this early extinguishment, the Company recognized a loss on extinguishment of debt of $7.3&#160;million in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Term Loan due 2026 is subject to mandatory prepayment provisions that require prepayment upon a change of control, the incurrence of certain additional indebtedness, asset sale, or an event of loss, subject to certain conditions set forth in the Senior Secured Term Loan due 2026. The Company may prepay the Senior Secured Term Loan due 2026 in whole, at its option at any time. Any prepayment of the Senior Secured Term Loan due 2026 is subject to certain make-whole premiums and prepayment premiums, the latter of which decrease until the fourth anniversary of the transaction date at which point no prepayment penalty shall exist. The obligations under the Senior Secured Term Loan due 2026 are secured by a first lien security interest in certain assets of the Company. The Senior Secured Term Loan due 2026 contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company. The Senior Secured Term Loan due 2026 also contains a minimum liquidity covenant of $75&#160;million, and an incremental minimum consolidated revenue covenant, measured as of the previous four consecutive fiscal quarters. The minimum consolidated revenue covenant ranges from $140&#160;million, beginning March 31, 2021, and peaks at $225&#160;million by June 30, 2023, continuing at that level until the Senior Secured Term Loan due 2026 is repaid. If an event of default occurs and is continuing, Hayfin Capital Management may declare all amounts outstanding under the Senior Secured Term Loan due 2026 to be immediately due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except interest rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate of the liability component, Senior Secured Term Loan due 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzY2NDM_94009178-062c-4376-a03e-e8613b1d82d3">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_____________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzItMi0xLTEtMzM0ODQ_424db012-4f45-4048-abe1-e9dec43c6377"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6e3c044f256444559188d07ee55b2357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzItNC0xLTEtMzM0ODQ_e1e924ab-41a8-408a-93fb-15351ce24ad0"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzMtMi0xLTEtMzM0ODQ_028f4846-efb5-44fa-b157-9c72033cd191"
      unitRef="usd">4571000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i6e3c044f256444559188d07ee55b2357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzMtNC0xLTEtMzM0ODQ_3ccde6fd-a5e1-408a-a239-27f9e01aac8b"
      unitRef="usd">6074000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzQtMi0xLTEtMzM0ODQ_8e53c999-9612-4cbb-ab67-9f8374a0d778"
      unitRef="usd">3439000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i6e3c044f256444559188d07ee55b2357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzQtNC0xLTEtMzM0ODQ_534ca8c1-de66-4754-950c-bd31ae443594"
      unitRef="usd">4569000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzUtMi0xLTEtMzM0ODQ_7e273c2c-bc36-4da2-a317-4cfe7e9b1cfe"
      unitRef="usd">391990000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6e3c044f256444559188d07ee55b2357_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo1ZmFmYmE4M2E3NTE0MDk3YjU3NGEwMjRlZjY2YzUxNi90YWJsZXJhbmdlOjVmYWZiYTgzYTc1MTQwOTdiNTc0YTAyNGVmNjZjNTE2XzUtNC0xLTEtMzM0ODQ_bd259414-7c51-481a-a775-7d7458fc80eb"
      unitRef="usd">389357000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8b64c874c8c44ab193d9b7e4e27fc831_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzQyMA_db50c889-ea29-4c0a-8c44-ee8b551a3650"
      unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <fold:DebtInstrumentVariableRate
      contextRef="ib2b5d30d91b5477cb000659e1d65b4e9_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzU2Nw_83fd3181-029c-4cff-9e35-2f5218fc8991"
      unitRef="number">0.01</fold:DebtInstrumentVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib2b5d30d91b5477cb000659e1d65b4e9_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzU4Mg_70a830ac-7f35-4540-b024-9532d3b19e27"
      unitRef="number">0.065</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <fold:DebtInstrumentPeriodicPaymentNumberOfPayments
      contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzcwMw_c24362c0-645a-4e4c-9342-5a8f23af3157"
      unitRef="numberofpayments">9</fold:DebtInstrumentPeriodicPaymentNumberOfPayments>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzcyOA_a4cfefe5-345f-43c7-b658-de93225f59dc"
      unitRef="usd">44400000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ProceedsFromSecuredLinesOfCredit
      contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzg2MQ_9cf33124-9a3f-4933-89b4-11ef28c3bc20"
      unitRef="usd">385900000</us-gaap:ProceedsFromSecuredLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7ede13529d0c4d9b9a5b6711cd1a2495_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzExMzU_4a9d9a21-d469-4fa7-af23-f593043b395d"
      unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:InterestExpenseDebt
      contextRef="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzExNDk_3fa616bf-7bbd-4e03-b464-bb236fcb4269"
      unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <fold:EarlySettlementPremiums
      contextRef="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzExNzQ_12680404-fdf8-4c7c-b849-2d0ce83c872c"
      unitRef="usd">5200000</fold:EarlySettlementPremiums>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6970bd6365484108a45d37ec5a98ed4c_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzEzMDg_b75a9544-0b4f-4632-8ca6-179e6be1171a"
      unitRef="usd">-7300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <fold:DebtInstrumentLiquidityCovenantMinimumAmount
      contextRef="i5ad1f23bb60642ff8435c7fbd02a2f92_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzI0MTY_942f6979-54bf-4b2f-b8f2-5ac8359d1fe6"
      unitRef="usd">75000000</fold:DebtInstrumentLiquidityCovenantMinimumAmount>
    <fold:DebtInstrumentConsolidatedRevenueCovenantAmount
      contextRef="i4688884f4dfe4ebb993267308aba950f_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzI1OTQ_ee6cd5a3-8eb5-4a64-84fd-74ad6befc920"
      unitRef="usd">140000000</fold:DebtInstrumentConsolidatedRevenueCovenantAmount>
    <fold:DebtInstrumentConsolidatedRevenueCovenantAmount
      contextRef="if96cae15f3fe42258129198c088db297_D20200701-20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzI2Mzc_0d5d4835-b78c-4cee-a6b4-86569f2c73f4"
      unitRef="usd">225000000</fold:DebtInstrumentConsolidatedRevenueCovenantAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90ZXh0cmVnaW9uOmY1MzMwYzM4NzE3NTRkNTk5NWFlYmRmODg1OTVlZWIzXzY2NDY_ac15ad20-3f45-47fa-b107-f22772989a43">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the years ended December 31, 2022 and 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.950%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except interest rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective interest rate of the liability component, Senior Secured Term Loan due 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzEtMi0xLTEtMzM0ODQ_cb16faee-4e92-4c02-aba7-46da80914b2b"
      unitRef="usd">34446000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzEtNC0xLTEtMzM0ODQ_4d8a9a7d-19dc-4b1f-9009-3958c0f7d6ec"
      unitRef="usd">30473000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzItMi0xLTEtMzM0ODQ_1f83f68e-abe7-4239-9db4-4e34c92ff985"
      unitRef="usd">1503000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzItNC0xLTEtMzM0ODQ_401224ee-6562-4a77-8256-6d5dfc741cf8"
      unitRef="usd">1462000</us-gaap:AmortizationOfDebtDiscountPremium>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzMtMi0xLTEtMzM0ODQ_57d79e8c-6b80-4016-8769-e2f6175e2cd2"
      unitRef="usd">1131000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzMtNC0xLTEtMzM0ODQ_b3300ff1-9279-43ed-9864-c392f8945c67"
      unitRef="usd">1028000</fold:AmortizationDeferredFinancingCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib91a2c830ad742d79faac258a290765d_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzUtMi0xLTEtMzM0ODQ_c9904e9f-0f38-4ff0-a687-361e32ec9b4a"
      unitRef="number">0.121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i77e2344e04a24467a4594a535befc1ac_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDkvZnJhZzpmNTMzMGMzODcxNzU0ZDU5OTVhZWJkZjg4NTk1ZWViMy90YWJsZTo0MDVlNjJmMGQ3M2E0YzczOTdlMzc0N2ZiZjNlZmZiNy90YWJsZXJhbmdlOjQwNWU2MmYwZDczYTRjNzM5N2UzNzQ3ZmJmM2VmZmI3XzUtNC0xLTEtMzM0ODQ_a79f22e8-2347-4938-b89b-bb88f6b867c2"
      unitRef="number">0.084</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEyMTk_6d46ae60-6b45-44f4-bf48-fcbe7fd847e5">Leases&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has operating leases for office and research laboratory space, equipment, and vehicles under agreements expiring at various dates through 2044, which include renewal options on leases which the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, and 2021, operating lease expense was $9.8 million and $10.0&#160;million and variable lease expense was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.7&#160;million and $2.1 million, respectively.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For the years ended December 31, 2022, and 2021, the Company paid $8.3 million and $8.4&#160;million, respectively, for amounts included in the measurement of operating lease liabilities and recorded $8.9 million and $0.3&#160;million, respectively, of&#160;right-of-use assets. For the year ended December 31, 2022, there were no tenant improvements paid through lease incentives in exchange for new operating lease liabilities.  For the year ended December 31, 2021, there were $0.3&#160;million of tenant improvements paid through lease incentives in exchange for new operating lease liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commitments under finance leases are not significant for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except year and discount rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzMzNw_d500d4a4-57ef-4a15-b6f8-ea9df0232969"
      unitRef="usd">9800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzM0NA_4a8586f1-f192-47f1-bc7f-af444c89fd48"
      unitRef="usd">10000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzM3OA_c8a7f623-cd62-4a6d-835d-bf06fc536b66"
      unitRef="usd">1700000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzM4NQ_62f53650-52e3-4cd4-bcdd-1414534e4ec0"
      unitRef="usd">2100000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzQ1NA_fc54843c-050e-4c14-bf1d-0a5775d0f298"
      unitRef="usd">8300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzQ2MQ_1f6151ad-6665-4507-8b54-1eb7005d8ece"
      unitRef="usd">8400000</us-gaap:OperatingLeaseCost>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzU2Mw_4d3a06ab-3019-48cb-9034-fe7b43cd6299"
      unitRef="usd">8900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzU3MA_fb68b18f-178d-4373-a8b4-fff1facfd892"
      unitRef="usd">300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEwNDQ1MzYwNDY1NTI5_d364bd01-4d2f-40ec-8f7a-c02212f582e1"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzE2NDkyNjc0NDM2MzM_da4d83fd-06ee-4426-84fc-12bc91006102"
      unitRef="usd">300000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEyMTE_82b9f5c4-a1ec-4e3d-a468-b9936476f52e">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except year and discount rate amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of the operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzEtMi0xLTEtMzM0ODQ_73b2b4c2-a60f-427f-93cc-7c37a7bd1117"
      unitRef="usd">29534000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzEtNC0xLTEtMzM0ODQ_0c9de150-8a75-4aac-a1f1-078bf816c2e0"
      unitRef="usd">20586000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzMtMi0xLTEtMzM0ODQ_899a01d4-9173-4dec-9fe4-fdd965b55754"
      unitRef="usd">8552000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzMtNC0xLTEtMzM0ODQ_afbe98c0-9080-4da1-9699-c9dd01204b8b"
      unitRef="usd">7409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzQtMi0xLTEtMzM0ODQ_97543071-7b5f-4b1b-83c0-f9364736e615"
      unitRef="usd">51578000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzQtNC0xLTEtMzM0ODQ_ca142902-1e41-44da-a136-560a809e9fbc"
      unitRef="usd">43363000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzUtMi0xLTEtMzM0ODQ_f9772e62-2296-4418-b9ea-9392a98d5d8a"
      unitRef="usd">60130000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzUtNC0xLTEtMzM0ODQ_5c4be6ed-e164-4d07-9287-e0e1674b6873"
      unitRef="usd">50772000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzctMi0xLTEtMzM0ODQ_4ea0eb59-71df-48a1-9ecc-25768ea326e4">P17Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzctNC0xLTEtMzM0ODQ_a7c011de-d93d-4c80-ad06-89a1982ab977">P19Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzgtMi0xLTEtMzM0ODQ_7bea2340-ae2a-4b5f-a342-934e47e9e851"
      unitRef="number">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTphMDBhM2ZjYWQyYmY0MGZiYWNkNjQ2NDU4ZWNhNzE2MC90YWJsZXJhbmdlOmEwMGEzZmNhZDJiZjQwZmJhY2Q2NDY0NThlY2E3MTYwXzgtNC0xLTEtMzM0ODQ_6c7405fd-7cc1-47c8-b10a-c054e3537ac1"
      unitRef="number">0.131</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90ZXh0cmVnaW9uOmI2ZDM5NWVlYjBkMTQ1MGI5NTY1ZWJmMDMzN2M3OWQ0XzEyMTc_00c95e9b-b9a2-4432-8fd3-9533e577e79f">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the future minimum operating lease payments were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:20pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(86,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzEtMi0xLTEtMzM0ODQ_51ed2e83-04b1-4b44-8918-296670e05a4a"
      unitRef="usd">9466000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzItMi0xLTEtMzM0ODQ_2432d159-7b93-4da5-b5db-7cf9e52d0ea7"
      unitRef="usd">8624000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzMtMi0xLTEtMzM0ODQ_1a50503e-d8c6-423c-ad4a-855dbf0274aa"
      unitRef="usd">8419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzQtMi0xLTEtMzM0ODQ_23945a6e-664e-42a4-a6b6-e54590e32458"
      unitRef="usd">8571000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzUtMi0xLTEtMzM0ODQ_88dced78-5064-4a40-b07a-d0e7befb47b5"
      unitRef="usd">8754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzYtMi0xLTEtMzM0ODQ_c7166298-e062-4536-8c6f-2ccb1d72c45f"
      unitRef="usd">124979000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzctMi0xLTEtMzM0ODQ_bea586fe-cbf6-4328-af60-3e35fb2c161f"
      unitRef="usd">168813000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <fold:LesseeOperatingLeaseLiabilityTenantIncentives
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzgtMi0xLTEtMzM0ODQ_a6d280af-9a44-4734-b3e4-a2056d16a712"
      unitRef="usd">22299000</fold:LesseeOperatingLeaseLiabilityTenantIncentives>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzktMi0xLTEtMzM0ODQ_1e97f7db-71dc-487d-ab6c-7d9236f29201"
      unitRef="usd">86384000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTUvZnJhZzpiNmQzOTVlZWIwZDE0NTBiOTU2NWViZjAzMzdjNzlkNC90YWJsZTozMTdiNjQwODE4MzA0NjM2YmQyNzA2NTBkNTkwZmQwOS90YWJsZXJhbmdlOjMxN2I2NDA4MTgzMDQ2MzZiZDI3MDY1MGQ1OTBmZDA5XzEwLTItMS0xLTMzNDg0_2464da1e-c296-467a-a197-95e20f3a0ce1"
      unitRef="usd">60130000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjI_49868de2-2b2a-439c-bc65-cc4ad40475f8">Income Taxes&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, income (loss) before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following were the components of income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2022, 2021, and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act ("Tax Act"). The Tax Act significantly revises U.S. tax law by, among other provisions, lowering the U.S. federal statutory income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Tax Act also introduced an additional U.S. tax on certain non-U.S. subsidiaries&#x2019; earnings which are considered to be Global Intangible Low Taxed Income (referred to as "GILTI"). After consideration of the relevant guidance and completing the accounting for the tax effects of the Tax Act, the Company has elected to treat GILTI as a period cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2022, the Tax Act eliminated the right to deduct research and development expenditures for tax purposes&#160;in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax returns for years 2017 through 2022 are open to examination by tax authorities. The Company is also subject to examination in any period for which it has net operating losses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest carry forward limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2022 and 2021, the Company recorded valuation allowances of $632.2 million and $581.8 million, respectively, representing an increase in the valuation allowance of $50.4 million in 2022, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years. The deferred tax liability related to business acquisitions pertains to the basis difference in IPR&amp;amp;D acquired by the Company. The Company's policy is to record a deferred tax liability related to acquired IPR&amp;amp;D that may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, the Company had federal and state net operating loss carry forwards ("NOLs") of approximately $1,183 million and $992 million, respectively. The federal carry forward for losses generated prior to 2018 will expire in 2029 through 2037. Federal net operating losses incurred in 2018 and onward have an indefinite expiration under the Tax Act.&#160;Most of the state carry forwards generated prior to 2009 have expired through 2016. The remaining state carry forwards including those generated in 2009 through 2022 will expire in 2029 through 2040. Utilization of NOLs may be subject to a substantial limitation pursuant to Section&#160;382 of the Internal Revenue Code of 1986, as amended as well as similar state statutes in the event of an ownership change. Such ownership changes have occurred in the past and could occur again in the future. Under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or Section&#160;382, if a corporation undergoes an "ownership change," generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation's ability to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income may be limited. The Company may experience ownership changes in the future as a result of shifts in the stock ownership some of which are outside the Company's control. The Company completed a detailed study of the NOLs for the tax year 2022 and determined that there was not an ownership change in excess of 50%. Ownership changes in future periods may place additional limits on the Company's ability to utilize net operating loss and tax credit carry forwards. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently decrease the amount of state attributes and increase state taxes owed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has research and experimentation and orphan drug credit carryforwards of approximately $36.4 million and $187.0 million, respectively, which will expire in the years 2030 through 2040. Deferred tax assets for these carryforwards are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjM_bc809115-77f6-4e4a-82af-c5f65447a781">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For financial reporting purposes, income (loss) before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(343,424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(365,332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(241,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(274,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzItMi0xLTEtMzM0ODQ_0978fe07-ba25-432b-a737-6aa4e4efaf75"
      unitRef="usd">-343424000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzItNC0xLTEtMzM0ODQ_869725b5-639f-4dea-86ad-f45668aaf5b2"
      unitRef="usd">-333571000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzItNi0xLTEtMzM0ODQ_0ad8f5f6-536a-494b-894a-c71bf623c145"
      unitRef="usd">-365332000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzMtMi0xLTEtMzM0ODQ_5b10db7c-f755-4c73-81a4-15ab4256a559"
      unitRef="usd">101385000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzMtNC0xLTEtMzM0ODQ_c0e8b690-f2e5-4f57-a83e-704931a69aad"
      unitRef="usd">92017000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzMtNi0xLTEtMzM0ODQ_c854bfca-8431-4112-bc7a-692d875f4b9f"
      unitRef="usd">91078000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzQtMi0xLTEtMzM0ODQ_bc2219e3-abb7-4ede-b5f1-4ce4b125554d"
      unitRef="usd">-242039000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzQtNC0xLTEtMzM0ODQ_199b39c3-869d-4999-b775-4333ee86e4dd"
      unitRef="usd">-241554000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZToyZDQxOWRhOTFlYjU0MTc2YWRkZDdjODFjOGI2MGU5MS90YWJsZXJhbmdlOjJkNDE5ZGE5MWViNTQxNzZhZGRkN2M4MWM4YjYwZTkxXzQtNi0xLTEtMzM0ODQ_719b5087-48fe-47f2-ac9a-2bb3e04733b8"
      unitRef="usd">-274254000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjQ_f70f81ac-63fc-4bba-92ae-8f2c2e3c844f">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following were the components of income tax expense (benefit) for the years ended December 31, 2022, 2021, and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzMtMi0xLTEtMzM0ODQ_bda365f6-48a6-4977-af5d-73ede3b0cfa2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzMtNC0xLTEtMzM0ODQ_1610801e-1d99-4eee-ac89-58662e1375af"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzMtNi0xLTEtMzM0ODQ_d7a1ffc2-35b3-4594-a8b4-2aa2563e9c4f"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzQtMi0xLTEtMzM0ODQ_2fe3d05a-6c3b-418b-bf53-86c81fb6d662"
      unitRef="usd">6000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzQtNC0xLTEtMzM0ODQ_15940e0e-699b-4ad6-851d-574cc799d197"
      unitRef="usd">15000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzQtNi0xLTEtMzM0ODQ_03b1d258-d37e-4808-bebe-3a16e3398b42"
      unitRef="usd">11000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzUtMi0xLTEtMzM0ODQ_c574f32a-b777-497b-8053-011826916a8c"
      unitRef="usd">-5760000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzUtNC0xLTEtMzM0ODQ_d4c7cb7c-be57-426c-9f6c-004806f66519"
      unitRef="usd">8857000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzUtNi0xLTEtMzM0ODQ_2169bc2b-b50b-418a-8050-6b04c3dfb256"
      unitRef="usd">4163000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzctMi0xLTEtMzM0ODQ_95a6994d-6fc8-4f69-98e9-97f680c3367c"
      unitRef="usd">274000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzctNC0xLTEtMzM0ODQ_462f6d1a-a6cb-41c4-b1f3-80cd8c03c4e4"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzctNi0xLTEtMzM0ODQ_fe71751f-ce0e-4511-921b-42e23448e478"
      unitRef="usd">-1421000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzgtMi0xLTEtMzM0ODQ_343bbc6d-5c37-404f-9a85-8f25eda84142"
      unitRef="usd">9000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzgtNC0xLTEtMzM0ODQ_a7c68717-9e2f-4410-9ed1-02df482a0b7e"
      unitRef="usd">34000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzgtNi0xLTEtMzM0ODQ_bb583a44-b642-4a80-98ef-340b8018233d"
      unitRef="usd">-155000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzktMi0xLTEtMzM0ODQ_904a1bd4-8b66-437f-9cbd-61a72b066a5a"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzktNC0xLTEtMzM0ODQ_32320887-cc06-41b3-8e8f-59ae0fc91251"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzktNi0xLTEtMzM0ODQ_e64db6d5-f9c7-410b-8d1f-6e91697abc20"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzEwLTItMS0xLTMzNDg0_c6115db0-00bc-4319-9ccd-f1c892f3d648"
      unitRef="usd">-5471000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzEwLTQtMS0xLTMzNDg0_dd101d04-953c-4bce-8d07-2ed8777eb35d"
      unitRef="usd">8906000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpjZWMyOWRhYzQxZWU0MDk1YjI0Mzg3NjA0MTc5ZDNkMy90YWJsZXJhbmdlOmNlYzI5ZGFjNDFlZTQwOTViMjQzODc2MDQxNzlkM2QzXzEwLTYtMS0xLTMzNDg0_29c112d1-f27f-4179-96e9-f221c901b84f"
      unitRef="usd">2598000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNjU_b268cbf6-9180-42b8-90c8-a2dc3ac43836">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2022, 2021, and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of foreign operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzItMi0xLTEtMzM0ODQ_3d6122f7-9bba-4e01-9a38-1dd7e950356e"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzItNC0xLTEtMzM0ODQ_55a91804-c29a-4026-8bbf-589224e0eb96"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzItNi0xLTEtMzM0ODQ_8945256b-f888-46be-be2c-dffadc596365"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzYtMi0xLTEtMzM0ODQ_f5837ac2-37c3-4f7a-9134-c64c19a4a3e0"
      unitRef="number">-0.11</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzYtNC0xLTEtMzM0ODQ_6e08db7c-42aa-4643-9f19-01cab3f491c0"
      unitRef="number">-0.09</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzYtNi0xLTEtMzM0ODQ_2db3383b-b467-4c09-9733-99407d2ab260"
      unitRef="number">-0.07</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzctMi0xLTEtMzM0ODQ_52a18680-1606-4de2-aeaa-2ad98707883f"
      unitRef="number">-0.18</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzctNC0xLTEtMzM0ODQ_67ab8276-a3fb-4973-8fb3-63096426b7a8"
      unitRef="number">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzctNi0xLTEtMzM0ODQ_ff8b3cb7-4797-464a-a598-85c1949dd8e4"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEwLTItMS0xLTMzNDg0_4c95c8c2-cd75-4b8c-add6-01591e142dc3"
      unitRef="number">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEwLTQtMS0xLTMzNDg0_311fbfaa-85bd-4b0e-a563-d58b1f7af89b"
      unitRef="number">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEwLTYtMS0xLTMzNDg0_42cf99cf-836f-46d1-af38-848cd2ce20d6"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzExLTItMS0xLTMzNDg0_fc53b6c7-73de-4e51-aa36-c62c1d3e5ad4"
      unitRef="number">-0.09</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzExLTQtMS0xLTMzNDg0_0329eb63-3074-4691-bb9b-40bfb92e06d8"
      unitRef="number">-0.28</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzExLTYtMS0xLTMzNDg0_e34f0d4e-4cc0-4644-a6a8-927eacd8d09c"
      unitRef="number">-0.23</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEyLTItMS0xLTMzNDg0_18ffd659-468c-4926-acf0-615b0f88e249"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEyLTQtMS0xLTMzNDg0_b524e923-c474-473c-b12f-163eac0b0e6c"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTpkMTA5ZGJlYWVjZjk0NTk2ODhkM2E4ZjRkZjVlMTE4Ni90YWJsZXJhbmdlOmQxMDlkYmVhZWNmOTQ1OTY4OGQzYThmNGRmNWUxMTg2XzEyLTYtMS0xLTMzNDg0_4add76c5-d418-4268-ba56-356a97593f19"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzUwNzU_4e5fc8ff-cfd7-4570-be1e-619b5123156c">The significant components of the deferred tax assets and liabilities are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carry forwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest carry forward limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;707,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,806)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;627,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(581,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <fold:DeferredTaxAssetsIntellectualProperty
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzMtMi0xLTEtMzM0ODQ_cc85c611-7ef1-4f74-bfcc-86271c7856e1"
      unitRef="usd">68567000</fold:DeferredTaxAssetsIntellectualProperty>
    <fold:DeferredTaxAssetsIntellectualProperty
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzMtNC0xLTEtMzM0ODQ_6976fbae-6769-45a8-a0ef-7c9c336270bc"
      unitRef="usd">105453000</fold:DeferredTaxAssetsIntellectualProperty>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzUtMi0xLTEtMzM0ODQ_c62eb1fd-2639-465b-ab8b-a9315e870f15"
      unitRef="usd">223366000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzUtNC0xLTEtMzM0ODQ_d7a4800a-7b5b-4133-ac66-8a74d43f0359"
      unitRef="usd">205095000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtMi0xLTEtNDA2NzY_15c54375-7ab1-47a8-8030-376057e091a9"
      unitRef="usd">29317000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtNC0xLTEtNDA2ODY_c69692d4-5a08-4310-a5cc-5d00ef452455"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtMi0xLTEtMzM0ODQ_f65fa247-c88d-49f0-9943-4692be52e497"
      unitRef="usd">315444000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzYtNC0xLTEtMzM0ODQ_320e9055-cde1-47a9-848c-ad04edacfb0b"
      unitRef="usd">334762000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzgtMi0xLTEtMzM0ODQ_69fbe9d9-7882-4f82-97b6-df41b3e503e5"
      unitRef="usd">16417000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
    <fold:DeferredTaxAssetsNonCashStockIssueNonCurrent
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzgtNC0xLTEtMzM0ODQ_b838734b-c8a9-4deb-adae-91c224f92934"
      unitRef="usd">11779000</fold:DeferredTaxAssetsNonCashStockIssueNonCurrent>
    <fold:DeferredTaxAssetsInterestCarryforwardLimitation
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzktMi0xLTEtMzM0ODQ_8bb94bf7-8bde-4d98-a0e5-b83c90b663d5"
      unitRef="usd">12558000</fold:DeferredTaxAssetsInterestCarryforwardLimitation>
    <fold:DeferredTaxAssetsInterestCarryforwardLimitation
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzktNC0xLTEtMzM0ODQ_f1d77cef-2ca9-445b-9c01-05cbe4b7f681"
      unitRef="usd">8285000</fold:DeferredTaxAssetsInterestCarryforwardLimitation>
    <fold:DeferredTaxAssetsLeasingArrangements
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEwLTItMS0xLTMzNDg0_3d688393-0533-4fe3-a2a8-de02c041d131"
      unitRef="usd">11428000</fold:DeferredTaxAssetsLeasingArrangements>
    <fold:DeferredTaxAssetsLeasingArrangements
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEwLTQtMS0xLTMzNDg0_0d47dbfe-52a9-42dd-9de1-5d2b97ccdc92"
      unitRef="usd">9105000</fold:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTItMS0xLTQwNjkz_1b706db1-2a7b-4b10-9b5d-7d7f12a7ddb6"
      unitRef="usd">10400000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTQtMS0xLTQwNzAw_ea93f430-780f-43c6-98e2-1f1ed4290d6f"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzExLTItMS0xLTMzNDg0_6131f383-718a-42ef-ab15-3deeee8bbd36"
      unitRef="usd">20109000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzExLTQtMS0xLTMzNDg0_68931713-f742-458c-9e63-ab2ef9c91bf3"
      unitRef="usd">17748000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTItMS0xLTMzNDg0_52691b58-72c3-438a-adf1-9e7e06587f38"
      unitRef="usd">707606000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzEyLTQtMS0xLTMzNDg0_426cf219-0532-4674-aafd-11324e990d3c"
      unitRef="usd">692227000</us-gaap:DeferredTaxAssetsGross>
    <fold:DeferredTaxLiabilitiesBusinessAcquisition
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE0LTItMS0xLTMzNDg0_d312a57b-25cd-4204-aace-16046ee21525"
      unitRef="usd">4939000</fold:DeferredTaxLiabilitiesBusinessAcquisition>
    <fold:DeferredTaxLiabilitiesBusinessAcquisition
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE0LTQtMS0xLTMzNDg0_d175f6bb-c168-4ed5-bc57-b15ddb536145"
      unitRef="usd">4930000</fold:DeferredTaxLiabilitiesBusinessAcquisition>
    <fold:DeferredTaxLiabilitiesRoyaltyPayable
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE1LTItMS0xLTMzNDg0_4f8ebf4d-249c-4e4a-910b-9e48fc9e4d1f"
      unitRef="usd">68567000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
    <fold:DeferredTaxLiabilitiesRoyaltyPayable
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE1LTQtMS0xLTMzNDg0_d9b1e345-78b2-47a0-bce7-140517392a09"
      unitRef="usd">105453000</fold:DeferredTaxLiabilitiesRoyaltyPayable>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE3LTItMS0xLTMzNDg0_1feb39f8-79e0-4b23-8c00-da453fefcb9d"
      unitRef="usd">6806000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE3LTQtMS0xLTMzNDg0_81bfc14b-fb50-4027-aeeb-4bdc6b03d016"
      unitRef="usd">4932000</us-gaap:DeferredTaxLiabilitiesOther>
    <fold:DeferredTaxAssetsLiabilitiesGross
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE5LTItMS0xLTMzNDg0_20dfe3f5-81c0-4e26-9891-fbddf0ae487d"
      unitRef="usd">627294000</fold:DeferredTaxAssetsLiabilitiesGross>
    <fold:DeferredTaxAssetsLiabilitiesGross
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzE5LTQtMS0xLTMzNDg0_79e46523-fba3-4fdd-aa05-e5945c12bcfa"
      unitRef="usd">576912000</fold:DeferredTaxAssetsLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIwLTItMS0xLTMzNDg0_fde3f255-e05f-4023-82c8-f57b82e1c096"
      unitRef="usd">632233000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIwLTQtMS0xLTMzNDg0_7bfe529e-98a5-4beb-b4d5-f96ab964d4ed"
      unitRef="usd">581842000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIxLTItMS0xLTMzNDg0_cce43000-3587-4f7f-a1e6-80fa0ee13617"
      unitRef="usd">4939000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90YWJsZTowYzM0YTIzMjYyZjQ0MWI2YTNhZGYxZmU3ZjZhZDc1My90YWJsZXJhbmdlOjBjMzRhMjMyNjJmNDQxYjZhM2FkZjFmZTdmNmFkNzUzXzIxLTQtMS0xLTMzNDg0_00f343a5-beff-4cef-b853-c27e5b60ba40"
      unitRef="usd">4930000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id6fb65dbd72b492e80987a09a840570c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzIyMjc_92f6f389-4653-440d-8f34-4565d7e9f80e"
      unitRef="usd">632200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if2fe03ce4e8348beb3ff495315b993c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzIyMzQ_2203fc1b-f835-497e-88cb-36f9382cfab9"
      unitRef="usd">581800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzIzMDc_46c8fdc8-4170-420e-a190-d213300a38a0"
      unitRef="usd">-50400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ieeca2fca010445d2b6ac75145dc51d86_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzI5OTU_ab74f1c4-39f3-4a4c-9bbe-a892eb931ea1"
      unitRef="usd">1183000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2ebce9bdfa62478e987dab4fc8cb80a4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzMwMDI_6113693f-df61-4ddf-985a-87d68f9c91fb"
      unitRef="usd">992000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i79b2989cb3ff43f08613f1bb07e232a9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzQ5MDI_b27a4cc3-a4ac-42c3-9c05-bd28b6bf6fdd"
      unitRef="usd">36400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ib98e12399cbf4ef187963beeca3c3e2b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMTgvZnJhZzo1NDM5NGUxMjRmNGQ0YWNlYTEwMDZlMWQ1MTI2ZWY5Ny90ZXh0cmVnaW9uOjU0Mzk0ZTEyNGY0ZDRhY2VhMTAwNmUxZDUxMjZlZjk3XzQ5MDk_18971ed2-eab8-40c6-9f06-79cdeeecdfa5"
      unitRef="usd">187000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzI2MjI_3c9f8a4d-5d67-4c9d-9dce-68342a138fd7">Collaborative Agreements&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;University of Pennsylvania&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, as amended, the Company entered into a collaboration agreement with the University of Pennsylvania ("Penn") to pursue research and development of novel gene therapies. The Company's gene therapy portfolio pipeline expanded to include Pompe disease, Fabry disease and other rare diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company entered into a mutual termination agreement (the "Termination Agreement") pursuant to which the Company and Penn mutually agreed to terminate the collaboration agreement, as amended. In connection with the Termination Agreement, the Company agreed to pay Penn an aggregate of $23.7&#160;million in connection with an unpaid portion of the discovery support payments, research program wind-down activities, and outstanding patent costs which was recorded as a component of research and development expense within the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently, the Company entered into a license agreement with Penn pursuant to which it obtained a license with respect to the pre-clinical research and development of next generation parvovirus gene therapy products for the treatment of Pompe disease and Fabry disease. Under the agreement, the Company will be responsible for clinical development and commercialization of the licensed products for the indications and Penn is eligible to receive certain milestone and royalty payments with respect to licensed products for each indication, up to an aggregate of $86.5&#160;million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GlaxoSmithKline&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2012, as amended in November 2013, the Company entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a monotherapy and in combination with ERT for Fabry disease (&#x201c;Collaboration Agreement&#x201d;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent milestone payments due to GSK are recorded within the other current and other non-current liabilities accounts on the Consolidated Balance Sheets. Sales based tiered royalties due to GSK are recorded within the cost of goods sold within the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;For the year ended December 31, 2022, under the GSK collaboration agreements, the Company incurred approximately $25.1 million of royalty expenses. As of December 31, 2022, $7.4 million was recorded as deferred reimbursements and the Company recognized a liability of $6.9 million related to royalties payable to GSK within accrued expenses in the Consolidated Balance Sheets.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fold:PaymentsForCollaborativeArrangement
      contextRef="ib99cd8bfa1ce4661a32f07a098c4ad73_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzEwNDQ1MzYwNDY4Mzkz_eb7e47c1-a662-4b43-a839-f7bab301fcea"
      unitRef="usd">23700000</fold:PaymentsForCollaborativeArrangement>
    <fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication
      contextRef="i9793bb80591f4cbe82d14a2f6ce6c5ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzcxNDY4MjU1ODU5Njk_09ef389c-cf1f-44af-a2e3-d656fc0d16f0"
      unitRef="usd">86500000</fold:CollaborativeAgreementConditionalAggregatePaymentsPerIndication>
    <fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments
      contextRef="i2a10a61a90a344cc83adebf491256426_I20131130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzE4NTY_e73e2190-d1e3-4b9d-a620-286667ce80be"
      unitRef="usd">40000000</fold:CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments>
    <fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones
      contextRef="i0c471c92318746a9b8b1e5af997f548b_D20131101-20131130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzE5MDg_618eb778-8e67-4522-8cac-bf0b5c4c9c70"
      unitRef="market">8</fold:NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba37a657d80947ab943a84d5c6b181e9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzIzODc_2fc93470-2266-4b4f-b48b-487c9ae377eb"
      unitRef="usd">25100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i5673e90eb6f14cadab1e4565ba42932c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzI0MjE_b2976c78-2bd5-4e06-82c2-a82bd8aa2183"
      unitRef="usd">7400000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5673e90eb6f14cadab1e4565ba42932c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjEvZnJhZzplZmU5ZGQyNDFkMTk0NDlkODg4NGZjOTBmMjhiMTUwMC90ZXh0cmVnaW9uOmVmZTlkZDI0MWQxOTQ0OWQ4ODg0ZmM5MGYyOGIxNTAwXzI1MDY_0f7841cc-0459-432c-9c53-be3033a20e1a"
      unitRef="usd">6900000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDQ0NTM2MDQ2NTYyMy9mcmFnOjY0NjhlY2EzNGZjMjRlYmZhMDhjZDdhN2ZiNjdmN2NmL3RleHRyZWdpb246NjQ2OGVjYTM0ZmMyNGViZmEwOGNkN2E3ZmI2N2Y3Y2ZfMjc0ODc3OTA3MTUyMA_a3bf8cfc-4fdf-4b93-b27f-f19dcb88f468">Legal Proceedings &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2022, the Company received Paragraph IV Certification Notice Letters from Teva Pharmaceuticals USA, Inc. ("Teva"), Aurobindo Pharma Limited ("Aurobindo"), and Lupin Limited ("Lupin") in connection with Abbreviated New Drug Applications (&#x201c;ANDA&#x201d;) filed with the FDA requesting approval to market generic Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In November 2022, the Company filed four lawsuits against Teva, Lupin, and Aurobindo in the U.S. District Court for the District of Delaware for infringement of its Orange Book-listed patents and will vigorously enforce its Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property rights.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <fold:LossContingencyNumberOfLawsuits
      contextRef="if0862ce94c414f10953150dfe32fbbaf_I20221130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMDQ0NTM2MDQ2NTYyMy9mcmFnOjY0NjhlY2EzNGZjMjRlYmZhMDhjZDdhN2ZiNjdmN2NmL3RleHRyZWdpb246NjQ2OGVjYTM0ZmMyNGViZmEwOGNkN2E3ZmI2N2Y3Y2ZfMTY0OTI2NzQ0Mzc1OA_eccd570a-0534-42eb-9e29-4830b40cfc93"
      unitRef="lawsuit">4</fold:LossContingencyNumberOfLawsuits>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90ZXh0cmVnaW9uOjAzYjlhMjA0NjkwNTQ0YWY5ZGU0Mjc2YmY2OTZlMTcwXzcyNg_4acdac25-16de-424e-8bbb-016ada5e8368">Basic and Diluted Net Loss per Common Share&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,057,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,421,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,867,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive common stock equivalents would include the dilutive effect of outstanding common stock options, unvested RSUs, outstanding warrants for common stock equivalents, and convertible debt units. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90ZXh0cmVnaW9uOjAzYjlhMjA0NjkwNTQ0YWY5ZGU0Mjc2YmY2OTZlMTcwXzcyMQ_169e6b22-4a51-42ad-b2f1-51cb90858a4a">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(236,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,057,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,421,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,867,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzMtMi0xLTEtMzM0ODQ_ebd856a9-106a-438d-bd92-8e1807581c34"
      unitRef="usd">-236568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzMtNC0xLTEtMzM0ODQ_57da3075-6132-4ac6-99a6-454592b3152c"
      unitRef="usd">-250460000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzMtNi0xLTEtMzM0ODQ_523c5cb5-ba20-4dac-9728-63ed9255276a"
      unitRef="usd">-276852000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtMi0xLTEtMzM0ODQ_0f2f2046-2929-4c9a-8e5c-582537639b84"
      unitRef="shares">289057198</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtMi0xLTEtMzM0ODQ_5a66b666-540b-4994-9ee1-cc6364f25233"
      unitRef="shares">289057198</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNC0xLTEtMzM0ODQ_c89a777b-f2ca-45bd-95dc-33a228eaf64f"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNC0xLTEtMzM0ODQ_eb97c6fd-aac2-455d-92de-4face3c872af"
      unitRef="shares">271421986</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNi0xLTEtMzM0ODQ_989f6df0-f7df-40d6-805e-3257ddff5e42"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZToxMWIxNjJjNGE2NTc0MGMwYjVjZGVkMGIyMmI2NzEzZi90YWJsZXJhbmdlOjExYjE2MmM0YTY1NzQwYzBiNWNkZWQwYjIyYjY3MTNmXzUtNi0xLTEtMzM0ODQ_b8f7b967-37bb-4cf3-9ce6-166442f46625"
      unitRef="shares">258867380</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90ZXh0cmVnaW9uOjAzYjlhMjA0NjkwNTQ0YWY5ZGU0Mjc2YmY2OTZlMTcwXzcyMg_8e359f54-5f96-4811-bed4-bd41618c3d61">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id13e58186fce456cb1f8099e4d16a816_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzItMi0xLTEtMzM0ODQ_180c5b91-092a-4e81-98f9-4c660622f607"
      unitRef="shares">19064000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe76a53ea05f4538ab0428dc6a0d71ba_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzItNC0xLTEtMzM0ODQ_27852600-0463-40a4-bd9d-ddf4fb22611f"
      unitRef="shares">14731000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i368b9dd19078410ea03a553d29d85a22_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzItNi0xLTEtMzM0ODQ_2c32673d-4a0d-42bd-9280-f5a6345ee85d"
      unitRef="shares">14032000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b4ae1b3663f48dc81a42db36e0a2c47_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzMtMi0xLTEtMzM0ODQ_410f39f7-cd7c-4bf9-89af-35a55053cbb7"
      unitRef="shares">9717000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic8b18190ecdd4603980cfb4ea1d75b83_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzMtNC0xLTEtMzM0ODQ_e269a846-14a2-4395-bbf0-f2155b3e8ef3"
      unitRef="shares">7341000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4ac3baf5d87f4121b825257bdbd8cdfc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzMtNi0xLTEtMzM0ODQ_d37c1f1d-2019-4953-824f-82e4bf350fd9"
      unitRef="shares">7080000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c9f9812c5e347c0a7f7930aed8b7d7b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzQtMi0xLTEtMzM0ODQ_f04bbe33-f7a4-43ea-9319-b9cafbb6fce6"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39d797c28b2c491eaa21d972d9a071a0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzQtNC0xLTEtMzM0ODQ_ebf4d1cd-5e3d-48c5-b7da-c96713828d93"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i080e37076a644122a897798491e8bdd2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzQtNi0xLTEtMzM0ODQ_f6ba1cec-e38d-4954-b48d-79a42c422305"
      unitRef="shares">2555000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7edd439e87db45d786c45396af394cbd_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzUtMi0xLTEtMzM0ODQ_ab7a87d3-48aa-4cb9-b44d-de5ed85fa130"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0fc776c099cb497d877ef435b98b54e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzUtNC0xLTEtMzM0ODQ_6f88a4eb-7a14-4184-95e4-eafa3d7feb5e"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i68a0f47df35a4dfa8f233290926fed7a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzUtNi0xLTEtMzM0ODQ_be16c886-045c-44dc-bad2-4898f7f28d66"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzYtMi0xLTEtMzM0ODQ_376efe94-57d4-4217-8bee-03f0daafe0f3"
      unitRef="shares">28781000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7fdf6397407c4008b7cdd224c6d8d6e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzYtNC0xLTEtMzM0ODQ_5f91b377-d150-4cb0-9658-6464c9e09ef3"
      unitRef="shares">22072000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i29a4a2e9ae9f40d7a2fc8284c747a118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xMjQvZnJhZzowM2I5YTIwNDY5MDU0NGFmOWRlNDI3NmJmNjk2ZTE3MC90YWJsZTo5MWU3MmJiYTczYjQ0ZjQzYWJmZTM1ODU3MzQ4MWEyMi90YWJsZXJhbmdlOjkxZTcyYmJhNzNiNDRmNDNhYmZlMzU4NTczNDgxYTIyXzYtNi0xLTEtMzM0ODQ_f89ae800-1ad6-4f56-8e4f-250f1831ce26"
      unitRef="shares">24129000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <dei:AuditorFirmId
      contextRef="i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwODY4YmI5NTE2YTQxM2M4MjMwM2Y2YjBkMWJhOTk3L3NlYzo2MDg2OGJiOTUxNmE0MTNjODIzMDNmNmIwZDFiYTk5N18xNjAvZnJhZzo3NjhkZmE5YTU4NDg0MTcxOWVmZTA5MzQ4Yjg4OWYxYi90YWJsZTphMzU3NjE2MzY0NmE0MWU0YmY2YWM4Zjk5NzM2ZjY3Mi90YWJsZXJhbmdlOmEzNTc2MTYzNjQ2YTQxZTRiZjZhYzhmOTk3MzZmNjcyXzEtMC0xLTEtMzM0ODQvdGV4dHJlZ2lvbjplM2NlYzA2YmNkOWY0MWQwYmIwNmE5MDRiYjhiZDg0MV83MQ_bb8d8b8f-0e31-45ae-920c-ea845d393928">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MM<+N%Z0!X/\+(?1^8!;H^^GL/U!+ P04    " #G@&%6@UM"N*8)   I40
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;+6<:W/;-A:&_PI&V^DF,U5$
M +QF;<\T%(G-S.XVTS3M9T:"+&XHTB4I.]E?OR#%B,)%,-F<?+%U.7@/A!<
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M]SS;\KH+$._OJJK]^J3[I;GSKR/>_1]02P,$%     @ YX!A5B0D5+&Z"0
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ME+>CFY&X=*YDP>>^78I9B;R@B97LLA>#R_/9X.507+0>N5M:<=4;:+94MGC
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M7DE_AV@$8V=MK)S//<2V[)]_>CN=[A]>S6;\-#E\V07;PK4>P?(-7HVP$@Q
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M.UH6H/.E,7[SP@[Z_P;F?P-02P,$%     @ YX!A5C$\Y'??!P  _14  !D
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M@DRU :>55CYONJP"^4(<Q=IGGSN2C%C6)3<E>9W*.8S]-:5@P>!CN/.<J6"
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M+PQMP/=<X]S1O)" ]L;W^B]02P,$%     @ YX!A5@CEZQ7N @  ; 8  !D
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MVA#RC]$=*D9!1;1#A9[1\/X!>FT<5:?0<9#U:>2*R&C\QB*]G+RUED(> G:
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M\].!</'V.+X$6_&-[=2&8$M^7"@)$VD!OL\L2JYY(07=%?[M?P%02P,$%
M  @ YX!A5E /V^&X"P  0"   !D   !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&ULI5IK<]LV%OTK&#7;.C,TS9=>>7C&3M+=?FCKC9MV=G;V T1"$C84H1"4
M%??7[[D7X$.R[+K;+Y9$ O>>^SX@_69OZL]VK50COF[*RKX=K9MF^^KBPN9K
MM9$V-%M5X<[2U!O9X&>]NK#;6LF"-VW*BR2*)A<;J:O1Y1N^=E-?OC&[IM25
MNJF%W6TVLKZ_5J79OQW%H_;"1[U:-W3AXO+-5J[4K6H^;6]J_+KHI!1ZHRJK
M325JM7P[NHI?76>TGA?\JM7>#KX+LF1AS&?Z\4/Q=A01(%6JO"$)$A]WZITJ
M2Q($&%^\S%&GDC8.O[?2OV?;8<M"6O7.E+_IHEF_'<U&HE!+N2N;CV;_#^7M
M&9.\W)26_XJ]6YNE(Y'O;&,V?C,0;'3E/N57[X?!AEGTR(;$;T@8MU/$*-_+
M1EZ^J<U>U+0:TN@+F\J[ 4Y7%)3;IL9=C7W-Y>U:UHKM*L0[LT&LK21WO;EH
M()W67.1>TK63E#PB*4[$CZ9JUE9\J I5' JX *P.6])BNTZ>E/A>Y:%(XT D
M49(\(2_M;$U97OJ4K>?7;.N-O$=J->*JKF6U4OS]WU<+V]3(D_^<LM[)SD[+
MIMIY9;<R5V]'* ZKZCLUNOSVFW@2O7X">=8ASYZ2_J>B]*2DTS@?$R]^62MQ
M4\I*;&MSIPME!=J :'!U!;<UNEH)LT1MPFTZ;[ ;^9I_%KM*-U;(JA!F2W*L
M:(S8[NI\#14B-YL-9+NENF)QI%56][1.;;:EN5?*!J+0-8K7U#84LKC3%M\"
M%IM#)LH.$*"F$1+X=*YH]T*A)AM5HU0 9W$_E/[M-[,DGKZVXMK(NB#D[WL%
MG:G: E2C*(<93I6;78W^),R^4K5=ZRWM=.@AOX/[ !A6#4VCV^0&YTD85&CR
MC2RA+D?ZH3EU[MWXE1O3*!9B=WFN[+',SJ#%SL)>Z\UX:%X@()=B0K[73:-4
M0'8B<%L UHM2L>;6<Q174J.K0@/L3I;6^Y;#KKJX!KRLVFT6JB:%;;B5S->#
MW>AI90EMN8*1;H];Z>.VQ6Y+.>BB2_?55U7GVO(];=@:%NKVA8]D9J[J!H,(
M2"NU)'N!^@L Z.4]V>0VR+K1N=YRC/9K(ZS")0E'+^%P025!F/:Z61_$K]AQ
M@A5*-FM*32L7NM3-/;EV5*L&OJ8N,A)GTE*\L!O.)#=C2' V[I!3KGH(R$MQ
M-OHG8]/<CWI4HY>A^-E[LG7XX5X"(L7)W>1(.!N)B/)TD)%8#00TNF0!"5PL
MJPJAJ"WF<)M3)Z5U&>:=Q(.4]D,%B>U30:Q5R07'IC\%#7ZB&/D(2TJ^'IR2
M=:E=,M'/#$'X*UA]MS*U7FDJ-?5UJ_VM@D+NY;59U7J]65-704^L3-.E8H$4
MJ%UI(*C'">IL6W A+96&9Y"DH"_GKJT^T2,?W&IC_D20C].!\.XI[T#:BEWI
M-G/<*8]]DVWV1MS#P2WDI2G!R=IB/ZGHNP-O.ALE6E&IN&((/G?<DB)$:;JE
M990!_;907%%G_T-?(%8/[CC#S ZIM99WJLTYN6RH97"1'1G%K688!H?I>18"
M:FE-P V)=ERAH@NJ:FI,]W29:3#Z]=.F'(7G;'3S\?83ZKKM@=UD.@DI."J4
M$LE+5=*&U%G_I^K H?5^ ,.AICRPYGA6->O:[%:N_ZFJ:&\/=WAWR^VVU+GT
M\&@O1X7M#<4M^\15E?A[S2WWEX&>G566)2^EKL6=+-&P-JI9NX:_4=*ZBN/A
MX%V>#PA*(&CPK8Y%M,-"?=E1@Y9[FH>^JL(# /G:6#=AV6N3U_Z#>"#Q^7/B
M3]ZA_@.$ R%?[-@F#Y9F#R)F<LF<: @1/VQ7Z+E95?IW53P&V.60GXW4:L4!
M$ HC6H^Y\^&G;"!]_8RDJ[4J)1<)F6W#TPZ_+F7^^?P6]I>X,IC&)&]C4-&8
MC0K)!PT;9U5'^USK', G\X<A:C5_LFR:Y&7.&TYT39%![> D4TG/OI$^&_E9
M=3-<6AP4?3_F84QL!72&%KI3'30Y<;K:[G T%1^^;MWE.P,7N.D,?QTDO_<$
MRAY='-P(R5L.UCMWH=4PY5.M0%29<J.\XY9]YO4B?64-),-5TLFLM?U\OJR5
M8GI)C4-P#QT"_!3>8G'->7\?B-]5;<Y!/ZF!:;A#>4](WQH8 )$,122''..H
MTQ TNY%BTO#-=NIQ($/QO>N2.XH%S3L?;FI0+2;X!N.9AJ\SW3<4A7ZL38W&
M"%"*Q@(D#"U'9,M[3M=EZQ>?9LM>J7/-824PWQT40D^":,+U"'U #RSR49'/
MRN^6X?5S<,^'>%6<MPDP2,)7XE\8,_YT*W V5<QZV_,I_8GI3]2GH;/"<=Q!
M2DZ2,!9_$Y-QF.%C.N9?'Y$>XD1ZQ.$4=Z-P@K\Q__UP$-\!ZSZC.6A?BG&8
M9OB31?@SF?;K0:0H"LS*J:MWM%N\<.TO>7WR&X6H]4Q7&NSN\^-.T(L<X&K#
MY^D3>8M]%CNZSS[;*X(Q"6-<?#$/HYF[ARM9%+2EC\E9HD*OVD=(1V.+1OE!
MWK2'5>8'ZI&XL69I?18@S#]UQYG?6J.[+U>K5:U69/09DRJSLX )G]//#:@'
MZ7W9\4B#MH3#8 &S@V/5\5S$DV":9/#T/(S';CY"1Q:DDX0OSF<(7DL^S\9!
MDJ4O<6,&+[652S?B()U.Z$8<A5E"\=;$Q<ZR=,Q7TS!-GP4)<8BS($J=]G'6
M04J#A"'%DW"<#C'%039C3-,P&@\QS;*,=2?A?-HC2M*)1Y3,GH<H)D33-*9=
M,=*B@S3&U=1=/80TF42D TAG0T#9?.P!C8> LO;J+'L>H$3$\R":9$XU@$U0
ME"]$.D&=_NK9:47G-4]5NV[LV=M)B=,@FR=.(GXBYTDB]84/@T,2.OB)K5$P
M3V<N]N,Y"C["]P0%Y.98EZYH*B@^J_.^SW:']8?G&U<R]K&:\9'IBQ?E\P*.
M;2L )3P;_N)*SJ)PWE\ZK.AWTJ[I))\K55A_#C^HY/\7XX,.DX7I "6<EAS#
M3(8KCAH/#[,3JOAT91HTUUTU8'D/>&#'S9 ,E:G.?8X\/NU>I#&RP,-A@'ST
M[%-JH8:TDIFA?-BLAP211@Q[+A0?^].+8^J?ND/IS>"HXYZ8/K+X+$??;%TD
M1OZ<0Q^.!CY\=D'38:4J("M+.BXL_NM9'0RGY2VKY><,M?*/,E;$$=D'W2.W
M[VSWF*-HG]N$7O5C.GKN(?322W+TTY,;L 4,;!H<IF732CH>VP)K#WT4K4-Z
M39&I6HK- ?<3BD %8-2:GHL=T$@7P^X\@+'V635'9(@&*J?>P:-3=FMYWU:#
ML_L$RPN(2*"#W/<'!Y\/OI8<K.&!8FBA*.76JJ.I.TA>Z'7O5HC:'(7Z60,8
M_OB#\7OETYA[OWA/QGU/SOJ5O?1@V<>.'#O&U@_M'[HNZ+8^.<1_ZFWT#VM.
ME3_&.$91V[WCV6",3[J>/F]'PUD2Q)/,S^II=#C%DXPG%XG)GJD=?6T:1+/(
M3Z/Q8&+'\]A-['G6:8^#V83'=3P.I]-#[=%DVH["Y+G:8VA/L]B-]'DT&,Y1
M-G.8YNG ]F0<>QW9X7!.VNO1Y+FZ$S$/IO'4Z8ZF@D@U:9QA'C_5J%'YW%G'
M($M=9Z5*^Y/]NYOP7'A\F/ ]R)^"VV)"CW*/^EVSL*I])%"KO];*_9,OB#UX
M:?/!-2&408?U@WL0<L7G<G?DZI_],;EPM0W-]/;#O>MUKUT[&0?.\(UN"+A[
MDU-94^I"ND&!#VJO'(^?M\H]CK)#N7QD'3RH>>J@=52O1^<N3"ALS-<\.0J%
M@62VW-M;M&!&R,S9G/*$$I>Y4A3,D$6W.,(RW_-3P[$!6=#;$'H&0_.MDS,&
M[4U2@9-)!HJ>S((4!ZY?.'^\)2>=!98\"<8Q-87Q-)@Q;<OF03R.Q:EWA!>#
MM[H;5:_XW36-/!S'W0O>[FKW>OS*O17NE[MWZS_*>J6IE:LEMJ+SC$>B=N^K
MW8_&;/D=\<(TC=GPU[7"-*YI >XOC6G:'Z2@^Z>!R_\!4$L#!!0    ( .>
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MDR4SD!\LRJ2H>9UD6[;)9)(QJ2D#80&DX7B5@V/T!7LGUB)G8_;]=[-X'/_
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M4X%.;3_B.@8M.G7A8+O\,#0( GLH.-RJ'&TX=G3WF>E4E^4:T7;4AW.*WO2
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M((2N3PFIW$)LY>P>)VY(G!DEV8QXY:@MS1VPBERCSKG!$*A9O<J:Z! D5YU
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MJ[6L"_>I.OQ-!7LF)&]5%9;_BH-?FV4#L:JMJW9A,S38Z=)_RKO@A\Z&>?S
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ME$/&L8J/-44M[S2B:NLQI(L(S6+OJ@X^GC42)*?%(79SOU*/,=.#_<';'L$
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M.(SV].&XV&"!81[.Z]#@ 10] WED?"!IT&W(T DL>XK"$IV0);:Q#;B '.B
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MX$P+\'Q=5:[Y0@>TO[U>_0]02P,$%     @ YX!A5J-_A/"=!0  7PX  !D
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M&_ @B9\+O #)\0:LSZP-[8 -=&_*RW\ 4$L#!!0    ( .> 85:FLW5';P,
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MX#(-/K[XVS>KJR??8655'Q&IW"J($T2)MK$^.B=?.HZ5IB/E(V"T#"-&/Y/
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M).IGB',_5@Y1*Z3,V<WY+,Z,XDB%[V@TB2:9@!L]C0M7B_?[MJF/?D&&3\;
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M.S?IR\)Q$&W6CL>YQ-7\8.$;C<O5TK.8R;#P=-+V.0!/&I#^_#H7XB6^2"X
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M1MVS?@"ZF2B-8E7MNWBI+,T$+Q8TA%$[![*OE+([Q25HQ_KT-U!+ P04
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MRE(G\,.26B]JMX'6ETK9K>$<M,T\_0502P,$%     @ YX!A5@V+^26 !
M\ P  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULM5??;]LV$/Y7"+4H
M$D"-14JR[-0VD*1-UX<"09QM#\,>:.EL$9%$E:3L]K_?D;)EQ7&]9,5>)/%X
MO[Z/QR,UV4CUJ', 0[Z71:6G7FY,?3D8Z#2'DNL+64.%,TNI2FYPJ%8#72O@
MF3,JBP$+@N&@Y*+R9A,GNU.SB6Q,(2JX4T0W9<G5CVLHY&;J46\GN!>KW%C!
M8#:I^0KF8'ZO[Q2.!IV73)10:2$KHF Y]:[HY75L]9W"'P(VNO=-+)*%E(]V
M\"6;>H%-" I(C?7 \;6&&R@*ZPC3^+;UZ74AK6'_>^?]UF%'+ NNX486?XK,
MY%-OY)$,EKPIS+W<_ 9;/"[!5!;:/<FFU4V&'DD;;62Y-<8,2E&U;_Y]RT//
M8!3\Q(!M#9C+NPWDLOS(#9]-E-P09;71F_UP4)TU)B<JNRASHW!6H)V9W7"=
M^\0^R:=OC5CS BJC??*5JT<P?%$ F4/:*&$$H)A7&;D';91(#62MW=F#5=/G
MDX'!A*S;0;H-?MT&9S\)3AGY*BN3:_*IRB![ZF" 2#HX; ?GFIWT^!'2"Q)2
MG[" L1/^PHZ>T/D+7TF/Y6&>2V7>/X JR9=JC:24=H[\=;5 ?K#:_CY&2!LN
M.A[.[L!+7?,4IAYN,0UJ#=[LW1LZ##Z< !-U8*)3WF=SW-%9@RLJERTDB^)J
MS47AUAEW.)GS)PM^#,')&,<1M"RF-B0<LECN"TUW<0E70-*":RV6 NN,:]P+
M2J$5:2JL-4TLU[BK<4Z:'-1&:" +VV*<TU1BU]"V0A$JSB.V N=$M;HD5]H*
ML5"@7(#JBH6<B0I59:/1@3XG-U(;\EE)C-4^;[E0>]H.P9"WA$8C?T1#_'KW
M9L0H^_#D:S=[(\L25"IX06I>8P(TBGPV'I,1Z[2M*!Q1NSG@QY8A$L9!I[![
M6]D-*(,LI=RXA<V@EEH8$M-GVBAZ2]@X]&.7)0;L)^@FQC'6<EHTN!L)\I'^
M,MR^M^-+;<$F07"(/\'Q@S1(4_KJZGD!RN-50'^]"E@4^W2<_(26W>SS*D@B
M/TY&)"%G<73>#D.*>JJ6RBYM!@O3QQ@R/V1[RLXH/7<R2A&;!O-^P=-'Y+UO
M$OA!$O1,,)"5Q</_I=*B$?/CX0B_+!MGR?A\*XS&PQ=7V<OH_/<J8V'BAPFU
M_-I$[-!NNO]>82?1G6C6<=>LXQ<WZWO AI:*0G!WD^FW[\.CZ=@)?:R+GPQ^
MO(L_]/LH:2FIE5R+S#9LO*$=)GF*5K5/T2DH+"9E1QMA<K<' 8N_TK(0&;?R
M:U[P*L7#R5YU-,YS8V^2Q$BG:]Q";KN]YB4^FA0I*F5C6=&YW%3DF-^YP5=[
M<N]XO46(^N*P%3P_,9YWCT-)\,(#8U_E=!CZ+ KZ2^@L\4 (&#Y9/";,'V/T
M4X?J(;NOAV]3B4.?TMBE-_8C[!(VO:%/A^QH@0]ZMU!L;BMWU\:#VZY >R'M
MI-UU_JJ]Q>[5VW\!O'VN1*5) 4LT#2X2+%?5WJ_;@9&UN],NI,$;LOO,\9<$
ME%7 ^:649C>P ;J?G-D_4$L#!!0    ( .> 85:4Q7 WG0(  *H%   9
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M;>:\3-'X!#Y?$;E7QS=HU_/L#U!+ P04    " #G@&%6\6^/X! #  "=!@
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M_;G";3.' !\U>1CPIX4@,[2_V=FWT )LG#X0Y3V1.2R8A17<<D.$L1)2!&I
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M_U<(M^D20(TE^1'530PX3HL52+&@3CH,PS!0TMGB0HDJ2=GQ?[\C]8QKN\&
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M.TWP#0W2$.#WI1"Z7A@%S:M\^B]02P,$%     @ YX!A5F=81'_E P  90D
M !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&ULC5;;;N,V$/V5@9IM$T"U
MKG82US:0;%(T0'81)&G[4!0%+8UL8BE22U)QW*_OD+*5F^/&#^9MYLR9&ZG)
M2NEO9HEHX;$6TDR#I;7-.(I,L<2:F8%J4-))I73-+"WU(C*-1E9ZI5I$:1R/
MHIIQ&<PF?N]&SR:JM8)+O-%@VKIF>GV.0JVF01)L-V[Y8FG=1C2;-&R!=VA_
M;VXTK:(>I>0U2L.5!(W5-#A+QN=#)^\%_N"X,L_FX#R9*_7-+:[*:1 [0BBP
ML Z!T?" GU$(!T0TOF\P@]ZD4WP^WZ+_ZGTG7^;,X&<E_N2E74Z#DP!*K%@K
M[*U:_88;?SS!0@GC_V&UD8T#*%IC5;U1)@8UE]W('C=Q^(A"NE%(/>_.D&=Y
MP2R;3;1:@7;2A.8FWE6O3>2X=$FYLYI..>G9V07.+1S>L[E <S2)+$&Z@ZC8
MJ)]WZND[ZDD*7Y2T2P.7LL3R)4!$7'I"Z9;0>;H7\0*+ 61)"&F<IGOPLM[!
MS.-E^QR\X*80RK0:X:^SN;&:BN'O7=YV6/EN+-<@8].P J<!=8!!_8#![,<?
MDE'\RQZF><\TWX<^NZ.&*UN!H"JXYFS.!;=K^*SJ1DF4UKA]NT3:D0^H+:>4
MP5=ET>QR9+^I>P]3-TRN?S)4Q!2B0E&CF2<KE1+4L%PNQG#()6VIUC!9FB.@
M#&$]1]UGZ<U. G<HN=(T%!3S$NY1UW"MF(2R12<Q&L.-YK+@#1-P 'D<AW$<
M/YM=HS'CCEE)R5.MI#)-CN P#X?';AR%\7%^U,M5J)VABDM&J'+1"6=AGIUV
M2B,:O](E5S"MUT[@@8FVB[62BY^M8^C-'4!VFH2GIXY-=G(:9L-C^&??SYNZ
MDH5HJ0/ Q\HGR2C!2V9I[YP)8H5PY]K44(?;)8F)EW8IN,!J18G]EU2L(B0Z
M1&,!'^D*-L25TN[!-;KKUCDA>(7;C+T;\]8X42>"587^&GP"U\00:J3\EH,]
M13SLBWBXM[)>ENN]LI3?JZVMRXTCMUBHA?1^WJ+P(2)_/US;^QG</R]>L.YF
M ^/"3B^87;Z-JGXBHU^3>=$AI.^WU\BT 73WW8Y><&ET+1 2FFFZ:(OUJR8*
MR7J!C7V5!DH_U?D'6XQ"Y>^QEB+\QBDJW3S,\Y&;Q&%^G,%95UK,OX64FI>M
M=0!).(PS/^:C=(?TFP9SHDF6^#%.3^#RG=K:5*?H;[1B6R+A_U\3D*2#!#[!
MR2"'3[O*,WKV]-6H%_Z!-^"]ZE[!?K?_ACCKGLXG\>X#Y O3"RX-"*Q(-1X<
M4YWI[E'O%E8U_B&=*TO/LI\NZ3L(M1.@\TI1Q6X6SD#_937[#U!+ P04
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M_Z]PUG1O[K"/:JSGJ6C$HC0[BVPO\F[#O1W6?2T@D)5B*X#EL)6,Q(;#O.<
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M@=R*%FAVC5RZ*(H^T-+8(D*1*DG%R=]W2,F*TSAN7L2+YG9FSI"<;I1^,"6
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M ^T$\/]*(:)NX1STC[_YOU!+ P04    " #G@&%6!A<:%TL"   [!0  &0
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M0S1)(BD:)*VW8;,;5QN'-FHHMW]QIZ6YI0:GDPVH5-+*E53D:%4KXZ 4NMR
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M(RD'BN_MJ<&:*YW@]G8'. -A#/3S#>?J>6 6J$^J%O\#4$L#!!0    ( .>
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M8G*2/'&<[<.OVO#)F?##!-9:467A5N68_TL0NURZA))#0JNDE_$&LPL8#;]
M,DB2'KY1=T"CP#<^P[?FBLM&GDJM%^AOTZ6M68;+R%T7B^8)H_3CA^%T\*U'
MUKB3-0[LHS.R3I?BE,KQ.ZB<="HGO8=W:XF[FX,Y-!:+1H!P5]">4MG/,X(7
M9,;V*)IVBJ;]Y63/Y\K9"_S/@YIULF9O5,[9.ZB<=RKG;U3.?I[)^7+&1ZU,
MHBE#P[80NE';U;K5[DVX:EOA7_?V05DS4W)E06#AH(.+F?O'3-ND6X-T'1KC
MO2;79L.T<N\:&N_@]@NMZ6#X -U+F;X"4$L#!!0    ( .> 859=GV%/10,
M %P-   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;+5778^;.!3]*Q9;
MK5II&\Q'&#*;(,T,W=U*[6HTV6D?JCYXX :L@IVUG63Z[VL;0D.&1%.5O@1L
MSCG<>\QUKN<[+K[($D"AQ[IB<N&42JTO75=F)=1$3O@:F'ZRXJ(F2@]%X<JU
M ));4EVY/L:16Q/*G&1NYVY%,N<;55$&MP+)35T3\?4:*KY;.)ZSG[BC1:G,
MA)O,UZ2 ):C[]:W0([=3R6D-3%+.D(#5PKGR+E,/&X)%?*"PDP?WR*3RP/D7
M,WB;+QQL(H(*,F4DB+YLX0:JRBCI./YO19WNG89X>+]7_\LFKY-Y(!)N>/61
MYJI<.+&#<EB13:7N^.X?:!.:&KV,5]+^HEV+Q0[*-E+QNB7K"&K*FBMY;(TX
M('C1"8+?$OQC0GB"$+2$X+F$L"6$UIDF%>M#2A1)YH+OD#!HK69NK)F6K=.G
MS*S[4@G]E&J>2I;->B.^0DM:,+JB&6$*7649WS!%68%N>44S"A*]1G>P!;8!
M]/ 5_0V\$&1=:GB%KO07AUZFH BMY"L-O%^FZ.6+5^@%H@S]5_*-)"R7<U?I
MB,U[W:R-[KJ)SC\1G>>C]YRI4J(W+(>\+^#J5+M\_7V^U_Y9Q12R"0J\/Y"/
M?7\@H)OGT[T!>OI\.CZ33="M7F#U@E-Z5)*B$% 06T1Z$?=+].F=AJ*W"FKY
M><CW1C<<UC6;S:5<DPP6CMY-)(@M.,GOOWD1_G/(LS'%TI'$>GZ&G9_A.?7D
M7[W1K@7/-YE"DE0P^,DV$E,K8;;5;1+X,S\(YN[VT)0!&)Y.O; /2Y_"_ C'
M<=3!>HE,NT2F9Q.YGRPG0[&?9?WHLH\IEHXDUG,KZMR*?E$916/Z.:98.I)8
MS\^+SL^+GR^C1B(Z^/ ];SH+HZ,R>@J;38/XXJB*GJ)BC,,3111W:<1GTWCS
M^/I4'9TE_NBZCRF6CB36,VS6&3;[174T&]//,<72D<1Z?GKX>W>&?[Z26HW>
M?X@7^,=%<C.(PYY_7$P#."_&<8B/RLD]:#MK$(5MWR6RG6/3D76SW1'ARC;&
M1_/7YNA@V]GO,LVYXST1!6425;#2DGARH8,232O?#!1?V^;V@2O=*MO;4A]_
M0!B ?K[B7.T'Y@7=@2KY!E!+ P04    " #G@&%6-^YM5B,"  !K!   &0
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MI+O6[@RKZM!.!V5=<X9EY5X#T-[!G1=*V8OA.W1X7[*_4$L#!!0    ( .>
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M+2N\B4!9 )XOI#3/@9U=P]V6_0%02P,$%     @ YX!A5J>A_<38 @  P0D
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MWN5 DQ)EOU!.%,]MR5URI0NX'::ZQP)A#/3W%>=J.S$;U%U;^!]02P,$%
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MLE@T+!8]UH?6@E@M^Q>?%@NUU@4*E253-0OF,)S..TB,25LB ;[4>+[-FN&
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M-6.4C]<DNA?GD+G%FB-=C,=E-.PJ6INB%/9P.GR+=:3&:[PNHV%7T=IXY:0
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M(#[?YCG__J+\14/SDY?5?U!+ P04    " #G@&%6D57Z[0H#  #1"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RM5EM/VS 8_2M6AB8F%9(X%RAK
M(T%;-!XF(0K;P[0'-_E*+!*[V&[+_OUL)PV]A*Y#O"2^?.?8WSF^]99</,D<
M0*&7LF"R[^1*S2Y<5Z8YE$2>\ADPW3/EHB1*5\6C*V<"2&9!9>%BSXO=DE#F
M)#W;=BN2'I^K@C*X%4C.RY*(/U=0\&7?\9U5PQU]S)5I<)/>C#S"&-3#[%;H
MFMNP9+0$)BEG2,"T[USZ%Z/(Q-N 'Q26<JV,3"83SI],Y2;K.YZ9$!20*L-
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MO=,SS2"J!T1547QF;\@)5_J^M<5<O[E F #=/^5<K2KFTFU><<E?4$L#!!0
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M@VTV&FCI0I-=[!==?DU+/W'),@?L*ZV2]H:/V6DO"JT9@](\*(VC:+JH*K/
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M$/T50EOL)L#6NOB:K&T@<5*T#^D&#=H^,]+8(D*1"DG9"="/WR$E*[)7$9I
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M1@#?@+7X^2=WZOS2I^V08,% 8"W=_5IWWX2^^*;+!XI)-\"Q')(8Y98G$95
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M Y.29;JY AH!5P;X?LF8?'E0 >I+RL6_4$L#!!0    ( .> 859\D#6L00,
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M;ZF>:<N/GS1M,?2%J16G(R1P293VF_- M05&VS&R<4_NHS3T@+MF2349*AM
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M(56JN9IAJ>B^4&2?4 1M\$A3L>+@8QKAJ$Y@2O=4/K+W/KJW.QD#'/:  V^
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M:[?!8&6)5"WWR+[<=R==\!\XIZ^W(PY^$GZ% D!* :"+%0!RJ@!<H>D\E0)
M;A0 ZJ_MQN[>9&?I[K%2 ?A\%5 7Y(!FWPX]-&.NT/2!4 H!7ZP0L%.%X I-
MYZD4 G:C$.PP@TGW=82EV<>=TPK[UL5!^0[H_>W @_G]"H&!E<# ]@,16_$Z
MW>-PA:;S5.H$V]7)V<7K=,,#]U6+I??'2K9@NVPY*-Y36P%VM,&D'*'IW)40
MPN.+*]:IX'&%IO-4@@?;3V[.KMCXG*T D]71K0"LU JVJY5.(6)C<$[/75RA
MZ4?'2O&$P<\='CM5-:[0=+)*U82G#F^&=YX-Y*D39)/9\2/D4 F4T"Y0+NU
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M5N[BK,_6NX[?%WMMGYR?Q1>DW#O<8,JMS!^IO..Y0BE;&61T-C(9D.7NX/)
MBTVQ_74NM!99\7%M[!Z3MH'Y?B6$WA_8#NH]VM/_ 5!+ P04    " #G@&%6
M1K#VSQP#  #)"0  &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6RM5FUO
MVC 0_BM65DV=M)%7PLL@4H%.J[1.56FWSR:Y$*N)S6P'VFD_?K:3IL "6S7X
M0/QR]]SS7'SQC3:,/X@,0*+'(J=B;&52KH:V+>(,"BPZ; 54[:2,%UBJ*5_:
M8L4!)\:IR&W/<4*[P(1:T<BLW?!HQ$J9$PHW'(FR*#!_FD#.-F/+M9X7;LDR
MDWK!CD8KO(0YR/O5#5<SNT%)2 %4$$81AW1L7;C#Z4#;&X-O!#9B:XRTD@5C
M#WIRE8PM1Q."'&*I$;!ZK&$*>:Z!%(T?-:;5A-2.V^-G]$]&N]*RP *F+/].
M$IF-K;Z%$DAQF<M;MOD,M9ZNQHM9+LP_VE2VW8&%XE)(5M3.BD%!:/7$CW4>
MMAS<\("#5SMX^P[! 0>_=O"-T(J9D37#$D<CSC:(:VN%I@<F-\9;J2%4O\6Y
MY&J7*#\9S6 AT0=T125P$!)=/JKS(0"=ST!BDHMW:O-^/D/G9^_0&2(4W66L
M%)@F8F1+%5^CV'$=:U+%\@[$<CUTS:C,!+JD"22[ +8BWK#WGME/O*.(,X@[
MR'??(\_QO!9"TW]W=X_0\9MD^@;//X#79!&J++:EJ$((VA%TS0[%"L<PME11
M"N!KL**W;]S0^=@F[T1@.V*#1FQP##V:JE?)5166.%?GXN_"*[2N0=/?EG7D
M!T$0CNSUMJ(6*R?H^8W5#M5N0[5[E.I%P;@D/['Y<+!4E;DZ] D1,2NI;.-:
MP85;+-RNX^]1;3$*0J^=:=@P#5_)- 7.(4$IH9C&A"[;Z(9_),UU?7>/;HN1
MX_7;Z?8:NKVC=.= ">/H*Y,@T"]43^<0EYKS'? "?6&8HJ0$76/AL(W]T1"O
MK8@3@>UDH]]DH__?Y=\_I=@3@>V('31B!T=?_66:@KF"7XJ?8PGZT,H,4$[P
M@N1$/J&8%2M&H;W0JABNLW4JG8[K[9_=5C.G'SC;/W?O+-M;MV(!?&F:!8%,
MT5=73+/:]",7YAK>6Y^H/J5J*UY@JB;G&O,EH0+ED"I(I]-3Y<6KQJ&:2+8R
M=^^"2763FV&F>BW@VD#MITR53CW1 9KN+?H-4$L#!!0    ( .> 85:,-5^,
M* ,  +8*   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;*V6;V_:,!#&
MOXJ535,KK<T?*- .(A6R:9/6K6K7[L6T%R8<Q&IB9[:![MOO[(2,%C?K4'D!
MMG/WY)X?B7W#M9!W*@/0Y+[(N1IYF=;EF>^K-(."JF-1 L<K<R$+JG$J%[XJ
M)="932IR/PJ"GE]0QKUX:-<N93P42YTS#I>2J&514/E[#+E8C[S0VRQ<L46F
MS8(?#TNZ@&O0-^6EQ)G?J,Q8 5PQP8F$^<@[#\^2@8FW ;<,UFIK3(R3J1!W
M9O)I-O("4Q#DD&JC0/%G!1/(<R.$9?RJ-;WFEB9Q>[Q1_V"]HY<I53 1^7<V
MT]G(&WAD!G.ZS/656'^$VL^)T4M%KNPW65>Q_;Y'TJ72HJB3L8*"\>J7WM<<
MMA+"WA,)49T0/4[H/I'0J1,ZSTWHU@E=2Z:R8CDD5--X*,6:2!.-:F9@8=IL
MM,^X^=NOM<2K#/-T_!D0FB)'Y N5DIK_@!PDH"G+U2&NWEPGY.#UX=#7>"^3
MX:>U[KC2C9[0#2-R(;C.%'G/9S![*.!CD4VET:;2<=2JF$!Z3#KA6Q(%4>0H
M:/+\]-"1GCP_/6AQTVFX=ZQ>IYW[C_.ITA(?_I\NQ)5$URUA-H0S5=(41AZ^
M\0KD"KSXS:NP%[QSX7E)L>2%Q!Z@ZS;HNFWJ\=<2S)/*%R0W$$DJE';1JU1.
MK(K9_5;QZ2 PGZ&_V@:S&Q<&@2,P:2UK3],GC>F35M.W5#(ZS>$?GBN1WK:7
MOLOS;EP4NBRW%K6GY5YCN==J>4)51DK*9@1/-T(+L>1:$<;3?(D["@Z(>/0D
MY(B(Y4PS4"XXO1W3@XX+CB.NZX+36OZ></H-G'XK''L^'XGYT1)]4Z4 T8@I
M[MN\0@/W:4;Y BP[CL?O?[+J[S(X=;':C7,A35K-[(EJT* :M*+Z!IQR35A1
M2K$";%D0E7VL=";%<I'50/#!PDMX +IP#';VB,<@=B.<(';#NOT'895%?^M$
M+T N;&>D\+7'=Z Z,IO5IODZMSW'H_4Q-F55#_57INKH+JA<,*[0_1PE@^,^
M%B6K+JF::%':OF$J-'8A=IAA8PG2!.#UN1!Z,S$W:%K5^ ]02P,$%     @
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MN/"E :O:RFH@:%YV9BLJ9)]77L:R%0>F)LCG&TK%RT U>TUS'_X#4$L#!!0
M   ( .> 859K0SI*S 0  "X6   9    >&PO=V]R:W-H965T<R]S:&5E=#8X
M+GAM;*U8VV[C-A#]%4+=%@Y01R)UL9S:!C;6%@W0;8-<ML^,/(Z%E427HN/L
MWY>Z1+)HBDX#OR26=,YP9L@9'G*V9_Q[L0$0Z#5+\V)N;8387MEV$6\@H\4E
MVT(NOZP9SZB0C_S9+K8<Z*HB9:E-'">P,YKDUF)6O;OEBQG;B33)X9:C8I=E
ME/^XAI3MYQ:VWE[<)<\;4;ZP%[,M?89[$(_;6RZ?[-;**LD@+Q*6(P[KN?49
M7T6$E(0*\2V!?7'P&Y6A/#'VO7RX6<TMI_0(4HA%:8+*?R^PA#0M+4D__FV,
M6NV8)?'P]YOUWZO@93!/M( E2_])5F(SMT(+K6!-=ZFX8_L_H G(+^W%+"VJ
MOVA?8R>.A>)=(5C6D*4'69+7_^EKDX@# @X&"*0A$)7@#1#<AN"^E^ U!*_*
M3!U*E8>("KJ8<;9'O$1+:^6/*ID56X:?Y.6\WPLNOR:2)Q8W><PR0 _T%0HT
M1O>"BIU@_ >ZHP+0* )!D[2XD)\>[R,T^G2!/J$D1P\;MBMHOBIFMI!>E+;L
MN!GQNAZ1#(R("?K*<K$IT)=\!:N^ 5NZW\9 WF*X)D:+$<27R,6_(N(0HG%H
M^7XZUM"C]],=0S1N.R-N9<\US\@H987,^Q/(V@:9\NJE**?I2I?SVJ:GMUDV
MCZMB2V.86[([%,!?P%K\\A,.G-]T^3JGL>A,QGJY]-I<>B;KB\<\$;"J5C5H
MEVI-]RMZV2)?%F/7<SWBS>R7PXSH<*[K3W ?%^EP@>^ZI,7UXO#;.'QC'++%
MR0:6ZR*HB<'!B-C!;N@K 1S#IL3!$\5]#0H[DU#O?- Z'QB=_U,NY.-UK(LE
M.!I^3#SBN%,E&"T.^[XR:Y$.-_'( :X7T*0-:&*LT.6.<\B%+H+).<OPG,:B
M,QGK)2QL$Q::ER^L@--4E[#P:(H<9;)/(B(3HN?OM/5W:O2WZA<Z;Z='(P6*
MM\<(K)1BI(%@O;_8Z79QYZ,-HF'VJL"?!&J:-; P]-4&H4%Y.' 'W#\0(=A8
M41&L0=;42NL_/F=-G=5:="YK_;21+FWDHW75, \G2K8^=<Z/06IM:2!C[)&A
M!=N)'&S<]X=+K.'U]B#5[6.(J[9^#68L=X@!MSL]@<V"PE1GWLE6=AH2&2%]
MISOQ@,WJX8&)@47B'\L5WU-%S5(#"Z=.H'I^C"+^=$ [X$X\X,#8&NX@9GF<
MI FMSHELC<0&4-&>4Z240+R4=T@>1ZIOL%Y#=9KLOFF#-ZJ6_]U7SFDM.I>U
M?LX[?8.-:F#1G0+Y4)6:#8P(OG2<GR^TF?HP-?H0M9^#3K)@LV:1)V(4RRTI
M$?K58V:/L"$!)ZC3X?A/,"<GP^\4$#9+H)M,KB]1EMNZ;GF(;>5>4]:@/A^U
MN?"P;UWB4.TD.I3CJIU$BQH0[:332,2LD?Z6S8'K?&]X9J^6[T)%>M3 \8]T
M HD8E<3B&TUW=0.D:<KV-(^U9=E84497]T\MBH1J)%K4@-0CG68A9LWR%V@/
M3B=8(S)83@US<+4TT6A1JHRQ#R[2,N#/U85D@6*VRT5]']6^;2\]/U=7?<K[
M:WP5U5>7G9GZ)O4KY<])7J 4UM*D<SF1&R:O+R?K!\&VU77=$Q."9=7/#5 I
M]$J _+YF3+P]E .T5\2+_P!02P,$%     @ YX!A5L:1]\:J!   ZA$  !D
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MW?%136+42>("4UT^VI:M,_"=M1G7M,:',W5\ .*^]WH0>)T5/;7V 5\ T\T
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M"I^6^KO?2Z[>4N4G%S=8T!3@,@.(YI4D&?BJDNU/)@38$@YN65&HKW._P9R
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MVH@BQ,14,B1WR:+3*S!S#(G5,8.VZ420"#-$1&R(<Y7K2K!;_M1EPGP04?L
MZCB^T(;[JHR=KHQH\Y.0#RTYB$4P$RM>,HB]N1 %E(8=,$P'$;$.SKB5>=,9
MI[*L?7)W"5>::6L9:(*%F)@7(F(OH,G3ERC$Q+P047L!Q8Q#3$P1$;$B\!RO
M\] Q4T34-0>6Y'4?.F:*B-@409+'#FXY7-S^&;)AYHB(S;$[V]N%&6-*B8F5
M@J9]G2<=8Y:)B2WS6FKUW)XA)B:;F%@V:(;5;4UTE(M8/3[#VODF8J*)B473
MIEH[L3"QQ,1B"7.NG7"83F)BG: Y1/=]PW02$^ODE=$A=C 5CLLRQ,1T$A/K
M!,\ADA 3,TN\S^&L+VDX2(V9)2$V"XZ9A9B861)JLZ"8HQ 3,TM";!8<\S#$
MQ,R2$)L%S6\[ 2E!9U"(78-CAM5"@KDGH9Y$0=/P#B9FH81Z&@7%#.-F@EDH
MV6M1TXF;F(62MRQJ6D%V$HX$<T^RIZKFF3.<>\3<D^ZUJ@D[3HJY)Z5VSX[!
M;/;>%S@59$KS$!-S3TKMGMV8EUI]K7D9SI^EF'M28O>\6B,"*N_,8*28>U+J
M ;77,?\5<A5BHO/WU -JKV/Z]R'$Q-R3[FG.!3!OYO]T A+FGI38/0BFCU$A
M)N:>E-@]^/A%)VYB%DJ)+81CA@E'AEDHH[80BADF'!EFH8S80LUH$/3JGQ7&
M3*L5NQ6F8G LQ,0LE!%;Z!G3A_)VKFE7<I1A LK>8ECMO:\GA!'6O60?.X8Y
M,DQ V=L,M/UG4V+VR8CM\X.Q^0(AT[K=D.CJ,6+W_(#\5+L:PON%7P=;5\TJ
M/-Y95Y1A[LF(W=,9P7S?+"&KH;[8LAL 8@<A)N:>C+SNZ6!.Q5(8 [KTX?..
M=WH/YIZ,V#V_8#9CK1/H2%LXVR,/L\P1YIX1L7M>FY9_[D4A)N:>$;%[?IN=
MW]G+1YAW1L3>P<?8PYQHA,EGU,BGW_S8GAP78BF5*"[A$A;VY[S,KPWS'^W2
MN23UZUZ6=5E.8-^5FFE>O*QJ?UF1?_(=4$L#!!0    ( .> 85:WQP,P0@(
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M#?4V KT-]38"O0WU-@*]#?4V KUM\K*;0&]#O8U ;T.]C4!O0[V-0&]#O8U
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M;3N\Y+/I?Z3K/U!+ 0(4 Q0    ( .> 858'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ YX!A5LXS
MQB+O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ YX!A5IE<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #G@&%6G$NY^J,'   Q
M+P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ YX!A5F!;-5\] @  Q 4  !@              ("!YP\
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .> 8598F;D%
M) <   T>   8              " @5H2  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #G@&%61,:H[.D"   W"   &
M@(&T&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ YX!A
M5FS_FY!'!@  A1H  !@              ("!TQP  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( .> 85:> E<V9@,  %L+   8
M      " @5 C  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #G@&%6@UM"N*8)   I40  &               @('L)@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ YX!A5B0D5+&Z"0  $R\  !@
M             ("!R#   'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4
M Q0    ( .> 858I2>N1ZPD  &47   8              " @;@Z  !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #G@&%6Q9=%4-<=  #
M6P  &0              @('91   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+ 0(4 Q0    ( .> 85;$[]9^? 0  !D,   9              " @>=B
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ YX!A5C$\
MY'??!P  _14  !D              ("!FF<  'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"% ,4    " #G@&%6".7K%>X"  !L!@  &0
M    @(&P;P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M .> 858NF,L?MP,   @(   9              " @=5R  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ YX!A5G@;/DL* P  TP8  !D
M             ("!PW8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #G@&%6UAZ%EI0)  #.%P  &0              @($$>@  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .> 8590#]OAN L
M $ @   9              " @<^#  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ YX!A5L<3?[B'"0  (!P  !D              ("!
MOH\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #G@&%6
MW"V^V<$'   @$P  &0              @(%\F0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .> 858:4?Z8SP0  ",,   9
M      " @72A  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ YX!A5E##K;7+"P  AQT  !D              ("!>J8  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #G@&%6HW^$\)T%  !?#@
M&0              @(%\L@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( .> 85:FLW5';P,  "@'   9              " @5"X  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ YX!A5EFN7QY2
M!   +@H  !D              ("!]KL  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #G@&%6+XFD]1P=  #E80  &0
M@(%_P   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .>
M859"!4OWP@(  .(%   9              " @=+=  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ YX!A5L04W_>X @  V <  !D
M         ("!R^   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #G@&%6#8OY)8 $  #P#   &0              @(&ZXP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .> 85:4Q7 WG0(  *H%
M   9              " @7'H  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ YX!A5O%OC^ 0 P  G08  !D              ("!1>L
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #G@&%64S%=
M,1L#  "P!@  &0              @(&,[@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( .> 8593-8D-#@8  /(/   9
M  " @=[Q  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MYX!A5D31>V&.!0  H0\  !D              ("!(_@  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #G@&%69UA$?^4#  !E"0  &0
M            @('H_0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( .> 85;MUEH&E ,  (,(   9              " @00" 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ YX!A5K>QE=^2!0
MWPT  !D              ("!SP4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #G@&%6"Q5W0# $   ("@  &0              @(&8
M"P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .> 858&
M%QH72P(  #L%   9              " @?\/ 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ YX!A5ARB28#9 P  M1(  !D
M     ("!@1(! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .> 85:$ZX&X<@(  .<&   9              "
M@9$A 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ YX!A
M5J>A_<38 @  P0D  !D              ("!.B0! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #G@&%6R57=IC #   ."@  &0
M        @(%))P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( .> 859G7]/]?@8  /XR   9              " @; J 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ YX!A5I%5^NT* P  T0D
M !D              ("!93$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #G@&%6F'#71:,"  !L!P  &0              @(&F- $
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .> 85;J93+N
M7 4  %4F   9              " @8 W 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ YX!A5F[BZO%3 P  B@H  !D
M ("!$ST! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #G
M@&%6UZWW%Y0)   S:@  &0              @(&=0 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .> 858I#]]#C0,  ,L-   9
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M970U-RYX;6Q02P$"% ,4    " #G@&%6[%\ -5H#   ?#@  &0
M    @(&T80$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M .> 858C:?Z4@ 4  &\F   9              " @45E 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ YX!A5E1C@?'( P  V1(  !D
M             ("!_&H! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " #G@&%6WA!"NG,#   D"@  &0              @('[;@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .> 85:FE1^+X@(
M *4)   9              " @:5R 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ YX!A5G[GAA#:!0  KRT  !D              ("!
MOG4! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #G@&%6
M1K#VSQP#  #)"0  &0              @('/>P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( .> 85:,-5^,* ,  +8*   9
M      " @2)_ 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ YX!A5A3/<K[\ @  U0@  !D              ("!@8(! 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #G@&%6+5C521L#  #H"P
M&0              @(&TA0$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( .> 859K0SI*S 0  "X6   9              " @0:) 0!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ YX!A5L:1]\:J
M!   ZA$  !D              ("!"8X! 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " #G@&%6QK:0&-X"  ##"@  &0
M@('JD@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( .>
M859)L'FZ:P4  -(C   9              " @?^5 0!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ YX!A5GG/NFL$ @  &@0  !D
M         ("!H9L! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M    " #G@&%6<>1!N<X$  #G&@  &0              @('<G0$ >&PO=V]R
M:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( .> 859OMG3D20,  *H4
M   -              "  >&B 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !1 %$ +A8  +&Q 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>379</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensation</Role>
      <ShortName>Share based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Basic and Diluted Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Inventories</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Share based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SharebasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Debt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DescriptionofBusiness</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk and Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk and Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Goodwill and Intangible Assets - Changes in IPR&amp;D (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Changes in IPR&amp;D (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Share based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails</Role>
      <ShortName>Share based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Share based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails</Role>
      <ShortName>Share based Compensation - RSUs and PBRSUs Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Share based Compensation - Expense Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails</Role>
      <ShortName>Share based Compensation - Expense Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Debt - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Debt - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Leases - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Leases - Future Minimum Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Deferred and Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails</Role>
      <ShortName>Income Taxes - Deferred and Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes - Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CollaborativeAgreements</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/LegalProceedings</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="fold-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage, us-gaap:PropertyPlantAndEquipmentUsefulLife -  fold-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="fold-20221231.htm">fold-20221231.htm</File>
    <File>exhibit1018_2022.htm</File>
    <File>exhibit1019_2022.htm</File>
    <File>exhibit1025_2022.htm</File>
    <File>exhibit1026_2022.htm</File>
    <File>exhibit21_2022.htm</File>
    <File>exhibit231_2022.htm</File>
    <File>exhibit311_2022.htm</File>
    <File>exhibit312_2022.htm</File>
    <File>exhibit321_2022.htm</File>
    <File>exhibit322_2022.htm</File>
    <File>fold-20221231.xsd</File>
    <File>fold-20221231_cal.xml</File>
    <File>fold-20221231_def.xml</File>
    <File>fold-20221231_lab.xml</File>
    <File>fold-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fold-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="856">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fold-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 856,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 162,
   "dts": {
    "calculationLink": {
     "local": [
      "fold-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fold-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "fold-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 584,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://www.amicustherapeutics.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 6
   },
   "keyCustom": 45,
   "keyStandard": 334,
   "memberCustom": 18,
   "memberStandard": 44,
   "nsprefix": "fold",
   "nsuri": "http://www.amicustherapeutics.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.amicustherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.amicustherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.amicustherapeutics.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Share based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensation",
     "shortName": "Share based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Assets and Liabilities Measured at Fair Value",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue",
     "shortName": "Assets and Liabilities Measured at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.amicustherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.amicustherapeutics.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.amicustherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Collaborative Agreements",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.amicustherapeutics.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Legal Proceedings",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.amicustherapeutics.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Basic and Diluted Net Loss per Common Share",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare",
     "shortName": "Basic and Diluted Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "25",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.amicustherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.amicustherapeutics.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Share based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationTables",
     "shortName": "Share based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables",
     "shortName": "Assets and Liabilities Measured at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.amicustherapeutics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.amicustherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables",
     "shortName": "Basic and Diluted Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Description of Business (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk and Revenue Recognition (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk and Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i0f3176f304064948be4451df697aa412_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i0f3176f304064948be4451df697aa412_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Geographical Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i16b7fa862c79461ba0d440ef1d4f8431_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fold:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Equity Incentive Plan and Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fold:ShareBasedCompensationNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information and Recent Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "if2fe03ce4e8348beb3ff495315b993c7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Goodwill and Intangible Assets - Changes in IPR&D (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails",
     "shortName": "Goodwill and Intangible Assets - Changes in IPR&D (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash and Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.amicustherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "fold:CommonStockVotingRightsForEachShareHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity - Nonqualified Cash Plan and Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Share based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
     "shortName": "Share based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "ieb57920f3b814e169748405b9928e37d_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
     "shortName": "Share based Compensation - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "ieb57920f3b814e169748405b9928e37d_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "if2fe03ce4e8348beb3ff495315b993c7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Share based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails",
     "shortName": "Share based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "ica44d8bb33204fffa5ffdcad376a613c_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "ia25971519a474cb89a00ac0fe4405077_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
     "shortName": "Share based Compensation - RSUs and PBRSUs Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "ifc0df69ddff74c2089537bf0e99a1af4_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Share based Compensation - Expense Summary (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails",
     "shortName": "Share based Compensation - Expense Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Summary of Fair Value of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i863463917abd46488618f36fe6140b3f_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "if2fe03ce4e8348beb3ff495315b993c7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Level 3 Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Debt - Summary of Long Term Debt (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
     "shortName": "Debt - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "iaa53fbe6c2bc4133aafe94d0be3cb091_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i8b64c874c8c44ab193d9b7e4e27fc831_I20200731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Debt - Interest Expense (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.amicustherapeutics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Leases - Lease Cost (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails",
     "shortName": "Leases - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Leases - Future Minimum Operating Lease Payments (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Statutory Rate (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails",
     "shortName": "Income Taxes - Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fold:DeferredTaxAssetsIntellectualProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Deferred and Valuation (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails",
     "shortName": "Income Taxes - Deferred and Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "id6fb65dbd72b492e80987a09a840570c_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fold:DeferredTaxAssetsIntellectualProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i40d6b75012b24abc830ece41c6c75656_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i40d6b75012b24abc830ece41c6c75656_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i79b2989cb3ff43f08613f1bb07e232a9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes - Loss Carryforwards (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails",
     "shortName": "Income Taxes - Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i79b2989cb3ff43f08613f1bb07e232a9_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Collaborative Agreements (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "ib99cd8bfa1ce4661a32f07a098c4ad73_D20221201-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "fold:PaymentsForCollaborativeArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "if0862ce94c414f10953150dfe32fbbaf_I20221130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fold:LossContingencyNumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Legal Proceedings (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.amicustherapeutics.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "if0862ce94c414f10953150dfe32fbbaf_I20221130",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fold:LossContingencyNumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
     "shortName": "Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20221231.htm",
      "contextRef": "i2c82049c86ed44b7a876cdf58795950e_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 66,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fold_AccruedContractManufacturingAndContractResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for contract manufacturing and contract research costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued Contract Manufacturing and Contract Research Costs Current",
        "terseLabel": "Accrued contract manufacturing\u00a0&amp; contract research costs"
       }
      }
     },
     "localname": "AccruedContractManufacturingAndContractResearchCostsCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedProgramFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable related to a pharmaceutical program, including but not limited to clinical studies or commercial preparation activities.",
        "label": "Accrued Program Fees",
        "terseLabel": "Accrued program fees"
       }
      }
     },
     "localname": "AccruedProgramFees",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AccruedSalesRebatesAndChargebacksCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Rebates And Chargebacks, Current",
        "label": "Accrued Sales Rebates And Chargebacks, Current",
        "terseLabel": "Accrued sales rebates and discounts"
       }
      }
     },
     "localname": "AccruedSalesRebatesAndChargebacksCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AmortizationDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Amortization Deferred Financing Costs",
        "terseLabel": "Amortization of deferred financing"
       }
      }
     },
     "localname": "AmortizationDeferredFinancingCosts",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AssetImpairmentChargesAndOtherAssetWriteOffs": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges And Other Asset Write-Offs",
        "label": "Asset Impairment Charges And Other Asset Write-Offs",
        "terseLabel": "Asset impairment charges and other asset write-offs"
       }
      }
     },
     "localname": "AssetImpairmentChargesAndOtherAssetWriteOffs",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AtTheMarketEquityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Equity Program",
        "label": "At The Market Equity Program [Member]",
        "terseLabel": "At The Market Equity Program"
       }
      }
     },
     "localname": "AtTheMarketEquityProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "fold_CallidusBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Callidus Biopharma, Inc.",
        "label": "Callidus Biopharma Inc [Member]",
        "terseLabel": "Callidus"
       }
      }
     },
     "localname": "CallidusBiopharmaIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities",
        "totalLabel": "Cost, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecurities",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross unrealized gain, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross unrealized loss, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure",
        "totalLabel": "Fair value, cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents and Marketable Securities [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_CollaborativeAgreementConditionalAggregatePaymentsPerIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Conditional Aggregate Payments Per Indication",
        "label": "Collaborative Agreement, Conditional Aggregate Payments Per Indication",
        "terseLabel": "Conditional aggregate payments per indication"
       }
      }
     },
     "localname": "CollaborativeAgreementConditionalAggregatePaymentsPerIndication",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of potential payments upon achievement of post-approval and sales-based milestones.",
        "label": "Collaborative Arrangement Achievement of Post Approval and Sales Based Milestones Potential Payments",
        "terseLabel": "Potential milestone payments upon achievement of post-approval and sales-based milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementAchievementOfPostApprovalAndSalesBasedMilestonesPotentialPayments",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CollaborativeArrangementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "xbrltype": "stringItemType"
    },
    "fold_CommonStockVotingRightsForEachShareHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes entitled for each share held.",
        "label": "Common Stock Voting Rights for Each Share Held",
        "terseLabel": "Voting right for each share held, number"
       }
      }
     },
     "localname": "CommonStockVotingRightsForEachShareHeld",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_ContingentAcquisitionConsiderationPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determination of contingent consideration, which is payable to acquiree.",
        "label": "Contingent Acquisition Consideration Payable [Policy Text Block]",
        "terseLabel": "Contingent Consideration Payable"
       }
      }
     },
     "localname": "ContingentAcquisitionConsiderationPayablePolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to clinical and regulatory contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Approval Milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Measurement Input",
        "label": "Contingent Consideration, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input"
       }
      }
     },
     "localname": "ContingentConsiderationMeasurementInput",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fold_ConvertibleSeniorNotes2016Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the \"Convertible Notes).",
        "label": "Convertible Senior Notes2016 Due2023 [Member]",
        "terseLabel": "2016 Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2016Due2023Member",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_DebtInstrumentConsolidatedRevenueCovenantAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Consolidated Revenue Covenant, Amount",
        "label": "Debt Instrument, Consolidated Revenue Covenant, Amount",
        "terseLabel": "Consolidated revenue covenant, amount"
       }
      }
     },
     "localname": "DebtInstrumentConsolidatedRevenueCovenantAmount",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentLiquidityCovenantMinimumAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Liquidity Covenant, Minimum Amount",
        "label": "Debt Instrument, Liquidity Covenant, Minimum Amount",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "localname": "DebtInstrumentLiquidityCovenantMinimumAmount",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentPeriodicPaymentNumberOfPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Number Of Payments",
        "label": "Debt Instrument, Periodic Payment, Number Of Payments",
        "terseLabel": "Number of payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentNumberOfPayments",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_DebtInstrumentVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate",
        "label": "Debt Instrument, Variable Rate",
        "terseLabel": "Variable rate"
       }
      }
     },
     "localname": "DebtInstrumentVariableRate",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Corporate debt securities, gross unrealized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "negatedTerseLabel": "Corporate debt securities, gross unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsIntellectualProperty": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intellectual property.",
        "label": "Deferred Tax Assets Intellectual Property",
        "terseLabel": "Intellectual property"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntellectualProperty",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsInterestCarryforwardLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Carryforward Limitation",
        "label": "Deferred Tax Assets, Interest Carryforward Limitation",
        "terseLabel": "Interest carry forward limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestCarryforwardLimitation",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsLeasingArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Leasing Arrangements",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carry forwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets Liabilities Gross",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesGross",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxAssetsNonCashStockIssueNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from non-cash stock issue and carry forwards expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Deferred Tax Assets Non Cash Stock Issue Non Current",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsNonCashStockIssueNonCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesBusinessAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 2.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Business Acquisition",
        "label": "Deferred Tax Liabilities, Business Acquisition",
        "negatedLabel": "Business acquisition"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBusinessAcquisition",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DeferredTaxLiabilitiesRoyaltyPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 3.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from royalty payable",
        "label": "Deferred Tax Liabilities, Royalty Payable",
        "negatedLabel": "Royalty payable"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRoyaltyPayable",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_EarlySettlementPremiums": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Settlement Premiums",
        "label": "Early Settlement Premiums",
        "terseLabel": "Early settlement premiums"
       }
      }
     },
     "localname": "EarlySettlementPremiums",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ForeignCurrencyRemeasurementGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "negatedLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GalafoldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Galafold",
        "label": "Galafold [Member]",
        "terseLabel": "Galafold"
       }
      }
     },
     "localname": "GalafoldMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_GlaxoSmithKlinePLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Glaxo Group Limited, an affiliate of GlaxoSmithKline PLC (GSK).",
        "label": "Glaxo Smith Kline P L C [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlinePLCMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_IncreaseDecreaseInNoncurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) In Noncurrent Operating Liabilities",
        "terseLabel": "Other non-current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentOperatingLiabilities",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_InterestIncomeAndInterestExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest income and interest expense.",
        "label": "Interest Income and Interest Expense [Policy Text Block]",
        "terseLabel": "Interest Income and Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpensePolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_LesseeOperatingLeaseLiabilityTenantIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Incentives",
        "label": "Lessee, Operating Lease, Liability, Tenant Incentives",
        "negatedTerseLabel": "Less lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantIncentives",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_LossContingencyNumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Lawsuits",
        "label": "Loss Contingency, Number of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuits",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "label": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of achievement of milestones"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_NonqualifiedCashDeferralPlansPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for nonqualified cash deferral plans sponsored by the entity. This disclosure may include (1) the groups that participate in (or are covered by) each plan and (2) significant plan provisions.",
        "label": "Nonqualified Cash Deferral Plans Policy [Policy Text Block]",
        "terseLabel": "Nonqualified Cash Deferral Plan"
       }
      }
     },
     "localname": "NonqualifiedCashDeferralPlansPolicyPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones.",
        "label": "Number of Major Markets Outside United States from Whom Parties to Contractual Arrangement is Eligible to Receive Post Approval and Sales Based Milestones",
        "terseLabel": "Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones"
       }
      }
     },
     "localname": "NumberOfMajorMarketsOutsideUnitedStatesFromWhomPartiesToContractualArrangementIsEligibleToReceivePostApprovalAndSalesBasedMilestones",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_OrphanDrugTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to orphan drug tax credit carryforward.",
        "label": "Orphan Drug Tax Credit Carryforward [Member]",
        "terseLabel": "Orphan drug tax credit carryforwards"
       }
      }
     },
     "localname": "OrphanDrugTaxCreditCarryforwardMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_OtherComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for other comprehensive income.",
        "label": "Other Comprehensive Income Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive (Loss) Gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fold_PaymentsForCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Collaborative Arrangement",
        "label": "Payments For Collaborative Arrangement",
        "terseLabel": "Payments for collaborative agreement"
       }
      }
     },
     "localname": "PaymentsForCollaborativeArrangement",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ProbabilityWeightedDiscountedCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to valuation technique of probability weighted discounted cash flow.",
        "label": "Probability Weighted Discounted Cash Flow [Member]",
        "terseLabel": "Probability weighted discounted cash flow"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProceedsFromIssuanceOfWarrantsAndEquityFinancing": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Warrants And Equity Financing",
        "label": "Proceeds From Issuance Of Warrants And Equity Financing",
        "terseLabel": "Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrantsAndEquityFinancing",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents tangible property used for research.",
        "label": "Research Equipment [Member]",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_RevisedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the License and Collaboration Agreement entered into by the entity on November 19, 2013.",
        "label": "Revised Collaboration Agreement [Member]",
        "terseLabel": "Revised Agreement"
       }
      }
     },
     "localname": "RevisedCollaborationAgreementMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_SeniorSecuredTermLoanDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loan Due2026 Member",
        "label": "Senior Secured Term Loan Due2026 [Member]",
        "terseLabel": "Senior Secured Term Loan due 2026:"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanDue2026Member",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage",
        "terseLabel": "Monthly vesting percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMonthlyPercentage",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share",
        "terseLabel": "Expected annual dividend per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Period Following Separation For Accelerated Vesting",
        "terseLabel": "Period following separation for accelerated vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodFollowingSeparationForAcceleratedVesting",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_ShareBasedCompensationNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of plans under the equity-based arrangements.",
        "label": "Share Based Compensation Number of Plans",
        "terseLabel": "Number of equity-based employee compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationNumberOfPlans",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fold_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Short Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockExercisesAt706Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Exercises at $7.06",
        "label": "Stock Exercises at $7.06 [Member]",
        "terseLabel": "Stock Exercises at $7.06"
       }
      }
     },
     "localname": "StockExercisesAt706Member",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockExercisesAt798Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Exercises at $7.98",
        "label": "Stock Exercises at $7.98 [Member]",
        "terseLabel": "Stock Exercises at $7.98"
       }
      }
     },
     "localname": "StockExercisesAt798Member",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants (in shares).",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_TB200PompeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ATB-200 Pompe program.",
        "label": "T B200 Pompe Program [Member]",
        "terseLabel": "ATB-200 Pompe Program"
       }
      }
     },
     "localname": "TB200PompeProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_TerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination Agreement",
        "label": "Termination Agreement [Member]",
        "terseLabel": "Termination Agreement"
       }
      }
     },
     "localname": "TerminationAgreementMember",
     "nsuri": "http://www.amicustherapeutics.com/20221231",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r341",
      "r371",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r292",
      "r622",
      "r696",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r405",
      "r559",
      "r571",
      "r593",
      "r594",
      "r619",
      "r632",
      "r641",
      "r694",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r405",
      "r559",
      "r571",
      "r593",
      "r594",
      "r619",
      "r632",
      "r641",
      "r694",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r292",
      "r622",
      "r696",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r398",
      "r405",
      "r435",
      "r436",
      "r437",
      "r535",
      "r559",
      "r571",
      "r593",
      "r594",
      "r619",
      "r632",
      "r641",
      "r690",
      "r694",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r398",
      "r405",
      "r435",
      "r436",
      "r437",
      "r535",
      "r559",
      "r571",
      "r593",
      "r594",
      "r619",
      "r632",
      "r641",
      "r690",
      "r694",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r230",
      "r231",
      "r341",
      "r371",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r621",
      "r640",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r578",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r621",
      "r640",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r639"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r20",
      "r599"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r87",
      "r186"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r503"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r664",
      "r665",
      "r666",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r113",
      "r114",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total equity compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r194",
      "r295",
      "r304",
      "r306",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r35",
      "r48",
      "r148",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r360",
      "r514",
      "r617",
      "r618",
      "r659"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and deferred financing"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r627",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r48",
      "r84"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Loss on impairment of assets",
        "verboseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r156",
      "r170",
      "r189",
      "r226",
      "r274",
      "r283",
      "r287",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r486",
      "r490",
      "r504",
      "r639",
      "r692",
      "r693",
      "r741"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r181",
      "r197",
      "r226",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r486",
      "r490",
      "r504",
      "r639",
      "r692",
      "r693",
      "r741"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gain, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized loss, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r297",
      "r312"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cost, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r71",
      "r296",
      "r312",
      "r563"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Debt securities, available-for-sale",
        "verboseLabel": "Fair value, available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r70",
      "r312"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Corporate debt securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r478",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r126",
      "r127",
      "r478",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r480",
      "r658"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Non-cash changes in the fair value of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r128",
      "r129",
      "r479"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures unpaid at the end of period"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50",
      "r184",
      "r596"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair value, cash balances"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r50",
      "r55"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at the beginning of the year",
        "totalLabel": "Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r147"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r248",
      "r249",
      "r251",
      "r253",
      "r261",
      "r262",
      "r302",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r369",
      "r370",
      "r373",
      "r377",
      "r384",
      "r504",
      "r595",
      "r652",
      "r660",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r102",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r698",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r160",
      "r176"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r323",
      "r324",
      "r580",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r664",
      "r665",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r639"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 500,000,000 shares authorized, 281,108,273 and 278,912,800 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Significant components of the deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r28",
      "r204",
      "r206",
      "r212",
      "r564",
      "r568"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r292",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r292",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r292",
      "r579",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r168",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r63",
      "r144",
      "r146",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r144",
      "r145",
      "r292",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r133",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Contingent Liabilities"
       }
      }
     },
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r92",
      "r338",
      "r339",
      "r350",
      "r351",
      "r352",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Liability Components of the Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r627",
      "r629",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r32",
      "r561"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r663",
      "r729",
      "r731"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r663",
      "r729"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r663",
      "r729",
      "r731"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r60",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r52",
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r224",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r354",
      "r361",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r157",
      "r158",
      "r169",
      "r232",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r515",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r158",
      "r169",
      "r365"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r22",
      "r149",
      "r367",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r232",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r515",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r23",
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r97",
      "r98",
      "r99",
      "r100",
      "r148",
      "r149",
      "r151",
      "r167",
      "r232",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r515",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r148",
      "r151",
      "r695"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]",
        "terseLabel": "Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r312",
      "r671"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Corporate debt securities, cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r300",
      "r313",
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Debt securities, realized gain (loss)"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).",
        "label": "Deferred Credits and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r663",
      "r730",
      "r731"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r124",
      "r663",
      "r730"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r48",
      "r124",
      "r463",
      "r469",
      "r470",
      "r663"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Non-cash deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r677"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "negatedLabel": "Less: deferred financing"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r663",
      "r730",
      "r731"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 1.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r122",
      "r728"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r122",
      "r728"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r122",
      "r728"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r122",
      "r728"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r120",
      "r122",
      "r728"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r116",
      "r727"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r122",
      "r728"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails": {
       "order": 4.0,
       "parentTag": "fold_DeferredTaxAssetsLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r48",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r48",
      "r272"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r396",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r409",
      "r440",
      "r441",
      "r443",
      "r448",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r213",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r246",
      "r248",
      "r251",
      "r252",
      "r253",
      "r257",
      "r495",
      "r496",
      "r565",
      "r569",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss attributable to common stockholders per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r213",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248",
      "r251",
      "r252",
      "r253",
      "r257",
      "r495",
      "r496",
      "r565",
      "r569",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss attributable to common stockholders per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r505"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of the statutory tax rates and the effective tax rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r228",
      "r454",
      "r472"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedTerseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r726",
      "r732"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r726",
      "r732"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedTerseLabel": "Impact of foreign operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r726",
      "r732"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r726",
      "r732"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation costs, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r725"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r725"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r96",
      "r179",
      "r208",
      "r209",
      "r210",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r245",
      "r260",
      "r303",
      "r386",
      "r444",
      "r445",
      "r446",
      "r465",
      "r466",
      "r494",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r528",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r497",
      "r498",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Subject to Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Significant Unobservable Inputs Used in the Valuation of the Contingent Consideration Payable"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r352",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r498",
      "r532",
      "r533",
      "r534",
      "r615",
      "r616",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r352",
      "r399",
      "r404",
      "r498",
      "r533",
      "r615",
      "r616",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r352",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r498",
      "r534",
      "r615",
      "r616",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Changes in fair value during the period, included in the Consolidated Statements of Operations",
        "negatedTerseLabel": "Changes in fair value of contingent consideration payable"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "verboseLabel": "Payment of contingent consideration in cash"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r352",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r532",
      "r533",
      "r534",
      "r615",
      "r616",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r518",
      "r522"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r363",
      "r382",
      "r492",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r612",
      "r673",
      "r674",
      "r675",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r48",
      "r93",
      "r94"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r187",
      "r320",
      "r562",
      "r613",
      "r639",
      "r678",
      "r685"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Change in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r31",
      "r226",
      "r274",
      "r282",
      "r286",
      "r288",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r504",
      "r611",
      "r692"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r659",
      "r689"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Change in IPR&amp;D"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r227",
      "r471"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r29",
      "r152",
      "r162",
      "r178",
      "r274",
      "r282",
      "r286",
      "r288",
      "r566",
      "r611"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (loss) before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r227",
      "r471"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r228",
      "r455",
      "r456",
      "r462",
      "r467",
      "r473",
      "r475",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r229",
      "r244",
      "r245",
      "r273",
      "r453",
      "r468",
      "r474",
      "r570"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/IncomeTaxesStatutoryRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r207",
      "r449",
      "r450",
      "r456",
      "r457",
      "r461",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Changes in IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r78",
      "r80"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "In-process research\u00a0&amp; development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsChangesinIPRDDetails",
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r150",
      "r164",
      "r211",
      "r271",
      "r513"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r35",
      "r358",
      "r368",
      "r617",
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r37",
      "r359",
      "r617",
      "r618"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Components of Total Interest Expense Recognized Related to the Convertible Notes"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r218",
      "r221",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r76",
      "r600"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r196",
      "r597",
      "r639"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r183",
      "r195",
      "r259",
      "r317",
      "r318",
      "r319",
      "r560",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories and Cost of Goods Sold"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r76",
      "r602"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r75",
      "r653"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r76",
      "r601"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r34",
      "r270"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r226",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r487",
      "r490",
      "r491",
      "r504",
      "r610",
      "r692",
      "r741",
      "r742"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r159",
      "r174",
      "r639",
      "r662",
      "r676",
      "r737"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r182",
      "r226",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r487",
      "r490",
      "r491",
      "r504",
      "r639",
      "r692",
      "r741",
      "r742"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r158",
      "r171",
      "r351",
      "r366",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Net carrying value of Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Abstract]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r49",
      "r163",
      "r177",
      "r180",
      "r202",
      "r205",
      "r210",
      "r226",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r245",
      "r250",
      "r274",
      "r282",
      "r286",
      "r288",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r496",
      "r504",
      "r611",
      "r692"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationandRecentAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r274",
      "r282",
      "r286",
      "r288",
      "r611"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r520",
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Cash paid for amounts included in operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r738"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liability",
        "verboseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesFutureMinimumOperatingLeasePaymentsDetails",
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of the operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion of the operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU assets, net",
        "verboseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r525",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r524",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease terms (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Amount of net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r131",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r131",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment (loss) gain",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r131",
      "r132",
      "r134",
      "r203",
      "r206"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive (loss) gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive (loss) gain:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvements paid through lease incentive"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r217"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Purchase of vested restricted stock units, net of taxes"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r69",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSecuredLinesOfCredit": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from Secured Lines of Credit",
        "terseLabel": "Proceeds from secured lines of credit"
       }
      }
     },
     "localname": "ProceedsFromSecuredLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r112"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r657"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross cash proceeds from warrant exercises",
        "verboseLabel": "Proceeds from warrants exercised, net"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r180",
      "r202",
      "r205",
      "r219",
      "r226",
      "r236",
      "r244",
      "r245",
      "r274",
      "r282",
      "r286",
      "r288",
      "r302",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r485",
      "r488",
      "r489",
      "r496",
      "r504",
      "r566",
      "r611",
      "r636",
      "r637",
      "r656",
      "r692"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r86",
      "r185"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r88",
      "r175",
      "r567",
      "r639"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net property and equipment",
        "verboseLabel": "Property and equipment, less accumulated depreciation of $22,281 and $19,882 at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Payment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and experimentation tax credit carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r50",
      "r55",
      "r155",
      "r172",
      "r184"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashReconciliationofCashandCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r101",
      "r173",
      "r575",
      "r576",
      "r639"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r179",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r245",
      "r303",
      "r444",
      "r445",
      "r446",
      "r465",
      "r466",
      "r494",
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r268",
      "r269",
      "r281",
      "r284",
      "r285",
      "r289",
      "r290",
      "r292",
      "r395",
      "r396",
      "r561"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyGeographicalAreaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue Disaggregated by Geographical Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r523",
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r292",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskandRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock that were Excluded from the Computation as they were Anti-Dilutive Using the Treasury Stock Method"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration Payable"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash and Available for Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Statutory Tax Rates and the Effective Tax Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r613",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Changes in IPR&amp;D"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories for the Period"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r55",
      "r155",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r406",
      "r408",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested RSU Activity under the Plan"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.",
        "label": "Senior Loans [Member]",
        "terseLabel": "Senior Loans"
       }
      }
     },
     "localname": "SeniorLoansMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesEquityIncentivePlanandStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units as of the end of the period (in shares)",
        "periodStartLabel": "Non-vested units as of the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units as of the end of the period (in dollars per share)",
        "periodStartLabel": "Non-vested units as of the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested units, weighted average remaining years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options vested and unvested expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and unvested expected to vest as of the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and unvested expected to vest as of the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails",
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r413",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Equity-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Non-vested units, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and unvested expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r56",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r248",
      "r249",
      "r251",
      "r253",
      "r261",
      "r262",
      "r302",
      "r329",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r369",
      "r370",
      "r373",
      "r377",
      "r384",
      "r504",
      "r595",
      "r652",
      "r660",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r96",
      "r179",
      "r208",
      "r209",
      "r210",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r245",
      "r260",
      "r303",
      "r386",
      "r444",
      "r445",
      "r446",
      "r465",
      "r466",
      "r494",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r528",
      "r572",
      "r573",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r260",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r26",
      "r96",
      "r97",
      "r101",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r96",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Common stock issued from equity financing and pre-funded warrants (in shares)",
        "verboseLabel": "Stock issued from equity financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r5",
      "r6",
      "r96",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Vesting of restricted stock units, net of taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r96",
      "r101",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised (in shares)",
        "terseLabel": "Stock options exercised, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/SharebasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r96",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r96",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issued from equity financing and pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r96",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock units, net of taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r96",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r68",
      "r639",
      "r662",
      "r676",
      "r737"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r103",
      "r225",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r161",
      "r190",
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Deferred compensation investment"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r298",
      "r299",
      "r363",
      "r382",
      "r492",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r673",
      "r674",
      "r675",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSummaryofFairValueofAssetsandLiabilitiesDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
      "http://www.amicustherapeutics.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r263",
      "r264",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/IncomeTaxesDeferredandValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r521",
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityNonqualifiedCashPlanandEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Outstanding warrants, convertible to common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r247",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=SL116692626-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r644": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r645": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r646": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r647": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r648": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r649": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r651": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001178879-23-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178879-23-000004-xbrl.zip
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M>@:3#M#D87Z8Y\(32'@>B>6I"57A=RJ7]!"C^RG4:ZF=6V(RZ@I8*@UJV[@
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M;^WN^^WRBW-Z=G-R?7Z%X*KF4_C'7N0]P7^&Z2CXZ?\#4$L#!!0    ( .>
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MG@'C=(+(-3H3<U+#H57T$N<0WY,I6^+U&%3-!YAR2$/0-&,TYP<]!)2B<YR
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MP-04,4R_.-="U3/K0 (?A)%GV@#(KZK&(=&I0N\J\=NXW5'CWSQ>J9ALHY+
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MD9&%H/*G>:E\E8LIL/KZL%(QG[@YD!O]AF,:RN?H%A:09U-7P %8>M!7=4U
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M6>-40M>?!2L#7^;T@7B1^OB[;<^=/%ZC2.T'V"XJ,4$USUMXY4B[]W1%3+B
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MM**M:;_U2D>+>J[9C<'F^!.!/.&^&JIHFFL6*%05NTY4NTR::5XJ6XEQJL1
MU1R+Z3^D[2ML*=QI1#5@K%(5KDZRF8P3Z:'*08TED-YSF[G#5P:OK\<Q>[CB
M;I8D'*H/Y3A*?76Y2&7!IU-QQ\]J5)N^/W@;8Q%T;,?DG'DS7.UU3N%P#B]L
MD@9RL5=-@Z,SLD0D-YD\@<\#9]#K.+N]?L_J)E(@)5-:U!R\;E?YW'+,4?49
MGR\287S^79A+S$LI%^$QJT(A</* 1F7^[9903B#$*"*RQI,C*OLWIQGI.6=1
M780N[LP]EW#8-M0[SY^/TV-/?MP!R]@SX!;"Y[!6KG1T@]3D6UQOXM_#F>#5
M(N4>2\O!=>*VPG!_V58'"W\885L7ODR-Z_+]X_8[;=>GK\L7HJ6F19)4-*UI
M%Z/IF$/%__(R9!MTL9#*=:>(N72M2D)X^*&G&CCIZI:B]*89 MP\3AYE^Y?_
ME<^ A)R8RF+ME97GU/Q]&:Q2IJ[1Z]*B6O=+K@N7W&%O?L,%6)[ Y;-0AJ,H
M=B4A[%7?P-^SV$\\W]65Q,JA?K2BJ+58IPC\SX>U!U7:(+80JPU4DQ@$\5AX
M*TF9"1<<URW6HO+(]5/;5/YJ2R#Y+U7YBWOMZ<Z;) DJ%(WW@/0JTG;)-ZL;
M]AFZYG"@DB[<<A"ECI5=HPPSN#IHK_AA4;8)\F'KY)MA"SRL1^W7RM:GS.,E
MF+YNTWCD$R8WZN.PH%V%$0=E\T%_CGXMM"(H;P&L#1?,>"ZBSM!^L,:S.#2]
M^F+YGPQ$",.7AX^4B3 ..7G!CRG3  MSJS+P#FPK IS8C.-2( F5 'GQ&Y'C
M5P\/-H4N%O*+UO=;VO);4RD98[['N!&@X97J6Z31ZU!VS=F5N/W@>%YSU88.
M\&3JNUF"IF0L9C(#K@5ZZT7H=IV^<RJQO/Z'.(KNG+,8;N:J"Q_4N<=WX>,Y
MR8:OOG;0$#%2%(MPF&$A'QSP5_12/3J]H_W^KN.25A;-@R:>GG]"+JL+<YUR
MPNY3Z*+5=[I%E[K?Y9W@2YUW7&KN1K> ?/F<?I6C40P4>RI Z@>!OY:+4/6%
ME#;BL,.;E!REOF/+KK#&XPZW%:L"F8S+3N.:_,&\5*J&MI;;O1#\7.$NE<J'
M45X*T/(6<_$.5#A-EY[AH])@;>44/E0MUHKAK4Y1;57NPS'("_1=8.[=UF"[
MT,I%-W,WC6&2B'1:UET;B.?66-!'*V7&-VJ7K4_YY;SC>>/./ZMZ1FXQY53>
MJ23%JPY.(Q](%BAZJ[]?)F:LN<^ET0I:IX)FJ+[+\):+ZQMLD39U]@X.CIVM
M&\1[ZG"Q[D*#A0$H<7R[$C4F359\)>>>*FE4J6S9LB+FK7=M]'NMN4,'RZY0
M1EABX+F-5\LI^#%4D55#Y52O+Y]KQ]$!(6Z_5983 D6\#\2(*519JK%(]L-I
M-&;0@A6/BL(\QDM1)O'$P-%KPI'[^_->UZ*;T)Z$F24WX?^%7+46C_]?40"D
MAI#X2Z$!M"T!#.5RQ.[A0OA@56VED$W#?6GA"C&NLG#%[GC% 3O#[]6:??5O
M#9;CD"^IT:!%P89EJ+Z-@HSJ718E@PK*XBV206(7ZQQQ/\<59XTY0*Z()<:O
MJ#N!5U?VF;_-84N@YZ=UKYSWAB$*7E-]%#G&##MH9J'*#4JDO&,M%)_6I5<Z
MRK(@=V?$I5;3-(I#^5B;%>%.(GQR2]0U9OB*C4LD DU&$9 98CRJ!U5E/=_/
M308JE%.I15<.\+B4;/5R_(-&?.>G\#9WA0OPC[\=]]_?P,3X7EZ)L03E1[F9
MCP<KF>Y/"G8]E7-O!M\$?__,P=^&CN+BTOER<7MY?G/C?/GE_/K\TT^= J:4
M>I$99;$D+%1R#?D$N .L&$;PO$*K?C=_[6$ZR[-O3&^EC9GG2V[J_U_F8NRM
MM!?.2]W+55Z_^%Z^V-2^EV58#,,ACO$M__M&)61WMSG39*F;^\E^BB97<_+Q
MXO3SC7,+K/'DZOSS[<7I3<>YN#Q]&FO[MB67Y,3>?O>XL7WX\,C]1MIYUYR"
M?';.3MM7HP0F>2FFDG?Q3(!IY)P&(KYK_Q6XQ89S/._3B2]'SI6,9H%T/E%2
M>_Q-Q+[!E%3F,T\#VFO**-C\;/.SS<\V/]O\;/.SU_G9Q@WU?&ZHUFA8WNI5
M9P=K5'7VL,[S7V.UZ4]?T?._("=[8?[^___EXL/%;5X^8[%)\FW+?8(-W+;]
MG%.^Y-/E3Q=GYY>W%R>_7=S^N^-<?KK<.;NX.?WMT\WGZW/GY/*,/CK]]/'J
M_/;B]N+3I7/R\_7Y^4?X3?7Z?JL78?/=YKO-=YOOVO;=/ #;T\7![J NL*X_
M?09YLWM$->++N-(GSO4;?_8Z2SRN#'Z\&7@S\#,.K'6C 6OA+V)VU*CR+Z0"
MKE;!KC]8G26VWO?\'931/E/FPVKRJ/]T3$]-T+5_T&TN2//Q\^WGD]\LR^+V
MDW-R#7MP?7)[[H ]<O7Y]OS&0>/CTKFX/+OXU\49_N##R<W%S?/LTN:[S7<O
MJ#;6@:E>P@>Q>>7FE9M7;EZY>>7FE9M7;E[Y%WUE3W6K+%LX_:J+3'VZ>>7F
ME:_^RK^DOVGO3^1O>A&::9\GZO0U/5&8;7A8)QKHT[9$SG_]],$Y.[\YO;ZX
MPJAXXSZ')W.XP;(XUN:[S7?S*,FPTFZOPDZQ!TP@'M_Y(=V:81"Y=^_OL9RD
M*P)U=8$$%3L>#+J]_</2$$6NLC3@NAI ZWC/ +0JZZF=\U1\W>%)]KI[_<'?
MWZ-,T1_@NFM6]6;5P5?8D+;/\J#W]^J.;M2>.6K/_K>I/6^'D?<(_YFDT^#'
M_P502P,$%     @ YX!A5K*(UZ^IR   3$H' !0   !E>&AI8FET,3 R-5\R
M,#(R+FAT;>R]:7/CQK(F_'U^!<9^QR.=H&BMK5[.=81:4K?E:2TCJ>TY\V6B
M"!1%N$& QB(U_>O?7*H*A8VBVE(3@G!OQ'&+!(%"5F96KD_^^[\?G1]>_^?B
MV)FDT\"Y^/S^T\FA\\/&SS__L7/X\\]'UT?.K]>GGYS=X>:6<QV+,/%3/PI%
M\///QV<_.#],TG3V]N>?[^[NAG<[PRB^^?GZ\F>\U>[/010E<NBEW@^__!L_
M@?^5POOEO_W[OV]L.$>1FTUEF#IN+$4J/2=+_/#&^<.3R1=G8T-==1C-YK%_
M,TF=[<WM'>>/*/[BWPK^/O730/ZB[_/OG_GO?_],#_GW*/+FO_S;\V\=W_NO
M'_PW(W=_/-[:?+VUL[L[?K7W^O7NUO9X9[SWYLUX=W]_\_]MP2)_ALOY-TDZ
M#^1__3#UPXV)Q.>_?;TUW'DU2]_=^5XZ>;NUN?D_?BA<FLJOZ88(_)OP+2T8
MOAU'\'KJ:S<*HOCMCYOT?^_PFXVQF/K!_.W_O/:G,G'.Y)US&4U%^#\'"1!Y
M(Y&Q/^8+$_]O^79K"Q[.?^(=W_HI/,SE3^YXB?MPY\ /I5XR+_+P_.S#R='Q
MV?7)P:=__XS7U[QH:U=__'^.#S]?GYR?.8?G%_\IKK^Z72*^@1T;16D:3=]N
M;<,SK1=S@4MDK-X,&"3^I9$<J[C1H]'ZC2;U0L)>G%\B6:^<7X\OCT_.'&:1
M#R?'1\[[_S@__?AFZ]V__O4O^._..^?7@]^/G??'QV?.\?\Y_/3Y"*[Y<'E^
MZES_>G(%'_UZ\O[D&KX_//A\=0P?'N>7G9Q].+\\/: -A&O?GU__ZJR=K#MG
MY]<.?'Q\"4SI')P=P8?P*5R!OR9M=/WKP37]=7G\\>3J^O+@#/Z\/#ZXOG(.
MKIR+RY/?X>?.^:5C\_>P53O:W^@YBD^NJA;*#YR2QV? [@<?+X^/3X']GN-+
M'($,':$\G7]PCHX/CT_?'U\ZV]L#/&VWG^,+@>I";?+^^/H/4%?/\0U( 5Y^
MOKH^/J9MP;\_GYW\?GQY=7+]'_SDXOCL[.H_GWX_.#LY>(YO"!OT+)=]>G+X
MF0ZHRX.+8[!)#J\&<+X=-I\YZN?[^!:SB.WFM[$,1.K?RD9#4KW[9OX3,4JB
M($NK/UFD0AN_*]M.RYG'N\8\GL1ZI3-Q(S=&8+Y_V1!CV)BW(K@3\^2'1A-Z
M?_AZ=SD3>K4B>/#^TS%*&I@6UZ#9KY8G[DI,ZL5V'FS20YFC42#WD).%YX&G
MMA'(,6SIJ^&N]1F]Z%ORD^CU_="#C7R[P9<].05VZP47#-U#V-"MGW[<>K7Y
MKOJ_1\<?3LY.R!INNF1K28WUK FTW?3VA^>?/AV\/[]D._[B\OSCY<%I,ZWV
MOI58K"D+I'I3IA32;D5TVAXVLM#YK8Q%$#@7<?2G=-,72)I&YKF4B12Q.VFD
MR:O.TF2GZ9T_9"$NVHG&3CJ1CB81LL]-+*:-I-KO+*EV&Y6SG[@12-?\!1-G
MKY$X(A7.^5THXV3BSUX@95XUO?.I"+.Q<-,L1CF[ENXDA$7=S#F$/99Q([%>
MOX2COE$SV0&[JU\/+D_./I)'?7+A?#P')_3LX.SP>/CXQ&LYI^TT'_TGX3B*
MIP(]->=J(HC?#J/IU$]3*5\@H1H-@=\B']9S HY=$("-E DREV8R3N=+$.Q-
M9PG6*(M7+E ';82#+)U$L9_.'Y\ZSTEI-=H(*A9[19KJ'",TSN7)QU^O&UV4
M[<V.<M-NLY[Z" =?BMSTR7=EF#1*6H=I<X]JNA I)J0O\3?)"R1/HR(R_HEB
M'2>-G L9AB^01HTZZ%*F J[W[F.?;XXDM9XTC5[*Y^'5T/F(3EPX74+ NDNA
M1F_%Z.:K;!0H&1O-M;@UJ^KNDFJ_Z9W/(N=D.@M\D+3[#K*=SE+G=6- X/*C
M[>P^&86>D]G8J)<^G* WBQ4H%Y?GOY]<+4H ;.]VE)GVFBW&"S%'?=VLJ;M+
MDT9+\=0/9))&H71>,'6:#<5H+H+4E\U$Z6H"9*_9,D1+V3[83T(WFC;KY*X&
M:_<6A+'M&+^7N2G^UY72:^:CKL;/]A:$M"./HD%*\3@B])S#+(YEZ#8&ACI,
MIT8+D970G.A3+WO.I9Q%\0+5W=5@XUZSY?A)I/>?:3M==>SWAF\:E9,<BRQ(
M-6U>(&FV-IM>^L!UHRQ,8>$OD2R-AO/[*/J2D/ZYE&X4-Q]C7:9.HPE]D'G^
MBU0Q6XUV\[7XVFPS[[R(XK-&L^?PT\G9R2$XZ4?'OQ]_.K_ 6OL!=H5\_G1P
M?7[Y'^?@PX>#DTOPW/?>O',.ST]/CR_1J3_YOY3%?GRJMIS/7C4[]$?R5@;1
MC*S'BT TQN\[3)OF&L=H.I6QZXO _YN2^2^0.(WZJ5!-\PV$>?)*^-65D-?3
MTO^V>OR^MKY]*UX[C-#"S:2W_K)K_5NOOA;D9F\RT#51W!@GZ;!27Q!U X:5
MH=L8BMQ9M@7P^1&ET=JD(F.9)/>%B+Z=-L_)*&^,L9V \O[TZ?CP^C-GSRZ.
M+Z__TTBKKB9B]Q?ESJB6Z /(6'B#X>Q$NAG5B&)8X%3X<**%8I'P=9=HC3:X
M(MIAE"P0O*ZFU?:;S>^3<(R&MUP8?^QJ9FU_06^('"\J;]CI:BIMO_E05R)T
M*N(OBURU[E*F\60W;3*80SL);V&IH(Z;]4QW2=1XJF/UT-('U\"QU?7 64I)
MO8CFFL8<FPU5<X+VTL[K=PIQ:W&LLJOYR-?-!A1XW6,?%^B+P+%Z;%X@C1KM
M):R;"*(D X<%_)6_,C^6'M6-BKNFG^QV-;WRNME\HB* VKZC%TBEYB8:56S<
M4TI1JMG&HGH2L=!\^':Z/*>3KK%HXO+XXO+X"DXZ.M>N!LX?!Y<(X7:BFK0.
MSW\_/H._&^MM=[L:D'O3?.2=9B1REW(&"AW6R1Q&=M<?(L86@065E1TFV )H
MB2*EL#AN05M2ATG4>/:1B2#@83%2IV>M$MT:3\/#Z!;=G#2Q.B8; PV[+R(8
MW%P&=G)V='QZ=O+!N#%8B7%R=O7Y$M$"2.%_.CD]X<, DW^?3@[>G[ +]-@4
M;3G+;6TN0A+PY#3TQ\JV6*8#K,MT:E3[)R&X/(MBY[M=C9T#51HU_4,E[)OC
MZ,]*9S4*V_7QY2EI)OS'R=G"^,NWTZKM_+35K(VN9=R(M=1E@C2J'22('[)J
M)N N/W$.;F))$4]G',7.881A97]13GVWJVD:H%QS>:M%N0]()Y$U9VVZ3*%&
M<_-X/)8N&YL6L1Z?1,]*=S=7D!\=$5SG4IV[NUW%%]Q:@$=Y2;65X.*I?!>B
M#%Z(>*&7UV$Z-7+2\=<9VM<ODBB-ZOIS0GV&9V+Z,@G3J*7/(@?C*;%_KX+N
M,'4:P^)7F>O*)(EBCBL=)(E_$R[*!N]V-<6^M0"8\D,6@S*.G0-W<?Z@P[1I
MK#\X#E,_EI9173ZY,*YT -]X"[M4%]#NY34B])T(?2="WXGPO55<8PD0PZ!A
M:=6B(HT.*__F/GL_F8%&13!T5*V+K*L.DZ<YR7(6I3[85V1;'<D SJMXD3?7
M91HUNKU_""1+(TVZ"H:"-&ET<:\DSJ88^<$"_.!.4V9!63V<Y;-8IHM]N2[3
M9D'^.R/JB 4]4 LH\P+M[&\TM+VE1W#M/\((+MJ0I<>(/:?Q;-V:D?=8TR7_
MS)+4'\\+.F>%*N<:<V8:1#IW\]<HE_;3CZ^WMS??Z3==!=G-DK[/(NJ)1'38
M>K?N $T\&HTM*#%T)%TY'<G8#.A$NLDVD(VS5Z#9G2-8;RMH-V+\MY%,[Z0,
MG6L@U'4,PB!EHJ-*GT,T%N&@F>O"P60>W(K0%P-'%/YVPBB<Q='83QTWBF=1
MS*G,M1:0'I?9!H(/..8[]=TL06K'8B;!B7.I,<@=(D5MTD7Q#1#V;QS[#DHI
MIOT(Q)W9FR1%.#IB>OA8Q+(5Q-;56&T@^-!A<$,DNRG=GXHYL+P3R[&,L1<D
MC1S8"NF'J$)$&U0%AG+G+: ?<.  .)+Z'$ -!/,!DJ@E! *_O@4D>I1AZM^;
M?)?'AR?7!Y^N5DN_O=?OGIO!5D_./WX]OCP^6"DU![EZ\U&)C?QH-A'Q5+AT
MP(@ Q'@Z$^'<N?/3B2._8K^2#_8E:#T\2KP<]&P "E(#64G2G&X9]0O/G$D&
ME^%O]2'FS!B6.*$JKQ3<K52GIVYD*/$*ST^B&$XR3E+UF_]HFX^'W  V(XZR
MFXES% ^=W[ NP?G##Q+5E(R[K/[\)$8#9R+ $DWS*0AX384M8CW3!K^U>$1O
MJMK_N=G[?F,??V.+ULL=F"K.C,\_-%W2B0"#&[9-P)Y1VA=](4)5)?O0,X-3
M!\XA'.5BI,U+[JRN.IJV.W4*MM+V:_2DMM[0X2_4$^#)>-W F65QDN%@%OCD
M;N(#KUC):#(>^(GPFUC>B!CC?-_&6Z17])L"?^CN0F<M7]? :8FW]\&/D[1$
M\%8YSKVDKE12";L_21P;;=1,$%LLF:=TS?8KBF]LUDME&QS!BZ-V<3S;)45C
M!Y7-3&V%.0QQOS@,CZHJLNPA_  VSU9/O1P]KAP)$]XH!LSJ)(QL&'*D@/?]
ML"QCJE78+JPOA%-;<5 L6F0;I.:^$U[9D;QZR7;FPL//6*.V?N"J-?RF%Z4G
M/)(\F6#M(&PD28V6F4J/#F[/C1ZW1TE9.L'RHPV=2##@9B"@?+1)9ZQJ-F-C
M;MIZMM&/U,):;_+1S^!_?#S6V +\($:QFEL"+BUXJ+&?H%[.8Z0+V0\T3!"@
M$A<N3AW #DE^'?PE\K%Z: 0/9?,RD404N(3#A-\:\FD9BYZ=_S%P< SP\8?S
MR^/5<BIL!Q \\6$'K=8QZ=S"YD99@OPP!;>4MX8V.A4(W5;=G$%!.0G<=3Q2
MQL ,T5WR'(-U!_ J;B"=K=5M4;%B8V=KN+M%;&OEPE=!F:/C#R=GU./47);:
M4I&L%X3/88"&:(1J\ [#,*A@J=4]"$@IWOIHY=N<SHQ-ABKIKF2"ZHT/Y<+7
M4RFPHC)YEG'7AMJ<86MD8GM[N+V'A&B!17EP\'L+#$=B.-# P"31ADB2",Y]
MM ]O_3A+GMT1VL2 VST#UC#@>.P'?CN*'!0;E@U6+%V(DRC$C/R\E'1G_>N,
M,C K41TCO&(Z5ZXE/#>.@F2 :1;U1\!X@O!#^(RM4+1THU!?P$]/,O"<]%-'
M&9C6(2AUM&B3R DB4-%@I]!%^F?RJY^DR="A=G#4YN")S:)$%V? TZXD-4@Y
MP(A\'-R!2:N]6G4;38@U/W2###EFP N"M];%AOIT&%A6</$N_))Y7EA_G5O=
M->]L(B^\"7B5 -X@D$IXZ"RZD_' D3[1VP//Q$T#)F1H_M))#9PF"]],HQBS
M$[A$Z?D"J[L'%/:BZ^D1P#KB)G<U9U'@NSX3S=H#O!GO+)!C(GG+YW2#R ;!
MI0?"WH?.V!\#&\S @Z'XP=[F_U@W=FI$L:(DC=POYCGZ[A'=F.@B8(F:P?"
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M%O/3+-LWW\A!81?Q,KV-B7[$M8QC'^<<#DS$9;G?J\:!1H;MC$;=[S5JC9&
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MY0;I8DP6\K :BFA(GF>D4DD:V9::0_+=[XZ@]Y4BM8+.?4 :O,:Y$D%[)'Z
M.1^AP3$V1O,-/:B$T-?4+$25(C:O0)!P", 1X7BI1'O\)*#3*&3P@EL19-+"
M2"L@<JAY7/PH_%F6J"QUF&33&=VM D0B<4AIPO.D-/#:H+FC"[ZPD%(9,91Z
MCEV!0"+DQ9-XUV!)J?G+(XGH@[H+;ZP!6/7"*06/1B9_;),"U9"F4JR2R]C^
M@7U\B)B%:>TSF1(WU %IE<%?Z3T++VC#PM8@P@YT6)2FUKBT9.KO,YA<:S0:
M-DFY>92NEMXZJ&U<4Y*# ,**I3^C,&X-I;BYKK+'1!"$ 8\V<,JF--/3TE@*
MAD@_.3LBQ+UDH%E271(*;(F;@75/K7)UEY#ZI3YE# <C\]!EUAPU^17T,RI=
M05X!'AR8]<>@NPG.CJ09CXL7.K6RVAW]W-<XU>GGBP]';5/'96G:R!5>+F&D
MH"O-=3QBIX!7:"MQCYM\=7:$/M."IM5R\=>=8?^=OG2ECOTS4I(OJN&E13S9
MUZ74T.7CP4&+9NP4HS@6(HZ+_BP;&+EQ!0ZD/T/S2=E3VK[6EA:K[>XP<%_,
M4L? P"3.L><33YA,L"];I$_#S TDADU<GT;YSJ<R5B 8,G1Q?A(8S*G$01AW
M-&0*6'LJJ*' C6Y">"[6:/P]Q]H3O$O*)60^U4T@+G'"\.NW6._A8R6N!.,C
M4\7(:(3 OS"$3\</Y565@W1T=H"77,)_$OE7IH:,:'AB52]#0ZQF@> A%!X\
M"ZNY";S$=S.<+C(2JE5?DN>"?RH@D)H'Z#H4,4H,N/Y]R]6_R6\'KE/CSNM"
M$"ZC8?QZ-7&# EX*L/_P\N3JXG+C$#VG>4(%QVMV,<Z8@'O 1Q%J"_&UU@?.
M_X6+$)?^!MQ-\SE6E]\(Z\_K@T_'9U<$\(74D1Z.:ZH$ZI0 -;Z*9B0ODDFA
MQL6=Q-$T2H!5 XKEW<0&PT2P-XS:$[\B$U:W#<*FW48TOMZY)9#^FMV07R/X
M;919;]T='=H7T33HT!A42]N:8*MX)@6U4PL_JP-& _CGC7HO%$(_,K.0:@>R
M#4R?+2L+=6L$\;A3L%!Y'&S)()B^HZ#XC8IJJ2AY(;A%LFD'?,P<'T*C8@0Q
MW2?&P2*A8D)J.$_$VA.I0QH\$6.9<M1,XHP@X<X9_!W4.NA!50]H8.#'M7?6
M@$AE0G=''?2E-'7JH(PHW1J%@()GC=LQH\_8%2"8M0$L4*#-@C'T*+RCP9"J
M7IC,FS0?G4CBAPC!6>CGO_>PW,%W+0"?/[/83SS?3+A!\8=G9[',!]&,.>5L
MGN3CO]52@LC%O\QC!J8,UCSBQM!<W=)=MSYCN.*_,O!G-@J?Y@._"LNR#1G\
MM/ ;769,)='Y'YX9J GZC0J5T'X"ZRN#_X)!@5E*'C?&M/43_AT2T?7AG4:1
MB+T!C6.+,WX6T9-_%*M_$%W GL349YA2G2,J+'O(* XKPMMY:E88%9CHRI/2
MM#78J5$6BF!=D<U;!S('J;^AF$.HZ3(S>(/\@_QI=#; D_+Y-'*=)NW<^EZ&
M2^7'#_1U8!UAO#K1(^GLVFGUE3H?X"^>ZSW T6A^$JAW_3/S%!6$55MS*\W4
M3F)-<!.(TE.$R1(\S#X57XM#WE#ATTB?PN9W1SOWY6-UR(MG[8FAX[28DQ#S
M\ KX$J0+G\.E8U:K@,!Y-&/*["F'PRXE,H-W[;FU]IQCJBXC0$;CGL*3K>&Y
M=EL"C?2ROZPUK-2H M8BN>05='VA1B&/U5]C>["^U=_FH86BS[[B6S/,;I$4
MSZ?B>T7T*I<+ZY12H)))#-V#?HK$9"N>#03T"&PA4IW8)W?(S(9*44#YUZ+!
M_;&&3VGGQ):$[IPI?5UG+9JOI[1G>XX6#5F/AOX%3KM!PQRC4<Y:"RC&*SKB
M%;6 :.NF6?*#&,7S5M&*5]0B6A7+D]3D5J+>@.;$9 F?^!=YM)0BM-=4[)CC
M8M5TJ^*4E([F3_O:XAJZU "0M(##[9F581F_CT%U*#*0H[U8F"[(QS4(-#1.
M/:T%L<)?Y,-M*Y P&-I4R%@*#V;0MW5WJZU[<3LWC49&B&]URT*:?^@ *S&X
M-J7H=)C;>FZ-D %A?#9JA9E.?#P><QK4.2+ J5C"'1-%HQ4J+U+A'M:B$H'?
MDB.+5_WPR_'7B3_R4V>UZO6'7[IS2O6%\35T^5^(F?9K=->>HZD6CE]CMJDB
M;CP.Y(;Q8E'[6...HS2"I;.:Y_G)_&-W(J=T"8:A70R()O:'J@IA$7Z=@I K
M0<09M#D+48[^Z>$C;.1= KX#M:8V7A._,9=?IVQ9W:O!SU7T,YHJ;?^=3Z.P
M,Y7=$>N^GKJ&+I]$*R0:>+$=Q&B1Z4V8F7E32 "+XW1@1B,_XRR0R<".=V-@
MV_-I##LK$XY,@X8),<%&TT.H4T;;1R.?32])5@\J$'B(-DTK*=S.:(+=OK2\
MCOEUA49>7-Z^,Q]E0J^J=&#1 9=;\N>Q#SP)K%LRZ;'^L!$PN8A]7_52]4"O
M.HQ4 J>U0^KD[JFY]]2).LZ"FHG9E3'9U+<FN!C'S,FN3H!13I:3!U[+E8$+
M=K3>@OBN2$ATQ[<^IOC=E^1>[/9-!(NT3_=UCHED&96#0;9%:N?>)YB4]OW*
MJQI)>^ LQ*A^N'=3./P)=6*E>+.B$4VE0!<;^'?[9HY%BJ1ME<ATPI)@\)!/
M*H'3M1C4_BU UC(=CQ94:6B"#CJ@2A:]QI<OSO/1XOP[\*OG'*+SCS_C?A!X
MEVPL*)8Q4!*DQ*PJ8/3?NR@+O $7]3->IJ(LQ;M56P?'_\>HVI0JX-Z1J0HX
MV]^IL@*JMJ,RF>*7['0TO0,NQOR@Z5VI,P3#ZUY>4_EXQ/[IQZU7F^^FPF/]
M5!B-A#79J1_X?U.D.M8)#TX!GE+4)Z_)?,3]Y^KPT(WB&2IJ] <)\02U9.+@
M6N&2.,IN)K2#:J0TWJARWFK[M=#@00T@J4I95K1K7O#H<4!_Z5]:J2(^&.D
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MUH8ZE3&N2-&@=D6EF."0,] C,?#9@*>+. C"3BAG(DDBUU>_*(X'1>0M>,B
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MP\>A0/4 LB]2$G>E!\K:D<XKGS0,RB1J(!?\&^&'%0U5K^US+0S?3WRXG!1
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M5;]:N(7\BKV/3(@1!A.U[..*8CE%]S'7&%F8^H%MUZL55%ZQ\:$="B3LM,O
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M972PHI[HF\(^TT/QO_"[*>?;,!1@91=-XW"A\4ZG$?+H@8]M$9PN28F!*+^
M52]PSS";CCAC4=RZO.=0UR=8P0:$4[2:</ ]X->!</E%\.GEN^$"@.+T1M2'
MAIV$8/#J)C1%8JLBO:_(>JH#]HJ;1%UD:.Y<\ .2CQ;4*6C.A;/_];M'Y("M
MW=V5L<":6%\=94N6]<[P-=(!597NN*UTT"\J2R6;K*^,,]*]4Z3%\ZF,:X]T
MC-HD'5LD'I:A;A4F<':\%.&Q>KRT%)5/_G(I5&._@%BV!,DV9/*0OD)1296-
MH)/YU3Z*2F+6JNE@%:#<D,3!B:T[>./MX>ZZ+N(P<,"ZM,""QZ5>3F/JU9MG
M=>@-=0'204-9PSWU!XMUU#.3#K=-TD'" ;?BUEJ!),^FIG KM\KU)FGWE^!C
M;GUYIU#*$S>CJI+Y8X@-APG@QEW9<J]-6[[UN'M>+]!+E3L-%NLPFUT*4130
M7(]:9/(RL'^6=28N]:&X8N?!\D<YZO!%RIEQAOD<PA"'RH&#7YHQ[YDBMR9
MJ7KDG131NMPLCC4"RDV4'Y\E]#O[N/88L0;_"0YXG%))HW:&=5F>@J(P2UNX
MD,B\925X<R?E%ZKH]6ZU#<%'+$8?)(TB*!:.BB")FB@W?C#EZL]IJX3<KE!&
M,>V.E+:F*X&E])0W>]4>_E&AUM8V;6OJBI22'Q0C6@2$8AA]"D^=!',JJ3'M
M,Q4P.RXU0/PX3K26YQJ4"W47/-#(;.6116BZ168\"EI#Y#-I0L'$$@."@(G,
M4>JGL@9.O0R\&<6U#\(I,+=^E"58ANMY*,8Y)"&\>RE,2<\&884W2= NAPM1
M@"-$3Y$Q@0+"@_#G,I#YAP2,N,$_LI5. AX'%3FOFTJE"<X?03)'&MI&!$#H
MD.LW$KRM73*(6VI5FG5(<[2FC)0UQUGD'$G71]22C5/Q9?4'O6;+'/O',DEU
M4JP Y!.J4G,K&Q&"&.FWFM);.;/H3L9=,A1;4PJG^H#MKL:QL^+L5X61=-.E
MM.89Y<5&]YT9<+O/F-6P6C?S8X0? &I[Q+Z.9WA00^TN@3G6E2*3UN1"3)')
M;V"XXR H"SKJ0C?GMB)MW:'#K2\U64XW'32VXMKF(:D1$ZO&M#4I%].95FP&
MA&^=/XG7ZV'2*">$RVAA24GK9;1=I26_G5RTL;;D_J*#:GD)GM+X.O^D6@*O
MGTI\9FVU!-W^*<LE5#E)(3Q3JI0Q*!#T1BCC^-<A0VNB97L2AM&M'E2XH/B"
M7J:OONBK+[[%',XE84VL6WD:CU&G]0@ 3X]JJRF2:@#ZS$.#Q>HEAZH#"CC@
M><^$F2U!&01K-F9M/#00/.Q+]Y3KWH$RU&S.Z1:H@6UM#S2,.@/KUL_0C1*<
M7D!V/AVP,L3P#HXI'1/X"O4VHQ?J2AL2@L2ZV,5]0-?R"5=*>*@HJWY47C;*
M3S-:HWC#]\X:=55S*5SAJP )05'P=D\Y.UJE,'">>VVT7IQTPCQC#ZI+BHS"
M$,#,R^9<Z3@T>,NR42V)<Q=U:4,$>0"\$6#ZI!#Q)>,E:!I^Y/EC"JVF&GW?
MK=A(]X=J!_?':OEN3Q6L=1R]3UHMYL0:V0$8"MWYX_LLI]Q@1'VOOJ6N1J2J
MZ\^X+XMP2>!*G?GJR]B,).\6:?%,R]CZG)^M"]L7MK_'V]/)^5P98(!C *<P
M&92$$3,PN>W;"/L_0U 8$Q&,69& GD"1GP\T=I*)\CLJRJ]US @1SQ'M,<H2
MXRH6I]J4IWI1EA)LXAGVXENNHX**TM\8+9: 55 > &]2@H<37XZ=8QJ!A5KL
M'$OF% Q3(7=X) 7%G$^E!YHLI#P;&A-ZK,N O$-EJJMYMP2R-!9@MQ8G\PR<
M272'&$@#A?A6G&VSRHA%9^+;K3&(3'S[2N,]'/#<AG3>ME*=6*8:%E-CME V
M+C&E8PQR9L"%0*+\M'E04JB&)91NIN1$W<OD#STP5QB_$"Y B-@<3P"S-VLJ
M@XZBOJY--OD5-5D2S NE+*6EX$PM]!GN_,3,T"JJ&,N^LQ)2:^0/XN/LPB&[
MODWH615&3<BO,G9]GA:"8: QC<<J:S^A.4"#H>.<"3,^A\A$MT<?'_S:R$.4
M,GB-.^'3->77HYH'OQ$IL)3".LN3K@6[STR5' >^F]Y[)QQ.Q=@F"LP/M;.Z
MIYC!>ERJ(@S$G9Y!IIOMM1?_K?Y7*SKE6V-E%#KE/YT<'I]='5]1>_SY]:_'
ME\[ER<=?KZ^ZHM=;D[DR>OTCS8<!IE?&Q8JU^E7>Q)P+[WV#717<$::L0#/6
M !93 HHZH/7L&M;Z&)_4&#%KWCKGQ5J0>6G!7AB<J:[4P[>O?6[-7Z><D,:N
M'" 0:>#=$?)Q',U%D,XW1I)KD7B"%DJ" N8>Y$><F:Z5F$E:!3@ %6N^]<W4
M*%TNNSM\M3Y0PM 85%[S<:$$5%M>ZP8N=@5KO0=IR5ECVO+:4:XCRCT,V$S!
M 0 #G*,YP"A3 -X@QL.X]$L$DOT^?TH(R^5T0MZKE7<8)?G(' QIP9H_)]*&
MA,7BGD[U$[6PVZ[]TO2^]=)4Q6]],KDZHL@#.4R]9+6Z4V\!KQK!<IZ>69OE
MZI">5X(S*Z9 2S!\3\RUX.VCRVA]LC&:;UC?CT3B,\3Y4KS=MR4^Z<E1<VIL
M?.]CP^)N$XTQ.,/ )S6)_7_ QC.;=S&V82#R+837!VKAS@#8M:;2IU1;7-C\
M]@1?*UYWJ09LD:V32]@XIB1$ADEKFNV1S0:8?)Y)S&2# H]C>1MQ3&XI*<0;
M!G-;&/-NPMHJF0=)4ZTP47>(C&]QR'1QH$O=%<M:.YV1J_;E-$S5ES* ];R5
M%0N7A8,1!&J LYX$4Q$F_%/CUJ)T\"<YWW,46Y]'0A\T-0#-+8A['4Q]-TLL
M>.LV1,#TG!&:**//29!-U8]908JKMN'4M*7>-P26ZA!)VV1U[=H:)J$IN:%+
MSU28TU^WX:09Q#YW1D.).0Z5_\!:2E!6>@X7%JJYL@#'KT?/W==Z.S 3Z$62
M%]C ?VT?<E "+C[$7 QFZHLC $AQ\C989D>U/_?^K2*C*L0CA08O825J[*JL
M#M],K3K'"Q]^IS+'>W+:JY"!\F0L) Q04A),P<"IR*N5TN3B4<D +34G;GD
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MXY,T"J73&QE=3O ?,8  29[9\Y;N]<LK0'M=I,7S*4!K3WZJ?<G\@X2G7HC
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MRXV2#?33>>"RY[F(8;0-XSO=6YEG@Z"DF.OT2ED10HS5UE230=D%\TSY*M1
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MA,4D%1"RWFHF>\S^;B8#FI9/Z'*V.I$_*F6L%%'2%_13BFLA"K2MCEKE4_#
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M"U7511;L$8%:614YYOM+(1E41E\X :)]DF3L(\HAB)(Z\^1%7#IBK$.4A!K
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M._(:L@8LDORJ<E:()EBI7A;=M+8TMY0<L%4+^'E3-!OE;?=*&XN?GUJ;;T>
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M@$LDLDB "CK=+%A/-?UHE,T14<E0IRE'E2'"![&7R(%-0PS!L&A$0VN%RC-
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MG4YC#JW/N3U Z88.E:/6+!33^1)EM 0SWA2A\^RBC&H34J3/"SJ>N%S!7'K
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MX*VO7[JPT%;? /SBUUP#/&L0&'<^[3J=EH:'AEFK_8_>U=>+SMEG ,$0%M3
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MH#*7(-^UO(,>G*NT: D">1F;C1@RI^PFADSGI0:8DJ))2/L"5=NY*H:^*J)
M#UJ(+#!M[$J^>#+P&$LI&6\8-"L7O-H=JBQ<JP&,@EO>8LSZ<FL\EH'D[J\5
MD0?P :QKXCIV(Z>*K&_7F0B0G; QH/>O3#*])^M10&(D]:9U29L)9JK'*F-G
ME@">)[1V@(M@UXL!X<[#';?SA9U.W(!-=VGD?<N?WZ5&7\!85-O9!LIQX2T]
M2L)A9 FRB81SZ<8V+ZQP/7(3 N3<V(( (:!]H#84$F<499R7LW8ZTBJ$1<M
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M(^\CU1<=JX+Q9%G%K^@5VO:D12,CX<U*=(PLZ0$<'+74D09:1:E!-*3JNZ4
M(RH>?B]\56I<CK4]3)!O WOZ!<&LH=,>=<2H+G7&5A%X"^>+\1-5!<I]04Y/
M#9";D.I,#5+*HL,7S2BTK??2)3HAYPL>%\<SHIMZ&EZ/[V&-VEJ_[A;8'R;
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M>/"+=I7'K=44/@%82OOPE(<^*C[XU;OZ]1_KW7\;./X/4$L#!!0    ( .>
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MY3B)[MFSZ^AC8]FM[S^ZD!EV5ZWWN^R[SNR]V[;/YJ9M[_RC?P%02P,$%
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MOS.A)3O;@]\SH]SW))<!X30B"B!+&(#=8B%%7H"*&5T7<9[CSSD)?=R,SLV
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MEIZ-ABK;/%%R?<W<*&(@0@(KSK!&'O4$B[@*W0UPCM:83$\G31RKB&N/80$
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MY#L\/FW:1G2[3O/?S8-SFP32/CHZ/FB:WTR(9K*-A/.F_;YY:J+B=2!\>S@
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MPJ23RW,(H&NS,LC:PRS#D(II.6X5%F/#D#/Q"B<FS^0[C18M<&.H>Z[;JGB
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M2E 'QEH^>"=;/J'&9/("@^>C;4_..?DZAE@>OWAUCG%7;^=2$4'')^B@7%O
M6KA1YR1K\UE;:Q4*!W;67S B#W[)1W),%]&"#)(*DY (P^0TQW"%V5SZ1:[;
MR!! M*H10<A%?/GRC750K7^WDK U[]$XQ'E0E#T@U&B,30'V/(RSP_RP;*$=
M6X([[8;:\N]*[6AB_'$;];;/)#G(TQ(^DANX]<J7%9WK-FB?>M1#C9XI8*KG
MPJD261&V&#M?P%6IC$I.O^J &2YUX1&N<G^4--H9 Q(1M/R5^GG'-BKDX?#C
MLV;+=NIV*L.W&U #;5V9J7W:6^(U-K'$1W1A3!.AAT4SK8,"@8FA1TYZ[-!O
M(VZ#1L^_N&7<_WZOZ:B@N&D[-0F$(IW+;L5-]YA.VEK:S%D61L(,Q5;I,IL@
M^(HZJW$\'T.J=AKVS<>>5;2\%.-'2M0W+^B1Y%Q!^'6FV:@4B&HD+#)C3G1>
M@^;VA>4\:*7 \ E,XT 9-BJAQ5=4DUM%E@Y.[G7GH^"]S\5QV<@XF57E53,?
MA'DYBY$43)L.JE)&9/:92^-+,&):H=(A-Q,,CO8B6\M2?!F2&_+MVIU=H6!_
M9:#TA!&1H@G=OD5;ZT2+%9=M&19[[A$1:+(50^P>+5'&@?<=IQ.T1">H/LR:
M5LDP@YXI)%PQ0]&>PX^JLDLIGIQH.;*/RX2W4$2OONR^U(]JL?VTS8.BS74W
M2H>YXWU5+;!B<C-Z>-X" #K]#&U;!:SU-E&+LR\(WM)DSJN@3KM;*,M& <K"
M61ESG=&,Y[M4?E1],(6>J[G R8U4_-3E6!I+;=BH-QH73F%TG:/*/+Z<V39G
M!W+B;;?R54K<HKUOM=!H7+69V_[*V'(U-E\8$"<L_.,'%ZF: <X"B]PN1IAP
M^?]XK/LBP%8#I@&)FL* =_$!"9Y!:!K0BUQ@?(R 8@!98B7CY /IQF54>#>F
M@=:.!_L2$F$@I2YCHFC%?H (L2 K!FGAS1R5)2)?>0<#*\LM84N9_W5<D!G/
M;!K;\392-<]U:@:U^(54=ZR?F<U2R?D*KJ>A3J<\.JL,L5@&6G!OKC#F$;)>
MOL)Q@&,DX!@HBLLDI5E,?M11/CPV#*=/J[OG:=%YJE8KZB)[:A&#[@)[B+3L
M,>55P 30:G)73\R:,N/*U<K/=TKB*5(K$,>6GI)RH(>!P8-1'+8]/#S=62"$
M//J.@/.^X_ELE63IW6LR#=)&RG'UH+0KN#B[Y*=/?I[LDI^W82V[Y.<72'[>
M1C?R%8=9S[Q>V%[=*1'E4 7:<JF.I\:]$I'SZ:V;+HAI.JK*5,<#2XVPM?V\
MS2[>F_[1Z4.%:_?+4Y1Z:<]&8"!6'[6RSUI"[$SB$TD1;8;W#\>'LLU(^QRD
MJ)&ZL/K8P9>1V^2@@S35[H8D0EY8_SDP+ <)>;/S+B$&UU+B2MJ.87^X'JK*
M<)LVJ,HMC19"=)'5R&.1AG[L(1=U76B5D+6Y-A<W5C#VYEWY +<6*)*T-; Z
MA@T;:I.,S'Q<'SD :#;WHR-A0Z^1YB,8@L@@#4\^I& +S%T@0?9:B@\Q(I)O
M&-842'SZG5E%#OQ4NC'4U++Q5=MA[L.)7?=8^F/?(9PL?H'T8Q@$)=,Q<00,
MS68U\':C#3(L@=ZVI8;]UXHE^%&_[NA_>D"ATXL@TS(!G5/K9I,PS99!^*94
MN#>)HR ,%]S9MTHI6B6#V]D49>9K2]2]M.0I$02BYW^XD>$C]UW>QUG,%=D,
M!^R&+FOSD_W'8_0*Y>GJIZS@7>0?/8YYKR?YS(^3K]7F?'0R/#I^"+.SJ>C_
M)_;!:I$.V2+]L9GT?/=H>/?^O8U?'PZ//O&[>P_O?M(OKUWLX?#^@Y._R&*/
M#X>'C_XJBSVZ/SPY_LNPP<GPY.[Q7V2QC^BN-UOKCWQVY?R2A( X^N^]DSWO
MDS*F[T_'R_?)42R' /.[5J'"\N$#CNBGJ:&''Y4P(WO@JU3'W!L>WV =FZIZ
MCH</KZOJV3^ZTW'2=/>NV9A#;,O>C2[MV4.)BVS<Q3]W P^EC,P6)#I2?']$
MT*S\=TR!LSP5&WQ'B@LV*K]/ K!,1\-3<H%*O8@(']!<:OZR!;UL!( LL6O]
M!%+=X-+=([^S1][VX\/R8U^:#%#&6M_I.T&=Q,S17?$E8[)4Y97\^ZXG43I^
M-^- U(&^"KGX9CJ]CCQ]1N,BFTQR\XV$:UJ4TRPY9="+FPC9#[[T37CK+T6X
MM7 /$TZJN9]*L/6O2K<_,UEX<[*F?ZP6YD_R7OI6\8G>2]R3\$$'YELQ1+^
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M!RC%4^5X?IL]F>W3?M^K27YQ_H^#D\/#^SNB[1S VZ[_=@[@=^  :F?J'_:
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MJFN^/A0'9UU8,V2-LY003%-#36S$2X1)<M(PA9EFS0'K6LEO$)GFV3)B%8D
M@<#8$!_&ZRI5_,!ZL>$-MO3$6JL,A3<N5&G$9GX-AF#&?2NI-=#P='*)TS/1
MTF..#F3(N_)/SCC_PX1\DHG,K9-G/E2'.[QQB5FZZNS)LS<#4?7D3N9<%*3I
M6[9*Z.%!DGJE7G7.DMIGM/%IWQN<D;,!N3 (WR#H3,#JZ86R&A'%,SKML)+8
M\DCQJ>'EX1"($XT5[?)M0;[MWB[?=AO6LLNW;6N^[67AE+=U(\.T -SDMH82
M)5U^:=A0)D, QD :Z.M _R-=,R%'3SUAQ'2X\J/K/_K(1UPCI#4_JC%8J$HV
MJ&SK9-9FXBA/RG$KSC&MEI[65VLDV2RR0/#6X1*1+2BKP%7'TZXRTO30$1DB
M!_0%)\A4/_/+X]5F$B\*<Y%>8=!K]E4+_61S-DN.1_FD@K@7-AX;+_^QJ)=7
M9Y']P"NNYQPL'QF;M9(H@F96?&+R<?C<B:F)^_A].$]!.[(@_P-NL VM<QY@
MS":9=?5\6%F]O>CV7)TD-ZG%("0FO$3@/D]78)F.69L%WM?5G!RSE!.C9$VB
M$JD6GZL;IXS)@G2$& )LC-'Z. OCGE G<V+N8?*\K?";@=M>ZRN@_ IQ<,N?
M&F6NW>+="CD XE(CH8UP8.V#M1>]9)84IX%T%Y>ABK$:%L6E"0*T< IH_5-$
MU24ARM0ND LU[U/4X<@9G);(Y-!C1JODZ'#M6G*C*^9WC7X@64*K$0>%?D+?
MU[A1D6:5&2:_OOS9Q2SEE%WB+"^Y? Z&]!@%C'! $S*54J1<A8JP:E!M]ZJ<
M9%/K [DP@;6YR%'W['JQ(D]Z84^B<FL=<33])S*_K+<!#P'[44N&+3&H#JY*
M>A@Q22D58.DXR[/&VW-:\:;.3YJOZDP(%6^/9(]KC?C6P\^IKKW%DOV4DS-:
M^A8$1EQVJ)L &G0B.T0\DE;D^X+#)0B]'EVV'HUUJ%TTM<?9&\:E!;J>^(EN
M=5HPX4-+G7R^3RF%Q2!OXQMRD-+F]ILX%0G/+I#&@\3_R]>+NMPV6(J)F>7N
M%7$^U!\L9I8HNKX?ZC PA%1O7\9:XP$V86T3^G6C.?9EZI+:2GWYLT.TH$IB
MF/S&>0^;X\_3J[4R%[KW L_@$D?<&S6.N(_7D?DJSJT%3XAJ7]J:GV5(&>3-
M'(4BS!%E12]?L%M;ZV&CBR2(<)62Q)OXQ FR=6I%%+8*<Q)MHHT)C^*$GX@_
MRP\< ;/>&>M4NS8A:[B$L&2(PW#,X05KB._ #;\?YG"G5;F(4KBR$0']HW 9
MZ5\U;4S$"&P^C8Q&G+048"KY-BG;T:(=@)Z/5S_4' :NL?D=V<%J.6N$KR%$
M,@[=^R)>'[AQ7'EIW?EA\AKF88?AP=KKZ_+& <L15C.TF1.Z;NYN%](MG55&
MI-\883!1M*S*\,Q9J;''.+@0';)A\JJO5%FXDLQ!8APSL3_FRO0Z+ U1>HI%
M,;1Y%;UN;*U"M0.L(2[IHZRL,DC@5SCX4KD2/A]4<3_0YTME!_ZI06MZMZ-C
M81UNS;$YUO.GOST_3?Z9[#=79:+?!-N_S%L$U8OP*[GO'4_?M$'61@Q3^WR)
MJ[E6+N6,FFR!;,8&RC1X-?LK76B=O=?G<5+8^S$C,MRO;%V*U%A(SX9J%.E)
MF(BY%6LYI"T"-T)?)XP:+M)_P?;SF5FO,X-M1-%<O31C29Q;ZNEJQGDY?N?I
M$B3$IJ9:WS2N=A-"N48XE+I%'XC]I3E$H@5.%:E!9QJR/M2 +$H#K>J69%YJ
MXU=C%[]BPDO#A2P["L4F)-]H4;)=UN@3[9JE6FLFZI7L?CI)]2#@B4$0BM8"
M+F^T:XR/B;Y)$GGWR"H33TV;A.4HNNYOY^:JA];>6=)36</F:L4O*H9Y+<<I
MO@V=]"=BP,@BUM2V%SXL.4.-!-:0:C6DUJ*J40Y=:V8*KENW@N+%V?DP.0VT
M>.<Q]N8L3,1\YAT/_N::KD99)DR+!5;+I(<_76Z R4>.#FN2L!*7+9V>4+R_
M&:\Q;,8(#3XO![1JJ/ORXQ>OSEEKV#I56_/;L3)A;:60]VR_2362!NU#,\?E
M55R8P%(")R7.N%FQ'V2'I+)M8M,"(VO*@GA/0UF@YHNUBE4:^8UCZC)EUK5P
M*FZPB>/?"]?OD4B2"/8GO?R;9Z\N!GP&#!Z!F@C/2HT6#\-LZMK:CO3$7'P7
M53;6LEX8]]J(T!C.BI+WA>/.)Z@M[/?+W$H \NBT1-BMP3[?UU:2R").X<QQ
MV/B"E.R<,T VO:=5AYEF4E6^,'78V<[^L+D_MK-?3AU]QZ454:F\&Q.(S.?)
M(*I#6W=7V+L0"0^A9TM+<9/'\;GK\G1P$[ NLF2IW9ZI\X&VU!0]=<6,H(_5
MG767,/;DQO6]7DH-Q$BL6^[=\P=(FK"XLWMCX]<0N9A-+6$:,!2O5NS/<6:<
M:1?V"XCLX+A"4/K 37LK5\(2^4[>?' %7U5OBE 3DE K&I/L*#I)"J-'0$)B
M*$Z)UNO#:_14>LTZ\MQ_" 2E5%TS%:WILN[M;]9=>+[-?G7W(;:@K3:=>#./
M:^E$@7K*"K')FH19ZBPY>CW;G1=T &@K8Z-AU/5*\NT]2.M<G[;$"!7=(X)(
M6 NBL"9CI:EVZ)BM0Y1;=^ONV3.P%P7U#J0*:CYA6@BEODX0*-:^UB:P%/J.
M1-S&*ASBZM[B7I+2-3OTG"-B@Q^QUK:Z-,26;!<TI2W9=*_]0]UGZ=HSNZ'(
M*XS>1GH(OW/)?*NLF('%@"+-2??E4E VC=E@$-WJ0LNV?T;@*Z99DX[4, N*
M \2OG55$-"BFKMG@O!=LZJ1*KPHHDJZ%5+EQP$&:1FWB!9E$,(OT[N1>+<0M
MU6*5C'UG&+S"(5D3<18;&+R5GMG"O<2=^#'F&E2-[S#!?7^7X+X-:]DEN+]
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MH TJM^:(@0N92(9'R=! U-C6XM"5U["$S0I7@HS00;PI&J]P-O',&ECD6MI
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MG$B)%A2^"^:'<7"2K0:KQ)QVX@>Y8-$7D *W\<C[.K;D==L 9,8YZMMY[CM
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M^:@0WQBSZ_H^>;Z4OFM >IDNTZRL0CW6AN]7I,6.#P_O)OL6:\ZPVF-R<\4
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M/K/@B&;2>*JF7UQPIO]K>8"@:EF$$]$:.@\>=0(H1(#"PPF@\#D\RP10N*L
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MG$5#:(3)_WK=D'&9_8W\R!PS_R8OKW+=TL^E/+B/@L/9[)=\WFB[Z*]%M0*
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MB4^I_FXP!PHSD1*_DZF G12'^R>KN3Y2SYM/BR?187X2LKPO5,5 *O<AE2O
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M 'M&;+R(P=U9JI]GH1T,NT%!KW(<6(O13M+.+$T5V$G"@9&9]NQR#"O=87L
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MRKZ.VK[,S."P4!*DWY"W8AO\>WJ>=9%7N_6"3ZR6&\4W9(!+YL8@&QGB?@%
ML_&_BT7_-^O"CZ."YFV,4)D6L/W(# -XAJG(#E-FV76SL )T:=B$?LDX)NX)
MKO;BQFG20PYF^:=OC09+&?YY.E.E$?&PI&9>,>Q*\^WHB4Z0?5)T$6%=6[&I
M'U+/^&"P'@'1TKIL*@;PQ&JYR#P#QY]SC "M:8GUYL,J:G<Z>YW4W'Q.,*]$
M)D< 2L+*"PK:;N>%+<1EH'7RQ.H/YW2694&5TN\^X2#2#2.$?C+BRHI0[@Q
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M'^T$#A7NZ,EG^0[:VTT]3=AMF\>0][G658>X%A*7TFIF .?(1F9%617T)B^
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M3A4>NX%@C<C(I#LVY]?*1A\]Q/U0K)!B@6@U2H]'\?9@>1[9K#N17=V"2GA
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M==E51;Z$%?%\_C15W&C4Y,O4K]%S8I\%5!P7]QD^/>>DE8Q,E[8/+J0 JZG
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MZS+B5<):-^2@VZ]42^O!#S]\R^VZSUZ>G]_[ZM@1$1<DUAM'16Y;A&8O8?6
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MAZR;GTV5D^7CJCS3BT"=7689<,*$EP=Z5^("T3O@6R%%0=X!W6M10/[YJR)
M?B.KFU_VW^5KOTP4K>V7R'=NW?041SY[\N3WF"<TP@TGZT Q)')@L<<PS)R&
MZ[28L(H@W+%,X$=.H!_5ESDFYLO'2H&[SZ5340AL:<=2P&\FP^XBD3ST<X*,
MVK,GSYYD_ %20>3ZS:B_)[V^[E:S41^O_FJTF,!@/_J,NO\^W$0#$U44J=EQ
M0&\MW;RJ1]L,#AB"PSW]XU>MU:X0,K-0'21%[*]_>&YDL-N0L)>#Q;L-DB60
ME<KI7!N A!S+X]5?D'XO@^*UKGC6?:[F[!>DG7W@QF4.&;]6;M>TW9Q."N?D
M-?=H9,F+#M.-=*:Y3UIQ(:4_'_MUHK.6FR-..D;-&2PQ?&9IZS64]1\CS3G.
M?E*J EH%V-8OGTO"'(_-H99R )A7*NTKT+D+X? )TR$O#2O_H=?EXON!3Z3T
M-X-!Y'0\I;5Y2&*(S6G*=@6PY9.OPN7P\].OF+,:U_>7T?J.]K'!DVKC77,N
M[!SJ0JN:A5'D2![0Q^+\$,9Q&4^2SB"<,G.(TG6I*YG%&2=-+F CE(A)/P3X
MP=O1IR?N*5FHQA%A\I;%L-_KQ78Z*A6U4%9$<QOA!$FGR<P.L<Z'B(#A(P1<
M")DV%%WJG<C M_5*E+M'PU2TYD'8)2LNIAGV^XGI]79\]=GLKOH,G7(3NTV6
M++-"Z==EU8H:_0:%R? #_#?Y&MO,7,7BRU-DDYQW#H1)FZW8W&[@-)CK_?F;
MX$F^A]IF. )H$<KA)\<#FX@I:I(U[\US$0CPRU-V/Y38AL:$O=F9+%^;-.3S
M]N>5'=_@MZVUUJD!N\52\ITY4 HMM'BE[82,!-M=->@7&>N86L =PLW9E1+Z
MMI.BWW0T&J+GHF.@AWN?$ZA)O /;T*QWTCK,SYCKLS$X+.6^OJF$)$,3NA2+
M]9COAD5YSU\&LJGQ#,HX<SHSC@I;"1$!,W70&)7UYEW$DLF&XNKK>%"&G>5S
MM].K:T5A>/W\EE&^TS!&P!XQD!G=2R[J<T7?UJE#KX,I"?VKIZP[8NW:G&:T
M9(1X&80FL9O/-2V7*<70:!@F!+O%P/\+5[S)HX=_,2><.F-O7.K1/Z?C0PKT
M?N/Y$SZ_H?WZO+\B">YG3Y[^,8MG4!LFDK@B#D<NG\Y4;P<$=*2(5_4$XO23
MW;1!57S.OY=8X^AW;DXB3=9X/%Y"W8\)=>G<#!'N]8?FBMBY)2(<6CM!)]AO
M.ZG22\#)@FK5F6,A$3@'$#=M6M$]S4?M+$K@<DEQOA/X[71^>4;75:O3 [0&
MQE;-?"]3&B._I(Z70^SP0DS?]S1J6Q9F4 4P1&X$7;=O[<?NVYZ C%'=?0+W
MPHX+&4>9DM813*-S$QD'$6XW^@%!QHG^H%+S,Z2=(7KEJ05X>TO+@1!.Y X?
M:N*%J?NJ:X)(/.">)!&>6&;%7^.*B-*M6O903A'):-2I=>,#+S3Z@BTK\Z6G
MEJ2 SDDUI54,%F+D*\W\1+%&RG#+^2U]^FU;;P@U+_BQJ-J6WCSQ=E@5/8S+
MZ,9:\+>.#KLUA!H[^L/&L>\#0R@A1]%IO,[S[%T#NBN62;A7%E=#F*Z65\O:
M24XN&4*_50]K'W-@Q@,^=4I&-L.#!;(X\S6SW$:O6ANM"7\&%5*-%_*VYQ/8
MFB%&W>)O9@ OA1IY,^:C79.$@D0M4\W4D4;O\.L\$;)-IWBH39?U=H50"LUM
M;OV.2IQ%=&'\W#F"NM#(R3=XO'HSQ4@&_,7L>D[[G729)-]F@$DR&MI FHY3
M)BT@$P\!X/?HXA/-5NGJ5.2&>AD+8,, -OZP #8>PK,L@(T/ VS(KRC>>?C>
MWS?>)*-]_MF39\\R[=YGREK8]I<A._1:C3+]^J_H./F'MYN?O_CKR]>_4S>!
MG43_)_F>?]CGWI?9G%:??_OR^>^\(U(?R6')8^M4??1."\2F6?@'2?FY*AOU
MA11^RY?]QG]_2SF+O-SE 5SH+[$N)$J&4W0H_&<)$BR!$IHN1!.[<X\(\MRM
M7E.2*"1!/O_AU>MO?D<M?O1JT%\$A)C"]' UJG8IJ3"=A7!?1IRTWI_P2X.S
M4/Y0KSHK(JK&/X!)ZF: !U1*V\E79IUE?1[IH>*#=I=?UTR(+&>2A2_&[I[6
M;>A<HEZTN9+@[--GJV__$='O5XZ$(X]['))WHVL-&,Z[@Q;_TT/65\G 4-U#
M/3(.2M!>TL)\[O-_Y\V6@J% ;JZP9_70A_(&KKHNFKHBOT)PW=1ORL22U!+&
M$/HROVE#%D*@-W)/Y$O#[73)7!=U*1R6K</7TQJ *>!:?!/JF@3+YHQE8?G:
M\^VU:^!R55RFWEP,;>0KD.F*1 7-P92\:C+AD,^AWH'MV;F/]<I#L6GJ-1JF
MKEB_W9]W34U-S!G9I!+_Q,UW97XXL&:/="BVL0O;W <;O*?TLZ%BL25YTUH8
MOW63MYWS9C*$TMH*8):VP"FLE*!FN]*49PJ79D]['M-.5A)U/2<]E*Q8-!+.
M%C9OP9&H^,BY73;H;!";:1;YSFTI,L_09R+$-C4-#';6E3?<364V5N9O4FU+
M[7WV9XP_^$)8W;KDSB4U_5SMT_X28>R5_6M"YQV0]:.+(PP>75TS+33!,/?\
M>_3]H.4E%AU#"_[1_W'3%&O&.>(M[6O+2-B<9F9*%\J/3EWVW+DL9/>4O4 .
M84/"QK!6*/$>].!& .8#TE/(K:;CE"0T<ATTQNN4H8]6,$2I631&,S;\4XFR
MS#<NR"Y+SF5%D]F"1ST,:/*MY*1C !&W(9]"[&MZ+FVN*UI3O ZZ**X%&9=7
M86A4E$L2G?8*Z7N-[?*>>J%*=/MAI6SS YK&)0IE-F,D'HB,@$R_VNJ37(1P
M..25$&=!BS8U.<R%O9B;*Z8. C3CY"&5T'I?^(B;(V"5)$_?Z#8<+E4^YV@$
M05--8***>X::_JAN8#+VQJU 8;]NW93I,2JFU$I.^8NIK>;>%\Q60$(@W!:X
MH:5 A W>[XNYN:!TJ[#EBMI&R[@KP\M-V_1NOL4+-_1.<EE";B*6Y<PY2C06
M.6P5Y52H^:6*W3=;7E!$"= W]'%JELF2Q24-5%@8TKNU4;*K=M]WWI6]X45N
M6/97+_S;7?'Z'Z]!;D[GZA=QB>FRYRTWK'KU\67 ":)+B!]!2B;6A<!ZC:E;
M<6;4E:D%@E#Y]^$&7)V(3#O983+,R>-WJY_@EKKIY(]^L=)$9UB<0Y,=UVCH
M9FI"DWQ @YOK3[4!#3;!B.,@[74.]E0;P&$KT*=H^[PC+WDRR$$< J/-OCDT
M=@HZ=(7A)2C[*NK1^U2U/TA_M>K1__E_ULW_^C]+KBOFNKY<<ET/X5F67-<%
M-R=-I4"&E:0T^Z&I#G)(=W1<%Z;U1YM4O,/IREB(B>P(21F*'<M!_F5>&B?<
MV7HYP=7ZN)S)@XR>G_Z!R*,H(35(_^E\R+$F(*N L(<XROLND'B=ZVQG+CM,
M#WMW@>6#16\GRV4@H,@9!#6!$@4K:4L0X:+=)WCX$*[^MIUBFL(Y_Z,[=B'_
M^C0VTC-UA#C?DBZDS@*ZP-^E)8GCC;0H%I_;9@S0?L%=5"P[)KZN7+B0"J*E
M!@)OW:'>PK&A"$[_F$E4Q0X(.4#TR3R(F\3>JRQV?AN%-GBI 89K]=J$3$B>
M/H:[5&8T3N] P8W?1-L$ G@CUL(GEI)"\A7Q48LVB]F#C)#W,_3*>T8Q/TYS
MP\L&Z1H!_G%WQ!8<WV08A(N/P[HX>]GJ*-EM'U> C#@R]A%)%'1%H^^(5N^"
MI7U>[+V/+^"B^-T]0+^N"BWBV][Q2FX)%<;1@O$VD=U_]7^__^;1TS^O_/;>
M4DY(&P4H7:TJ9EMA9>DH;!=4?&S3@/^O7XN*=RBG1S)>$489MODYRGS)JRG7
M$P_454,IJ/"VP;[6?;<10C.$@?KZMS*3)9_F1%"7OW,<ZW/N*+QP6!,37TH)
M,6WJ*4K "3@C1JZ, =,19.SGVJ W*>JV]"RA*D#A?LNSR,G\\0+.,"-S) '\
MO?FE+Y#3<([A_))I9LAIJ&QD^E"61B]]+A4&KRA]HG]*SSXJ(T340* 4,RDH
MOPM[!?_N$G8/Z03HXF$'DRBA85)ED!$?\$L# (NO,*VTO]]5[\VR?]['JX\[
M-7_U0W+:C7D#\,^;-(BTE"Y*7?<BY$LONJ*2,)G<QG]2^25?)GPG6=BT[RBI
MT4U2%G'[*F'#.&1FK>$QG-MF^]G;,(UX\4RZ7&Z:5^P-[/S5IN9%<K(XM((!
MFJ#8"IUA/PGF/]\HPFXOTI8B14F,DB'U,> 'HZO@VV!60]79V!/""/:<<:W/
M56U4;:763HWTQ?P\DC]P.U$F/>J@&N1-XJ$=:#MJ7ZCBA9-M/B1 TQ8%)N*?
M)K)/DX(@^,_"<2<MG1-/)>_14J%J.TA*=99ZCXFRTM1>Z&K(M&\S,X4GN_P)
M'*!SE73O\5@;)C9(#=2)#^LF*5QG>,K 49:>)[F6>M0[ZDY'%ZB"T:8*@Z'M
ME.JV:FI0CD#UX<(ZU-5^._"3''FV21.6"Y,C722#F5>X):$O(X<Q!I%<'.E%
M!$-3:#_*_#<ZXM,E:$(5"(M#]%0J\VC@,$6PPU[#'%)=ESWW0%[UWCFO"#L2
MDNFSNQ.+E_#QQFT8#506&F+P\:!SFV@HROJ5)1/N,/@NX4OZHY%XU@SI%IMN
M\'2Z0?3;\".$O_:? OL@Z"@@+JBOQ$WTD;;\H?@5-,XOQZEL=2]HL8U=#=[F
M_F/?2&"P0>[Y+55A5J]S\.!>K#OR#ZUGT<L>^67EF JC>%_=.1_TZ ^Y7^<#
MYV 5\G9"E"Q*XZ'RG&QK.CQA5&:[Z9;Y^O7G:ZJ#NN'CSTP&1^<2;P+4XGV9
M23)(D]@QHN36S4&CXP LHI[>A;CB$8H8.^;EW.=RKALDFT1+4).>5N?#),9D
MKB1WM?0:?D2O8;!43.,=9JG,I9LY>CG!/<Z/L1H^.%FH/]^5Q/2"5-S,_+7^
M5T[!?9M]7;?#F&/NLBA&<Z_<CC)HXX8D_Y I/;8>AH*_. ?Y:@>#0)T<>'G!
M*]F5BFX+/TCYE8 L+$R,6S%FZ@ 3E@:>CCFPV6D?U/ '#G$(9T-5PL9>B.:Z
M0H($/V5D#(W3.<R))H9I%U4ATI=&TJ(@D5QY18X@!#_(N(%(F9S-(1$"B\PX
M0GK^]NMG3YY@\S,BVCOU>[]@%<0AZBE"3N!=.XJ?O?\>,B:J<1!,!,:245,<
M52JR*OD*\$S&KK ('=T*C,[\3W\0"#8)[VO'D,HO(;%J2S!31PM/+Z18&O9.
M=YIX[-)GE0SD.,\Z*? BA")FIPT;]F_G-5P0$1$1\<<%$?$0GF5!1%PP(F)*
M\@6[GODN\JO&249O-W B"$(6H*RS!WPSOKQW28G4,?'C*:&7LNN;AV"C'!]E
M=+"Q)X$2_?A("P4\PG-3-A,>143 ^1OT[7\+/:L98,N6&^$+G-,4"H6\::C0
MR_-_?J:I\B<03V3)YQ8$X42INFD@G/ <S6'^OQ<E[%_+/D[J*:<3YXPK?!*4
M2<C)&B"O=<A"F6,1,;_?J4M0]I7:Y,3KC,H[+$KBH\>-:F<+]J$ 3P8TS0I3
MNTE"HF5F[W=F$\UK&\,EA&.1\G*&)$65SSDLEHK*,I</9"[7>>=W8!OG<D6P
M(S@@7: .5B,;FK*^NBMH99F_7V'^]J#&01<4?"24H-\5Z-Z\J9MWY.1$EI-Q
M(BTDCI9=^"EW(6VVM'>II2[Z^"%K19>INN>I$AQ?);"<8]\EW/X,NF 09[$[
MGU/._&4V+L76;[, 90SLF%OG+[,-7P\-4,O<W^_<,XRF;0L*3=?<U"T.Z: "
MH/D [;DS<<LR:9]PT@Y%&_7<3:LN_\J?FA"*3.15-8V/;MV&X#BMVS3:;TQ@
MI4?[^F9Q?#[!M%+U)\!=TQT8&^'A#^4WL3GV*_K5SP;Y+-/U\;N0(9*!3:&J
MJ\95[B;2.9ZSGP!:,-I9B:VEE1O$#)NZNG85D#(LN/BQ./J'DAZENJ"2+<2B
M(--*<(_TP-FPE.S8*8/FG4"D,23O%78+H ;S;C]6.T]T9U$L5$UNUM2,-?,?
M"22C3\WW$;83O9DF  R]0YD7!XBK\%\:1\SMYA>M*_X-BA&B>!#9;C 61%2Q
MW)()%)E!E=^G+*Y=<\K$:EP39X/E+ C551$Q08F5DNU]:QL\(K-#$T0X\/ 7
MDHI_JXU^ T+)*9[.E)I3:6S.KTO+%++YR\O7EJ1%B_*6BYKI)@AID0L?S)3;
ME>E49\-RO+P(P:G?.7?D)H?(RS G6B'T(P%.H=@\*ALE3KOU$Q;,T<]?=UGH
M+%:<[BWM,U&K:!J_;Q;L@:!WS-M$ZD!4>LL2UJ6T[?', BX,+;6TB60)O7=L
M8,.1EMU-:G=90;\L0_[CU3=!L?G*U<>:<&EH"='>3E0&C;"\=I]F\4#H*1CP
MYLBA',F<-2H3+CV4VDH2OC.] #/;]R>\SK+D5 MD<K5QHQ;Z8'"Z\<T'/?9C
M5L.<($32;S+=8*B] C"ZEW%NO9K?M!,,T>=.(2!\18)FKGXQ8G.FVP<7C0%7
MQF,;TCT-:M2#!QIKMLI).$9],>T02 OI)^Y]GVKK48:!TG#?3=G45S_C/-0N
M%SD;CZX3XL=9$0F!"4;6UAQ=S&E>.D7^:CL/\ &AJ3]V=0\<#33Y")@8<)OQ
M-#-RE4H<(%);"X:5<4+I8R1HT,O8+]]/5%/#K+KJBIBW9FI\40HY8EG)_6I3
M1*O #]L]UNV&>QUJ;-*BZ@WFAC7'0)78"K-46;RC!7TC=&^A!U$,(<@@"8LJ
M0%6Z<F!H8^XT$(GY\8[%JAW= =E9A)<IV=3-!. HL/V/OL0]EP0.D@[*QE+;
M KHS:$R,X!9TLJ=W"&QMM^]0-2X0.3!J=.@B'<R7_]P!7&Z*-4)77>PBYB#9
M]JF=\89U8P>^C?)2(AZ<'(SN%CL7FU(%>+Z-+6/]4=5QVJ#5-T^K9D>1UM?(
M5AO. (XF5SQVL5W-N XZ3?-39(AZQN;Z3#=C(CD1IYMYL"%!L4" #03X3PL$
M^"$\RP(!OFP(<$/62'&;MFV5.$=A %7'TW@B"=-%Y'M6<SIP3S)Q ^MVZ MI
MU.!]#RH*K5H_<2US!Q70O0Y!.SGZDDY"W7;K\FULOY;>"Z+CD?P"0KJ?H8+V
M<(_0V-%'SR*\2VC.D7D:^(31@YSR;SY@5L]$,G/K)POL!2_>O"*.\H2)+7*T
M^B>YRBOIP/2?@QHINJ7\T'=]C"'"!;B/JKAB5@@^197UF::>'J#2@$^7%7NO
MN[Z2:'SUW+;\C)>D%E#@WA6-N.H&"]U+/^J) >+23P=%O@&(OO3_K'!*)Y!J
M=AECUVHRPM/S<"'+F#GR$]CQ: YV,PLT)?6;7JVL&=[&!&-=HA"AK03QDVMP
M' MQ8R,TT'U8[Y*Z*M8A.$Y$=V]HZ1\X=I$/"M<V!)\X:/*+1%$,4UUCJ*UA
M]XJ\-1A)HJ@#B-&8;]HL?(;.^WBITAB_J_WL14N(JS]>O?212 T%2B46#/V*
M_:A,$,I5($ Y@->O44X[6LCMZB]UO5V]B#Q3-)0;QW0R?WGQ.I,V$;P/J@1<
M$="631_B"?6B-+>J*LAP5+HZ"M_Z 0SDC7P!%Q5%*-+;$$43C7Q,R@E!O=(C
M"V%0!@*7JT8!T/Y!=QR_YJ%Y<%Q\RSEFZ,#Y 7N'^EK>I#J!WMLO6MKTNFKK
MZJH&MGKP;I@PJHT-QR!PR8TZ"REH8&$!6NJ/L-9JNB\-#.6&LS I;_F\\Y_.
M,*N%[0F%J=HU^0%+.=+*<WZ *&5BU5#T.U2JX]BORR) QS=^ \E>;,#L3_(B
MP;3^*%D]OR)X&L"PG3>0 4KR>_E1) FZH<*\?;QDD?91 47-:/ 0\ D1-, 7
M!P,9=YI-+#+C%&[*=R<:*AH,S#,8Z&<*'ICVG? 2@7>'+?X&C;'#DBY6,8A+
M.S &MI@9H35\^?SYA5CWA&U^.N^E#H/Z)[<9=(3T-!E@ZN"8UZ^T?7%L;0;4
M"5&$B%PF=(QK+9ARO T!@.^GCW]QL5)R7G]RHR5=W %-@??TT#W?E%&EJ@D5
MO=-H$J=/@+'1GTV'\W!!@<-8_2QA,S'I=\Y[9:8/S]!$!C:Z;%*_\8SOB$3>
M^'9S]R%!!:%0HP^=(3V^2[;<+A'N$\>C!)H7Z1^<RF4:F,(Y>MA+<;/TI-+=
MQIMD%.3I(B'=@R!XX->F]XU"_E/2I5,9Z3-QX'EA U('IFU*CCXG5R5S:T_5
M8]]L]C2MD6TN/ QH?M,]360P-=9@M,LY";/1:[?Q:@14P9D'$N!Z[ST\SK4R
MC <JMQ(C2 "!S1E*37Q@J?D&MXR.F<@H)'AST5F3!JVI![?T-7?S=R=E5\\G
MM,>$-R.T-/\+ES0J&W6 ^?FHLV%N6?:21Y1W2N9Z(7OH6^;&0V3*AH0,6'N4
M7Z),$*%V)E"^/:1N)D\#[Q7DZH4IF859@7)]$_Z?BXLI\F;S*+Q(W-_[3DH4
M#.K+)A/56BR:XDL9UR1YJP@Q-!UH=&M_, I92_"%;QD7(.(&7M,0(<9;A#U[
M?(#]:5F&PE3B=UBAE%_1P^ZB-!GNQ$'2Q9+1I:+-EL&Z"D :.0Y#!S@W@YIL
M2IOR:TT65B9*)WY2,A-XL),/!:=*HU>V7A)L1A_@PNJ_/_&99L94XY3C_M3Z
MB"J'_O<F9RYVF_7*5ONZ!740&6;&?]($U" Y);;T8TL1=^^C]I@FBW%BY%9-
MX%1MZX^JF%P8< \E."JPJIKDQ4S^#WD(/JS;W@501R)P::IO+(&(;2M?=-[B
M]*H.Y]="P?N5>^QX20Y/+J$ %H]$::\:3KPQQ3X.WE(D#=(4X9C:@,(\6*@1
M\>FZJ -=-%N7O"KDS>%?T29KG7N74BFDNR@D9MJ\1*P0CV[K<$V<R2K81V@9
MO(W56M6T(_\!+^R?(Q7!2[F]*..5BI!PDXVA^I XNU"./7.Q3.U^TD"5XG6A
M$U!<F[0\FPH7L"B"SZ-U@%'<1>D].JLL<H'_9(DY0L64&\+HA8,'A)Z3P2/;
M)-B919"KH*IP7 ']3FWQ_4%J#I6[JCNZOO<$ZDT?*+X+^A)87U?G+*X)@UCD
MMSIE8_*-<+'A^HG:J3/I9,9I,EA"P.OIZ\8KV/<.4!1]C/APYE6&H(NE2!V+
MU']>BM0/X5F6(O6'%:D?KLOT?&2Z(EXN5-4F[2S;0/DY0LSGC'XT=1(C44BU
MVKO\NM""I@NI*RXN#"NB@Z/F>S1+":HND/ZGYS%_LS5\Y@EM?]%2ZZ.<;LIU
M'\1SS,,8!G0I<YQ$[!A9AL"<E1XDPD@/NDX;R*7ZK50UT%8R<1P&YY'R.,*U
MJ"G%LG WW7O+WX3:\7VNI:7/^E-.=P#.<-0U5)ZY+=DW3[L-;E<$%'1Y"R4&
M'5CE7_!6)FT-\[*HO#/(ZTA>)I.L48A3DI?\[8IHJ3I'=+70<*&["<$53!/D
MU%!X(!6+AO(*HCL6X">@#/]77[1%/$NVU*,(]EZC94T%!!H"B3"0KBJDU+<L
M]4^]U#GO-X*54;JR@("'(?"7=2&TCL/.6EZ:*'@<QW^FKZS]?D#1?;1!*%EZ
M='EGBWJT(2;(@+7Q+<<'*(,K+1%S^C0)Y[K4JI9U]RG7G72A)5@[,7W9*DJ^
M&'+,B'Y+,>$*Z]_Z%;$)G?3A)RYBW]K"J-)]Z5,F\O464![S>(UD_-4SK5._
M.;X6"R&*N%#*FB/]/8-V#%80\ENA/M"ZI<1PA\IXP4^$Q,=B/N]Y&>?)$N'E
M=2;E&/74ZLH%7:BP?-33H/50=%8I)5%ABMQ,<WE-',EC_V-9'I_\=(4CV5 G
M'\G^:I<U3-S.":2;RC<E^84]GZ*D<7#2M2-^(]7<S[#](&,+OVQU0YB>EH/-
M:U*Y)8CEE8GWV?C^T]7>I&Z!#H%NEY]HG);S3U3/WQY^(NGL"OPQEJ\#.<:R
M%C_U6O031A4<I0PXM^AVPU,W KZ2>39K*RD7+]/^J:;='PW'/K3K-52M7[ON
MAG1!AQX.R\JT8BWHK_4-X?OWQ9%6P/0*H4O2,;15'/8@>;',]_W.MZ09KT@=
MTOH;PQRJ^*;@'JO++3>=4Q+5>!:,P/UWR$3ZT\12Y"Q3^PFGUKW?E#VT2,],
MLMII[GY1L;9>,'T36 EN!%XF]L':Z%:-M'1 :Q<!(TS0W=2DI'0[16=!=#F[
M/:4XQ$7,YB\'CR#4=<8%H".E61>=K2YI1M TIOE EKP$\1E"J+.0&WY2+Q$V
M7RI6H4EORX S2H^$7V6" ]9UD'-S'G*"$=NJXFP1OK3C_H4[+4BAH5(:F0]1
M]/J/*LF^2&NH$2NDL2.Z9"+^[^R@3>6UA-F9VJ)<R"[XQZ[( 6C0:5F60#L-
M4ANAFNJX5VA-(<,U-,MYT@,PR3_+6JR/")A+66/+,U]PW<0=CGLB8E#^Z:F^
M@W,E#XE;8P^$-VW4(E6T>TZNQ15ZB8M#Q?Q2&%U S1D2N;01@2GC**-H-G7=
M,'I?>FK?'RF?+GRE0GI$/$]"@ID"L1O^O#$8(^PJ.1S*V17X.&CRQGQ?8Q9R
M]EDL]D[LQ\!4X70A#1;B$RM/^A8X@]R=%L-_'Z;J#T\63-5#>)8%4W7!Q!\O
ME:W[3H(E,^ZVY?P+97DHN.KQ6"KA6%3ZR^*1;C-VVMGQ2V$9+N1X3421(]7&
MA 3B6 1Y2NLX-,$AV+9TB485$9>?7!]\41?X5JC]8+HSL.WZ+9*RDUPP8S%)
MX8>C5\R8>+HL]2<EB>!3/WWS@33E&3!]B!)PJSUQU#HEAQLWTV6A">I,^\./
M8<QT*W@/HY2GC4,H69 ![RAS  !J'KA#]NX J/8M>XCQB&6I-;4"(N%H,FQ)
M5[,0L/:N[#?*Q<IDX(7(]R4Z<5N&VW.G?MV(JX/^VLRVE!ABQTRNI?K364H!
M2Q!#GNB([]$Z,:V( XHXBDD7"EA_RZ+9] ?I" 6B7MJQ@6YC-&7*Z!&$L&OP
M&X@@./=Z1=A/H'J)<[(^C><D8/BG55"3CE3A>8@7E#UW+<0"A\E9SX1\E!?)
M.>%TW19M6V\*^,.",ZC!Q\"/$5I 9 ,.5E@S0;0X'(<S>W>JC3>RQ&L_=5I2
MF:2]FVU+O1E%2RGS*E, *SGH=*?9';O(O]]-C!#9&3<8IS#%4R-U1TM3-][,
MD5,Z.1[^ZOZ=G3;ATVM//[5&JN&>9>[7R:@A:\;:#P=76"W]RX:_Y$0<ZI<=
M]VWRDDO3LX8'>;KGC^EI.J>MOZV>+-SM],N?U?]A;I9EN"W:MD\2JJ;4'2@,
M[*Q.K1ZF/6"QA0%//DSSA3@^Z<C=;<5;>J.1102D4\C!++U=(!QH560B<'/F
M35CH;.QP0*C!U&OQ@0'2ETC$3#V;FW?Y%0"J=(?HS\J)]0A!/"6J>%4P2W(>
M2#^(Q,"/BJ:<* -=]IJ#" V==^33"/?5<P1_+"G%-F8<0I9&:7FGF\.-38JN
MTQE'Z7O;AACZ" -]L+?SO;*XVX9CJYG"VX.$:QL_#-X56)]FF> CZT?299^T
MGTZ\6A9N$[[+]-;T=D0J B+[*']BCE4K3Y",U']UH/)3__\5JZ\+:IXM-NWJ
M1?TX6_W0;1^O/O_LI_Y]\=GO,F1T*3UX$JRX)-A>>V^R=+]M5V\<DT_1ZGJQ
M+ZI\]3G]_;/7;U[@ZQRN^+T1==UU(:[EQG%//G_[];,G3QZOGF^$F(R..SX3
M"U OD-N*C3A'$JW=,HF;H@?L^A1)<#;$;N*]BA 7#[@=!LHJP41D:A\29H8Z
M9B.'=H./Y4 W)Z,97%DT*5,CK:U[#-3TE+;^],A[/K3KX99J5) J#+.[%Z0>
MNJ8/E,R8MS<O., ?,UFD! "6QRDI+/HK"'V;L/[',"QF?F%M&VDN9XN1]JXW
MBD8DUK:$>087Z3M.'6)^?WS^YL<LB%/$L$1;V7TD6K'661$?,=&H$"N!+OQN
M14O;K['2&Z2>!-3"MN"5%MR_JEZE:I?&K1*S(E& ?TA>NIG&R?0_NH^08M5^
M=1#'?JARDFWGD*]$$S7?6J"]51UEVU>&Q9\S^'@Q2>OP\\5M*>U@',104S2W
M(L?7B ]LYF/);IOL]M,EN_T0GF7);E]P=CND<=0K#WH,3"@XE!U)5+"L ZH:
M1)Q9&B7.+'GI9%KS<IP[0=6.>?4D%8/QB4+:)3=+,:&8TK/&X7G4;B@Y,*DI
MRN1,_FF)?#;X-?I'9@3540Y!F+K:=]$S8V^/W)&J=0FE"%U%56^2$,<^)@G8
M@ O5OWQR.WI%N@(YLC%O%*FP_5'<'@IBV$URZB.=/5I64^^19$2C5P$/ +'*
MS>"!9IZ;HQ^6Q^H(NI&DFV="9I4-O/6#\+W\2LFY"\\_2+&5_/XM3@BEP&G@
M]3E54<74EIK0HMRZ>,<1<0R3<1(0A*4(@_<:6(Z9LXQ3*""2V8AJ9_!?AND_
M]4D'*I]EK:0Y4\ORP(1^ X0C\]2+[1EE70?XDJ$T4J(B8O0Q2]$0X1*'0F:L
MYSLKX[>N.=W;!%B,L-Y@")4$/>B:T1H_L\XBDL);3\I6-\55W=1]R,]P-MT*
M1(['%:.MC)WS5G;89\<L94S@DRFECZYYS;@'ZH/S.2)=?C$UK(+QK4M>Y2.-
M_*]NTZ?/R#<(\MY(,"G%BN^"BMUK<:TO-C7[DV/+650PI8GHFY)>^HA[H\U&
MJ*L)'#2J%X6U-+)!N*Y>* F?+L0I>%NON"GZ1D82/?K<[F^=@D&)1NW9KFC:
M+J9F%E'.CY%U5>&58W'$4P77AZ4ZR?NX<9#W'7I)S",'\E"DFBEED,+WIC"0
MWG\BKEQ_ A'=>L^C15FOG'H BXXJJ/[0;E4]#;7!_NC//R(W$]0M,JK^<(*0
M-))09@=&0SW5+8_=IC1T5W.9:O+%.!&75-.O"S+H)D,#'OB>FH?\W+V@/M>V
MQ8GY^J4<F71T8HVCSX$0QS;'NZS=CUF[4;7"Y9TR4>9;\+9*H@E:#<V!B-6+
M_*JJ@=#=K;[+UWZZMT6+PAG#.FK%"JQR?RV<W+3:_>NOKG/OR5&&57-HC:IK
M=$9574D:;]R$.4]6Z%3W0C8NR!F?*]00FO3858;<F(;SJS-F4#,K:QC]O6QP
M@,6S!J2.%*O5VZDS3*F 3][E)AS%VEDO$OYE55=D.%Y#VX/^S_ITD$"AR3KY
M5U\1+<)V]8T/9B 0^L73;/7LR;-G\42@%"$?IC1=OWGVQ9>/OUSY152&APB?
M! ]^#Y8,\.<3#+SC;SW^PVK-WR&_=G2["SE.?W(B'S#4[QRO/"X!JT]A]),E
M/0MKO]!QW7>3BO(D]<V=,(R\ <#9.G%X(:613:0P%B7S7US)7+<2B[^DJC#9
MZF_Y,;=&G#:<?YE8@T(5,C8"+8V*][[Q&.-@^KK&BE*4V*F;3L(P)K<+\+1E
M'WW$/C*;)\A;/3)P):*-"0HV/"'+%OE$9Q/-1D];(W97P]R]? XC%O+2 !_D
MK-V&^8PHGU3":T*+?(F(/FX-+9OC$VT."L8H2BI ]#X$OD"[#7F!4(O:S<KP
M+.O_(PX4E><3Q$\X6()$8.J'6?:/EAH[&B=S0<CJQ37[A%MKW1?E5I(-RBK6
M)^A1HGO*(XJLK3GG5R#%2)5  5Z(^S:1ISE/.K=LQ(^,D)">XF[KR<Y]SIO:
M*,D"]Z39FPKY).EM\7J:^6F\SU%<<WL"PY_Q\U1,O&S?^]V^Q\:1<"O#(D+K
MR53,/%!1Y6E/#3-5I<4J)]#M)1CXE(DJK@0)V@:<\=19Q_7RRH]C2)"SVR,=
M$YSXONO$+3PXO\;,337LU;L)03S.CDQ]]MLW;UDUS((Y:+._^.:;A>CH4T]P
M@,WX?4?XI%!+ BMK&UOK<IKM%;E'WM,IZL>K!6X=X=;/%KCU0WB6!6Y]*0)-
M(VQU7X7^?:UO9PG@6H!XR#HF6KK15>RK=Q7!5U6^(S1#3DJ.:BN4*#ZAV9%M
MH11 I1)NA)V@.$W0/J636*%IV7]-OG+5U#==:*T.A7H-@<YU/#,SV3FF"$!5
M$/M,2$5L:_\!JNS/X5C04&7<YTPN1^P$FSW8_SD(IA*Z.X(](?18:H4?,)A8
MY7^\^M8_O.BEZU7TS_RJQ63/YD!D7@#?XZ\2\,?]J\?)!"!"4'(OZL:*2G/1
MF[CYDKE#;+C/M]/*D $SP,N#:.-<[*-JNWKSC@EDV]^BM4X0H#=U\TZ@T(1
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M%62NLBB"Q:"-]ZO270F ;B=0Y'_UI/6AN.!]+A$MY<&E]WKM'&]"C=-)J8'
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ME;".&8IOJ#FQU6"XQ((HB(B"/R^(@H?P+ NBX,,0!?]1 B:BOQ7%[:)G.0(
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M9I@.")A#(E<C)<JN;Y-I^$<LGD**:9&JEG=1%C-27Q2@JY>X4B\4;8%4=1D
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MR?@H; Z766<1S$8'1;#[#H-S/-A::G<-X^A%XPGX,&:X)%)904UPJ9H4W$8
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M6NSMH_W6SN[>?:"W]PY:[<[A=P!=WMN[WU/O@-[NM.\[H&:P=PUV_S'AK)>
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ML,$B6%3,J4=C>0\1%]F]2=+RUB4]2G>B,Y(FH^8R?XRX?Y["(P).&H+AU*<
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M,L,7W+*I;W]O.G!(:K&6C:%ZS<N3-&N2Z6MP4;D*!;:G&(5$"<<U+H;,C/4
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MK!6>,JILT F!A4U5SA\EN=Y93A_B?GKC*',6SSL>90DUYOVE^N:48Z13816
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MERPP"N?4SSF[,R*"\>@4YCGT1UAR>T@2$5HPD,IQ%%@DGH4<"91MN7@)MA+
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M/6)'#7+0$JF=!XM^FQBE$%=]Q/5UUKD2*$AA+'B,(S#ADA32B;BDM\%%+'%
M(3>#N2E%O6SU-!O5CWS2I*!Y^6B>+GL6%$XB P/V(LD0ICTH$T(R&:?<,B:M
M1KE1A$:+I)L4(#<8R$LX<%* O'0@SYQ#5X+PF%9D8W4"LF4"- LFH9G18"W7
MI,H(;?.%JIV5G9Y;8"AOA&$GC%N]O-MCQN-AUYZ,C>TE_V&0'OCX>)!O9^"^
M'@YZR36;*9N\W'A*XWRK?RSO^9\052_-E4HSM52F7 )3'\VVO*%88R)RD=G
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M?/?L/?^T_Y[N;G^*N_MO\O;?M?:E6"$5N'" (R' @K=@M! @&:<T1",%S2=
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MA989M[:#"\<V#%L4MUL92#5UCL-SMOIL'%?-5XB7:((,=5*'P%F:\)9+SE'
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M1M<IIBV2Q%3]ESAG;:U+P<.G@NXE'M']%;(KK7$#L(N^F _%4P>"G H*12%
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MD!T>3C0+AAF)= Q$:*$PIY9[O4#!I:3<)K[0'TF^%=>E/M?EX&H/M(GK(K5
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MY:[XR9^%5,6@F%S2[G+86-YG6SL?.X\<1Z^._CIEC*4RUX; A>ZPGUU&I+9
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MMUM$]).CU?8=F:':2E#7$A53D-S2B$B3<"*52(7,=):G:N\@Z_/T)LGO7;?
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MW_.RF<]8GEFB2BL_$NE@ND_DX+.\K/9^6UC513%LAL]B>/[RZJ]<HW.WML;
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M$K_YWU8.)N<:-Q@69Z9Z4O7>V+,I2,HCV)YV\./_?@.C+^X]+ @.^J*8X'-
M7)\[XOI4FU/N#8'<>S"6K1<4#J* 213#^B3P%PO;5OV0"/!P> ZW$&1 V(MJ
M,AK:IJ-+O:O_JN:IN>K](0<2_FA#1#<ZXW0_^1[!=56#PFTF;']-,4H%)Q?D
M:Q#E,O[[K<S[.W>Z]XL<5"/@-^#3,M H<#@H*F>PJ15<T\@O+4YX"AP-!Y<U
MHR-N(7  !NBB0JIM4,FS^-B.QB"' W A@7MF7H24S^<C0)1/H-R",.!E=F0
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M%&A)P>\9#,*D;;.Y;HL<09HLJE=NB10OP[^/FAR/_C[-HX3G6EB2)#8A'"Y
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M]-*;)YC= 0TW'>HZ7D$W*_5!EZ-JLN;2KS=E'AS0A O? H$!F&5N&,SA*7O
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METS0^;3T]LP$E/:RH\:VE]MTE<+JY070\,@"1XLG\'*V?SYJBI9+1X\5 H'
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MB==*AIAHH/6)9JWM]Z[MM4_A'K1]WJ? DXV66(/ @,2(8RJ1YCK"+L^\"DF
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MDUZK) B6'-&<)L&E=<@J01%63#,E@B78E\;95#RW=+*U1J@Q\QV \ \:_>A
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M%/_^U_BJ"0 -RB?D]U\GS7"!\G[)*G[:L3Z.V\?.*?\MK3@2G%?14P<;"U=
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MQ/[D!-UA50 _I_> T8*\/<V)=46&KC:F5QGON5:Y@JU>%VRC3CNU 7A?9._
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M%V>_E[KC7:3LIC&Z5<+H',<9UZX9[9\70W^.X;Z?SW9T0AF*$W.:\%CXLN3
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M!KM'GI)58+?*8#>MZT63%&'8(&QSMFC-$W*>:\14BL1AJVGT%=A58+<4[_8
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M1B/KO4J"L" ) 36;UHVJ#*-+V\;K,(P^/'*J,HL^%QNM(J<>#=H_9M@HP0+
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M!X;%OPDG_;-H^]7"O^/"_W)UX5-L6101]%K.".+<8%!X0T*18ZU(@-\-SSY
M%SF.1L*T<:,^4=&*BE:$^:A08H%\XB, 2ZL[:/F_;?ODDD'("DCN""1^RBW%
M49NLX4@:+H%!.  2C37B1.H$&PDH36EM@\GZ,AW>OH;#RK_C #;6&D@]K-#O
MY1_QQW'T^9=AKY8OS<M>-)OJ@\',A-Z):\?*8/34!J-RYC>[X=UHNG=Z^5)E
M1UHD,O+9I.;"6BXL13AZ#!2+<62D,$"K/>8\8$UESK6CUD%6YI]KYY8%6!VD
M5@>IK\"0=#L45O:EN6+@=/YS1P214N;8$@$8&!VRV$EDC=)2$2XXTX5]B;[
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M_(E"G*: C)<,N6 L7':Y@,/:QBAH<8E\;BJLJK#J9UAE99(2,Q6239P3;83
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MKE,GBR)V@UJK.^P5!>J*F(T:K7D[C >]_D41O*DB>67QO,M2>;G<WM173NT
M0& (3X0^AEIV@3BH_?>DETOP'<.0PRO#.J\-6C (MG^E6!\\+PO<]SC*=358
MSV7V3F-9;J_5/3X9#N!Q=EA4V>LY&*KO17Q@;K"H[3>V-=9^Z<'?^2*\\Y6'
M_W.]-CCQAV6#T,LX&-9R(O+K&[;95;O3Z77;9^-FBKO@50?U6AYS;_O]L_R*
M5RH4WC[^]OBXW_L!T%8^>G((Z_<I#K@2$ED+L+"[O6'MT,+DY@NEO+&+LHW7
M5E.D-1C#O+5,C4A>P[YPI#DI#,]7QFC4!YX#/H][@U;^PIM^;-LL6+^.*^,5
M.^#$7:,AQ9>W6 =X=#*\^9:9X*-G&F<$"@Z:&J")GX?]R^BI@XA</]IOR";H
M[QO;/K5G@[5_794Q$+!1^RH+V/3KW_B2*2WL)4N1!BK0*]VEWL!F$_OY6] G
MNS1]J1WV,U_ZGY8$E5,[9P21EA/F-668)>EP(,X:H_85+(\"8$#JLTM8/BCY
M][_LQG73."7L)?T1A$62F/':>.XX<Y9X0K5G&#/%C"L9'-P3PV9F5#)R@SG%
M6"KH$0&]F GKG)5,16X%7WLDSE"U2)RY>U!9L2+>VL'A>JW,FM@H=I+:>YBE
MLCIL>:$8_+]F$SR_&,3U;8#67(,6]CD 6 ]#<L.>/K&;#VH3L9LD_PW?'<0+
ME(;-L;CG^FT];]]3.WBQ,Y?E<(&C7;0S+/HP452W%F ?+#?4BQ<8^4>6_6]U
MO\-.7=;?A>=T+B?Q,DMW[J_];H%6P'4$3T8#F_=PF/2)T;CZ1B/^TIG(L%E+
MA:S<;[!H'@2X'R:U=C($#G*>Q\?U>]]@.RN&J1P?V 6[:':(<N/EZBX)Q&#R
MO>JU9J_F#_.):M'(Y9>'T1]V6_\]@>MYG$N"U//%X6H KE%41LYO<!:!:D40
MT#"[R1;-#_L@=RF/-G1@-#@N#D]C[$[)!(S8E?>>K=(\.:^7XW7O;LUQ32X7
M.EV& 5[Q :[].14&N/)8Y&\)>*P!^SYI9P1)_5ZGD CK_WO2*AE8L3>"EM(*
M)X/:;ZW>\:'M=^QZ[6/7UVN_K(T_6OMG7A/-WO=2?"@FK 223B]3^YBYV<22
MN58]L;!Z>VZL.Y3OE26U-?"@U^9?"_Q,[=[I1%,%A;?^L%[[8%O=4>WQ'JR=
M$BE;7=\^"9<UP/-D9PVW*$;^UQ#^*>$,7G/[>#0R@Q?$_6^=_0Q\%Q-\:#/@
M -I<0'4H\'P2;-A$O?=+5<^6.\3EO/0CR!"(%BAZ;C"TT O8>HY.PD&!2'F6
M8"O)FM=(R!+@<:\_H0!F367DH )P/J$.CF:R!.YZ[6,"$4F FD6[@\%)Y[B8
M1) @:.5DD 5[I)E^AZVA=W*IQ/9&5Z=E:;VX/NI?OO\25D$4VP'&"%3G@RX,
MD+=%]PYAV$'NX3D@G6.5=PJ1AY.JV(7PUVM7A>V*962J1 -06,R!;<H8.'?*
M:B5]2$(K(XS <7\K0S8FF*#\2VD*O&K\N[#XE6FJ-KMAPAS8*+>,L-W]/)[A
MTD_H8L)_LX/6X._Q>.U<;'P%C=Z!CO[6[OEO*VH<W/O/(?:=O[OVJSG9/MH[
MVOZP2[*!L-GY\J-Q]+D#]_'F^;?\_-/FT>?V]M?W;>@O^\_Y)]8XW]T'%8,;
MFC#RF#'$@\+(*ID0<=*JZ*FB ;23./#V."NN_9/X6+[_S-B2>FV0]HP#$XNA
M=M*]LE:+E7:Y%$>+=YIJW8Y3D_O0>#UO[OP&RE3MS^S^EO<)D-^8-Y&#ONV\
MF3^&/VT:+$/K@K.'I,$"VL:9GGNR)E('3)E_LB96-_ANR9KN]YG0"\@LI>N,
M/;1#3]U9RNI,RQ7I+*%U*6[^>#XYNY8O/=&-:L@?]PBW>JFYFS)9J15LY2;3
M]"L>G L65KN@8:]X-+Y,DHZ/F72\XL'XG(U4]\IY-J=T5O=Q_GY@-K7K1QN:
M>7E9%Y=U5I[[D8\-Q'[NO&SW# A?@&S?T3GI>H>351[R)YRV3BN$=GRN./Z1
MS;1PJEB6"5R%@;O1'Z][DHGG=,W4Z$VT3DJ9,/?&6>:BU(&G%)3AB18N>73:
M)>_"(R_UVN'-#;E(&I?'-P6=N7"]0W1%S6NC#/&GC:^-T^81/.=KL[-[_@6N
M?V2[<%]SY\M9\_RPM;T5VKM?/['&M._=T>:/W?--"N]$=NG>47/G\^'N48#O
M>]+<^<BV/WSD3?KWX=Z6/\UI1[:G2RM*81F+'@6.%>(L8.1@4T=>1^<2I<(J
MM;9!<)W.>-[]XW$)9!^6)?-9U\%;N%0>%G=#K1\/3MIVF!W2X%%Q,.QU%U.-
M^3XC>&?/YV<=QP7G<EI.K)SU7=:2<<D,4=8%+KG6DNC$9(J2<.Q8NAXHJUQ.
M2P:JUV0P$9'32"EB.E>)TU@B':E!(C%N:+2$&;NV0<DZ)^I9<SE=K)1YXM5+
M1?\_[WH.OXA-X#4,:G;O\8>M^+WTSX$_%[NQ/L68_LPK=8DX.Y-<::)X9-9R
M;Z5EF&J&K?-Y(PKX^JV(5IS]*;:7*<[^/7SXFX?_]WM[C[:_NZ/C5O/\$]WK
M?#S?_@#]W_&Y[V)[:Q/&ZS=X=QBKG=\ZN[1!FW]KO.] &]-&!Z0,B8CSH)$Q
MS")NL+=$ZN1Q6MO0L]6@_H'N)U+8Y,30W$9E!2=<V\0(=TK9%+B()%0B]3)$
MBNW+9*DB&B/%/$8\$HHT2PQYF&O.:(A6D;4-<XU(3?F45W;,RHZY&M/VW)SI
M*/I,.0LG9>!)Q_:L4\9I+,=LKL(HPN[#9BU8KR,B\\9R+Y,AC]G=-&^RI?MC
M]@N=<-N,P-3AT^->/S=4.X9^],8NRV'2SCY8GW!@SLU>BNMZ84<[OI#FT>4B
MX&)0KUV*^80;W/@[MI.?,*@5T7-E[_P-UKDB[=N$*E&\V(3>EJ5Y[/4Z<JV]
M^C[V>F_K3B_$=CW[?/>SBUT1_W#UU2]B.(8P>?D1X]YW[-G(P3S?5#K'7A^E
M,)A\0*^?F=+ET[+/;.$IV!O$2_?=@YCC2]?+L(M::]!K%W.[/O54.^6L6_8"
M;AIY[5[?G\)_/7N0#VK=7N%8W+=='T<.RN/^%)Z+H55Z'(_]$B]FX *N:J>M
M=CN[#7?B\ 5YEX_=F?MYD61?\6MMQ7D._HK'PW%L ,U!38.>;Q7RG$-\:N^W
M-DOO:YB&BV"65G\PK/WVQV8A7%?#"ZYIXEUC,T]B=NV?\"MM;&ZNUV! #R?7
MST\=3N_K:%K&.>3DBX,T4A<NPH<FEN)%E,7( S;[B\91"-*TN.0&_O<>YE65
M0I+,*(Z5A\G23OD0*.5>!AUD9(5C.!D[AL_FB!!KQ0J!WV[T%Y]01+[":$_Z
MVQ2*R>!SA"YY@+YB%#]?\1B_,,;^%8?#=KG:[V:7E2NJY3S<E_S@K+FU>]XX
M]V<->)?FT>Z^U$K0(#V*U#G08VE".BB*L@4CQ60%571M@]#Z;'*S+%IM^*4*
MW?YYZ+:I0K>7H2]/&+I]AU#LQ4;B_)4WS)-VW$[C0ZW-RZB[P6]G$W_=8!MZ
MS?$VS:W-_:0UXU%:E#R,,P]*(RMQ0H[(Z 6#V77FGO$VU^HURT&U+H-M1F$H
MA[W3,F=)&90\YA7.M@N:"@OC3K%_MT4 %^0KLX;U3&&.2\H";UBKW4ACGSUT
M1ILZ*PN WS=T1I&Z6DB AR0/"\BYK<XY7DQ1]H5T5M]Q9.\8X#$//U2SFA[>
MN[!@!U,K=A2=2];OXZRT%,6)5L35>B4DXXY1,7,K8/V2!HZ\NCKQ/S4;_U8R
MB?6:B[ !=S/U&!E52IOA(DSP<QO<EY88]=[O7^4]G9,I:W"#+:MHZU5X%Q)X
MUFESZQO?ZT#?.@V\U]GK[!XUSG;S&?[YWZW=\]W3W9V/8GOFK/X+O-<FWMXY
M[.SN[,'W/L.=>ZW&^>^'N^>;K/GU]Z/FT6^'C:-O_+I2W%Q9%X/R**8H$$]%
M2O] D03]&\BDD2G71YM/#NH'H/=S%E.J@+("RFG/M@"K!6M*?1"<2*H3=LEJ
MGR$SZEA&H^ **%\ 4$XGZT^2BT"H0%I&B[@S#!G. N"F4L*SI+$@15YI3<6J
M .43A=D\Z^I^>YE/<.(0>B(W7\FTUQ^6QJRV4%?BGU7QNVN\SDKC[8,. :X"
M[].<NN;$>'_T!H./(R'ZV'UG^UF?N^,A;(7*=T'EV>"88(QB,7KD04H0]\DC
M$S5'+ 7093SQ.KBU#;*.U:S#Z//5.:]P8LXX\5COC HG7AA.3+,WPI,Q.FHD
M4L2(*RZ0DU0B2JG2).' "%O;D.N"\"7"B<>ZKZ\"/_OSTA_KQL-48&394W*A
M#LFOOF+R8[F6>"['MA=7/OVI8'*VRB>AUF(B)<+6:H!)(%:&"4!-[$0(*2F9
M8XVK\NFK"0:_O$1&=6]_UPH;[H8-,]4JC0V4.8N(P SQ:"UR6@&/(B00*1S5
MT68?V75\30G@&6>"IT"%IS9O/5MX]L4Q<NR&ZP^0Y]HK4=?B#OVZQK4YFS(1
MJY-K7,QR8$WI+?L+^>="NFWN-):U:\)(JYJERY&YIZI9.KM1!YF<%,$%15W.
M!Z.QT<IB8S7'0F%_U[P_U9'4DN_(7V:-GU1A+H-"+$:%N!4&618)TG#5)T.R
M8,PY,]#SESJML+C"XF7%XLJ/ZM5@\;1V1$4*DD>!*$P]XCA19%@("%/MG%."
MPK8\+S^JI<'B*TD.GB-J9_^G_STN"'S><',7K8FNH-943$1M<U#ST#6;:U9>
M38X0?QR7B1>&O1R=/XYCGR@[V86QKPU/8_M[4:!R>#@HJX/-!DJ-(Z]R<;M^
M#F\,X^IIXUP+E^72KG/C&"G*M;\.8QQ.UZ";SL]Q?0AO&=IX6_ DP6;M;H(W
M%0^W\$WN^EJ-A-1K"X[&W(INF)-FMWMY2UN>R,IOH_WFN-/< 33_T#B'/>9'
M\_P+WMOZ(K9W_C[<^_K[-]A[>'/G&]G[^G>K,1U9V=DE<.?I[GF#-\_?L>;.
MYV_-W/[7]^W=3HZR/"#03GOOZ\?S_YSOTN;6QWWA#;'<.:2TM(A3G)"57B/-
M.;"'J)6S8KJVL:'>^<BB=S%R')AUACLN5&"4*^?=="1F'O':K%A/RORU@;NW
M/^=JOX(T\%WF/:>"BR" ]N#D"#,N8:6(7GB@+ZSQ A=A'\KOO&2E\IY#P!K[
M!H#:$*41EM0CSI1$%K.(HI:$.1(T#>Q%E<H;)4KYOUSVU(U.D >EO]YP,KCW
MS2U1M<M6H\[4%7Y0H*W4=8+G7Z,.UP5CBZA1)^0B FT7UEF^X$IJKRDX=*7"
M&*L2:3>/Q7SB.Q^4]O*G.#[OT9G6BJX?G;]BM]7KU_[*5AG0/G9BOU/[HP?=
M""<QCY9\\XC#ICEF6KS14+ T&37OV<,YG?P61A'U+'E7[W98^6>_U?6M8]M>
MF5(ABP&KNXW6@BN%/.>KW<-(;:U@R47IJ?.<L"+#F>$!N\B\ Y7AK@>&6=/Z
MV!V YI#-TV]MOW\&8[59I-)<%5OSPU2SL:UYK_.^L]MYQQLTJV3PK*UO;/?H
M"VM^>'?:./K<WCN"/IY#/UK3MN:_.[M?]Z ?!^>[.YXT=CZ=;N^$5G/'X]V=
MS;/FA[\[S:.<=_L=O39FE_+@,*&()RX0QUPCZR)!T< (<^8ERV660%"N=<59
M^;"'"I=>)"Y)P!_,>:*@6G$NA"%:!ZQB%,)1)NY\>%;ATE/ATO096"314&X=
MXB1[#V-MD8&M!A'!!/$1/@IX&7'IN=24T?TH?_F-G+_Q[&Y+](\X&+PI;687
M":=7W&UP@=K4BGF&WTT$[N,8OACZ^ 4^S-G?SV,8%U:ML'I^6#T;.(NI3EQS
MB6)RP"%YLL@1H9#QBF+&?""& %:O"T66PYF[6LAS7LB+X5O50E[P0IXF7<S[
M$&4*R I0 0O292DSB*ID(B;6>NUR9"M6LY&M+SDJ8\G95HK];!).K:[M^IR*
MY/51KA>:W6"9*5<I==L)_H7A>ML;K$[0W"J@\VQ K8Z">6,,,C+;Z[QSR#H)
M-"MIIKC%02F]ML'6^35>H7='Y^6ST56+=_XTJUJ\"UZ\T]1*,.ZM]@0&5$K$
ME>#(".R1"XS8R#D3AA<ZDER2Q?NDAJQG6'?-.*SYD4%WE,BMEVI_](#5#?/9
M>C9B/6/*Y+&OW-4#ZMN/KE_@0<4<!V:I=X)G8'%9W+,G2=:[*_R?'_[/QE>J
M2!7S% #?,\#_8"FRC*B<9BZJ:!R!?X&\&;)NS*//,^:W8E8C;7(%EA58+IXU
M5V"Y*+"<)LLN4*##A"/E!4%<$XNL4@*IH+C0R6L<'8"E-NLP?:L/EM?4=[[)
MUOB,<1&/"H_,(\=RA<KIEZF")1\9+/GQ9ZFFK\8HCN,DVU>4G*)BW,5!2XZL
M;&7/\#@8%N&6W0$H1O#R1>/]V+&MHK1,NY7B.!SF1M?DLDIU_@JLL%'UW(O&
M<R'J7%_YL!=N"9Z<:W%SJA:Y@HH6W[2&\'Q_AU#)6YVZ7T;MZ8_=VN\G[;/\
M1GA])*5E)>HB"*$07I [F\\R0+P*.;$'_5@D*RC*'MI[%5C63G*O%?S?<VX=
M,2P8IR('#@Z;!RO5(XS5U1W_8_/]S)8/K[*=WD(/6\/WUA?!P W[H]4YZ?S6
MZ_>+&+"W]A@^&9ZM2H7DIPXA_'36V-P/3F"OM4'14@-*#[8HSPV*43LAB&52
ME.Y<-^SFH\+(-5],12V-YJ(L)?[_[!F(30TF(B^\6L-V[4$I.K_D])(4_WKK
M.BN^1W[]9]F@[4[!5/SO"30,(LI0$51>^^/C;]N?UVN#$W<$N%8KA/=& 059
M<+$_):...A$8#H8XP94"M1UC*4PD00K'HRE"54%&RU#5GPEKZK7#U,GYW[;?
MRG3B,W3^0O00?76R]X4V3_<U2X$131"F95[WA$QD M$D*,ELTF3WE%G7E'_4
M4KO7ZZ_7CMLG@V>;W>M=(XJ<+'\=]Z,-V]W)V2:O>KIYXV!?8:L9MAZI!)/,
M!<?(89K-[8P&!IL![ )K&[(^6UGE'SG1(2Q^F-&"%/5AV;?Z1;V/$@Q0KPN[
MV'&997H (C!LM6N=5LASR.NUG9]QH3'2 ,*TVV7RBF/;*FC;+:+52^,G3@F9
ML($DRIR36'*:DN9,>)5<P-329.BC(.3/(N=CRX]R:C>+KFRG/R^Z,K'; 2_P
M><<[!35I$+L7(HA?G03ZT\;IOJ><2>HQDEQ8Q"//F8\Y1<)JF"Z;&!$@@4"C
MXXP(UF"CZ8.P38H9L.S[D)]'2L5L[NV?RD7%>FX0A+/MS7V;K;NY%A[C(B'.
MO$)."@W#8QBE(@D3/+ >7K^I4,"(]@#1&()8%"4]+ZDT+\E*D9"@U05^,LYH
MDZ&F5VJ#,#,G_4R4LCZ8L69\L\QPU1K4AGW@]2.A H@[:0]+5;(;A[7C?L_'
M&)Y? O\<=>1]O]<9(6MFYH,Q-:^$\'HA/*"-3_O&)\9(W@ M R$TC"%M'$>$
MQ$2U9\Y3G(UIHGY3,K$+*;0)H EF*ISX0AA3S'F98*<<&0H&Q1[8C[73_*/;
MJYW:/LA7QK!^YM!9$'V17V6012C%+)VYB<&@YUN%Q>)"I&_=2,O]=JQ(G@RR
M[2+G*AX++7#R[[TV[-' CD#F!T5N[Y\W73S\MU;OST,+XE0KA:OVYQ]OUVNG
MARU_>%G7*S=SGR6A8HB$"6H"]AR446.%DXH0'XBEW(A*(WW"9?'N1^/\RSZW
M)AA+"0I<@DJ:K$(64 L!*C/,F6-&!% +Q&TJZ?$X;GK]7A(AC<(N2%!\N>8$
M:\M!85#1"VMT#-S?&R0_CDCJNW(MWOV4XC4*0'/KVSY+5A+I$E+.!:!IF"''
M)4?.42:3=YQ* P)0G]4,KPJ ];Y_4MJPB@E8+R#Q662AX/'O+-#'RU(&?_9C
MIW72N:-_UZL4AO-<K41JS#%'*22-N%<>.<T-H@#8N?J;5A2HFJC36X0!J%/,
MXS_:;PHKU/%H!NHYLZ$=T:S2> X,K/PZR (@]TEK<)AON6HDS=D)#[J%==[6
MVKW!(+.[JS?DU@IC_CVIVAPD[X;2'+DZV2"7)P.:UGUWI;/;J0*GG\@C].-@
MWRF8 L$YPHX#:Y.,(NVM1$29*%TD1!&[MJ'J['9YO',!TOK+.&VXFQD&5MZ$
M]18>"F/3ZY_EQ3K2O#.5_-X:%*59AX=V.+8'37[EY#AO #5?%(8=UQWK]]KE
M @9B4*02]>5'HYRF^0@TCS=H;'FP'$P)Z#*#]4R#0>L:@-RO9\(,O8W?1VL[
MK_HKYN9Q8_"\LK5!1IR\I(:'XTF_)X7NV/';W^WN_)C3PU[N+0Q.*TO3<8$W
M-I\I0B,PJ0!YW2MC>MN1X0WS<Y$/UGZ+J'CH!:H6N^V562NOEU/0ML.LL\!C
M2P8/^-*/=A!'QKLRF]])OS#Z=UM9,[$@!*->3BK'A0(-;U8V<]R#W3YK.),/
MCC"EH.$,#FV[#?C<&@S+ >XY6":C&K\G,./].PY!SG@[&'WLSD#,4JL_R&EI
M8[>\7J:F'1U49&$82U@6I(MLA:/YO:M],DMPQNY+$8/E#:NRGS<B>-T!O.OH
M9?+(CU2\5LP"G*"''5N>W\%GW7A0_N%[(,B%(EAHB]_'V!-BLGDOM,?'[98O
M<B'"9#^@T[ ;]2Y[;FN=5C>K1#!6L&1#J7>677AB8\;/C:Q_C+OW=M2[1MGO
M^V28>'T[Y$?HS^Z^@=D ^F*0X,#AN:,)&%O*5E:OF3 P:U'"#GE3 ?5+HT9V
M?\@;I2^3X]OVA?3XR5VSG\7VY%*6UVN=,J-^D35Z7"D)OM7JG0P*4"GN!YDM
MED!JY?D:VW=+2\G='E3KEU7'4[_7N9?H<JGA/YYX2)%'E^L&4*D8L#P'W *G
M1XGN)*/X7/9X+,25]/Y4>N'W3_LQ2A^$94C''#-O0>^$F0K_/WM?WM16DNS[
M513,N^_U1*CHVA?/!!&TP;[TM43;QNV!?QRU@D +5XLQ?/J7=8X$0@*;18"
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M<WXRKW,N%YN>_/2]L"L0K$#P=B"H4DB2&<6Q\O P[90/@5+N9=!!1E: ()F
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MQ]Y&?N9>>^_PB/WG[,M)\W#K&S= 9R%21%VNR\*,1\Y+@;SG-G#,E4BZU%D
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MA38O6')R?Q=A<>X8T'#/NK8OV:%ZU127VR7ZE)'F8\P=T^*</^>R,S.U?L2
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M+[P+2!*KJ,-26F$K1^@K8.R'.^&H&/LQ&'O6[F"44:RU0MYC8&SB&-)1)R1
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MQ]R'6861S[][H&W;ZDZ/*.3O"CB\O"Z LCVX;MCOP??P(J"!S#_Y2IC<^?K
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M#*,-\,+_';7R,VU[+"'RMQ,)=;/AE)( I"TH86?P_"SC:REW>2B>U0)NCZ5
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M44("?T:@PEH$P#K.+OC^**ZL7=J%VCJ8%V4GX0FOCG=_QKEZI5OUUZ^^/-0
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M_0636!_/8;T;/N<9_)$GT#@?_U^]K'@#D4^D;"58KS&^>'-G]UM4+-(BCIZ
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M1J>_JKK.K#%UPY"]G([(<L]J(2E[7M%[XA&B]SJ=5G$4F!'Z[<3,\[";2QC
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M*C%&F$N&.+;9UV8""B'QY"B5A"0 #EY7;+["?@4<%7!DX&!2.Q,",3B72L<
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M!1>T#\E7=M(+X/X9V1^8\B21D#M@&\2-8$A3GN!'!$6 "9R"R=R/KXC(?.(
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M_%H8.- <_).;8$<C_VT'0PK?B5P]$/SO'&_!>(^X]\ 'X4%A;*X=MYN\OV3
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MA=)OOTF0\# :%31 )9"F-L5 Z,N'L (P[L!@$Q8BVG41WJ8T#?S<5BB=W]P
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M[__VZ6CV[",M5]/%_!_?R+^*;Y[1/"_*=/[N']_\]O8EA&_^[9]_^<O?_P_
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M(FCK&6(6"!C:291%59.*J:JPE=O^T"=O1:.O)#<_O&CZ#?; SRVR>+E8WI<
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MGA\U5WE20[4:187J<FOTS$HU"?:%8]3M6%PYD6QWY70[GE'9P%TY<%V_=!)
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ML\IRT&\\Z\[6GJ4BJU+2*@N%I:;>E3:[HQU?X/U5D'<7+G3C[@^U4F[U@>>
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MWNW7;D:R#1WB5T2'AV__EK4^I]]O7]K(R'_^Y7\ 4$L#!!0    ( .> 859
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M/!I47K>N1K <R;X.!O>UH&POWF,Y*'PPE!^__(C#=$YFY9^SN'=$*,*ZP#2
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MI[\/1W%"4JY>_54H9P_7&39Y_4'N,&PMEWL7%S2@*QP%F?A2<^UH)P(;E,C
M2W"8-[ZXL F0PR=>W*0"1(DY<,T9I\$R#=8S,(HS*PT&!Y$'T?IFYU'=5GA*
MZJ#2UA;$4)O(TMJDN*F7L33C*>L,-GK;//WIJ\CT/!PS6R2$;J/5AEY-78Q[
M*\#=.@R8K2 ]*5UV 1.CO1&83@H8"2(S 9Q' *44AW5K_38O?(X<ZDPA79ZY
M[GPN *!CSIQ$8X5A&C$RKZ5AQJ=@2N:0XS'N U]Q$MXNZ]MA]'XL27B+U?U%
M^O=E?]*_+L*@BC(N6\Z$KW6G$<G4M]$PR[/A,GDK=%<W,.Y!^?K/";?BQ8K=
M=Q?]='BIYS:L^N48%[4H-P'8T>'?6G"'.=%KHLH-Z+&['@Y"&!LLK=.RL!#)
M4M3!6=K^DV-26FD1-0 /IT&4-0=JA^')-N)OR(\K"Y%,A7Z^G/S8'WT\A_$%
MO!ZF160RAV)\#N0Z!*B=,VJ>%2@F"DFAB%2\"9M9Z2O?L7_#O+$V1NU%V<E1
MTU(WX,<OUS6THTE%:>%82I8&#8H&+;QBNH#.)5O(N?UQTQI0S]OZ:*NS#DX.
M5@"L\!;![PT =F2'K 5W&#NDL5(WH\R.&NDD+V,=4,-I2^5 7J7Q-'-2TBR4
M8EC!X(-129OFS8X.1)DU%LFA&;.-(IK;)FMBG2_IK_II5@OL/9Y=#NJSOOS2
M'^!D.AK>'-#S$G-QDGEE+=/<"1:"]2P'X;.-M1.?V\R,:0%G_Q9/8QUO$%[L
M4$$=&$?W@Z'7$PO)X(,,@B4C:R<P2 R@YJB;:(N1/$)L75A[%9;G;0HUT5 '
M=\>7X5H4.MP 64>FSVI4A[%YVFAO TKL(/H.;)Q'$ IE+%B=F=/U+IU$PWQ"
MR:S$P)-P.:K6X99]DV*-5;-O3FPC\3UPH9:_&%T.I^]ANBA[*Z3.U@?'HE*A
M#EPP7VQB.3H575'.8.N#J_6H]F^LM-+A&FKLJ(#6Y^;WX;T;C^+<A'I;KNVE
M%^F\CY]FGUH4N06N@0PFAJXVIHC(60TGL2B%#Z $N/L]-E>8MD\$\-7S8V_2
M[^+V#7WN;;E5BVFV@ 8:K9;<DI+)$=2N> +E(B,KWA$P*$6W3NI9"N1Y6ZR[
MZ^8A8?3.J>*WRG9=#1MN?C++>H545;3PRS:!VY$-NR74PQBV#91\/T]\#QKJ
MX@["EK!IIY6AUH)SLD:L>.8LH!<LRVA0QVATT:=(J#5&\>'YM(UB6@?[?OM1
M<OZNUAND_?=L#!=S3$44&Y7V+*9"NZPD(40I"W,E1NF*2?I^6;45-LZ*%QR@
MW'&76ADU%FD' ;>Z/5^%(#&=#_O_OKQR_6QR4B)$\O60AFD!R12O'4]+Y"4;
MH5UH'6Y;CN1YFRX-M/.0,Z8]9Q:G]1O@ZLA(687I,-9("[VMI<(.0N_ [EB)
M+Q1N-5>"%97K B<3B[5KH_)<<..2]LT+?>V7#&LLB7UR81M9M[89;GGJ?V#_
M['R*>1'9P=FE[U>#T5_S34^I C1,SE3)DKQU)1EX'QG*&(RP K(T&]D16[QT
M_[9%&S6-]B#CAH;%9#SMO:\&U(SE0A:7<D+F@B00J W9.2(RF0ORD!-HNU$$
MA)YZ:^+3=S>3_LX+GZ>Y\'29/U2\W5GQUS'<]3"V,08VH< A(A ["/^^^G:0
M7,/5_#Z<#$;%Y,CE 3Z+Y9+3&PT! W)VBG:FE(U.0PZMP!7[='O];2.PQGK[
MA21U<;GP+0&22_1&5B\?,^T];0&B0.WPEW@B7S-N5B)SC>;NO'1_V^Q.8A^U
MD%GC;?,7^'P;B/51V9)82DA :#L@4]&2N6!12VN\YJ&)\FZ_]"M4WI-EMG+F
M=52.85:P9M&#\,UH>/8;CB_J#W>HL;#VF4T+)VPW@GO5$+AR2NC,E0>GL=;=
MT)A*TDY;:1-M:&N?OFMSG#B]*0GRYOK*I$X:=,UOL+'Z8=IH%A 3\RDK)XO2
M*%N7NEL!9??V/[<?.[GN%X*U0"^G/2R[VGTU*\,@B<Q,1)_ A"*S['2$D\,U
M*6NA]8?]>':7<P>1W+NP7L)X_*4Z&A?5.>Q%Z23&')D)0(LJ]YX%0\NK=3SK
MD(RVS1N)/8;GT$1XHM(>)<(.$N\@''<7V^]#N!B-I_W_<Q,OZ!DNDHIDY(HL
M/:N+,8O>(?V#Q2=:D;5K71Y[+:A3Y,6NLN_@MM"BH]C;0O\ERKX<3::3'A05
M%"3"D] P7;0E$TPIAEHI;DK69%HU)\02(*="@EUEW$&2]&VSJN=L;9\-FM4J
MW140,"AD@=.6"($,-,M=ZVL]M]]_&FI^LD0[R"FZ.[ZK<&*TWAKN$Y,N1*9#
M5@0)D#RL+*-.1+X0.UWE]UI-I7MS;WNI'DN%D\K4Z9RIURG>R6,LSBHF(@ Y
MV\G6TOW$6'*=?> N:=4Z^V<9CD.%[7?6[9+58"<9=V )WL<T/X/:!%5'9_7+
M$1WFI'YWC:VAP [BWA\9C \0:R\I8^S<'J4=$&N'=^&(_"*YKI>! Y[0[XL#
MVTBY ]U_P&%_-'XS@IMD-E^B">24HJZ&3XJ<>869N21M(!\UZV0:J_T!B .T
MV6V@G5%+T78>#+I*.(E!)"-H5&H6D'">Q<P3R^2%1.NXX]AM".B4-OH=Y=N)
M3W\;T:]P<9T?M@&NCC;Z59@.L]7OJK-'*;"CP#N/ -["!^28!M2!%>LR\=XH
M%FOW2)6*L$4%'V+K57^_1%BSW>^+!]O(N74RWM6&-.MO@+G&)^K>]-,EDF;L
MXJPTZ%"TX"Q;64O7%\VB5Y9979*4*A@T]VR^%3EXZ]]UZ%#/4Y4RZDZB*_?\
M#D^??ZU7&Z;]3[CCB?.#YS0_97X<Z;V395!2:W#6>,?)JLH^*:E* F%X"#:8
MWM(G=G.:G)P"4]O>UZZ7Y#4XHE<*AI$K80)X7LQF^8Z'/TU>6,DO1\-/.)[V
MR6*J;WIY.1[757.6OYCFWRP"J=*ZE K2Y.*&3.BZ@H*B66!4"$(I94-I7;CN
M"3 /O1H]C2VK?,RN]-.!4U('_K:\I/6S/WT%:9;&/,_?^7$T'H_^JL<D\)%^
M,_W2X[&VQR/_*ZG:6<6$6DG+(0,7M9>N.,Z;GTYL@>]P;FMG"K]/L*ZTU=K6
MN3N[_@7C?G7O:C6)GH])1LR&92%G]S7M53\GI8,O) UCXV8U&5:_XW2)T%*X
MG3N\LPSZ#Q_'"/GM\#9,T3.9YZ1\9J%(J#=M(HN1_K%DU#OTQI:._9W5V$Z7
M/)UJJ>')^!*2O\-Q?Y3[Z1U\F3D/EU6B;\O\VTE/1>V\LY'Y5'=M;P.#6&JR
M."B:#AF-5$]85-:\]G2ITK$*.C]HOP>V%S(XG17)($.J3"XU'R 05BZ5)V<E
M8+?YEO< G2YSVNNC@]O2[\:CA)@GKTA,\_!!-:TF"]NJATD*#H)X'%VJ_7X*
M"\;6N(12)D01H/D9_#I,IT^9IEII>(MN@>_UD*2!D^G/GS_B<#*312\4V@P]
M:I8LV5HZ6LV"-I(!YSHX9X2$U@O+$ABGSXU=9?^0#FXG\^1G& ^^?,#I]"HC
MZ-T8+_J7%Y,> CB>:&18(#,MHZO=Y3)++D?+4U1P_T1OA2&RX@6GJ^EF8GVH
M:K_KS/\G"6KR9C29T&(T_/ESK>E\V9^<5XAORXR+.?*BT7%FO*IU.6W-'K:.
MH8Z03(DDC=85%=:".EVN=*.7A\0)#5V8-_U_7_9S+?H]^H1#&$[G=QSG=Q.D
M"K0 >,YL EK,A 861#!,^B 5\=TG;9_@P3S^UM-E2+<*6!(NVZW Z;UK*Z/A
M9#3H9W+"\WLDL)>XP#P'RX6H;8M]O1)=*]+3_@>!1")35B9"X1+$$]BR]L7/
MBC!MU;"$,XWS":Y2:+R0V0<#C*N:\&Y-8K&8S)13G#NGG6I^A> (L\MW.<;9
M5:K'DEU^]YQ@EE3AH43'E22_V];ML&06<R&SBEL4(AL9FK=_?8CBF!+.MM+K
M_>8PN\FW@_RBNXCFZ16;8.JJR]02/ =J++6CKAY5_0Z"WAL)HN9><,MRJI6G
M>)*,OB6>![ Z8(H@6A^X[$_YZUI$[4/W6\BWDSSR6;BLKG"+9&<"%+C7+.5$
M"YOCFH48'$NBJ&"D"+*T-@,>@#A +Z>==?,@BWP7P7:<L+&H3>4R8HU^.3"*
M;!W.68R\FJ(J>0C"%-<ZB_PABA/0]8ZB[3Q?>+9R90B<FQ1HRX/"=,GU/JM%
M&F7.MBCMBFA],G'<5P9VL>!VE.\^KPQL@NNY7AG82F>;IHH_1>#[O#(0!1<J
M9,W(6+%,^YP9&&>8XLXG9XJG3>FK)L+V5P8ZX<$V<C[ E8&2G:[1#":SS$P+
M3L-%61A*KPPF6Y*Y=_!P"E<&ME+*EE<&MI%H%P;>LINO61J%AGL6@JJ!1N$9
MH"3WI889G<DZWS\=./F: +OL^SO+N*,Z,$NNP&Z"ZKG6!-A*8YO=!W^*N/=7
M$T 0J%COQ#GT2.C('0F1UJ?@K!(RHL#F=?N/O29 !QS81LI[J0D01=12$!;'
MZP4Y2XN>UXC,!FUM-&!%:9UD=+PU ;;2SMJ: -N(MI-6/S?YUC,Z%V$X;5S$
MWR+JM7<>6+"V,!#2&",EU\8W5O5]#*>RR>\DVPXRE&_CF7-Y$T2=->>YC^90
M;7EVT=(C*M]!Q)VTXGF 3&>'"-(QJ6'6#*26(_&6@?29 S=";5;#_PB5OK;]
M3K<ZWT:RW1AO>32<9:Q&&/XYJS:)N>)[\_K'M^_G.X\MX+Q#P5SQ!#)EQ0*
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M[A\B[ZRD+NH'/A &+!__XO!K [@=Y:1L"?5 .2J[*_G^MKP'#1T!L3*WP=7
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M0>OL9_/V]F4Z'8'?3Y9XR.;I*2HP\ACRGC; GW7[+Q3J.]G1,@2&'2J0(%.
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M!P_* 1+75XTZ^>M(\:DGP,'A5;H= 7<X(#"C2P4<^JZ-/I?7N&JVE3"D4HN
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M9PQW-?NC9%_N^4LJ)1E2@0/!( K:F!+JYO!#\R:]PR]]Y3>( \E'!=Y"]*A
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M$0/M!#W8AXSP=?/0&@A2[#DQ\TC,I-C.E869)>3)#*X=9MQA3)#M&8G4N!-
M/(UH0G$G8M!M>[E37MWR[*UN;125>K0 L3O,-G\!7!-;UFX5P"QJ%!^"PEZR
M,9E;@8ZKX<<(H51 B'*H\^MH;_Z9:AWLSH'ZHE-O8R,KYOC*UJ7/W=>50IV"
MC0TGYMZ[U@.5P9:@QA&&"WW;OC!$.,1 _?FZQV/K>E>Y(-?B^*2E2XJ[B[7#
M/$]IV6J+#=$#V:P/[J.(Z13"F0F*?JV$9/S^M*,X^9H--Y"1EK"XM%0IHY5A
MOA-(%]&#*HMO0H[)-8.PH21.K'A5$D.65B;B<W=0ON$'YYH795]/2J5=$I:2
M-6D/E!?,YA X;#P^"-\&/]W:C!J7&U@8ZWSJQ0B_ 5J&W3RRUVEC=39(M2I)
M'QR853^?03PBIYT1)5>!_4?%?3F);HI>T/2WS>C=U-'"_^KTM^L4N-PP.\T;
MX4@)BL0M"%NC(DSK/[+VNDDMO$;^EI\D1UPNH^T%Y_T\9P0WM:)Q]',0$A_2
MJA(KW*EI88X;6?WJY9D\)4ZXBZOLR)UY^%[HM-'Y_>^',P^8.HO8"7"9'L>O
MF0UO:0JWC:N,1,#ULB8@2SO#&XQKL:OL/RY;A%VS?"Y3E5!@M#EH U;HM[5(
M,1JXN%/V?&/Y:G98^[GQV9P-6;4;:9^VYDNDS]=F#5@;&9SBQ.X\J. 6OFF.
MD,465[KEN];>+[MF"1G]=/3UI_,S2F_CLL)-6?:'A5G(88QY2(J$$1K\?C4"
MU9*F?-BGD#^'O!M@H>B'*0D__G9@68+W4X!^4';*R81/3N5-QF+/9RHBMU.:
MD;%(=O1-:,2^@'946)I2Q8BON*D\OGHX_B,5$/#(Y12+@CE=%S%F8#LVBG:3
M,7@UGU=M.P)K+,#9*#_Y>CMQV=<QIL7X>Q6HR'B/YNX1/3O]XI%;AI8GY2_E
M1,D6#S3])U+ZU7* *EG@ISMT_@#]=0(^4OO7Q9\WZ2=_T8Y ;>A-X3XJL+)%
M!;X<JOJ+]G]5)_Q>^G7@]D<M_+\E69Z?O.&EOHK=;7<[BJB-H:6US;."IV?U
M!&XI?7C?QGB93BH-$-S4BZ$"4'0TJ&(Q2A'!\?V&#SBO.T;?_8;J^$X'-X_N
MN]DBWEJUAU[/=L.]!>D@M:./6"6?\4=GWC=\,=F0,(36(4L/90YWE5U$0 ^?
M.BQ[SNJ#<3*/[;Q,QJ9UEXV.6OHZK>>U8"P__CSV,>((86CN?$7R6GT#Z%R9
M,=ADZ,;;/7)N?KN?'2Z(S J\_M3%Y;;8C*W##]*T&8^J1GP4/I7;K!B6HM&*
M)5ZHG< 8\VH'<NK.<&^I/_$+T5T5,A=AEPZ$KM)@)\,FP0L+;N^'>Q%R,;'G
M,-#VH/D/F3CV]KOZRC+,._Z7$TR[#B0(7EE@,UB?N \Z,Z(XA%.?]-):!3^B
MF4C;,!68M0[PUD2M72R(('_*#K)>"?P:%TVI'T!R)^E/!3ONNSW?R 7G(Q@1
MM6!\ [.H9B2=ZY38Q]6(]=O*7U3#;P-._B==G=1% H[V?$I=OIG1L/>L,B93
MT*E6<M[-O"BRX$BET_SATU43[M5#U07V.@)F(O_08N>_ YC])\'#<)EX'4(#
M40ZN-XAT@Q!D;J#HGEU.60/Q-'+J*R;EP%XPRVN^!,G3$MG]>:UI8T<3R,$Z
M/@Z>%3@3 VN55VZ^Q)*AVWA7FA7XQ)@;6YOF/$Y7<6VQ;O%:DR;D%,FB ^65
MG\Y/EZ6L^=$ 5!,!05$F..<9,Z[=FW;&R83[7:A_87BN7H03ZL,ZOU?PNNAZ
MU4"HI_;VOMU,?!$YG*2#47S 2K1&=-H=J<:".S15Q<NOE3E>Q-F^Z;A=*9L2
MP2' ^$PTA7WDEA*4THFJEHE NHJ^T)LU;E-DNP83QG3>[^@5)FD-?6*=E:1?
M4RV$U53>#BU3\!3Q:974$CAN=GCPZO%3^JO?# <JZCH7BJNVRCE0[%$MAL>[
M;)($<0,>V[+3N^C49X&Z&;:/!YW=B+37:1>R.?O?/?/RES7=?YFJ[AC\58TA
M$)3]BP<O?[6N_'?H_B]K4?\&>/K#AT+_L&SF%K'U7C/3X5."#;C.-I# Z,U:
MU6>LR52 EDSVL^P_,_GB+?W IX>'53.*\4=X7NCGG;%MX+.N(DJ:U]O@7Y'K
M*"R(+B/767=$T 8?;-JR!>8SNWC?O6>A)/_MV*B0P+M85N:=^)!6]T^ZX[C)
M<_@*<A[-_=GLDKZOZA(^@EJTZ+]:<UZ9*XGV[6!7"HO8I_/\KDJKIW:RM@#/
M&=X7A<&)>#/R/0HSI8L]  /FM)XB1'2D=D#:4#SP*YY0E5A3W?GNBZ2.>R'$
MBA:LFH>DUU=$)41D?5:XCK0!)?H%E]A*+N"U*IW&$.<;<GPG"@:XF5VIP">K
M6_D*N.%<W70_R4[EZ3%1/(I<[\>B\;VZCQ/'#K-I:C%[T]_( -.[8B]P5RQ]
M:$/R0#'D[L4+9T/I&+GFP3:P$\UVW 2?V2!%!AAS"WZ?0GQ.TX'7_5MUYT/9
M?4$M#^XRBA/$+[F91BVU7E^R?Y90ESAE;$X)KD]*^!(OH]+K55/H:&!^?R]<
M8*;&'J13]/G;ATM74JR.T=!:'NX_5VWJC?'MY%)?Z%BT;E7_5H.2O'';^'-=
M0U&1YP]>/A"[TS_WHH:!<>_1,Y^OI^*[2-]=>"(5N(ULM5P!CP>14*M$T.K:
MI :J/,=K;>$..LYM':[QUE/C7)M!N**U9_0S&Q^KK)2<:L0% ICW39AX:[WJ
MRLQ6_DG9P]!NWXG@$F?GA;??SR]%(P;["*G&?+G1%;@%0**3N(];*N\+.@ !
MGKFS4U**=BR9$-8EY_JZO5"\.G!P0,,HY[Q48^G]=U&PR,X70G<F$NBN)&3%
M73I3\CYP!T4XU(GO)*G$Q9*?HM]1>ALI?1,#[XBGY[2F7)((&+3SG!W;[!AV
M+7!+5C?)P,3[TF%=TBN\?^6&FUM1;SL,%*>>(*9_]G[@UX)+A8/2(M5R/J=M
M[=:LZI:RX_MK93/03XR7K_]>!%/X:Z#X=Z[UX+@GV/$'L) U0_=<V,@Y'.=(
M&$(:=OTI7!C'?UX4ZKO$="'J(N_B1*F4\D6O\-N\;Q8GOA06?,Q^D+,T:&'\
M;5>K-WTB96'O^Q)AL4M"'B?B(3*91IK[W/2$4MUT4[6NDU.0[AO[6G$'P([3
M$_&MPXV\A'(HB*2_S<(U*=F1/!?B9W\ N!,A<E/]NL]=EIMSWQ#UT_@,\F,*
M%V($Q9E%<,<AS[B:GM3JRUS&F][YJ8H_1;6<[DF6*=UZ4<PQ^W88=PMJO&!.
M9M5DCJR&MZ-I.MPM.N_F> QF8':Q4U&QNWPH FM]RRE!OK@)M+)W#<ZGW_SH
MC:1=\1Z#M -3XC(378C@[/(5%W2_63<6KF]@^;R83;#?PU?HPWC-Q^41*]-A
MDRF-/K3,Z*"IG%R>[_4S(@P2+-DEEPESOY)%_)[5.KD/5,"-FQ6&ZD"5HZ,K
MD,PD*QPHM))NECCFOKW!U@T5_WRT:E.0[6NKK/$S9F]&SZONSHM@561S[90&
MS;U1 8*D<3/M-1K@D@LPXD%F%<.Y@]M%/I<3UM?7KQ0O _7E!N\W50$1!V,!
M.GR#X"[K3T62#6![]+@DA>TTDLA!&0!CKX!BD.7)\=CECOX!W2$M(5BX.Q,W
MSTKUTX2O:^/Q8S<BW=<R;"P=OZH>[-H)>NY^C:Q"O  _B]TA\5 !"@N.YNPH
M *%O#A55C=@W(+'1JG684(3!CU2*6UP9+':L+E/ZQ*B3,*66QL>GHK/I(+-Q
MXB1 #(\B-9!?-8J2KI/OH6<2K65( F%-8$&X10$\""L1_Y* [JS%UV&"WLWB
M'KQ)G2#:7&RH<N78\[;31RV13Q=]8_/ )KPL"]4W'082(*GA>F=V[FNIPE2>
M?Z$<QPZ%UV2+''\S83N1A7,1<W&*UA:7_W/AXI?D\T:)4-1)4N0T#>8 G-J<
M17S%!M<7?\>=ZO&8B8 J5MZ.3/FC$<PL(4]+FU0V^PA)1#=D\P7N40JCS3*:
MGL+Y":<8KV+CGG8()\;<<(^!"J2?G\M:#;A><!BL[-?YH&,@7=I(YG!#1O5V
M,-]7?[VZI,]["SNBVSX8)$LH]!><SLL=5S7Z@/P4ZKW<;YV60C2B90_G&L7A
M@KA0.#M!?]:&"D12 2'%J]'<$12!ZYLV:> [P5IL5N>5V(5W[QZH6MN-X)U!
MC3)C4&MRF&>*L2#L%8B8-2%G8=C+YR5)\J-M8NLI43_(21]:[N%I?=9B0\'I
MFN,G\ WC,?X9F=7H669L2C.8H=-IYZ+4T/:SZJ_;G.8>^LD+LXUW+!,NJ9L=
M]7\5%K75U:)^ZDU*;TS &B.V!+* J/6W-3Y[!\\O&Y;YJ+V]0?R.S7@W6KHX
MKQT?[>.F9Y+;E3ZP1>0\U"(N9U :/CX\+ATU-3ZU_U%;U+&\5^IF  #,T%TQ
MT0D, AV:\%BEI5D,_P7CC%)ONL\&14>:J_<9GJZ[+BN6H/]%]I.JJ)^?NZ.[
M]-I:FV?K]_L'+-CR_O/^@0/PFX0K!<CF<R1;M:A&$1LK5PD0MJ=P^!0DJG*O
MU&3)-2A#!MW;ZK.B?->?EU\7>]BP4%G@-ETU';F(=;E7XG%42]#5PLZNKDB[
M70HG]?9.54AMM*?>^[D-_S6[G?0O@>!PWR H-PQI%/ZAHXLQ?'AXZE@^GVS3
M969MQN!P;GZ+L)R"9BI0I9*Q9*"XFV+U+C@EBW]DRBUESNO)K6LNK)=3J8"#
ML<5P8?*G$C\6=$7E,^N@R!K$;1D2?R8^.[&M'^:J(9.+.KIG9WKBV)T#QKK$
M"1P5 'HK@S9:H:,3&"JP&IUC []&,"NQ(3QK\]+&$5"M-X"'RT).!7N+G"0#
MWV:?82!O,G<=+Z4\__D"@-S >[@1YNAP0J:=,ADU'A5=,>)J6TT%[KZIV+;.
MNF,%O?])[?&0W^O-_#6M]\^39H@=[Q1)K/HJONO/3BJ&(??!N7&=+6X8%.-4
MHR-2SF2@V,*YY][<QCDE/W-FK4X1AJ@5M[=:QTD 3DKB*%@"[!)$\(W?=Q:%
M.U:6.%^&8Y!,Y&S!TJ-F$T.YE/0X&KB;T/$44<)0[K6QX%!WT;94PUV[ ]B.
M],U/HP;J&F+0&%3MS/48%^:HW><>-F>+Q>>\\9.*E<*%^=7]MAC*^_[RL7%K
MT)60]Z4"I>ST3Z1>D9_*'S!3*%V3QK^<'%YZLQPP:*(#TZO_?6<_?V4A^ ]X
MKVL;[=![5( +H4Z@-R78XEQ:A +70PJ:'- #T,Q/<:?"&;SC<CF*LY1>,_!H
MJ_297)'M\/)*J+WQ^-50NKG*8?T.DP"CT\K#/2KE>FVG+&(0*LAFZ4HW) O<
M:K R7H+RP>>3?&/DG$QLL1^4+ORT8U4#VPG-AU)'NI@NVVN#I-SQ$>$:)K.]
M^PC^W>U3W"/N*D:*IE6&L6"3UV^L[-]$AIO]=)+Y[<&<H:U8.4A_L:]\P,7J
MAK+ZD)GZ\KK[3E&P)X).OM?/'68(96EF0N\#SV2#14E^-/C>0J@IIG1!7D]W
MRD//8-%1%7F5[C:M^UF9[Q??>/0N_M(;!Z=JOI=376_&Q7C&)%WN1[<CKYOX
M26^8C-&4U2>W >K0<H/V;5[,I!RT.VF?;YU\:N1Q(?G%A0(? X/#FU<MZER]
M!U>Z-5V(W#_7@<4F+1*QRV!D2-)@[',JT!)<A'3?;73!=^(+IV]-DS?4_$G$
M195OM(G!<(*&:C+@!N1TE6[T&!@?@Y.J':YSSM'<N0_7A^W6-(0?9*@JK[9R
M,KN^<F#WJ;E1VT/6F2Y"'><33!+K@*?WV-12XX0<2+]#B^7&)\6$7J7T2+,Y
M(SNWI.9V/[>I%"5;?U<WQZW:*-F28C#/;^&6DZA8T*8>G!8M'7IH$""Q >Y%
M!9AH6*:+^_M9O%$U:RHPL)X)<8)#"&["'=P1J:C6(+3(2J!@<8F;=-'V1D1N
MN%Q.Z'FG!)4$RZS-'3G>&FVO(2MCE29**RT,"[?T$F1VFD\KC@W,&$>2C-5"
MMY(??K&6>5"IOB%\\:M+\IU[2KN&"B/)+@[%ZW3$=&]ONGY$_W39R"J9: ^7
M&:2P4/J1;!5((0+4K!J64SI4)'2.76G&B .%8$UYU2UB84K'P N)!8M3@1NH
MV'$T:5\2SG"FIPJ=1R@P(D!PPA;0B/'L=TI&KV#G]' GXTZ_U+-,GI)[^I \
M?4AJ8I.QI!_,0@M5XD@7"#T->L7'PE5PY7/N.6%SDX$KECAPZS-HM/4]+5!M
M78V/U.K^R&0S*Y&X+7Y&O]-[!5HL!FJ1(1J\682#H/! 2-A6'93+9LDMQ^8+
MCZ5NLLG84<3E*DOMT8.\I#1+47]<S&7F9B26]J)C) 2'J<#,9*\XZ>)'CP1,
M:P>(;8OAHP[Z@T=<MN8]_Y6]8C50S0OTU9H%*]RC<K-ZD5KTE%8PDQ8SH4,H
MW@(+;8GG^A)8Z'''\)F1ZA2K!18V:L$Y4T*0CE\=F!G"IH1+#Y$@13#AV?6J
MVL[6Z?!]E$8%7Q#75.:),T>/WW%P;6,<;18<'&B';CY)4'I@L70$D)/I-$<<
M1V-CR:A6LL. \7#6W=A3^&^?NCF4G.Q?,$_M[14LT@%HF&L_&'O9^)LBA88/
M6DR-*4=*P3-IJEH:D)#:A-[BT8JPCM2\I/OYK1<.M3[J!:HPS-=U@D&_4"7U
MDOO:O]6-<G_SQKD3URIQ!LNG;DW>2OZPYGV>XS6/8-6V5N70\%_41?UYU^$_
M_:[#G!HW3-*@[U#MD/R+\<\/1*[OEW-?#G8S_J'<[\>E\W^3,L/_][B%/=XC
M[7)Y2P5^KVQ.5[[C46K2-I\8_#9B\<^]0-?.BVA &0;3H9WB&9$M7KC.3O]O
MUZ[PI=YXL5=I:MD4]Z#H)23-7"JD:;R&,2KNUI&KN;I<?OOT/:8Z=?E9HSH=
M)"-:SWSP]C>)<J_^G)P+^>&0P<A[L C->:<WRJ(PTIVKBT1!V(UIS'0;[%*/
MCF_%1 8L**'Q1GK0B^B*,&+6Z4C3>YG7Q:[,E$RX4=CT*(]P!NZ.,\;-0<6.
MV.R89@TSC(W/^*9=,L^;%1[1!T<+Q02]MIF;:"X'PHR\,0U,P(\3#F"I@#%V
M/=JM:WRT/3P)2Y=@):JH'$&O,/]DQJ?]#F5$.*X_OH9[P6T*.6L,M5*\L*V%
M6K92XW:+<^-] -E<5B)_ I$U\X4W5$B/)^L&C=11&J3#-.P!A96W07C<P3=+
M)N(QP:AV\ ,A*J#UU#GHYO2HA+A4V/SHV$.>A]KDU>@W2>;C8A[@2]$@4;J0
M(JO_.&HSEE&+)5BK6U8:0>LFJR>K"Q"Y$:DW=L.]K(SY3^<5Z!Z6;6'?M1>\
MV7Y'JJ[![S</\=1R'_O7>OM0;1$9P$^9+@K?J!S+D>!6=>25TOOASX!FX$B8
M6VIOF_&$8IOP-&<]-\;$#;MR\<TF7!]C8_D>.6%:,E5>9=^M0]X1XUUFF<Z>
M4Q0D).*;<,Z++:#[@?5X"6# 91/NC)DP;[WEH;5]/]/WB![W_CGFVH=2.]RL
M!./6-$;L).H>7#+KG'W.J/;!BHH0S](\LKZ,5.([J01]E:VM.2ZQG%>#%NWO
M[(XC-Y<TLVFS""R!BR9HR6Q8*2;GG\3)ZQD\J^)3Z$^@ BE%T+WH77S5\Y1.
M;(G_VCP,VCS>&[8E:LQ.<'!7ZC0N#;&OJ*@N/_)H_Q>@=V4PS<CN+]Y#_0 ^
MDISA.QUJ?5M5554_J,@N/<C&:N^]2+K.IX=.=L  1W6-&(NV19$.;MGFP4['
M5]XMIZK6)]S):]5?;W\[_"&<Z_YDYMZ2NC+#3;TSO^?LC\HF![)RL9-E>U=E
M:V2-_L*>AFJ\KYV525^@1R>)76M["[*Z1CR_A!;U'2N$%B9T6Y=I[YB7EAX^
MPA^OI/$U!GOF@]+)DR4/9S?X8&Z1-&.ZTEIS-I-PM?_:\.K +?SPA_=S+0NC
M%VV-741S%P=7?[#!K]"8Z?*(*'A0X3C<" N.+E(&B2ZQ4@&^'N_Q3WDOD(M3
M,QR1#IHGF46^Z%XE<@I^N\0N'ME=RE;):E5T.B=M*3?3^$9:S+1X2,N">H!N
M/52XY*=C$*;&5X?ST]2P5^9&8C201;:D8X30JD91W(<$-.[8Q^*7F%EF4KV-
MJM=1O1*&1^O'.@=^F L+C:?@=-C>CAZE\07#I2TDKZOB(@S9-H[L]K$_]OEZ
MC,=9Q"9_V 0S@P^*&0&&I7:W%V!%\=&E8?JXY_HTV2?/*B9WMQWG8AA>:^)#
M!FIQ!=)UE10]:)HM/\77/H\KCZI?\IB;NKQR)'BX+,*F!+9Y;'35W,I.7:/#
MPM0_U\)9IO_$TKX7:8]08^4[QA=^>T[MSGWY=SJ*\*\ZME, X6N4)9R>!4?T
M/JBWSWN2>6,,RF!8:S5=/&BW^&F&Z[-%^!FB_Q=/0E7P%8K@Y%A%JDI\ #YT
M]R[]B,=[EXF .8C*<Z\(3J>]]\^!(B\_6W*1^6IR:?JT6!)N]*)RS:U+O=]6
M@Q9_]92=6>,^D@DVH#V>.YX7!C91ZB@JP[!:W'X-MBUNB'_S5C.R.+QA54&.
M,[:UHU'BEF="K>NDRN</3RX)'LP6]OT-]15U_7L<Z/SWY)(4:?%SER2-F[Y+
M!:!%AIV4([%9I;B<"/L[65-93N<Q4^.G]1V8B5T?P^4&6:]2 9Z2J:A-*C#>
MB=<D\!-=22>@]Z?%X;2DM[3KQH"?J#Z\H$<5[M@3>DT\5XSGG"27B*5%-&K>
MIZ=L1Y>KWT@EN+@D<U<5$3*;N[=O)DTF[E2]6+Z! G_5LI+K9(!K^VD_"[VO
M(,AM9#.]%A]AHQ-5/?QLC@JP=?2-$A3/H>N'2NR4',YXN4MGF?"3%URC&9?/
M7T3>&^G'(ILKIKD.$2(UXTDJ_E7*%\R<B2#2P8_DO'1P0.]7O NY1$YBZ!L]
M40;1B=Z#=.@-=\/6S5C<'_\PK']^/#DS0/'9G7SCF#OEW2%OYNX"5TU:7D41
M5E/N^^RSNB?G8!IS?6!2=7S";7L=L8)ACODD'S,;11#+\2BRQGHB5C/21>3T
M&YV*5\?U;2$V7P)^*W&"9*/>Z?Y;''&UQD7PYB6%N&=ZT8>ZWOSUZVY^82?"
M;ND7\V#?7]S_^UL7^0"C?[ HBOZWBX?^8)75[Y0O;T-17IFH#]U8SPQED725
M27-A>Y01D^P  P!]F>P[S&MF1&\2&SG!75ZY5_160&!GU+8W?VL:/7:HM'Y8
MQ=5RUES.=_[J0]V=\1J&/9<$")6HU6JB!;)96P&#@ZRM%!G-&$?('^S)A7-A
MTW):; 8_7%T1+IW-TF0-UZ!K)D\<9@ZO.JF;F:VK\76U"H()UE2!9KCTS:@'
M^GEVB\;GKQ[;<%6Y<VGBU>6^GJW&A\:85&52\/?;1 G1Q#.P6N), (G_=%-R
MH\J0_"'5\9UV<4=O&*1U-?"1K$CC$ZZS.DD:Q[X"UT]1@;$""NOD#.3>E H8
MU'B2T$'$Y+8_>[EOI5-+-N98J09EP[AJX;3ZB)3"]),]VLY7*H)2[B) ,-%9
MEWNWZQFQTRW6B/L92Z\?%/HV*/39APOBS0"GYPF!"?HG#U4=<9UYOO *X]PK
M748\OF5+!>K7B3:.%RUX6L(E+#5R4*^SI5T-=@I,D(A :T5*<&NR^&#J IML
M1@/]PB_;)7OGE I.;\T&0^P-!3%M1Q;"0;D]GPF+'>:YS\)(YD*Q?4_BQ#NT
MF0<BI0B)<QM"E/XII7H"'19LF="I_3KQ'6XZ5MZ8EQM36ND1*\<1;M\20UP<
MJ' #WYLNWPDIK)=S"<CYLD_GWFGYC+39R^@";Q_)Q 1CJ42(3D_X+%RI'3-N
M-EY_M>B6_IIIP,#3#9:&BL>-74AYNXHWH5EYIBD*0@H#J?[X6"@+^+/-)3=D
M*-BU",D(^WZ>@XLD[SR#9KKY<=2U%G[PM,U-/;;3"8'E_ F6GQ/TI1*MDQ82
M*/U"C0<?%6GQD#2'ZZ\<,HA^4]13]$0KW%6[<]Z("MQSQ#_$3?=@H&*NC?SE
MB*I 1C3*VZ(O)_$^U+>D=]E+%R1JTLTJ@G&:G BMMPFVM5(?0/@G(O1J+C6P
M^0YI:'@DE)F81QDZI3TJVSR]P0/+;;7C+SL5'[E-U-2BHP+R4 7S8\'A&*7@
M^W SXB78Q 4<%>B0UVN3$!^ZO_[<(53N<(M2OEGLN?_%WGN'-=6]Z<+Q144I
M1D! BD0%!$$,53JQO(" $&G2B2@=*4IOB6)!NH* TJ+T(D1Z)T H M*;@)2$
MWA-*"*2=..>;,[]WSGPSOV]FKKG.-=_Y8_\1]F;MO9YG[>>Y[[V>=2_ >:8X
M.80Z>Z@^=GNB'.L8%Z00XZ170SB910D*?UMBN:6ED:W810?$CB$VF<B*SK/G
M]X)=? *_#/NZJPA?^#!C>SE@%WFU=<]ZYQ2Y5DUPO(TP<Z?=VOB=[@<[@S.<
MQB8C:3F25[XN'5ZN<)]*,G,)[A1R>-/Q6'I,1]+-?>IP!5W<'^DV@':41 C9
MA%A6OL3.?'%S@[N+S:IOW,-_M3KC7[BCY?=B.[(&6<;;>5KA4/[X@#NK%I-Z
M/S':UMQXL&ZKD\*L,?H/R%S5!7V\8@*%0AD=6#;>3#8S+#C-R82\SD#F.SH=
M=P79S!9">)O5="+[5T;:[J>S^"SD7)6?VQL;G*@BUDT%9UQANM;>S\4K7I.]
M-3/KM;T!F<Q_IN:+Y=2^Z5/['%(,^KU\C<I&.\6@"I)( DHG$YT-&5VSD>%&
MXY_0 3^.4(6=AXMTP NYWB8,V5+[0&'V6!?R<-7-3^:0?['I.N4L:9]0SQ@Z
M^*B #1++G[&&"HF+9;;:W@[2J]=DSQB&+P2=U>;>,GGP,R0CE[/![7Z'673F
M5DJ19-[:X[<]7J0ZSBR+VMNZO8H^@[M6%$=J-HTMH.A/$IC =1\_X/;SN"4T
M6DWS0DO5B/WY-GTUT:>*2H?SMY_&ZSRT&J+T3^YHV%>3?"_NQ6Q_B.NKHP/>
MPH!J%PC05G_X*<)2^)DON3-71,,,NS/ZLI]%J[PY?W$\>D5(E="_\:)XDJ)&
M&BVR7M< U'V\A44+WE/4R^5JM9SEH AG]@PS#5^&N":?'NASAK%&E91*;&(F
M$5PH!8@_;AM:@J>9XDP+WG:Y37$KJ\F516]3--(J(?63>?IYGA$'(%=J,2/8
M\^+I !H=,&.$<(&/Z>T@V4D7WM)$&^H M$>-_#,XUAK.M3&?I*OWU9YIM22.
M1(>=F@M3'5Y?I@.^28C1#F%T !/L*_2+N5M183QY_%#(G5I,-LO[0>/$6[\D
M%R"\3E/NYM"FJ86(E3OX.!K[%080V8L4I[46#PM8T0%_A-,!%T$/DBF4Y!GT
M]UU/D@[$]<]#&!;U1I ."%1(9MH_AV@U)-]'_8#SD)X^7RLJD1;;Y5Z5-Z2&
M1S 2R]IL*(3V /0 R?A_+$T[E0YHM?L]U3PH.,#P\Q<015^,<F6VHB$$TL)^
M!1I T7T.['4;<LXB<_$.@QBW%Z<#=CX?-= !RQOH'1CM3\8#&- !+K"CBT>>
M-&X.!$$>C?]&!SC/'BE:P2B2#'.14GX_?7NGSP_)T!&(Y:7](.0N$7;(0("7
M TM)[\F:FHR,[EB3TT_9)21^ZURJ0+3V4;\PS/P3LK-?00?@_N'V @S8^"71
MD\(,I .ZF=;V$?]T?TOTA4X@6?;7<I.:J:OV<B0$^R3$"YKB.9&!!Q+5])YT
M[OS1>"424KH+.3H_QG@5O.@ 2K;Z:\]#,K@.0HE8FL57-\DA!BM=822-:H:Q
M(=AG(>:P)-A$O06;RJO1AW:'X]F#VD0M-SK@#C^2= )(,Q%JK:90$3Z(0RX<
M=#*U<T:<T-F& 46$J'MGI:L,*7T9VG(T<ZX&+$;8GG9O7O #^*%NH KH $8+
M$_,P0N,O&&<(ZZ-Q__=6;WT%3KVQ3^15M;]%N7>LQ3;[6&SB+HAXLIZ:18VC
M1OD3&Z?@/43'7;G5:KY>A.33+?TTAU_Z-KB1O$V17X[C'1E3(B5),2+%[IP/
M-!1E,>,Y4<GJTS-QM2N(,O^V>G XB%LXV6;,J$=W1,H^C&;Q\=#U=G),7-,<
M0+T::0Q[N"*D@C>+?*[!3_#[A,B(<@H5#-\QNHOBI"8@'(NU,?J0.+CH2G["
MKZF/3WSJ:U[*.[?QQ&NJGW_Q/._=Z7Y#VU04K0]Y/.2NGBOHC/S*S]VF#KDG
M$_L_- -14R'*/0'5XMB/FJT\'W)$66*]X@VFC=(3ROV\ZAIGB+ [B48= ZVB
M#D6-Z<-4A'!E9L,XC:]5"K2$%VM'\:S4D)/6"P.)\[2)[V<0*A L+S5?3;4O
MCJ"*F3P"_SDN[U?U2%WNF++&4M,V&2;_A49X@2Q6ONU&^"!V<',OM-&9XC/;
ME4>#XM4E(G=A) NTD,\9-5,\UV8I:J8.3RL7K#WZ<QZQKHNL!&-Z3G($#&L1
M@&]^I7$4KSS[W#_*]'0;2G7NLLL)BDVFAKY:I<E%F_V:!);8C;<=AAK#/JW*
MFRECZ8!H$*N:<:4/Z*V*)J;ZKN;.->0!YNQLCL_#-[\U"N8BB=*DANNR@GL2
M6FX-EF[;VG^*L402_/<8V**.Y5]=\_A_*_G_S>,W%>PA8AA4D)M!!2,A%T+N
MC_F5Z=H-^ZPKO:I.^4#J3SQN(1"K?$TW,YK'H1<.7T/@G_5C&K4[DA["N_F'
MG*N2@VG3=,!IDRNK">?[)R@QS\F!-0<H1CB<FX-$SD@2T)1SO":DT*+I'FKR
M7",KM&QP,T+#DIHYJ5KKP)2[%$A,6OM3%_+*K$WAL,2WW2+F6JN/5Z^6M/N3
M5'?/QB,BI#@$@G=Z79HF<^="ZJW1(EL6MYD/)L*B 3G=H],I[O7K.7&K"&(@
MM0'B")Q\/!<ZN\DT!XKP\\L #7U@A.3;OJOQ?3;<S5UZGS>K-)39:[(0K H!
M'2BR/7P(42U4\'0.2!(#O7D3@3WWJ7@_+D[H^K#%DV'F,W6FV<\5%K+25&.>
M1TM;%XTO0B@<N]C^Y_ ;\&E;+I(4P1,#+2'!+'F3%8\$QXVD<MJ(26:\/#M0
M?FG.PC)IE@GCI;.WCK^DLKGP:R5@J==G[PSXU <+2"H]$-!35>(1_QRCQ<UQ
M#E (  "D3X3R0&,[G'XJ*#?=S7-YMGWEZQ["P:*XA"P/-^M44WU'<D>JJ9]2
MT]1I-T!65I?G\4R:1=*N#4=5*U[CK)9W"E5S(II2PYI8:#UF_G"E,D9LY F@
M \Q[ J)PBE%B9-MB^(:&E\B30YF,#,N'#\4?+3@VUD5*KJP,9(7G?M&]80L;
MHSDMFE,Z+Z0\LA7F->SS+-JHTLO4LT^,MQ1]F!DI:1S]UU%3JF9# #7#_WC9
M3PB/NN9#!R1+"N[&R823Q34<*<>^NN&D298&Q2[Y[1Y3.N#4@4^ZTF8)93=6
M4'*0BC.5N-GID LDPZ]NA;/>QHV&#HZ(2:"8U'HTDPX=<(JY<UN00E,E%9Q\
MX4H'!.OCTVLY'\_@H)^@ QRVH*/..URY,%U?"JX82.'3,%>@\8HM>%,]Y&CG
MK!MOD*>3I[VK"69Q:KQSP9Z5I/IV'I5G'(F\9BP,>KN%>G $<&NE25.>$,8[
MUZ_2>.$]8^/#=RYQD%ZV28O%#]Z>W>F^DO#'E:?(=/Q-9M>,+& [C07?'T.[
M:!URG)KN,ZA1P 0D&6A<6C-2F'(Y%2!SN\\OM:H%=)W%>^"-_1$OUI^![DY2
M+N!M\IY36'.BW 1,NQYYB^R &J_%4#PZX^'/'P*8ZZG(-I**"<$\90 SDIC#
M[Q59I""4D%8H>JJZX>$J(_MSN3S;#8"8MRV/NMK9;0V812_S;"V.G0VRG3+0
M^Y,Z,K6TN.OY9O:8QK4 1$L5_$05X0URKO?,D-J53]A@;]$?KZC+\4L&(:V!
MUVJ[*.%V6-1$)Q82[D$'5'KL,8_Y_O'L*+91N3ZQOV!VY^76.3-?S4#83^70
M)WIMN,-2;JOZ= N5V&V_6M1Y-#X_8P8$;K4KZ#@;^U[G>I=4O!4X_K:VH%='
MJ29_87YK831 _834.;.*^+N;?W>D+81?Q-,B<,4\ZY@,D:'/3=\:7[7[NGB?
M#UB\,W(V:+1;(NOJ;5U#/S?'>UE\[1VZJUMQ&?X!4T0A].2L!X&Y57EICC)L
M&V!22KE750LQ/:(#OAXT,L$&U8PSIP*B,"E?><=XOT6X>VQF P7S@Z2%B\UK
MJZH;JN.'MHXS$&1VZ=TO# 1Y]A8#09H]7Z>=)'1NA'Z=#KE%DLFQ7H<!MW)=
M*-IS;PU6?<H"@XL8 /#4VJ!/9Q4;0C?OSMO1W!&94($AA9"<(055/1=JD9Y%
M".8UG-\_-PV?;E2?"%+:3]0@D+X0/2\([[%S1S%0+8[W9=/5 (/A#MKQ\4LC
M\E-MTVSXC/ Z:;4BIA;C,'9WLS[3G >OM0VRK>W34X+DQU:S5EU,<VP_N!K'
M?[ O21F5)[H0&98ME_^75^#_I2CM;PJ%_^EC3+:/SKGL2+Z[+<?M.?0T!5[\
M"'@YAV[U/.?A[HV=>2]7/?/I2:((!"]_#&VY#-RHGW.73\9#(AKTL%5K6=KC
M(B8@T] )H=%5$[.8".Q&%*]&4(VS,D(VTH@!^Q)S2&F[K=C<K3G4S"1U.841
M9FNIGQL@_6\T5##Y'1J+J+?R)I"TTO3.G2P:)R/!>&)^N2%/[ZG[\F[K?5Z_
MPA1WOSP:F1-DRMU/0]U.)I=<J820WRXUK15F'EZ&%V;A#?26$52)WPUC=%TF
MM;OFT6^$I 9*#[:NR[^\QK0J8K^\4QP'I T@3ZCI5_J@(_@?.I)+IWN)?F+#
MG*^52[I+]^F \"8FPH-Y'/2DB_^/:=NU5D7/EK??L]8:],)I0E?2-2=]?L%H
M)TZ+T@$?, F\%W*1A51C*KN>7H\JB6>M8TTYT[->Q.BD\=[E;)1R/35)@R-P
M:1<SQA\;[C7M(6_SP-D*?R(RKCN+#GBM3'"ZM=R"J-! E0;=0OUL#ZW_6=L"
MNB].&^S/1X!.]-(!MH5:L->:>EOUA^&5;9VX/(06<KF;T?LE]"2H$A:.F%_'
MS)PCG-,;WC![-GEO%B:WP+RJ30%O<ZX@P;$TIH B:.=LJL%K, [ZC/"^LXE!
M'"R\SC%8DYU1,FFU%TQA%P-2/FI4ZX2X=(Y"^CW;]@HE7S"PA<ML&'_#K(.G
MH.9C):4 A;LB5?8:K[Y_05AN5" X A!MTM2LF^-/MK,Z0GI4LS_ 7?6#E-2F
M)'Y IMU:\TCVR(5>E_$LL[EX>'2MYCFSSZ[_=T.\OZ,)[UDN#2G*=9(,MD#M
M,<$3)Q2%+;Y^;0L]KB"^F2G&-\D6K:B8&9WPTZ3;\)5U]D;,5:,BV\P\@^M&
M02*)4WMW5YQ1\;Y DL0SBDU3*@;V37&C=QX4K>AVZ2TIQMT@#KLB*'CA8-Q5
M]E;7Y%D/P*;'/I B&T<Y!R:FT0$ZU&*$VPKEV.?^'QG'2:*LEM^_(\)LC+P<
MQ4"2$F^TNEK^J(%4%(SZ831'=F% VO&-IG6T\&HRRR.OJ%2%(C8)FD75&@.T
MY>?)D[WSM<F=I7 &CZV&;B#)U[0&*&ZD\:S5E%CFQ,]3W1Z5?!'D+^X/@6 Q
M@,S]AAW-@&W*#;'-1?(]1":M@PXHK<C@&A3#@4$4]T]?A240B]F63T3Z+PHO
MF749=]SLDQQ#.\7]Y"7>I2:+V.AA@2VAUZ?,12IF1$824;[*UCL_//+ EY/4
MWN68J1?]+ @6Q'!0+"-9*Q00R@J'FA &>W7VZK/*!;*M]Q^NUVN/&KZD X;6
M]#5*(9<1<[D@O#9X2JPSZ"HU?PJW'F)-6,^'<J]:.KW!#O^TNOSB;-D;83(=
M<.V/'.BVH/M%SE.H7B;\.$Z: *5<7&[F_SGVH^G^8%^BXF3UWM2B^RSRB2.Z
MT/)OX36*27KNUQ59=&6>82MY=@:=/M4X:V-QY,1&(J3;!_J/R@28/S <8E?0
M2_2)N_9POKM*1WS"Q7LWCW;*B3'2ZTF)9'4W?T0E8I,/6^MC$W1P+QC$0O(@
M//5V8'O%Y^%D6WJW^PN/W*Y$^1;@&]/>;YBVLX$&)MEQLZA>1_F1RW=*)' A
M/5&[!4OF8[4Y]O&3,E::@>#VJJ/7YPQM.OO^YTXV9HKST"@Z@%U#Z(W0=4)B
M8G:A'!$F%]))F\B%[96$/ "SAF6NX22T.&SLAV#! Y_ZSLT'JH+ELC,;>FB\
M_G$4!S+Z%?+DOL#'U*VUF8MV#NYQVQ+(#,VCAXRHPI(USQL#1T3,GE\JJT:@
M<P)T0>47A3*"';4N?-,,0*^S/55QV!.S(G<]NT,',"$EW/H$:>&0,086?\T+
M;@G=FGW=5]\!.T>[0(%$HZ/5[!X_:G;Z'O_0P6Z3?[%_3O(]XSH";O8\?!W+
MW,IN9AS3M%14A.L8!LTP,H_\RY\/Q^B ETTG0J[BKX5MW\:[%]0Q/VUJ.!G8
MX^^^8Q\66FKC"WJ 4_,DK&N]"C:V9K";ED1>\+3>DN#'0N2Y#V9)J&W$0F R
M11(:JZ%X2!,.L>'7+Z=2P:UG [6%D,X)X,UH#BLX!^D8/K4E@8HVP$?S*N94
M:WPIX/)653RHUDG/H_XR<]!TOQ/^+$7!U/4=L9)W,G]:!ZQ]Y1"Q.9+\WK!U
M(+HVI7YK'Q$[>Q%P[+ED&TTFQ)* ;$/S]Y)OT/J.GD>9F#*UTZ[=JI/Z8[I&
M_%7H>A+?L5O=Y+,6(J1A0GB'K1PA@<;(&>6-0XRT>D?D(2FY[;G'2TQ5[TB\
MRB]I<L&([]Q.XT'+[,L9=M*EN7PU[KFI!S^_.C0VIFUE$/W(N[JS;1L(@/1)
MP!_HFYC[6?$#L7+<W!)E9GGZ&\FZ"39UK6 <"5GK &;FLFWR?YL$/"W&+^-7
M8.@\M6Z0NCWD#0.V-I)KNO#)6/!+#1;2E:GF)N9A2JJS[&[_I6F%D<[M7DD$
M5^E:L-=) ,!GQ-#V1-!^J6F.945:CIC?3''U*/)6.&:P=2"&7\;PE6F\I4CR
MGXR<8?_DWY,\F-]0;I(4YI%A&M?J25BRC,NZ[#0D%=</>#/E69A/'K9ZT68&
ML,=+S[Q:A W2@"&.>,5.1G>B0KC@/PIIIOLQK1LUI6FA*XX&^<TTYGP1;QN;
M@(,.T',-L6&*)1T@A':2_"F/XM-"$N2&'0Z?--PYN]"NLG!,[,!^;KE 4)8J
M>LU60"7W&VE5?%1WH)#H-ZD07/(^@S!I%E,+=RT!<L6;)@D?XY60FO%)6B/W
M)3N-W9^TZAA"*WX;M 8U]\?-\)$F<GZUL'\XTG[KD[<3<@N;?M.];GA)\.PM
M0!G7@36;$$F9J0$%Y'W5-O>4\XOM==E81M:RS*MSTZJT%%KBXGO3B9V' 47%
M]1S1Q?P3>85!ZK<CQ4N\L_]SY"9^'RQ!G>%JZKCS\'[4R@/_P7D!L)2185P6
MD[5'*5DFA&-TB6P9<%F2KZ4;FM,O6GIG[?@3WKV2H\A=PB<MTX]T0./]UU""
M%GA7RU3<L(C0#C$)1%'$P5PK#22N^?'(KS('ET9R]4@)/T6>/]U,T6@AFP;X
MT]0KZ8#3I%C1=6*/A;N89U[R#K"C42)R%SWZ]03DP&4DA\:24$T#3(73=!WV
M=?7F/#1B:%9PYM\8<X&$^DR8AT[,FT\V.@V ,YNFMSB\M =2XH>)>:3;3CRV
M%T<4V,]@ZZS6+4T&OAV]R]%>MHTQM)FP6#NK4$S--FZ;#5+.8LM;8P=-3.P#
MYQX'HM<WE7H(N:NA1(0TT?PC10&\ED"IO=</I-S&@R+Q:@KSZM>IJ9F6LUJ;
MI'QE[@[X(*3"(!6OI_^FHZ,+[%LT G9S$S[[_J+2KDBG4C^ S8GY?>3$.!W@
MA K+$/WE"WDS^:@\=+DB?&,#6O)(PALF2AL68BW',[?W;+.[Z'A5<5@UC_VQ
MA,VQ$]#*?OY#ISET+E1R/F W0JDH7/:TZ?W<'&5QB7<?4J-<ZG=T>2RO)"S[
MN3M[.9HW.'*Q!TO9E*0.+XRO.6N3;4.\XF ),'WX@/QSR2F$D^9BX@7>W U$
M<_DV3)/6-\MX9D*U?DK'4=>URB(1H*^; &?\%Z5=X7ZE_N."\\()*:241F.B
M+(T1W%\?Y(5&^2<2]9!5[JN+A_K19,\)$@Y]9<Y6!6<9HA>.P<EP%1M4_+,U
MI;S7?SQUXSW?;:!K,+E>2V3D(-AH^,3?NWOM?S?MGT#P)I#L\WMKKK(V=V '
M.B9(XU/^7* E>T/NNN%'9!W/&&!GQXN)F[5?Q"R6P7 >P6=@%9U'X U/LH .
M5IT3?OGW9-U$2JML'LU2,[?UWLX?&@XAB6KV;+B:PJ7SEL9$_Z7DG79O2(I5
M4+WPBK2U3-ICKW7.N8)!Q,Y.ELD<5532&R+NK??]"+>V-M8QJ3<U]1'[YASX
MVE"-J2:3:(0:@#GHL!Y73>%V(AHR*)\ MK]UT]B<A)KG2HQJ1;/Z5(TN75,Z
MS(D[.'4,V_2LI[^GW3L)C=?K]9RW^1%T0#G'1,PG(-I=%". K[Z*J8B%/WJR
M )Z0NNO"@F=*-FH.P:0<:6/-6CQ?P9C4;C0!28KXX3_Q'1]K>G,C<CL]2K0)
M&LVLU44W=/JOE"W_* 6QF2HL;^MM01,1<T9[*M2XTXO(]@(UZ_&[MHE@RAF7
MD?BM1!6XD88KV8G"G47,PW5TMB+*D:]+((N58_UG Q+GU5O9K.XD;CR]S#7R
MW@:(@9)$F3<:L?V<G030O"=QNP-XGHV7 &J_8%JIGJ<\=:'\T?&;\+4/CSX#
M^)M2,PN5/2YTZ9;[BLY84@>')!>BUPB.3OP>L2>T6?571KF[)S<E8NK*;(U2
M;?]4@2/MLG^VY[H\D)ZRLNH0#IN9N1C!?^QY8=9SP(:$JSCJSN,E*_?IW\,^
M[*_R>M'43(1SNN)<4BI[3$R\[;I9ONW8F-:ERS>?+NG$/LT G.\#"G/OIH]O
M!A):#\S"36O&-RW<%W<O5]+ZWFH!\_3;$,U%<P'A;1G\V ;$".&,<7Z3Z'&D
M%+D*AW)_4M(OQYUJ)YVHGE8RFWQG,TBR%^+D.2FF3YK*[7T<:I]D.1K/7%<9
M$Z%S/RWP_7*:4]B9I^^[>CT#>N;S6I%_W'57V.:S3/WL%R5PVRFMVF%"Z"[$
MVFS(+B!.I'W1ZX>=K41TU8>4R%T#8CE4JUH%&XGIBRS,KH69?1D;M+77N!9B
M1ZCNPG?.+8SY;1\H>/+T$.V91F[6O@\/>:E-N0I^JR%+W6Y'1:?$M.D?5""!
MXF75G0<6X?V7J5YN2#+<O%B6HL8@'8$H)R"%Q<\]L%5.;/TZHO5E<D;/-B+3
M26<>&@-C;0*5W\'%\4U@O/) CR,H$[NKB[GF\,NU:)(UXER(RTZ(!$DAX)OB
M]&B#X<6*5\#M4RW@R^27-M PVMD0.5((=X/PW)2DA0FB<S#NQT>J?0AZW484
M9(QC\R1W7)9_3*E(7&1 2@DQ1*(26IH8P(")M6;.VP?H'>U/B-9T4LX\%(E#
M=;BUOV@B)F #:%VGZ #[[EN!O#]?V(B%T5@H4GBF:S/G\0YI9H#ES02Q=&7U
M_H^'=J2SD@69==*_U#]@BR1F^C,RR=X>WH>Z[I4K7QLBW_"\$NUU:]HV._B6
M&2DYJ?(_ZR&\Y\,[XGC=,JZ#RO,V]@B]N*G\EVZ670+%%&77:<=W>W)GX7^N
M?Q?+/PF-10LTF((CA:E(#4 G]W),Y7G_69C2M"=VW3CZ5U^@ %ZK;4WG^,M$
MLW6-4R$<>%1S_VD0<,5(+S#8_VK-V'X1IF[9J,[#TN7\PKX8:\+SX'B=HVO7
M^=\8A\<J\G%?[;$TF;4=O8)..'Q,G#TP1O?B" J[T?>^*2DK#4=56D;E!7DA
M^BE#9%;RIB4L;/8$11BOV%* A;"*).B)O DU-JE3+5%@36) T6D]KJEO<V8V
MFMRX1T\5"(F+#)R8Q\")FQE; NSA+=CYVZ],[+CMD[H8.<!<X&\3QO]7 9IC
MO_=LACB%$[:*W G:V-@Z-<7Y:5$(SJJX#2TZ!#STJ[L/">;R6>!LFI>PP8.)
MX;"W*:_',;"W=1SXV3AY'SH@HNJ%:DBY.!V0'.4H=O"MVO:T9(;.^<>KH\T4
M7RJ2HDS(@U:B]6^[\[;5W3EL$B)H('=^_>Q69A(6F!?;OJ1T,>WAKBV-2QKS
M6)K0X@B>MKR=@Y* 0[\6',029BX\!F=T./Q,$[ILOE$9W&\QW)AEW.L3H^<N
ME5-QI*N^S[T .DF#D&+!W'$O0!4:R#-Q\\Y<-WC?AU397GSEDS%1(]"GX4RZ
MN QX6'A$#:RAH+F2QHF^26NKQ8_%&W-XRZ'HKHG<."CXA]=$.M!-<V-C^,$'
M^^KHI-62606?81;QS)K8N?],38=_/':ADV)$OV'XC=5OL^8S.4F5]J^E/+*-
MC$S$-*P_+O,M<*1Q!BBC]#(;*.,2S4[FI^<([Y;RI,87AJ?E]_7Y'F1!.7YO
MCO6)H O_#A,4&5\8X+I5(76>[0 R*1-H!]5:KP?A!<EF@XCRZHW-7 KGL&-3
M4Z/>M.O^'S8V6MDB=\^$U.SVR76)\5WTDK%)_QO1&Y@P9D; :YQ]GE8;;I2N
MB:^M./2<$$G<S)F>:'_=[?51-V-(T;/_LZ$F]T%G]O\/Y'"X+XR.%L=4)%=7
MRV#8Q&TM<KP*(T_J<08 SNSO^K=[DB3Z-[+F$)R*&.3KR=Q2 JQ#3)+W-9QG
MU;WHA_G373W0UEDF3,AB,C(YLK5)$O@F9JU+>QR5AWB_LCBAY9(ZXM5BF*A5
M75:GUY Q:.N>'2II?=#6'X5@;6(+<(6>IUB1PC-);GI1JJC]7EU5YX@.OY?"
M[+TK62)$[EVQ*<A<,:@2PG-#@XN:1I%Z2@=(E50%O&Q#\6V=?30IB'H<<38C
M.W(%SH]H$8<X;)\)2(*\I0,$$-5PZ8#FA^BW-/&UXH)-Y;Z?FZEG+S,=F&1Q
M P"C7?L-IHB#((/97HAO2'(;S24H8YQX!9KL]FF>*YE"_N):MN==E]WX6"4&
M<34B']%BG(S;W)OAI[Y .WJ>I]C56[!IM[FY^B" -^?FMIOJ#>//& R\]&)V
M\\]'8#\@YKX@*I:/H)MN9)CV'/M)N#U>K$7<<DSK#H5S+>&EC-*AA8GL#8-3
MW/M5R+R?+C=D7%),HV^,C1'>SE57O[VL]?RA1/X<0)4E)2Y_I+CD2E9R_,'C
M S'_W03;6[12K!>_@])=(T2_ZH.B@RYQ3:)7'M_UY5A:/^@;>.,]^?K=NN16
M4-B13=4W'9<&G0))V[5GM8L?IPUL-:\%7M(M"38K-=3T&\S2!I[1-32TB2_=
M)?V"J\JVJ9#JR@H4B=F_D#-;K9'BQ08W,R,[". VR!\!"GH!11W\[B^8-&Q&
M<9+(S(0$$DMWT^4W_*D%EJXR-E8ZH1O_SP2>,^I&,O$S7BM'V"H$@M]^JV8H
MKNJ=Y<)YON7WMV9GIMD43XHHK*(_DC2@P;^2(?BZ#HI:<\3="WKU*B1OHJ@M
M!/IAQ ^C_ "QMR;+X'/-N%K>OKO+1XO,>%O;"'2G9]M>7?]X@QD6P7J+B.(*
MB.V$QO$!@_W>,^W]TG)[Q2 G,@1(&UJQ#1Q75Z\U&]2/J5I]^!SA'] C?;1K
MR0_<&,7#;B,WB^>^5[+&/SNP;$#Y](7>?9?8/\ "L\6Q0?'2D2G;#UP@E),I
M!0AMI?"*=BCV-;J-#M!$](*NP4=L989"GA*01F,-D*^=B(>7PB1U<"(EHQ'^
MQY#$'IKO<B41V8F>0&+H )X*/3\\J6JHTD9#-LDH^Y)=0%?_!ZPVDUH8,Y^:
MX'B_&:P,U,DJ97M!8OYF!>M3Q63N@9%',@GKT5M,-"98+\6I.<T""BFVE1>U
M,$U *BA5H<3\BK>5)NHE&XL+=CY2ZOE+99/!BG*-0]N'?'1 N?;+BX2#]B(P
MVYJL3?&KL=VJS&M;EE><DV1O)]GZ)9\Z=8 JI0C@R[&SF)76 -46XHUK)]5(
MV.FK0CLWK&E7:B$34[^#]&F7<AC,-F>K,NC%]9(L(TX19@WK0$:03HA^IW0>
MI8>:H"C/;>\C1*,)(UG[$3K=FV+B8O:9.<-N]>H3VXOFP$+L< 'WC_U=VUN:
MY\Q6M;_^)2XNH(7@RJ0$*($-](?&"4O-?-+N@W#ONW2 0M/K)T]3ZU^&G3QV
MXOZ^B*!@80,2I*&ZGB$X)@5G#>$=QHTVA!9KICH+?)3_"#RYL[##;5980.X4
M%&)RIYPD<7VA<.(IJ]0OUXM1:\.A>6WPRPU+H5IS"TDB"Z^.IQ>D 7Z#%T$A
M7F"2759L1^>G'DN?V4D:A0Y8G0P&5^W9KCTY_.$(YDIYY/"\N2=16[>2=X*V
M %F=MVHL*(8U#(F0N/%R& 13 _C*I[QIO?RUR>A9%\))=&!O7\ZS9Y;:CW28
M1#:MT_X(BM?97,EL>/) DB.F3;<QT-O 8!.][A$AQ3GH'!QP[PJ(Z4T,"\?B
M*]-XV!C5*JBZ:$0\,W)9Y=^_[^@_'0M-LB$\>$@GB 7$2NKKQ?Q)\V.\FE4]
MJ:<[IU-XU[Z>$NH\?W$\(T2%-#P?]W+F>B6)EPRUS>I]-@-[K>;#ZU!2EO7B
M7&>VF?#S6Q#%DKM.!RP84A1^O@7)31'VG4,(K3R%K8Z[15Q^]RQF8C!<?#[?
M[CO*[=BGH1A@P?RCY5OU12$F4^3[GG3 E:@#A[&^(=LK=HFCB8B2.?LO-I*J
M% 5.LAR#[(C&'WP96B,$?S!['N"-8XY%V(<^&\=V=DK9SIOCI7ZU ME(6W9U
M>G_ -XL)%V0&'59?K+X'-;6H*4KG]%;TB#P3=U[0.F%Q]_O%V,S:7<&R$IAX
MEXY!VOZK<8SHD0(Q<S]J-BN4S\-%3R8Z$X=]P&\ Q$51']%^),5;^>J,&&H&
MYN7^9TI1_.-7@/^(DIY9.FU,B), B8$X(7B=:4!2.0YRPI4)<U VM3[#G32C
M^MW"?4&">_G-?>2-,PLL<_F3/7WP)PPJXML0.!\700?@M9!A,Q!2XKR469L*
ML<BE&%JP;KGT171Z^E>>S<BQ0,?$3PM/ +)M&>),#-JW&T<\0Q"-H_!(SB,V
M^0CK\X[U.%9TN"T3*=T7/X45>^.#Y)Q9K:KB6,5W' 0UDT5*>1MK@M^F7S__
MZ:*F271>;WV_QGDZH,510P+>!\/K0B:#VY'\^X,X5"2R#-FF;H7MK:HLS'<B
MG,/M/ZD(U5HT$YA(,=TM?7FQ\OT.:SP 8K:"ZIF=+,*B.X _]6BG%3(1+7?5
MF AF[4'5G>AC*T? *$HPRJU)K"$#=#XJHAA=6=$SY?BN^5JTOUR@C(@;T?,R
M2*Q'0H=Z@21#@&(0@C1@@/&\TTN+OKAY$+NY6XIA@D!,Y70=E.=IA]_=BF-#
M@PSD_[\78+E-_^^*^_+'MC[\F_O5VYX@/X8/"HD.4>[.GJ(P%??D1=W-2K!N
M*G^?52.K$J[G^_0E_RO[]Y\,K()*3"2+**/4]+S-*>+YIVBXVI>#\O19ZP-4
M5TU6>UI]^*[.0^<!WQQFER:'<TB3BL3)];*F9+401^\[IZTF\FL5T.^/3#5#
M1LF"-,;]1M7NHD]10DOT\EEKLA/N-#6\SZ[AO)P<[.>=</F#V7N+6+/'U\UE
M)4(E8<&86AI3Q+.:Q]^2%_WUU7%CJX<TUQ][7C\C PHELF_8,<)RC<??BV3_
MW^'H/XSMOQO!R7ZPX[VJ*JQK4CB>7S <]2$C0M2/RJG"+[F0?H?&DH;F]<S%
MCV^PD^4".N?9)[\_TA"V,LXB!3$S,X?N3T:_>^;W2N"YJE7C'3J +8L..,%*
MS8,,(=Q@DT<0@+/<KM@+C=.WQ\ID07/))FE\$9W=W5_>EWG=+ %N2OC:?!OT
M51MGI.,7JN"Z[>]'#JT?TRXO];IB6-!)[G5HDL357HU?:QPTP@:L K(Y3!:C
M]7!40/AI"BM'CEDO%IUO[*06:SV"KUB9,_5T-;.9@-7>VZK2 >P1Y$#X,&@%
M78K><!=[M:=#BNID $Y'MU/=R$,7GM33<M]/'2;NF!#>R47NHR;FB2>H\1"'
M+EXCTAT\3*]J[+248H2"J-NT@9E:N4!!S_><.)&KIOVN1 G;3NDV!$]FV"8[
MK$\?;@C]@9@4E$M:?8E1V:4%;0WNFSRD _;J$J!?H>\W$7/)*;,=]1_WMTGB
MS)N&.#H@<LB3$W3:W, '>J9MXCNLS/+=$/<<\_6<YX?A"GMQK:BPV5--)P/<
M0T!X3VQN!#9&YFFJ/I=^[+1U'"[T.:_G@R<)&?H^>P_VI,VMY6N_@(+KQZ!C
M!ML$M5^=;^6BQU)RWA924R8Y=,^-YRB)MP3E_Q+/]K\[T"5\PI3OF@& ^SL)
M.3_;,GN*1]\3QY,F8LO/:M%P>&SO*@\..&+</O]-B04^S/U ?G[&R! 6[(Q?
M-DH7#:QH-&B*W(62G-4?MT'$,-"P&=$Q.5K)V@YW:14B.][IT)"(F$2V(]8K
M&;G!X.3JPI_CXSK[T^1R6^VCGK#B7,YTW=FYEPQ>W[S8 Z4#Q*2/II5#3O<,
MNAS4@QE0<5G-D!",1;Q4!$<T^.=:?D<&,?D4@ZEDZ^I5:S1%+LQME@$6(S.N
M$$YN[R?EDC?&BNF )YFKA^/:6$08^C2%K[)!>8Y=]C375A^QU4*;PKXS6PRR
MP%F;X?-O1VX;>3QCW/AB+6(GWQNW7&$2:C/["_UC&8+-\>GU/T"P:P@&)+?9
M4WM2W>5;GL#+>F+0B:!)2"4XD@Z8[\<T">"SV4=F;10VN^,\P1P)^RB]U:'?
M==/7M,DS-SR[4V*4J+1]:-WG8)9RTAHD,?D0W<:PU'VX.(&WGR VG_QV7WH6
M/G[/_ENUYZ/WR\($[G(L:F)[KO_5+_V<$(UO@2_Z)\'O?G75DZ=RKMTZ>E0O
M(6DIJ/A^(+\P^(0RJE)U))EV0O$J7%3[='@46FK6OX@\W=%^[K[6MQ;^3/'6
MS.L H>?&^9F-;?$/M&_^N^HHS)(H"-)N 4F"UH^%M(9>5W?KG-SAR%F=^.$G
MXZ.8+$:Z;'N7>9MC-269^)QTX(M?LP*'@]CW?,?5 G$ XSN#'Q;M;&_5U0AO
MW?XH)B90]?X=$X?3''.S'NS5#=Z,2X0KWR:7HWV7N4C);?Y,X*=B, DUZG>S
MS/S.FUY*3"O2YFH:3.R"<!5%*,EG=LIM4Z\P-X/J2/U)S6WR%XAN6SK_R8%T
M^EDE13=J0XSX>'#$S>.=[5Y3]P<D@,;D@CSI$URTJ6T2ZM3./X)V)H#?;KUQ
M;/RX^P)9S[EG(GALV_:%)O?"8YF/T? KINL]*4;3-!VI>+T_DR*<*]33A(#L
MSS':P-MJI;$]N^Y;4T%5^YYF^8::W#]\_J7YCG^OCO(QO39;P8$0FR_3 4YM
M1_=XCT(WKDC6ZWW$9.<'A0$/F5/PSDN$Z@WU_%-@(7(;Z+18*D>?OWX@UJCS
M^;2EE75&H]GZ"[&!T0NCQ97[%4EF581>ML$/*7SW9>O>AV4+G1(.8P^J]7/&
M/TUD&21^<"+<8KC94Y/ZJ23>-D:I"IGPR4%/0'P\"^QD"V(;:RJ-)]\/?40U
M-M+)]U'WUB+<B'/' 8&N[VQ_SMPNFYR>TA52OA_]YH$@QX.BY6GO%K@2-=8W
M"BD4<FEHJQ(=;B8G3[N$M[]GZRZ8D%Q7UF]RP1*\NBM6&<#:.7.6E(ZU@O*3
M>*W##8<]'T^?:),Z+&+J_J;&K701K_G@<>)7!84(C-[D_82RI%[(8@I9%N:3
M5.K.E;2$XC+%/I4A^N)*YH-ST1G S5M40I#.%<9 Y5X0:OZ/*D__)WGQ'SSY
M@^),!\2KXOK)/ P,O9>^/A]'NN%/NQ^(!]%:ZL9I2%]^LC CP&/,FZ1#U$9H
M M.D?JN!8M]@"RE/5(BZFHR-/*>PR/NO\>UBR;7F,=U,L87=@27,1!#U;1,/
MH@72='H"WH?\(P2*"VS@S:X(OSVHIEG0&5#GE*I6_N-2<K>%7T.Y*K>_%W":
M->$=,)J!C2:0IUU!QVF<\"%TV7+T)3<$5P"0F$\0#$K_^O(,<7?R)S5EF3D^
M_NOU[]-\)AQIX\TP!BYT K]%5P IG <T%G>R3@"77DW=D-HMLO&TFX80QR7A
M^\/R-O9=_GX?R8-?>665[3K<TWR-XZ9F&3#VFU/KK!#%9EQ#E:38V21/"L2A
M>5:JCK1C]CW#ZW[Y@7&JXDRL/G6<FN*<;26K%T8N2WX<[/[:<I.I@:1#5J-P
M,1@:]!XU#7Z.HC"T%\>TRF_E,F8K$ N4G=WHK_^A<SPUNN/VUI#\ZQ0M?Z=K
MYO''"% *#V*>^;4OFJ3HW8G@DA?(KOE&"&]M/";/X;F;FE4 M;M0U\%\W:K?
M"+#9[WJ$(;*0#''0YXPG[6^)>T&3>9TURJ#369@ZH2*!#*.E8?WJ,%.*T UN
M3( D[?1CLCQ)(404&^&+X%VW/4$*+BXIQ1]@WZ!14>G,F.K\'P-Z;+;F*4^/
M^4EK^LH3K"BY(M&9W$>ZSUFZ"*/(:$^*,,()3P>85PSO%UP4-FALJI;%L'TZ
M[W3KX(U<NYOA32%>.N 4D'*.BQ;%0#80_(<$1N[_"B6)Q<3%\<YY9)>O5TE=
M).06BMJY>@V=_K;@W2Q5\^(G!TQ[_%]8BS"N\7_"$O5_?E;C$O5K!>SL*DC(
M]Q/ECF!PY2EW#_<K40!]X,20U,^-.^V7YW9WG+YP+RL<H-NWPS*82:.9=[))
M=9,F*8,]/UUO/.'$_:Q2?/WHE$0SH+NYH#7-P]0!'P,EGD8/ESS9A& ];R]M
MK>32 23M4Z<:@T+S$F+ECOQ02UMR^.JW3Y6I3VRMN(W2790IAE%1"0VH'Z.C
M4Y6HO#N+NVRI',:<:T;E1N/#M3@A;KQG&TQ@C0Z80+.%0$+SUVX,J(^4KJ:,
M$T/;O*YS9"@?7'W04S@G^.V9BF.USS9P53&E!C\>AW"=C4*>J:P2=@B/5K,H
MGM)J>_KAH^U'W>"J8WNH,OA9RCD\I,6&TUVL]<90P[B'$!U@V/#P@%?4^YL<
M &!Z_+7I,2WS>6^Y&P<1(5>Q<7RKT"^D>DR52LX']+J4 JM)RHW?8I.7T19S
M'DQ82O)%\WNX#\N61L\2=4T+AS]8Z3S+SND2/5?7?F/JH-C-9[!YN39$^-I)
M69-9\^!?,0<'HJ?%W"2GBWGK&VGWDQDAI$!!X-R(&BL9'O!K2E_(?4N8$)(@
M7*#<73'0!QR_4J8 F0#36#PSBT LM.D9\4_AXA[&.G5\1WJ/A;2KN3?]Z8!2
M__ &N> KM63U$.UQ&@BFZND6*KOR:W6G^FM2.6?QWO%CJ_?I@-9.*JJ)(P3)
M2>,R)^WJQFV[:9Q.[FXTW0_6@8PI5@0PC365V0HN?BQ^]K6O$-$E4<)%!W3'
M>L$?I'J6K@S/:USJJ>@<CM?;S#=NN[/<:V#*BY2_5E>^G$?29%"&@D%13T7B
M:%W2+T3A'7PUYN ><[U(I,Y1Y!L<F<9Z^G/U-AW@;%_'%'^ /IYILM?B+*K$
M5!SJ@%\F5I(X"-</R$!]0HI+2HU[_$H01:M[$T1.%6WV(]X>757 S2M)JO=(
MD%4^;OPI.IF#7/CBNQ1Z!ACS]--KL$MX!O_7X*\WN"E(4?'ZHS4X@M'/#3H@
M+&^EP152 6T]U\DW3KNP1CSL1+V+B3[H-!C]8D?68KRDIN>9W EN1*,FZ%$
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M1='D:'VW)Y=4JW<;H'/FPE=/?H9$NODN:"L)8I_6?Q-;]/R\@KIS_4?1XJA
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MF[8JP5_C1;MFV6.7X(WT4]?0ZO1G*+>-^/1@VH([I45F_G6/8P&$W WA9;O
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ML@A9^/ ZW<2+!=KER8A:H-YB9)1'R0%"A)M]T.#<"^RO!3.POK2SB#UUNO6
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M+K;5F6CKK>OK<++P4LRGU>\B_)$-2U)1(7'C@!SM')V74= JQ"8!RM1@ $O
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MRO%\U?4*1QDGVT<&G\/)0[?V&0B"13XAYV"4QZUFY"+JN08&$7&!,JY7%/=
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MF_-I*?IHJBM<".]Q?2&L46"P')@FGTA*JN/8/;6(E04@A*"(>O48E&#K_0(
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M7AMVZ YC0(]M,0+3)G"4JX6 $=6U^;S"ZV-#Z[&-NK,?DLZM7$C6LQK#UK%
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ME=(&VX?6?+DLK& -K<.*3GN<$R-L;J3Q7IU_G._'6_9?W,#BW\>_C___'25
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M&S@ATLPOOP9D.B;FH.,ZZT7U;Z/Z#<-<U@S+W_$*I?0K/Q#:) *W23&DGUH
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MRY>,!6S=N4;$36'IWM"OKP_/J)HE/]=3P@ER.A%UG 1N:3^<()(+)S@':0I
MB"> D(F"QU);6IG(UM3PH=F*G?RK7[>DK3\I2-VAH >S[X/H6$#=Y.$:1@3;
M?@)[.PC0,(EA.5&= 2>R@T>'S)S ETISITCU*3#C\V.+[E671J1>4YQ](N/I
M(WW)_0K!VFA?A@B[G'.(TX6GV>"F<QG)0^8.Y2A\%TQD%^2W"U*81"$<Z;<K
M+$OO'$JWT/W8MYCU;<YNW!@UVUBM+59S_S"AF_V$>(TX-<C <H,6S1F"-.PD
MU>,2<O*J>G,]);GM%.K]!G'ZM^'4F=BLAA1&=KUJZ"/C0T$Z0@O-9<C-Z5QV
M$K>.,KPL@6M,/<P74@W_6B05+@B4=2 @+>%4J.2R"48B8WEN$9[MFB[[K>%T
MOG[QQ[_*'P^^/]CV4?G%GJQ:;NX5CF#]2%^YZ*G1-?@07_>YG@Q/:RA] =3,
M,Z+3?$:WT^ZZ/O1YG[Z4UH7PJV_:^COE9E!MSRM#-U;]I!L!6A/3#J&%A$?=
M@_+-7O%O1G -NNGIZCIQ+U>A3_PSTU&^L)31&V62-2(IM#\WW'B?70GL1A!P
M&,*2*B CHLIAU[FTC.:X"^(/A-7V) B.W HR) H,0E+7?ZJ$I:FMB<XY/+D)
MG?GUX6;.L3ZWYT(]?<LPKBQC2>PP"NC9:]VT*HZ0&%,(?8ZV+V$>M@<XS^PP
M74S J"V%WUTRS4\)T7AFK'#XLG>6AJ_/A;CK3MHOSS;Q/^?TA)DH<T,4\Q ;
M"(ZW%"3D=YY*H"#B0D7,3C(O511/SETY7:%=[;$^*;WSZYG*E0SXQ<#ON$G\
M/*DM4J&'P,M.A)'+B,)H>YH!HVR(H^%OVEW<DW==T[V?ZCGPNE%D4KBLYZ.N
MSOICD<;)[X?'87K2%N5)XI&Y3#-LN\$N*)#$!<:+\&1((QS'59@XP<!QK(0Y
M_VL_]\_9D)B;R?=?-S[DB4!F"^2@]3[(J5J;I ]Y?WI<>-@JAA[($7S*O(Z9
MY"([%RJOPJ?_\&/A^@JMSISX!.-2>LRI)J(IN\OT7C7LMU'L>(>91]]\XG0?
M2O?KK9R;TKN@OT[P_!9$*&/;VQ";\;@I,*?+9!<TG!BX:OIKD"/TDJG-NL5N
M@GF#Y3 ?B/OJ2<(_TN8'H$R8,QV2=+,I:!4X/62++D-Y6X:8%E2ZVW;<N?.K
M#?1GU35G[$<H]N8&4R4?O L:.52$AM&T& @@DNG*+6@4-F@7E "1#<6)V5,.
MCUC*Y7EWFFIP&6M3??2<X@79=_D#U":_$5'TTZ?>=W\]1EQ',A<9_( >'<NX
MQ<ZPA' &\+(;YL>QD;2M]F9$?(51E<C,Y^NC%:M(M8;T\&2_)VW?KE\I\><Y
MKI*ZIJS)A'(ZL?78-AQP9&*-CQD*9%\&(MZXL4)KAM0L96M&-UYF6T="X,99
M,6LB 1W!*D*'+-V1,Y>MD)M?>:D;D^%<).0B]5X6]ZYL,;.=;?E_C1D5,(^A
ML71$#$%L!DC?WA:LRY5NKJVKMO9/D;LH>/O<M(=*1ANKQ;42,\3EP[#I!"J\
M<R.!)+$+NK8&H01U8E,XDN/:1A'8U!V8LA'[XE878^ZRR8%E(OT@?.U(Y=W4
M#A<?$-*QY"S^S#]+5C_RLAS"R&'&8"!L($D<!>]2%F$7MT16 N\=+<5SEA5:
M15<N^AP6Z*)+/3GMK)Y^_218Z+OQ_K M2 V.):'!$=H%T1(Z7&#5^!XLH F.
M19]A6OI+SY^+7CE/2ZT&>IA6%][ZP_RQLY,]0YB%3U6&0SUGNWZ<T@<%(^J*
M5]=)<C R-8^7@:&[]D 2P[Q$Z56K127+<W_1OC^G@R\=&-!:WCQI:'Q7KG-I
M"/8TZ!T2_:A?T/.%_>&-DT V4XZUC_V$<)0SN L"H1%T4C?D $<!L&IOGL.3
M-R;?7V[([G+O33-*NGVNT^G=Q:7]#,;CLT-)4#$D$H1;Q(79% ']##%V:6@0
MH$6*Y_JB@*- U^A<P>Y'A5!B"3R(?8,6/]XWCQ2V9/V8_;7"GRW9/JMWP-JS
M>HVT%>2^"ZK78$FL,(AC1'+Q/].!,CD]"&6T\*OE8#0TD[(+2C4_SOVZB9RX
M7/^;OZI<J&-(W[A/'2ZGO+=4^?L@EDIQ(/02-_IMF3U>6MST?8#Y9-I0,5_%
M#WBW(<2V><D(D6G4'"H4O*_;$J_3^[4B2/NV6[OB757][OT#0GEMMUV0<W"F
MY)^MDLNYQK\@T4["]W"^Y,/8A01-2/)O;(S1 )Q"3-0QOQ^!#*(PIR//<FP9
MT[TJ=E/^!;-&72_7P<]C,XS2C>"56%\BH %>TV,JH,^PWW",@7E&_I#Y90HT
M97S'2S6C!RHDC'1!GKG7]PIK>B9XK_3RYV_7DXW#)@7]LV\E05.Y)H M(9@Y
MK#C7CEB$*$>(!:7;=.9!.[F!_-SH4P1P.-^93$2G<:-\WJH3W\C%?3&.><+G
MAL[>7GMR.]$<7IT:I5BURN8V535V,?$68E*& 0).4@-3D#9>[!>WT=<@N.)1
MUN60%V#Q=HK;^D'I$<24QQ5[@9;'5W.N*5[&]Z,$W;X_^*U!YN9D.*/YSW1]
M/MD&@$1&"*$UN:Z%H:K:PTU-N@>C?\MT*3E=KAVK0I<.$ K\?8(+/=RG^XFK
M0Q\D7_AE.6T9/)HBUB^R#LQ3-KJA7XO)NZ#51>9AM-LH1AH8880U-Q(!D_D?
M5.;IAO#')5MIPY4DO=N>IVMJ'C+;% */^.%;V5QF>A,!:!Y%39P%\KAV&++?
MM$C-:PT*JA-IB:A "CX>#W_+O/'6+NAP:83AFXPK5^Z+#XB?2E(42UI 5D[O
MO_IGJYJ]!VGI:70SQFUV)4:$9<OT(E):#1CM])ZXUTO-XR^-OM2-5+P8.=/:
M E?+3KL^)814*1!IBQE AWA3IL$X&,V'#F33<U8<Z<:ME!^AD59V8T9Y+M3[
MUYN5=7/XGJ? -N2NWSP#?>^GKJNUL3$YP1%L9(9C^O!UL)X\&;+)FA:75IT'
M#M&+J6%%\],, FU@K#?YIX6-XR6F3VNFC/0UC_XS=J\O-^QUV71;,-%BFF+;
MQ3''46H<@?M4'*#NVX.?@G5,C 2:.LRXB[ZC#.Z_4OC HFMGH^1ICEVE021D
MRO97K,OJ@<?UZ2*@NR3:I<'):<IB&PDPB>GQ.@0H8*G8?:1)0.+T>/=@? OR
MC;M"2FDN/#[(XB)9IPLN=N.O#_)Z[^\XMOVU^N<E&8YP9(R@@6GG(A$<!IP+
M50)WPA0-(V9MJ/N*7@?HNWL&&)OJ/A19>'!QQKI?U2;\#KVP6\ZSP$IY]6Q[
M<]64Q)_7./?_V>;DK)(O@P\HH$]3*@93S.U?^3<?FDBLFQ7='#PW?$L[?_+I
MJ]CG-]^_RUU=Z%/KVQ]P0T&51R ,,PVAV04E[X(:X*M%-.]S(P0C?Z(HP1(-
MRA_>H4QTP<#JC6%ZL^W[]6QKSAQ52]2U'!2NN<9J2#NY]4C_ \\25H!(SF$@
M:A/6UH*9%SB?2;(^-$1G9$A;C#4=VC:K=5:K,$"^^:R7CA>,)+#V7>R:K(WH
M]Z]VV+QN3!CZ(+!%L^G :'&MOU8%:/-W0L30TNRB:>KI!_D)3*OE ^?ND2!V
MTG6-=Q*W_;Y":NP/>#CY:QH_MG:V>4*YCOOIRCC^SS#>%V54)C@%2[N(G;)O
M]](91YL%:BN+TZHZH:+]UPHF!X_*%HVNJS=9AHY-GQH4 E5WBSM82J6^@\O\
M>;^XMYM=2PS$?Q7^(VB0F"EE'<"5*B+:_C.QB@-=RD08-S=D2721IY>VIG[Y
MHVE=R*F?L^3RFN,/&PUO\/X\F@QLS!.XY)!/$+C/_;0!K()H$_.#<5"" .K-
M1P<-#\#ZMSRA2C;^\V9@1?#Z)^O3\3(>LC'/3\GIJB7V>#G?_+US*=,IX5Q3
M]IFZ:"K]:H@_WUBGE61&G)GSPJ6[R>=YKJ:>4(^[=34*<QW;KKZ6L<41CN->
M1Z'VZ8)SMB?MKL$9+;4H)+3'^4ET\9=H@;4K6)9$(T,7P#*=,1-_YC2WX:8@
MU*"N04D W$F4+5]=-=?!TLW<]MP(O.P.J_/2^=#ZSNW26KJFAAZXY<-Z=4TD
MF"F*;3?CRDOXI"M'B)>^Q1BDXU(Q"BO-X;VSUAV+3K3O>2'8(.-$[=C^VZIY
MY- F]LRGJG=J,VU_:>Z<WUC58HIBQK$U-FM*S#-H-/U\-6VK2XQUC_X E3%H
M^W8,6G$^)5CR;J]2[<?Q*D;LD1_RCH\?.;ZU>A\0A=:B\7.$>)BG.!^(M"!P
M5ROV%%!5,@MDMY$4MV%QG'WT[,2;3,\>W-7?Y=+T6=O-Q4^!?AK/>HE'BU2O
MW'*LW\%U0P%U1.PK.A?3N1T,7Y/=*^)-\4WF]M6:J5U0CZ7F2>/B2#JO+<^9
M[_BR 9T.H^G/!R!UYV\>L9<Z;VU>R_CSEN<@ZAV1G ^3)Y+S$ U@G+E!A1]"
MBA5<"M3T=\V)>"16WHM@EI+?I0KH2HBJ-#7:\=Z/>9"I<&1O]0_8C7\&:8U1
M\M0Z2=R<6.MDH@"U[EV0H+GB>/5T-P4F! <GHCW\ SXBR[?MWWVPK?C\H:M?
MON]0AYJ->J&=VE_\I$NNJ3](7&J(3,%.U[H"F15H-&V!RQ 6:9(N#TPZG[',
M4TJG ZGW?%LC6G-S# Z$3G^7^M6V^:3JV=S _S'T$J(3R 4$5\0DOC-G;2.A
MJH6'[K#X]GW&G&\C$/R 7EL@=<AMO_["'9L+SC *G52SR)883($ 2"@6R/G=
MD;PUJ_CQMPN.P[,+FH; %3OC))UI4M!=$(*;4)J6<"Y%[>4J\)]P2VTLI:Z5
MJV$#/\)N(P!M:,>:%<../I=&\^"6\L]!B0#3@]4C1DJN[3)ACNZ_UA_U'<QK
M$]/O67=NWA!.#T:\V/[ B@ ,*+ I"+DWB5LP% 03VO7;?%Q&__0^(+RJ_ZAO
MV@^F9TC/)9=C?^OZ.X&/6=>\=T!++Y%RX4Y?/M:FBW1\?Z+EW';I6RIU=D53
M2_/P!N3&N[JET,A*W+>&9 9IBLD1W&&>X_0H'VNED;K!"1-;2V+G.\_1;^;=
MW/2?BKW\R],'%'M=[]E,@M.H]UY\#9@EL<%XSJYE!?M0B-PZ U>1AP_E61=3
M!ZP'YD?J@-HML[,G1-M\Q5[J]K[HL64%+1\;+&<C)@F1%4CX!G@[197SD3/R
M^Y-E5>#6EJ['@YW-N=_NB\N^JT;<FHT#/(LY?99[APB&@#?5LIB*-#LM;9I?
M4(1276<(5QV<DUV0>*'JXC<D;.+YK?9SX!A7:?ZOP1$F:[3C!3F#D'WF!C2K
MMN5=T"1&=HCRMB'#T62@&N./4 P*GUE+U^]I7F;C1.(&-"D401=7.XUU1#$&
M&0DGLR:.D6=<_+WJM?G.7S[OX%Z37)L9,,2 9Y_/#IM:_07C0)28NM@A<Z!Z
M%Q0_O+,+2BKXUS]5E1^I8,?[[()@!;N@*"RCEY^1((C]P@=G'4&P"DM?!!H3
MU+Z4MUAY*_;QL0O##Q1UG5&_%+J?5_.;!_^C!_+ RCQQM9?FS?C K;:'Z.OL
MG%V0'UB@NP)PZD;4;,2N&6F9M-V#T1ZAT@KR-=KU!A3B,H[S'_U1>*^J3FL1
M*LP29)<;DH CUJU,MT PC078> *118 51VP%Z?)S6?KM9(#,1&#DHM';],L*
M:YNE,0%'IO"MY*P-UX;B3W;%&DC< (R7,X*0X[:.+)*0I3&V781(?D& 9E\8
M+@9,J$E8[JTE_\;U@1/K\*O]CY5Q6IFQ3;C8='T[EWV@L[F>NZ * C^ (Y-B
MB-7C:?1 ZN%ZY=P7* 2EHJ&B8EDB<CK0/M+B9H[5:DDJ5F@+#&AQTXJ?3&1)
M^3(NCNZ"?#>2JKN+5\+>;Z"%J0N-8,N8TKB#AY3F9"B'4H[=,[\VIN2'F=P%
MU<#7G.G3C  :=+6=%M.CS/OV2]U*!0]'=1?4<:XQ ]MQTKL8'F38?.FZI/(E
MF<,S7 3)TC-[/?@LYSH,1@PDQ5NJLFM@Y$S\@37S"\PCK.!:@#Z/E>NG!SJ,
MJ0(>)5+#VQ\2Y4-3PP^B; V?O1@Y'466\N=W9RMSHW(.,_T[B"4)XY8/;9I1
ME+XL/;:=)H)$>^QU@_B.(Y.BM\-P316&2%7>79#V0NI/U5:&(.OBG(Q];AX4
M[NGW=5^$.C&L7L9#WUM"-N;9#OW[_9,-6[4P'317U._-Y5X@ /,507/82,%+
MO1K#:*!-QS"2K OTM9WDM1:Q5U:1>PD2[YO"S;3G3FL:>B$>"VO%JGOTM)7N
M+^?A<MHZ$Y;8/*.'_=12?P5/NX  3'88F;4C'KT2V"!4 3F_/EQQ3HE^/-=
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M1%F<Y8PZG>2?[&UJ+-%(J!T.-R*"1UUNM[XOEZN[>S#7^4U L="1T:<JK_4
MWHX^O,$Y,(6LY01J80,MK%U1_=&(%2*>J.1T7Z/2B97:SRG%[J6>N3<>'N?+
M)R$^B_)KP<3A@XX/R\574>FS"GVD47U9ZHN SN]OEE7]85G_AZAU'/G=0AM(
MVY::EXS[W9=[LFA/1&:<"\8DQ<J424.(11I $N8!%(0I*A-ARKA3-?87TV1J
M=*B-U+7L@'7/9YG2SC%QQXM]'G;$^J<8]!&/XS>G[-NCR2NPT7]]^/[F.YNO
MN+8/&VW4[E9!H)ZKP9.HP18%M4LV >$><XB\](#YRCKR8GJ,FZ?DI8=K+[/)
MBPO4\W:[)K69CA_E^@J]VB:N0DE PSR!>6[\_F0(*<8<9E'"64B0H-0I6OY4
M9U-;K3:RZHWKQCNDLG$)<0?:\FK7$WQ#\WY_Y-QO22T@\76C>:JK<6\?+93>
MNRFT><>-0K@H9F],X8YKSM4'5)D^/I:W:@^@][2S-&4R3U ">8P)Q"AEBCFB
M'*91D/($88[MDFV<ZVAJU-'("EIAKX 15T$*U@+;,<=9?$^SAD_4!F:,_H!9
M$X8M&@?(HA+LY[OEUU]4$PU/J+]LZ>%LPZ-0@ZUZ:UJP?G[D(@^M4?-Q55<U
M6>BMP#-WA$]"^R&KG^ND<9J\5F3^190/:":QVIMSE,$0)X&.=29J!Z\/'9.$
M\T!R@8/$V6UN7!VF1F2OB/HG$X#4;94FOL[*^6A<148J%7'!1V%I6$U[J$?<
MI_<L,['QFNL@<<!7;H,&Z, !-!X3J$-Q^5B^=)6*"S3X<]2PN'R(O%6X\"!*
MS^!NW?L7]>[U]Z*:L9 &B!,$@R!.E8DM$<Q"A"#C-,DPE1D73H?5.ZU/;3EJ
MBMEHZ=1>4LGGN /?1<YN9>B-Q\"<;0^%>^SN(95]!>CNM#UN%.XAM?9";0\^
MU&^B-EF-[W2N!T44!6\S&^O6V_!.%J*<!'D$:4 QQ&D@8,;5-)898DF:QB%+
MG";OV1ZG-J&W H,=B=L/NU=,[7G8[6:^5S '9H,+<72F"&ML/-'&^?Y&I1)K
M]9_3B_V+/3WU1*T/]\PFG@O^ZNDW9;6\6VQ<?JYU[O4FST7*)4IX'$(D: :Q
MVALK%F(4TI2D*<<<JX]N5NL+"CONL>_:B80V @SHGB;J)IIV59FJQ&"Y\5(C
M&Z$=O?KLQ\&.C(9!=V!6TL":X_^UV'H3^>-O#<H_=9P!K\_#[.X.Z(R8+_]
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MQT.P;U!W#[,_#K@=-?N"<6!^WOU:6T$W"5$\EA:VP<-?&/WQKL:.GS^K]('
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MR5X=4-:I+25=23L7-+VLW2&'V/+T>QH#-_21>K\Q<S]J'QY-7^?W THZ[J7
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MS;E@>1;E,(I)!G%.4D@B3F"&:9R'$65Y&#@Y1>QU,;7YK"74?JN-C(X.$/L
M6KHX7 3+T$X,.X@,D'WQN/:^G!#V.QC7S>"H@GN.!,>?O" 9V2O"_A!\&\30
M?ILL",,H0"$,U*(,,4_T6JT=H+!,\S"3C 5.]_HG^IK:+#>B0FID!=5&V!X9
MS(Y@:WDPZ >QH4\&#5B-F#N!6=Z9P (/GZG1CO0T?KZTTRH?3*)VYI5+LJ>\
M7U95$R"ESR!7Q>*N]6Q:+JI70BY+L2EDK".JZI*H/HH%*9_>U>*A^J 45V\J
M$%1/=^L3CAD/8T(022##'$$<I8IH4"I@%%#$:4S5[P*7"]4!99W:#:Q6$E"C
M#2B:G"0U^=XG9\LP0VM[[CF) 1O\_-2,SX]:SY^:XE1;5<%6U_5X;FNVZY.3
M7?7 6C_?B68&'02OB6J&D?0%$MT,"OGA1#G#=MG3=;5>LC_NEW/U1O7FOU9%
M_;2Y2TV)R'D0$1@S2=0"02DDRBB%02!YG.8HP-*I8/WQKJ9FC78E_1<@C*Q_
M<73_/(ZK'3O[06M@<MT%JA$37-=U6=!5;0Z<ZB6X)653J]7_W?5YD'SY+1[O
M:%P?P[,*[_D#GG^C;^U6\4@*WMZ472_XQ_I>E$T>F/5%2Z)3_#,40QH* ;$,
M.,P2'$(AHRA.98)1[E08T*+/J7%)*_+Z:KO)H;748@/62 Q(CVS=-NC;$8UG
M3 =FG#6<K;@&32-PFZ)L@,LN!X"\U1T]W^/(Y4>M(=BO0FK_:L\;=BF%]MW;
M6D^?2"T^":U;,2^,??56&5?%W6+GB=>%>E'W7Y#YC.$4TRR@,&"20IRH?3')
M$P0CGN4H25(A2#);B#M];??%X2[>@VQ6LR]O9M^>A -NK![4+VI]$"T;!<!R
M8\TZ7MC[&$#+._VQQF.D:_^U.IUM*]#R@EV5KD"KU-YS7<6N=# +\^LHX!%O
M7[X$/D0:U]W (XA['@D^V^YY)?*P+.OB'VWBIXT_MKY U0D%=:YZDYED%B99
M*O,L@#Q3NU*<IQG,*1602Y0':8+2G+EY3UMV/#63LBNWYE_M+ EX*ZVQB+A0
M@Z/S+FR"01QO4FR'Q/):90"@A[YC>8:Q*5CQKJI62G1A_"<:2WXCN\=+%T>T
M?-W V'8[[G6,(QA[=S.N[_NI?[%--";22$:4,A@Q&BG2RI1AF:013$08IA%#
M69CRV5=1TF7?$AB],HYU>QQN%NG\KJR=)_.5]DO4457F^D3'5=\L'Q[4]#):
M7%83PS6QFQ<,AS;N#E3%&"0;VUDP!BJ,\4)YU,ZJ>ZXTAJ]<Q:_;55J95!U/
M4+,_GL4XHEG.,BC"C"O:B!@D,LH@I:GZ!T)4(+3>C]K1QHG>>NPP!R8.(Y9K
MP:SC:-J1PJ4(C54ZJ[7M]!YNQ\W[-&@]ZF>=A<-;$:WC/8U<2>NLROOEM,Z_
MXD8/55G/?B7_N2QO5E6M=EQEDYJ:A3*.LCR!',7:DSMAD+(HAU29$T&"]?]9
M>8<=;GYJ>YRU<$X9PH\@=WKV7X['P!/>%@KK"7Y:XU-S6KW9F<_J7]NY?*31
M4:;O:876,_;,4Y<FCSZ<5,-<O[69-72AA"8;A]I'/C0_>Y:6.(T1CW4A+(20
MFN2<!C"GF8"Y2$D69@E*9=0OG;0/\:9&$MV\QITB)^I?K4I]$TI[&4O+>_X7
M&Z&A?0,Z@W,BJY+1;YM;::,BZ.@X4BYJGP/@/3NU%^%>*%^U3V"/9[#VVLNE
MJX%.OK1<Z'1+'^7FX+R]!'W5A+4^HPLADT!*&4+)I-KQZ3\(X1S2.(@I$7'.
MB%-HSP6R3)GG.Q=8:Q^ 'ULE7#/T73!8KMP^Z!",2.1;/<Z-Q4B<W1M8[P3M
M+LD+L7%OR(Y3;_\FQTZX:O[XHGJ]7O!;]9E_4!_^Z^4#*19J@\USQ$@&"4J0
M(N!4<2\-,YC%H114!"$*G/(P#"'DU)C92 JTJ.#W1D+'7$Z#C*0E.[_P^ Q]
M@^DP-",F(3V/W8NG&CTAXI\DH>AYD/VE#;7H:SB_OIM[+=^[1><4MG$MW)KZ
M\_GRF[ZTG^41R7B )62"Q!#3/(4D"3(H(I3(6.94$#F0BY^#F!/U]MONR\E:
M4O].?BZC:7G/^P*#,S77OT8_G:MZY^JH+>G<.7!9:_E"?H ]QF%$ET 7Z2;G
M'=@#VCZ.@GVZZ;<VW,Q)I?8:?R=Z@:H_EI]TBNH/*QUR_5%N@[!O%%GI5*_M
M<U7[8#7#88B0)O\<DP!B*975GPL,)4X9RS#/ ^I4RO=">:9FUC>2ZRT^:UQT
M3 6$"C COTZ$_*W5P-1*:'[K>/QRZ1#:+0 C#LS0UX!:$STDK8QJO@ CY!78
M#E<G&\3-9JS62FW>\.BLZ E?3T1^J32C$K<GZ)X3M:]F+TMW^5F47PLF#F\K
M/NB*8Y4N*:#W#M47G;*A^WOMG?EA6?^'J/7Z<K<H_J&V'*86P=MEV?Y(/Q?.
MN$Q83E@"M3^4+LF>P"S.)8Q"]>^(!.KON$_NS''$GQKM_[8H-P+O9N/4:?2J
M*^VTJ;30 3^@W.IAUH G04K7)6#DC\5RRS#93V#H<_Y#E[3; P"3#*-1>GUW
MJ[7491K5X-=@J^A56Q3'?"<=9?WG'QUWC#PG,QU)^!?)C#KNP!Q+LSJR%/U6
MS+^28E%IEWA1?5R\^:ZSS*^*ZEY/N8_2I#$/**(9"R.(N,X(+U$ 22 "F*-
M9G&8H#APJC%_ML>IK4LF8$"M,V)'UG7HD]N:<QYNQ'".HB"'DJ>)LBD4YA2%
M,919F-(@#6*2QSW."?V@/O[)W[C@VZW17K_@@9=5+>LZ_92"\<T>C'[S^5M#
MXVDU.]_?J N0M?K/UPS[%R^XLJ8G+EC:^Q5ZNBR;OD5_5I#MDWAH:F_KO%(Z
ML<N*S!4Q/(2S $N!111!@M-0+1R"0LI"M45*,4G"F(4H<2JA_ (Z3&TIZJ@
M2&U*G0N=T$6:OS;[HQXWX"-_& X7Y-,=[A&W0\=*ACI6#-5('*@4ND$#=.
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M?B7E'Z(IO+#U]+LRJ\XGI519,'WNK-]S/ [J,6R61T7##L;0QTA'QD$#;G2
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MX6S/+U7XP1:2$X4@K)OHZ^N\J);S@ANG[%OU-_:TO7:A*8H0203$49!!',L
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M*#E<)_M :Z3;Y%ZHN=THGT/CY(7RT9?'NT\^)__.=?+9AWM,W+W<;A^6"UT
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ML7/(C9%Z]IT=5PW?(P.S6.- \$OCPC],ON:VCVHWR@ZI'6G7VO-'<]<AZ8D
M>QHQ*C5>!]0A:5[YM-YT6B4;[,X5=[450Y7$@B44**6HB:AE &.( !4DCC&E
M,4Z==HJ[&IL:->Y2:GJPW'E(K;G,"U##,U:3=M0N43U(J)(-)/ZHYWQ38Q/,
M1:=/T,CE>_KJ'++-+D6[RL3.>1T].>>QH'IYEH(,1YE>MTD&B"0(8*B@"&G(
M.'-2&.ML;6ITT9AG9E*/7:EV/8"UXPQO< U,&J7$Z\[06;"%[NL%Z'H(&%I
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M*Z#GQ[(*YYE'*8.1% J@6""CXY\ HH@) .&*QCA,N)NTVY7V. T7(^C 56H
MO.U/\,NBC(^ZIWGA-DI<VU=V8\&(/3 PXU?@[[FR'Z,V"TS8FA[)M4M&.GM5
M':H.+ #F"6!/A'ZM-:/2MB?H#LG9UV/[UHC2[&](O9Q>M.;H@B!DY >0+"-J
M"06:5#,@5<I)3#EGL5-L[9EVICS#+DTN]_=<*T"=AM2. 3T -3"SU;6;RHW/
M(6>E%Y#P5I?I="LC5U_J=/6XQE+WY?VHX,WS.B_D>JVYB.5%O558F&#^4JU7
M4Y.0E4KXMI[3G"<THE(E("2AGH8IB0%%B0 0(HD)Q"3!3@7C>M@P-0K9V:NG
M7BV#@R?Z:KK+C4SZ=(H=T0P,]< DU%@?M,PWG+3%?L^#5J4Y?_QT!8">N*N/
M!:/RVA40'7+>-8_JJR5.-Y52^8*NUU]4N;5Z]S-?SR%+$8DY!I&*&$ TXH#R
M2()0QD)P2568.K'>V98FQVW&/C,WJC?SC8VNV=MG4;7<+?2!U= G'DXP]1!Q
MO@"!-RWG<^V,+.E\P=UC9>=+-_3.J=;KLG(YME_+B].80H4S@'%HRN8B HC9
MC))<I&&"&9'2B0_.-30U.JCW,[2AKF<.9Z&T(P$?  W, 3MLQJJ+U@V)OV3F
MT\V,G;K<Z>R)1.7NZWON7V^KW"[UQ*2E#;W^I.<J'S4)K><HBB34$P(0TDS/
M%3 W.E%( (J31 D$LQ [U4>S:'-J--$J^[PT,_:VT<$?QNR@M-MQ)F&#ON6N
MLU],A]Y9OAI.]UUC>X!\[0Q;M#CN[J\]!$<[O ZW]LB2_/%&^_/5G-]]72WO
M5_2QCAP260JI";:*LC@VLY(8$$U"0* ,)6D<9ZFR"KOJ:F1J5'/WXXU^E\*@
MM#2H375()CN'93>/^$)H8.+X$;PYPN9R0);#"V>?(^<!K-MDM>6%_G8?ZPT]
MN3)) (:)-\M@_]5[JMSRE8UV :_._+%S]XZ7\77!^KT<K4O77KF74RG#<9::
M<K4",$8X0#!) (EQ"+*8) FC"4UQW&L#9Y(:?%OK>NKM[6/GN$TS->T\>S#Z
M[\L,HH:W__#;[,!T*]N=OJJORC;;[&3Y2RU/N=Y\TRV\5TJ6JIY?Y<H4KJ7W
M<H[2D"=&'5\AE0#$]'R'<"% **B1XTTS29W$\IU:G]KGOC51#U:5X<'*U/>H
M$ZD;$;O7,C)H65B+]O;K&CNZ& SP@=G$V-VJP#(+&M,#8_LLV/7%SGR?0N ]
M4/.F#^[2]LBRX3U@.583[_.0J54!^U>9"/2QJ((W+U=S2BDE49(8(:W(A.:G
M$N HDB!%"4FRC/ P<CO9FHIG4R/IROR)%P)S?7LLIX93L7="X\AXY<#J%T^_
M=Q5*_R?5!.O9_Y,O"^;JU_\AE<%Z=N=XQ<'Z&M@_L5;/.'*Z^$KU6/%Y:30V
M%\]"BG_GFX>W=/UP5PCS'V/W"UT8B^N=.1F)F!&,0:88 8AB!DC$(2"*IBD)
M&<.QDTAF?U.F-@[O/ F>C"ONZ;H]N\1NK!P'Z($'MQ;&I1>S4B^A<23X2WL2
M&!_JW#?]0\N;@3*&KP/58VIQ3T-&ST&^#K!3R<I7/K$?B7YX7A5E.4?]_ _Y
MS[*P8_U%9AF+$JQ7/&DL&$"IR@#+L (8DB2"D$*>.J4EGV]J:B2XM;3\ E5M
MJQL5=@!K1W5^X!J8RO:1:LP<@*,NH^&)@SH:&I5C+CM\R"$6=_3CB*IZ7%TP
M:BN53RB23!J-<8SUOZB4@(@P C$/111E)$F0T];(R5:FQ@RU>741%,>2 Z=Q
MM&.#J]$9F B:THX-0$-4%NC$P-/G?[J-4;_\3C<//_KNBZ\-XS-Y5=OT@<_:
M_+H<8:9$RLQGGX51"E!,"&")TLLIP85@,>%1G,[ULH\MW</XSK3I\JZW6QXC
M[FQ19D:VJB'U#=P[AS=5(DQHG($0(5-,%Z6 F3+8D4!,<1S+*(SZ!4UZ0'N4
M*B_+ M2F!4]U:GA]?K<<KQOLJ-HKN /3=BMVLLIBW9I;2OQQ7U4YG;'Q'C9Y
MKKT;!4U></]\R.2E&ST5\=8_O-5_SC=[\9G?Y%KJ9S_,&94X3&4(*,HX0$@Q
M0"$E(!:QA&%&A)1.$G:.[4^-GAJ[@@W]&?#2[BN+@%_ WS:*8#!4!X\C.%$V
MW/Q<F;\?Y#T+&@\&K"EN!]U0Q<8OM'[;*N1VT%PL3V[YF)ZZ'LOBWI1#>&O$
M0/7\@2VDB6AH)LZ%V%'I=F4F4@EE@C!(LR@$* LUR24R I)QAHE41'*G5)4>
M-DR-Z%JF!\9V1R60'IU@QW0#0SOX@< ^JH.LGJ^ R)>T2 \+QI4=Z0_1D23)
M%8_JN9/?JLFAV50W\6FW$OJGGC8^:W+]4GR3IED]DZQL6#5_?$/7^=K<7YX&
M_Y#\H<C_^UFN#T1[LDPF'%$*B HE0%&6Z8F?Q"!D4!(1,2D2I\C24:R>&HNV
M596^Y_=%KG)N0DQ^+Y9L+5<OI8;0Q^+I>;,.?E]7T2EFJ;MUM%G[GM/W,+$P
M[MHJX[Q!EJ<?4WLOACY(V94$J[TK8YGJE\ <KNPZ?^?.H'I3HW:!K].;46P>
M]R!HS&XX.E,:M7&W@6^]VLR_F9BE2H,&)YACR0"FG /$LABP-*( $41AB(60
MH545E[VG3F[@,-E]ZXT>+19[-.$B/+,/6S<;]P9C8+;LB8,U!9[TNXNB] TM
M>M)_VE'3_K-&H8Z3YC>?]NF_[#?GK*,#/RQ7E[2G/N0%+;AA"),J4-+'/$I4
MRE2$0)CHI36*,0$X3!F @J4XC E,)9L7\MZ4._MA/Z6\RBBKEYQ4+_F1:<.]
M\$ULLY[W\3-Z>FYSO>MZSFX.-WQ'C,,V#?AJN3H_XVX=G&R]"7;N^)N6>4'5
MTW3K.EM&G49Y@>UP>N3GH5<H%9NBL!\?GU;+EW( W%;'1%1/=S %<:;I%46&
M6:,H 21)339WJ,+8;>?R?%M3FR)M30WREJT]%(O/0&NY'^D'L(&);8=5V\P!
MHO<LX/ I7WRFI?$EC+M=/BEC?.&6OD5T7V3Q+#]H*]__U%]A01=OG]>;Y:/^
M(-^\_B:-L,330\[O5MJ$@_T:O7A*2!8J$'.: B2Y7EBQ$((8D51E42P@@VZ5
M=GO;,C6NJ5T)WN5K>G^_JJ:#)BUMYX5>H!A'7*OT]N\N.WX:J1,&YJ\&?_/U
M!8T?P=:1_9XH^V'8'3,/J'HK(-S?DI&K#%\-V7$IXNL?Z:=6>:M<=UVM6[.I
M4BJ*&%"1)E+$,P8H11!P),URV.Q5)=?4+3]N<FJDV:YA+GS4,#^!,J94,3T!
M!B3-D$G;%X!@0D$*LT@@RD2$([?X5+\XCQ.@.@;2ML.-3_0&'U4.J\C_TD:R
M-OB\*,'5)>7/HS-0>?D3#=ZTU/QY "Z5G>^XLV?N"^>FW.#ZF^0R+P]F/\OF
M%'^>H"BF*60@2SD%*,$,X)0K #F*22(PCKEP2H'I:&R"-%[:&JRVQCIFPW0A
M:T<KOO :F%"V4.WLG 54Z5X*3&G!OZC^2*K-Q2JXT<BB;C-I/*;/6*#E*XNF
MJZEQDVDLG#[*J;&YYZH#D_6/Y1W_[^=\)?])5W_*LH#9=W-H6FVO(V$./]((
M,"GTDMM$VK!048 )H8130I,4-P<C3F<BW>WV./L8^MA#/^B!KF59/.)Q:W*P
MWMK<Z]3C OQ.IQL>(!WU%&-=:K-6%@<[DX/OER'M>U1A!Y'?(XD+;=[BZ,$.
MAC-'#)8W7ZD&6RF\O&UT$-=EB !.$\4E5" 4D ,49D8#39KZAYJC8I[$DCJ)
MI72V-K5I3JNL>&7D=45^3@)LQS?>8!N89YP1ZZ\KVX6$;YG9DVW=1G6VR^VS
M(K2=-XTLTUC+1;W_:21/UH;*#K2BZK^17U<YEW/("(^R5.C%56IBCN,44$P%
MB+,X22"1(H9N!#2.W9.CLIW9 =V4\<.R$$TH\5.IV75; 4;']\*2-Z?7VP,S
ML ?QQ*T\8LO[$\J(#0)!"<$$)!'[]=FM!0\=K?Y[R!GVZPIO8H4]F^]1;\;(
M<AU(<]T5NA6:+TRS:KE:TRK[I[7&5"PEE$,&TD1BH!?\"K H$X!'),[",%%1
MELPWRPU==(]IO2UP&IVV=@Q'6J9\\RS@1NV.T879$JO2'FCC!=!N ..'\^J_
M?R]UCS"C8#_P6&%,GQV+#&H7@KMCY,OD1(N= D_P.Q30&;H;1JJN4W9$7DG_
MK8,J09"_!GKL?B@_AG7PEUPLS'^%?#2_$?)IN<YUCY6JD8P6?ZXU<P6J"C>D
MNA>*]2;?/)=D^&OP<1/0Q7JY:V)92B+_F1>BW&.CS5;UYD%/$1_HBRPGA_>R
MT)RY"+BF6LKU9+4,OB_O.+2C3%6KIY>\/G8/'NEK<T5 A<B--?IQZMDTJR^F
MQ6NPR1\K%3G9Z,DO7LL;C6=B1?\Z<;GYJ^7S)GC2<]=54"RU4=*XKP<*NMB\
M_EJ]V'+W3LP"^=-X;H)S<U-H+."F)FJN<EFB>W*/<=; I6?#R]4&F+S.6?"@
M1Q-MX2+73Q?!Q^)%KC?U!IOQ7X]) =/H!BM)1;XPU25V2;Z;9?!GL?RK".AC
M!;>)ZRZ_1 . [I]"4B-4+7.#W<;8\;J%]36H*S %CWF1/VH<=7?\63[BP8R*
M91^\E*ED3'+ZO)8'?[=7!D._%+]5O;MXG>D735N:MWPI7ZOE*K_/38?5MN35
MANQ&SYMD\+@L-@_E2[<P]<?_^YDN<O4:Z+ZJM+8WY=ES4?;YK\'=WMM7N6^>
MM6O36"@,SY3O0K69L.L+#=-&WFN#_D=W6"'S\O75'?<@%P)LEF"+5J$-VJRH
MZ6E?1:>NX9C.BE2]'CQ>N:IK_-ZK9775@WKN4<A[\U)]DZ5J5'%?%3P]K+*;
MI3R)6:@ 5%@!!&,.L HSP!44 @J5A-(I7MJJU:GM#]1&:RK;EG1S7/=;86VY
M:O>-X-!K[AJ\K<'C5#EV@LG7,M>JS7$7J2XP'"TQG6X>:*MT?7$=^Y17*27K
M,_KZ^WMC+(0J(DJ C'-39IE20%$D 6.Q7F F N'$*6I[; >F1HZM#3'MQUB5
M:GR_%9YV3&_8UQ/8.EW;[YUN8>BL+W.S7=2!^G&L[53?YD]K7W6@SG'>8!W*
M#K>!5,A\_J[>@_F0KSE=_)=>(G_0OUG/.849$1P"&1,)D! I8$D4@RB.,H15
M$@O%;,:ZCC:F-APU9@:5G8$Q-"@MM1N!NN#L'B0\@30PC_? QYI>+1 XP8!K
MR7^]7[[\A[Z[(C_]PX[SNIXY"BU9.-4PA\VE_6;))Q4@JQBDB$B&4@2R$$<
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M:?>Y=S][E(_=RKWF4[>[V)-.BSERJ0J8+!;+O\RQ_YQA/: SG(),F=I_3$"
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MJ<!1Y"8RW]G:U AG9VRY;PL^%D%MKZL*4!?$=M3C#;B!&><0LWR+V0#5=*Q
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MR-UTTZ?DW=1&*?U.@3J \+G(C2C'7TW0%JV#ME;;H"TCAN-:5&Y*X-^\ALK
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M5[2=9U>]4/,TBW)K>]394B]8#F=%_1[2,\;#)'15S_Z\K!3*BLV<11PFD9(
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MNV.4VI=R,^"^*%6KOLE*SFJS+ >)M\OB1:XV9>KBY^7&58&L=W?:#05C=-+
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MKZE[<BEZ]86)TW3N>/%553T_=J4_S>V<%/]8+W4SAN[J--R8(R[C6()$Y0A
ME,6 Y2G1?(2%S)C0>S0Z295F>YGG1F6=E UQ14^;DLOHVT[DB=(X.HRY'2?.
M;"0G9%?/5(][(SOJ:7X7[;Z/O?*U&\\,TC^Z#]5+)X1TD/BOD2+2?0B")8WT
MZ-KC#N:SK*1^XV%WZ]M:9D3$,4$Q 2HU*T^1Q #'4("4I7DFH(0<"^L+F N=
MS&VIZ,1T=>08!-+BWB4 /*-?P+;([$3TN7&Y!)'#=4L J%X@.X#^>9TG;.<M
M]&P6*+7>&+>L6I]0,?Y7\!F\@KGT[G3W+U>D/[A\N?:LIU%OC,3WFG"E>%.?
MQWZJCV)K'NYM(#01RPTO]2@N*!2D@"(&&4XYT+28 Y(@_4\$\SA1B!3(*D&.
MMP1S8]%:R&C=GB#(3LPZ]YVCM>T\&):V\Y@0CVT)U^@VPD>-]-&G]KJ@/4)N
M'NF.<'9*!#1H??$+99XZ]S^ML>D+SXGIZ-W0Q"<:AH--=K-JNWEN?(1,[.[7
M![IJ)7RWWBA9;LVA;:/#0D(4,R$82*EQ'*:4 QKC%"089YPQG,2,NUTH3BC]
M_*X4=R*^0(D*C]$?^8QCI!']RYQU-/I'/0#ZT?2[HA?[CT9_,PT.,SCU\!^\
MES[]\)#\KW$*XC\DP4Y#;A#!;S&LV_]MO5HWCA6K^R;7?)M@?I'G,%>QC '#
M1*]?.8T!%E0 D4$2)SP50A(7LW^XN[G9^ V;E$T5AI]D(Z3C>G,%8+LE(AQL
M([-Z@UA?TJZ(Q4]OK\'GS+UVJ 2BRRN=3<IP=HH?DY+E6WX\<A"1@6.4%7F6
M &[2>T.E$*#41#QRA!,%4\*XDT.!;[S&%!SQX8:0E@/0TI0414(+XWL8ZZU"
MHD$C4)I4@I!1'G.509<80V_0)HHIK&L&&(+8>8T&@]*.5&<:!316W,^(L3XO
M%]]C$],3*H[GPCE%;<A5_Z3&N-OV#NED&@N69\2$]0@ <1Z;L!ZJF9 *17A<
M%-"*!#WZGAM'=@+NCTG=]^\^0V!Q*34>L"]X0MI(?Q?M<+]^.GHSU@ZW6^-A
M/E6 T4.IO^5E<T:QV=^ -6-2-F-BR&KWP9OE[<]N-'K??J@+,3](!^_)')N<
M[OK,3]>#6S7/)KS*J;'M?CO_H=3[>Z%W^*_7W^1*=_)KN2H?GQ]?U4G5%P)B
M"&$,@4"QMIN3(@<D8PQHTX]R6.2$VA6R=^YY;@M&*URT[*2.>"NV4X$P!^@M
MEHJQ !UYH3!B]\Y(3=1$!VHG^EW4 =Y(/Q;(3@79Q@%[HA4B).BN=<[<@;M2
M\LRAP2FKG[GK>50(S:,!SQM'NI0?5;WH?#*.N7JUJ9>:!>5*<8(U[$F2ZSV"
M2 !.T@)0%M."2*%0P9V\*BYT-#=^/S"4C#DD3/K:365" AO3R/56[Q+"EE=P
M 7 ;V][7(AHKLA;R+JK%- 9_8^P'O-"Z D6HVZ=+W4Q[571%V9-[G6O/>Y<:
M>325TG2SC0GZZGG[L-Z8XML+!5,ETIAKBC#'""A. 1$% HCR#.>LX%EN91-:
M]#4WEGC="\6Z:W=,$=V)Z^\#,(2W'6$$0G%DSF@!;"FC$33:2QJTKL<U.,+5
M[[C8T]1U.JZI?*8>Q]57?/TYVR#YCVI7*]S</&_D@UQ5Y3?9_K2K>,-CO9E,
MM;6!((/&[E  DYP"0DA<*"I50J&;-Z=3_W,CFIWX9H$]D+N[O;0HAA-D8"S-
ME?'@'OW4,@#2'IZ<7G@%\^-TZWUB+TXO:$Y]./V:\;27EK2J/JKVH.[CYG-Y
M_[!]];VL%C*+64HIUM92KC=4B<2 )6D""IID.<H%Y@(Y64N7>IH;A=6"FDG5
MBFIJ(-?"Z@FEQ76DK<L 6YI'(6 ;VSCR1<S=.KJ&1BC;Z&(_TUI&U]0]L8NN
MON#IV]8YNK0N+M5"H;1(8\J 4J;X?,PXH&F,@4HSP81 *4V0BX_%20]S<[3X
M:OJ(]LY8K0^;8_:D4R#M:. F>$:>_CO9HK?7,'%W3+ND=RA?M)/VIW4_NZ3>
MB<?9Q0?=)G2UV2Y^I=_->6P;2YFS(BVP4H!!6K1Q%;Q  ,HX2S&$7(K89IT_
M:7ENZWHKG-U\/<5I>)[>I/W(\[.5*V FF8O:#LU*_5)O1NI_[6?C:7N3S,*+
M:G2S[_(#'O?7?U_2[^LOC^7VX3_U(_+3A]?=#"Q0IB>9!#$WI8XQ)H"H+ 5(
M+["I2" JB/U=]:5>YC8;__[E/QWN1B]B-SPK@R$R\@RM18QJ&:-:R.A3]"%Z
M[1,R?Q$IAQOC$(B]0-#\@XP:(/^^63\_11_*1Q/=84HF152I.EE<?>]SI%ZD
M]8M^TM]C,!>B:_@-7A)??'FZ"^%K\A]<_EY]V/-@HBDS=%1<Z-7V=>OK7,>T
M+E22THRQ#""%]"X$D4SO0B0$%.8YS5$B(7=*=V75Z]RHM*X!9BJC')>"<SRI
ML$*<RR2!L<FNSY@V%Q-( >,T!1Q+(M*4JB)-7?9]X1&?8"\X*>*6YT2A<1S[
MS*B#\+2"'=U&G=1-AH* YT<N*(4Z2[+J<]IS)1<83LZ8G%[V8_]7526WU>OG
MS4:WO6!<<@AS" H)$\TYA %,4@PR*3$M4L%RHEPXYZ#UN7%+<\[$&^$B6HOJ
M1BN'X-G1AS<D(]-$(]==U$H6C@G.*AQHQA^V/>G,/JO6\0P^_Y#?3/U*O\OJ
M4U.+H/ODE#8%<@0+P#"ES7REM*!ZTB8ISU.50K>@Q3-]S,T&>\7YQGC@;8VH
M;M/U'()VD_9&7$:>NK5T42O>"#-X0/M \_A<#Y/.Y@$5C^?TT*,W!ULT,1TE
M;_,K_/9L-G@?5?O/:E'('%,N*$!(< !SE ,,$PIB+D5!*$X5PY[1%E>ZGAL/
M-/*94X:N^IEW!, UT"V.OD:#<F3J./'Y[T3O\M;<12W0'U7WH_& ]HZU" CX
M2P5;W 3\+>$6EM@YQ%M<:_&E BXL-1V(N+!MP<_":_R-VO6E%'41YYS3!#$&
M$AGK#1F%'&!*E*9_2M.4Q7D1.P5;G'8Q-UZO3RF>M&QU$M8VCXV'L7<&3#M;
M[S:(1N;KUN&PL_A*$;@T\V7E UEZ9SJ8U-"[K."QG3?PI-OT%K)<O%UMR^V/
M+X]TN?SEN2I7LJH6>G\F*>$YH"8S+4Q1"HA"!!0)9WJF%Z+(K8[4+[0_MXG=
MB!C5,D:=D'9S^A*"PQ,Z "XCSV8W2*PG\Q7%S\SD2O*_W:^__7_ZS682Z[_L
MY^ZE]B:9N%>4Z6;MM<?\5N1N@?\LG]8;XQ3T^ZK4=JIBG&%3_9A1D0$(BQPP
MG"< 88(D9(@6&7-9E<]W,[<)O-]Q;3HYHV<CJ-O"? %3N\7Y=J1&GM)[D'8B
M1K\/@N2\1@]C$&B=OM#)I&OUL*+'Z_65IV](.O^@-P)Z?C5Y+G];;^6;LN++
MM2F<]U5^W_ZB9?[7(F.)BE'.@"@(!)!( FA:<)!+CG&*<4)4XIQLWJ;GN=%$
M7_!_;_/=>B27MP+=CC1&@7)D'CF'8F3$CO9R1W\8R:-:]*"11XYPA<P=;]7O
M]#GC7> XFRO>J8$;0P=,*<[ZCECOH$V"WNJK.:M>*%SD*,Y-0?%8[S=B;;\0
M3E*009)+2A%.[9*[6?8W-U[:.\\;>:,#@?5,,B([1AQ= ]R.G0+".#(GW82@
M?T#","ZAPQ,N]/8RP0K#JE\,7;CRFJ<I5-ZO2E5RNMJ^XMQDF#$YR-;+DI>R
MVB_)1#&6\QP#ENIM$:2* 8P) 2DE4.4)S.-".=E!5MW.C6R^/#\^TLV/.OG)
M7H%HKT'4J>!H&MD-@J5=%!S:L8VB82C'LH><8 IE#-EU.JTEY 3$B1GD]O;$
M=7+:4@4?G[?5EJZ$%NWS>KE\U_#G@B-.),\RH$Q='*AX#HBA-YDD7.F-7:+L
MCFK'%7-N)+@_"VE2ATQ4]&9X*"VI\<4':&PJO;V4S:Y834_9Z ^C;M3J&Y*$
M1QV0ERY/,RSD7Z,2C170P8K.V/7FMXA\:FN!?EJ:M6HE=G4LSQU!81)G%!49
M2.J80H$YP(EQGH9YDBF4)XH[%9ETZ7QNA-_)7H<;[ 1WHWTG\.W(?"Q(1Z;H
M3NR[J!;\$-3QCP%]4 O$HTY=3\J./J <<YY7&Y[1'8_F*N1_:E+]J(POD^G#
MV-Z?-O*Q?'Y<Q"E/$4T3$#.D22N7*6!2_S,O$ES(3*(X<4K5>+7'N7%67V!C
MJIHR+I%H978,![F*MAU?!<5P9)(ZAJ_V:^S$C7YJ!0Y80,L:G% A)E?[FS;L
MQ%;]DU 4ZQ>]G-B5W&RD^$J_-R$O[U=;N5Q*OGVFRX[O%II*C,H2P(QKKLEB
M!C!$"#"!5(QBI$@F')S7+;J<&]GT9=R5G'=RI[;!>9AEQD%O9)KIY#6>CU$C
M<70 YJ>QP'3R20\,ZD2^Z$V^^(A)M=;6)%W6)-SRN2ETUOS#_/Q/JDFJ:I;)
M=D"V>D#JV,F(;K>;DCUOS5U#M%WK1\0SWY;UO^3CTWIC#L1%J?2+LFZFKC93
MGIL2H?)#.(W(%0]WFY:F]&QWT.S(H]WES1<_AM72;<I55?(V#P5## F<@8+S
M D 54T"+W,1#R1RJPKC:Y"]T$GLHZ=R6GE?W]YNZWKF9<8V<^RJ&ZT:9:+W7
MYL4.:X\&?/+S6O]A_&L>V=Y%.XU#)X$8?53F=VY[).=?]>CV/-PCGMY>Z##P
M >Y7W=Z;]2,M5XL89ACGE +C]F2R+BM 1(8!*B0K9 9Q411!SFWW?<YM21@\
M8+R+C.#1'XWHCIY1-@-PX]FM'ZPC4W1=!_=#^:W>J*SN:]NW-K*NXQCN?/84
MF;&/97L]SN,T]A0"ZT/8,Z]Z1W-NI":^-[+Y[_M5Z_90?99<EM]J%T%(TRS.
M8 H40<8GDV2 %=JZ)=14U$XS@95<K&J[3=CQD$VW5C.&-#.FW_F(UFDK8[39
M">D<[GD=;3O*"8;@9"&AM9C13YW /VL3/]HA^ODZHCYAHM80A0L<O=[EU*&D
MUB"<"2ZU?]<]W/2+Y,^;<OLC2=G7<JN__"S1) .% #+#R$2G<("SC +-/0J1
M+)$"6L>:'C<^-[.F%LKL:I/T)_9SU(EK'VIZ@MXP;]R*R<C\X J'4YCI);V]
M8DQ/&ILLP/22&OWHTHO/>$9K;.[IJKV/>:WW0NME*9KMTTI\:C+MMG<U[\H5
M7?&2+G<%:ZISOA"4Q4@@<Q3&4P*@4E2;$ED.>%8@P3&6.'8*2@TMX-QHXHVL
M^*9\Z@ZZW2+21QM%.Q/E)<=F9+KJJW87'2A7;U#[ZIEQVRD8[34<WSEFK $(
M%<T26KQIPU]& O<D7F:L?FZ[0?]04E8NRVTIJXZ47G&]/:W*^@H2IBG.3+DP
M@8@ D G-\Y@5(.<PS@6728&8W9;1K>/Y;1H[(2.ZE]+O_O<*Y&X7Z@%@?(%+
M]9[4=[O%,'HU,K)^M^OA$)XLVUL0I+TOO^T L[T O]+:BUR"VVEXZ2+<\FW/
MVX@F5VBE5Y4Z>2U=5KO:J33-(44)!UD60P#S. %8F:P1V"3;AIRD&7&ZA;C<
MU]SL[T[4VJKKA/4N6CL$LN5-0QCH1N9L;]3<[Q>NXQ'J7F&@IVGO$ZZK?'*/
M8/&*'VT<9I[\H$GIO38]JP5**>4\1D#D)L"Z(!B0##&0<,AY7C!5I$XI(2_T
M,S>Z.$J8&OUA)(UJ41VIXA*P"24,09@#$K,4P(Q00!37Z.:4*\9QGC.X^"8W
M;#TAM/W^)@/7\1#D$J!VO!L I-'M9(]/SYEOK^ 0B&LO]3(ISUY1]9ACKSU^
M:[H<<P'368 _%BK+$%&Q!(1A"2!7!&"9,A"S(D58);PP*=8]ZNT>]N/$KR]0
M=7=9WRDN.W%],^,<8IMAG*D<9D#%!0$P-=@*Q<U!-5(PIVF!4S>*#8#N-!0[
M";Z6I\>W8S;V(? ^TY 1\6ZW9PYP;66)0O"\0H>]O% ^H;.J7LXC=/[QD#[A
MC2>@MI[?:TU6V_*;-!XY59T71'-QG"(&]<ZX@%3SA7'YI@1)P),XYK%(8T&=
MML<>,LS-#FXRR %VX@8<PF%[>#3LV&5DC$=FGK/.TSW_ZC\:B:-Q,@WY0S>J
M)_2P!#/P<;:"R,Y[V:XI3PJ42_W;^[_+E2;8I3DR$(_EJC3'!::CKN)\6T>8
MYS0OBD0!54B]'Z5ZH\\4S0"1^J\)DP7*W3*IN?0^-]IKA;^+[AOQ[^H#,'J@
M020;%1R9T&E0+#EP+*C'9K\.Y5;RYI3Q$.1.^(!5[F^"+13S.?4]+>?YP'+"
M=EZ-^!Y=GKM966!*4YF9LS6%%8 XD8#E&0&,%04BL9)4PN[F^JO]!OM\;Q[7
MU5\GV&;_)K>'L;.>.\ +$-L>N7DC]M(WTT&KW0SC$.S$[6PG$Q^X#2EZ>MXV
M^+0?)_1:TN1SFA-[=UL'TSP1M([$,G7/"42 %ED*LASED%.,*'%*J&7;\=PL
MGI[<]3)\>UY]ZR&P8Y$Q@!V95XXQ;?/JCW%]ZHI.(+:Q[G92_G$%XYB1G-_W
MO!+8/LB-V0QNY(.VAK19U!0!>[?>R/)^U51[Y3^^;O2&4/?6[!/K?RT;OT'Q
M7\_5MJX,*+<?E>;/3R;ICOY%+S7&U_4G6I<>QIKH,#;Y9#6Q 1A+!$BA_YEC
MFJ:%4 5A3JD,)I5^;FS9*MF6<^<_HNU>,;U-[#2+?EJNJ^KGZ)Z6C@=FTWX;
M2K)<Q@DQ7IT<P"1+]+8_3T">8Y*@F)#8^:)DKE_'--<OEM_'G+\)R\N=N8[S
MV%=&1N_H0/&HK9;YDZF'\/-=U'T#'091#X3:'.C!$.UQJ#<=)M1 8W$7M6A$
MKXZR'36 !+R>>HEQ#'7I-:GLTUZEO<2PG%S0O8@0(Z6"JJXD"?F[?M(DJ6IJ
M+_]3*_BPE>*57C;HO7S[76YX6<E/FY++18:1@#36=E2>ZJUCK+>.!.<4J%P(
MGN*84HR#)H<*)_O<[*E=IJ!:!2FBG\I5)-;+)=U4T9-FVLKH?3FOYXM_"[=<
M5K[X"$]XR7DIDU1EFTJJ0<"D'&@PN(LZ%*(6AJC#(:J!F#"_5/C1FRKC5$#)
M9W _.^J0.&>E&D$$O[7Q'2TW=;ZK)A&C7J1[!QV_2FJB"\7'U6<3>;XI5_?Z
M@=_6JTWW3RU_V9::BT6&BX(E(*V=PB5%@-:^RY*F28'TPI@Z!7\'DVQNZYI1
MK$ES=Q?MI*^-_[[\?O4 PPVGW>+U(H,T\M(4:'R<EY+@6 9:*,+)->DR$!S.
M8Y(/WX%GA85OM%R:=O3>ZPM=2N.KWF8*,8?53=)ULQ)5V[K/!2)0*9YSD F2
M *@( 3AC# @1QW&!6 HI='$O=Q7 B9 GN! W@MU%M-,"J/4&5%J/J-HIX5B%
MP75$[,AV3)Q'OTUGVV@OZUWTZ@!MHXW^6:=!9%0(6*_!$[=0Y1M<NY^VFH,G
M."?%'7S;\2.](Y.XJ?/W4355_GI)77<7RD)(F,>:]"!B4/]10$"S0@&>P2+C
MA<ISZ70PXRK W*S0-W*U?BQ79NK\AQN[.4-OQVYC CHRNYV<-AR7G3Q,=OVF
M7#Z;I\>X\_=%,1#7.7<_*=?Y@G/,==[M^*9Q_297>MA__":WBSQ#DB:8 I*H
M D">4(!%!D'.,>2R0$@R)Y?L?N-SXZA.-F<#[!"QE"1YKF)MW^:91DQPP*A,
M@!0<$8YRFN7,Q=SU1FRR$,HR"&YVM.V+QLB4O!,KL+_F.76#I9?M-3UQ&ME3
MI4[3Q9YYQG/#VN:9;1-7-'>%VT4*BS1%>HIBIND-&K<D5F08) GB<9YF0M+8
MJ0[@V6[FQG&[),E/C9B..\WS4%KN)V\&:.1)O,.FE?"N]9L(N3<<Q"#4#O!\
M)]/N\P85/=G-#3_MG8Y^_2A-T:?G[</:)+)]];VL%BR#2!LU&9 (ZGDO3-*3
M/,GTO$]B EG*\\S)"?%\-W.;]ZUC4%U,KI-3[PBTI(Y'_A=0M5V];\5J]'7<
M'2:?7/(#*(3+'G^NDZGSQ0\H>B9#_-#3(7)*_:['OCT9ZFJ!+C"D&<TI HBE
M&$!28("10$ H1C%AL$!"[6*T?)-,G>G8ZJL_"M>:(@A#5M5_W%(3^#KB=EP1
M!L 7R9=T%_7$W=4&'BMQT@ THZ10.M??"R93&E!_.*W2T(L>^8Q?KU<F@XCQ
MK-@GTC1)EDM1)Q=9KUKKI@FLWR= SQ3.DD03$.8J 3"A$%":"A,-EB9IK$0&
MK>IRW23%W.R5O1[1@?2=;>Z0F]=[8(9Y:C*X1^:N'M(]'<ZC[I0,).!(."1-
MGF)$ILJAO,_IOU81;?9(QA?DJ1D$M=[HA5K/QOIBI:T.P/?#R?M:WT5_/I3\
M(2IW6W_CPU_G$=](&:K\\*WH#R9D]FY\NOS,M^I_D*[YYL9>II3Q/V1E+BM6
MPF18X'66 ?.C_D5%5YGWJ/(MXBF6*6* H"8&3 %6% JDF)"BX$Q)D4Y9ZMA;
MD[FMIE:ED+_5VM:>9\^K]A^R5=QPA?G1M#62_;\DNRW&7^+[&'GY#UEC^1_[
M+^AM[\,Q/SXJP+S_(&=;BOGFP9U)J69_/>;E1C_V<(4N]7R[0%Z;T*7^^[K)
M<-23=6]*[MQDTB0NN,P)2"6A *9)#BA69K&EG$*:2\6@P[;3MM^Y+8T'DFM>
MTL:P0T)P5]"MMI1C0#GZ)M(11==MA2LF5S82ULU-N75PU?%HL^#\NGN5U5?/
MHM3#],&,EMF)XQ@16:0(9"HN %2I $0D"9"29DG"49Q@*PXYT_;<>*(5+^KD
MLR^N>@S:, ?<",785^2V*#C55+V@KU=)U>.V)JNH>D&)?D'52X_<5CVOB0<Q
MF:N-3=$+^EO0A" $L0**"@$@A0D@7!  ]1)?<,APAJV225OW.+=)^\$GY;P]
MOA:K>6C41K_(ZJ4A; 2^BUJ1#V*E0T/I5Q8O"*0O41'/"UKO8GA78;*M@W>Y
MH1<I@7=5KTO5[ZZ_Z!DF0DU;VS9S,DPY*[" ("WTO@K"E #"$ .Y8)PG"4DQ
M<LKE?]#ZW*BV%<[1 _@(,)0769+F(".Y,(6^$N.:Q?4?# N9PK1(J%L.,&_(
MILG1U3L,B/YL ;PS]S:Z^VW9WM'P]>/C>A55)@?@+>C:G8EZ(S;RRM3*-4(.
M[K,:API0.6A[VNB3<VJ=A):<?<A]8_AVM=7VU;MR*3>OZ5;>KS<_%B0I]/X0
M90!CR@!,8PYHK!*0QQ#BC),4V5F?%]J?&P$V(D:UC%$GI/TN\1R"UW>*-^(R
M\IQU@\1IRSB@N->V\5Q[DVT=!Y3I;Q^''O,LU+M9<RE%]4Z+\[ZJGJD6]:-Z
M72\X=<[9!91(YCC)0<%S;<-0E0*<9@5061*K/$T+6KB5Z[W6X]RF=2=P9(8L
M*EN1&T\+WW7Y.NQV:W50,$?F@D,<W_=P;.1MLGT'+.9KBTVHDKY7^YNVL*^M
M^B?E?:U?'#>2WD3M\X6,<Y@S@4 FXE1OH9 "!"4,Q!PG62%HQI53D)93[W.C
MHDYX0-NX[XZ!FJ#O=6\S 2)F-*AS&#:_=DQ<Z#9,EEN+L< ?>^OA%F]?BS]]
MB/T!:A/'US=]SS*X_@ 6W\CZPT;\B*\-:GLGC?/>\BO]WA8@^D6NI"JWBT)P
MFD), 2THUMLEP@$6, 9Q+#..4FV$4:<JYU?ZFQNYM7*ZL=0U3.UX*2!2(S-1
M*VG4BEH?);?"1C^UXEXF>F?JL00F$-E<ZVU2>K%4_9A0;%]SHY#:\7OS8_'[
MEP66LH R1P"3+ $PQA*PM$B-_PZ1-,8\D5;!(OLFYT8$O__MRV5O]$NP#$]T
M/V5'GLN___;^Z]LWT9>OK[Z^_7+[G#W5<> <I'VXF97M/_83LM?4)'/N5/1N
M6IWYS<VUN'9Y%,^X9PF- >=Z=F42ZMG%TPS@%)NH4*(081Q!B3PK<0UT.[<9
MV)/:,5>7)<QVRW)X\$:>T0=E^_9I7:->',_(=;<L< I?=6NHTY>JN64!Q$#%
M+9NW/7QVWM+-\L<7N=TNZ\OF3QOY6#X_5@NEK868X%2SCKDH4=B4<Y YB#/(
M<4:+1-@5<1CJ9&X<4XL953LYHZ=64 ?'DDMX#M-+*)3&OCNI =J+&'T*!Y"#
MLTT H";RKW$'S,V?Y@H2@RXTE]Z=SFOFBO0'CC+7GO5,P[6L 9;B?&!%NU%:
M) 53>AM#@,J*.GNJ %AA"(C(M,Z<H0(ZY?6WZW9N]-@DUI--L4[>#\ORJOAN
MB;V=718>T9&I]&SHVM[IZZX[0@F8YLL)HE!IO^PZG38-F!,0)VG!W-[V/)==
M/SZ6=6DPDU-_%W/-37'Q6-!8I#(%(F$Y@&DF 64Y!E2(@D"4I@5R(J.!ON;&
M0#U1ZX!.WA?6\91V &'+$]HPN(U].GL$V6LKR-Q/9:^#$>I$=J"G:4]CKZM\
M<A)K\8J[GUN;8O['V^_\P:P?O^G/85'D#.>F]A 3' %8B 20+&/:@L',A%JD
MS,[/]U('<Z.&3L:H$S(R4MJ[NIT%<9@(0D SMI7AAHJ3M]N0ZE[N;F<;G,S?
M;4B=OL/;X',OD]RD=RD\6(PQCI&>]RD$4M%8;V-X#HA,<U 4L6 D3R5E9/%4
MEUO[LJ6;K9W],)'T+K/J6(?Q)M@O=%F[C-%MM'V0$9/WY6IEG%W6JOY!(\DT
M93L#?24\A7&,I0 P%Q)  AF@>68LS20M4L(2C$3[E;Q=B;_X-])I,-D7(K4-
M]M?]-NPLXQF.]H2[^5L3UASX;<VGB&O8,9M)'AI;J?]266<<AR)TCAG7[CU/
M2):TJCZJ-E;HX^:SZ>G-^I&6JP7$IM9)6H BS9E>P80"-,T5,'&/"A8("Y8Y
MG9!<[FMNVZ!:5+/ =*%IZTU4BQO]T0CLF%E]"&;+8Y(PX(U]3.*/F_M9R75$
M0IV5#/0T[5G)=95/SDHL7IEXN_6VOOK8)VNN/FHS;O-5;P-;ZGLE1)T/DR[W
ME_35SL.$,X5@ @L@<*RW7[$D@.4I!CS/.2*4%3&BDV22O$V/N5%>8U,Q2]N+
MG;.]&D!ZR=*KJ(9$F^ETM;?,]K#TW&<J&_^967V'(QOQTWU=\S?J1_^PIK/S
MPPSK2]O]-VKQU]@'A!FJ8/N"0.)X1Q,_R<WVQR<]M;<F\:46YLE(\:%<R?=;
M^5@M)"WT8ASGYH)$ ,@1!UAB 51*$)49DR)V#2>^TN7<EM!.XB9+;B>N<_SP
M-:#M%IZP\(V\1G3"WD6UN(< 1G\8D:-:YH 4;@]0N##B:QU.'4=L"<"90&+;
M-X/N+3K3"PM"J!(YD%EA\ML6"6"JB$&L8B$3'L>8.]5Y&^YN;C33+ 1G3/4@
M=G,0\W;>5NA91['?]*2AU<,NYFY"JW%2XVY.-IB?J13&HODLO\G5LS2Y$(P'
MB6GQG^7VX?5SM5T_RLW;[WSY7&?RKBJI_V=2RRUHG-,$)1!DF!$ F2A,75D.
M.$$$,YXR&5M%Z-T@P]S(Z#=I_/O7XIEOHXHN7?W'?$;!CIE&QG9DNFJE;S*J
M=/)'?VH%HDX#X]O:ZA!U2IBHX7!T=0.$@3C,1X))B>T&B([9[I:F/*TLD_/%
M)(*1XLWS1C?]J7'XJ%,DO*XS%5::<$V*F%W6PM9OQ_AW"@4E$4( @20&$!;8
MI'3, 4TT*<HX*W*[*@-AQ)D;,;[=._BO5\;::-T5^AD@5^NMK/P3N=PX?I86
MWF2C,K8%:!2)&DVB1I6HT>6NS?5R%^WU:;)7[8=JKU) <S (M*',Q=N$F=:<
M# +<B;D9IE7?#)O_E,OE?Z[6?ZZ^2%IIRA"U*!MS#2^(2%) 4DE,X#H%C.,"
M0)(B JGD@EH%KE_M:78,VJ28--*"?QEQHT[>9A9O7#-P7D)XF B#XC8RQ_E#
MYI&A\PH<-^3JO-3RQ%D[KRAXFK_SV@L>@>6OME\?Y*]T\R^Y;2R*3YOU_88^
MMHF?,Z5HIAD %$4B 2SB'&"(,H!ECK(XS5.16%V&6_0U-WIXM8VTN%$C;W=%
MV$KL$$A]!>!A;@@,V\CL,(38]>3;SM YA**'@W"BB'2OC\\M*-T.D\'8]"M-
M3!>B;J?+0:2ZY2N>UYG-"?"[]69?B/>@^FZ7,>3'QZ?Z)WK;S;?EMV;C1%6*
MI, I2%.< )BG#. L@R!/D*9;S/7?U6)5E_\37QTN/&\1RFJ.D&:.G(@VXL5>
M>]0^4+W:\7[TII&SO#H=?2 FNE5MP3?%Q'NEX _+O^]T,;[SK3;17IV ]ZTA
M4 UU%7N3+-/>TH: [>0"-TBC7D5,=\FF_[$VS=;^J)46Y"WE#_56^_]*_9S,
M1<P(T13+90Y@+#) )(F!A%002E3,,JL;7I=.YV;@-K)&F]I_VLQAJ:5M3@JC
M!RWO7;2JD]HZE3.U@]_"ZAT!U)'IL)^,/FK!;82NT35B-P>!D1%\!%0=#.(1
MT)W(,OXLGW1SM8^F.>Y>[?)I?ZL/NZ79*"^E./=!7\X-ZEI2U@F\*_5D[=J:
MLIBLDW9'E63=WG4_RWR]_B8W.R<2FG&)4P@!XBG7-)XKXQ.8 <:PS)12 A-I
M>W9YT/+<N+H6+GJB]](RP>TI5M=/(;T1&)U8C?(A'68N:NMUJ'C8TF2'B&<5
MZ!\:GG_ ;T?[1K+MWC?X*V5+N2@*B"3/*$ *%6:?"@%#@@..$>5<Q9AD3NXJ
M9_J8VSS\PA^D>%[6Q6<^K%?W0'?Z&!G!#Z('_JB%=PPT.0>QW8;R1N#&OA@]
MQNRK%V;.&\(!5 )M\\[U,.GF;4#%XRW9T*.>B;&-FXBLZR17G];+DO_X*K]O
M?UF:(E0*YI+P3.^JDC@!D"4*$))CD!'"8TP9*E*W;-B7^YH;131".B:_'H#2
MC@(" 30R%312-K6+3>14(VED1(UJ64/FMKZ.2*B$U@,]39O%^KK*)ZFK+5[Q
MHX==)NSWJZ=G4S'YFUQF[=6-2A):Y)D"N5!,V^U0V^VIRC5;I((+F. T5R[T
M,-#7_.A!R_:__U=2Q/\G<R.)(4#M2"(03".3Q#[]_5W4"&H(0XL:92.4\+7
M)!!-#/4T*4U8J'Q,$S:O^#HF_6.]?%YMZ:8I3UHM4BR+7%$)$I5@ 'F>F33.
M&"!$<R$(E4PX.B0=]3 W2FB]:G92-E5O+4V(RSA>W_#?C,[(3. *C(>3T07E
M;W N.FYQ8J>B"PJ=.A-=>M!OM7^KE#0W.)H@^/I1?J7?/].M_"R-W.6RK ^%
M]0]?;Z0HMR:85^*<QA#0),GU_D#/=FHNNQ,!.9)QPM+,*<F&6_=S(P!3BXTW
MHKF9!(ZHVUD)XV$Y-EUT@D>-Y'6-.R-[="C\7?V+1OX[XZ/-A\*HG2T*/_P"
M&1F.G4]J=_@!<VR*>+;B>>RYRW10%S+>!0E^EDOCXO)Z76VKDW0*U7[SGJDL
MIH5(01$GF8DDEH 0JADORR#.\CC)I55]GD#RS(WXFNO06R.-;QTDRT/6Z: ?
M^T!V.%8Y^F.4\YA ^(4ZNKU1FFF/><- =W(D'*A9_Z(^?YJ<N^_6FS?K9[95
MS\M7O"[;6&DVE^6W^@:$4::* G.09::.!I$(4)Y!@#()&8X5RX63I6C7[=R(
M<B=U[=<@6KDCV@H>;7:2NU?WL1@$.X8,#^W(1-@)%^VENXL.H6[,B.C#N@KH
MJN@&5, :/Q:=3E[CQQZ(<S5^'-[VHZGWJV^:]=:;'_]<;_[U?O5IL^:RJGZ3
MVX_JLZSDYINL%@3F>5KH[2O2VU;-44A;>0AF)EZF(%SD&,/4A:,L^IP;01E)
M0;D"3XVL;BQD@[$=!05&;F3^V4E[%QEYHW(5M1+?12;QQ5I%G=3AR,<!HD#,
M8]/CI+3C ,$QY[B\ZN&_?'A+_P^Z*0V%F0WN0G(6QY0S@$V&&$TR"6"<<I 4
M0J&8P 02*V^;*_W,C5@ZV:*-%L[!:78 R6$J"8C/R/1QY$)S%^VP^AP,*P>?
MXC"83>1&[(F=FZ/P=40&?8,'7I_.'?BZ#@<>P!:/^X1UT.K!_-]$ZGVC2]E4
M9GOUC99+T[PVU$UN*-/W/F'"F4K<BQPA7C"3VUL9MR2%("!22< (1U#S*BX$
M7&Q- 54+#@TDE!/A[D0;^?K]6W/]7F>L8TUIG*8P(>W4 UH_8!2,JNNI2\8;
M40LN?X%Q&IGXC39WT>LZG>!>J4AK%;TZ'9^:ZO:J17O_BEX:ZQ<8.I=PE>F'
M\&7"69[6FVV;':@N5-96I:H>I-X.T*J2S:_KZ2E,L2JUFZTFQWE3NJJ^-/_S
M0=8IS*MG_A#11[,ICLHJ:GLS+^L)K>?N$S6&E9[I3TW'F^87^L?Z,=U&R>DR
M$CL(_];+@K[4^Y;M@VY4MF73'^F/B,GHV1PLZ[V,7EY6YJI&-UMGEC/2]>05
MO1SJ&U.O>M.\5C^V7F]-]JJ#A[;KYG?E2H-2:K$J/3IUS]7?ZG#Y"W*P==OY
M$9QZNNR;[WJN]&!IT-AC69EL/*9AK6&I^]%"[L:J)L:ZMJWYB^Q-0O/#QSJL
MO+8F]N08+/HH[%P8CDX*U->$T4MAT3F,;@K<]L1U47:BO*JJY\<FI_OGLOK7
MNXV4[S4EZ&][6]O\,:=Q0@IFCMRIR0B5 983"A"".:,))7G,)ZF 8BOQW/:L
M1L9(:2$UJ312.NQ>IQMGNR.U68W>A#>CGK5$>M953^^[J/XFC.I1IWN@G>;D
MX_32Q4&LY9U#"NKP\ <K^.'<L;N#[YO6B*Z,K\Y&&[?F7OF7'Y_UGEN;EUSN
M?3",WU_,BQQDQ%RA,"D @WD&4 (32(N"%+FUTZ]UKW-;-W:"1WW)#>'L9+=W
M"K;'?G@=& W1L4]'KX,9V-/%"RDO3V/[7B;S/G96O.^1[/[R37FYJM;#Y>OZ
M*_UNDF _:/.^7-V_6V_.L^FBP#*/L<1 PH281 ,"X$2EH$A1SC$2LE!9EY++
MSBCV%<5JAATFXAJ9M3[IAAZTF'42#KUFZ$EFEHY-R<U?JSH=RO.J-&$\J^92
M<TN_NT9(>H^<G9$[ZFA,FHVK<6[NR7YWWEK=VP?!4W!YHQ@V^Y:[&"^1>,L;
MK LYM_S;\XP";S-YE=(<AM2I7TR/VEIJTBHNH.*IC%4&1!%+ !7% ".H ,U2
MF/)<:%-/V-RYV'8XM_N4KZ:/J"=U?438E_O?VP2?CC'CUX"W8[Z0<([,<,<8
M7D'-/6+<$HI08>/7NILV=MQ2^9, <MOW/*Y]F^#T78K .DI]ESGPJUS1U58;
MC.;"PWB(%7'!4LIS !.]<808ZBUDQB3(BCA'-.%2%,(A;:J[!!ZFV10Y4HT.
MT=)('I4[61WN^]Q&P>)"-CRHTV:OV.<QK46_Z^<X;<2/WH\/M,/UZ6B 3W1)
M&A9XM^LV+^P&+]7<6ISNZLQ+TX,+,K\6/*_!VJQ2']4;<TJPJ0M6F=I5]:5<
M;U6J4QWM#[OR/*<IQQ D=1R>B@4@3!* ,KVAES"5K'#RU?:48VY'C_TD75_*
M^U6I2D[K9,YM?:FJ\TGHU*SWF8VBM3764]7QHLMS)"VOK\8?G[$OI7I#8P%^
MFTAMG*1*-Z(9ZNK(4XII+X1N@^KDFN?&YOQ8]JM^[:/J'1:]^EY6BU2H/)$2
M I&;.J6$,< P(0!#GL<2T90BI_1-9WN9&T.^7B^US.9HVF08Z%\(FPG8__?'
MVO%J^T!7T>%+?QB]'+-"GA\!.^Z[&=>1F6U\2)T);A"R0/1UOH])R6E0S6/J
M&7[8\]APO;HWN5.-MY1IO_ZJ8TPE,Y? /&$%@)1G "=Q!I)89BG#L%"9$Z^<
MZV1NM'*815;O8W0/7D1Q%E'+,\ ;<1I[WWV0--8.(O?#OP$,0AWXG>MBVD.^
M 25/#O:&GO6;]']?K\6?Y7+Y65/XN_7&.*$L()0QX29K=,(1@ G7^S&]10,H
M5QD7+(LS<SU@/^?/]#&W*?_ZP1!I93R.[UMIW:;Z.1SM9OJ-Z(P\T3OIHC^,
M?%$K8,!)/J!^H#E^KH=)I_B BL<S?.A1SU5=VVUM1M)<JDP44H(<8E.: 6)
M5 8!59RBC.K?Y4[S>M_TW*:SD<QQJ=[#9+E >RD_]K)LC/3P"5E/=0VU_.X;
MGG;1/5'H9*D]?<)O_OVV7OU>=3F6$4=,Y@1P'@L 60H!QDD.1,Q3 E,B],KJ
M,@%[;<]M!K[]#G[_VQ?+RBCGL+*;A9X(C#P-M53ZOR-,Q#/J!IJ)_98GG8IG
M5#J>B^<>\9N,'S?W=%7^3WTW9HK?K9>E:'RS5^)3$TA6__.C>M=%M'W9!;3M
MRO9@4A18R1@D.:< "JZ74%2D@$$&"5=9HMS.VH)(-3<"Z"MU%QVH51\E]14S
MQ^@[U:*];C8%AD8<9SL*FGST1B:OJ0;.F?R" AV(-L/(-"GA!H7QF*K#-NY;
M%^OH,N;OFW55+?*XP$FBN1IBF "(< P8@L9]7!"2HD06!7)Q>CS?C1,-3^#J
M6 L5B>Z.<DN_US'KKEFM+V!JQY"W(S4RY9VYPKV+:B%#EKX: B%8]:NSG4Q<
M &M(T=,:6(-/W^J(TB2D_L4$@N^34[_1_ZFV)=><]$[_O+Q?';DQL P2 97F
M!B0(@!PAP 1* "Z$2'&"64P\'5*\Y)F;:=?W?FC3NO]DLG'^'#6*]7*]^SN>
M^(V<'2%-.!XC,]>9H6#'8W 7=0K5]ENKTD0^*3<!'-PWQ4^:%_)1N0FZR[XJ
MMS4;KO!8VA[T("05RF,)XLQX_^$< ZQX#)0H"JB--IE0J[KO%GW-C4A[A<?2
MVPN/I3<7'O. :61^NUQX+)VH\%@Z6>&Q="Z%QU+WPF/'K_C1A/%LW<@'N:IV
MM43:;QHKFF=9?26=4@#3. ,4"@%4SN-$LB(F2>)"$A=[FAM%-%Y6!^)&?Z?E
MJK6XW%CC,KYVG!$$M9$9XQ"JU@H*3Q57H0A$%)?[F90FKJI[3!+77W!/7?+Z
M>6,RX+TK*TZ7_[^DF[<K\<9D34JDB)5@ L0),2:$S $5N0 $,9D5F"&46)D0
M0YW,C1A:.:-&T,A(&FE1HS?66:T&(1TFA%! C<T%/A@YY1:Y!H)7*I&+C4Z6
M.>2:6OU$(5>?]:Q%TU:-^$1_F)V(R>K'^>99]OWJ]PG\]B< 1:8*#F,$6)&:
MLYL$ I*F!<AHP0D1<>Y8^,%3CKG112MT]/:[R3+01FNWQD4[2[RCA7R'RL[H
MF&  1J:A74V;5H7&E;X=D'Z8T%Z-D0I^W8AEJ+(WGE),6P?G-JA."N/<V)RG
M\]]0].?O*Y-JUT@EQ=OOIF;&JSHG\0)S*H04!$B"(( "$X!)K/_(&>4%D5@2
MY1"U?Y,P5M/XA0+XRT>]_ZWS&3>9^1P]#KW&QHXSQX-Z/F']?36B1H^H422@
MX^,M.(;RD?2285IWREM@.O&\O*DQ/Y[\=9<=?)\FNC6+%D2EBB<2@UCD&, "
M%]J@I *D25ZP+%$P9<S%H!SH:VY&HZFL5&T;CYYR=3Z'NAOI#0%M1VV!X!N9
MP/92]LH\W'6F=CB"LD C$ T-]30IV5BH?$PI-J_X$<<_S*W9ZKX.[%,9281*
M4B +&NN=9V[.J"4#"$(FJ$Q8@9W<0GMMSXT86M&\@B+[D-E->4\@1I[BEA@X
M3^DSV@::POV6)YVR9U0ZGJ+G'O&;DF_I9J5;JC[))KOBFW)IK/0%%R1'"98
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M7O)TBSCKH-GS(?[EQ_Z1]N;CU9]T(]Y^?RH;=FN\-Q>282%$S@#G16[<*0J
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MB(Y1=,%!BI>KQ> .U6")!H_F?"]HOFF#:[WYL?.':>^1JP6B<<+CG((8)01
M"$D3B96Q3!"*).>IDR?*Y:[F1H>=@X2)K2X[J5WO;2[B:GN%$P*MT6]S6B&C
MO0==)V;(FYUK4 2[Y+G8T<3W/=<4/KWZN?K&C?RPOQO>YV)(5,(8H1E(4,X
ME"0!-$=";ZY(D: 4)D(A+X8XT]G<.**3U=DB&D34D1MNQ&DR=N@EL?AC%.<R
M&T1"D\2YKEZ&)@:4OD@40^_X4<7;_WXVF[O=*3-,A2(Y!%D=[Y@9<LCTWS((
MLQRF*DLD<2&'P^;G1@>-=-X.8$?8V=& /R(C3WQ[,)PG^GF= TWMH\8GG<SG
M%3N>OA>>FMC#HY%B7\>RJM,E?WV@JX/;L/== OD\9AF6. ,H@]I.X)(#)@H%
M<AJG!948"EJX>7U-)?K\W,G:6_>?RE54&0VKR[&X+SOH=APVJX'\R_A@M 3;
MTSYJ,I9OM?XG'AKE2*4')ARVE_:N<!7[K^%,X3D8P7PG?/OW2"_T=[JDYB]M
M3AB$]):54@8R5A  XR(#.#&9-9."%%S6O[;.+738]MPLTTXZAQPZ1V -,_F-
M$(Q,MIU@/JF$CF!PR"/D#\=$282N?A1N"83.ZSN8/>CHE>E2!YV7]2!OT(5'
M@IV@[?9Y/$4R0UD".(IC34,P!R3%L3:,L5 %1"R73I7W!OJ:&RV=/QSRW#X/
M8>Q]I#;#C;4O:"'.TT;:<P_U]-*G:==VXS:O^*1"I,ME*9ZK7\KUD[:;'NG[
M%>\*J6-)>5Q04""8F$.U&!!&)2 Y(B2)$Y@J>[OE<C]S(XM.4I<\@)=!M+!G
MPD S,AMT0D8[*4U^"J^DB9?!<LF>& 2TB2R@S_))-U=OG<N56FMINTJ+6UJN
M3+*S[3HZ1;A. 1(J:_5UP(83,%Y^?<),C%=U.$S)>/UQWRHJ7^GW]\(D-C>I
MQLU@_O9<?\%QBFDA*05IJ@H "T4 RU,$!)=4_TA!8I=*[&I/<V/-MD:(25]S
M*&[4R.M:3>42P,-\&A2VL2\N?!'SJ*IR!8T;*JM<:GGBZBI7%#RML'+MA8EO
M.9K>/ZKZMU6;ZOI_I%AD1,@T(P0H#A6 LDY+J,VQC* \RW($,[=ZZ<$EG!L1
M-7(:7\;FRB+:-,XIHO&PJJIGDW_I!>XT+@[QR)<7(09N_K<4^V%O](SVBL[@
M)N+:&+STE<-%^?X:=PO7X UVB7"U(X\=^'EANI[JRB@+EF1)3J@"A.08P!SJ
MK;A$&"2DD%DN"BZYE7^+;8?S)7597^. NFQU)!^?ENL?TM0$ZI%&78;(84-J
M,P 6V_C L$Y!N=$9RMU#_6D$'!UV^('QG'ZK;_*GKG9H-L6QGE>BOCF7AQ\R
MW5-/L#)5#O@-[OQMVIGN",!!JX.S )?W/$B\#2_]M%G?;^CC.RFK18JXX"@1
M@!*& (12 D8@!-IBYPK!&.=V(0T7VI\;17<1U4^-B)&2ML[*EP"TX-S;8!F9
M8CM$6NFB=S<CXL">MR$S$5E^76_ITI"C(42N2?"'.0NMLP15$:VZWS"ZK/=L
MU8.4VTB8W"XFAQ!;EO>TR2-4KOASG3YY^[!9/]\_- 4$ZR=-A%N79&$CE[3-
M'$.CYDB0R^=MR4WQP@:IN[8DH1&$/6^CU7H;+<O'LGV-:R3JQZNM?D9+J?>4
MVOAX-)DWZD;D$]VT";/YMOQ6ATV%8O3+8SI(X&=>FXZO+\M\0,\#C_F=Q)B0
M%/W2PZN5>"._R>7ZR7S/;;:R74V)5UROPIO:Z\=$Q%75ZW6U710L0SE)"4@3
M:,IAFYPE24I!DJ"8<(@S1:PNO@+(,C>6[U2IIY78*^-VAG++X-B=EDP$^<@K
MR ':/3VZA(;]<CF=+K4'9J--9-0)6#XG *B!#CIND632(XT D!T?7H1H\L8,
MS;TL*K]*:EP1Q,?59Q,FO-%=:RN[K'Y?K9DY=S7K[OO5T_-6_UI#IM^J5\?7
M=,F?ETWPX'JY?+?>F..5!96)BKG" *4\!3 F"2",<$!S+AC-*"9V5<<GDWAN
M_+Q/>7S7SVT4=4I'==!LJW94ZWT7]36/:M6C0]WOHI[VT1]&_Z@%P#?Y]&B?
MD-WZ,*L/8^159$;?A']>[;''*71R[M'D?9D,WV/#?S%-^.@=>U[T\@<IGI?R
MHWJKE#0[/;DK5/Q9[S$/1?AJ1-L'7K,D@4*R!. TU:M<"C/ *))ZT4MCPB#%
M118[W>G>(,S<%K!.%[/#/Y2[.PWXLJ7;Y]HOU;A.&/VJVCXVO]OIO_^=X^WN
M+>-J>9$[T6B-?8'0&Z@][+V*Z4:7XR'\HU9GG)HO(7 -=0][BRC37KD& .WD
M=C5$FYY9&&GU8/YO@KV^T:6Y3M';I>VF-%ERS2_TINGP![TGF\"OKNI:5W/M
M?7<<J+=6=9$NHT*CV((662I1 D&>)@Q I3D<,VBJ!W(1,Q[3+*&+K3GDM"/R
M:<5WHOZ=$B->\LJM.7S=U1_D6K^[^L_ZLJQ5\Z[-'=>A4#_@F&)RVJ_$;EF8
M[]B/O)"\KH?9_!F][0_S7MFH><2,^]$/#]]H4#A?-W&'1=2!T2Q0#1P!$W&^
MR#"&2O(YK?#3)A!]D8$Y24[Z,E($6TVU>%\>UIOM5[EY-!%)U;;V6=@%P,40
MY2+.$<B08N;JA "2I!*D+,9<Y1G/"J<L7>XBS&U#<XG>#)O5>@ MQ6/4T\0[
M,M%CO+S7IH"C\$+KRWX OGH,0(B%P1+#\<C]F@ O3="6 %F0K&U+OO% KW5K
M&[I\OQ+R^W_*'PM)$"MP!H$HX@3 PMQAQ#@%1<HPRWB1YLSJ(N-B#W.CN3::
MI94RJL6,M)RN<3_'0 X35!!X1N8?9V0\XGLN:']#7,]QBQ/'\UQ0Z#2.Y]*#
MGA5N=)NB7#Z;,XM]VN/?].B^63_2<K50$@N]Q<>@($@!R'D!&$<84(9X7,B$
M(N24T_U:AW.;YGUY#_*$&Y&C/QJA'<V6JZ#;&2DAH1R9$FY$T;WXC"4TH2K-
M7.MNVK(RELJ?U)"Q?<\_54MCA32'HUU!S45.,A$G* ,T0WH+1;(8$)QE(&<I
M*7**>8:X:YZ6<QW-C5IVU5K+6DSWI"QGT;3CCA 8C<P9>Q';2Q9SIM5(&385
MRQ . ?.PG.UF\B0L0\J>R\ R^/P(GJJ?ULN2_U@@D7-"N-(DP%( E=Y)$)9"
M@!*D6,ZPWELXE4>PZ'-N]'#1%](XMCG>\MI ;D<<@8$<F4.N^9/>18W(T1_M
M?T>YJ'7 ; IWT;;'^;B%'D+@Y/YY].K<4C7_MJXI5(I_RO+^P=0P_28W]%[^
M73>]?4.W<N?VT_?HXX62--7;+<0E!I#&"& A!4"2"I1G"2_P-"D0QM%O;D3;
MR1ZUPD>U])$1/]J[$LXE$;3?)V7IJ3,OJ6>TD$R75GJ'U%UD]V&.<G@_TR_A
MI=-&C*3=7R/IQ+A#.UW>Z]O$O-5]]JI>U27%:L>Q1<JP2$4F $-9!B!"!6"X
MR$$.2:YR"O/<,3]2*,GFMJSW_34;6F:#]%WM^9N=\G?KR>EXTAMNV"T7\)<8
MS+&7WI-Q'%Z&J\%U^.HXWN"&&PCSX#ZYM\KU0@ZZ@>"\[*T;J@-/9R.]N%"V
M-L'SWV2OTW.5ZY#B2DB5 %0D$$"94( 3)D"J"!*<Q4DAG0*T'?J>&ZT?B!Z]
MNM_(9J@</8<<P+>CWI$@'9E<C]#L;69&KRKH 5@HQR"'GJ?U"'*'Y,05R*,)
M7_[2.AE?A#K0K*S^U=2A-W];$)IJ*Q7E &6< T@8!42F&$B$E<HRE!;0S2OR
M<E_SXZ>>J,9F:42-C*RN''498%M."@+;Z!S41\P(=]<';9HS>@NH@K'/Y9XF
M9INK*I^RR_57_-BDWJ2W27%Z(;"O39:CU7:!6)*E/$^!8L;-FC,(,$49B%&<
MHSP6#&*G/ G#W<V-4VIIW<CC"IYV_!$.I9$II#E([?*/]4353-((&XXI[$ )
M1!97.IN4+^P4/Z8,R[?\6*.-D&]<%)Z>MU]U,Z^^E]4"9PE#6 I3#Y4 2"D&
MA&.IMTZY)(G>-)%$N?#%I8[FQA0].=LD%D;2Z \CJ^/9U45L[;@C!&(CLX8?
M6,Z$<0V)0%1QL9M)2>*:LL?T</5Y]P"%UZ:(\T;2UVLA%Y@R0GFF]Q]9J@T'
M/?$!@SD$B<J*%''%D\3*N?"XX;E-?"-;9(2+C'3V00@'8 W/[%L@&'L+8:>]
M4Z#!.56]X@L.&IHLK."<^/UH@K._]PPBV.6R5+*J],Z +DU"R\[6)"R/%4("
MX-24@R68ZK^9BHP<I2E*LR3E3OZ]P]W-;6+VT@3OQ'7(%6R)L=V:' ZYD>=S
M+Y/P'C0CZ@CVO!THH2(%ACN;-D[ 2O&3* &[MSR9I*ID+UA7LA12F&< %YQJ
MVYW$@**< 0HE3;!>P#/AY 5\V/SLF**6SI$6#@&SI %O&,:>]K5@HS@TG=<Y
MU*P^;'S:67Q6L9-9>_XIOUGZ8;VZ-S'\;R2K[?4V:DWD+$TS!H%,<[VZ,Z4
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MR P*BRSA(E&J %1!;3X)KK=9J?Y#R3A'A&4%<KOY/=_-W'BD'T/8K],=(H/
M38'\,R*.L_%Y^VB%.@R^3H3?YOD8.[(]]-;K?"<SB/.^N.D:?GKBQ"IMI'8=
MD5V]7S5YP*^&:R\@P4A033!)5E  488!P0D$*!49HK(H,'+R$I]8_KD1V2[_
M!&WS3]P;D4%=95B9_!/?FAIKZT;;Z*=R%0D3?[1I[*C*8'.Y'.<L/IE;^'06
M'\*$1.V9^&27VJ1!H:[76N-@F^%D!FE-;AO'ETY;XBG]#):KT8<F6-J1&\7P
M6V#_03>E"44W%3#J,WBJ9*)R(O7'DR4 YH7)JII2@ J:H4+!%',GCZGC#N:V
M1'7R-;5M?.XS3B"T6Q%N 69DRG;"Q)E"+RD>B.-.FI^4A"XI=\P2%Y^[(?BQ
M%QQE-C^M8R_+99PBE@-&9 Q@DA& N40@SX2YIL10NI7.O-S5W*9V$].W6J]
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M,:KH %07MR?OPK=Z=7*1IV).92-4@JSJ*R:2",3$&'#!I$">)1.M ;6;DF[
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M2& )39WU23%RZ_=L#Y"S%XZ:-Z)]4ARU4D8']N<!"4E5E*ZS'&QT=98#6=*
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MYNKMHD.9L^405:+#6]+A'8/7(*U,(JM(D&D^W_!>:HY.RCTDV:M]@N@%<\6
MYI*<7:X%^3\Y4KQ5HK7<2M7\$-J/LI$G.K9!R9V$7'NE]&^\_K98Y#^GLUF8
M9PKTP_QD6AMB;CO9'F"Q'OJXQF9J;\H;V::+]9[=7>_JC+L$HJ'C5FI%H8NK
M<^I48A $>G#"&8I<&>?-*UD>1>#1@^WV6>QJT^B2BM>&=DG4%,G%0I((*8,Q
M];XO^1A$Z[SOXR@<UZ(-AZT[L^R&TUO_QF['Y=^NID/A]A7@(9;PX+4:F\DV
M/#>RH3N((2!^^+18KNL3UVTSB5N!BPC*A*# U()=%8P"QT4"ZRV:G$/AK/6,
MB\=3.4!IP3TK7FU-;G-((BGR0["V72T(GL(JB-9XVI?DC?C6[Q</('-<NSHP
MWO8H+FBJQOXM[/7A' <8S3NS/=K9P7LI:V3:+C[_VZX#FV,66D9@SAE0FD=P
MA6UN+J)F0D8N0O.4_[WD''^G<>>CK^ LI2B12PE)HB!6G:, C#/0UC&1HDWH
M6[^:>8B>L4<1M<'$W;N-1AKHWZ!<-#T+U_O '6!9=GY.8Q/S?5H;V9I[.\%=
MHDMGCYX96V](.2B.!@)J"3[I'(63(IK65;+?):K!J]'="^S:!2H)EEF1P',B
M*>2@20"B4* D0THJH1[B%>G>](UKE]KB9\<CTF'TU+^U.A\C<S[]J 95F_%'
MVU'"Z^MC4 XP8?M_>&.[=B!7K8S==DC/ZF)*3YA=.>M%6A>88R",JLU8Z1"-
M,AK0Z+6V,C%YN_=9BW+"^\@YUL#M,Y9H9Y+&15&RLN!$9+4%0*"0Q3C:0S';
M>N9'V]K6'4CJR&:O$9)N&[RGT%O_MF_3F:+V1Z$%M_WP#KKRO/LIK:\WOT-G
M([.U_>BK U4;YK7W((5"4*QHB$A1OR4U"T%_84WK$/ F!4=?6=X1VV^+->Z\
MW<^9*<,4%*T)UDQS8E5J^I;K8(.R,;?.]>]-W+@&Z A,W+FL'$0=/X"5J6V7
MXIW>5(=8FMV?U-K:[$%O(XMSI?RWY?IBYSVL-BW\KLBY>!=PB4;F8VU792$:
MX6M13H#@:B,A--(+;="8UCTCCJ/X6(NV]^K/KZ]^+7/K)?.V(+!0^S48C22P
M0O(3@4<,*HOQ!+:;Y'&MWQ/B\[:U?$I5]V]#M]>]%,9=\T]_Q5#%D\/Z59@N
M_SO,SO 0H[KO1[>.4 _AJ)'9O?ST*Y!=@=;*(J2)&I)# @ZK#YV3X1!LXC::
M++-L_4#I(7J.[JBZX[.O=HG'0G$+RX"YSNK!+,'3]R!"LL4*5$FW-H@/$C2N
MN6N&BSN]4YLIH7]3M>G\?8 =NNH8WO()PVU:6CEN],$[;HA8=DP*.N:***G>
M$"%$'>M=$3KEO$VE>?/UW90<[6C=^-0KJ!;)&#(3(&$M+G(F02A2@:83/<J<
MD\G-':C=I(SL&!VO_SL.3P.1]V\=-NVC#\JEG__+QA9B%SV-;,3VHZ]->Q9,
MA<A!;B8^62-J*Q4-FJ+Z)'W)/+>^W[M)P;$VX0V2RX97\] W'WZ%4Q<#]T[$
MZMT33DWQ$!-ZL%)YZ6.F [(]?P]1-*Z%.$+[MRU#0\'W;R"N/0(]K!SIZI\W
M+T>ZA[)FY4CGG[_C8,DN)4%A*R3K99W/Q<&3SPC2<%.**:[(UB65#Y#3[(GU
MSF(8ES2/5D'BBH$J.4!D]*TU0:&2F?/2OD'$_?2,78[4!A/W/K4^5@/]&Y07
MBQE!<%%MYQ=\=K+$\S8R!QB7^SZJ=?WW/A0?:70V0[)N+E1[AY_@S:J/2[ I
M[CA+A0%S(H!*#,$KBGY+0J5]5#FK_4:6[;_FT17:WUWI^AG*K=%ITR.=0G!-
MP7U4@OZDC/.>%4>A>.O*[/W)&\<&#0F1.V78 ^FJ?_/T!D_"[+R)/SEW!X9&
MMSZC>9#T$(VM'IHL3D^GYY7]\WS9(S[=J,2X!!LRI[7@&7)D A32,1BEKVW]
M*$PV6I%?W;I'P:,(/-YX[;'8M9H\DC]WICZ!8!:4(W'0(;XI3DDQ)RVD'44<
MG;A1PV'KKB$;3&_]V[+G857?8N>7T]G9&FL#GS>+U8KBUBJ5Q7QS77>(?=OK
M<QO;O,?STJH**2SGU<B^P^W JDM81IFT09? V7KN<<W!U5Y(S.C,4:IZH=JZ
M'ND>6HX>1'#K<Z\V1)+:AJPS.,GK">]U?:5/H4B,M844AIA;CVF^EYB1*X]:
MX.#.0( F@F\X*FCD%B_#MWH9M^7+6*U?& HAD<[,XC.=:[H6?1C+04<7M2^<
M H+6^:KA6K_4HV#UMMQ:X-OVZ[6X!(T/Z"5Q*B7%/V'SO%\"LYGB(*\=#ZW?
MT>U'6;>M7QZ#DMN6; "E=-!\\D:OKMN\B&*(]FC A3K4B'$#/K!0$_U%)1F\
M;MZ@Y"%ZQNVC.Q"LFBF@ S"]6BR1#H?MHQ_B8QGF*Y)/G4-)L<GFV]F&S]5M
M1C%+E-)C/?T-*,$9!(:^OG!GO&3I$[;VP@XF=MQ.NP/!\&E4UP%&?U_AV_++
M:CT]#6M<U6('1')IP;#ZB#&:",$(!]9JYXUW.DK6&'@W*1BWR^Y :#I"R"-"
M9)M_WMF?8U<[G-L;@6D3?1 2@JSM,S%8\%)3F*0P%B^3$K<CR?MN+ XE8=Q1
M68VQ](3:Z, LD1N0B+OM8-+WT]4?+XB&Z;K^:2*\MTJ&"$PK4]\_NSH CX)P
M7E)D&%)RS<=9W4_.N,.JAO/"FHB_ R3=^[3^S@[)6AM,'HJA?:$D2W4@N(90
M C>L,,=NW[ .U_[@$$,VV&"I@3 VB&(Z -Q[_(+S,ZSSP.OU0Y73WZ?K3R_.
M5NO%*2YO<Y=X1&4$KZZBKO.0R!DHS$+F(B,K)9(;V1AVCZ-PW%E2 X%O0"5U
M ,'+9D=W FC/.$^V@/8QD1=0;[JR)0FJDK/"8D,8K*O6(; :;*3U0+!J(O@.
M '3Y7N;\1=B56;ZS,U!IQZ6#Z'E-R;CJ"$A)?F5!GA5#G5LWTMB;N/WRKNP'
MP]@PNND =)>7]9?]<;Z])Y4MO^!%Z+QE<%*2],)( UI$!XJ7 M%I#HQ;QZ+B
MC+G6B?Y]:=L/<C]:KG\0S72 N,H$$5 'F+XDAV"VV/B?YTV;SEFR.LN2BP%C
MW*88U]:K# Y!IV*94(XU'RB^!UG[X>Q'2_ZWUL?8R;.+.8#;:N]M__#-#VZP
M=.W-/$IMBV%@ZSP&16$UQ!02,!F*CMXY>;OIZ3TILT<NO!^:?I0<_N"B[\!R
M7;X?N,.'=2XI[FK;!3KS,5GP+BM KJ/.V>906OMC]]&R'ZI^M%Q^$\F/;9BV
MS0@7I[3X)]H-TR^X96NW'RFL2\D$#@:U)W%1&!.XCR0NA9SY$'3F>YFE1RV[
M'WQ^J/3]<&+OP"1M7TEN'T?>9B7JPHO0&>PFA2<86=?(Z5OEM$S>>8>MKQ4?
M(&<_9/UH.?M6\A_;-OVVF/_C+,RF9;J=JO%R0T.8U3SQ:O=.P1A32MR#-K5?
M6VU'Z72=0F!LT286(V]W4+_'0#U^[?VP]*/DYI]" 1V8JJN^5=<[6[W]?#Z@
M\?7F\HNL\S6.)TX&N2EDXT'4,6F:0EN6$434R9H@B-'6MXX'D+D?''^T;/W0
M^NH DK<+PV_O,.T]'?I8P'@M*#XI#GP*" Z1I< 3CV[HQP<'6;X?+8/?4@\=
MP.H#GM04RGO\O%C>7Z0;LW+21@/)9=HKMJ93T'% %XL@IKP7K5_?[D78?A6N
M/UH"O[U..@#:Q7QR,M!Q.K]>&CFQEAECR0@GS^MTA%+O[VGS9.DMMUJCQ=8]
MJ^ZG9C](_6@)^D;2']OUO[IG>);^<39=32_&9T\S;FN1SOO%W]XL-G%E$F8P
M/!"3!FN#>)4!M=.,=@LSMT_'>[LC'$;!?K#Z4?+Q3Z>,#BS7 ^,][SQFX3%G
MQ2)8$1+YE-819T$ Q<_%)AV9T*V=L/VIVP^"/TH2?V#M=("[W_#/:S);+N;T
MQ[3M-+/;(_#2\&R8ALAKMXTBZLCN>KEJ3<;,=,ZR=:788VG<#X,_6LI_4$WU
MWU5@OY>N'S=S8FYRU?(=[_GGC_**=Q=OP[_A=3YQQCP"#P5!<;)GY,)I$-I$
M4WSTLGEEZ'!O>*\57/Y"DEO.P^RBV'+U_-O?<'%"VODT3<^6&+;ROE;'%+/5
MEFRZ=G70$%JRZ8&<65&GOOI8:$.U+\$XF-QN7_L^!D\/U,L.JK[^K>&%0Q+N
M.B2'F\#O?VACN_=(+AH9NP><N1UM@$)642<7H:CZ3(YE!L'J -:JK&--@#0O
M5GX4@4?GYM(GS&<S?%M>DVS+=#Y=XYOI%]RMD6N9(5&X\:8 XY+VDXX(3A8/
M1LGL/*80FY?<'DCJN*9P.+3=R>@]@28[B%BNV+P0[;4NZ20AQ3%"J$]S%(5:
MX'-R($OV(3D38FE=D_L .>.V1A@#>,=II/]C=\?+UUW/7ND\>X\DV&E:;R^O
M#S^3CURQ=4_:AORW:ABY\S'RAT^+Y?HC+D_K6YC5^N9 *A&\";4E0O$JUQ2-
MH< X:V E9Z$2QHRM/?G'4]G.3.Z_]JV#H:"63!L#PI*_OFDI[Y-6(.JP&^=R
MCJ7U6]3CJ1ZYQ>2P:+S?\CZ)DKLZ_6]:F-IF\R;[UV[+=5).9 ,UOT8L<E/[
MH$BP)2=EDQ)>M*[[.X#,<;V%T8 [C!K[=R4N'FD>E;2\^R'-IUT\2&6SF1?G
M#U9W.:;:^R(30BFNWN,QTGJ-4Z+3PA?%HL+!'@L/&VV?+[+M[K2^99:=*4EH
M15ZX1-I< A-X)+93T8Y9R;UM_KIP7]K&GH71!BL/1<_---._&;KH?Q&NM;XX
MW!X]\&F-#=.^=#>R4/>V";D:[829>ZX"Q<Z23B?T$;SQ&= &CX5Y)5/K7J??
M)6JPKC77W$<OHI$IU &8CG:#5;4AL03'>)3.L.2L>BJV.[%0;;&R=\.:PW32
MOX5ZEM+R#//YB\F:6]@^8-H:YVMS@P\W6X]=HO40Y&,X;&7@ME54U>G?D!-F
M5XX^%N\\N=>0=3"@DN=TXID"R1<KK7>QA-;QTP/DM'/!SF\I5^>+7:R%^;;(
MK[86G?T4+&L!R=*YK[BH31.S Y3:J1"3BW:XE,CCZ1W9$#;"U/VNVL :[-\X
M;EX'Q-MO4HZH@GGH\UI7O>Q->ZMQS9<1P]MR?<GW. LU_[!8K5=71!&F;N8[
MK$U"IF3 <Z=!V9S %26!ETQ!AM8EZ-9F\#B*VUG*JZ=/YVL\^S,L\X<U;:CM
M^Z=5[06T-2RKU=GI]F>W=I[5,B;M)""7=4Z7(+>D6 )@+LF48&U)K=M)M^5@
MY&'33X?>^PWNDP.AJY3S[A> U[E_EM;3+]/UMUL<"VE$=)9!3'5B7:XOGYD.
M@,*YI)$5'9H_VSR:ZG$3TIW!?4"%]P?Q.X?R59)^P_NSZ_>[FY_\/I^N[Y.%
MSS%[KPK)'CDH'R)$%34XF:*,(BKO6F=PA^1GW$D#_6R+\4#2U8;YA=SJQ3?$
M#[C\,DVXVV(\FVT^LCX7+^\Q+4[FTW^2=G Y76Q5=JV!3Y:&ZVHO,DE#117
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M(;==X*JY3'&H>=*09$Z@1'80@[5@G-&8@Q12M[YGN4G!\;V[Z=-JOO-VM$$
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M\259$;&Y/W@_.7O!3O_+PZZ5PCK WM7@E_OO6]]<-E-D661N JN#[FL[>F?
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MUYH)'Y&L/?;C&F=M.U/>*'W;?._=19A=OKCUT1O ">1!>8:@BUB]MO*Z_"T
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M8^LH:#LUXUYP#HVH1EKH $\?YN7RS[!B9//+7_$;7LQ7XJHS/#:,\131YE1
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M9AKB].+VN(U#"D7W_D;CZM'C>&Q54AJ^UY1T-5JGTA,N?C2ALJ"]XQXA%B%
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MI:X55\9(ZU,1K</OEO2/VP[?V2DZ&C Z,(J-L[ACX9LNW6L!W&G9C99I)72
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M?/:J0.&%0G)=-,1H.0CE598J:%E:7W =1W$_%;?1)QDXQ6C%4TJC=)VD95@
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M2<3[Z[#LUU:.@\F1B?AOLSYLY5_7'7&S?/-B.:^_=5\VW"9>5$I@:[^IDJC
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MW$V+^)Z\G6G5XW,RPR/ =MY["IZ4S'H$S2WA1)U+9B5!$BA L4B1 O,:*/-
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M0*87O6J^$G8'LKH$UR$@N#\!J*E&.@#9![R@/_KT#YQ1T']!C+W(7Z:S:8U
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ML_^LJB4P5W[>O/[E[?O-MN,2K+/(P19'3*4LP8=@H:#AJ00AD;6>MKH38?U
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M$G\83)0[#7OA),FW;L@;+E(/SA+.?.@M>_.\)*58?[!=Z!N[(U,EJ!U,I17
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M8.2N 4.BYG!!5W%R_K9=X.-6.>?V'?C5-_$\,,23:A1P@YYK@)SBGM"8.DD
M.-A&&2UV*]O>*T7B59+&3;L>%$LEE5&!#3K2%SU[S!3SR!S3QI'H<C0E7236
M2" Z&&"RL4!3Z4'&I6BOI=/%[Q[5'@:&WW\1/#3858ZK&'"]Q] $(@/WQ$?I
MB.8FH00@5^C7M0+V:(E<:S!\(.;* O\   R?0/;P17[QKH,___@/4$L! A0#
M%     @ YX!A5G,5?4(%-0  G,P! !0              ( !     &5X:&EB
M:70Q,#$X7S(P,C(N:'1M4$L! A0#%     @ YX!A5C>TXHMK-   5;T! !0
M             ( !-S4  &5X:&EB:70Q,#$Y7S(P,C(N:'1M4$L! A0#%
M  @ YX!A5K*(UZ^IR   3$H' !0              ( !U&D  &5X:&EB:70Q
M,#(U7S(P,C(N:'1M4$L! A0#%     @ YX!A5M9+V3,&.P  HJX! !0
M         ( !KS(! &5X:&EB:70Q,#(V7S(P,C(N:'1M4$L! A0#%     @
MYX!A5M/6"ERF P  DR0  !(              ( !YVT! &5X:&EB:70R,5\R
M,#(R+FAT;5!+ 0(4 Q0    ( .> 858$M%1J6@4  )0H   3
M  "  ;UQ 0!E>&AI8FET,C,Q7S(P,C(N:'1M4$L! A0#%     @ YX!A5AS5
MC(CP!P  :R   !,              ( !2'<! &5X:&EB:70S,3%?,C R,BYH
M=&U02P$"% ,4    " #G@&%65G6-FM$'  "1(   $P              @ %I
M?P$ 97AH:6)I=#,Q,E\R,#(R+FAT;5!+ 0(4 Q0    ( .> 858V3<0+/@0
M 'T,   3              "  6N' 0!E>&AI8FET,S(Q7S(P,C(N:'1M4$L!
M A0#%     @ YX!A5L9PGN O!   3@P  !,              ( !VHL! &5X
M:&EB:70S,C)?,C R,BYH=&U02P$"% ,4    " #G@&%6#W2NGG_K P!W;"4
M$0              @ $ZD $ 9F]L9"TR,#(R,3(S,2YH=&U02P$"% ,4
M" #G@&%6BW_&T+T2  !,U0  $0              @ 'H>P4 9F]L9"TR,#(R
M,3(S,2YX<V102P$"% ,4    " #G@&%6@(G][@TJ  #EK $ %0
M    @ '4C@4 9F]L9"TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ YX!A
M5D!A#FE&3@  E7$# !4              ( !%+D% &9O;&0M,C R,C$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( .> 85;$'Z/L%AH! %6' 0 4
M  "  8T'!@!F;VQD+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( .> 85;V
M2U&'"!L! /:5"P 5              "  =4A!P!F;VQD+3(P,C(Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " #G@&%62<2?^D6D   O@0< %0
M@ $0/0@ 9F]L9"TR,#(R,3(S,5]P<F4N>&UL4$L%!@     1 !$ 600  (CA
$"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
